

MRC/BHF Heart Protection Study of cholesterol lowering
high-risk individuals: a randomised placebocontrolled t

Lancet, The

360, 7-22

DOI: [10.1016/s0140-6736\(02\)09327-3](https://doi.org/10.1016/s0140-6736(02)09327-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Selective release of newly synthesised and newly captured GABA from synaptosomes by potassium depolarisation. <i>Nature</i> , 1975, 258, 254-256.	13.7	41
2	Anosognosia and the intracarotid amobarbital procedure (Wada test). <i>Neurology</i> , 1994, 44, 978-978.	1.5	18
3	ISCHEMIC STROKE: MECHANISMS, EVALUATION, AND TREATMENT. , 1995, , 551-586.		0
4	Common Drug Pathways and Interactions. <i>Diabetes Spectrum</i> , 2002, 15, 249-255.	0.4	10
5	Polypharmacy in Elderly Patients With Diabetes. <i>Diabetes Spectrum</i> , 2002, 15, 240-248.	0.4	48
6	Niacin extended-release/ lovastatin: combination therapy for lipid disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1763-1771.	0.9	25
7	Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. <i>New England Journal of Medicine</i> , 2002, 347, 1557-1565.	13.9	3,201
8	Attaining United Kingdom-European Atherosclerosis Society Low-density Lipoprotein Cholesterol Guideline Target Values in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2002, 18, 499-502.	0.9	16
9	Missed Opportunities to Treat Atherosclerosis in Patients Undergoing Peripheral Vascular Interventions. <i>Circulation</i> , 2002, 106, 1909-1912.	1.6	123
10	Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2998-3007.	3.8	1,276
11	Reducing the Risk for Stroke in Patients With Myocardial Infarction. <i>Circulation</i> , 2002, 106, 1595-1598.	1.6	10
12	Treating to goal: new strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis. <i>Vascular Medicine</i> , 2002, 7, 187-194.	0.8	9
13	Unraveling Pleiotropic Effects of Statins on Plaque Rupture. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1745-1750.	1.1	77
14	Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury. <i>Circulation Research</i> , 2002, 91, 696-703.	2.0	85
15	Fluvastatin. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1631-1641.	0.9	18
16	Targeting Cardiovascular Risk Associated with Both Low Density and High Density Lipoproteins Using Statin-niacin Combination Therapy. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002, 9, 339-347.	3.1	4
17	Evolving concepts and a new approach for management of hyperlipidemia. <i>European Heart Journal Supplements</i> , 2002, 4, J1-J3.	0.0	5
18	Combination therapy: its rationale and the role of ezetimibe. <i>European Heart Journal Supplements</i> , 2002, 4, J19-J22.	0.0	14

#	ARTICLE	IF	CITATIONS
19	Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. <i>Annals of Medicine</i> , 2002, 34, 514-522.	1.5	3
20	Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond. <i>Current Medicinal Chemistry</i> , 2002, 9, 1831-1850.	1.2	54
22	Diabetes and Impaired Glucose Tolerance: A Review of the Epidemiological and Trial Evidence for Their Role in Cardiovascular Risk. <i>Seminars in Vascular Medicine</i> , 2002, 02, 383-390.	2.1	6
23	The Need for Risk Factor Assessment in Atherothrombotic Vascular Disease. <i>Seminars in Vascular Medicine</i> , 2002, 02, 231-232.	2.1	2
24	Early Statin Therapy for Acute Coronary Syndromes. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1749-1758.	0.9	16
26	Review: Type 2 diabetes: how far have we come?. <i>British Journal of Diabetes and Vascular Disease</i> , 2002, 2, 446-449.	0.6	3
27	The ALLHAT Lipid Lowering Trial—Less Is Less. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 3042.	3.8	39
28	Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy. <i>Circulation</i> , 2002, 106, 2526-2529.	1.6	259
29	Primary Prevention Lipid-Lowering Drug Therapy. <i>Circulation</i> , 2002, 106, e35-6; author reply e35-6.	1.6	1
30	Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1907-1917.	0.9	30
31	Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F ₂ -Isoprostane Formation in Hypercholesterolemic Subjects. <i>Circulation</i> , 2002, 106, 2543-2549.	1.6	114
32	Causal Structures for Evaluating Statin Class Effects. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1961-1965.	0.9	1
33	Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. <i>Vascular Medicine</i> , 2002, 7, 323-331.	0.8	36
34	The future direction of cholesterol-lowering therapy. <i>Current Opinion in Lipidology</i> , 2002, 13, 663-669.	1.2	24
35	Lowering blood pressure for cardiovascular risk reduction: moving the goalposts or spreading the net?. <i>Journal of Hypertension</i> , 2002, 20, 1945-1948.	0.3	3
36	Early initiation of statin therapy after a coronary event. <i>Current Opinion in Lipidology</i> , 2002, 13, 631-635.	1.2	3
37	Safety considerations for statins. <i>Current Opinion in Lipidology</i> , 2002, 13, 637-644.	1.2	85
38	Role of lipid-modifying therapy in the prevention of initial and recurrent stroke. <i>Current Opinion in Lipidology</i> , 2002, 13, 645-651.	1.2	12

#	ARTICLE	IF	CITATIONS
39	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 339-347.	1.5	12
40	Ezetimibe: The First in a Novel Class of Selective Cholesterol-Absorption Inhibitors. Heart Disease (Hagerstown, Md), 2002, 4, 399-409.	1.3	37
41	Risk factors for non-haemorrhagic stroke and the effect of lipid-modifying therapy. Journal of Hypertension, 2002, 20, 2359-2362.	0.3	0
42	Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension, 2002, 20, 2513-2517.	0.3	8
43	Treatment of Dyslipidaemia in the Elderly. Journal of Pharmacy Practice and Research, 2002, 32, 188-193.	0.5	1
44	Cognitive Pharmacotherapy of Alzheimer's Disease and other Dementias. Canadian Journal of Psychiatry, 2002, 47, 715-722.	0.9	14
45	The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics and Genomics, 2002, 12, 647-653.	5.7	21
46	Lipid-lowering therapy in people with type 2 diabetes. Current Opinion in Lipidology, 2002, 13, 617-623.	1.2	18
47	Adherence to statin therapy: why aren't we doing better?. American Journal of Medicine, 2002, 113, 685-686.	0.6	14
48	Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. Journal of the American College of Cardiology, 2002, 40, 1777-1785.	1.2	112
51	A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke. Drug Safety, 2002, 25, 943-963.	1.4	8
52	Who Should Receive HMG CoA Reductase Inhibitors?. Drugs, 2002, 62, 1707-1715.	4.9	15
53	Cardiovascular risk assessment using ultrasound: the value of arterial wall changes including the presence, severity and character of plaques. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 367-370.	0.5	21
54	Simvastatin reduces cardiovascular risk. Inpharma Weekly, 2002, &NA;, 12.	0.0	0
55	Health-Related Quality of Life and Long-Term Therapy with Pravastatin and Tocopherol (Vitamin E) in Older Adults. Drugs and Aging, 2002, 19, 793-805.	1.3	33
56	Management of chronic critical limb ischemia. Cardiology Clinics, 2002, 20, 535-545.	0.9	13
57	Controversy surrounding the safety of cerivastatin. Expert Opinion on Drug Safety, 2002, 1, 207-212.	1.0	52
58	MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, The, 2002, 360, 23-33.	6.3	1,413

#	ARTICLE	IF	CITATIONS
59	Prevention of coronary heart disease in south Asia. Lancet, The, 2002, 360, 1015-1018.	6.3	105
60	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, The, 2002, 360, 1623-1630.	6.3	3,147
61	High-risk elderly patients PROSPER from cholesterol-lowering therapy. Lancet, The, 2002, 360, 1618-1619.	6.3	35
62	MRC/BHF Heart Protection Study. Lancet, The, 2002, 360, 1780.	6.3	4
63	MRC/BHF Heart Protection Study. Lancet, The, 2002, 360, 1780-1781.	6.3	4
64	MRC/BHF Heart Protection Study. Lancet, The, 2002, 360, 1781.	6.3	4
65	MRC/BHF Heart Protection Study. Lancet, The, 2002, 360, 1781.	6.3	5
66	MRC/BHF Heart Protection Study. Lancet, The, 2002, 360, 1783-1784.	6.3	11
67	HDL in risk prediction and its direct and indirect involvement in atherogenesis. Atherosclerosis Supplements, 2002, 3, 3-12.	1.2	19
68	Long-term pravastatin treatment has sustained benefits for people with coronary heart disease. Evidence-based Cardiovascular Medicine, 2002, 6, 146-147.	0.0	0
69	Introduction. American Heart Journal, 2002, 144, S19-S20.	1.2	0
70	Is atherosclerotic vascular disease related to a high-fat diet?. Journal of Clinical Epidemiology, 2002, 55, 1064-1072.	2.4	7
71	Pharmacologic therapy for peripheral arterial disease and claudication. Journal of Vascular Surgery, 2002, 36, 1283-1291.	0.6	73
72	Statin Lipid-Lowering Therapy for Acute Myocardial Infarction and Unstable Angina: Efficacy and Mechanism of Benefit. Mayo Clinic Proceedings, 2002, 77, 1085-1092.	1.4	43
73	The Heart Protection Study: implications for clinical practice. Medical Journal of Australia, 2002, 177, 407-408.	0.8	12
74	Low-Density Lipoprotein Lowering and Atherosclerosis Progression. Circulation, 2002, 106, 2039-2040.	1.6	21
75	Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive. Hypertension, 2002, 40, 781-788.	1.3	95
76	Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 821-826.	0.2	15

#	ARTICLE	IF	CITATIONS
77	The Current View on Hypercholesterolemia after the "Heart Protection Study" Do We Need New Strategies?. <i>Cardiology</i> , 2002, 2, 201-203.	0.3	0
79	What's new in Ischaemic heart disease and MI. <i>Medicine</i> , 2002, 30, 1-4.	0.2	0
80	Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year later. <i>American Journal of Cardiology</i> , 2002, 90, 524-525.	0.7	2
81	Getting more people on statins. <i>American Journal of Cardiology</i> , 2002, 90, 683-685.	0.7	15
82	Approach to lipoprotein management in 2001 National Cholesterol Guidelines. <i>American Journal of Cardiology</i> , 2002, 90, 11-21.	0.7	267
83	Lipoprotein abnormalities related to women's health. <i>American Journal of Cardiology</i> , 2002, 90, 77-84.	0.7	80
84	Usefulness of lipid-lowering therapy in elderly patients. <i>American Journal of Cardiology</i> , 2002, 90, 870-871.	0.7	1
85	Alternative approaches to cholesterol-lowering therapy. <i>American Journal of Cardiology</i> , 2002, 90, 1135-1138.	0.7	13
86	Justifying lipid-lowering therapy in persons ≥65 years of age. <i>American Journal of Cardiology</i> , 2002, 90, 1330-1332.	0.7	6
87	Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. <i>American Journal of Cardiology</i> , 2002, 90, 8-20.	0.7	49
88	Use of combination therapy for dyslipidemia: a lipid clinic approach. <i>American Journal of Cardiology</i> , 2002, 90, 44-49.	0.7	10
89	Combination therapy for dyslipidemia: safety and regulatory considerations. <i>American Journal of Cardiology</i> , 2002, 90, 50-60.	0.7	97
90	Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , 2002, 90, 30-43.	0.7	136
91	Antisense inhibitor provides new treatment approach for hypercholesterolaemia. <i>Drug Discovery Today</i> , 2002, 7, 840-841.	3.2	1
92	Atherosclerotic risk factors in patients with ischemic cerebrovascular disease. <i>Current Treatment Options in Neurology</i> , 2002, 4, 445-453.	0.7	10
95	Statins: the new aspirin?. <i>Cellular and Molecular Life Sciences</i> , 2002, 59, 1771-1786.	2.4	86
96	Secular trends in cardiovascular disease. <i>Journal of Human Hypertension</i> , 2002, 16, 663-666.	1.0	11
97	Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. <i>Journal of Human Hypertension</i> , 2002, 16, 815-817.	1.0	14

#	ARTICLE	IF	CITATIONS
98	Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. <i>Nature Medicine</i> , 2002, 8, 1211-1217.	15.2	623
100	Literature review and commentary. <i>International Urology and Nephrology</i> , 2002, 34, 425-436.	0.6	0
101	Clinical findings, outcome and treatment in patients \hat{A} 75 years with acute myocardial infarction. <i>European Journal of Epidemiology</i> , 2002, 18, 781-786.	2.5	9
102	Choices for treatment of hyperlipidaemia. <i>Journal of Inherited Metabolic Disease</i> , 2003, 26, 289-298.	1.7	0
103	Lipoprotein disorders and cardiovascular risk. <i>Journal of Inherited Metabolic Disease</i> , 2003, 26, 267-287.	1.7	61
104	Mechanical Factors in the Production of Atheromatous Disease with a Critique on Antilipid Therapy. <i>Cardiovascular Engineering (Dordrecht, Netherlands)</i> , 2003, 3, 39-42.	1.0	1
105	The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 265-285.	1.3	75
106	Impact of statins on novel risk markers. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 361-366.	1.3	2
107	A Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering Drugs. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 459-465.	1.3	106
108	The prevention of secondary stroke, cardiac outcomes and cognitive decline in patients with cerebrovascular disease: The PROGRESS trial*. <i>Seminars in Cerebrovascular Diseases and Stroke</i> , 2003, 3, 171-180.	0.1	0
109	The fast assessment of stroke and transient ischemic attack to prevent early recurrence (FASTER) trial. <i>Seminars in Cerebrovascular Diseases and Stroke</i> , 2003, 3, 25-30.	0.1	21
110	Stable patients with atherosclerotic renal artery stenosis should be treated first with medical management. <i>American Journal of Kidney Diseases</i> , 2003, 42, 851-857.	2.1	33
111	Therapy to reduce risk of coronary heart disease. <i>Clinical Cardiology</i> , 2003, 26, 2-8.	0.7	17
112	Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. <i>Clinical Cardiology</i> , 2003, 26, 509-514.	0.7	14
113	Comparing HMG-CoA reductase inhibitors. <i>Clinical Cardiology</i> , 2003, 26, 15-20.	0.7	18
114	Treating hypercholesterolemia: Looking forward. <i>Clinical Cardiology</i> , 2003, 26, 21-28.	0.7	27
115	Reaching goal: Conquering the treatment gaps in dyslipidemia management. <i>Clinical Cardiology</i> , 2003, 26, 1-2.	0.7	3
116	Risks and benefits of continued aggressive statin therapy. <i>Clinical Cardiology</i> , 2003, 26, 3-12.	0.7	27

#	ARTICLE	IF	CITATIONS
117	Benefits of statin therapy in patients with special risks: Coronary bypass surgery, stable coronary disease, and acute coronary syndromes. <i>Clinical Cardiology</i> , 2003, 26, 13-18.	0.7	10
118	New features of the national cholesterol education program adult treatment panel III lipid-lowering guidelines. <i>Clinical Cardiology</i> , 2003, 26, 19-24.	0.7	29
119	The power of statins: Aggressive lipid lowering. <i>Clinical Cardiology</i> , 2003, 26, 25-31.	0.7	89
120	A matter of heart: the general practitioner consultation in an evidence-based world. <i>Scandinavian Journal of Primary Health Care</i> , 2003, 21, 3-9.	0.6	8
121	Diabetic dyslipidaemia: from basic research to clinical practice*. <i>Diabetologia</i> , 2003, 46, 733-749.	2.9	717
123	Aortic source of brain embolism. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 211-219.	0.4	9
124	Use of statins for secondary prevention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 63-73.	0.4	2
125	Infrarenal abdominal aortic aneurysms. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 137-146.	0.4	9
126	Atherosclerotic carotid artery occlusion. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 501-509.	0.4	20
127	Atherosclerotic carotid artery occlusion. <i>Current Treatment Options in Neurology</i> , 2003, 5, 381-389.	0.7	0
128	Implications of the heart protection study for reducing coronary events in high-risk patients. <i>Current Atherosclerosis Reports</i> , 2003, 5, 358-363.	2.0	0
129	Isoprenoid metabolism and the pleiotropic effects of statins. <i>Current Atherosclerosis Reports</i> , 2003, 5, 372-378.	2.0	84
130	Evidence-based management of dyslipidemias in women. <i>Current Atherosclerosis Reports</i> , 2003, 5, 379-385.	2.0	4
131	In-hospital initiation of statin therapy in patients with acute coronary events. <i>Current Atherosclerosis Reports</i> , 2003, 5, 394-402.	2.0	2
132	Toxicity of antilipidemic agents: Facts and fictions. <i>Current Atherosclerosis Reports</i> , 2003, 5, 403-410.	2.0	1
133	Clinical trials in stroke in 2002. <i>Current Atherosclerosis Reports</i> , 2003, 5, 239-240.	2.0	0
134	Management of dyslipidemia: An update. <i>Current Atherosclerosis Reports</i> , 2003, 5, 284-290.	2.0	1
135	Efficacy of over-the-counter nutritional supplements. <i>Current Atherosclerosis Reports</i> , 2003, 5, 15-21.	2.0	11

#	ARTICLE	IF	CITATIONS
136	Vascular pleiotropy of statins: Clinical evidence and biochemical mechanisms. <i>Current Atherosclerosis Reports</i> , 2003, 5, 33-37.	2.0	16
137	Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?. <i>Current Atherosclerosis Reports</i> , 2003, 5, 38-43.	2.0	9
138	Cardiovascular risk in diabetic women. <i>Current Atherosclerosis Reports</i> , 2003, 5, 79-81.	2.0	2
139	Clinical trials report. <i>Current Atherosclerosis Reports</i> , 2003, 5, 93-95.	2.0	7
140	Statins and myotoxicity. <i>Current Atherosclerosis Reports</i> , 2003, 5, 96-100.	2.0	27
141	Newer pharmaceutical agents to treat lipid disorders. <i>Current Cardiology Reports</i> , 2003, 5, 463-469.	1.3	2
142	Prediabetes mellitus and its links to atherosclerosis. <i>Current Diabetes Reports</i> , 2003, 3, 11-18.	1.7	14
143	Lipid abnormalities in the metabolic syndrome. <i>Current Diabetes Reports</i> , 2003, 3, 65-72.	1.7	19
144	Heart disease in diabetic patients. <i>Current Diabetes Reports</i> , 2003, 3, 223-229.	1.7	71
145	Reducing CVD risk in type 2 DM. <i>Current Diabetes Reports</i> , 2003, 3, 363-364.	1.7	0
146	Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 21-26.	2.0	8
152	A phytosterol-enriched spread improves the lipid profile of subjects with type 2 diabetes mellitus. <i>European Journal of Nutrition</i> , 2003, 42, 111-117.	1.8	57
153	Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects. <i>Clinical and Experimental Medicine</i> , 2003, 3, 45-53.	1.9	23
154	Pharmacological treatment of diabetic patients with respect to prevention of macrovascular disease. <i>Acta Diabetologica</i> , 2003, 40, s338-s342.	1.2	0
155	Interventions in diabetic patients after myocardial infarction. <i>Acta Diabetologica</i> , 2003, 40, s348-s353.	1.2	1
156	Managing the spectrum of dyslipidemia in primary care. <i>Journal of Vascular Nursing</i> , 2003, 21, 81-89.	0.2	4
157	Long-term prognosis after lacunar infarction. <i>Lancet Neurology</i> , The, 2003, 2, 238-245.	4.9	207
158	How many claudicants should be prescribed statins?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2003, 26, 110.	0.8	1

#	ARTICLE	IF	CITATIONS
159	The abdominal compartment syndrome following aortic surgery. <i>European Journal of Vascular and Endovascular Surgery</i> , 2003, 26, 110.	0.8	0
160	Cardiovascular complications of diabetes: Prevention and management. <i>Clinical Cornerstone</i> , 2003, 5, 22-37.	1.0	6
161	Reducing major vascular events among VA primary care patients: An extraordinary opportunity. <i>Clinical Cornerstone</i> , 2003, 5, S2-S10.	1.0	0
162	Lessons learned from recent lipid-lowering trials: Why physicians should change clinical practice. <i>Clinical Cornerstone</i> , 2003, 5, S11-S17.	1.0	1
164	Smoking and endothelial function. <i>Progress in Cardiovascular Diseases</i> , 2003, 45, 443-458.	1.6	135
165	Statin rebound effect?. <i>Translational Research</i> , 2003, 141, 235-236.	2.4	4
166	Improving outcomes for women after coronary artery bypass grafting: A case for prevention. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 1704-1706.	0.4	2
167	Coronary heart disease: the female heart is vulnerable. <i>Progress in Cardiovascular Diseases</i> , 2003, 46, 199-229.	1.6	115
168	Update on the National Cholesterol Education Program Adult Treatment Panel III Guidelines: Getting to Goal. <i>Pharmacotherapy</i> , 2003, 23, 26S-33S.	1.2	22
169	Role of the Pharmacist in Establishing Lipid Intervention Programs. <i>Pharmacotherapy</i> , 2003, 23, 41S-47S.	1.2	8
170	The Importance of In-Hospital Statin Therapy for Patients with Acute Coronary Syndromes. <i>Pharmacotherapy</i> , 2003, 23, 506-513.	1.2	14
171	The Role of Lipid-Lowering Drugs in Cognitive Function: A Meta-Analysis of Observational Studies. <i>Pharmacotherapy</i> , 2003, 23, 726-730.	1.2	61
172	Statin-Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature. <i>Pharmacotherapy</i> , 2003, 23, 871-880.	1.2	308
173	Are National Cardiac Guidelines being Applied by Vascular Surgeons?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2003, 26, 623-628.	0.8	26
174	Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. <i>American Journal of Cardiology</i> , 2003, 92, 1106-1108.	0.7	78
175	Effectiveness of lipid-lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs System**The views expressed in this work do not necessarily represent the views of the Department of Veterans Affairs.. <i>American Journal of Cardiology</i> , 2003, 92, 1177-1182.	0.7	12
176	Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection. <i>American Journal of Cardiology</i> , 2003, 92, 1224-1227.	0.7	19
177	Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. <i>American Journal of Cardiology</i> , 2003, 92, 1414-1418.	0.7	125

#	ARTICLE	IF	CITATIONS
178	A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. American Journal of Cardiology, 2003, 92, 1447-1451.	0.7	60
182	Comparison of effectiveness of statin monotherapy versus statin and niacin combination therapy in primary prevention and effects on calcified plaque burden. American Journal of Cardiology, 2003, 91, 348-351.	0.7	9
183	Mechanisms of plaque stabilization with statins. American Journal of Cardiology, 2003, 91, 4-8.	0.7	188
184	Effects of statins on inflammation in patients with acute and chronic coronary syndromes. American Journal of Cardiology, 2003, 91, 9-13.	0.7	56
185	Effects of statins on the vasculature. American Journal of Cardiology, 2003, 91, 14-22.	0.7	69
186	Prevention of stroke and dementia with statins. American Journal of Cardiology, 2003, 91, 23-29.	0.7	119
187	Treatment for patients with the metabolic syndrome. American Journal of Cardiology, 2003, 91, 29-39.	0.7	81
188	Introduction: rosuvastatin— an efficacy assessment based on pooled trial data. American Journal of Cardiology, 2003, 91, 1-2.	0.7	5
189	Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. American Journal of Cardiology, 2003, 91, 3-10.	0.7	128
190	Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. American Journal of Cardiology, 2003, 91, 11-17.	0.7	82
191	Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50637 Td (0.7	50637
192	Impact of minor electrocardiographic ST-segment and/or T-wave abnormalities on cardiovascular mortality during long-term follow-up. American Journal of Cardiology, 2003, 91, 1068-1074.	0.7	123
193	Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. American Journal of Cardiology, 2003, 91, 1134-1136.	0.7	6
194	Prognostic value of endothelial function. American Journal of Cardiology, 2003, 91, 19-24.	0.7	160
195	The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. American Journal of Cardiology, 2003, 92, 3-9.	0.7	28
196	Regulation of reverse cholesterol transport and clinical implications. American Journal of Cardiology, 2003, 92, 42-49.	0.7	168
197	Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. American Journal of Cardiology, 2003, 92, 270-274.	0.7	19
198	Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50637 Td (0.7	50637

#	ARTICLE	IF	CITATIONS
199	Relation of aggressiveness of lipid-lowering treatment to changes in calcified plaque burden by electron beam tomography. American Journal of Cardiology, 2003, 92, 334-336.	0.7	31
201	Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the heart protection study on standards of efficacy and safety. American Journal of Cardiology, 2003, 92, 3-9.	0.7	105
202	Clinical significance of High-Density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. American Journal of Cardiology, 2003, 92, 10-16.	0.7	215
203	benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. American Journal of Cardiology, 2003, 92, 23-29.	0.7	180
204	Statins and safety: applying the results of randomized trials to clinical practice. American Journal of Cardiology, 2003, 92, 692-695.	0.7	12
205	Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. American Journal of Cardiology, 2003, 92, 711-712.	0.7	178
206	Current options in the management of coronary artery disease. American Journal of Cardiology, 2003, 92, 4-8.	0.7	17
207	The multiple negative randomized controlled trials in perinatology—why?. Seminars in Perinatology, 2003, 27, 343-350.	1.1	11
208	Are all monitoring boundaries equally ethical?. Contemporary Clinical Trials, 2003, 24, 585-588.	2.0	7
209	A matter of life and death? The Heart Protection Study and protection of clinical trial participants. Contemporary Clinical Trials, 2003, 24, 501-505.	2.0	6
210	The lipid and non-lipid effects of statins. , 2003, 99, 95-112.		217
211	Translating tomographic plaque imaging into treatment: interventional lipidology. Progress in Cardiovascular Diseases, 2003, 46, 149-170.	1.6	2
212	Statin therapy for the treatment of diabetic dyslipidemia. Diabetes/Metabolism Research and Reviews, 2003, 19, 280-287.	1.7	14
213	Effects of Atorvastatin on LDL sub-fractions and peroxidation in type 1 diabetic patients: a randomised double-blind placebo-controlled study. Diabetes/Metabolism Research and Reviews, 2003, 19, 478-486.	1.7	10
214	Influence of diabetes mellitus on heart failure risk and outcome. Cardiovascular Diabetology, 2003, 2, 1.	2.7	163
215	Coronary artery disease - more disease, more patients, better treatment. Journal of Clinical Pharmacy and Therapeutics, 2003, 28, 1-4.	0.7	3
216	Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. Journal of Internal Medicine, 2003, 254, 67-75.	2.7	118
217	Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes*. Journal of Internal Medicine, 2003, 254, 45-66.	2.7	192

#	ARTICLE	IF	CITATIONS
218	Genotype, obesity and cardiovascular disease - has technical and social advancement outstripped evolution?. <i>Journal of Internal Medicine</i> , 2003, 254, 114-125.	2.7	67
219	Cholesterol Lowering for the Prevention of Stroke. <i>Practical Neurology</i> , 2003, 3, 224-233.	0.5	3
220	Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. <i>Kidney International</i> , 2003, 64, 565-571.	2.6	42
221	Calcium on trial: Beyond a reasonable doubt?. <i>Kidney International</i> , 2003, 63, 382-383.	2.6	6
222	Why do we need a statin trial in hemodialysis patients?. <i>Kidney International</i> , 2003, 63, S204-S206.	2.6	43
223	Study of Heart and Renal Protection (SHARP). <i>Kidney International</i> , 2003, 63, S207-S210.	2.6	268
224	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Applying Multiple Interventions in Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2003, 16, 157-164.	0.7	16
225	Editorials: Are HMG-CoA Reductase Inhibitors Underutilized in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2003, 16, 179-185.	0.7	13
226	Lipid Apheresis: The Only Therapeutic Option for a Very Small Group of Cardiovascular Patients with High Low-density Lipoprotein Cholesterol or Lipoprotein(a) Blood Concentrations. <i>Therapeutic Apheresis and Dialysis</i> , 2003, 7, 283-284.	0.4	1
227	Guidelines for Improving the Care of the Older Person with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 265-280.	1.3	625
228	Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1753-1757.	1.9	22
229	Use of Nonantiarrhythmic Drugs for Prevention of Sudden Cardiac Death. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S87-S95.	0.8	61
235	Recent trends in lipid management: raising the bar and shifting the goalposts?. <i>Internal Medicine Journal</i> , 2003, 33, 95-102.	0.5	0
236	Stroke prevention: what's new?. <i>Internal Medicine Journal</i> , 2003, 33, 177-181.	0.5	2
237	Management of lipids in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, s3-s9.	2.2	4
238	Facilitating best practice - cardiovascular risk management for patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, s29-s34.	2.2	1
239	Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, s19-s27.	2.2	162
240	Diabetes and cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, s11-s18.	2.2	14

#	ARTICLE	IF	CITATIONS
241	Decreasing levels of tumour necrosis factor $\hat{\pm}$ and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, 195-201.	2.2	47
242	Metabolic syndrome - a new risk factor of coronary heart disease?. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, 359-370.	2.2	29
243	Prediction of cardiovascular risk in people with diabetes. <i>Diabetic Medicine</i> , 2003, 20, 515-527.	1.2	29
244	Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 604-608.	1.1	87
245	Does sticky blood predict a sticky end? Associations of blood viscosity, haematocrit and fibrinogen with mortality in the West of Scotland. <i>British Journal of Haematology</i> , 2003, 122, 645-650.	1.2	38
246	No acute impact of lipid apheresis treatment on free radical scavenging enzyme gene expression in white blood cells. <i>European Journal of Clinical Investigation</i> , 2003, 33, 134-140.	1.7	3
249	Hypertension in diabetes: what's new, what's true, what's next?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 247-254.	0.2	3
250	The impact of increased statin prescribing. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 312a-312a.	0.2	0
251	Meeting the challenges of self-management. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 312a-312a.	0.2	0
252	Increased statin prescribing in patients with diabetes after the introduction of the NSF for Coronary Heart Disease. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 313-317.	0.2	2
253	Development and validation of the hyperlipidemia. <i>Journal of General Internal Medicine</i> , 2003, 18, 984-990.	1.3	10
254	Efficacy and Safety of a New Whole-blood Low-density Lipoprotein Apheresis System (Liposorber D) in Severe Hypercholesterolemia. <i>Artificial Organs</i> , 2003, 27, 1116-1122.	1.0	53
255	Treatment Options for Patients With the Metabolic Syndrome. <i>Journal of the American Academy of Nurse Practitioners</i> , 2003, 15, 361-370.	1.4	8
256	Inflammation and cardiovascular disease: is abdominal obesity the missing link?. <i>International Journal of Obesity</i> , 2003, 27, S22-S24.	1.6	56
257	Statins â€“ the heart of the matter. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 343-344.	21.5	8
258	Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 517-526.	21.5	703
259	Clinical biomarkers in drug discovery and development. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 566-580.	21.5	686
260	Rosuvastatin calcium. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 769-770.	21.5	60

#	ARTICLE	IF	CITATIONS
261	Mechanisms, challenges and opportunities in stroke. <i>Nature Reviews Neuroscience</i> , 2003, 4, 399-414.	4.9	1,584
262	Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. <i>Clinical Biochemistry</i> , 2003, 36, 499-504.	0.8	100
263	Wound Care Principles: Heal It or Lose It. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, P30.	0.2	0
264	Lipid Management: Case by Case. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, P29-P30.	0.2	0
265	Tratamiento farmacológico del riesgo cardiovascular metabólico. <i>Medicine</i> , 2003, 8, 6382-6395.	0.0	0
267	Inhibición de la absorción intestinal del colesterol: nueva diana terapéutica en la reducción de la colesterolemia. <i>Clínica E Investigación En Arteriosclerosis</i> , 2003, 15, 261-275.	0.4	4
268	Achievement of low-density lipoprotein cholesterol goals: new strategies to address new guidelines. <i>Cardiology Clinics</i> , 2003, 21, 363-375.	0.9	6
270	Treating Type 2 Diabetes Mellitus: A Growing Epidemic. <i>Mayo Clinic Proceedings</i> , 2003, 78, 411-413.	1.4	16
271	Factores de riesgo cardiovascular en el paciente de edad avanzada. <i>Medicine</i> , 2003, 8, 5819-5825.	0.0	0
273	Putting prevention into daily practice. <i>Cardiology Clinics</i> , 2003, 21, 471-482.	0.9	3
275	Guía del manejo de las dislipemias en los pacientes infectados por el VIH: recomendaciones farmacológicas. <i>Clínica E Investigación En Arteriosclerosis</i> , 2003, 15, 29-34.	0.4	0
276	Cardiovascular risk in women with type 2 diabetes. <i>Medical Clinics of North America</i> , 2003, 87, 955-969.	1.1	11
277	Day Medicine: An Urgent Internal Medicine Clinic and Medical Procedures Suite. <i>Healthcare Management Forum</i> , 2003, 16, 17-23.	0.6	1
278	Angiogenesis y estatinas, ¿a mayor dosis, mayor beneficio?. <i>Revista Espanola De Cardiología</i> , 2003, 56, 631.	0.6	0
280	Statin-fibrate combination therapy for hyperlipidaemia: a review. <i>Current Medical Research and Opinion</i> , 2003, 19, 155-168.	0.9	156
281	High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. <i>Atherosclerosis</i> , 2003, 168, 195-211.	0.4	194
282	In the statin era, how important are intense lifestyle changes?. <i>Journal of the American College of Cardiology</i> , 2003, 41, 273-274.	1.2	6
283	ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article. <i>Journal of the American College of Cardiology</i> , 2003, 41, 159-168.	1.2	920

#	ARTICLE	IF	CITATIONS
284	Insulin resistance and compensatory hyperinsulinemia. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1044-1047.	1.2	110
285	Antioxidants, statins, and atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1205-1210.	1.2	71
286	Atherothrombosis, inflammation, and diabetes. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1071-1077.	1.2	236
287	Clinical decision making on statin drug interactions. <i>Journal of the American College of Cardiology</i> , 2003, 42, 396-397.	1.2	1
289	Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2003, 42, 398-399.	1.2	7
292	Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2003, 348, 383-393.	13.9	3,894
293	Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. <i>Current Medical Research and Opinion</i> , 2003, 19, 689-698.	0.9	141
294	European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S78.	3.1	52
295	Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class. <i>Drug Safety</i> , 2003, 26, 13-21.	1.4	48
296	Benefits and Risks of Simvastatin in Patients with Familial Hypercholesterolaemia. <i>Drug Safety</i> , 2003, 26, 769-786.	1.4	5
297	The Pleiotropic Effects of HMG-CoA Reductase Inhibitors. <i>Drugs</i> , 2003, 63, 139-152.	4.9	47
298	Pharmacological Treatment of Patients with Peripheral Arterial Disease. <i>Drugs</i> , 2003, 63, 637-647.	4.9	10
299	Current Management Strategies for Coexisting Diabetes Mellitus and Obesity. <i>Drugs</i> , 2003, 63, 1165-1184.	4.9	76
300	Low High-Density Lipoprotein Cholesterol. <i>Drugs</i> , 2003, 63, 1907-1945.	4.9	59
301	Metabolic Complications Associated with HIV Protease Inhibitor Therapy. <i>Drugs</i> , 2003, 63, 2555-2574.	4.9	85
302	Comparison of the Effects of Policosanol and Atorvastatin on Lipid Profile and Platelet Aggregation in Patients with Dyslipidaemia and Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2003, 23, 639-650.	1.1	29
303	Effects of D-003 on the Lipid Profile of Patients with Type II Hypercholesterolaemia. <i>Clinical Drug Investigation</i> , 2003, 23, 789-802.	1.1	12
304	Near patient cholesterol testing in patients with peripheral arterial disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2003, 26, 267-271.	0.8	3

#	ARTICLE	IF	CITATIONS
305	Pharmacological prevention of cardiac risk in claudicants with ischaemic heart disease. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2003, 1, 296-298.	0.8	2
306	Insulin resistance and endothelial dysfunction. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2003, 17, 411-430.	2.2	58
307	Routine β -blockade in vascular surgery. <i>Vascular</i> , 2003, 11, 459-463.	0.5	5
308	"Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease?*. <i>International Journal of Epidemiology</i> , 2003, 32, 1-22.	0.9	4,018
309	The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 465-480.	0.2	129
310	Tackling ischaemic heart disease in rheumatoid arthritis. <i>British Journal of Rheumatology</i> , 2003, 42, 607-613.	2.5	143
311	Agents that stabilise atherosclerotic plaque. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1681-1692.	1.9	2
312	Recommendations for special populations: diabetes mellitus and the metabolic syndrome. <i>American Journal of Hypertension</i> , 2003, 16, 41-45.	1.0	83
313	Role of lipid and lipoprotein profiles in risk assessment and therapy. <i>American Heart Journal</i> , 2003, 146, 227-233.	1.2	56
315	Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. <i>American Heart Journal</i> , 2003, 146, 1052-1059.	1.2	35
316	Evidence-based care for all patients. <i>American Journal of Medicine</i> , 2003, 114, 333-335.	0.6	6
317	Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor. <i>American Journal of Medicine</i> , 2003, 115, 122-128.	0.6	7
318	LIFE and ARBITER. <i>Preventive Cardiology</i> , 2003, 6, 108-111.	1.1	0
319	JNC 7: a Moving Guideline Responds to a Moving Target. <i>Preventive Cardiology</i> , 2003, 6, 177-178.	1.1	3
320	Bridging the Treatment Gap: Improving Compliance With Lipid-Modifying Agents and Therapeutic Lifestyle Changes. <i>Preventive Cardiology</i> , 2003, 6, 204-213.	1.1	19
321	Characteristics and Lipid Distribution of a Large, High-Risk, Hypertensive Population: The Lipid-Lowering Component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Journal of Clinical Hypertension</i> , 2003, 5, 377-384.	1.0	13
322	Statin-Associated Myopathy. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 1681.	3.8	1,227
323	Lipid-Lowering Drug Use and Breast Cancer in Older Women: A Prospective Study. <i>Journal of Women's Health</i> , 2003, 12, 749-756.	1.5	135

#	ARTICLE	IF	CITATIONS
324	Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia. <i>Circulation</i> , 2003, 107, 2409-2415.	1.6	627
325	Diabetes and Vascular Disease. <i>Circulation</i> , 2003, 108, 1655-1661.	1.6	397
326	New Insights on Oxidative Stress and Diabetic Complications May Lead to a "Causal" Antioxidant Therapy. <i>Diabetes Care</i> , 2003, 26, 1589-1596.	4.3	644
328	Managing the high-risk patient: therapeutic approaches in 2002. <i>Atherosclerosis Supplements</i> , 2003, 4, 15-20.	1.2	3
329	Old and new cardiovascular risk factors: from unresolved issues to new opportunities. <i>Atherosclerosis Supplements</i> , 2003, 4, 5-17.	1.2	31
330	Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes?. <i>Atherosclerosis Supplements</i> , 2003, 4, 11-16.	1.2	10
331	Human requirements for fat-soluble vitamins, and other things concerning these nutrients. <i>Molecular Aspects of Medicine</i> , 2003, 24, 317-324.	2.7	10
332	The PROSPER trial. <i>Lancet, The</i> , 2003, 361, 427-428.	6.3	2
333	The PROSPER trial. <i>Lancet, The</i> , 2003, 361, 428.	6.3	3
334	Heart Protection Study. <i>Lancet, The</i> , 2003, 361, 528.	6.3	3
335	Heart Protection Study. <i>Lancet, The</i> , 2003, 361, 528.	6.3	3
336	Heart Protection Study. <i>Lancet, The</i> , 2003, 361, 528-529.	6.3	2
337	Heart Protection Study. <i>Lancet, The</i> , 2003, 361, 529-530.	6.3	412
338	Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. <i>Lancet, The</i> , 2003, 361, 717-725.	6.3	499
339	Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. <i>Lancet, The</i> , 2003, 361, 777-780.	6.3	429
340	More on PROSPER. <i>Lancet, The</i> , 2003, 361, 1135-1136.	6.3	10
341	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2003, 361, 1149-1158.	6.3	3,420
342	What are the odds at ASCOT today?. <i>Lancet, The</i> , 2003, 361, 1144-1145.	6.3	16

#	ARTICLE	IF	CITATIONS
343	Alzheimer's disease and angiogenesis. <i>Lancet, The</i> , 2003, 361, 1300.	6.3	1
344	Lipoproteins and cardiovascular risk. <i>Lancet, The</i> , 2003, 361, 1988.	6.3	0
345	Selection bias introduced by the informed consent process. <i>Lancet, The</i> , 2003, 361, 1990.	6.3	10
346	Age and the treatment gap in the use of statins. <i>Lancet, The</i> , 2003, 361, 1925-1926.	6.3	8
347	Appealing to editors?. <i>Lancet, The</i> , 2003, 361, 1926.	6.3	4
348	MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2003, 361, 2005-2016.	6.3	2,587
349	Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2003, 361, 2024-2031.	6.3	861
350	Statins in coronary bypass surgery: rationale and clinical use. <i>Annals of Thoracic Surgery</i> , 2003, 76, 2132-2140.	0.7	38
351	Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 19-23.	1.5	65
352	Ischemic heart disease in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 6-12.	1.5	15
353	The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1478-1483.	1.5	127
354	Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1279-1286.	1.5	29
355	Antiatherothrombotic effects of nicotinic acid. <i>Atherosclerosis</i> , 2003, 171, 87-96.	0.4	78
356	Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis. <i>Atherosclerosis</i> , 2003, 171, 109-116.	0.4	17
357	Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid- β (A β) ⁴⁰ or A β ⁴² in humans. <i>Neuroscience Letters</i> , 2003, 350, 161-164.	1.0	46
359	Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia. <i>Diabetes Research and Clinical Practice</i> , 2003, 61, S27-S34.	1.1	20
360	LDL-cholesterol, HDL-cholesterol or triglyceridesâ€”which is the culprit?. <i>Diabetes Research and Clinical Practice</i> , 2003, 61, S19-S26.	1.1	46
361	Managing diabetes: what to do about cardiovascular disease. <i>Diabetes Research and Clinical Practice</i> , 2003, 61, S3-S8.	1.1	9

#	ARTICLE	IF	CITATIONS
362	Comments on the MRC/BHF Heart Protection Study. <i>Lancet, The</i> , 2003, 362, 744.	6.3	0
363	Dyslipidaemia. <i>Lancet, The</i> , 2003, 362, 717-731.	6.3	314
364	Stroke. <i>Lancet, The</i> , 2003, 362, 1211-1224.	6.3	372
365	An analysis of cholesterol control and statin use in the losartan intervention for endpoint reduction in hypertension study. <i>Clinical Therapeutics</i> , 2003, 25, 1186-1199.	1.1	8
366	Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. <i>Clinical Therapeutics</i> , 2003, 25, 2352-2387.	1.1	73
367	Results of the Heart Protection Study: can we still assume a class effect?. <i>International Congress Series</i> , 2003, 1253, 253-259.	0.2	0
368	From cholesterol levels to risk analysis: the revolution of the Heart Protection Study. <i>International Congress Series</i> , 2003, 1253, 217-222.	0.2	0
369	The role of vitamin E in atherosclerosis. <i>Progress in Lipid Research</i> , 2003, 42, 405-422.	5.3	117
370	Serum cholesterol levels and in-hospital mortality in the elderly. <i>American Journal of Medicine</i> , 2003, 115, 265-271.	0.6	35
371	More on PROSPER. <i>Lancet, The</i> , 2003, 361, 1136.	6.3	4
372	Don't miss this opportunity: Diagnosing diabetes. <i>American Heart Journal</i> , 2003, 145, 195-197.	1.2	6
373	Treating dyslipidemia with statins: The risk-benefit profile. <i>American Heart Journal</i> , 2003, 145, 387-396.	1.2	61
374	Effects of statins on lipoprotein fractions. <i>International Congress Series</i> , 2003, 1253, 247-252.	0.2	4
375	What's in a risk factor? "He who strikes the ball". <i>Diabetes and Metabolism</i> , 2003, 29, 6-13.	1.4	321
376	Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. <i>Diabetes and Metabolism</i> , 2003, 29, 201-205.	1.4	46
377	Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events?. <i>Diabetes and Metabolism</i> , 2003, 29, 470-476.	1.4	35
378	Cardiovascular disease in patients who have diabetes. <i>Cardiology Clinics</i> , 2003, 21, 399-413.	0.9	29
379	Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>Circulation</i> , 2003, 108, 2292-2297.	1.6	412

#	ARTICLE	IF	CITATIONS
380	Peripheral Arterial Disease in People With Diabetes. <i>Diabetes Care</i> , 2003, 26, 3333-3341.	4.3	928
381	Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. <i>Cerebrovascular Diseases</i> , 2003, 16, 389-395.	0.8	170
382	Ezetimibe: a novel option for lowering cholesterol. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 11-21.	0.6	35
383	Dyslipidemia treatment: current considerations and unmet needs. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 121-134.	0.6	0
384	Treatment of children with familial hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 135-141.	0.6	3
386	Niacin as a Component of Combination Therapy for Dyslipidemia. <i>Mayo Clinic Proceedings</i> , 2003, 78, 735-742.	1.4	66
387	Pravastatin. <i>Drugs and Aging</i> , 2003, 20, 1061-1082.	1.3	8
388	Benefits of Optimising Drug Treatment in Home-Dwelling Elderly Patients with Coronary Artery Disease. <i>Drugs and Aging</i> , 2003, 20, 585-595.	1.3	6
389	Statin Therapy in the Elderly. <i>Drugs and Aging</i> , 2003, 20, 263-275.	1.3	19
390	Pharmacotherapy for dyslipidaemia – current therapies and future agents. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1901-1938.	0.9	154
391	Pathogenesis and Management of Diabetic Dyslipidemia. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2003, 2, 231-245.	1.8	10
392	Cost Effectiveness of Diabetes Mellitus Management Programs. <i>Disease Management and Health Outcomes</i> , 2003, 11, 439-453.	0.3	8
393	Atheroma of the aortic arch: the missing link in the secondary prevention of stroke?. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 487-489.	0.6	5
394	Cardiovascular disease and lipids. <i>European Journal of General Practice</i> , 2003, 9, 16-24.	0.9	5
395	In light of ALLHAT and ASCOT: Are there benefits of statins as add-on treatment in hypertensives?. <i>Blood Pressure</i> , 2003, 12, 132-133.	0.7	0
396	Expanding indications of statins; implications of the Heart Protection Study. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 509-513.	1.9	5
397	Management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2003, 24, 28-66.	1.0	1,188
398	Prescriptions. <i>Pharmaceutical Medicine</i> , 2003, 17, 187-193.	0.4	0

#	ARTICLE	IF	CITATIONS
399	The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 11-18.	1.0	0
400	A Pharmacoeconomic Evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study in the United Kingdom. Pharmacoeconomics, 2003, 21, 25-32.	1.7	19
401	Stable Angina. American Journal of Cardiovascular Drugs, 2003, 3, 1-10.	1.0	7
402	Reduction of Serum LDL-C Levels. American Journal of Cardiovascular Drugs, 2003, 3, 271-281.	1.0	16
403	Preventing Macrovascular Disease in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiovascular Drugs, 2003, 3, 283-297.	1.0	18
404	Implications of the LIFE trial. Expert Opinion on Investigational Drugs, 2003, 12, 871-877.	1.9	6
405	New drugs for the treatment of hypercholesterolaemia. Expert Opinion on Investigational Drugs, 2003, 12, 1777-1789.	1.9	29
406	Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003, 42, 1206-1252.	1.3	11,852
407	Primary prevention of cardiovascular diseases. Scandinavian Journal of Primary Health Care, 2003, 21, 68-74.	0.6	9
408	Early vascular benefits of statin therapy. Current Medical Research and Opinion, 2003, 19, 540-556.	0.9	159
409	Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management. Journal of the American Society of Nephrology: JASN, 2003, 14, 1396-1405.	3.0	102
410	Acetylcysteine and Renal Function Following Coronary Angiographic Procedures. JAMA - Journal of the American Medical Association, 2003, 289, 2794.	3.8	0
411	Major Risk Factors for Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2003, 290, 947.	3.8	97
412	Risk for Myopathy With Statin Therapy in High-Risk Patients. Archives of Internal Medicine, 2003, 163, 553.	4.3	404
413	Review: Lipids and stroke. British Journal of Diabetes and Vascular Disease, 2003, 3, 170-176.	0.6	2
414	Management of stroke. Postgraduate Medical Journal, 2003, 79, 87-92.	0.9	10
415	Commentaries on "Embracing Complexity: A Consideration of Hypertension in the Very Old" and Author's Response: Commentary. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M659-M660.	1.7	12
416	Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. Journal of Lipid Research, 2003, 44, 978-985.	2.0	95

#	ARTICLE	IF	CITATIONS
417	Clinical Trials: Evidence and Unanswered Questions â€“ Hyperlipidaemia. <i>Cerebrovascular Diseases</i> , 2003, 16, 25-32.	0.8	13
418	Simvastatin Initiated Early After Heart Transplantation. <i>Circulation</i> , 2003, 107, 93-97.	1.6	230
419	Potential Nontraditional Applications of Statins. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1063-1071.	0.9	15
420	Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 107, 966-972.	1.6	285
421	Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?. <i>British Heart Journal</i> , 2003, 89, 417-421.	2.2	130
422	Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease. <i>Circulation</i> , 2003, 108, 1481-1486.	1.6	446
423	N-3 Fatty Acids. <i>Circulation</i> , 2003, 107, 1834-1836.	1.6	27
424	Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs Lovastatin on Serum Lipids and C-Reactive Protein. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 502.	3.8	511
425	Clinical Utility of Endothelial Function Testing. <i>Circulation</i> , 2003, 107, 3243-3247.	1.6	139
426	Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. <i>Journal of Lipid Research</i> , 2003, 44, 800-806.	2.0	68
427	The challenges of treating peripheral arterial disease. <i>Vascular Medicine</i> , 2003, 8, 109-114.	0.8	19
428	Dyslipidemia in Patients with Type 2 Diabetes. Relationships between Lipids, Kidney Disease and Cardiovascular Disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 1174-81.	1.4	46
429	Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. <i>Journal of Lipid Research</i> , 2003, 44, 2152-2160.	2.0	22
430	Management of stable angina. <i>Postgraduate Medical Journal</i> , 2003, 79, 332-336.	0.9	6
431	Secondary Prevention of Coronary Heart Disease in the Elderly. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1867-1876.	0.9	29
432	A RATIONAL BASIS FOR SELECTION AMONG DRUGS OF THE SAME CLASS. <i>British Heart Journal</i> , 2003, 89, 687-694.	2.2	9
434	Simvastatin reduced mortality and vascular events. <i>Evidence-Based Medicine</i> , 2003, 8, 10-10.	0.6	1
435	Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. <i>British Heart Journal</i> , 2003, 89, 327-328.	2.2	58

#	ARTICLE	IF	CITATIONS
436	American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25-26 August 2002, Washington, DC. <i>Diabetes Care</i> , 2003, 26, 1297-1303.	4.3	66
437	Should I start all my ischaemic stroke and TIA patients on a statin, an ACE inhibitor, a diuretic, and aspirin today?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1461-1464.	0.9	7
438	Review: Diabetic dyslipidaemia – the case for using statins. <i>British Journal of Diabetes and Vascular Disease</i> , 2003, 3, 402-407.	0.6	0
440	Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. <i>Journal of Public Health</i> , 2003, 25, 47-52.	1.0	35
441	Lowering of LDL Cholesterol Rather Than Moderate Weight Loss Improves Endothelium-Dependent Vasodilatation in Obese Women With Previous Gestational Diabetes. <i>Diabetes Care</i> , 2003, 26, 1667-1672.	4.3	68
442	Rosuvastatin – A Highly Effective New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor: Review of Clinical Trial Data at 10–40 mg Doses in Dyslipidemic Patients. <i>Cardiology</i> , 2003, 99, 126-139.	0.6	44
443	European Stroke Initiative Recommendations for Stroke Management – Update 2003. <i>Cerebrovascular Diseases</i> , 2003, 16, 311-337.	0.8	575
444	Detecting Occult Coronary Disease in a High-Risk Asymptomatic Population. <i>Circulation</i> , 2003, 107, 702-707.	1.6	50
445	Unstable Angina and Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2003, 107, 2640-2645.	1.6	36
446	The current cost of angina pectoris to the National Health Service in the UK. <i>British Heart Journal</i> , 2003, 89, 848-853.	2.2	74
447	Stroke: neuroplasticity and recent approaches to rehabilitation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1465-1465.	0.9	5
448	Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 564-72.	1.4	6
449	New lipid-lowering agents. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 365-376.	1.0	12
451	Vascular viewpoint. <i>Vascular Medicine</i> , 2003, 8, 289-290.	0.8	54
452	Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE). <i>Journal of Biological Chemistry</i> , 2003, 278, 38829-38839.	1.6	332
453	HMG-CoA Reductase Inhibition: Anti-Inflammatory Effects beyond Lipid Lowering?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 169-179.	3.1	34
454	Associations of Diabetes Mellitus and Ethnicity with Mortality in a Multiethnic Asian Population: Data from the 1992 Singapore National Health Survey. <i>American Journal of Epidemiology</i> , 2003, 158, 543-552.	1.6	52
455	Rapid Effects of Statins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 156-157.	1.1	27

#	ARTICLE	IF	CITATIONS
456	Statins in Threatened Stroke. <i>Stroke</i> , 2003, 34, 351-353.	1.0	7
457	Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia. <i>Annals of Pharmacotherapy</i> , 2003, 37, 106-115.	0.9	14
459	Modulation of Coagulation and Fibrinolytic Pathways by Statins. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2003, 10, 35-41.	1.7	33
460	In-Hospital Initiation of Lipid-Lowering Therapy After Coronary Intervention as a Predictor of Long-term Utilization. <i>Archives of Internal Medicine</i> , 2003, 163, 2576.	4.3	73
461	Differential Effects of Lipid-Lowering Therapies on Stroke Prevention. <i>Archives of Internal Medicine</i> , 2003, 163, 669.	4.3	137
462	High Cholesterol and Its Management. <i>Cerebrovascular Diseases</i> , 2003, 15, 31-36.	0.8	0
464	Drug Therapy for Prevention of Recurrent Myocardial Infarction. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1465-1477.	0.9	21
465	Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 581-9.	1.4	55
466	Safety and Statin Therapy. <i>Archives of Internal Medicine</i> , 2003, 163, 657.	4.3	62
468	Clinical Impact of the New Criteria for the Diagnosis of Diabetes Mellitus. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 1239-45.	1.4	11
469	Data-Driven Clinical Care. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 5-6.	0.7	0
470	Clinical diagnosis of subcortical cerebral infarction. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 703-711.	1.4	0
471	Statin Therapy in the Elderly—The Evidence Mounts. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 65-67.	0.7	0
472	Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways. <i>Circulation</i> , 2003, 108, 426-431.	1.6	380
473	High cholesterol may protect against infections and atherosclerosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 927-934.	0.2	96
474	Effects of Rosuvastatin on Nitric Oxide-Dependent Function in Aorta and Corpus Cavernosum of Diabetic Mice: Relationship to Cholesterol Biosynthesis Pathway Inhibition and Lipid Lowering. <i>Diabetes</i> , 2003, 52, 2396-2402.	0.3	76
475	Does Vitamin E Supplementation Prevent Cardiovascular Events?. <i>Journal of Women's Health</i> , 2003, 12, 123-136.	1.5	19
476	Consultations on Patients with Venous or Arterial Diseases. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 540-558.	0.9	4

#	ARTICLE	IF	CITATIONS
477	Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Expert Opinion on Drug Safety, 2003, 2, 269-286.	1.0	15
478	Costs of dyslipidemia. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 273-281.	0.7	1
479	Management of Glomerular Proteinuria: A Commentary. Journal of the American Society of Nephrology: JASN, 2003, 14, 3217-3232.	3.0	194
480	Novel microsomal triglyceride transfer protein inhibitors. Expert Opinion on Therapeutic Patents, 2003, 13, 479-488.	2.4	7
481	The National Diabetes Register in Sweden: An implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care, 2003, 26, 1270-1276.	4.3	199
482	Trends in Lipid Management Among Patients With Coronary Artery Disease: Has diabetes received the attention it deserves?. Diabetes Care, 2003, 26, 991-997.	4.3	50
485	Specialist Nurse-Led Intervention to Treat and Control Hypertension and Hyperlipidemia in Diabetes (SPLINT): A randomized controlled trial. Diabetes Care, 2003, 26, 2250-2255.	4.3	154
486	Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB. Journal of Lipid Research, 2003, 44, 943-952.	2.0	27
487	Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol-Lowering Effect in APOE*3-Leiden Transgenic Mice. Circulation, 2003, 108, 1368-1374.	1.6	157
488	Prevalences of Diabetes and Impaired Glucose Regulation in a Danish Population: The Inter99 study. Diabetes Care, 2003, 26, 2335-2340.	4.3	250
489	Drug induced QT prolongation and torsades de pointes. British Heart Journal, 2003, 89, 1363-1372.	2.2	796
490	Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint. The American Journal of Geriatric Cardiology, 2003, 12, 357-360.	0.7	9
491	Are Statins Indicated for the Primary Prevention of Coronary Heart Disease in Octogenarians? Protagonist Viewpoint. The American Journal of Geriatric Cardiology, 2003, 12, 351-354.	0.7	1
492	International variation in the use of evidence-based medicines for acute coronary syndromes. European Heart Journal, 2003, 24, 2133-2141.	1.0	35
493	Lipid Management in Patients With Diabetes: Translating guidelines into action. Diabetes Care, 2003, 26, 1309-1311.	4.3	12
494	The Need to Improve. Diabetes Care, 2003, 26, 1633-1634.	4.3	0
495	Cost Effectiveness of Statin Therapy for the Primary Prevention of Major Coronary Events in Individuals With Type 2 Diabetes. Diabetes Care, 2003, 26, 1796-1801.	4.3	42
496	Incidence, Risk Factors and Prognosis of Stroke and TIA: The Need for High-Quality, Large-Scale Epidemiological Studies and Meta-Analyses. Cerebrovascular Diseases, 2003, 16, 2-10.	0.8	50

#	ARTICLE	IF	CITATIONS
497	The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 451-455.	3.1	21
498	Antioxidants and Atherosclerosis. <i>Circulation</i> , 2003, 107, 926-928.	1.6	172
499	Ubiquinone: cholesterol's reclusive cousin. <i>Annals of Clinical Biochemistry</i> , 2003, 40, 207-218.	0.8	102
500	Cataract and the use of statins: a case-control study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 337-343.	0.2	41
501	Lymphocyte Function-Associated Antigen-1 Blockade by Statins: Molecular Basis and Biological Relevance. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2003, 10, 43-47.	1.7	36
502	Mechanisms of oxidative stress and vascular dysfunction. <i>Postgraduate Medical Journal</i> , 2003, 79, 195-200.	0.9	151
503	Primary Prevention of Coronary Heart Disease in the Elderly. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1654-1663.	0.9	18
504	Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function. <i>Circulation Research</i> , 2003, 93, e98-103.	2.0	153
505	Review: Reconsidering the value of fibrates: lessons from the trials. <i>British Journal of Diabetes and Vascular Disease</i> , 2003, 3, 162-167.	0.6	4
506	Pravastatin was not better than usual care in reducing all cause mortality or CHD events. <i>Evidence-Based Medicine</i> , 2003, 8, 106-106.	0.6	0
507	Is the Efficacy of HMG-CoA Reductase Inhibitors Dependent on Baseline Plasma Cholesterol-Level?. <i>Clinical Research and Regulatory Affairs</i> , 2003, 20, 341-348.	2.1	0
508	Utilization of Lipid-Lowering Drugs in Elderly Persons With Increased Serum Low-Density Lipoprotein Cholesterol Associated With Coronary Artery Disease, Symptomatic Peripheral Arterial Disease, Prior Stroke, or Diabetes Mellitus Before and After an Educational Program on Dyslipidemia Treatment. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2003, 58, M432-M435.	1.7	27
509	Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. <i>International Journal of Epidemiology</i> , 2003, 32, 563-572.	0.9	315
510	Should we add screening for and treating left ventricular hypertrophy to the management of all patients needing secondary prevention of cardiovascular disease?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 449-452.	0.2	6
511	Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 582-588.	0.4	78
512	Gastrointestinal Cancer and the Long-term Use of Pravastatin in the Elderly. <i>Acta Oncologica</i> , 2003, 42, 347-348.	0.8	1
513	The importance of cholesterol, blood pressure and smoking for coronary heart disease. <i>European Heart Journal</i> , 2003, 24, 1703-1704.	1.0	6
514	Potential antitumor effects of statins (Review). <i>International Journal of Oncology</i> , 2003, 23, 1055.	1.4	56

#	ARTICLE	IF	CITATIONS
515	PREVENTION OF CARDIOVASCULAR DISEASE : PLEA FOR A RATIONALE USE OF DIET AND LIPID-LOWERING DRUGS. Acta Clinica Belgica, 2003, 58, 149-151.	0.5	0
516	Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. Journal of Lipid Research, 2003, 44, 1192-1198.	2.0	45
517	Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes. BMJ: British Medical Journal, 2003, 326, 528-529.	2.4	15
518	Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ: British Medical Journal, 2003, 326, 689-689.	2.4	23
519	Resuscitating clinical research in the United Kingdom. BMJ: British Medical Journal, 2003, 327, 1041-1043.	2.4	75
520	What do we gain from the sixth coronary heart disease drug?. BMJ: British Medical Journal, 2003, 327, 1237-1238.	2.4	8
521	Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ: British Medical Journal, 2003, 327, 1264-0.	2.4	50
522	Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction. Circulation, 2003, 108, 28III-37.	1.6	52
523	Cholesterol and the Risk of Ischemic Stroke. Stroke, 2003, 34, 2930-2934.	1.0	131
524	Diabetes: can we stop the time bomb?. British Heart Journal, 2003, 89, 28ii-30.	2.2	11
525	Low-density lipoprotein cholesterol targets in 2003. European Heart Journal Supplements, 2003, 5, D3-D7.	0.0	0
526	Cardiovascular complications in the diabetic patient with renal disease: an update in 2003. Nephrology Dialysis Transplantation, 2003, 18, 1993-1998.	0.4	27
527	A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease. Current Drug Targets, 2003, 4, 97-112.	1.0	198
528	The risk of dementia in relation to statins and other lipid lowering agents. Neurological Research, 2003, 25, 601-604.	0.6	24
529	A strategy to reduce cardiovascular disease by more than 80%. BMJ: British Medical Journal, 2003, 326, 1419-0.	2.4	1,300
530	Psychopathology in people with epilepsy and intellectual disability. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1464-1464.	0.9	9
531	Endothelium-Dependent Effects of Statins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 729-736.	1.1	372
532	Monitoring drug treatment. BMJ: British Medical Journal, 2003, 327, 1179-1181.	2.4	27

#	ARTICLE	IF	CITATIONS
533	CHD prevention: the importance of identifying dyslipidaemia. British Journal of Nursing, 2003, 12, 950-958.	0.3	0
534	Therapie der Arteriosklerose. Deutsche Medizinische Wochenschrift, 2003, 128, 41-47.	1.0	5
535	Treatment of Diabetic Dyslipoproteinemia. Experimental and Clinical Endocrinology and Diabetes, 2003, 111, 239-245.	0.6	35
538	Is Impaired Flow-Mediated Dilatation of the Brachial Artery a Cardiovascular Risk Factor?. Current Vascular Pharmacology, 2003, 1, 107-109.	0.8	26
539	Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?. Current Vascular Pharmacology, 2003, 1, 123-133.	0.8	17
540	Rosuvastatin Decreases Caveolin-1 and Improves Nitric Oxide-Dependent Heart Rate and Blood Pressure Variability in Apolipoprotein E $\alpha\alpha$ Mice In Vivo. Circulation, 2003, 107, 2480-2486.	1.6	169
541	Testosterone for secondary prevention in men with ischaemic heart disease?. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 521-529.	0.2	44
542	Oral Anticoagulant Therapy in Patients with Peripheral Artery Disease. Seminars in Vascular Medicine, 2003, 03, 339-344.	2.1	6
544	Diabetology for cardiologists. European Heart Journal Supplements, 2003, 5, B5-B13.	0.0	13
545	PPOGRESS beyond HOPE and LIFE: The ONTARGET trial programme. European Heart Journal Supplements, 2003, 5, F40-F47.	0.0	1
546	Prevention of macrovascular complications. European Heart Journal Supplements, 2003, 5, B21-B26.	0.0	3
547	Blood pressure lowering and ACE inhibition for the avoidance of cardiac and cerebral events. European Heart Journal, 2003, 24, 391-393.	1.0	6
548	Diabetes mellitus and cardiovascular risk: just another risk factor?. European Heart Journal Supplements, 2003, 5, F26-F32.	0.0	3
550	Sensible prescribing for older people. Clinical Medicine, 2003, 3, 409-412.	0.8	2
551	Type 2 diabetes is cardiovascular disease. Journal of the Royal Society of Medicine, 2003, 96, 371-372.	1.1	1
552	Proven benefits of angiotensin receptor blockers in the progression of renal disease. European Heart Journal Supplements, 2003, 5, C9-C12.	0.0	3
553	Early and More Vigorous Detection of Diabetes. Journal of Cardiovascular Nursing, 2003, 18, 103-107.	0.6	7
554	Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial - Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm. Current Opinion in Lipidology, 2003, 14, 593-597.	1.2	1

#	ARTICLE	IF	CITATIONS
555	Statins. Journal of Obstetrics and Gynaecology Canada, 2003, 25, 231-234.	0.3	2
556	Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized controlled trial Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. European Heart Journal, 2003, 24, 1216-1222.	1.0	31
557	Title is missing!. Coronary Artery Disease, 2003, 14, 329-334.	0.3	9
558	Cardiovascular Disease in Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2003, 163, 33.	4.3	132
559	The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers. Current Opinion in Cardiology, 2003, 18, 295-300.	0.8	20
560	Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?. Current Opinion in Lipidology, 2003, 14, 575-583.	1.2	44
562	Role of non-HDL cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials. Current Opinion in Cardiology, 2003, 18, 503-509.	0.8	20
563	The Use of Non Face-to-Face Communication to Enhance Preventive Strategies. Journal of Cardiovascular Nursing, 2003, 18, 267-273.	0.6	12
564	Women Do Benefit from Lipid Lowering: Latest Clinical Trial Data. Cardiology in Review, 2003, 11, 4-12.	0.6	17
565	Medical treatment of peripheral arterial disease. Current Opinion in Cardiology, 2003, 18, 425-430.	0.8	2
566	2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension*. Journal of Hypertension, 2003, 21, 1011-1053.	0.3	2,917
567	New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. Journal of Hypertension, 2003, 21, 1599-1608.	0.3	33
568	Strokes and their relationship to hypertension. Current Opinion in Nephrology and Hypertension, 2003, 12, 91-96.	1.0	22
569	Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Current Opinion in Lipidology, 2003, 14, 353-359.	1.2	130
570	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 169-179.	1.5	51
571	Critical Pathway for Cardiac Rehabilitation After Percutaneous Coronary Intervention. Critical Pathways in Cardiology, 2003, 2, 7-14.	0.2	0
572	Raising high-density lipoprotein cholesterol: where are we now?. European Heart Journal Supplements, 2003, 5, D17-D25.	0.0	0
573	Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Current Opinion in Cardiology, 2003, 18, 301-308.	0.8	24

#	ARTICLE	IF	CITATIONS
574	New Methods of Delivering Secondary Preventive Services. Journal of Cardiopulmonary Rehabilitation and Prevention, 2003, 23, 349-351.	0.5	4
575	Inflammation in atherosclerosis, not yet time for a paradigm shift?. Current Opinion in Lipidology, 2003, 14, 325-328.	1.2	1
576	Therapy and clinical trials - coronary heart disease: current and future perspectives. Current Opinion in Lipidology, 2003, 14, 333-335.	1.2	0
577	Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Current Opinion in Cardiology, 2003, 18, 278-285.	0.8	21
578	Cholesterol-Lowering Drugs Bring Benefits to High-Risk Populations Even When LDL Is Normal. Journal of Cardiovascular Nursing, 2003, 18, 44-49.	0.6	9
579	Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy. JAMA - Journal of the American Medical Association, 2003, 289, 1675.	3.8	401
580	International Society of Hypertension (ISH). Journal of Hypertension, 2003, 21, 651-663.	0.3	45
581	Developments in Cardiologyâ€™2003. Journal of Pharmacy Practice and Research, 2003, 33, 146-148.	0.5	0
582	Critical Pathway for Cardiac Rehabilitation After Percutaneous Coronary Intervention. Critical Pathways in Cardiology, 2003, 2, 7-14.	0.2	0
583	The insulin resistance syndrome and coronary artery disease. Coronary Artery Disease, 2003, 14, 335-348.	0.3	50
584	Rosuvastatin: A New HMG-CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia. Heart Disease (Hagerstown, Md), 2003, 5, 72-78.	1.3	29
585	PROVE-IT TIMI 22 Study. Critical Pathways in Cardiology, 2003, 2, 188-196.	0.2	6
586	Diabetes and Heart Disease. Cardiology in Review, 2003, 11, 262-274.	0.6	28
588	Risk of Fatal Stroke in Patients With Treated Familial Hypercholesterolemia. Stroke, 2003, 34, 22-25.	1.0	46
589	Current Concepts in the Prevention of Alzheimer's Disease. CNS Spectrums, 2003, 8, 846-853.	0.7	16
590	Statin therapy restores sympathovagal balance in experimental heart failure. Journal of Applied Physiology, 2003, 95, 700-704.	1.2	85
591	Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 289-295.	3.1	26
593	Statins and Stroke. Therapie, 2003, 58, 49-58.	0.6	3

#	ARTICLE	IF	CITATIONS
596	Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2003, 139, 670.	2.0	167
597	Determination of Lipid Profiles and Use of Statins in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2003, 34, 105-110.	1.0	36
598	Cerebrovascular Disease in Italy and Europe: It Is Necessary to Prevent a "Pandemia". <i>Gerontology</i> , 2003, 49, 69-79.	1.4	8
599	Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2003, 138, 215.	2.0	93
600	Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. <i>BMJ: British Medical Journal</i> , 2003, 327, 777-782.	2.4	160
601	Prevention of Alzheimer's Disease and Other Dementias. <i>Journal of Pharmacy Practice and Research</i> , 2003, 33, 138-143.	0.5	2
602	ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina" Summary Article. <i>Circulation</i> , 2003, 107, 149-158.	1.6	651
603	Statins and their role in vascular protection. <i>Clinical Science</i> , 2003, 105, 251-266.	1.8	100
604	Diabetes Mellitus and Coronary Artery Disease. <i>Heart Disease (Hagerstown, Md)</i> , 2003, 5, 119-128.	1.3	7
606	Aggressive Lipid Management for Cardiovascular Prevention: Evidence from Clinical Trials. <i>Experimental Biology and Medicine</i> , 2003, 228, 769-778.	1.1	11
607	Statin therapy in people with diabetes and high-risk patients. <i>British Journal of Hospital Medicine</i> , 2003, 64, 16-19.	0.3	2
608	Statins in the Era of Evidence-Based Medicine " Who Will Not "Prosper"? <i>Scottish Medical Journal</i> , 2003, 48, 64-68.	0.7	2
609	Emerging Therapeutics for Alzheimer's Disease: An Avenue of Hope. <i>CNS Spectrums</i> , 2003, 8, 834-845.	0.7	8
610	Strategies to improve outcomes after acute stroke. <i>Medical Journal of Australia</i> , 2003, 178, 309-310.	0.8	14
612	Type 2 Diabetes is Cardiovascular Disease. <i>Journal of the Royal Society of Medicine</i> , 2003, 96, 371-372.	1.1	1
613	Identification and Management of Vascular Risk: Beyond Low Density Lipoprotein Cholesterol. <i>AAOHN Journal</i> , 2003, 51, 521-531.	0.5	3
614	Treating to target: using cost-effective statins. <i>British Journal of Health Care Management</i> , 2003, 9, 305-309.	0.1	0
616	Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. <i>Medical Journal of Australia</i> , 2003, 178, 113-116.	0.8	48

#	ARTICLE	IF	CITATIONS
617	Statins' role in reducing mortality. <i>Practice Nursing</i> , 2003, 14, 555-557.	0.1	0
618	The place of ezetimibe in clinical practice. <i>British Journal of Hospital Medicine</i> , 2003, 64, 473-478.	0.3	3
619	Platelet hyperactivity after statin treatment discontinuation. <i>Thrombosis and Haemostasis</i> , 2003, 90, 476-482.	1.8	62
620	Mortality in British vegetarians: review and preliminary results from EPIC-Oxford. <i>American Journal of Clinical Nutrition</i> , 2003, 78, 533S-538S.	2.2	77
621	Metabolic Syndrome and Cardiovascular Disease. <i>Sunhwan'gi</i> , 2003, 33, 645.	0.3	15
622	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Protect Cortical Neurons from Excitotoxicity. <i>Journal of Neuroscience</i> , 2003, 23, 11104-11111.	1.7	236
623	Prevention and Health Services Delivery. <i>Stroke</i> , 2003, 34, 367-369.	1.0	6
624	ASHP therapeutic position statement on the use of statins in the prevention of atherosclerotic vascular disease in adults. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 593-598.	0.5	3
625	Strategies for Optimizing Treatment Outcomes. <i>Journal of Managed Care Pharmacy</i> , 2003, 9, 20-23.	2.2	2
627	Determinants of the Cost-Effectiveness of Statins. <i>Journal of Managed Care Pharmacy</i> , 2003, 9, 544-551.	2.2	29
628	3: Preventing complications of diabetes. <i>Medical Journal of Australia</i> , 2003, 179, 498-503.	0.8	68
629	Ever Decreasing Circles: Advances in Antiplatelet Therapy and Anticoagulation. <i>Stroke</i> , 2003, 34, 348-350.	1.0	1
630	Different Locations of Atherosclerosis " Different Risk Factors, Different Therapies?. Pathophysiology of Haemostasis and Thrombosis: <i>International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 262-266.	0.5	2
631	Investigation and Treatment of Subclinical Coronary Atherosclerosis. <i>Cardiology</i> , 2003, 3, 97-106.	0.3	0
632	Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2004, 11, 253-264.	0.9	92
633	Strategies for the prevention and treatment of statin-induced myopathy: Is there a role for ubiquinone supplementation?. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 515-519.	0.5	22
634	Secondary Prevention of Atherosclerosis and Related Events by Statins. , 2004, , 93-112.		0
635	Statins and Reduction of Stroke: Cholesterol-Lowering versus Pleiotropic Effects. , 2004, , 113-141.		0

#	ARTICLE	IF	CITATIONS
636	Statins, Inflammation, and C-Reactive Protein. , 2004, , 219-232.		0
637	Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. Medical Journal of Australia, 2004, 181, 150-154.	0.8	87
639	Evaluating the Cost-Effectiveness of Statins. Journal of Managed Care Pharmacy, 2004, 10, 79-81.	2.2	4
641	Development, implementation and audit of a cardiac prevention and rehabilitation programme for patients with coronary artery disease. European Heart Journal Supplements, 2004, , .	0.0	0
642	Prevention of cardiovascular disease: an evidenceâ€based clinical aid 2004. Medical Journal of Australia, 2004, 181, 1-14.	0.8	4
643	The control of lipids with a statin. Practice Nursing, 2004, 15, 611-614.	0.1	0
644	Prevention of cardiovascular disease: an evidenceâ€based clinical aid 2004. Medical Journal of Australia, 2004, 181, S1-S14.	0.8	10
645	Challenges in Evaluating the Cost-Effectiveness of Statins. Journal of Managed Care Pharmacy, 2004, 10, 81-82.	2.2	2
646	The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines. AMA Journal of Ethics, 2004, 6, 550.	0.4	0
648	How to improve primary prevention in asymptomatic high risk subjects?. European Heart Journal Supplements, 2004, , .	0.0	1
650	Statins for Primary Prevention: Strategic Options to Save Lives and Money. Journal of the Royal Society of Medicine, 2004, 97, 66-71.	1.1	2
651	Statins and Micronutrients: Unanswered Questions. Journal of the Royal Society of Medicine, 2004, 97, 459-460.	1.1	1
652	The Case for Statins: Has it Really been Made?. Journal of the Royal Society of Medicine, 2004, 97, 461-464.	1.1	10
654	Prevention of coronary heart disease in women. , 2004, , 209-224.		1
655	Medical management of chronic ischemic heart disease. Postgraduate Medicine, 2004, 115, 39-46.	0.9	2
656	Lipid-lowering therapy. Postgraduate Medicine, 2004, 115, 29-36.	0.9	2
657	Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data. Journal of Managed Care Pharmacy, 2004, 10, 251-258.	2.2	10
658	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation, 2004, 110, .	1.6	99

#	ARTICLE	IF	CITATIONS
659	Hypercholesterolemia and Endothelium Dysfunction: Role of Dietary Supplementation as Vascular Protective Agents. <i>Current Vascular Pharmacology</i> , 2004, 2, 45-52.	0.8	17
660	Stroke prevention in general practice. <i>Practice Nursing</i> , 2004, 15, 585-590.	0.1	0
661	Stage 2: The High-Risk Foot. , 0, , 35-61.		0
662	A Systematic Approach to Managing Hypertension and the Metabolic Syndrome in Primary Care. <i>Southern Medical Journal</i> , 2004, 97, 932-938.	0.3	11
663	New nonlipid effects of statins and their clinical relevance in cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1065-1077.	1.8	60
664	Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses?. <i>European Heart Journal</i> , 2004, 25, 716-719.	1.0	1
665	Obesity as the core of the metabolic syndrome and the management of coronary heart disease. <i>Current Medical Research and Opinion</i> , 2004, 20, 295-304.	0.9	104
666	Risk Factors for First-Ever Stroke in Older People in the North East of England. <i>Stroke</i> , 2004, 35, 7-11.	1.0	57
667	Reducing low-density lipoprotein cholesterol ? treating to target and meeting new European goals. <i>European Heart Journal Supplements</i> , 2004, 6, A12-A18.	0.0	11
668	Guidelines and management of global risk: the European perspective. <i>European Heart Journal Supplements</i> , 2004, 6, C5-C14.	0.0	4
669	What does the future hold for the patient with peripheral arterial disease?. <i>European Heart Journal Supplements</i> , 2004, 6, C43-C48.	0.0	1
670	Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath?. <i>European Heart Journal</i> , 2004, 25, 1769-1771.	1.0	7
671	Evolution of statin therapy: an ongoing story. <i>European Heart Journal Supplements</i> , 2004, 6, A3-A7.	0.0	2
672	Managing dyslipidaemia ? multiple patients and multiple approaches: metabolic syndrome, familial hypercholesterolaemia and hypertension. <i>European Heart Journal Supplements</i> , 2004, 6, A23-A27.	0.0	0
673	Hypertension in Peripheral Arterial Disease. <i>Current Pharmaceutical Design</i> , 2004, 10, 3615-3620.	0.9	38
674	British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. <i>BMJ: British Medical Journal</i> , 2004, 328, 634-640.	2.4	713
675	Statins and Endothelial Dysfunction. <i>Seminars in Vascular Medicine</i> , 2004, 4, 333-346.	2.1	14
676	Lipid Lowering Therapy in Atherosclerosis. <i>Seminars in Vascular Medicine</i> , 2004, 4, 357-366.	2.1	27

#	ARTICLE	IF	CITATIONS
677	Statins in Atherothrombosis. <i>Seminars in Vascular Medicine</i> , 2004, 4, 407-415.	2.1	6
678	New Strategies in the Treatment of Dyslipidemia: Do We Know How?. <i>Seminars in Vascular Medicine</i> , 2004, 4, 305-310.	2.1	0
679	Effects of Statins on Endothelium and Endothelial Progenitor Cell Recruitment. <i>Seminars in Vascular Medicine</i> , 2004, 4, 385-393.	2.1	55
680	Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 707-713.	1.9	1
681	Stroke prevention with lipid-lowering therapy. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 233-239.	1.4	3
682	HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 241-247.	1.4	6
683	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2004, 351, 714-717.	13.9	18
684	Inhibition of HMG-CoA Reductase with Cerivastatin Lowers Dense Low Density Lipoproteins in Patients with Elevated Fasting Glucose, Impaired Glucose Tolerance and Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2004, 112, 269-277.	0.6	11
685	Population-Based Measurement of Quality of Diabetes Care Using HbA1c Values in the State of Thuringia/Germany. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2004, 112, 531-537.	0.6	14
687	Metformin Ameliorates Treatment of Obese Type 2 Diabetic Patients with Mental Retardation; its Effects on Eating Behavior and Serum Leptin Levels. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2004, 112, 422-428.	0.6	11
689	Global Risk Management in Type 2 Diabetes: Blood Glucose, Blood Pressure, and Lipids - Update on the Background of the Current Guidelines. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2004, 112, 493-503.	0.6	26
690	Chronic Angina Pectoris: Inadequacies of Current Therapy. <i>The American Journal of Geriatric Cardiology</i> , 2004, 13, 261-266.	0.7	4
691	Extended-release niacin for modifying the lipoprotein profile. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1385-1398.	0.9	61
692	Risk stratification for the prevention of cardiovascular complications of hypertension. <i>Current Medical Research and Opinion</i> , 2004, 20, 1137-1142.	0.9	16
693	Medications and Cardiovascular Health in Older Adults: Room for Improvement in Prevention and Treatment. <i>The American Journal of Geriatric Cardiology</i> , 2004, 13, 161-167.	0.7	1
694	Guidelines of the Cardiogeriatrics Department of the Brazilian Cardiology Society: Commentary by Editorial Board Members of The American Journal of Geriatric Cardiology. <i>CARDIAC ARRHYTHMIAS. HEART FAILURE. CORONARY ARTERY DISEASE (CHRONIC STABLE ANGINA, ACUTE CORONARY SYNDROME)</i> , <i>Tj ETQq.1 1 0.784314 rgB</i> <i>American Journal of Geriatric Cardiology</i> , 2004, 13, 200-209.	0.7	1
695	Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, 745-749.	1.6	287
696	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. <i>Expert Opinion on Therapeutic Patents</i> , 2004, 14, 1553-1566.	2.4	5

#	ARTICLE	IF	CITATIONS
697	What Did PROVE-IT Prove?. <i>Diabetes Technology and Therapeutics</i> , 2004, 6, 864-867.	2.4	1
698	Brain Cholesterol: Long Secret Life Behind a Barrier. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 806-815.	1.1	866
699	Correlation between CXCR4 and Homing or Engraftment of Acute Myelogenous Leukemia. <i>Cancer Research</i> , 2004, 64, 6832-6833.	0.4	16
700	ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. <i>Journal of Lipid Research</i> , 2004, 45, 653-656.	2.0	84
702	High-Density Lipoprotein and Cardiovascular Risk. <i>Circulation</i> , 2004, 109, 1809-1812.	1.6	113
703	Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy*. <i>Current Medical Research and Opinion</i> , 2004, 20, 1571-1578.	0.9	10
705	Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. <i>Heart</i> , 2004, 90, 1431-1437.	1.2	77
706	Masterclass series in peripheral arterial disease. <i>Vascular Medicine</i> , 2004, 9, 303-306.	0.8	0
707	Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8497-8502.	3.3	97
708	Atherosclerosis Imaging and the Future of Lipid Management. <i>Circulation</i> , 2004, 110, 3509-3511.	1.6	20
709	Thirty-year Trends in Cardiovascular Risk Factor Levels among US Adults with Diabetes: National Health and Nutrition Examination Surveys, 1971-2000. <i>American Journal of Epidemiology</i> , 2004, 160, 531-539.	1.6	118
710	Giant and fusiform aneurysms of coronary arteries following early and adequate treatment of suspected Kawasaki disease. <i>Heart</i> , 2004, 90, 1437-1437.	1.2	2
711	Perspective on Selected Issues in Cardiovascular Disease Research With a Focus on Black Americans. <i>Circulation</i> , 2004, 110, e7-12.	1.6	22
712	Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease. <i>Evidence-based Nursing</i> , 2004, 7, 82-82.	0.1	2
713	New evidence in hypertension and hyperlipidaemia. <i>British Heart Journal</i> , 2004, 90, iv14-iv17.	2.2	3
714	Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease. <i>Circulation</i> , 2004, 110, 1557-1563.	1.6	351
715	Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. <i>Journal of Lipid Research</i> , 2004, 45, 1375-1397.	2.0	865
716	Nurse led clinics controlled hypertension and hyperlipidaemia better than usual care in diabetes. <i>Evidence-based Nursing</i> , 2004, 7, 48-48.	0.1	3

#	ARTICLE	IF	CITATIONS
717	High-Density Lipoproteins: A New Potential Therapeutic Target for the Prevention of Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 387-391.	1.1	127
718	Rhabdomyolysis in Association with Simvastatin and Amiodarone. <i>Annals of Pharmacotherapy</i> , 2004, 38, 978-981.	0.9	74
719	Secondary prevention of stroke: more than just aspirin or warfarin. <i>Age and Ageing</i> , 2004, 33, 218-220.	0.7	0
720	Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization. <i>Archives of Internal Medicine</i> , 2004, 164, 659.	4.3	1,394
721	Women and Heart Disease. <i>Archives of Internal Medicine</i> , 2004, 164, 934.	4.3	144
722	Tracking Trends in Secondary Stroke Prevention Strategies. <i>Annals of Pharmacotherapy</i> , 2004, 38, 215-219.	0.9	8
723	Too much of a good thing: 2004 guidance from NICE and BHS-IV on hypertension in diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2004, 4, 365-368.	0.6	3
725	Prevention of cardiac complications of non-cardiac surgery: stenosis and thrombosis. <i>British Journal of Anaesthesia</i> , 2004, 92, 628-632.	1.5	8
726	Are patients receiving maximal medical therapy following carotid endarterectomy?. <i>Neurology</i> , 2004, 63, 2011-2015.	1.5	18
727	Association Between Cholesterol Level and Mortality in Dialysis Patients. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 451.	3.8	638
728	Inflammation in Atherosclerosis and Implications for Therapy. <i>Circulation</i> , 2004, 109, III-20-III-26.	1.6	267
729	Dyslipoproteinemia and Peripheral Arterial Occlusive Disease. <i>Angiology</i> , 2004, 55, 135-138.	0.8	7
730	Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 12S-20.	3.0	14
731	Utility and barriers to performance of the ankle brachial index in primary care practice. <i>Vascular Medicine</i> , 2004, 9, 253-260.	0.8	125
732	Review: Ezetimibe â€™ clinical and pharmacological profile. <i>British Journal of Diabetes and Vascular Disease</i> , 2004, 4, 163-171.	0.6	2
733	Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 41-46.	4.3	99
734	Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. <i>Thorax</i> , 2004, 59, 777-782.	2.7	277
735	Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease. <i>Evidence-Based Medicine</i> , 2004, 9, 143-143.	0.6	0

#	ARTICLE	IF	CITATIONS
736	Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*. Current Medical Research and Opinion, 2004, 20, 1197-1207.	0.9	59
737	Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics. Kidney and Blood Pressure Research, 2004, 27, 259-266.	0.9	131
738	Mandate for Creation of a National Peripheral Arterial Disease Public Awareness Program: An Opportunity to Improve Cardiovascular Health. Vascular and Endovascular Surgery, 2004, 38, 121-130.	0.3	1
739	Clinical trials and p-values, beware of the extremes. Clinical Chemistry and Laboratory Medicine, 2004, 42, 300-4.	1.4	13
740	High-Dose Statins in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 1365.	3.8	99
741	New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders. Archives of Internal Medicine, 2004, 164, 697.	4.3	166
742	Chapter 2 Primary Prevention of Stroke by Modification of Selected Risk Factors. Blue Books of Practical Neurology, 2004, 29, 5-54.	0.1	0
743	Surrogate Markers for Cardiovascular Disease: Functional Markers. Circulation, 2004, 109, IV-31-IV-46.	1.6	215
744	Managing the cost of cardiovascular prevention in primary care. British Heart Journal, 2004, 90, iv26-iv28.	2.2	1
745	Coronary artery disease in the elderly patient. Reviews in Clinical Gerontology, 2004, 14, 105-118.	0.5	0
746	Mandate for Creation of a National Peripheral Arterial Disease Public Awareness Program: An Opportunity to Improve Cardiovascular Health. Angiology, 2004, 55, 233-242.	0.8	7
747	There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients. Circulation, 2004, 110, 2333-2335.	1.6	86
748	Vascular cognitive impairment. Reviews in Clinical Gerontology, 2004, 14, 45-53.	0.5	3
749	Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease. Diabetes Care, 2004, 27, 2887-2892.	4.3	94
750	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 2004, 110, 227-239.	1.6	5,602
751	Prior Statin Therapy Is Associated With a Decreased Rate of Severe Sepsis. Circulation, 2004, 110, 880-885.	1.6	366
752	Increasing Severity of Cardiovascular Risk Factors With Increasing Middle Cerebral Artery Stenotic Involvement in Type 2 Diabetic Chinese Patients With Asymptomatic Cerebrovascular Disease. Diabetes Care, 2004, 27, 1121-1126.	4.3	28
753	Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 1307.	3.8	1,166

#	ARTICLE	IF	CITATIONS
754	Stopping Statins. <i>Circulation</i> , 2004, 110, 2280-2282.	1.6	14
755	Targeting High-Risk Young Patients for Statin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 377.	3.8	7
756	Lipid-Altering Drugs. <i>Cancer Research</i> , 2004, 64, 6831-6832.	0.4	1
757	Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. <i>European Heart Journal</i> , 2004, 25, 656-662.	1.0	159
758	Mixed Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2901.	3.8	293
759	Glucose-Cholesterol Interaction Magnifies Coronary Heart Disease Risk for Hypertensive Patients. <i>Hypertension</i> , 2004, 43, 983-987.	1.3	21
760	The mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health. <i>Vascular Medicine</i> , 2004, 9, 78-86.	0.8	3
761	Coronary Event Secondary Prevention with Statins Irrespective of LDL-Cholesterol. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1060-1064.	0.9	6
762	Atherosclerotic Vascular Disease Conference. <i>Circulation</i> , 2004, 109, 2634-2642.	1.6	54
763	Beyond the Laboratory: Clinical Implications for Statin Pleiotropy. <i>Circulation</i> , 2004, 109, II-42-II-48.	1.6	161
764	Statins for Stroke Prevention: Disappointment and Hope. <i>Circulation</i> , 2004, 109, III-44-III-49.	1.6	58
765	Should Angiotensin II Receptor Blockers and Statins Be Combined?. <i>Circulation</i> , 2004, 110, 1013-1020.	1.6	86
766	High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial. <i>Circulation</i> , 2004, 110, 1406-1412.	1.6	209
767	Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. <i>Circulation</i> , 2004, 110, 1418-1423.	1.6	210
768	Chronic diseases, locomotor activity limitation and social participation in older women: cross sectional survey of British Women's Heart and Health Study. <i>Age and Ageing</i> , 2004, 33, 293-298.	0.7	40
769	Lipid levels and the use of lipid-lowering agents in England and Scotland. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2004, 11, 484-488.	3.1	6
770	Comparison of cardiovascular risk factors and drug use in 14544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2004, 11, 394-402.	3.1	5
771	Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1071.	3.8	2,100

#	ARTICLE	IF	CITATIONS
772	Inflammation, Cholesterol Levels, and Risk of Mortality Among Patients Receiving Dialysis—Reply. JAMA - Journal of the American Medical Association, 2004, 291, 1833.	3.8	2
773	Do statins offer therapeutic potential in inflammatory arthritis?. Annals of the Rheumatic Diseases, 2004, 63, 1535-1537.	0.5	29
774	From Finland to Fatland: Beneficial Effects of Statins for Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 2161-2168.	3.0	24
775	High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome. Evidence-Based Medicine, 2004, 9, 144-144.	0.6	0
776	OTC Statins: Opportunity or Threat?. Canadian Pharmacists Journal, 2004, 137, 11-13.	0.4	0
778	Regulatory Decision—Making in the United States Based on a Single Pivotal Clinical Study: Principles and Precedents. Clinical Research and Regulatory Affairs, 2004, 21, 101-143.	2.1	2
779	Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia. Journal of the American Board of Family Medicine, 2004, 17, 424-437.	0.8	41
780	Effects of Simvastatin on Plasma Lipoproteins and Response to Arterial Injury in Wild-Type and Apolipoprotein-E-Deficient Mice. Journal of Vascular Research, 2004, 41, 75-83.	0.6	26
781	Patients with Alzheimer—™s Disease May Be Particularly Susceptible to Adverse Effects of Statins. Dementia and Geriatric Cognitive Disorders, 2004, 17, 109-116.	0.7	24
782	Familial Hypercholesterolemia, Peripheral Arterial Disease, and Stroke: A HuGE Minireview. American Journal of Epidemiology, 2004, 160, 430-435.	1.6	63
783	High-Intensity Statin Treatment for Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2004, 291, 1132.	3.8	34
784	Effectiveness of Statin Therapy in Adults With Coronary Heart Disease. Archives of Internal Medicine, 2004, 164, 1427.	4.3	231
785	Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients. JAMA - Journal of the American Medical Association, 2004, 291, 1864.	3.8	369
786	New Perspectives on the Pharmacotherapy of Ischemic Stroke. Journal of the American Pharmacists Association: JAPhA, 2004, 44, S46-S56.	0.7	12
787	Statins and Stroke Prevention. Cerebrovascular Diseases, 2004, 17, 81-88.	0.8	28
788	Effective Stroke Prevention in Patients with Symptomatic Carotid Stenosis. Cerebrovascular Diseases, 2004, 17, 89-104.	0.8	15
789	Statins for Secondary Stroke Prevention in Patients without Known Coronary Heart Disease: The Jury Is Still Out. Cerebrovascular Diseases, 2004, 18, 1-2.	0.8	15
790	Secondary prevention for coronary artery disease. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 127-131.	0.2	6

#	ARTICLE	IF	CITATIONS
791	Statins for the prevention of cerebrovascular disease: the rationale for robust intervention. European Heart Journal Supplements, 2004, 6, C34-C42.	0.0	4
792	Implications of recent end-point trials on future management of hypertension and dyslipidaemia. European Heart Journal Supplements, 2004, 6, G13-G17.	0.0	0
793	Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study. Nephrology Dialysis Transplantation, 2004, 19, 528-531.	0.4	19
794	Improving outcomes through statin therapy ? a review of ongoing trials. European Heart Journal Supplements, 2004, 6, A28-A31.	0.0	8
795	Treating dyslipidaemia in the patient with type 2 diabetes. European Heart Journal Supplements, 2004, 6, C28-C33.	0.0	6
796	Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor?. Nephrology Dialysis Transplantation, 2004, 19, 23-26.	0.4	13
797	Secondary prevention for stroke and transient ischaemic attacks. BMJ: British Medical Journal, 2004, 328, 297-298.	2.4	12
798	Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. BMJ: British Medical Journal, 2004, 328, 693-697.	2.4	57
799	Emerging Therapies for Cerebrovascular Disorders. Stroke, 2004, 35, 367-369.	1.0	9
800	Favorable Outcome of Ischemic Stroke in Patients Pretreated with Statins. Stroke, 2004, 35, 1117-1121.	1.0	190
801	Editorial Commentâ€”Statins, Stroke Outcome, and Stroke Prevention: When Should We Start Treatment?. Stroke, 2004, 35, 1121-1123.	1.0	9
802	Cholesterol Is Associated With Stroke, but Is Not a Risk Factor. Stroke, 2004, 35, 1524-1525.	1.0	18
803	Cholesterol as a Risk Factor for Stroke. Stroke, 2004, 35, 1523-1524.	1.0	24
804	Stroke and Cholesterol. Stroke, 2004, 35, 1526-1526.	1.0	15
805	The Willis Lecture 2003: Evaluating Treatments for Stroke Patients Too Slowly. Stroke, 2004, 35, 2211-2219.	1.0	8
806	Chapter 10 Risk Factor Modification for Secondary Prevention. Blue Books of Practical Neurology, 2004, 29, 197-210.	0.1	0
807	Statins in patients at high risk of cardiovascular disease presenting with peripheral artery disease. European Heart Journal, 2004, 25, 712-713.	1.0	1
808	The Value of Clopidogrel versus Aspirin in Reducing Atherothrombotic Events. Pharmacoeconomics, 2004, 22, 19-27.	1.7	27

#	ARTICLE	IF	CITATIONS
809	Oxidative Stress During Myocardial Ischaemia and Heart Failure. <i>Current Pharmaceutical Design</i> , 2004, 10, 1699-1711.	0.9	186
810	Statins and micronutrients: unanswered questions. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 459-460.	1.1	2
811	The case for statins: has it really been made?. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 461-464.	1.1	12
812	Beneficial effects of statins on the kidney: the evidence moves from mouse to man. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1032-1036.	0.4	16
813	Critical Limb Ischemia: Definition and Natural History. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2004, 4, 219-225.	2.0	118
814	Target intervention against multiple risk markers to reduce cardiovascular disease in patients with type 2 diabetes. <i>Annals of Medicine</i> , 2004, 36, 355-366.	1.5	15
815	Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive Patients. <i>Circulation</i> , 2004, 110, 3687-3692.	1.6	275
816	Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. <i>FASEB Journal</i> , 2004, 18, 805-815.	0.2	73
817	The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. <i>Journal of Clinical Pathology</i> , 2004, 57, 728-734.	1.0	316
818	Management of dyslipidaemia. <i>Heart</i> , 2004, 90, 949-955.	1.2	24
819	Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients. <i>Hypertension</i> , 2004, 44, 180-185.	1.3	47
820	Diabetes and atherogenesis. <i>Heart</i> , 2004, 90, 336-340.	1.2	34
821	Simvastatin Induces Heme Oxygenase-1. <i>Circulation</i> , 2004, 110, 1296-1302.	1.6	260
822	Comparing Hyperlipidemia Control with Daily Versus Twice-Weekly Simvastatin. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1789-1793.	0.9	6
823	Cholesterol and stroke. <i>Reviews in Clinical Gerontology</i> , 2004, 14, 25-36.	0.5	2
825	The Metabolic Syndrome: Pathophysiology, Clinical Relevance, and Use of Niacin. <i>Annals of Pharmacotherapy</i> , 2004, 38, 277-285.	0.9	13
826	Intensive Integrated Therapy of Type 2 Diabetes: Implications for Long-Term Prognosis. <i>Diabetes</i> , 2004, 53, S39-S47.	0.3	91
827	Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. <i>Journal of Lipid Research</i> , 2004, 45, 174-185.	2.0	78

#	ARTICLE	IF	CITATIONS
828	Relationship Between Arterial Stiffness and Subclinical Aortic Atherosclerosis. <i>Circulation</i> , 2004, 110, 432-437.	1.6	67
829	Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. <i>Heart</i> , 2004, 90, 1404-1410.	1.2	103
830	Mendelian randomization: prospects, potentials, and limitations. <i>International Journal of Epidemiology</i> , 2004, 33, 30-42.	0.9	833
831	Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2004, 11, 521-528.	3.1	42
833	Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*. <i>Current Medical Research and Opinion</i> , 2004, 20, 1253-1268.	0.9	248
834	Management of Type 2 Diabetes Mellitus: Is It Time for a Paradigm Shift?. <i>Metabolic Syndrome and Related Disorders</i> , 2004, 2, 251-262.	0.5	3
835	Statins: can the new generation make an impression?. <i>Expert Opinion on Emerging Drugs</i> , 2004, 9, 269-279.	1.0	26
836	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2004, 109, 837-842.	1.6	598
837	Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. <i>Neurology</i> , 2004, 63, 1868-1875.	1.5	267
838	Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. <i>British Journal of Diabetes and Vascular Disease</i> , 2004, 4, 78-85.	0.6	20
839	Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. <i>Cardiovascular Research</i> , 2004, 61, 745-755.	1.8	115
840	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, e149-61.	1.1	189
841	An isolated single coronary artery supplying the entire myocardium in a patient with congenitally corrected transposition of the great vessels. <i>Heart</i> , 2004, 90, 1410-1410.	1.2	4
842	Progression of Coronary Artery Calcium and Risk of First Myocardial Infarction in Patients Receiving Cholesterol-Lowering Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1272-1277.	1.1	298
843	Update on Statins: 2003. <i>Circulation</i> , 2004, 110, 886-892.	1.6	196
844	PROTECT. <i>Neurology</i> , 2004, 63, 1217-1222.	1.5	94
845	Management of the Elderly Person After Myocardial Infarction. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2004, 59, 1173-1185.	1.7	9
846	Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer's disease: A pilot observational study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2004, 19, 275-278.	0.9	15

#	ARTICLE	IF	CITATIONS
847	Statin use and stroke outcomes in the Heart and Estrogen/Progestin Replacement Study (HERS). <i>Neurology</i> , 2004, 62, 968-970.	1.5	16
848	Effects of Long-Term Daily Low-Dose Supplementation With Antioxidant Vitamins and Minerals on Structure and Function of Large Arteries. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1485-1491.	1.1	141
849	Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). <i>Current Medical Research and Opinion</i> , 2004, 20, 765-772.	0.9	13
850	The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screening. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2004, 11, 250-253.	3.1	38
851	Health promotion and health education about diabetes mellitus. <i>Perspectives in Public Health</i> , 2004, 124, 70-73.	0.5	10
852	Statin therapy and risk of dementia in the elderly. <i>Neurology</i> , 2004, 63, 1624-1628.	1.5	243
853	Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. <i>Current Medical Research and Opinion</i> , 2004, 20, 55-62.	0.9	44
854	Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. <i>European Heart Journal</i> , 2004, 25, 742-748.	1.0	104
855	Efficacy of Extended-Release Niacin With Lovastatin for Hypercholesterolemia. <i>Archives of Internal Medicine</i> , 2004, 164, 1121.	4.3	58
856	<i>Epidemiology of Stroke</i> . , 2004, , 13-34.		76
857	Low Cholesterol Levels Are Associated With Short-Term Mortality in Older Patients With Ischemic Stroke. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2004, 59, M293-M297.	1.7	46
858	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 635-641.	2.9	214
859	Secondary prevention for stroke in the United Kingdom: results from the National Sentinel Audit of Stroke. <i>Age and Ageing</i> , 2004, 33, 280-286.	0.7	60
860	Evidence based medicine, guidelines and common sense. <i>Age and Ageing</i> , 2004, 33, 335-337.	0.7	2
861	The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. <i>International Journal of Clinical Practice</i> , 2004, 58, 494-503.	0.8	8
862	Improving lipid management - to titrate, combine or switch. <i>International Journal of Clinical Practice</i> , 2004, 58, 689-694.	0.8	24
863	Believe-it then PROVE-IT. <i>International Journal of Clinical Practice</i> , 2004, 58, 325-326.	0.8	1
864	Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. <i>International Journal of Clinical Practice</i> , 2004, 58, 706-713.	0.8	48

#	ARTICLE	IF	CITATIONS
865	Statins - threatening the evidence base of effectiveness and safety. International Journal of Clinical Practice, 2004, 58, 539-540.	0.8	2
866	Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International Journal of Clinical Practice, 2004, 58, 653-658.	0.8	44
867	The care gap: underuse of statin therapy in the elderly. International Journal of Clinical Practice, 2004, 58, 777-785.	0.8	22
868	The influence of statin characteristics on their safety and tolerability. International Journal of Clinical Practice, 2004, 58, 945-955.	0.8	39
869	The relative importance of cardiovascular risk factors in type 2 diabetes. International Journal of Clinical Practice, 2004, 58, 20-24.	0.8	0
870	Statins: potent vascular anti-inflammatory agents. International Journal of Clinical Practice, 2004, 58, 41-48.	0.8	24
871	A review of the efficacy of rosuvastatin in patients with type 2 diabetes. International Journal of Clinical Practice, 2004, 58, 30-40.	0.8	14
872	Cardioprotective and other emerging effects of statins. International Journal of Clinical Practice, 2004, 58, 49-57.	0.8	10
873	The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2004, 6, 133-156.	2.2	122
874	Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes, Obesity and Metabolism, 2004, 6, 353-362.	2.2	32
875	Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine, 2004, 21, 238-245.	1.2	59
876	Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabetic Medicine, 2004, 21, 403-414.	1.2	67
877	Educational outreach in diabetes to encourage practice nurses to use primary care hypertension and hyperlipidaemia guidelines (EDEN): a randomized controlled trial. Diabetic Medicine, 2004, 21, 599-603.	1.2	34
878	Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study. Diabetic Medicine, 2004, 21, 1108-1112.	1.2	9
879	Evaluation of delivery of enhanced diabetes care to patients of South Asian ethnicity: the United Kingdom Asian Diabetes Study (UKADS). Diabetic Medicine, 2004, 21, 1357-1365.	1.2	85
880	Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine, 2004, 21, 901-905.	1.2	22
881	Strategy for treating elderly Japanese with hypercholesterolemia*. Geriatrics and Gerontology International, 2004, 4, 151-156.	0.7	3
882	Effect of atorvastatin on impaired vascular function in healthy old men. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 157-164.	0.7	5

#	ARTICLE	IF	CITATIONS
883	Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 525-528.	1.1	205
884	Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 640-651.	1.1	259
885	Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 310-316.	1.1	7
886	Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 528-535.	1.1	42
887	Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. <i>Journal of Internal Medicine</i> , 2004, 255, 494-502.	2.7	61
888	Rationale, design and methods of the CASHMERE study+. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 131-138.	1.0	19
889	Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 718-725.	1.9	33
890	Do we care if statins prevent venous thromboembolism?. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 695-696.	1.9	5
891	Epidemiology and prevalence of Alzheimer's disease and risk factors. <i>Psychogeriatrics</i> , 2004, 4, 120-123.	0.6	1
892	Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. <i>Kidney International</i> , 2004, 66, 1123-1130.	2.6	93
893	Managing dyslipidemia in chronic kidney disease. <i>Journal of General Internal Medicine</i> , 2004, 19, 1045-1052.	1.3	70
894	Increases in Serum Non-High-Density Lipoprotein Cholesterol May Be Beneficial in Some High-Functioning Older Adults: MacArthur Studies of Successful Aging. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 487-494.	1.3	41
895	The Association Between Lipid Levels and the Risks of Incident Myocardial Infarction, Stroke, and Total Mortality: The Cardiovascular Health Study. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1639-1647.	1.3	186
896	Prospective Association Between Low and High Total and Low-Density Lipoprotein Cholesterol and Coronary Heart Disease in Elderly Men. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1975-1980.	1.3	39
897	Primary Cardiovascular Events and Serum Lipid Levels in Elderly Japanese with Hypercholesterolemia Undergoing 6-Year Simvastatin Treatment: A Subanalysis of the Japan Lipid Intervention Trial. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1981-1987.	1.3	26
898	Lipid-altering agents: the future. <i>International Journal of Clinical Practice</i> , 2004, 58, 1063-1072.	0.8	22
899	The case for blood pressure control in risk groups. <i>International Journal of Clinical Practice</i> , 2004, 58, 844-849.	0.8	4
900	Are you sure - the importance of "reasonable doubts". <i>International Journal of Clinical Practice</i> , 2004, 58, 1097-1097.	0.8	0

#	ARTICLE	IF	CITATIONS
901	Clinical Update on the Use of Niacin for the Treatment of Dyslipidemia. Journal of the American Academy of Nurse Practitioners, 2004, 16, 526-534.	1.4	4
902	Obesity in Youth: Implications for the Advanced Practice Nurse in Primary Care. Journal of the American Academy of Nurse Practitioners, 2004, 16, 326-334.	1.4	5
903	The FABP2 gene polymorphism in cerebrovascular disease. Acta Neurologica Scandinavica, 2004, 110, 355-360.	1.0	8
904	Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatrica Scandinavica, 2004, 110, 299-305.	2.2	104
905	Women and heart disease: new AHA guidelines. What oral health care professionals need to know. International Journal of Dental Hygiene, 2004, 2, 193-195.	0.8	0
906	Release of TNF-alpha From In Vitro-Stimulated Monocytes is Negatively Associated with Serum Levels of Apolipoprotein B in Patients with Type 2 Diabetes. Scandinavian Journal of Immunology, 2004, 60, 535-542.	1.3	12
907	Statins: novel additions to the dermatologic arsenal?. Experimental Dermatology, 2004, 13, 337-339.	1.4	74
908	Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine, 2004, 10, 1344-1351.	15.2	1,200
909	Cardiology and vascular disorders. Nature Reviews Drug Discovery, 2004, 3, S13-S17.	21.5	0
910	Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004â€”BHS IV. Journal of Human Hypertension, 2004, 18, 139-185.	1.0	1,072
911	Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. Journal of Human Hypertension, 2004, 18, 781-788.	1.0	78
912	Pathophysiology and Longâ€”Term Management of the Metabolic Syndrome. Obesity, 2004, 12, 174S-80S.	4.0	20
913	Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. American Journal of Transplantation, 2004, 4, 13-53.	2.6	320
914	Fluvastatin Prevents Cardiac Death and Myocardial Infarction in Renal Transplant Recipients: Post-Hoc Subgroup Analyses of the ALERT Study. American Journal of Transplantation, 2004, 4, 988-995.	2.6	116
915	Statins in Solid Organ Transplantation: Is There an Immunosuppressive Effect?. American Journal of Transplantation, 2004, 4, 1013-1018.	2.6	54
916	Selenoproteins, Cholesterol-Lowering Drugs, and the Consequences Revisiting of the Mevalonate Pathway. Trends in Cardiovascular Medicine, 2004, 14, 273-281.	2.3	94
917	Epidemiology of coronary heart disease in women. Progress in Cardiovascular Diseases, 2004, 46, 287-295.	1.6	157
918	Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Progress in Cardiovascular Diseases, 2004, 46, 524-538.	1.6	35

#	ARTICLE	IF	CITATIONS
919	Mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health. <i>Journal of Vascular Nursing</i> , 2004, 22, 24-31.	0.2	3
920	Update on statins. <i>Journal of Vascular Nursing</i> , 2004, 22, 49-50.	0.2	1
921	Reduced Incidence of New-Onset Diabetes Mellitus after Renal Transplantation with 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (Statins). <i>American Journal of Transplantation</i> , 2004, 4, 1897-1903.	2.6	55
922	The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2004, 43, 45-52.	2.1	61
923	The metabolic syndrome: Diagnosis and treatment. <i>Clinical Cornerstone</i> , 2004, 6, S5-S13.	1.0	14
924	Metabolic syndrome and risk of stroke. <i>Clinical Cornerstone</i> , 2004, 6, S30-S34.	1.0	9
925	Cardiovascular Implications of Thiazolidinedione Therapy. <i>Progress in Cardiovascular Nursing</i> , 2004, 19, 85-91.	0.5	0
926	Medical management of risk factors for vascular disease. <i>Surgery</i> , 2004, 22, 265-267.	0.1	0
927	Statin-Associated Peripheral Neuropathy: Review of the Literature. <i>Pharmacotherapy</i> , 2004, 24, 1194-1203.	1.2	80
928	Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia. <i>Pharmacotherapy</i> , 2004, 24, 1692-1713.	1.2	33
929	A Clinical Comparison of Calculated versus Direct Measurement of Low-Density Lipoprotein Cholesterol Level. <i>Pharmacotherapy</i> , 2004, 24, 167-172.	1.2	44
930	Statins and Liver Toxicity: A Meta-Analysis. <i>Pharmacotherapy</i> , 2004, 24, 584-591.	1.2	179
931	Impact of a Cardiac Risk Reduction Program in Vulnerable Patients Hospitalized with Coronary Artery Disease. <i>Pharmacotherapy</i> , 2004, 24, 768-775.	1.2	9
932	What's new in vascular surgery. <i>Journal of the American College of Surgeons</i> , 2004, 198, 600-625.	0.2	6
933	Viscous dietary fibre and metabolic effects. <i>Clinical Nutrition Supplements</i> , 2004, 1, 39-49.	0.0	40
934	Does the Modern Concept of "Best Medical Therapy" Render Carotid Surgery Obsolete?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2004, 28, 457-461.	0.8	17
935	Manipulation of the Renin Angiotensin System in Peripheral Arterial Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2004, 28, 573-582.	0.8	14
936	Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. <i>American Journal of Cardiology</i> , 2004, 93, 92-95.	0.7	12

#	ARTICLE	IF	CITATIONS
937	Atherosclerotic risk factors revisited. American Journal of Cardiology, 2004, 93, 73-75.	0.7	14
938	Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels < 130 mg/dl. American Journal of Cardiology, 2004, 93, 84-88.	0.7	49
939	Relation of response of subclinical atherosclerosis detected by electron beam tomography to baseline Low-Density lipoprotein cholesterol levels. American Journal of Cardiology, 2004, 93, 101-103.	0.7	1
940	Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. American Journal of Cardiology, 2004, 93, 154-158.	0.7	182
941	Subclinical atherosclerosis as a target of therapy: potential role of statins. American Journal of Cardiology, 2004, 93, 737-740.	0.7	6
942	Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. American Journal of Cardiology, 2004, 93, 3-11.	0.7	28
943	Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. American Journal of Cardiology, 2004, 94, 144-146.	0.7	44
944	Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. American Journal of Cardiology, 2004, 94, 720-724.	0.7	50
945	Is there value in liver function test and creatine phosphokinase monitoring with statin use?. American Journal of Cardiology, 2004, 94, 30-34.	0.7	55
949	Update on statins. Intensive and Critical Care Nursing, 2004, 20, 53-55.	1.4	2
950	The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Contemporary Clinical Trials, 2004, 25, 178-202.	2.0	50
951	Influence of socioeconomic status on the quality of prescribing in the elderly - a population based study. British Journal of Clinical Pharmacology, 2004, 58, 496-502.	1.1	57
952	Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease. Cardiovascular Drugs and Therapy, 2004, 18, 67-75.	1.3	8
953	Cholesterol and Coronary Disease—The Altered Landscape. Cardiovascular Drugs and Therapy, 2004, 18, 9-10.	1.3	0
954	Effects of Lovastatin and Pravastatin on Amyloid Processing and Inflammatory Response in TgCRND8 Brain. Neurochemical Research, 2004, 29, 1897-1911.	1.6	70
955	Lipids and the Elderly. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 359-364.	2.6	8
956	Evolving targets for risk reduction in diabetes. Clinical Cardiology, 2004, 27, 125-128.	0.7	1
957	Dyslipidemia in patients with angiographically confirmed coronary artery disease-an opportunity for improvement. Clinical Cardiology, 2004, 27, 577-580.	0.7	0

#	ARTICLE	IF	CITATIONS
958	Secondary stroke prevention: Review of clinical trials. <i>Clinical Cardiology</i> , 2004, 27, 25-35.	0.7	4
959	Medical prevention of secondary stroke: A cardiologist's perspective. <i>Clinical Cardiology</i> , 2004, 27, 36-42.	0.7	1
960	The importance of aggressive lipid management in patients at risk: Evidence from recent clinical trials. <i>Clinical Cardiology</i> , 2004, 27, 12-15.	0.7	14
961	Optimizing lipid lowering in patients at risk. <i>Clinical Cardiology</i> , 2004, 27, 22-26.	0.7	2
963	Comparison of secondary vascular prevention in practice after cerebral ischemia and coronary heart disease. <i>Journal of Neurology</i> , 2004, 251, 529-536.	1.8	8
966	Lipid-Lowering Therapy in Patients with Average Cholesterol and High Cardiovascular Risk, Insights from the Heart Protection Study. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 387-389.	1.3	0
974	Cardiovascular complications in Type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetic state. <i>Diabetologia</i> , 2004, 47, 145-146.	2.9	56
978	Management of Acute Coronary Syndrome in Diabetes Mellitus. <i>Herz</i> , 2004, 29, 532-41.	0.4	6
980	Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women. <i>Osteoporosis International</i> , 2004, 15, 459-67.	1.3	32
981	Low-density lipoprotein reduction in high-risk patients: How low do you go?. <i>Current Atherosclerosis Reports</i> , 2004, 6, 348-352.	2.0	15
982	ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. <i>Current Atherosclerosis Reports</i> , 2004, 6, 353-358.	2.0	1
983	Lessons learned from the prospective pravastatin pooling project. <i>Current Atherosclerosis Reports</i> , 2004, 6, 366-374.	2.0	4
984	ALLHAT-LLT: Questions, questions, and more questions (and some answers). <i>Current Atherosclerosis Reports</i> , 2004, 6, 375-380.	2.0	3
985	Evidence-based treatment of lipids in the elderly. <i>Current Atherosclerosis Reports</i> , 2004, 6, 388-397.	2.0	8
986	Randomized clinical stroke trials in 2003. <i>Current Atherosclerosis Reports</i> , 2004, 6, 257-260.	2.0	4
987	The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy. <i>Current Atherosclerosis Reports</i> , 2004, 6, 148-157.	2.0	106
988	New and emerging data from clinical trials of statins. <i>Current Atherosclerosis Reports</i> , 2004, 6, 12-19.	2.0	10
989	Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: Beyond cardiovascular diseases. <i>Current Atherosclerosis Reports</i> , 2004, 6, 36-41.	2.0	10

#	ARTICLE	IF	CITATIONS
990	Treatment of lipids and type 2 diabetes. Current Cardiology Reports, 2004, 6, 443-450.	1.3	4
991	The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes. Current Cardiology Reports, 2004, 6, 300-307.	1.3	2
992	Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome. Current Diabetes Reports, 2004, 4, 330-334.	1.7	1
993	Do statins prevent heart failure in patients after myocardial infarction?. Current Heart Failure Reports, 2004, 1, 156-160.	1.3	2
994	Combined antihypertensive and lipid-lowering treatment. Current Hypertension Reports, 2004, 6, 300-306.	1.5	5
995	Chemoprevention of melanoma. Current Oncology Reports, 2004, 6, 406-413.	1.8	6
996	Management of hyperlipidemia in the pediatric population. Current Treatment Options in Cardiovascular Medicine, 2004, 6, 431-437.	0.4	13
997	Will NICE guidelines on the management of type 2 diabetes improve diabetes care?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2004, 21, 3-6.	0.2	2
998	Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 23-30.	0.7	63
999	Potentially inappropriate prescriptions for older patients in long-term care. BMC Geriatrics, 2004, 4, 9.	1.1	106
1000	The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. , 2004, 3, 9.		77
1001	The Asymptomatic Carotid Surgery Trial: bigger study, better evidence. British Journal of Surgery, 2004, 91, 787-789.	0.1	9
1002	Cholesterol and prostate cancer. Journal of Cellular Biochemistry, 2004, 91, 54-69.	1.2	237
1003	Should nurses be screening for ischaemic heart disease in nurse-led rheumatoid arthritis clinics?. Musculoskeletal Care, 2004, 2, 60-64.	0.6	0
1004	Prevalence of silent myocardial ischemia in asymptomatic individuals with subclinical atherosclerosis detected by electron beam tomography*1. Journal of Nuclear Cardiology, 2004, 11, 450-457.	1.4	84
1005	Faut-il revoir les indications des statines à la lumière des dernières données de la médecine fondée sur les preuves?. EMC - Endocrinologie, 2004, 1, 158-162.	0.0	0
1006	Place et impact des régimes chez les personnes âgées. Nutrition Clinique Et Metabolisme, 2004, 18, 224-230.	0.2	5
1007	Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with I^2 -quantification in a large population. Clinical Biochemistry, 2004, 37, 785-790.	0.8	184

#	ARTICLE	IF	CITATIONS
1009	Risk of stroke in men is not associated with dietary fat intake. Evidence-Based Healthcare and Public Health, 2004, 8, 74-76.	0.0	0
1010	Does the use of statins compromise the effectiveness of platelet inhibition by clopidogrel?. Platelets, 2004, 15, 201-205.	1.1	7
1011	A new era in atherosclerosis drug discovery. Expert Review of Cardiovascular Therapy, 2004, 2, 633-636.	0.6	4
1012	Coenzyme Q10 and Adverse Effects of Statins. Journal of Nutritional and Environmental Medicine, 2004, 14, 17-28.	0.1	4
1013	Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Current Medical Research and Opinion, 2004, 20, 1385-1392.	0.9	15
1014	Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Current Medical Research and Opinion, 2004, 20, 215-223.	0.9	43
1015	Gender differences in risk factor control and treatment profile in diabetes: a study in 229 Swedish primary health care centres. Scandinavian Journal of Primary Health Care, 2004, 22, 27-31.	0.6	71
1016	Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions. Circulation, 2004, 109, III-50-III-57.	1.6	469
1017	Lipid-lowering therapies in development. Expert Opinion on Investigational Drugs, 2004, 13, 1405-1418.	1.9	6
1018	Role of fibrates in reducing coronary risk: a UK Consensus. Current Medical Research and Opinion, 2004, 20, 241-247.	0.9	53
1019	Evidence-Based Indications in Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 1-7.	1.0	2
1020	Endothelial Dysfunction, Vascular Damage and Clinical Events. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 15-27.	1.0	3
1021	Selected Presentations from the International Workshop on Endothelial Dysfunction and Cardiovascular Disease, Rome, June 4-5, 2004. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 187-204.	1.0	0
1022	Current lipid management and low cholesterol goal attainment in common daily practice in Spain. Pharmacoeconomics, 2004, 22, 1-12.	1.7	52
1023	Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics, 2004, 22, 13-23.	1.7	104
1024	Cost of care for patients treated with lipid-lowering drugs. Pharmacoeconomics, 2004, 22, 25-35.	1.7	24
1025	An Economic Evaluation of Fluvastatin used for the Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention in the UK. Pharmacoeconomics, 2004, 22, 525-535.	1.7	20
1026	Secondary Prevention of Stroke. CNS Drugs, 2004, 18, 221-241.	2.7	11

#	ARTICLE	IF	CITATIONS
1027	Dyslipidemia in Visceral Obesity. American Journal of Cardiovascular Drugs, 2004, 4, 227-246.	1.0	94
1028	Genetic Polymorphisms in Cytochrome P450 Enzymes. American Journal of Cardiovascular Drugs, 2004, 4, 247-255.	1.0	35
1029	Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention. American Journal of Cardiovascular Drugs, 2004, 4, 299-314.	1.0	29
1030	Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Current Medical Research and Opinion, 2004, 20, 1437-1445.	0.9	85
1031	Intensive Statin Therapy "A Sea Change in Cardiovascular Prevention. New England Journal of Medicine, 2004, 350, 1562-1564.	13.9	175
1032	Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Current Medical Research and Opinion, 2004, 20, 1087-1094.	0.9	15
1033	Simvastatin: a review. Expert Opinion on Pharmacotherapy, 2004, 5, 2583-2596.	0.9	105
1034	Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?. Circulation, 2004, 109, II-18-II-26.	1.6	417
1035	Statins in Stroke Prevention and Carotid Atherosclerosis. Stroke, 2004, 35, 2902-2909.	1.0	686
1036	Statins After Ischemic Stroke and Transient Ischemic Attack. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 793-793.	1.1	12
1037	Chronic systemic inflammation in uremia: Potential therapeutic approaches. Seminars in Nephrology, 2004, 24, 441-445.	0.6	14
1039	Funci3n antioxidante de las lipoprote3nas de alta densidad: un nuevo paradigma en la arteriosclerosis. Revista Espanola De Cardiologia, 2004, 57, 557-569.	0.6	26
1041	Aterosclerosis: 2mantequilla en las arterias?. EMC - Tratado De Medicina, 2004, 8, 1-6.	0.0	0
1045	Secondary Prevention Strategies in Ischemic Stroke: Identification and Optimal Management of Modifiable Risk Factors. Mayo Clinic Proceedings, 2004, 79, 1330-1340.	1.4	34
1046	The Mandate for Creation of a National Peripheral Arterial Disease Public Awareness Program: An Opportunity to Improve Cardiovascular Health. Journal of Vascular and Interventional Radiology, 2004, 15, 671-679.	0.2	1
1047	Importancia del colesterol ligado a lipoprote3nas de alta densidad (cHDL) en la prevenci3n del riesgo cardiovascular. Recomendaciones del Foro HDL. CI3nica E Investigaci3n En Arteriosclerosis, 2004, 16, 262-280.	0.4	0
1049	Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy. Endocrinology and Metabolism Clinics of North America, 2004, 33, 525-544.	1.2	13
1050	Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinology and Metabolism Clinics of North America, 2004, 33, 595-616.	1.2	23

#	ARTICLE	IF	CITATIONS
1051	Beyond hypertension* Toward guidelines for cardiovascular risk reduction*. American Journal of Hypertension, 2004, 17, 1068-1074.	1.0	23
1052	Guías para el tratamiento de las dislipemias en el adulto: Adult Treatment Panel III (ATP-III). Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2004, 51, 254-265.	0.8	10
1053	Mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health. Journal of Vascular Surgery, 2004, 39, 474-481.	0.6	34
1054	Patients with abdominal aortic aneurysm: Are we missing the opportunity for cardiovascular risk reduction?. Journal of Vascular Surgery, 2004, 40, 691-697.	0.6	48
1055	Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. Journal of Vascular Surgery, 2004, 39, 357-365.	0.6	142
1056	Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. Journal of Vascular Surgery, 2004, 39, 967-975.	0.6	557
1058	Hipertrigliceridemia. FMC Formacion Medica Continuada En Atencion Primaria, 2004, 11, 454-467.	0.0	0
1059	El papel del bloqueo de la absorción intestinal del colesterol en el tratamiento de la hipercolesterolemia. Revista Clinica Espanola, 2004, 204, 554-560.	0.2	0
1060	Medical Treatment of Peripheral Arterial Disease: A Comprehensive Review. Journal of Vascular and Interventional Radiology, 2004, 15, 1197-1207.	0.2	86
1061	Evaluation and Management of Transient Ischemic Attack and Minor Cerebral Infarction. Mayo Clinic Proceedings, 2004, 79, 1071-1086.	1.4	29
1062	El cribado de la diabetes es eficiente en pacientes hipertensos entre 55 y 75 años de edad. FMC Formacion Medica Continuada En Atencion Primaria, 2004, 11, 532.	0.0	0
1063	Peripheral Arterial Disease in the Catheterization Laboratory: An Underdetected and Undertreated Risk Factor. Mayo Clinic Proceedings, 2004, 79, 1107-1109.	1.4	4
1064	The Antioxidant Function of High Density Lipoproteins: A New Paradigm in Atherosclerosis. Revista Espanola De Cardiologia (English Ed), 2004, 57, 557-569.	0.4	22
1065	Clinical, diagnostic and therapeutic aspects of (inherited) hypercholesterolemia. Drug Discovery Today Disease Mechanisms, 2004, 1, 165-170.	0.8	3
1066	HMG-coA reductase inhibitors: lipid-lowering and beyond. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 189-194.	0.5	4
1067	Intensive lipid lowering with atorvastatin reduces progression of coronary atherosclerosis, as measured by intravascular ultrasound. Evidence-Based Healthcare and Public Health, 2004, 8, 298-301.	0.2	0
1068	Actualités en cardiologie. EMC - Cardiologie-Angéiologie, 2004, 1, 177-186.	0.9	0
1070	Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. Journal of the American College of Cardiology, 2004, 43, 642-648.	1.2	319

#	ARTICLE	IF	CITATIONS
1071	The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis. Journal of the American College of Cardiology, 2004, 43, 464-473.	1.2	99
1072	Prognostic value of coronary artery calcium screening in subjects with and without diabetes. Journal of the American College of Cardiology, 2004, 43, 1663-1669.	1.2	551
1073	Prior convictions. Journal of the American College of Cardiology, 2004, 43, 1929-1939.	1.2	105
1074	The cardiologist's toolbox: improving care**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2004, 43, 2174-2176.	1.2	0
1075	Optimal low-density lipoprotein is 50 to 70 mg/dl. Journal of the American College of Cardiology, 2004, 43, 2142-2146.	1.2	444
1077	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2004, 44, E1-E211.	1.2	1,028
1078	Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. Journal of the American College of Cardiology, 2004, 44, 1772-1779.	1.2	130
1079	President's page: The promise of prevention: So, why aren't all cardiologists "preventive"? Journal of the American College of Cardiology, 2004, 44, 2082-2084.	1.2	2
1080	A pharmacological surveillance study of the tolerability of policosanol in the elderly population. American Journal of Geriatric Pharmacotherapy, 2004, 2, 219-229.	3.0	8
1081	Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA). Drugs, 2004, 64, 43-60.	4.9	189
1082	Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2601-2607.	1.8	398
1083	The Metabolic Syndrome and Inflammation. Metabolic Syndrome and Related Disorders, 2004, 2, 82-104.	0.5	178
1084	Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis, 2004, 173, 1-12.	0.4	233
1085	Approaches to measuring cholesterol absorption in humans. Atherosclerosis, 2004, 174, 197-205.	0.4	55
1086	Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. Journal of the Neurological Sciences, 2004, 221, 5-10.	0.3	103
1087	Management of Hyperlipidaemia Associated with Heart Transplantation. Drugs, 2004, 64, 1053-1068.	4.9	20
1088	Medical Lipid-Regulating Therapy. Drugs, 2004, 64, 1181-1196.	4.9	68
1089	Fluvastatin. Drugs, 2004, 64, 1305-1323.	4.9	23

#	ARTICLE	IF	CITATIONS
1090	Role of Fibrin Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease. <i>Drugs</i> , 2004, 64, 2177-2198.	4.9	67
1091	Risk Reduction Strategies in Ischaemic Stroke. <i>Clinical Drug Investigation</i> , 2004, 24, 245-254.	1.1	15
1092	Efficacy, Safety and Tolerability of Combined Low-Dose Simvastatin-Fenofibrate Treatment in Primary Mixed Hyperlipidaemia. <i>Clinical Drug Investigation</i> , 2004, 24, 465-477.	1.1	13
1093	Prevention. <i>Cerebrovascular Diseases</i> , 2004, 17, 15-29.	0.8	59
1094	Biomarkers of Alzheimer disease in plasma. <i>NeuroRx</i> , 2004, 1, 226-234.	6.0	241
1095	Efficacy and Safety of Coadministration of Ezetimibe and Statins in Elderly Patients with Primary Hypercholesterolaemia. <i>Drugs and Aging</i> , 2004, 21, 1025-1032.	1.3	49
1096	Strategies to Increase HMG-CoA Reductase Inhibitor Use After Acute Myocardial Infarction. <i>Drugs and Aging</i> , 2004, 21, 583-595.	1.3	1
1097	Effects of Calcium Supplementation on Circulating Lipids. <i>Drugs and Aging</i> , 2004, 21, 7-17.	1.3	78
1098	Lipemia, Inflammation and Atherosclerosis. <i>Drugs</i> , 2004, 64, 19-41.	4.9	59
1099	Evidence-Based Endocrinology. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004, 3, 1-10.	1.8	8
1100	Cardiovascular disease: different strategies for primary and secondary prevention?. <i>Heart</i> , 2004, 90, 1217-1223.	1.2	73
1101	Diabetes in the elderly and in women: cardiovascular risks. <i>Cardiology Clinics</i> , 2004, 22, 541-551.	0.9	21
1102	Pharmacoepidemiology and disability in older adults: can medications slow the age-related decline in physical function?. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 407-413.	0.9	11
1103	Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. <i>Lipids in Health and Disease</i> , 2004, 3, 7.	1.2	41
1104	Treatment of metabolic syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 213-228.	0.6	67
1105	Extended-release niacin/lovastatin: the first combination product for dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 485-501.	0.6	22
1106	Achieving lipid goals in Europe: how large is the treatment gap?. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 431-449.	0.6	20
1107	Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 405-415.	0.6	6

#	ARTICLE	IF	CITATIONS
1108	Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Review of Cardiovascular Therapy, 2004, 2, 641-652.	0.6	15
1109	Recent advances in the secondary prevention of coronary heart disease. Expert Review of Cardiovascular Therapy, 2004, 2, 877-889.	0.6	6
1111	Risk for stroke after elective noncarotid vascular surgery. Journal of Vascular Surgery, 2004, 39, 67-72.	0.6	52
1112	Vitamins in human arteriosclerosis with emphasis on vitamin C and vitamin E. Clinica Chimica Acta, 2004, 339, 11-25.	0.5	95
1113	Simvastatin reduces interleukin-1 β secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clinica Chimica Acta, 2004, 344, 195-200.	0.5	34
1114	Rosuvastatin in the management of hyperlipidemia. Clinical Therapeutics, 2004, 26, 1368-1387.	1.1	64
1115	Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clinical Therapeutics, 2004, 26, 1821-1833.	1.1	51
1116	A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clinical Therapeutics, 2004, 26, 1758-1773.	1.1	171
1117	Cytokine imbalance in acute coronary syndrome. Current Opinion in Pharmacology, 2004, 4, 166-170.	1.7	48
1118	Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Research and Clinical Practice, 2004, 64, 137-151.	1.1	104
1119	A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients. Diabetes Research and Clinical Practice, 2004, 66, 97-99.	1.1	5
1120	The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone, 2004, 35, 766-770.	1.4	31
1121	Commentary. Evidence-based Cardiovascular Medicine, 2004, 8, 337-338.	0.0	0
1122	Time trends in three triennial surveys of cardiovascular risk factors and their treatment among patients discharged from divisions of internal medicine. European Journal of Internal Medicine, 2004, 15, 298-304.	1.0	2
1123	Fingertip guide to clinical endocrinology PDxMD Endocrinology edited by a thirty-eight member editorial board. PDxMD, 2003. US\$49.95 (xv + 734 pages) ISBN 1 932141 17 0. Trends in Endocrinology and Metabolism, 2004, 15, 92-93.	3.1	0
1124	Get there quicker Early Diagnosis and Treatment of Endocrine Disorders edited by Robert S. Bar. Humana, 2003. US\$115.00 (xi+369 pages) ISBN 1 58829193 6. Trends in Endocrinology and Metabolism, 2004, 15, 93-94.	3.1	0
1125	Targeting eNOS for stroke protection. Trends in Neurosciences, 2004, 27, 283-289.	4.2	238
1127	In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis?. Transfusion and Apheresis Science, 2004, 30, 213-220.	0.5	4

#	ARTICLE	IF	CITATIONS
1128	New trends in specific immunoadsorption. <i>Transfusion and Apheresis Science</i> , 2004, 30, 223-231.	0.5	16
1129	Impact of fluvastatin on hyperlipidemia after renal transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 2141-2144.	0.3	7
1130	Cardiovascular disease in renal transplantation: Management by statins. <i>Transplantation Reviews</i> , 2004, 18, 122-128.	1.2	6
1132	Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 454-460.	2.4	189
1133	Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 744-748.	1.5	76
1134	APP intracellular domain is increased and soluble A β is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. <i>Neurobiology of Disease</i> , 2004, 16, 124-132.	2.1	80
1135	Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. <i>Neuroscience Letters</i> , 2004, 369, 87-92.	1.0	45
1136	Rosuvastatin reduces caspase-3 activity and up-regulates β -secretase in human neuroblastoma SH-SY5Y cells exposed to A β . <i>Neuroscience Letters</i> , 2004, 371, 209-214.	1.0	29
1137	Past, present, and future clinical trials of cardiovascular risk reduction—the hyperlipidemia perspective. <i>International Congress Series</i> , 2004, 1262, 265-268.	0.2	1
1138	Hypolipidemic drugs, blood pressure, heart rate, heart rate variability and sympathetic activity. <i>International Congress Series</i> , 2004, 1262, 458-461.	0.2	2
1139	Drug prescriptions and referral to cardiac rehabilitation after acute coronary events: comparison between men and women in the French PREVENIR Survey. <i>International Journal of Cardiology</i> , 2004, 93, 217-223.	0.8	28
1140	The role of coronary endothelial function testing in patients suspected for angina pectoris. <i>International Journal of Cardiology</i> , 2004, 96, 123-129.	0.8	10
1141	Optimal management of hyperlipidemia in primary prevention of cardiovascular disease. <i>International Journal of Cardiology</i> , 2004, 97, 355-366.	0.8	28
1142	Contemporary management of silent ischemia: the role of ambulatory monitoring. <i>International Journal of Cardiology</i> , 2004, 96, 311-319.	0.8	17
1143	Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. <i>International Journal of Cardiology</i> , 2004, 97, 239-244.	0.8	36
1144	Atherosclerotic disease regression with statins: studies using vascular markers. <i>International Journal of Cardiology</i> , 2004, 96, 447-459.	0.8	33
1145	Reduced creatine kinase release with statin use at the time of myocardial infarction. <i>International Journal of Cardiology</i> , 2004, 96, 461-466.	0.8	14
1146	Mandate for creation of a national peripheral arterial disease public awareness program: An opportunity to improve cardiovascular health. <i>Journal of Radiology Nursing</i> , 2004, 23, 21-31.	0.2	0

#	ARTICLE	IF	CITATIONS
1148	Vascular basis for the treatment of myocardial ischemia study: Trial design and baseline characteristics. <i>American Heart Journal</i> , 2004, 147, 875-882.	1.2	17
1149	Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The Pravastatin in Acute Coronary Treatment (PACT) trial. <i>American Heart Journal</i> , 2004, 148, 91.	1.2	78
1151	Effects of multivitamins and low-dose folic acid supplements on flow-mediated vasodilation and plasma homocysteine levels in older adults. <i>American Heart Journal</i> , 2004, 148, 517.	1.2	16
1152	Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2004, 148, 263-268.	1.2	193
1153	The triglycerideâ€“high-density lipoprotein axis: An important target of therapy?. <i>American Heart Journal</i> , 2004, 148, 211-221.	1.2	82
1154	Treatment of hyperlipidemia in cardiac transplant recipients. <i>American Heart Journal</i> , 2004, 148, 200-210.	1.2	56
1155	Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin. <i>American Heart Journal</i> , 2004, 148, 447-455.	1.2	155
1156	Introduction. <i>American Heart Journal</i> , 2004, 148, S1-S2.	1.2	2
1157	Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction. <i>American Heart Journal</i> , 2004, 148, S3-S8.	1.2	14
1158	Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: The rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). <i>American Heart Journal</i> , 2004, 148, 1053-1059.	1.2	12
1159	Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. <i>American Journal of Ophthalmology</i> , 2004, 137, 615-624.	1.7	84
1160	Beyond hypertension toward guidelines for cardiovascular risk reduction. <i>American Journal of Hypertension</i> , 2004, 17, 1068-1074.	1.0	48
1161	Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. <i>American Journal of Medicine</i> , 2004, 116, 96-103.	0.6	242
1162	Current overview of statin-induced myopathy. <i>American Journal of Medicine</i> , 2004, 116, 408-416.	0.6	259
1163	Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies. <i>American Journal of Medicine</i> , 2004, 116, 540-545.	0.6	84
1164	Introduction. <i>American Journal of Medicine</i> , 2004, 116, 1-2.	0.6	303
1165	Past, present, and future standards for management of dyslipidemia. <i>American Journal of Medicine</i> , 2004, 116, 3-8.	0.6	182
1166	Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment. <i>American Journal of Medicine</i> , 2004, 116, 17-25.	0.6	21

#	ARTICLE	IF	CITATIONS
1167	Atherosclerosis measured by B-Mode ultrasonography: effect of statin therapy on disease progression. <i>American Journal of Medicine</i> , 2004, 116, 31-36.	0.6	54
1168	Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials. <i>American Journal of Medicine</i> , 2004, 117, 596-606.	0.6	132
1169	Effects of statins on vascular structure and function: A systematic review. <i>American Journal of Medicine</i> , 2004, 117, 775-790.	0.6	65
1170	Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. <i>American Journal of Medicine</i> , 2004, 117, 823-829.	0.6	216
1171	Role of statin therapy in the coronary bypass patient. <i>Annals of Thoracic Surgery</i> , 2004, 78, 730-740.	0.7	48
1172	Atorvastatin Reduces Remnant Lipoproteins and Small, Dense Low-Density Lipoproteins Regardless of the Baseline Lipid Pattern. <i>Preventive Cardiology</i> , 2004, 7, 154-160.	1.1	20
1173	Should the National Cholesterol Education Program Guidelines Be Changed for Persons at High Risk for Cardiovascular Events?. <i>Preventive Cardiology</i> , 2004, 7, 71-72.	1.1	1
1174	Cholesterol Management and the Reduction of Cardiovascular Risk. <i>Preventive Cardiology</i> , 2004, 7, 34-41.	1.1	10
1175	The Effects of Niacin on Lipoprotein Subclass Distribution. <i>Preventive Cardiology</i> , 2004, 7, 182-189.	1.1	19
1176	Coronary Heart Disease Risk Reduction in Postmenopausal Women: The Role of Statin Therapy and Hormone Replacement Therapy. <i>Preventive Cardiology</i> , 2004, 7, 131-136.	1.1	3
1177	Hypertension and End-Organ Disease in African Americans: Case Presentations. <i>Journal of Clinical Hypertension</i> , 2004, 6, 48-53.	1.0	1
1178	Apolipoprotein(a) size polymorphism is associated with coronary heart disease in polygenic hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 193-199.	1.1	5
1179	Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 215-224.	1.1	39
1180	Diet for preventing cardiovascular diseases. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 52-57.	1.1	23
1186	Management of French patients with type 2 diabetes mellitus in medical general practice: Report of the Mediab observatory. <i>Diabetes and Metabolism</i> , 2004, 30, 35-42.	1.4	45
1187	Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. <i>Diabetes and Metabolism</i> , 2004, 30, 327-333.	1.4	11
1188	Effects of simvastatin on blood pressure in hypercholesterolemic patients: An open-label study in patients with hypertension or normotension. <i>Current Therapeutic Research</i> , 2004, 65, 239-254.	0.5	2
1189	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2004, 350, 1495-1504.	13.9	4,527

#	ARTICLE	IF	CITATIONS
1190	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Journal of the American College of Cardiology</i> , 2004, 44, 720-732.	1.2	1,207
1191	Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. <i>Atherosclerosis</i> , 2004, 177, 219-234.	0.4	84
1192	Oral antidiabetic agents: 2004. <i>Medical Clinics of North America</i> , 2004, 88, 847-863.	1.1	32
1193	Stroke prevention, blood cholesterol, and statins. <i>Lancet Neurology</i> , The, 2004, 3, 271-278.	4.9	115
1194	Consistency in Efficacy and Safety of Ezetimibe Coadministered with Statins for Treatment of Hypercholesterolemia in Women and Men. <i>Journal of Women's Health</i> , 2004, 13, 1101-1107.	1.5	27
1195	Role of Oxidative Modifications in Atherosclerosis. <i>Physiological Reviews</i> , 2004, 84, 1381-1478.	13.1	2,186
1196	Glucose interaction magnifies atherosclerotic risk from cholesterol. <i>Atherosclerosis</i> , 2004, 172, 115-120.	0.4	10
1197	Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2004, 173, 55-68.	0.4	425
1198	The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes. <i>Atherosclerosis</i> , 2004, 174, 141-149.	0.4	17
1199	Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. <i>Atherosclerosis</i> , 2004, 175, 287-293.	0.4	84
1200	Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. <i>Atherosclerosis</i> , 2004, 175, 305-313.	0.4	64
1201	Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin. <i>Atherosclerosis</i> , 2004, 175, 369-376.	0.4	22
1202	Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. <i>Atherosclerosis</i> , 2004, 175, 377-379.	0.4	21
1203	Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. <i>Atherosclerosis</i> , 2004, 177, 147-153.	0.4	13
1204	HDL: a recipe for longevity. <i>Atherosclerosis Supplements</i> , 2004, 5, 25-31.	1.2	39
1205	Impact of age on cardiovascular risk: implications for cardiovascular disease management. <i>Atherosclerosis Supplements</i> , 2004, 5, 9-17.	1.2	29
1206	A Dietary portfolio: Maximal reduction of low-density lipoprotein cholesterol with diet. <i>Current Atherosclerosis Reports</i> , 2004, 6, 492-498.	2.0	66
1208	Protocolo terapéutico de las hiperlipidemias en pacientes con antecedentes de eventos vasculares graves. Prevención secundaria. <i>Medicine</i> , 2004, 9, 1153-1156.	0.0	0

#	ARTICLE	IF	CITATIONS
1210	Tratamiento farmacológico de la hipertensión arterial. <i>Medicine</i> , 2004, 9, 1481-1493.	0.0	0
1211	Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. <i>Lancet</i> , The, 2004, 363, 757-767.	6.3	1,016
1212	Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. <i>Lancet</i> , The, 2004, 363, 1139-1146.	6.3	510
1213	Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). <i>Lancet</i> , The, 2004, 363, 1925-1933.	6.3	914
1214	Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2004, 363, 2015-2021.	6.3	750
1215	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. <i>Lancet</i> , The, 2004, 364, 685-696.	6.3	3,502
1216	Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). <i>Lancet</i> , The, 2004, 364, 771-777.	6.3	299
1217	Statins for patients with type 2 diabetes. <i>Lancet</i> , The, 2004, 364, 1933-1934.	6.3	3
1218	Association of dyslipidemia and effects of statins on nonmacrovascular diseases. <i>Clinical Therapeutics</i> , 2004, 26, 337-351.	1.1	21
1219	Prevention and treatment of stroke in patients with hypertension. <i>Clinical Therapeutics</i> , 2004, 26, 631-648.	1.1	41
1220	A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study. <i>Clinical Therapeutics</i> , 2004, 26, 878-888.	1.1	9
1221	Dyslipidemia in the metabolic syndrome. <i>Journal of Drug Evaluation</i> , 2004, 2, 3-34.	0.0	5
1222	National Survey of Pharmacists About Coronary Heart Disease, Hypercholesterolemia, Nonprescription Statin Therapy, and Pharmacists'™ Services. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, 562-568.	0.7	12
1223	Role of Statins in the Treatment and Prevention of Stroke: Introduction. <i>Stroke</i> , 2004, 35, 2706-2707.	1.0	10
1224	Preventing clinically evident coronary heart disease in the postmenopausal woman. <i>Menopause</i> , 2004, 11, 484-494.	0.8	13
1225	Recent insights into the expanding role of high-density lipoprotein cholesterol in dyslipidemia and disease. <i>Current Opinion in Cardiology</i> , 2004, 19, 363-365.	0.8	0
1226	The cardioprotective effects of statins. <i>Coronary Artery Disease</i> , 2004, 15, 243-245.	0.3	9
1227	Emphasis on pleiotropic effects, a new paradigm shift?. <i>Coronary Artery Disease</i> , 2004, 15, 223-225.	0.3	13

#	ARTICLE	IF	CITATIONS
1228	Statin therapy in the elderly. <i>Current Opinion in Lipidology</i> , 2004, 15, 453-457.	1.2	7
1229	Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. <i>Coronary Artery Disease</i> , 2004, 15, 235-242.	0.3	60
1230	Current and future concepts in stroke prevention. <i>Cmaj</i> , 2004, 170, 1123-1133.	0.9	32
1231	Cardiovascular outcomes among participants with diabetes in the recent large statin trials. <i>Current Opinion in Lipidology</i> , 2004, 15, 439-446.	1.2	32
1232	Phenotypes, genotypes and response to statin therapy. <i>Current Opinion in Lipidology</i> , 2004, 15, 387-392.	1.2	34
1233	CETP gene variation: relation to lipid parameters and cardiovascular risk. <i>Current Opinion in Lipidology</i> , 2004, 15, 393-398.	1.2	59
1234	National Cholesterol Education Program Guidelines and Supporting Evidence. <i>Critical Pathways in Cardiology</i> , 2004, 3, S8-S11.	0.2	0
1235	Statin policy and target populations: evidence-based or evidence-biased?. <i>Current Opinion in Lipidology</i> , 2004, 15, 381-386.	1.2	2
1236	Statins for primary prevention: strategic options to save lives and money. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 66-71.	1.1	3
1237	Effect of Simvastatin Versus Placebo on Treadmill Exercise Time Until the Onset of Intermittent Claudication in Older Patients With Peripheral Arterial Disease at Six Months and at One Year After Treatment. <i>Perspectives in Vascular Surgery and Endovascular Therapy</i> , 2004, 16, 334-336.	0.6	0
1238	The Health Effects of Restricting Prescription Medication Use Because of Cost. <i>Medical Care</i> , 2004, 42, 626-634.	1.1	253
1239	Preventing cardiovascular disease in diabetes. <i>Clinical Medicine</i> , 2004, 4, 311-314.	0.8	0
1240	Genetically defined hyperlipidemia. <i>Pharmacogenomics</i> , 2004, 5, 295-304.	0.6	2
1241	Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. <i>Current Opinion in Cardiology</i> , 2004, 19, 480-487.	0.8	17
1242	Post myocardial infarction care by the GP. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2004, 46, 15-18.	0.2	1
1243	Perindopril-based blood pressure lowering in individuals with cerebrovascular disease. <i>Journal of Hypertension</i> , 2004, 22, 653-659.	0.3	42
1244	Les effets non lipidiques des statines au cours de l'athÃ©rosclÃ©rose. <i>Revue De Medecine Interne</i> , 2004, 25, 783-785.	0.6	2
1245	Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinicsThe alliance study. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1772-1779.	1.2	229

#	ARTICLE	IF	CITATIONS
1246	Quality of Life After Coronary Artery Bypass Graft. <i>Chest</i> , 2004, 126, 487-495.	0.4	10
1247	Management of Peripheral Arterial Disease of the Lower Extremities in Elderly Patients. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2004, 59, M172-M177.	1.7	51
1248	Management of the acute coronary syndrome patient. <i>European Heart Journal Supplements</i> , 2004, 6, C49-C57.	0.0	0
1249	Plasma Levels of β -Amyloid(1-40), β -Amyloid(1-42), and Total β -Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins. <i>Archives of Neurology</i> , 2004, 61, 333.	4.9	109
1250	Answering important questions reliably-GISSI Heart Failure, a factorially designed trial with composite (co)primary outcome measures. <i>European Journal of Heart Failure</i> , 2004, 6, 531-533.	2.9	2
1251	Diabetes Mellitus: An Imperative for Prevention and Intense Management. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 394-396.	1.0	1
1252	Antioxidant supplements for preventing gastrointestinal cancers. , 2004, , CD004183.		31
1253	Is high-density lipoprotein the protector of the cardiovascular system?. <i>European Heart Journal Supplements</i> , 2004, 6, A19-A22.	0.0	8
1254	Practical strategies for cardiac disease prevention. <i>Postgraduate Medicine</i> , 2004, 115, 41-44.	0.9	1
1255	Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation. <i>British Journal of Nutrition</i> , 2004, 91, 393-401.	1.2	17
1256	Simvastatin-induced myocardial protection against ischemiaâ€“reperfusion injury is mediated by activation of ATP-sensitive K ⁺ channels. <i>Coronary Artery Disease</i> , 2004, 15, 53-58.	0.3	31
1257	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2004, 15, 97-99.	1.2	0
1258	Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. <i>Current Opinion in Lipidology</i> , 2004, 15, 637-643.	1.2	47
1259	Markers of Myocardial Injury and Dysfunction. <i>AACN Advanced Critical Care</i> , 2004, 15, 547-557.	1.9	9
1260	Progress in Clinical Neurosciences: Pharmacotherapies for the Secondar Prevention of Stroke. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 295-303.	0.3	1
1261	Progress in Prevention. <i>Journal of Cardiovascular Nursing</i> , 2004, 19, 287-289.	0.6	0
1262	Diabetes mellitus and unstable coronary artery disease: improved clinical outcome of coronary artery stenting in an era of glycoprotein IIb/IIIa inhibitors and lipid-lowering therapy. <i>Coronary Artery Disease</i> , 2004, 15, 353-359.	0.3	2
1263	Can we identify vulnerable patients at risk for ST-segment elevation myocardial infarction based on their clinical characteristics?. <i>Coronary Artery Disease</i> , 2004, 15, 467-469.	0.3	2

#	ARTICLE	IF	CITATIONS
1264	Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting ??-hydroxy-??-methylglutaryl coenzyme A reductase inhibitor therapy in men. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 53-60.	5.7	20
1265	Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 601-605.	1.0	15
1266	Type 2 Diabetes and Chronic Systolic Heart Failure. <i>Journal of Cardiovascular Nursing</i> , 2004, 19, S35-S44.	0.6	8
1267	Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration*1. <i>American Journal of Ophthalmology</i> , 2004, 137, 615-624.	1.7	127
1268	Peripheral Arterial Disease in the Catheterization Laboratory: An Underdetected and Undertreated Risk Factor. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1107-1109.	1.4	13
1269	Cholesterol, statins and dementia. <i>Current Opinion in Lipidology</i> , 2004, 15, 667-672.	1.2	76
1270	Optimizing LDL-C Lowering With Statins. <i>American Journal of Therapeutics</i> , 2004, 11, 54-59.	0.5	25
1271	The Top 12 Advances in Vascular Medicine. <i>Journal of Endovascular Therapy</i> , 2004, 11, II-21-II-31.	0.8	2
1272	Time trends in three triennial surveys of cardiovascular risk factors and their treatment among patients discharged from divisions of internal medicineThe FAPOL-1, FADOL-2, and FADOL-3 studies. <i>European Journal of Internal Medicine</i> , 2004, 15, 298-304.	1.0	2
1273	Evidence for anti-inflammatory activity of statins and PPAR α activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. <i>Blood</i> , 2004, 103, 4188-4194.	0.6	166
1274	Interventions to improve adherence to lipid lowering medication. , 2004, , CD004371.		41
1275	Lipids in health and disease. <i>Biochemical Society Transactions</i> , 2004, 32, 1051-1056.	1.6	11
1276	Strategies to reduce oxidative stress in cardiovascular disease. <i>Clinical Science</i> , 2004, 106, 219-234.	1.8	171
1277	Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians. <i>Annals of Internal Medicine</i> , 2004, 140, 644.	2.0	125
1278	Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians. <i>Annals of Internal Medicine</i> , 2004, 140, 650.	2.0	162
1279	Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2004, 140, 689.	2.0	140
1280	Diabetes Care Quality in the Veterans Affairs Health Care System and Commercial Managed Care: The TRIAD Study. <i>Annals of Internal Medicine</i> , 2004, 141, 272.	2.0	254
1281	Primary Care Management of Chronic Stable Angina and Asymptomatic Suspected or Known Coronary Artery Disease: A Clinical Practice Guideline from the American College of Physicians. <i>Annals of Internal Medicine</i> , 2004, 141, 562.	2.0	52

#	ARTICLE	IF	CITATIONS
1283	Early, aggressive lipid management in the treatment of acute coronary syndromes. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 213-216.	0.2	0
1284	ACE inhibitors and target organ protection. <i>Postgraduate Medicine</i> , 2004, 116, 11-48.	0.9	11
1285	Adapting Root Cause Analysis to Chronic Medical Conditions. <i>Joint Commission Journal on Quality and Safety</i> , 2004, 30, 175-186.	1.3	12
1286	More Western Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals With Rosuvastatin Therapy Than With Atorvastatin, Pravastatin, or Simvastatin Therapy. <i>Circulation Journal</i> , 2004, 68, 107-113.	0.7	10
1288	A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction. <i>Archives of Internal Medicine</i> , 2004, 164, 1490.	4.3	54
1289	ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 286, H1425-H1432.	1.5	61
1292	Management of Dyslipidemia in Patients with Metabolic Syndrome. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, 478-490.	0.7	16
1293	Chapter 6 Large-Vessel Atherosclerosis. <i>Blue Books of Practical Neurology</i> , 2004, 29, 99-122.	0.1	1
1294	Importance and Management of Dyslipidemia in the Metabolic Syndrome. <i>American Journal of the Medical Sciences</i> , 2005, 330, 295-302.	0.4	29
1295	Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) Trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 75-81.	3.1	24
1296	Non-Attendance at Secondary Prevention Clinics: The Effect on Lipid Management. <i>Scottish Medical Journal</i> , 2005, 50, 54-56.	0.7	5
1297	Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome. <i>American Journal of the Medical Sciences</i> , 2005, 329, 292-305.	0.4	69
1298	Preventing Cardiovascular Outcome in Patients with Renal Impairment. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 255-269.	1.0	8
1299	Are Statins Being Underdosed in Clinical Practice?. <i>Critical Pathways in Cardiology</i> , 2005, 4, 169-173.	0.2	8
1300	The Vascular Surgeon's Role in Risk Factor Modification: Results of a Survey. <i>Perspectives in Vascular Surgery and Endovascular Therapy</i> , 2005, 17, 145-153.	0.6	10
1301	Clinical Characteristics, Risk Factors, and Medical Treatment of 561 Patients With Peripheral Arterial Disease Followed in an Academic Vascular Surgery Clinic. <i>Cardiology in Review</i> , 2005, 13, 108-110.	0.6	19
1302	Toxic neuropathy. <i>Current Opinion in Neurology</i> , 2005, 18, 574-580.	1.8	55
1303	Effectiveness of using rosuvastatin in difficult-to-control dyslipidemia patients: an audit in secondary care. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 895-900.	0.2	0

#	ARTICLE	IF	CITATIONS
1305	Hypercholesterolemia and LDL Apheresis. <i>International Journal of Artificial Organs</i> , 2005, 28, 1025-1031.	0.7	14
1306	Milestones and New Perspectives in Prevention of Type 2 Diabetes and Its Complications. , 2005, , 325-341.		0
1307	ADAM10. , 2005, , 85-121.		5
1308	Screening for Diabetes Mellitus - the World Health Organization Perspective. , 2005, , 105-123.		0
1309	Statin Initiation Following Coronary Artery Bypass Grafting. <i>Chest</i> , 2005, 127, 455-463.	0.4	18
1310	Tamoxifen for the Prevention of Myocardial Infarction in Humans: Preclinical and Early Clinical Evidence. <i>Circulation</i> , 2005, 112, 3018-3024.	1.6	62
1311	Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants1â€³. <i>American Journal of Clinical Nutrition</i> , 2005, 81, 380-387.	2.2	224
1312	Management of Peripheral Arterial Disease. <i>Cardiology in Review</i> , 2005, 13, 61-68.	0.6	82
1313	Optimal goals for statin use in patients with coronary artery disease. <i>Current Opinion in Cardiology</i> , 2005, 20, 525-529.	0.8	2
1314	Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. <i>Journal of Hypertension</i> , 2005, 23, 1575-1581.	0.3	77
1315	Treating to Low-Density Lipoprotein Goal. <i>Critical Pathways in Cardiology</i> , 2005, 4, 174-176.	0.2	0
1316	Dementia Update 2005. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 100-117.	0.6	58
1317	Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. <i>Current Opinion in Rheumatology</i> , 2005, 17, 286-292.	2.0	94
1318	Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. <i>Current Opinion in Cardiology</i> , 2005, 20, 301-306.	0.8	28
1319	Time to Benefit. <i>Critical Pathways in Cardiology</i> , 2005, 4, 43-45.	0.2	8
1320	The Evolving Use of Cost-Effectiveness Analysis in Formulary Management Within the Department of Veterans Affairs. <i>Medical Care</i> , 2005, 43, II-20.	1.1	26
1321	The clinical epidemiology of cardiovascular disease in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 550-557.	1.0	30
1322	Clinical implications for statin pleiotropy. <i>Current Opinion in Lipidology</i> , 2005, 16, 624-629.	1.2	123

#	ARTICLE	IF	CITATIONS
1323	Beyond guidelines: achieving the optimum in LDL cholesterol control. <i>Current Opinion in Lipidology</i> , 2005, 16, 635-639.	1.2	1
1324	Statin therapy in heart failure. <i>Current Opinion in Lipidology</i> , 2005, 16, 630-634.	1.2	6
1325	LIFESTYLE MODIFICATION, ANTIHYPERTENSIVES, AND CHOLESTEROL-LOWERING MEDICATION FOR PRIMARY AND SECONDARY STROKE PREVENTION. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2005, 11, 47-60.	0.4	3
1326	Aggravation of Focal Cerebral Ischemia by Tissue Plasminogen Activator Is Reversed by 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor but Does Not Depend on Endothelial NO Synthase. <i>Stroke</i> , 2005, 36, 332-336.	1.0	48
1327	Should We Distinguish Between Periventricular and Deep White Matter Hyperintensities?. <i>Stroke</i> , 2005, 36, 2342-2344.	1.0	39
1328	Statin pharmacogenomics: what have we learned, and what remains unanswered?. <i>Current Opinion in Lipidology</i> , 2005, 16, 606-613.	1.2	13
1329	Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting. <i>Circulation</i> , 2005, 111, 488-493.	1.6	91
1330	Statins and Cognition: What Can We Learn from Existing Randomized Trials?. <i>CNS Spectrums</i> , 2005, 10, 867-875.	0.7	22
1331	Lowering LDL Cholesterol: Where Is the End of the Journey?. <i>Cardiology</i> , 2005, 5, 39-50.	0.3	1
1332	Expanding Indications for Statins in Cerebral Ischemia. <i>Archives of Neurology</i> , 2005, 62, 67.	4.9	39
1333	Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. <i>Neurology</i> , 2005, 65, 253-258.	1.5	97
1335	The Future of Statins: Alzheimer's Disease?. <i>The Consultant Pharmacist</i> , 2005, 20, 663-673.	0.4	2
1336	Stroke: background, epidemiology, etiology and avoiding recurrence. , 2005, , 1-46.		2
1337	Torcetrapib/atorvastatin combination therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 789-820.	0.6	27
1338	Cholesterol levels and cholesterol lowering in idiopathic dilated cardiomyopathy: reply. <i>European Heart Journal</i> , 2005, 26, 1931-1932.	1.0	1
1339	Atherosclerotic Cardiovascular Disease Risk in the HAART-Treated HIV-1 Population. <i>HIV Clinical Trials</i> , 2005, 6, 5-24.	2.0	28
1341	New Guidelines in Statin Therapy. <i>Plastic Surgical Nursing</i> , 2005, 25, 109-110.	0.3	0
1343	The Hyperlipidemia. <i>Journal of Cardiovascular Nursing</i> , 2005, 20, 35-42.	0.6	10

#	ARTICLE	IF	CITATIONS
1345	Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: A National Veterans Administration study. <i>Kidney International</i> , 2005, 68, 826-832.	2.6	24
1346	We Are What We Eat. <i>Journal of Cardiovascular Nursing</i> , 2005, 20, 451-460.	0.6	7
1347	Oxidation, lipoproteins, and atherosclerosis: which is wrong, the antioxidants or the theory?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2005, 8, 139-146.	1.3	71
1348	Cardiovascular Drug Therapy in Women. <i>Journal of Cardiovascular Nursing</i> , 2005, 20, 410-419.	0.6	0
1349	The Numbers Needed to Treat for Neurological Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 440-449.	0.3	11
1350	The Impact of a Stroke Prevention Clinic in Diagnosing Modifiable Risk Factors for Stroke. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 496-500.	0.3	14
1351	Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. <i>Current Opinion in Internal Medicine</i> , 2005, 4, 517-522.	1.5	14
1352	Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit. <i>Annals of Internal Medicine</i> , 2005, 143, 241.	2.0	295
1353	Combination Pharmacotherapy for Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2005, 143, 593.	2.0	53
1356	Large-Scale Cohort Study on the Relationship Between Serum Lipid Concentrations and Risk of Cerebrovascular Disease Under Low-Dose Simvastatin in Japanese Patients With Hypercholesterolemia Sub-Analysis of the Japan Lipid Intervention Trial (J-LIT). <i>Circulation Journal</i> , 2005, 69, 1016-1021.	0.7	42
1357	Efficacy of Colestimide Coadministered With Atorvastatin in Japanese Patients With Heterozygous Familial Hypercholesterolemia (FH). <i>Circulation Journal</i> , 2005, 69, 515-520.	0.7	14
1358	Elevated Preprocedural High-Sensitivity C-Reactive Protein Levels are Associated With Neointimal Hyperplasia and Restenosis Development After Successful Coronary Artery Stenting. <i>Circulation Journal</i> , 2005, 69, 1477-1483.	0.7	34
1359	Clinical Characteristics of First-Ever Atherothrombotic Infarction or Lacunar Infarction with Hyperlipidemia (J-STARS-C): An Analysis of Data from the Stroke Data Bank of Japan. <i>Internal Medicine</i> , 2005, 44, 1252-1257.	0.3	12
1360	Cutaneous melanoma: pathogenesis and rationale for chemoprevention. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 225-239.	2.0	25
1361	Drug-drug interactions in oncology: Why are they important and can they be minimized?. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 117-142.	2.0	153
1362	Controversies in Dyslipidemias: Atheroprevention in Diabetes and Insulin Resistance. <i>Annals of the New York Academy of Sciences</i> , 2005, 1055, 159-178.	1.8	2
1363	Management of Peripheral Vascular Disease. <i>Annual Review of Medicine</i> , 2005, 56, 249-272.	5.0	63
1364	Is aggressive lipid-lowering effective and safe in the older adult?. <i>Clinical Cardiology</i> , 2005, 28, 404-407.	0.7	4

#	ARTICLE	IF	CITATIONS
1365	The benefits of statin therapy-what questions remain?. <i>Clinical Cardiology</i> , 2005, 28, 499-503.	0.7	11
1366	Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. <i>Journal of Neurochemistry</i> , 2005, 92, 1386-1398.	2.1	185
1367	Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 117-125.	1.0	920
1368	With what to treat which patient with recently symptomatic carotid stenosis?. <i>Practical Neurology</i> , 2005, 5, 68-83.	0.5	2
1369	Novel determinants of plaque instability. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1962-1975.	1.9	37
1370	Medical management of peripheral arterial disease. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1628-1637.	1.9	50
1371	Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1618-1627.	1.9	173
1372	A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression ¹ . <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2554-2562.	1.9	51
1373	Ambulatory hypercholesterolemia management in patients with atherosclerosis. <i>Journal of General Internal Medicine</i> , 2005, 20, 123-130.	1.3	33
1374	Management of dyslipidemia in women in the post-hormone therapy era. <i>Journal of General Internal Medicine</i> , 2005, 20, 297-305.	1.3	10
1375	Low-Density Lipoprotein Cholesterol and Mortality in Older People. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 2159-2164.	1.3	66
1376	Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. <i>Kidney International</i> , 2005, 68, 1419-1426.	2.6	12
1377	Cardiovascular risk factors in type 2 diabetic patients: Multifactorial intervention in primary care. <i>Kidney International</i> , 2005, 67, S55-S62.	2.6	18
1378	Clinical benefits of slowing the progression of renal failure. <i>Kidney International</i> , 2005, 68, S152-S156.	2.6	6
1379	Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertaintyâ€”When Is There Sufficient Evidence?. <i>Value in Health</i> , 2005, 8, 433-446.	0.1	93
1380	Patterns and Effectiveness of Lipid-Lowering Therapies in a Managed Care Environment. <i>Value in Health</i> , 2005, 8, 601-612.	0.1	18
1381	Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective. <i>Value in Health</i> , 2005, 8, 618-628.	0.1	21
1382	Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 88-97.	2.2	66

#	ARTICLE	IF	CITATIONS
1383	Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 642-653.	2.2	50
1384	Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. <i>Diabetic Medicine</i> , 2005, 22, 1670-1676.	1.2	37
1385	Atherothrombosis: management of patients at risk. <i>International Journal of Clinical Practice</i> , 2005, 59, 407-414.	0.8	8
1386	Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. <i>International Journal of Clinical Practice</i> , 2005, 59, 619-627.	0.8	41
1387	Type 2 diabetes mellitus: a cardiovascular perspective. <i>International Journal of Clinical Practice</i> , 2005, 59, 798-816.	0.8	44
1388	Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. <i>International Journal of Clinical Practice</i> , 2005, 59, 839-846.	0.8	15
1389	Achievement of English National Service Framework lipid-lowering goals: pooled data from recent comparative treatment trials of statins at starting doses. <i>International Journal of Clinical Practice</i> , 2005, 59, 1171-1177.	0.8	8
1390	Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. <i>International Journal of Clinical Practice</i> , 2005, 59, 1377-1386.	0.8	38
1391	Ezetimibe/simvastatin (INEGY [®] , [®]) in the treatment of hyperlipidaemia. <i>International Journal of Clinical Practice</i> , 2005, 59, 1464-1471.	0.8	14
1393	Diagnosis and management of the metabolic syndrome in obesity. <i>Obesity Reviews</i> , 2005, 6, 283-296.	3.1	111
1394	Cardiovascular Risk Factors. <i>Nephrology</i> , 2005, 10, S231-S234.	0.7	4
1395	Prioritizing health-care funding. <i>Internal Medicine Journal</i> , 2005, 35, 409-412.	0.5	14
1396	Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2005, 32, 76-85.	0.9	16
1397	The Heart Protection Study and bias in the interpretation of RCTs. <i>Journal of Evaluation in Clinical Practice</i> , 2005, 11, 405-407.	0.9	2
1398	Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine'. <i>Journal of Internal Medicine</i> , 2005, 257, 313-314.	2.7	13
1399	Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. <i>Journal of Internal Medicine</i> , 2005, 257, 438-445.	2.7	63
1400	The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia. <i>Journal of Internal Medicine</i> , 2005, 258, 442-449.	2.7	17
1401	The pharmaco-economics of peri-operative statin therapy. <i>Anaesthesia</i> , 2005, 60, 1059-1063.	1.8	26

#	ARTICLE	IF	CITATIONS
1402	Statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease. <i>Anaesthesia</i> , 2005, 60, 1106-1114.	1.8	55
1403	The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 227-232.	1.1	51
1404	Ineffectiveness of lipid-lowering therapy in primary care. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 456-463.	1.1	33
1405	Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 564-573.	1.1	125
1406	Statin use after acute myocardial infarction: a nationwide study in Denmark. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 150-158.	1.1	33
1407	Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 534-542.	1.1	77
1408	Factors influencing clinicians' decisions to prescribe medication to prevent coronary heart disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 77-84.	0.7	15
1409	Review article: hyperlipidaemia and cardiovascular risk. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 28-30.	1.9	14
1410	The effect of atorvastatin on serum lipoproteins in acromegaly. <i>Clinical Endocrinology</i> , 2005, 62, 650-655.	1.2	12
1411	Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. <i>European Journal of Clinical Investigation</i> , 2005, 35, 305-314.	1.7	76
1412	Statins – a cure-all for the brain?. <i>Nature Reviews Neuroscience</i> , 2005, 6, 325-331.	4.9	104
1413	Statins and cancer prevention. <i>Nature Reviews Cancer</i> , 2005, 5, 930-942.	12.8	724
1414	HDL as a target in the treatment of atherosclerotic cardiovascular disease. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 193-205.	21.5	418
1415	Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 977-987.	21.5	760
1416	Direct comparison of dietary portfolio vs statin on C-reactive protein. <i>European Journal of Clinical Nutrition</i> , 2005, 59, 851-860.	1.3	64
1417	Statins and Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1093-1110.	2.4	170
1418	Screening for microalbuminuria. <i>Kidney International</i> , 2005, 68, 1899-1900.	2.6	0
1419	Improved Cerebral Vasoreactivity After Statin Administration in Healthy Adults. <i>Journal of Neuroimaging</i> , 2005, 15, 266-270.	1.0	29

#	ARTICLE	IF	CITATIONS
1420	Review of efficacy of rosuvastatin 5â€ƒmg. <i>International Journal of Clinical Practice</i> , 2005, 59, 92-101.	0.8	11
1421	Pitavastatin. <i>International Journal of Clinical Practice</i> , 2005, 59, 239-252.	0.8	148
1422	Simvastatin Effects in Normo- and Hypercholesterolaemic Patients with Peripheral Arterial Occlusive Disease: A Pilot Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 96, 413-419.	1.2	10
1423	Effects of simvastatin on cardiac performance and expression of sarco-plasmic reticular calcium regulatory proteins in rat heart. <i>Acta Pharmacologica Sinica</i> , 2005, 26, 696-704.	2.8	23
1424	The Nurse Practitioner's Role in Helping Patients Achieve Lipid Goals with Statin Therapy. <i>Journal of the American Academy of Nurse Practitioners</i> , 2005, 17, 256-262.	1.4	12
1425	The Effect of Pravastatin on Intima Media Thickness of the Carotid Artery in Patients with Normal Cholesterol. <i>European Journal of Vascular and Endovascular Surgery</i> , 2005, 30, 464-468.	0.8	22
1426	Serum Lipids and Anthropometric Factors Related to the Prevalence of Intermittent Claudication. <i>European Journal of Vascular and Endovascular Surgery</i> , 2005, 30, 582-587.	0.8	5
1427	Management of Acute Carotid Occlusion. <i>European Journal of Vascular and Endovascular Surgery</i> , 2005, 30, 614-616.	0.8	1
1429	Comparison of flow-mediated dilatation of the brachial artery in coronary patients with low-density lipoprotein cholesterol levels <80 mg/dl versus patients with levels 80 to 100 mg/dl. <i>American Journal of Cardiology</i> , 2005, 95, 93-95.	0.7	16
1430	Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. <i>American Journal of Cardiology</i> , 2005, 95, 360-366.	0.7	96
1431	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. <i>American Journal of Cardiology</i> , 2005, 95, 367-372.	0.7	43
1432	A "œpoly-portfolio" for secondary prevention: A strategy to reduce subsequent events by up to 97% over five years. <i>American Journal of Cardiology</i> , 2005, 95, 373-378.	0.7	44
1433	Classification of systemic therapies for potential stabilization of the vulnerable plaque to prevent acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005, 95, 379-382.	0.7	24
1434	Usefulness of noncoronary vascular disease in predicting adverse events in the year following percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2005, 95, 575-580.	0.7	7
1435	Do Statins Increase the Risk of Idiopathic Polyneuropathy?. <i>American Journal of Cardiology</i> , 2005, 95, 1097-1099.	0.7	26
1436	Cost Effectiveness of Rosuvastatin in Treating Patients to Low-Density Lipoprotein Cholesterol Goals Compared With Atorvastatin, Pravastatin, and Simvastatin (a US Analysis of the STELLAR Trial). <i>American Journal of Cardiology</i> , 2005, 95, 1314-1319.	0.7	23
1437	Implications of the Metabolic Syndrome: the New Epidemic. <i>American Journal of Cardiology</i> , 2005, 96, 3-7.	0.7	28
1438	Recent National Cholesterol Education Program Adult Treatment Panel III Update: Adjustments and Options. <i>American Journal of Cardiology</i> , 2005, 96, 53-59.	0.7	208

#	ARTICLE	IF	CITATIONS
1439	Pharmacologic Options for Aggressive Low-Density Lipoprotein Cholesterol Lowering: Benefits Versus Risks. <i>American Journal of Cardiology</i> , 2005, 96, 60-66.	0.7	66
1440	Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2005, 96, 24-33.	0.7	243
1441	Review of Primary and Secondary Prevention Trials with Lovastatin, Pravastatin, and Simvastatin. <i>American Journal of Cardiology</i> , 2005, 96, 34-38.	0.7	38
1442	Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA). <i>American Journal of Cardiology</i> , 2005, 96, 39-44.	0.7	54
1443	The Case for Intensive Statin Therapy After Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 45-53.	0.7	26
1444	Safety of High-Dose Atorvastatin Therapy. <i>American Journal of Cardiology</i> , 2005, 96, 69-75.	0.7	67
1445	Comparison of Efficacy and Safety Assessment of Fluvastatin in Patients <65 Years Versus ≥65 Years of Age. <i>American Journal of Cardiology</i> , 2005, 96, 1142-1148.	0.7	9
1446	Lipid Management in Patients with Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2005, 96, 26-32.	0.7	23
1447	Fourteen-Year (1987 to 2000) Trends in the Attack Rates of, Therapy for, and Mortality from Non- ST -Elevation Acute Coronary Syndromes in Four United States Communities. <i>American Journal of Cardiology</i> , 2005, 96, 1349-1355.	0.7	30
1448	Effect of Statin Use in Patients With Acute Coronary Syndromes and a Serum Low-Density Lipoprotein ≥ 80 mg/dl. <i>American Journal of Cardiology</i> , 2005, 96, 1491-1493.	0.7	23
1449	Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy. <i>American Journal of Cardiology</i> , 2005, 96, 3-13.	0.7	68
1450	Rationale for Targeting Multiple Lipid Pathways for Optimal Cardiovascular Risk Reduction. <i>American Journal of Cardiology</i> , 2005, 96, 14-19.	0.7	15
1451	High-Density Lipoprotein As a Therapeutic Target: Clinical Evidence and Treatment Strategies. <i>American Journal of Cardiology</i> , 2005, 96, 50-58.	0.7	76
1452	Non-High-Density Lipoprotein Cholesterol: The Forgotten Therapeutic Target. <i>American Journal of Cardiology</i> , 2005, 96, 59-64.	0.7	27
1453	Pharmacogenomics of Statin Responsiveness. <i>American Journal of Cardiology</i> , 2005, 96, 65-70.	0.7	52
1454	Erectile Dysfunction Therapy in Special Populations and Applications: Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2005, 96, 62-66.	0.7	10
1457	Cholesterol in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2005, 4, 841-852.	4.9	292
1458	Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. <i>American Journal of Kidney Diseases</i> , 2005, 45, 2-14.	2.1	100

#	ARTICLE	IF	CITATIONS
1459	HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 119-126.	2.1	144
1460	First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2005, 45, 473-484.	2.1	184
1461	K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 16-153.	2.1	543
1462	Outcomes of Acute Coronary Syndrome in a Large Canadian Cohort: Impact of Chronic Renal Insufficiency, Cardiac Interventions, and Anemia. <i>American Journal of Kidney Diseases</i> , 2005, 46, 845-855.	2.1	97
1463	Canadian Randomized Trial of Hemoglobin Maintenance to Prevent or Delay Left Ventricular Mass Growth in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2005, 46, 799-811.	2.1	179
1464	Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus. <i>American Journal of Transplantation</i> , 2005, 5, 2236-2243.	2.6	132
1465	Long-term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study. <i>American Journal of Transplantation</i> , 2005, 5, 2929-2936.	2.6	299
1466	ORIGINAL RESEARCH—EPIDEMIOLOGY: Erectile Dysfunction Is a Marker for Cardiovascular Disease: Results of the Minority Health Institute Expert Advisory Panel. <i>Journal of Sexual Medicine</i> , 2005, 2, 40-50.	0.3	132
1467	Invited Comments on Billups, K. et al. Erectile Dysfunction Is a Marker for Cardiovascular Disease: Results of the Minority Health Institute Expert Advisory Panel. <i>Journal of Sexual Medicine</i> , 2005, 2, 50.	0.3	6
1468	Invited Comments on Billups, K. et al. Erectile Dysfunction Is a Marker for Cardiovascular Disease: Results of the Minority Health Institute Expert Advisory Panel. <i>Journal of Sexual Medicine</i> , 2005, 2, 51.	0.3	0
1470	Pharmacological basis of different targets for the treatment of atherosclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2005, 9, 818-839.	1.6	23
1471	The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. <i>BMC Medicine</i> , 2005, 3, 6.	2.3	99
1472	Rosuvastatin for the Treatment of Hypercholesterolemia. <i>Pharmacotherapy</i> , 2005, 25, 990-1000.	1.2	23
1473	Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy. <i>Pharmacotherapy</i> , 2005, 25, 1035-1043.	1.2	98
1474	Long-Term Impact of a Community Pharmacist Intervention on Cholesterol Levels in Patients at High Risk for Cardiovascular Events: Extended Follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). <i>Pharmacotherapy</i> , 2005, 25, 110-115.	1.2	28
1475	Caring for Patients with Chronic Kidney Disease: A Joint Opinion of the Ambulatory Care and the Nephrology Practice and Research Networks of the American College of Clinical Pharmacy. <i>Pharmacotherapy</i> , 2005, 25, 123-143.	1.2	25
1476	Statins and Osteoporosis: A Clinical Review. <i>Pharmacotherapy</i> , 2005, 25, 228-243.	1.2	27
1477	Cost-Efficacy Analysis of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Based on Results of the STELLAR Trial: Clinical Implications for Therapeutic Selection. <i>Pharmacotherapy</i> , 2005, 25, 270-278.	1.2	12

#	ARTICLE	IF	CITATIONS
1478	Low Myopathy Rates Associated with Statins as Monotherapy or Combination Therapy with Interacting Drugs in a Group Model Health Maintenance Organization. <i>Pharmacotherapy</i> , 2005, 25, 345-351.	1.2	26
1479	Achieving Cholesterol Target in a Managed Care Organization (ACTION) Trial. <i>Pharmacotherapy</i> , 2005, 25, 360-371.	1.2	30
1480	Substudies of ALLHAT and Heart Protection Study. <i>Preventive Cardiology</i> , 2005, 8, 250-253.	1.1	0
1481	Considerations in the Treatment of Dyslipidemia Associated With Chronic Kidney Failure and Renal Transplantation. <i>Preventive Cardiology</i> , 2005, 8, 244-249.	1.1	10
1482	Time as a Variable With Niacin Extendedâ€Release/Lovastatin vs. Atorvastatin and Simvastatin. <i>Preventive Cardiology</i> , 2005, 8, 226-233.	1.1	3
1483	Decreasing LDL Cholesterol and Medication Cost With Everyâ€Otherâ€Day Statin Therapy. <i>Preventive Cardiology</i> , 2005, 8, 197-199.	1.1	37
1484	Statin mediated protection of the ischemic myocardium. <i>Vascular Pharmacology</i> , 2005, 42, 265-270.	1.0	27
1485	Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 225-230.	0.8	24
1486	Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 667-674.	0.8	59
1490	Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. <i>Diabetologia</i> , 2005, 48, 856-861.	2.9	142
1491	Interaction between simvastatin and metoprolol with respect to cardiac Î²-adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005, 372, 115-124.	1.4	19
1493	Lipids and Lipoproteins in Women. <i>Herz</i> , 2005, 30, 368-374.	0.4	9
1494	Short-term reduction in bone markers with high-dose simvastatin. <i>Osteoporosis International</i> , 2005, 16, 1272-1276.	1.3	37
1495	Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment. <i>Clinical Biochemistry</i> , 2005, 38, 509-513.	0.8	6
1497	Heart failure and statinsâ€”Why do we need a clinical trial?. <i>Clinical Research in Cardiology</i> , 2005, 94, 223-230.	1.2	23
1502	Secondary prevention after ischemic stroke. <i>Journal of Neurology</i> , 2005, 252, 14-20.	1.8	40
1503	Management of ischaemic stroke: statins and antiplatelet agents. <i>Neurological Sciences</i> , 2005, 26, s24-s25.	0.9	0
1504	Changes in prevalence of and prescribing for Ischaemic heart disease in Ireland 1990â€”2002. <i>Irish Journal of Medical Science</i> , 2005, 174, 4-8.	0.8	7

#	ARTICLE	IF	CITATIONS
1508	Treatment of vascular dementia: Evidence from epidemiologic studies. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 219-225.	0.4	0
1509	Pharmacogenetics of response to statins: <i>Where do we stand?</i> . <i>Current Atherosclerosis Reports</i> , 2005, 7, 204-208.	2.0	23
1510	New insights in the treatment of dyslipidemia: A focus on cardiovascular event reduction and the antiatherosclerotic effects of atorvastatin. <i>Current Atherosclerosis Reports</i> , 2005, 7, 335-343.	2.0	6
1511	Statins and proteinuria. <i>Current Atherosclerosis Reports</i> , 2005, 7, 351-357.	2.0	13
1512	The role of statins in the prevention of ischemic stroke. <i>Current Atherosclerosis Reports</i> , 2005, 7, 364-368.	2.0	12
1513	Results of new statin trials: Should the low-density lipoprotein cholesterol treatment guidelines be revised?. <i>Current Atherosclerosis Reports</i> , 2005, 7, 11-16.	2.0	2
1514	Issues with care in the elderly patient presenting with acute ischemia. <i>Current Cardiology Reports</i> , 2005, 7, 270-275.	1.3	1
1515	How aggressive should lipid lowering be among patients with acute coronary syndromes?. <i>Current Cardiology Reports</i> , 2005, 7, 283-287.	1.3	0
1516	Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome. <i>Current Cardiology Reports</i> , 2005, 7, 457-464.	1.3	5
1517	Effective use of combination lipid therapy. <i>Current Cardiology Reports</i> , 2005, 7, 471-479.	1.3	9
1518	Cardiovascular disease in women: Sex differences in presentation, risk factors, and evaluation. <i>Current Cardiology Reports</i> , 2005, 7, 166-172.	1.3	40
1519	Treatment of multiple-risk patients: Using combination therapy to treat beyond LDL lowering. <i>Current Hypertension Reports</i> , 2005, 7, 265-270.	1.5	1
1520	Transient ischemic attack: A neurologic emergency. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 13-20.	2.0	17
1521	Cardiorenal Disease: A Clinical Intersection. <i>International Urology and Nephrology</i> , 2005, 37, 175-184.	0.6	4
1522	Beyond the Statins: New Therapeutic Perspectives in Cardiovascular Disease Prevention. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 135-139.	1.3	27
1523	Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients – The PRIMO Study. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 403-414.	1.3	1,039
1524	Secondary Prevention in Coronary Heart Disease: Goal Achievement and Drug Prescribing. <i>International Journal of Clinical Pharmacy</i> , 2005, 27, 472-474.	1.4	2
1525	Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005, 6, 9.	1.5	71

#	ARTICLE	IF	CITATIONS
1526	The "Statin" wonder of the world: a panacea for all illnesses or a bubble about to burst. <i>Journal of Negative Results in BioMedicine</i> , 2005, 4, 3.	1.4	8
1527	Prevention of coronary artery disease in cancer patients. <i>Pediatric Blood and Cancer</i> , 2005, 44, 620-624.	0.8	16
1528	Strokes and diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 215-221.	0.2	4
1529	Statin therapy should be considered routinely for people with diabetes mellitus. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 233-236.	0.2	0
1530	Improving diabetes care in general practice using a nurse-led, GP supported clinic: a cohort study. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 295-301.	0.2	10
1531	Theoretical exposure of chronically treated patients to lipid lowering agents. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 61-67.	0.9	4
1532	An application of propensity score matching using claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 465-476.	0.9	183
1534	Diabetiker und akutes Koronarsyndrom. , 2005, , 255-271.		0
1535	Similar Medication Compliance and Control of Dyslipidemia With Simvastatin or Atorvastatin in a Staff-Model HMO Medical Clinic. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 499-504.	2.2	8
1536	Clinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 681-686.	2.2	19
1537	Lipid Levels and Use of Lipid-Lowering Drugs for Patients in Pharmacist-Managed Lipid Clinics Versus Usual Care in 2 VA Medical Centers. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 763-771.	2.2	35
1539	Modern intervention strategies for managing dyslipidaemia: the case for combination therapy. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, S17-S23.	0.6	0
1540	Tratamento hipolipemiante em situações especiais: pós-transplante e/ou terapia imunossupressora. <i>Arquivos Brasileiros De Cardiologia</i> , 2005, 85, 50.	0.3	0
1541	Preventing dementia. <i>Advances in Psychiatric Treatment</i> , 2005, 11, 176-183.	0.6	22
1542	Efficacy and safety of rosuvastatin in treatment of dyslipidemia. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1033-1047.	0.5	72
1544	Reducing the risk of coronary heart disease: targeting cholesterol. <i>Nurse Prescribing</i> , 2005, 3, 115-120.	0.1	0
1545	Lipid-modifying drugs. <i>Medical Journal of Australia</i> , 2005, 182, 286-289.	0.8	13
1546	STATINES IN PREVENTION AND TREATMENT OF ATHEROSCLEROSIS CONNECTED DISEASES: EFFICIENCY AND SAFETY. <i>Rational Pharmacotherapy in Cardiology</i> , 2005, 1, 48-53.	0.3	1

#	ARTICLE	IF	CITATIONS
1547	Decreased Heart Rate Recovery in Patients With Heart Failure Effect of Fluvastatin Therapy. <i>International Heart Journal</i> , 2005, 46, 845-854.	0.5	13
1548	RHEUMATOID ARTHRITIS AND CARDIOVASCULAR RISK: PERSPECTIVES OF TREATMENT WITH STATINS. <i>Rational Pharmacotherapy in Cardiology</i> , 2005, 1, 47-53.	0.3	2
1551	Raising HDL-C and lowering triglycerides: benefits beyond LDL-C modification. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, S12-S16.	0.6	0
1552	Real-World Effectiveness of Lipid-Lowering Therapy in Male and Female Outpatients with Coronary Heart Disease: Relation to Pre-Treatment Low-Density Lipoprotein-Cholesterol, Pre-Treatment Coronary Heart Disease Risk, and other Factors. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 37-45.	3.1	18
1553	Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, S1-S15.	0.6	0
1555	Should We Screen Asymptomatic Individuals for Coronary Artery Disease or Implement Universal Lipid-Lowering Therapy?. <i>Cardiology in Review</i> , 2005, 13, 40-45.	0.6	4
1556	The Era of Statins – Is There Still a Place for Other Classes of Lipid-Lowering Drugs?. <i>Cardiology</i> , 2005, 5, 34-38.	0.3	1
1561	Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?. <i>Current Vascular Pharmacology</i> , 2005, 3, 69-79.	0.8	24
1562	Doensa arterial obstrutiva perifrica: que ateno temos dispensado  abordagem clnica dos pacientes?. <i>Jornal Vascular Brasileiro</i> , 2005, 4, 255-264.	0.1	12
1563	Scientific Evidence to Support a Vitamin E and Heart Disease Health Claim: Research Needs. <i>Journal of Nutrition</i> , 2005, 135, 348-353.	1.3	38
1564	The Status of Lipid Management in 1,836 Patients with Coronary Artery Disease: A multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005, 12, 338-342.	0.9	15
1565	Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005, 12, 111-119.	0.9	107
1566	Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 1320-1326.	2.2	129
1567	Is Neurointensive Care Really Optional for Comprehensive Stroke Care?. <i>Stroke</i> , 2005, 36, 2344-2345.	1.0	13
1568	Predictors of Health Care Costs in Adults With Diabetes. <i>Diabetes Care</i> , 2005, 28, 59-64.	4.3	193
1569	Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 145-147.	1.0	13
1571	Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1468-1475.	0.5	61
1572	Do Statins Reduce Risk of Incident Dementia and Alzheimer Disease?<subtitle>The Cache County Study</subtitle>. <i>Archives of General Psychiatry</i> , 2005, 62, 217.	13.8	300

#	ARTICLE	IF	CITATIONS
1573	Lipid Management in Patients With Coronary Artery Disease by a Clinical Pharmacy Service in a Group Model Health Maintenance Organization. <i>Archives of Internal Medicine</i> , 2005, 165, 49.	4.3	59
1574	Long-Term Therapy to Prevent Stroke. <i>Journal of the American Board of Family Medicine</i> , 2005, 18, 528-540.	0.8	12
1575	White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin. <i>Circulation</i> , 2005, 111, 1756-1762.	1.6	59
1576	Clinical Significance of Statin Pleiotropic Effects. <i>Circulation</i> , 2005, 111, 2280-2281.	1.6	67
1577	Efficacy and safety of <i>Monascus purpureus</i> Went rice in subjects with hyperlipidemia. <i>European Journal of Endocrinology</i> , 2005, 153, 679-686.	1.9	128
1578	A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events. <i>Annals of Internal Medicine</i> , 2005, 142, 95.	2.0	205
1579	Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective Survey. <i>Angiology</i> , 2005, 56, 279-287.	0.8	40
1580	Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis. <i>Heart</i> , 2005, 92, 752-758.	1.2	35
1581	Statin Therapy Helps to Control Blood Pressure Levels in Hypertensive Dyslipidemic Patients. <i>Renal Failure</i> , 2005, 27, 297-303.	0.8	11
1582	Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation. <i>Renal Failure</i> , 2005, 27, 259-273.	0.8	0
1583	The management and investigation of elderly patients with acute coronary syndromes without ST elevation: an evidence-based approach? Results of the Prospective Registry of Acute Ischaemic Syndromes in the United Kingdom (PRAIS-UK). <i>Age and Ageing</i> , 2005, 34, 61-66.	0.7	34
1584	Role of Anti-Oxidants in Atherosclerosis: Epidemiological and Clinical Update. <i>Current Pharmaceutical Design</i> , 2005, 11, 2017-2032.	0.9	103
1585	The Predictive Value of Lipid Markers in Vascular Disease. <i>Current Pharmaceutical Design</i> , 2005, 11, 2209-2224.	0.9	8
1586	Calcific Aortic Stenosis: Molecular and Cellular Mechanisms, Medical Treatment Alternatives. <i>Current Cardiology Reviews</i> , 2005, 1, 231-238.	0.6	0
1587	From Traditional Biomarkers to Transcriptome Analysis in Drug Development. <i>Current Molecular Medicine</i> , 2005, 5, 29-38.	0.6	36
1588	Can statin therapy alter the natural history of bicuspid aortic valves?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H2547-H2549.	1.5	17
1590	Neuronal Nitric Oxide Synthase Mediates Statin-Induced Restoration of Vasa Nervorum and Reversal of Diabetic Neuropathy. <i>Circulation</i> , 2005, 112, 93-102.	1.6	112
1591	Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention. <i>Stroke</i> , 2005, 36, 1218-1224.	1.0	743

#	ARTICLE	IF	CITATIONS
1592	Optimizing Percutaneous Coronary Intervention Outcomes. <i>Circulation</i> , 2005, 111, 125-126.	1.6	5
1593	Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo. <i>Circulation</i> , 2005, 111, 1841-1846.	1.6	136
1594	Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects. <i>Stroke</i> , 2005, 36, 1372-1376.	1.0	112
1595	Cardiovascular Disease Risk of Type 2 Diabetes Mellitus and Metabolic Syndrome: Focus on Aggressive Management of Dyslipidemia. <i>Current Diabetes Reviews</i> , 2005, 1, 127-135.	0.6	8
1596	Statins and cognitive function in the elderly. <i>Neurology</i> , 2005, 65, 1388-1394.	1.5	140
1597	Simvastatin Versus Ezetimibe. <i>Circulation</i> , 2005, 111, 2356-2363.	1.6	416
1598	The Effect of Vitamin E on Endothelial Function of Micro- and Macrocirculation and Left Ventricular Function in Type 1 and Type 2 Diabetic Patients. <i>Diabetes</i> , 2005, 54, 204-211.	0.3	74
1599	The Break-Even Point: When Medical Advances Are Less Important Than Improving the Fidelity With Which They Are Delivered. <i>Annals of Family Medicine</i> , 2005, 3, 545-552.	0.9	184
1600	Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. <i>Heart</i> , 2005, 91, 451-455.	1.2	14
1601	Pharmacological modulation of plaque instability. <i>Lupus</i> , 2005, 14, 769-772.	0.8	14
1602	Aim Low. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 599-600.	1.7	0
1603	Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework. <i>Journal of Public Health</i> , 2005, 27, 338-343.	1.0	27
1604	Commentary: Over-correction for regression dilution bias? Not for blood pressure vs coronary heart disease. <i>International Journal of Epidemiology</i> , 2005, 34, 1368-1369.	0.9	0
1606	Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective?: Table 1.. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S11-S17.	3.0	54
1607	Safety and efficacy of atorvastatin in patients with severe renal dysfunction. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 503-510.	1.4	26
1608	Improving secondary prevention in coronary bypass patients: closing the audit loop. <i>Heart</i> , 2005, 91, 456-459.	1.2	7
1609	Lipid Management with Statins in Type 2 Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1714-1719.	0.9	5
1610	Small-vessel cerebrovascular disease in older people. <i>Reviews in Clinical Gerontology</i> , 2005, 15, 207-217.	0.5	7

#	ARTICLE	IF	CITATIONS
1611	Aggressive Versus Moderate Lipid-Lowering Therapy in Hypercholesterolemic Postmenopausal Women. <i>Circulation</i> , 2005, 112, 563-571.	1.6	256
1612	HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size. <i>Circulation Research</i> , 2005, 96, 1185-1192.	2.0	75
1613	Rho GTPases, Statins, and Nitric Oxide. <i>Circulation Research</i> , 2005, 97, 1232-1235.	2.0	434
1614	Serum cholesterol and risk of Alzheimer disease: A community-based cohort study. <i>Neurology</i> , 2005, 65, 1045-1050.	1.5	140
1615	Review: Managing cardiovascular risk in patients with diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 325-329.	0.6	5
1616	Author's Response to Commentaries. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 602-602.	1.7	2
1617	Low-dose atorvastatin in severe chronic kidney disease patients: A randomized, controlled endpoint study. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 489-497.	1.4	42
1618	A trial of education, prompts, and opinion leaders to improve prescription of lipid modifying therapy by primary care physicians for patients with ischemic heart disease. <i>Quality and Safety in Health Care</i> , 2005, 14, 258-263.	2.5	27
1619	Uses and limitations of randomization-based efficacy estimators. <i>Statistical Methods in Medical Research</i> , 2005, 14, 327-347.	0.7	88
1620	Hyperlipidemia in Seniors: Too Much, Too Little, Too Late?. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 595-597.	1.7	1
1621	Intensive Lipid-Lowering Therapy in Patients with Coronary Heart Disease. <i>Annals of Pharmacotherapy</i> , 2005, 39, 329-334.	0.9	1
1622	Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2416-2421.	1.1	146
1623	Chronic kidney disease as cause of cardiovascular morbidity and mortality. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1048-1056.	0.4	523
1624	Commentary: Incubation of coronary heart disease—recent developments. <i>International Journal of Epidemiology</i> , 2005, 34, 248-250.	0.9	6
1625	Preoperative statin use and in-hospital outcomes following heart surgery in patients with unstable angina. <i>European Journal of Cardio-thoracic Surgery</i> , 2005, 27, 1051-1056.	0.6	26
1626	Large simple trials in psychiatry: providing reliable answers to important clinical questions. <i>Epidemiologia E Psichiatria Sociale</i> , 2005, 14, 122-126.	1.0	28
1627	Gender differences in the presentation and management of acute coronary syndromes: a national sample of 1365 admissions. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 376-379.	3.1	25
1628	Vascular and Metabolic Effects of Combined Therapy With Ramipril and Simvastatin in Patients With Type 2 Diabetes. <i>Hypertension</i> , 2005, 45, 1088-1093.	1.3	146

#	ARTICLE	IF	CITATIONS
1629	Estimating the risk for atherothrombosis: are current approaches sufficient?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 427-432.	3.1	2
1630	APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study. <i>Neurology</i> , 2005, 64, 1531-1538.	1.5	223
1631	Lipids and Stroke: The Opportunity of Lipid-Lowering Treatment. <i>Cerebrovascular Diseases</i> , 2005, 20, 53-67.	0.8	19
1632	Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 18-28.	3.1	7
1635	Cardiovascular Disease in Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2005, 2, 44-49.	3.5	63
1636	Statin Use and the Risk of Incident Dementia. <i>Archives of Neurology</i> , 2005, 62, 1047.	4.9	261
1638	Peripheral Arterial Disease: A Missed Opportunity to Administer Statins so as to Reduce Cardiac Morbidity and Mortality. <i>Current Medicinal Chemistry</i> , 2005, 12, 443-452.	1.2	50
1639	Physician Perceptions of Enhanced Community Pharmacist Care in Cholesterol Management. <i>Canadian Pharmacists Journal</i> , 2005, 138, 33-39.	0.4	4
1640	Does intensified cholesterol lowering provide greater protection from cardiovascular events among patients with stable coronary artery disease?. <i>Cmaj</i> , 2005, 172, 1294-1295.	0.9	0
1641	The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed. <i>Cmaj</i> , 2005, 172, 1027-1031.	0.9	16
1642	Cystatin C and Incident Peripheral Arterial Disease Events in the Elderly. <i>Archives of Internal Medicine</i> , 2005, 165, 2666.	4.3	86
1643	The domino effect: obesity, type 2 diabetes and cardiovascular disease. <i>British Journal of Community Nursing</i> , 2005, 10, 358-361.	0.2	8
1644	Cost offset of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 193-205.	0.7	5
1645	Beyond blood pressure: pulse wave analysis " a better way of assessing cardiovascular risk?. <i>Future Cardiology</i> , 2005, 1, 69-78.	0.5	18
1646	Association Between Long-term Statin Use and Mortality after Successful Aneurysm Surgery. <i>Perspectives in Vascular Surgery and Endovascular Therapy</i> , 2005, 17, 173-174.	0.6	1
1647	Rosuvastatin: achieving cholesterol targets. <i>Future Cardiology</i> , 2005, 1, 289-297.	0.5	0
1648	Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials. <i>Future Cardiology</i> , 2005, 1, 461-471.	0.5	0
1649	The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor. <i>Diabetes and Vascular Disease Research</i> , 2005, 2, S1-S8.	0.9	5

#	ARTICLE	IF	CITATIONS
1650	Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. <i>Cmaj</i> , 2005, 172, 177-180.	0.9	34
1651	The analysis by Manuel and colleagues creates controversy with headlines, not data. <i>Cmaj</i> , 2005, 172, 1033-1034.	0.9	4
1652	Effect of thiazolidinediones on lipid profile. <i>Cmaj</i> , 2005, 173, 344-345.	0.9	0
1653	Are the benefits of statins a class effect?. <i>Cmaj</i> , 2005, 172, 1195-1196.	0.9	2
1654	Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. <i>Cmaj</i> , 2005, 172, 1187-1194.	0.9	49
1655	Multi-targeted and Aggressive Treatment of Patients with Type 2 Diabetes at High Risk: What Are We Waiting For?. <i>Hormone and Metabolic Research</i> , 2005, 37, 76-82.	0.7	18
1656	Medical Management of Carotid Artery Disease. <i>Seminars in Neurology</i> , 2005, 25, 376-383.	0.5	4
1657	Use of fluvastatin following percutaneous coronary intervention. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 113-123.	0.7	4
1658	The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease. <i>Current Drug Targets</i> , 2005, 6, 453-474.	1.0	141
1659	CARDS on the table: should everybody with type 2 diabetes take a statin?. <i>Current Medical Research and Opinion</i> , 2005, 21, 357-361.	0.9	10
1660	Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease. <i>Current Medical Research and Opinion</i> , 2005, 21, 1091-1097.	0.9	12
1661	Over-the-counter statins: a new controversy. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 174-175.	3.3	6
1662	Lipid-Lowering Therapy for Elderly Patients at Risk for Coronary Events and Stroke. <i>The American Heart Hospital Journal</i> , 2005, 3, 256-262.	0.2	10
1663	Medical Management of Myocardial Ischemia. <i>The American Journal of Geriatric Cardiology</i> , 2005, 14, 205-209.	0.7	1
1665	Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. <i>Cardiovascular Research</i> , 2005, 66, 462-471.	1.8	97
1666	LDL-C goal attainment with the addition of ezetimibe to on-going simvastatin treatment in coronary heart disease patients with hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2005, 21, 571-578.	0.9	46
1667	Beyond statin therapy: why we need new thinking. <i>Current Medical Research and Opinion</i> , 2005, 21, S3-S8.	0.9	7
1668	Global Risk Stratification to Improve Cardiovascular Prevention: Integration of Traditional Risk Factors, Emerging Risk Factors, and New, Noninvasive Cardiovascular Imaging. <i>The American Heart Hospital Journal</i> , 2005, 3, 265-268.	0.2	0

#	ARTICLE	IF	CITATIONS
1669	Prescribe by Risk: The Utility of a Biomarker-Based Risk Calculation in Disease Management to Prevent Heart Disease. <i>Disease Management: DM</i> , 2005, 8, 106-113.	1.0	9
1670	Metabolic Syndrome: Therapeutic Considerations. <i>Handbook of Experimental Pharmacology</i> , 2005, , 107-133.	0.9	32
1671	Antiretroviral therapy-induced hyperlipidaemia. <i>International Journal of STD and AIDS</i> , 2005, 16, 2-13.	0.5	4
1672	Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 671-679.	1.9	20
1673	Peripheral Arterial Disease in People with Diabetes. <i>Journal of the American Podiatric Medical Association</i> , 2005, 95, 309-319.	0.2	7
1674	HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma. <i>British Journal of Cancer</i> , 2005, 92, 1593-1598.	2.9	23
1675	Comparison of Pre- and Postsurgical Concentrations of Blood HER-2 mRNA and HER-2 Extracellular Domain Reflects HER-2 Status in Early Breast Cancer. <i>Clinical Chemistry</i> , 2005, 51, 254-256.	1.5	5
1676	Antisense oligonucleotides as therapeutics for hyperlipidaemias. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 907-917.	1.4	26
1677	Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both?. <i>Heart</i> , 2005, 92, 729-734.	1.2	51
1678	Should the NCEP III Guidelines Be Changed in Elderly and Younger Persons at High Risk for Cardiovascular Events?. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 591-592.	1.7	12
1679	Best practice in primary care pathology: review 1. <i>Journal of Clinical Pathology</i> , 2005, 58, 1016-1024.	1.0	31
1680	The Challenge of Achieving National Cholesterol Goals in Patients With Diabetes. <i>Diabetes Care</i> , 2005, 28, 1029-1034.	4.3	46
1681	Drug therapy for prevention of cardiovascular disease – should surrogate measures be abandoned?. <i>Clinical Medicine</i> , 2005, 5, 282-286.	0.8	2
1682	Managing Abnormal Blood Lipids. <i>Circulation</i> , 2005, 112, 3184-3209.	1.6	199
1683	Effect of Pravastatin in People with Diabetes and Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3748-3754.	3.0	160
1684	The contrOL of dYslipideMia in outPatlent clinics in GreeCe (Olympic) Study. <i>Angiology</i> , 2005, 56, 731-741.	0.8	19
1685	Statin Therapy Has No Significant Effect on Skin Tissue Cholesterol: Results from a Prospective Randomized Trial. <i>Clinical Chemistry</i> , 2005, 51, 252-254.	1.5	18
1686	Temporal Trends in the Incidence of Intermittent Claudication from 1950 to 1999. <i>American Journal of Epidemiology</i> , 2005, 162, 430-437.	1.6	44

#	ARTICLE	IF	CITATIONS
1687	Rosuvastatin Attenuates Monocyte-Endothelial Cell Interactions and Vascular Free Radical Production in Hypercholesterolemic Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 557-562.	1.3	25
1688	Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. <i>New England Journal of Medicine</i> , 2005, 353, 238-248.	13.9	2,363
1689	Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. <i>Current Medical Research and Opinion</i> , 2005, 21, 665-682.	0.9	99
1690	Systemic antiatherosclerotic treatment for the peripheral arterial occlusive disease patient. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2181-2192.	0.9	2
1691	Hierarchical Graphical Models. <i>Journal of the American Statistical Association</i> , 2005, 100, 719-727.	1.8	3
1692	Statin response and pharmacokinetics variants. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1291-1297.	0.9	12
1693	Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1897-1910.	0.9	10
1694	Translational Research on the Way to Effective Therapy for Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2005, 62, 1186.	13.8	50
1695	The IDEAL Cholesterol. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2492.	3.8	44
1696	Long-Term Benefits and Limitations of Combined Antianginal Drug Therapy in Elderly Patients with Symptomatic Chronic Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 29-37.	1.0	5
1697	Over the counter statins – a good idea?. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 51-53.	0.6	2
1698	Lower Extremity Arterial Disease. , 2005, , .		2
1699	Statins and Blood Coagulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 287-294.	1.1	235
1700	Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke. <i>Stroke</i> , 2005, 36, 1316-1329.	1.0	256
1701	Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>Circulation</i> , 2005, 112, 3058-3065.	1.6	113
1702	Treating Diastolic Heart Failure With Statins. <i>Circulation</i> , 2005, 112, 300-303.	1.6	24
1703	Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?. <i>Heart</i> , 2005, 91, 1-2.	1.2	163
1704	Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1624-1629.	0.9	101

#	ARTICLE	IF	CITATIONS
1705	Lipid lowering agents to delay cognitive decline in Alzheimer's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1611-1613.	0.9	3
1707	The Need for a More Stringent LDL-C Goal in Patients with Diabetes. Journal of Pharmacy Technology, 2005, 21, 325-329.	0.5	0
1708	Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care, 2005, 28, 1151-1157.	4.3	377
1709	Secondary prevention of coronary heart disease in the elderly. Heart, 2005, 91, 396-400.	1.2	15
1710	Lipid and Non-lipid Effects of Statins. Handbook of Experimental Pharmacology, 2005, , 365-388.	0.9	13
1711	Outcomes in 45 Patients With Statin-Associated Myopathy. Archives of Internal Medicine, 2005, 165, 2671.	4.3	224
1713	Clinical Use and Pathogenetic Basis of Laboratory Tests for the Evaluation of Primary Arterial Hypertension. Critical Reviews in Clinical Laboratory Sciences, 2005, 42, 393-452.	2.7	5
1714	The Role of Statins in Oxidative Stress and Cardiovascular Disease. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 165-175.	2.0	9
1715	Non-invasive Atherosclerosis Imaging: Use to Assess Response to Novel or Combination Lipid Therapies. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 557-564.	2.0	5
1716	Cholesterol Absorption Blockade with Ezetimibe. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 455-462.	2.0	34
1717	The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 256-265.	0.7	86
1718	Prevention of Stroke in Patients with Diabetes mellitus and the Metabolic Syndrome. Cerebrovascular Diseases, 2005, 20, 24-34.	0.8	22
1719	Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 75-81.	3.1	1
1720	Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 37-45.	3.1	11
1721	Cholesterol and the Aged: ... and the Beat Goes On. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 600-602.	1.7	2
1722	Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 845-856.	0.2	257
1723	Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure. Circulation, 2005, 112, 357-363.	1.6	282
1724	Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. New England Journal of Medicine, 2005, 352, 29-38.	13.9	1,234

#	ARTICLE	IF	CITATIONS
1725	Aronow's "Should the NCEP III Guidelines Be Changed in Elderly and Younger Persons at High Risk for Cardiovascular Events?": What Do We Do for the Very Old?. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 593-602.	1.7	1
1726	HMG CoA reductase inhibition modulates VEGF α -induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. <i>FASEB Journal</i> , 2005, 19, 1845-1847.	0.2	65
1727	Pericardial tamponade caused by transvenous temporary endocardial pacing. <i>Heart</i> , 2005, 91, 459-459.	1.2	3
1728	Effect of Combining Psyllium Fiber With Simvastatin in Lowering Cholesterol. <i>Archives of Internal Medicine</i> , 2005, 165, 1161.	4.3	104
1729	Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. <i>Journal of Lipid Research</i> , 2005, 46, 779-789.	2.0	83
1730	Statin Use and Survival Outcomes in Elderly Patients With Heart Failure. <i>Archives of Internal Medicine</i> , 2005, 165, 62.	4.3	103
1731	Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?. <i>Postgraduate Medical Journal</i> , 2005, 81, 401-403.	0.9	15
1732	Managing Cardiovascular Risk in Patients With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 115-123.	0.9	52
1733	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Archives of Internal Medicine</i> , 2005, 165, 2479.	4.3	244
1735	Benefits and risks assessment of simvastatin in familial hypercholesterolaemia. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 171-181.	1.0	8
1736	In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes. <i>Chest</i> , 2005, 128, 3641-3651.	0.4	16
1737	Total risk factor management in patients with type 2 diabetes. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005, 66, 529-533.	0.2	0
1738	Effects of a 5-Lipoxygenase-Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2245.	3.8	212
1739	Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. <i>BMJ: British Medical Journal</i> , 2005, 330, 1059-1063.	2.4	118
1740	Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. <i>BMJ: British Medical Journal</i> , 2005, 330, 821.	2.4	78
1741	Sensitivity and Specificity of the Ankle-Brachial Index to Predict Future Cardiovascular Outcomes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1463-1469.	1.1	306
1742	Editorial Comment: Secondary Prevention of Stroke Is Important. <i>Stroke</i> , 2005, 36, 1225-1226.	1.0	24
1743	Evidence for Age and Sex Differences in the Secondary Prevention of Stroke in Scottish Primary Care. <i>Stroke</i> , 2005, 36, 1771-1775.	1.0	80

#	ARTICLE	IF	CITATIONS
1744	Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients. <i>Stroke</i> , 2005, 36, 2072-2076.	1.0	188
1745	Transcranial Doppler and Carotid Artery Disease Strokes: More Than Just Risk Stratification. <i>Stroke</i> , 2005, 36, 2340-2341.	1.0	0
1746	A Systemic Review of the Risk Factors for Cervical Artery Dissection. <i>Stroke</i> , 2005, 36, 2340-2340.	1.0	9
1747	HMG-CoA Reductase Inhibitors Improve Acute Ischemic Stroke Outcome. <i>Stroke</i> , 2005, 36, 2344-2344.	1.0	15
1748	Use of Quantitative Magnetic Resonance Angiography to Stratify Stroke Risk in Symptomatic Vertebrobasilar Disease. <i>Stroke</i> , 2005, 36, 2341-2342.	1.0	1
1749	The initial management of stable angina in Europe, from the Euro Heart Survey. <i>European Heart Journal</i> , 2005, 26, 1011-1022.	1.0	77
1750	Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVENT Intervention Trial. <i>European Heart Journal</i> , 2005, 26, 1314-1320.	1.0	51
1751	Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. <i>European Heart Journal</i> , 2005, 26, 2032-2038.	1.0	83
1752	Combined pharmacologic treatment with clopidogrel and statin for patients with acute coronary syndrome: is there a survival advantage?. <i>European Heart Journal</i> , 2005, 26, 1932-1932.	1.0	0
1753	The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 599-614.	0.2	44
1754	Optimal diabetes management during medical weight loss for cardiovascular risk reduction. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 761-775.	0.6	5
1755	Changing lipid-lowering guidelines: whom to treat and how low to go. <i>Country Review Ukraine</i> , 2005, 7, A12-A19.	0.8	5
1756	Current status of stroke prevention in patients with atrial fibrillation. <i>Country Review Ukraine</i> , 2005, 7, C12-C18.	0.8	6
1757	The realities of dyslipidaemia: what do the studies tell us?. <i>Country Review Ukraine</i> , 2005, 7, F27-F33.	0.8	15
1758	Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. <i>Country Review Ukraine</i> , 2005, 7, F34-F40.	0.8	19
1759	Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 974-980.	0.4	72
1760	Under-treated high-risk patients: identifying patients in high-risk subgroups and treating them to LDL-C targets. <i>Country Review Ukraine</i> , 2005, 7, A20-A28.	0.8	5
1761	Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. <i>Country Review Ukraine</i> , 2005, 7, F56-F62.	0.8	12

#	ARTICLE	IF	CITATIONS
1762	Can a Marker Be a Surrogate for Development of Cancer, and Would We Know It if It Exists?. , 2005, 166, 99-112.		4
1763	External validity of randomised controlled trials: "To whom do the results of this trial apply?" Lancet, The, 2005, 365, 82-93.	6.3	1,959
1764	Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet, The, 2005, 365, 176-186.	6.3	776
1765	Endothelial inflammation in insulin resistance. Lancet, The, 2005, 365, 610-612.	6.3	188
1766	Type 2 diabetes: principles of pathogenesis and therapy. Lancet, The, 2005, 365, 1333-1346.	6.3	1,976
1767	Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals. Lancet, The, 2005, 365, 1779-1785.	6.3	106
1768	Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet, The, 2005, 366, 1267-1278.	6.3	6,113
1769	Factores metab?licos de riesgo cardiovascular. Relevancia epidemiol?gica. Tratamiento farmacol?gico. Situaciones de especial relevancia. Medicine, 2005, 9, 3032-3043.	0.0	0
1772	¿Hasta d?nde hay que reducir el colesterol en el paciente de alto riesgo cardiovascular?. Hipertension, 2005, 22, 318-331.	0.0	0
1773	Utilidad de la medici?n de la apolipoprote?na B en la pr?ctica cl?nica. Cl?nica E Investigaci?n En Arteriosclerosis, 2005, 17, 142-146.	0.4	1
1774	Implicaciones cl?nicas del estudio TNT. Cl?nica E Investigaci?n En Arteriosclerosis, 2005, 17, 249-254.	0.4	0
1775	Estatinas y enfermedad de Alzheimer: ¿son concluyentes los estudios actuales?. Cl?nica E Investigaci?n En Arteriosclerosis, 2005, 17, 2-6.	0.4	0
1778	Antiangiog?nesis y estatinas. Cl?nica E Investigaci?n En Arteriosclerosis, 2005, 17, 15-22.	0.4	1
1779	Statins and the Risk of Colorectal Cancer. New England Journal of Medicine, 2005, 352, 2184-2192.	13.9	706
1780	Lipids for Psychiatrists - an overview. Journal of Psychopharmacology, 2005, 19, 66-75.	2.0	17
1783	Management of dyslipidemia in elderly diabetic patients. Diabetes and Metabolism, 2005, 31, 5S74-5S81.	1.4	6
1784	Markers for silent myocardial ischemia in diabetes. Are they helpful?. Diabetes and Metabolism, 2005, 31, 205-213.	1.4	26
1785	Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes and Metabolism, 2005, 31, 479-485.	1.4	29

#	ARTICLE	IF	CITATIONS
1789	Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis. <i>Atherosclerosis</i> , 2005, 178, 147-155.	0.4	25
1790	Gender-specific effects of estrogen receptor $\hat{\pm}$ gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism. <i>Atherosclerosis</i> , 2005, 178, 331-338.	0.4	38
1791	Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. <i>Atherosclerosis</i> , 2005, 179, 201-206.	0.4	90
1792	Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. <i>Atherosclerosis</i> , 2005, 179, 293-297.	0.4	45
1793	Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. <i>Atherosclerosis</i> , 2005, 179, 361-367.	0.4	71
1794	Projected coronary heart disease risk benefit with ezetimibe. <i>Atherosclerosis</i> , 2005, 179, 375-378.	0.4	10
1795	Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. <i>Atherosclerosis</i> , 2005, 180, 107-112.	0.4	23
1796	A promoter polymorphism in cholesterol $\hat{7}\pm$ -hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. <i>Atherosclerosis</i> , 2005, 180, 407-415.	0.4	58
1797	High-density lipoprotein cholesterol in the cardiovascular equation: Does the "œgood" still count?. <i>Atherosclerosis</i> , 2005, 180, 217-223.	0.4	21
1798	Markers of inflammation and their clinical significance. <i>Atherosclerosis Supplements</i> , 2005, 6, 21-29.	1.2	125
1799	Diabetic dyslipidaemia: Effective management reduces cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2005, 6, 37-43.	1.2	4
1800	Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes?. <i>Atherosclerosis Supplements</i> , 2005, 6, 15-19.	1.2	22
1801	The US experience with cilostazol in treating intermittent claudication. <i>Atherosclerosis Supplements</i> , 2005, 6, 21-31.	1.2	33
1802	¿En quÃ© grado de riesgo vascular es coste-efectiva la simvastatina en prevenciÃ³n cardiovascular?. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2005, 12, 729.	0.0	0
1804	Control de la hipertensiÃ³n arterial y de otros factores de riesgo cardiovascular en poblaciÃ³n de alto riesgo asistida en AtenciÃ³n Primaria. Estudio EVENTO. <i>Semergen</i> , 2005, 31, 53-60.	0.2	9
1805	Role of Lipoprotein-Associated Phospholipase A 2 in Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 923-931.	1.1	430
1806	Preoperative Statin Therapy Does Not Reduce Cognitive Dysfunction After Cardiopulmonary Bypass. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2005, 19, 294-299.	0.6	34
1807	Chronic Stable Angina. <i>New England Journal of Medicine</i> , 2005, 352, 2524-2533.	13.9	195

#	ARTICLE	IF	CITATIONS
1808	Rosuvastatin: A High-Potency HMG-CoA Reductase Inhibitor. Journal of the American Pharmacists Association: JAPhA, 2005, 45, 503-513.	0.7	11
1809	Effects of statin therapy on the progression of chronic kidney disease. Advances in Chronic Kidney Disease, 2005, 12, 187-195.	0.6	12
1810	HMG-CoA Reductase Inhibitors Improve Acute Ischemic Stroke Outcome. Stroke, 2005, 36, 1298-1300.	1.0	129
1812	Discontinuing Cardiovascular Medications at the End of Life: Lipid-Lowering Agents. Journal of Palliative Medicine, 2005, 8, 876-881.	0.6	47
1813	A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. European Journal of Heart Failure, 2005, 7, 1059-1069.	2.9	127
1814	Role of Neurohormonal Modulators in Heart Failure with Relatively Preserved Systolic Function. Heart Failure Clinics, 2005, 1, 77-93.	1.0	3
1815	The Dyslipidemia of Diabetes Mellitus: Giving Triglycerides and High-Density Lipoprotein Cholesterol a Higher Priority?. Endocrinology and Metabolism Clinics of North America, 2005, 34, 27-48.	1.2	26
1816	Updated National Cholesterol Education Program III guidelines. Journal of the American Medical Directors Association, 2005, 6, 160-161.	1.2	8
1818	Lipid-Lowering Therapy in Patients With Peripheral Arterial Disease: Are Guidelines Being Met?. Mayo Clinic Proceedings, 2005, 80, 494-498.	1.4	5
1820	Heart Disease in Diabetic Patients. Seminars in Nephrology, 2005, 25, 372-378.	0.6	15
1821	Getting There: Statin Plus Ezetimibe for Low-Density Lipoprotein Cholesterol Goals. Mayo Clinic Proceedings, 2005, 80, 585-586.	1.4	5
1822	Hyperlipidemia. Primary Care - Clinics in Office Practice, 2005, 32, 1027-1055.	0.7	35
1823	Management of Peripheral Arterial Disease in Chronic Kidney Disease. Cardiology Clinics, 2005, 23, 225-236.	0.9	38
1825	Cardiovascular risk prevention in peripheral artery disease. Journal of Vascular Surgery, 2005, 41, 1070-1073.	0.6	19
1827	Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. , 2005, 15, 71-76.		16
1828	The role of lipid management in diabetes. Cardiology Clinics, 2005, 23, 153-164.	0.9	0
1830	Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study. Mayo Clinic Proceedings, 2005, 80, 1163-1168.	1.4	22
1831	Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. Journal of Vascular Surgery, 2005, 42, 75-80.	0.6	78

#	ARTICLE	IF	CITATIONS
1832	Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial. <i>Journal of Vascular Surgery</i> , 2005, 42, 456-464.	0.6	149
1834	The Safety of Rosuvastatin as Used in Common Clinical Practice. <i>Circulation</i> , 2005, 111, 3051-3057.	1.6	157
1835	Effects of Concurrent Therapy with Policosanol and Omega-3 Fatty Acids on Lipid Profile and Platelet Aggregation in Rabbits. <i>Drugs in R and D</i> , 2005, 6, 11-19.	1.1	13
1836	Effects of Addition of Policosanol to??Omega-3 Fatty Acid Therapy on the??Lipid Profile of Patients with Type??II Hypercholesterolaemia. <i>Drugs in R and D</i> , 2005, 6, 207-219.	1.1	20
1837	The DISCOVERY PENTA study: a Direct Statin COmparison of LDLâ€™ Value â€™ an Evaluation of Rosuvastatin therapY compared with atorvastatin. <i>Current Medical Research and Opinion</i> , 2005, 21, 1307-1315.	0.9	30
1838	Critical appraisal of revised cholesterol guidelines for the very high-risk patient. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 173-178.	0.6	7
1839	Statin Therapy Helps to Control Blood Pressure Levels in Hypertensive Dyslipidemic Patients. <i>Renal Failure</i> , 2005, 27, 297-303.	0.8	29
1840	Coronary heart disease prevention in menopausal women. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 695-705.	0.9	1
1841	Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2209-2221.	0.9	16
1842	Effective management of dyslipidaemia among patients with cardiovascular risk: Updated recommendations on identification and follow-up. <i>European Journal of General Practice</i> , 2005, 11, 68-75.	0.9	5
1843	Myeloperoxidase and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1102-1111.	1.1	653
1844	Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 131-139.	0.9	32
1845	Statins and LDLâ€™cholesterol lowering: an overview. <i>Current Medical Research and Opinion</i> , 2005, 21, S9-S16.	0.9	45
1846	Drug Insight: statins and stroke. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 576-584.	3.3	25
1847	Costâ€™effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 603-623.	0.7	0
1848	Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. <i>Current Medical Research and Opinion</i> , 2005, 21, 1389-1399.	0.9	76
1849	Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation. <i>Renal Failure</i> , 2005, 27, 259-273.	0.8	6
1850	Emerging drugs for diabetic nephropathy. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 747-771.	1.0	9

#	ARTICLE	IF	CITATIONS
1851	Fluvastatin: efficacy and safety in reducing cardiac events. Expert Opinion on Pharmacotherapy, 2005, 6, 1883-1895.	0.9	3
1852	Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. Current Medical Research and Opinion, 2005, 21, 299-305.	0.9	23
1853	Pharmacoeconomic Impact of Non-Compliance with Statins. Pharmacoeconomics, 2005, 23, 13-25.	1.7	27
1854	Real-World Trials to Answer Real-World Questions. Pharmacoeconomics, 2005, 23, 747-754.	1.7	24
1855	Management of Diabetic Dyslipidemia. American Journal of Cardiovascular Drugs, 2005, 5, 83-91.	1.0	9
1856	Testosterone and Atherosclerosis in Aging Men. American Journal of Cardiovascular Drugs, 2005, 5, 141-154.	1.0	106
1857	Statins and the Response to Myocardial Injury. American Journal of Cardiovascular Drugs, 2005, 5, 163-170.	1.0	13
1858	Industry Pulse. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 53-56.	1.0	0
1859	Global Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 125-133.	1.0	0
1860	Adverse Effects of Statins. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 141-148.	1.0	1
1861	What Should We Expect from the Next Guidelines on Hypertension?. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 199-202.	1.0	0
1862	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart, 2005, 91, v1-v52.	1.2	731
1863	The Issue of Statin Safety. Circulation, 2005, 111, 3016-3019.	1.6	87
1864	LDL/HDL ratio in subjects with cardiovascular disease and a low HDL: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Current Medical Research and Opinion, 2005, 21, 1865-1874.	0.9	58
1865	Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies. Journal of Clinical Oncology, 2005, 23, 8606-8612.	0.8	214
1866	Statins and fibrates for preventing melanoma. The Cochrane Library, 2005, , CD003697.	1.5	30
1867	Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease.A subgroup analysis of the GREACE study. Platelets, 2005, 16, 65-71.	1.1	29
1868	The Role of Statins in Preventing Stroke. Preventive Cardiology, 2005, 8, 98-101.	1.1	7

#	ARTICLE	IF	CITATIONS
1869	Achieving National Cholesterol Education Program Goals in Coronary Artery Disease. Preventive Cardiology, 2005, 8, 18-22.	1.1	1
1870	CARDS and A to Z. Preventive Cardiology, 2005, 8, 59-62.	1.1	2
1871	Womens€ Health Study (Aspirin) and TNT. Preventive Cardiology, 2005, 8, 181-185.	1.1	0
1872	Differences between statins on clinical endpoints: a population-based cohort study. Current Medical Research and Opinion, 2005, 21, 1461-1468.	0.9	20
1873	Gp78, a Membrane-Anchored Ubiquitin Ligase, Associates with Insig-1 and Couples Sterol-Regulated Ubiquitination to Degradation of HMG CoA Reductase. Molecular Cell, 2005, 19, 829-840.	4.5	317
1874	Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease. International Journal of Cardiology, 2005, 98, 479-486.	0.8	12
1875	Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. International Journal of Cardiology, 2005, 99, 269-275.	0.8	59
1876	Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial. International Journal of Cardiology, 2005, 99, 395-401.	0.8	11
1877	The benefit of fibrates in the treatment of â€bad HDL-C responders to statinsâ€™. International Journal of Cardiology, 2005, 101, 231-235.	0.8	9
1878	Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. International Journal of Cardiology, 2005, 102, 477-485.	0.8	25
1879	Preoperative statin use and outcomes following cardiac surgery. International Journal of Cardiology, 2005, 103, 12-18.	0.8	57
1880	REVERSAL and PROVE-IT: Are clinically oriented trials really better than â€pureâ€™scientific studies?. International Journal of Cardiology, 2005, 103, 235-237.	0.8	2
1881	Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. International Journal of Cardiology, 2005, 101, 111-114.	0.8	10
1882	Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. International Journal of Cardiology, 2005, 104, 251-256.	0.8	18
1883	The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. International Journal of Cardiology, 2005, 104, 264-268.	0.8	91
1884	Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. International Journal of Cardiology, 2005, 104, 338-345.	0.8	24
1885	Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. International Journal of Cardiology, 2005, 102, 327-332.	0.8	47
1886	Characterization of Ischemic Events and Use of Prescription Antiplatelet and Anticoagulant Agents After Stroke or Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases, 2005, 14, 145-151.	0.7	5

#	ARTICLE	IF	CITATIONS
1887	An ezetimibeâ€“policosanol combination has the potential to be an OTC agent that could dramatically lower LDL cholesterol without side effects. <i>Medical Hypotheses</i> , 2005, 64, 636-645.	0.8	7
1888	Safety and Efficacy of Rosuvastatin Therapy for the Prevention of Hyperlipidemia in Adult Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1008-1013.	0.3	18
1889	Ten-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1736-1740.	0.3	165
1890	Response to â€œThe UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomesâ€“ <i>Contemporary Clinical Trials</i> , 2005, 26, 417-418.	0.8	0
1891	Quantifying the use of the statin antilipemic drugs: Comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia. <i>Clinical Therapeutics</i> , 2005, 27, 497-508.	1.1	17
1892	A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in korean patients with hypercholesterolemia. <i>Clinical Therapeutics</i> , 2005, 27, 1074-1082.	1.1	49
1893	The long-term course of low-density lipoproteincholesterol after initiation of statin treatment: Retrospective database analysis over 3 years in health maintenance organization enrollees. <i>Clinical Therapeutics</i> , 2005, 27, 1622-1628.	1.1	1
1894	A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention. <i>Clinical Therapeutics</i> , 2005, 27, 1467-1477.	1.1	13
1895	Compliance with a statin treatment in a usual-care setting:Retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. <i>Clinical Therapeutics</i> , 2005, 27, 1639-1646.	1.1	81
1896	Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. <i>Cell Metabolism</i> , 2005, 1, 179-189.	7.2	236
1897	Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways. <i>Current Opinion in Pharmacology</i> , 2005, 5, 135-142.	1.7	40
1898	Increased risk for cardiovascular outcomes and effect of cholesterol-lowering pravastatin therapy in patients with diabetes mellitus in the pravastatin anti-atherosclerosis trial in the elderly (PATE). <i>Current Therapeutic Research</i> , 2005, 66, 48-65.	0.5	2
1899	Status of lipid-lowering therapy prescribedbased on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP). <i>Current Therapeutic Research</i> , 2005, 66, 80-95.	0.5	43
1900	Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-label pilot study. <i>Current Therapeutic Research</i> , 2005, 66, 613-629.	0.5	3
1901	Diabetes worsens the outcome of acute ischemic stroke. <i>Diabetes Research and Clinical Practice</i> , 2005, 69, 293-298.	1.1	82
1902	Can the atherosclerosis prevention targets be achieved in type 2 diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S48-S51.	1.1	8
1903	Long-term risk reduction: Who needs treatment?. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S15-S22.	1.1	5
1904	Prevalence and control of dyslipidemia among persons with diabetes in the United States. <i>Diabetes Research and Clinical Practice</i> , 2005, 70, 263-269.	1.1	106

#	ARTICLE	IF	CITATIONS
1905	Commentary 2. Evidence-based Cardiovascular Medicine, 2005, 9, 109-111.	0.0	0
1906	The metabolic syndrome: A vascular perspective. <i>European Journal of Internal Medicine</i> , 2005, 16, 314-320.	1.0	13
1907	Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial—Secondary analysis of a randomized controlled trial. <i>Bone</i> , 2005, 37, 190-191.	1.4	19
1908	Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. <i>Cancer Letters</i> , 2005, 224, 203-212.	3.2	57
1909	Statins as coronary vasodilators in isolated bovine coronary arteries—Involvement of PGI ₂ and NO. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 72, 133-138.	1.0	7
1910	HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration?. <i>Survey of Ophthalmology</i> , 2005, 50, 194-206.	1.7	52
1911	Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/2. <i>Neuroscience</i> , 2005, 134, 901-906.	1.1	35
1912	Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005, 15, 36-41.	1.1	28
1913	Implications of emerging risk factors for therapeutic intervention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005, 15, 373-381.	1.1	27
1915	Cholesterol homeostasis in neurons and glial cells. <i>Seminars in Cell and Developmental Biology</i> , 2005, 16, 193-212.	2.3	184
1916	Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. <i>American Heart Journal</i> , 2005, 149, 234-239.	1.2	85
1917	Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. <i>American Heart Journal</i> , 2005, 149, 473.e1-473.e10.	1.2	127
1918	Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS—TIMI 16) trial. <i>American Heart Journal</i> , 2005, 149, 444-450.	1.2	30
1919	Diabetes and progression of coronary calcium under the influence of statin therapy. <i>American Heart Journal</i> , 2005, 149, 695-700.	1.2	77
1920	Development of a multicenter peripheral arterial interventional database: The PVD-QI2. <i>American Heart Journal</i> , 2005, 149, 1003-1008.	1.2	34
1921	Statins in acute coronary syndromes: The sooner, the better?. <i>American Heart Journal</i> , 2005, 149, 377-380.	1.2	3
1922	Association between lipid testing and statin therapy in acute myocardial infarction patients. <i>American Heart Journal</i> , 2005, 150, 419-425.	1.2	16
1923	A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. <i>American Heart Journal</i> , 2005, 150, 478-483.	1.2	25

#	ARTICLE	IF	CITATIONS
1924	Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound. <i>American Heart Journal</i> , 2005, 149, 520-526.	1.2	50
1925	Plaque regression—A new target for antiatherosclerotic therapy. <i>American Heart Journal</i> , 2005, 149, 384-387.	1.2	6
1926	Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction. <i>American Heart Journal</i> , 2005, 150, 838-844.	1.2	34
1927	Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. <i>American Heart Journal</i> , 2005, 149, 464-473.	1.2	237
1928	Management of risk in peripheral artery disease: Recent therapeutic advances. <i>American Heart Journal</i> , 2005, 150, 35-40.	1.2	28
1929	Is it time to prescribe statins to patients with calcified aortic stenosis?. <i>American Heart Journal</i> , 2005, 150, 41-45.	1.2	6
1930	Impact of combined secondary prevention therapy after myocardial infarction: Data from a nationwide French registry. <i>American Heart Journal</i> , 2005, 150, 1147-1153.	1.2	52
1931	Type 2 diabetes, dyslipidemia, and vascular risk: Rationale and evidence for correcting the lipid imbalance. <i>American Heart Journal</i> , 2005, 150, 859-870.	1.2	79
1932	Stroke Prevention, Treatment, and Rehabilitation in Sub-Saharan Africa. <i>American Journal of Preventive Medicine</i> , 2005, 29, 95-101.	1.6	88
1933	Risk of Myocardial Infarction Attributable to Elevated Levels of Total Cholesterol Among Hypertensives. <i>American Journal of Hypertension</i> , 2005, 18, 759-766.	1.0	10
1934	Evidence for a Combined Approach to the Management of Hypertension and Dyslipidemia. <i>American Journal of Hypertension</i> , 2005, 18, 1249-1257.	1.0	25
1935	A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. <i>American Journal of Medicine</i> , 2005, 118, 276-284.	0.6	236
1936	Low HDL-C: A secondary target of dyslipidemia therapy. <i>American Journal of Medicine</i> , 2005, 118, 1067-1077.	0.6	65
1937	Perioperative cardiovascular mortality in noncardiac surgery: Validation of the Lee cardiac risk index. <i>American Journal of Medicine</i> , 2005, 118, 1134-1141.	0.6	321
1938	Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. <i>American Journal of Medicine</i> , 2005, 118, 618-624.	0.6	67
1939	Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. <i>American Journal of Medicine</i> , 2005, 118, 843-849.	0.6	191
1940	Bridging the quality gap in diabetic hyperlipidemia: A practice-based intervention. <i>American Journal of Medicine</i> , 2005, 118, 1414.e13-1414.e19.	0.6	17
1941	Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?. <i>American Journal of Medicine</i> , 2005, 118, 3-9.	0.6	14

#	ARTICLE	IF	CITATIONS
1942	Barriers to effective implementation of guideline recommendations. American Journal of Medicine, 2005, 118, 36-41.	0.6	59
1943	What impact will current trial data have on future guideline recommendations?. American Journal of Medicine, 2005, 118, 42-47.	0.6	5
1944	Statin therapy in the treatment of Alzheimer disease: what is the rationale?. American Journal of Medicine, 2005, 118, 48-53.	0.6	41
1945	Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. American Journal of Medicine, 2005, 118, 10-15.	0.6	15
1946	Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapyâ€“Thrombolysis in Myocardial Infarction 22 (PROVE ITâ€“TIMI 22) trial. American Journal of Medicine, 2005, 118, 28-35.	0.6	60
1947	Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. American Journal of Medicine, 2005, 118, 22-27.	0.6	38
1948	Improving quality of care in vascular surgery: the tools are available now. American Journal of Surgery, 2005, 190, 333-337.	0.9	3
1949	A Comparison of Lipid Variables as Predictors of Cardiovascular Disease in the Asia Pacific Region. Annals of Epidemiology, 2005, 15, 405-413.	0.9	121
1954	Respuesta del autor. Medicina ClÃnica, 2005, 125, 438-439.	0.3	0
1956	The Effect of HMG-CoA Reductase Inhibitors on Coenzyme Q10. Drug Safety, 2005, 28, 659-676.	1.4	78
1957	Angiotensin Antagonism in Coronary Artery Disease. Drugs, 2005, 65, 1073-1096.	4.9	14
1958	High Prevalence and Undertreatment of Hypercholesterolaemia in Participants in a Public Stroke Prevention Programme in Austria. Clinical Drug Investigation, 2005, 25, 709-717.	1.1	8
1959	Clinical utility of extended-release niacin: update and summary. Future Cardiology, 2005, 1, 571-578.	0.5	0
1961	Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. Revista Espanola De Cardiologia (English Ed), 2005, 58, 934-940.	0.4	4
1963	The influence of physicians' guideline compliance on patients' statin adherence: A retrospective cohort study. American Journal of Geriatric Pharmacotherapy, 2005, 3, 229-239.	3.0	17
1964	Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: Subanalyses of data from a randomized, double-blind, placebo-controlled trial. American Journal of Geriatric Pharmacotherapy, 2005, 3, 218-228.	3.0	20
1965	Statin Therapy Is Associated With Improved Cardiovascular Outcomes and Levels of Inflammatory Markers in Patients With Heart Failure. Journal of Cardiac Failure, 2005, 11, 607-612.	0.7	62
1966	Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. Journal of the American College of Cardiology, 2005, 45, 336-342.	1.2	262

#	ARTICLE	IF	CITATIONS
1967	Impact of microvascular complications on outcome after coronary stent implantations in patients with diabetes. <i>Journal of the American College of Cardiology</i> , 2005, 45, 464-466.	1.2	18
1968	Simvastatin improves endothelial function in patients with rheumatoid arthritis. <i>Journal of the American College of Cardiology</i> , 2005, 45, 461-464.	1.2	99
1969	Optimal lipids, statins, and dementia. <i>Journal of the American College of Cardiology</i> , 2005, 45, 963-964.	1.2	6
1970	The Gender-Specific Impact of Diabetes and Myocardial Infarction at Baseline and During Follow-Up on Mortality From All Causes and Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1413-1418.	1.2	68
1971	Plant Sterols in Serum and in Atherosclerotic Plaques of Patients Undergoing Carotid Endarterectomy. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1794-1801.	1.2	102
1972	Treatment of Asymptomatic Adults With Elevated Coronary Calcium Scores With Atorvastatin, Vitamin C, and Vitamin E. <i>Journal of the American College of Cardiology</i> , 2005, 46, 166-172.	1.2	380
1973	Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions. <i>Journal of the American College of Cardiology</i> , 2005, 46, 106-112.	1.2	257
1974	Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1411-1416.	1.2	306
1975	Stabilization of Carotid Atheroma Assessed by Quantitative Ultrasound Analysis in Nonhypercholesterolemic Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 2022-2030.	1.2	91
1976	Evolution in Cardiovascular Care for Elderly Patients With Non-“ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1479-1487.	1.2	297
1977	Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1855-1862.	1.2	397
1978	Perspectives on Dyslipidemia and Coronary Heart Disease in Women. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1628-1635.	1.2	67
1979	Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1219-1224.	1.2	48
1980	The Forgotten Majority. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1225-1228.	1.2	345
1982	Towards Consistency Between Guidelines and Policy: Lipid Management—2005. <i>Heart Lung and Circulation</i> , 2005, 14, 237-238.	0.2	15
1983	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. <i>Heart Lung and Circulation</i> , 2005, 14, 275-291.	0.2	115
1984	A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. <i>Journal of the Neurological Sciences</i> , 2005, 229-230, 147-150.	0.3	14
1985	Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 939-946.	1.5	14

#	ARTICLE	IF	CITATIONS
1986	Risk Factors for Atherosclerotic Vascular Disease. Handbook of Experimental Pharmacology, 2005, , 71-105.	0.9	21
1987	PLEIOTROPIC EFFECTS OF STATINS. Annual Review of Pharmacology and Toxicology, 2005, 45, 89-118.	4.2	1,574
1988	Second-Generation (Atypical) Antipsychotics and Metabolic Effects. CNS Drugs, 2005, 19, 1???93.	2.7	921
1989	Pathophysiology of Alzheimer's Disease. Neuroimaging Clinics of North America, 2005, 15, 727-753.	0.5	68
1990	A LIFE COURSE APPROACH TO CHRONIC DISEASE EPIDEMIOLOGY. Annual Review of Public Health, 2005, 26, 1-35.	7.6	692
1991	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. New England Journal of Medicine, 2005, 352, 1425-1435.	13.9	3,152
1992	Atherosclerotic risk factor control in patients with peripheral arterial disease. Journal of Vascular Surgery, 2005, 41, 816-822.	0.6	88
1993	Management of Diabetic Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2005, 34, 1-25.	1.2	34
1994	Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes. Diabetes Care, 2005, 28, 514-520.	4.3	300
1995	A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis. New England Journal of Medicine, 2005, 352, 2389-2397.	13.9	951
1996	Cardiovascular Drug Therapy in Elderly Patients. Drugs and Aging, 2005, 22, 913-941.	1.3	35
1998	Impact of Coaching Patients on Coronary Risk Factors. Disease Management and Health Outcomes, 2005, 13, 225-244.	0.3	13
1999	The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia. Disease Management and Health Outcomes, 2005, 13, 255-265.	0.3	3
2000	Effectiveness of Interventions to Increase Adherence to Statin Therapy. Disease Management and Health Outcomes, 2005, 13, 73-82.	0.3	2
2001	Clinical Outcomes Associated with Pharmacist Involvement in Patients with Dyslipidemia. Disease Management and Health Outcomes, 2005, 13, 31-42.	0.3	10
2002	Cardiovascular Disease Morbidity and Mortality in Patients with Type 1 Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 75-86.	1.8	9
2003	Therapy Insight: potential of statins for cancer chemoprevention and therapy. Nature Clinical Practice Oncology, 2005, 2, 82-89.	4.3	109
2005	Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?. Arthritis Research, 2005, 7, 55.	2.0	36

#	ARTICLE	IF	CITATIONS
2006	Cardiovascular Biomarkers. , 2006, , .		5
2007	Managing Hyperlipidaemia in the Elderly. <i>Drugs and Aging</i> , 2006, 23, 181-189.	1.3	13
2008	Drug Treatment of Peripheral Arterial Disease in the Elderly. <i>Drugs and Aging</i> , 2006, 23, 1-12.	1.3	10
2009	Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1177-1185.	1.4	28
2010	A modified calculation of ankle-brachial pressure index is far more sensitive in the detection of peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2006, 44, 531-536.	0.6	151
2011	New therapies for familial hypercholesterolemia. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 349-361.	2.4	0
2012	Assessment and Management of Lipid Disorders in Men. <i>Primary Care - Clinics in Office Practice</i> , 2006, 33, 93-114.	0.7	1
2013	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	1.0	1,617
2014	Stroke prevention in diabetes and obesity. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 487-502.	0.6	20
2015	Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 461-476.	0.6	44
2016	Diabetic Dyslipidemia and the Heart. <i>Heart Failure Clinics</i> , 2006, 2, 37-52.	1.0	1
2017	Optimal Medical Management of Peripheral Arterial Disease. <i>Vascular and Endovascular Surgery</i> , 2006, 40, 312-327.	0.3	62
2018	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. <i>European Heart Journal</i> , 2006, 27, 1341-1381.	1.0	1,192
2019	Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. <i>Aging Clinical and Experimental Research</i> , 2006, 18, 144-148.	1.4	17
2020	Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50.4		7
2021	Primary and secondary prevention of heart failure with statins. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 917-926.	0.6	13
2022	The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine. <i>Pharmacoeconomics</i> , 2006, 24, 35-54.	1.7	10
2023	Aggressive risk factor modification and pharmacological therapy are the basic steps in managing peripheral arterial disease. <i>Drugs and Therapy Perspectives</i> , 2006, 22, 17-20.	0.3	0

#	ARTICLE	IF	CITATIONS
2024	Lipid Management and Cholesterol Goal Attainment in Norway. American Journal of Cardiovascular Drugs, 2006, 6, 121-128.	1.0	16
2025	The Role of Oral Antiplatelet Agents in Atherothrombotic Disease. American Journal of Cardiovascular Drugs, 2006, 6, 149-157.	1.0	16
2026	Different Effects of Simvastatin and Losartan on Cytokine Levels in Coronary Artery Disease. American Journal of Cardiovascular Drugs, 2006, 6, 169-175.	1.0	3
2027	The A-SACT (Achievement in Singapore of Cholesterol Targets) Study in Patients with Coronary Heart Disease. American Journal of Cardiovascular Drugs, 2006, 6, 383-391.	1.0	23
2028	Treatment of High-Risk Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 13-19.	1.0	0
2030	Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medical Research and Opinion, 2006, 22, 511-528.	0.9	54
2032	Anti-Inflammatory and Antioxidant Functions of High Density Lipoproteins. , 2006, , 399-436.		0
2034	Inadequate treatment of dyslipidemia in people with type 2 diabetes: Quality assessment of diabetes care in a Danish County. Scandinavian Journal of Primary Health Care, 2006, 24, 181-185.	0.6	11
2035	Colesevelam hydrochloride in the management of dyslipidemia. Expert Review of Cardiovascular Therapy, 2006, 4, 283-291.	0.6	18
2036	Emerging drugs in peripheral arterial disease. Expert Opinion on Emerging Drugs, 2006, 11, 75-90.	1.0	8
2037	Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2006, 7, 1-10.	0.9	77
2038	The potential for CETP inhibition to reduce cardiovascular disease risk. Current Medical Research and Opinion, 2006, 22, 2467-2478.	0.9	10
2039	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2006, 37, 577-617.	1.0	1,510
2040	Is atrial fibrillation an inflammatory disorder?. European Heart Journal, 2006, 27, 136-149.	1.0	502
2041	Introduction: beyond glycemic control in type 2 diabetes. Current Medical Research and Opinion, 2006, 22, S1-S4.	0.9	1
2042	Management of Dyslipidemia with Statins in the Patient with Peripheral Arterial Disease. Techniques in Vascular and Interventional Radiology, 2006, 9, 50-55.	0.4	3
2043	A simple and valid tool distinguished efficacy from effectiveness studies. Journal of Clinical Epidemiology, 2006, 59, 1040-1048.	2.4	176
2044	Statins: panacea for sepsis?. Lancet Infectious Diseases, The, 2006, 6, 242-248.	4.6	114

#	ARTICLE	IF	CITATIONS
2050	Statin wars following coronary revascularization – Evidence-based clinical practice?. Canadian Journal of Cardiology, 2006, 22, 54-58.	0.8	8
2051	Cardioprotective medication use in hemodialysis patients. Canadian Journal of Cardiology, 2006, 22, 755-760.	0.8	39
2052	Lower is better: Implications of the Treating to New Targets (TNT) study for Canadian patients. Canadian Journal of Cardiology, 2006, 22, 835-839.	0.8	9
2053	Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Canadian Journal of Cardiology, 2006, 22, 863-868.	0.8	19
2054	The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Canadian Journal of Cardiology, 2006, 22, 939-945.	0.8	8
2055	A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-technology (NEPTUNE) II survey. Canadian Journal of Cardiology, 2006, 22, 315-322.	0.8	6
2056	The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention. Canadian Journal of Cardiology, 2006, 22, 419-423.	0.8	2
2057	Profound regression of coronary atherosclerosis with statins. Canadian Journal of Cardiology, 2006, 22, 709.	0.8	1
2058	PROVE-IT proved it: Lower is better – Pro. Canadian Journal of Cardiology, 2006, 22, 91B-94B.	0.8	1
2061	Tratamiento de los factores de riesgo cardiovascular en pacientes con accidente vascular cerebral. Clínica E Investigación En Arteriosclerosis, 2006, 18, 115-120.	0.4	0
2063	Lipoproteínas clásicas, terapéuticas modernas. Farmacología de las lipoproteínas de alta densidad. Clínica E Investigación En Arteriosclerosis, 2006, 18, 10-19.	0.4	0
2064	Controversia terapéutica: clopidogrel y estatinas. Clínica E Investigación En Arteriosclerosis, 2006, 18, 34-48.	0.4	0
2065	Controversies in stable coronary artery disease. Lancet, The, 2006, 367, 69-78.	6.3	56
2066	Aspirin resistance. Lancet, The, 2006, 367, 606-617.	6.3	503
2067	Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet, The, 2006, 367, 413-418.	6.3	290
2068	Statins: a preventive strike against sepsis in patients with cardiovascular disease?. Lancet, The, 2006, 367, 372-373.	6.3	18
2069	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Journal of the American College of Cardiology, 2006, 47, 2130-2139.	1.2	526
2070	Medication-Attributed Adverse Effects in Placebo Groups. Archives of Internal Medicine, 2006, 166, 155.	4.3	141

#	ARTICLE	IF	CITATIONS
2071	Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2006, 295, 2046.	3.8	146
2072	Risks Associated With Statin Therapy. Circulation, 2006, 114, 2788-2797.	1.6	444
2073	Ischemic Stroke: Basic Pathophysiology and Neuroprotective Strategies. , 2006, , 1-26.		0
2074	Mo-ML1:1 Dyslipidemia in renal impairment â€” from pathophysiology to evidence. Atherosclerosis Supplements, 2006, 7, 9.	1.2	0
2077	Factores de riesgo en la enfermedad cardiovascular y la rehabilitaciÃ³n. Rehabilitacion, 2006, 40, 282-289.	0.2	2
2078	Which progestogen is more likely to increase the risk of fatal myocardial infarction: A combination of epidemiological and trial evidence. Maturitas, 2006, 54, 154-163.	1.0	6
2080	Statin use and the risk of Alzheimer's disease: The MIRAGE Study. , 2006, 2, 96-103.		48
2081	Commentary on â€œCytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.â€• Atorvastatin's effect in Alzheimer's dementia (LEADe) study. , 2006, 2, 282-283.		1
2082	Endothelial function in conduit and resistance arteries in men with coronary disease. Atherosclerosis, 2006, 184, 130-136.	0.4	19
2083	Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis, 2006, 184, 348-355.	0.4	61
2084	Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: An observational study. Atherosclerosis, 2006, 185, 58-64.	0.4	18
2085	Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis, 2006, 185, 394-399.	0.4	192
2086	Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis, 2006, 187, 170-176.	0.4	39
2087	Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective caseâ€”control study from the LIPID study. Atherosclerosis, 2006, 187, 198-204.	0.4	22
2088	The evolution of European guidelines: Changing the management of cholesterol levels. Atherosclerosis, 2006, 185, 12-20.	0.4	21
2089	Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: A population-based study. Atherosclerosis, 2006, 189, 369-374.	0.4	51
2090	Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis, 2006, 189, 408-413.	0.4	137
2091	Serum lipid concentration in relation to anthropometric indices of central and peripheral fat distribution in 20,021 British men and women: Results from the EPIC-Norfolk population-based cohort study. Atherosclerosis, 2006, 189, 420-427.	0.4	45

#	ARTICLE	IF	CITATIONS
2092	A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. <i>Atherosclerosis Supplements</i> , 2006, 7, 21-29.	1.2	6
2093	Introduction. <i>Atherosclerosis Supplements</i> , 2006, 7, 1-4.	1.2	38
2094	Managing diabetic dyslipidaemiaâ€”beyond LDL-C:HDL-C and triglycerides. <i>Atherosclerosis Supplements</i> , 2006, 7, 17-21.	1.2	26
2095	Type-2 diabetes mellitus related cardiovascular risk: New options for interventions to reduce risk and treatment goals. <i>Atherosclerosis Supplements</i> , 2006, 7, 29-32.	1.2	63
2096	Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. <i>Current Opinion in Pharmacology</i> , 2006, 6, 162-168.	1.7	26
2097	Elevated Lipoprotein(a)â€”A Genetic Risk Factor for Premature Vascular Disease in People With and Without Standard Risk Factors: A Review. <i>Disease-a-Month</i> , 2006, 52, 5-50.	0.4	56
2098	Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2006, 43, 1205-1210.	0.6	20
2099	Meeting AHA/ACC secondary prevention goals in a vascular surgery practice: An opportunity we cannot afford to miss. <i>Journal of Vascular Surgery</i> , 2006, 43, 781-787.	0.6	23
2100	Dyslipidemia in Adults With Diabetes. <i>Canadian Journal of Diabetes</i> , 2006, 30, 230-240.	0.4	24
2101	Peripheral arterial disease versus other localizations of vascular disease: The ATTEST study. <i>Journal of Vascular Surgery</i> , 2006, 44, 314-318.	0.6	58
2102	The Application of Evidence-Based Principles of Care in Older Persons (Issue 3): Management of Diabetes Mellitus. <i>Journal of the American Medical Directors Association</i> , 2006, 7, 234-240.	1.2	42
2103	Les statines : intÃ©rÃ©ts en cardiologie, implications en anesthÃ©sie. <i>Praticien En Anesthesie Reanimation</i> , 2006, 10, 156-165.	0.0	0
2104	The Application of Evidence-Based Principles of Care in Older Persons (Issue 2): Management of Lipid Disorders. <i>Journal of the American Medical Directors Association</i> , 2006, 7, 173-179.	1.2	7
2106	Common Questions in Managing Hyperlipidemia. <i>Primary Care - Clinics in Office Practice</i> , 2006, 33, 903-921.	0.7	0
2107	Angina Pectoris: Evaluation in the Office. <i>Medical Clinics of North America</i> , 2006, 90, 391-416.	1.1	3
2108	The Safety of Aggressive Statin Therapy: How Much Can Low-Density Lipoprotein Cholesterol Be Lowered?. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1225-1231.	1.4	23
2109	Is There Evidence for the Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women?. <i>Gender Medicine</i> , 2006, 3, 5-12.	1.4	0
2110	Coronary Artery Disease Screening, Treatment, and Follow-up. <i>Primary Care - Clinics in Office Practice</i> , 2006, 33, 863-885.	0.7	5

#	ARTICLE	IF	CITATIONS
2111	Assessment of Progression and Regression of Coronary Atherosclerosis by Intravascular Ultrasound. A New Paradigm Shift?. Revista Espanola De Cardiologia (English Ed), 2006, 59, 57-66.	0.4	1
2112	Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?. Revista Espanola De Cardiologia (English Ed), 2006, 59, 247-258.	0.4	11
2113	Morbimortalidad por cardiopatía isquémica en el paciente diabético. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2006, 53, 405-417.	0.8	3
2114	Overcoming Ageism Bias in the Treatment of Hypercholesterolaemia. Drug Safety, 2006, 29, 421-448.	1.4	48
2115	Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin. Drug Safety, 2006, 29, 1061-1067.	1.4	41
2116	Fluvastatin and Hepatic Reactions. Drug Safety, 2006, 29, 1163-1172.	1.4	18
2117	HMG-CoA Reductase Inhibitors in Chronic Heart Failure. Drugs, 2006, 66, 145-154.	4.9	25
2126	Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure. Journal of the American College of Cardiology, 2006, 47, 332-337.	1.2	310
2127	Peripheral Arterial Disease in Patients With Diabetes. Journal of the American College of Cardiology, 2006, 47, 921-929.	1.2	430
2128	Cardioprotective Medication Is Associated With Improved Survival in Patients With Peripheral Arterial Disease. Journal of the American College of Cardiology, 2006, 47, 1182-1187. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower T	1.2	151
2129	the American Association for Vascular Surgery/Society for Vascular Surgery, when Guideline initiated, now merged into SVS Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines. Journal of the American College of Cardiology, 2006, 47, 1239-1312.	1.2	1,012
2130	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2006, 47, e1-e121. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower T	1.2	435
2132	Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional		

#	ARTICLE	IF	CITATIONS
2138	Assessment and management of transient ischaemic attack – the role of the TIA clinic. <i>Irish Journal of Medical Science</i> , 2006, 175, 24-27.	0.8	9
2139	The involvement of lipid rafts in Alzheimer's disease (Review). <i>Molecular Membrane Biology</i> , 2006, 23, 111-122.	2.0	182
2140	Brain cholesterol turnover required for geranylgeraniol production and learning in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 3869-3874.	3.3	228
2141	Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, F262-F272.	1.3	397
2142	Preventing Cardiovascular Disease in the 21st Century. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 87-101.	1.0	65
2143	Standard Lipid Profile. <i>Clinics in Laboratory Medicine</i> , 2006, 26, 707-732.	0.7	15
2144	Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 4808-4817.	0.8	154
2145	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	1.0	1,144
2146	La dislipidemia nel paziente diabetico. <i>L Endocrinologo</i> , 2006, 7, 23-31.	0.0	0
2147	Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. <i>European Heart Journal</i> , 2006, 28, 154-159.	1.0	130
2148	Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. <i>Heart</i> , 2006, 92, 1207-1212.	1.2	161
2149	Cardiac Syndrome X and Endothelial Dysfunction: New Concepts in Prognosis and Treatment. <i>American Journal of Medicine</i> , 2006, 119, 560-566.	0.6	71
2150	Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met. <i>American Journal of Medicine</i> , 2006, 119, 676-683.	0.6	148
2151	Clinical Perspectives of Statin-Induced Rhabdomyolysis. <i>American Journal of Medicine</i> , 2006, 119, 400-409.	0.6	210
2152	Tolerability of atorvastatin in a population aged ≥65 years: A retrospective pooled analysis of results from fifty randomized clinical trials. <i>American Journal of Geriatric Pharmacotherapy</i> , 2006, 4, 112-122.	3.0	25
2153	Peripheral Arterial Disease: A Review of Disease Awareness and Management. <i>American Journal of Geriatric Pharmacotherapy</i> , 2006, 4, 365-379.	3.0	28
2154	Low high-density lipoprotein cholesterol and cardiovascular disease: Risk reduction with statin therapy. <i>American Heart Journal</i> , 2006, 151, 556-563.	1.2	43
2155	Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. <i>American Heart Journal</i> , 2006, 151, 273-281.	1.2	105

#	ARTICLE	IF	CITATIONS
2156	Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials. <i>American Heart Journal</i> , 2006, 151, 282-287.	1.2	156
2157	Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. <i>American Heart Journal</i> , 2006, 151, 745-753.	1.2	67
2158	Missed opportunities in the secondary prevention of myocardial infarction: An assessment of the effects of statin underprescribing on mortality. <i>American Heart Journal</i> , 2006, 151, 969-975.	1.2	43
2159	Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: Results from the LIPID study. <i>American Heart Journal</i> , 2006, 151, 1305-1312.	1.2	22
2160	Coronary artery calcium scanning: Clinical paradigms for cardiac risk assessment and treatment. <i>American Heart Journal</i> , 2006, 151, 1139-1146.	1.2	62
2161	Persistence and adherence to cholesterol lowering agents: Evidence from R��gie de l'Assurance Maladie du Qu��bec data. <i>American Heart Journal</i> , 2006, 152, 164-169.	1.2	34
2162	Intravascular ultrasound assessment of novel antiatherosclerotic therapies: Rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. <i>American Heart Journal</i> , 2006, 152, 67-74.	1.2	27
2163	Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: The Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: A randomized, controlled trial. <i>American Heart Journal</i> , 2006, 152, 585-592.	1.2	73
2164	Circulating biomarkers of cognitive decline and dementia. <i>Clinica Chimica Acta</i> , 2006, 364, 91-112.	0.5	124
2165	Statin-related adverse events: A meta-analysis. <i>Clinical Therapeutics</i> , 2006, 28, 26-35.	1.1	243
2166	Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: An analysis of patient data from a Maryland-based health maintenance organization. <i>Clinical Therapeutics</i> , 2006, 28, 591-599.	1.1	24
2167	Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. <i>Clinical Therapeutics</i> , 2006, 28, 1425-1442.	1.1	7
2168	Improving the management of patients after myocardial infarction, from admission to discharge. <i>Clinical Therapeutics</i> , 2006, 28, 1509-1539.	1.1	8
2169	Expanding options with a wider range of rosuvastatin doses. <i>Clinical Therapeutics</i> , 2006, 28, 1747-1763.	1.1	6
2170	Simvastatin inhibits lipopolysaccharide-induced tumor necrosis factor-�� expression in neonatal rat cardiomyocytes: The role of reactive oxygen species. <i>Biochemical and Biophysical Research Communications</i> , 2006, 351, 947-952.	1.0	20
2171	Renal impairment: a risk factor for ischemic heart disease. <i>Current Opinion in Pharmacology</i> , 2006, 6, 221-225.	1.7	3
2172	Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. <i>Current Opinion in Pharmacology</i> , 2006, 6, 154-161.	1.7	58
2173	Effects of combination treatment with policosanol and omega-3 fatty acids on platelet aggregation: A randomized, double-blind clinical study. <i>Current Therapeutic Research</i> , 2006, 67, 174-192.	0.5	16

#	ARTICLE	IF	CITATIONS
2174	Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. <i>Current Therapeutic Research</i> , 2006, 67, 321-333.	0.5	1
2175	Evaluation of diabetes care in the Otago region using a diabetes register, 1998–2003. <i>Diabetes Research and Clinical Practice</i> , 2006, 71, 345-352.	1.1	14
2176	Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. <i>European Journal of Internal Medicine</i> , 2006, 17, 495-499.	1.0	12
2177	The evidence for medicine versus surgery for carotid stenosis. <i>European Journal of Radiology</i> , 2006, 60, 3-7.	1.2	26
2178	Lipid Management Reduces Cardiovascular Complications in Individuals With Diabetes and Prediabetes. <i>Preventive Cardiology</i> , 2006, 9, 102-109.	1.1	8
2179	Rationale for Intensive Statin Treatment in High-Risk Patients. <i>Preventive Cardiology</i> , 2006, 9, 91-95.	1.1	5
2180	Lower Is Better-The Contemporary Concept of Low-Density Lipoprotein Lowering in the Preventive Management of Cardiovascular Risk: Does This Apply to All Patients?. <i>Preventive Cardiology</i> , 2006, 9, 219-227.	1.1	0
2181	Fibrates in Combination With Statins in the Management of Dyslipidemia. <i>Journal of Clinical Hypertension</i> , 2006, 8, 35-41.	1.0	52
2182	Incremental Risk-Factor Reduction Improves Overall Cardiovascular Benefit: Is It Time to Abandon the Silos?. <i>Journal of Clinical Hypertension</i> , 2006, 8, 686-688.	1.0	5
2183	Niacin-ER/Statin Combination for the Treatment of Dyslipidemia: Focus on Low High-Density Lipoprotein Cholesterol. <i>Journal of Clinical Hypertension</i> , 2006, 8, 493-501.	1.0	9
2184	Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial. <i>Journal of Clinical Hypertension</i> , 2006, 8, 571-583.	1.0	51
2185	C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: Inhibitory effect of fluvastatin. <i>Life Sciences</i> , 2006, 78, 1021-1028.	2.0	45
2186	AT1 receptor antagonism improves endothelial dysfunction in postmenopausal women. <i>Maturitas</i> , 2006, 53, 176-183.	1.0	18
2187	Protective role of pravastatin in the pathogenesis of the metabolic syndrome. <i>Medical Hypotheses</i> , 2006, 66, 609-611.	0.8	6
2188	Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 819-828.	2.4	115
2189	Statins and tissue mineralization: Putative involvement of alkaline phosphatase. <i>Medical Hypotheses</i> , 2006, 67, 524-528.	0.8	5
2190	Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. <i>Neuroscience Letters</i> , 2006, 406, 92-96.	1.0	24
2191	Effects of statins beyond lipid lowering: Potential for clinical benefits. <i>International Journal of Cardiology</i> , 2006, 109, 7-15.	0.8	121

#	ARTICLE	IF	CITATIONS
2192	Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys. <i>International Journal of Cardiology</i> , 2006, 111, 12-18.	0.8	29
2193	Prevalence of conventional risk factors in Jordanians with coronary heart disease: The Jordan Hyperlipidemia and Related Targets Study (JoHARTS). <i>International Journal of Cardiology</i> , 2006, 110, 179-183.	0.8	37
2194	Reducing cardiovascular risk in diabetes: Beyond glycemic and blood pressure control. <i>International Journal of Cardiology</i> , 2006, 110, 137-145.	0.8	16
2195	Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants. <i>International Journal of Cardiology</i> , 2006, 112, 72-79.	0.8	4
2196	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). <i>International Journal of Cardiology</i> , 2006, 110, 242-250.	0.8	25
2197	Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?. <i>International Journal of Cardiology</i> , 2006, 110, 276-277.	0.8	2
2198	Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY) Tj ETQq0 0 0 rgt /Overlock 10 Tf 5		
2200	Disparities among the disadvantaged: Variation in lipid management in the Ohio Medicaid program. <i>Preventive Medicine</i> , 2006, 42, 313-315.	1.6	11
2201	Bias from industry trial funding? A framework, a suggested approach, and a negative result. <i>Pain</i> , 2006, 121, 207-218.	2.0	48
2202	Management of Type 2 Diabetes in Youth (Part 2). <i>Journal of Pediatric Health Care</i> , 2006, 20, 88-97.	0.6	11
2203	Impact of LDL-C lowering on recurrent cardiovascular events and hospitalization in secondary prevention in German clinical practice. <i>Prevention and Control: the Official Journal of the World Heart Federation</i> , 2006, 2, 5-14.	0.3	1
2204	The impact of lipid-lowering treatment patterns on LDL-C reduction and goal attainment in secondary prevention in Germany. <i>Prevention and Control: the Official Journal of the World Heart Federation</i> , 2006, 2, 15-26.	0.3	2
2205	Effect of dietary and antismoking advice on the incidence of myocardial infarction: A 16-year follow-up of the Oslo Diet and Antismoking Study after its close. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 330-338.	1.1	25
2206	Cholesterol lowering and mortality: Time for a new paradigm?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 387-390.	1.1	14
2208	Peripheral arterial disease. <i>Postgraduate Medicine</i> , 2006, 119, 21-27.	0.9	2
2211	Interventional Strategies in early Atherosclerosis. <i>Monaldi Archives for Chest Disease</i> , 2006, 66, 54-62.	0.3	8
2212	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2006, 113, .	1.6	416
2213	Distinct Effects of Pravastatin, Atorvastatin, and Simvastatin on Insulin Secretion from a β-cell Line, MIN6 Cells. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 329-335.	0.9	70

#	ARTICLE	IF	CITATIONS
2214	Skin cholesterol: test performance, evaluation of potential determinants and correlation analysis with cardiovascular risk factors and circulating markers of inflammation. <i>Vasa - European Journal of Vascular Medicine</i> , 2006, 35, 167-173.	0.6	3
2215	New Frontiers for Cardiac Risk Assessment: C-Reactive Protein. <i>The Consultant Pharmacist</i> , 2006, 21, 188-206.	0.4	1
2216	Common Reasons for Hospitalization Among Adult Patients with Diabetes. <i>Endocrine Practice</i> , 2006, 12, 363-370.	1.1	20
2217	Análisis crítico de un artículo: La terapia intensiva con atorvastatina tiene un beneficio marginal en pacientes con enfermedad coronaria estable. <i>Revista Medica De Chile</i> , 2006, 134, 391.	0.1	0
2219	Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 582-591.	2.2	160
2220	Treatment of Hyperlipidemia from Japanese Evidence. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 267-280.	0.9	20
2221	Statins: Beneficial or Adverse for Glucose Metabolism. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 123-129.	0.9	79
2222	Statin and β -Blocker Therapy and the Initial Presentation of Coronary Heart Disease. <i>Annals of Internal Medicine</i> , 2006, 144, 229.	2.0	78
2225	Medical treatment for carotid stenosis. , 0, , 59-71.		0
2226	Monitoring pharmaceutical interventions with IVUS. , 2006, , 451-463.		0
2227	A Case Presentation. <i>The Diabetes Educator</i> , 2006, 32, 137S-145S.	2.6	0
2229	A dual approach to cholesterol targets. <i>Practice Nursing</i> , 2006, 17, 144-148.	0.1	0
2230	Statins for Treatment of Dyslipidemia in Chronic Kidney Disease. <i>Peritoneal Dialysis International</i> , 2006, 26, 523-539.	1.1	65
2231	Pravastatin Decreases Blood Pressure in Hypertensive and Hypercholesterolemic Patients Receiving Antihypertensive Treatment. <i>Circulation Journal</i> , 2006, 70, 1116-1121.	0.7	18
2232	Effect of Combination Therapy With Simvastatin and Carvedilol in Patients With Left Ventricular Dysfunction Complicated With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2006, 70, 1269-1274.	0.7	9
2233	Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) Rationale and Design. <i>Circulation Journal</i> , 2006, 70, 1624-1628.	0.7	33
2234	Cross-Over Trial of Intensive Monotherapy With Atorvastatin and Combined Therapy With Atorvastatin and Colestimide for Japanese Familial Hypercholesterolemia. <i>Circulation Journal</i> , 2006, 70, 14-20.	0.7	8
2235	Clinical pharmacological implications of over-the-counter sales of statins. <i>Future Lipidology</i> , 2006, 1, 17-24.	0.5	0

#	ARTICLE	IF	CITATIONS
2236	Management of Dyslipidemia in Diabetes. <i>Cardiology in Review</i> , 2006, 14, 125-135.	0.6	61
2237	Lipid-lowering therapy with statins in postmenopausal women: a few answered and many unanswered questions. <i>Future Lipidology</i> , 2006, 1, 375-379.	0.5	1
2238	Dyslipidemia treatment in African-Americans: should race be a factor?. <i>Future Lipidology</i> , 2006, 1, 653-658.	0.5	0
2239	HDL/apoA-I infusion for atherosclerosis management: an emerging therapeutic paradigm. <i>Future Lipidology</i> , 2006, 1, 55-64.	0.5	3
2240	Future approaches to reducing low-density lipoprotein cholesterol. <i>Future Lipidology</i> , 2006, 1, 463-476.	0.5	1
2241	Does optimal drug treatment of acute coronary syndromes depend on management area?. <i>British Journal of Cardiac Nursing</i> , 2006, 1, 247-252.	0.0	0
2242	Statin therapy in cardiovascular disease. <i>British Journal of Cardiac Nursing</i> , 2006, 1, 270-277.	0.0	2
2243	Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem. <i>Annals of Internal Medicine</i> , 2006, 145, 520.	2.0	148
2244	Potential role of statins and PPARs in rheumatoid arthritis. <i>Future Rheumatology</i> , 2006, 1, 259-274.	0.2	3
2245	Inflammation and cardiovascular disease mechanisms. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 456S-460S.	2.2	891
2246	Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 expression of glomerular mesangial cells in hypercholesterolemic rabbits. <i>Biomedical Research</i> , 2006, 27, 149-155.	0.3	13
2247	Diabetes as a cardiovascular disease: Addressing the risk. <i>British Journal of Cardiac Nursing</i> , 2006, 1, 117-125.	0.0	4
2248	Effect of Lipid Levels and Lipid-Lowering Therapy on Restenosis after Coronary Artery Stenting. <i>American Journal of the Medical Sciences</i> , 2006, 331, 270-273.	0.4	11
2249	Therapy Modifications in Response to Poorly Controlled Hypertension, Dyslipidemia, and Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 2006, 144, 475.	2.0	175
2250	Is aggressive or moderate lipid lowering more effective in slowing vascular calcification in postmenopausal women?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 20-21.	3.3	0
2253	In Hot Pursuit. <i>Anesthesiology</i> , 2006, 105, 1077-1078.	1.3	2
2254	Prevention of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, S97-S99.	0.6	42
2255	Clinical implications of inhibition of the late sodium current: ranolazine. <i>Country Review Ukraine</i> , 2006, 8, A14-A19.	0.8	4

#	ARTICLE	IF	CITATIONS
2256	Preventing Type 2 Diabetes in High Risk Patients: An Overview of Lifestyle and Pharmacological Measures. <i>Current Drug Targets</i> , 2006, 7, 211-228.	1.0	76
2257	STATIN MYOPATHIES. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2006, 12, 169-184.	0.4	0
2258	The Stroke-Prone State. <i>Stroke</i> , 2006, 37, 1140-1140.	1.0	4
2259	Total Serum Cholesterol and Recovery From Disability Among Hospitalized Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 736-742.	1.7	15
2260	Do the Right Thing (or Do the Market Exclusivity Thing?). <i>Anesthesiology</i> , 2006, 105, 1074-1075.	1.3	4
2261	Forehead Pulse Oximetry. <i>Anesthesiology</i> , 2006, 105, 1075-1077.	1.3	11
2262	Cardiovascular Disease. <i>Journal of Cardiovascular Nursing</i> , 2006, 21, S20-S42.	0.6	7
2263	Protection of Endothelial Function: Targets for Nutritional and Pharmacological Interventions. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, S136-S150.	0.8	58
2264	Suivi cardiologique de l'opÃ©ration vasculaire. <i>EMC - AngÃ©iologie</i> , 2006, 1, 1-4.	0.0	0
2265	Few Stroke Survivors Receive the Rehabilitation They Need. <i>American Journal of Nursing</i> , 2006, 106, 44.	0.2	2
2266	To See or Not to See. <i>Anesthesiology</i> , 2006, 105, 1071-1073.	1.3	15
2267	Rosuvastatin Increases $\hat{1}\pm$ -1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1337-1343.	1.0	25
2268	High-Density Lipoprotein Cholesterol-Raising Strategies. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 196-204.	0.8	12
2269	The gap between theory and practice: what do the trials tell us?. <i>Country Review Ukraine</i> , 2006, 8, F10-F16.	0.8	0
2271	â€œBut Heâ€™s Just a Childâ€™. <i>American Journal of Nursing</i> , 2006, 106, 46-47.	0.2	0
2272	High-Density Lipoprotein Cholesterol Therapies. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2006, 26, 1-8.	0.5	3
2273	COX-2 and Atherosclerosis. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, S26-S36.	0.8	67
2276	Statins. <i>Anesthesiology</i> , 2006, 105, 1079-1080.	1.3	24

#	ARTICLE	IF	CITATIONS
2277	Primary Stroke Prevention. American Journal of Nursing, 2006, 106, 40-49.	0.2	9
2278	Raising Stroke Awareness in Rural Communities. American Journal of Nursing, 2006, 106, 40-49.	0.2	0
2279	The ACTIVATE study: lessons for the future of atherosclerotic therapy. Future Lipidology, 2006, 1, 421-428.	0.5	0
2280	Differences by Age and Race/Ethnicity in Knowledge About Hypercholesterolemia. Cardiology in Review, 2006, 14, 1-6.	0.6	23
2281	A Projection of the Impact of Lipid-Lowering Therapy on High-Risk Employee Disability and Medical Costs. Journal of Occupational and Environmental Medicine, 2006, 48, 1014-1022.	0.9	7
2282	Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention ??? the HIV polypill study. Current Opinion in HIV and AIDS, 2006, 1, 482-487.	1.5	4
2283	Predictors of Long-Term Mortality in Patients With Ischemic Stroke Referred for Transesophageal Echocardiography. Stroke, 2006, 37, 204-208.	1.0	31
2284	Beneficial effects of statins on perioperative cardiovascular outcome. Current Opinion in Anaesthesiology, 2006, 19, 418-422.	0.9	12
2285	Changes in serum level and metabolism of cholesterol with plant stanol esters in postmenopausal women with and without coronary artery disease. Menopause, 2006, 13, 286-293.	0.8	14
2286	Partners in Lowering Cholesterol: Comparison of a Multidisciplinary Educational Program, Monetary Incentives, or Usual Care in the Treatment of Dyslipidemia Identified Among Employees. Journal of Occupational and Environmental Medicine, 2006, 48, 675-681.	0.9	22
2287	Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Current Opinion in Lipidology, 2006, 17, 510-518.	1.2	60
2288	A Cost Effective Method of Identifying and Recruiting Persons Over 80 Free of Dementia or Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2006, 20, 101-104.	0.6	32
2289	Statin-induced myositis: a commonly encountered or rare side effect?. Current Opinion in Internal Medicine, 2006, 5, 34-41.	1.5	26
2290	Treating dyslipidemia in the elderly. Current Opinion in Lipidology, 2006, 17, 54-57.	1.2	2
2291	Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation. Vascular Disease Prevention, 2006, 3, 229-234.	0.2	2
2292	When it comes to the FIELD study, what is...is. Future Lipidology, 2006, 1, 275-281.	0.5	2
2293	Vascular surgery critical care: Perioperative cardiac optimization to improve survival. Critical Care Medicine, 2006, 34, S200-S207.	0.4	22
2294	The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Current Opinion in Lipidology, 2006, 17, 626-630.	1.2	24

#	ARTICLE	IF	CITATIONS
2295	Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism. <i>Vascular Disease Prevention</i> , 2006, 3, 235-245.	0.2	0
2296	Managing cholesterol in the elderly. <i>Aging Health</i> , 2006, 2, 623-638.	0.3	0
2297	Possible mechanisms for statin myopathy and its relationship to physical exercise. <i>Future Lipidology</i> , 2006, 1, 143-151.	0.5	5
2298	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <i>Current Opinion in Cardiology</i> , 2006, 21, 400-404.	0.8	59
2299	Lipid Abnormalities in Women. <i>Cardiology in Review</i> , 2006, 14, 276-280.	0.6	15
2300	Contemporary Scientific Insights. <i>Critical Pathways in Cardiology</i> , 2006, 5, 191-210.	0.2	5
2301	Aspirin resistance: is this term meaningful?. <i>Current Opinion in Hematology</i> , 2006, 13, 331-336.	1.2	9
2302	Prevention is better than cure. <i>Current Opinion in Lipidology</i> , 2006, 17, 188-191.	1.2	1
2303	Statins: are any questions unanswered?. <i>Current Opinion in Lipidology</i> , 2006, 17, 418-425.	1.2	10
2304	Multimodality Stroke Prevention. <i>Neurologist</i> , 2006, 12, 14-31.	0.4	17
2305	Dyslipidemia in Menopause: Mechanisms and Management. <i>Obstetrical and Gynecological Survey</i> , 2006, 61, 608-613.	0.2	22
2306	Role of Thyroid Disease in the Development of Statin-Induced Myopathy. , 2006, 16, 279-285.		19
2307	European Society of Hypertension Scientific Newsletter: Control of hypertension in patients with peripheral artery disease. <i>Journal of Hypertension</i> , 2006, 24, 2477-2478.	0.3	1
2308	Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. <i>Current Opinion in Lipidology</i> , 2006, 17, 631-636.	1.2	141
2309	10-Year Follow-up of Subclinical Cardiovascular Disease and Risk of Coronary Heart Disease in the Cardiovascular Health Study. <i>Archives of Internal Medicine</i> , 2006, 166, 71.	4.3	88
2311	The clinical implications and management of concomitant hypertension and dyslipidemia. <i>Postgraduate Medicine</i> , 2006, 119, 37-45.	0.9	5
2312	Safety Issues with Statin Therapy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2006, 46, 479-490.	0.7	54
2313	A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]. <i>Implementation Science</i> , 2006, 1, 11.	2.5	17

#	ARTICLE	IF	CITATIONS
2314	Lipid treatment strategies for metabolic syndrome in established cardiovascular disease: a consensus guideline. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2006, 23, 78-85.	0.2	1
2315	A dietitian-led lipid clinic is effective. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2006, 23, 221-226.	0.2	5
2316	Treatment with statins after acute myocardial infarction in patients ≥ 80 years: underuse despite general acceptance of drug therapy for secondary prevention. Pharmacoepidemiology and Drug Safety, 2006, 15, 261-267.	0.9	21
2317	Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiology and Drug Safety, 2006, 15, 454-461.	0.9	7
2318	HYPERTENSION AND OXIDATIVE STRESS. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 872-876.	0.9	61
2319	Management and outcomes of acute coronary syndrome with minimal myocardial necrosis: analysis of a large prospective registry from a non-interventional centre*. International Journal of Clinical Practice, 2006, 60, 383-390.	0.8	1
2320	Statins and the acute coronary syndrome: "the early bird catches the worm"™. International Journal of Clinical Practice, 2006, 60, 716-727.	0.8	4
2321	FIELDS of dreams, fields of tears: a perspective on the fibrate trials. International Journal of Clinical Practice, 2006, 60, 442-449.	0.8	57
2322	ASTEROID - when spinning a star leads to a collision with reality. International Journal of Clinical Practice, 2006, 60, 505-505.	0.8	0
2323	Residual risk for acute stroke in patients with type 2 diabetes and hypertension in primary care: Skaraborg Hypertension and Diabetes Project. Diabetes, Obesity and Metabolism, 2006, 8, 492-500.	2.2	8
2324	The metabolic syndrome in type 2 diabetes: When does it matter?. Diabetes, Obesity and Metabolism, 2006, 8, 690-697.	2.2	14
2325	What's in the CARDS?. Diabetic Medicine, 2006, 23, 711-714.	1.2	2
2326	Changing attitudes to the management of ischaemic stroke between 1997 and 2004: a survey of New Zealand physicians. Internal Medicine Journal, 2006, 36, 276-280.	0.5	6
2327	Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundamental and Clinical Pharmacology, 2006, 20, 321-330.	1.0	22
2328	The impact of simvastatin on warfarin disposition and dose requirements. Journal of Thrombosis and Haemostasis, 2006, 4, 1422-1424.	1.9	21
2329	Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End-Stage Renal Disease. Seminars in Dialysis, 2006, 19, 391-401.	0.7	2
2330	Incidence of and factors associated with achieving target lipid levels in patients with peripheral arterial disease. Journal of General Internal Medicine, 2006, 21, 711-714.	1.3	13
2331	Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG-CoA Reductase Inhibitor. Cardiovascular Drug Reviews, 2003, 21, 199-215.	4.4	108

#	ARTICLE	IF	CITATIONS
2332	Colesevelam: Potential Uses for the Newest Bile Resin. <i>Cardiovascular Drug Reviews</i> , 2005, 23, 15-30.	4.4	21
2333	Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 63-70.	1.0	91
2334	Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 71-77.	1.0	100
2335	Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 87-92.	1.0	14
2336	The role of pleiotropic effects of statins in dementia. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 115-118.	1.0	15
2337	Efficacy, safety and LDL-C goal attainment of ezetimibe 10mg-simvastatin 20mg vs. placebo-simvastatin 20mg in UK-based adults with coronary heart disease and hypercholesterolaemia. <i>International Journal of Clinical Practice</i> , 2006, 60, 914-921.	0.8	24
2338	Aortic Arch Atheroma. <i>International Journal of Stroke</i> , 2006, 1, 74-80.	2.9	37
2339	Statins as Acute-Stroke Treatment. <i>International Journal of Stroke</i> , 2006, 1, 224-225.	2.9	9
2340	International Aspects of Global Stroke Burden. <i>International Journal of Stroke</i> , 2006, 1, 222-223.	2.9	1
2341	Plasma Lipoprotein Abnormalities in Hemodialysis Patients—Clinical Implications and Therapeutic Guidelines. <i>Therapeutic Apheresis and Dialysis</i> , 2006, 10, 305-315.	0.4	30
2342	Cost-effectiveness of nurse practitioner management of hypercholesterolemia following coronary revascularization. <i>Journal of the American Academy of Nurse Practitioners</i> , 2006, 18, 436-444.	1.4	32
2343	The Role of Statins in Reversing Atherosclerosis: What the Latest Regression Studies Show. <i>Journal of Interventional Cardiology</i> , 2006, 19, 3-9.	0.5	22
2344	Studying Coronary Plaque Regression with IVUS: A Critical Review of Recent Studies. <i>Journal of Interventional Cardiology</i> , 2006, 19, 11-15.	0.5	24
2345	Cardioprotective Strategies to Improve Long-Term Outcomes Following Coronary Artery Bypass Surgery. <i>Journal of Cardiac Surgery</i> , 2006, 21, 198-204.	0.3	11
2346	Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. <i>Clinical Endocrinology</i> , 2006, 64, 292-298.	1.2	38
2347	Statin therapy in patients with chronic kidney disease: to use or not to use. <i>European Journal of Clinical Investigation</i> , 2006, 36, 519-527.	1.7	10
2348	Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up. <i>Journal of Internal Medicine</i> , 2006, 260, 272-280.	2.7	18
2349	Who should receive a statin these days? Lessons from recent clinical trials. <i>Journal of Internal Medicine</i> , 2006, 260, 305-319.	2.7	46

#	ARTICLE	IF	CITATIONS
2350	Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer. <i>Journal of Internal Medicine</i> , 2006, 260, 592-593.	2.7	2
2351	Prognostic implications of renal dysfunction in patients with stable angina pectoris. <i>Journal of Internal Medicine</i> , 2006, 260, 537-544.	2.7	5
2352	Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. <i>Journal of Internal Medicine</i> , 2006, 260, 551-559.	2.7	79
2353	The impact of a consultant anaesthetist led pre-operative assessment clinic on patients undergoing major vascular surgery*. <i>Anaesthesia</i> , 2006, 61, 234-239.	1.8	42
2354	The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 494-501.	1.1	19
2355	General practitioners' ranking of evidence-based prescribing quality indicators: a comparative study with a prescription database. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 218-224.	1.1	17
2356	Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999). <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 592-600.	1.1	8
2357	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 295-309.	21.5	230
2358	High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. <i>Cell Research</i> , 2006, 16, 799-808.	5.7	19
2359	Cochrane reviews on dietary advice for reducing intakes of fat and salt. <i>European Journal of Clinical Nutrition</i> , 2006, 60, 926-928.	1.3	3
2360	Statins: another class of antihypertensive agents?. <i>Journal of Human Hypertension</i> , 2006, 20, 320-335.	1.0	55
2361	“Hypertension” and “microalbuminuria”: The bell tolls for thee. <i>Kidney International</i> , 2006, 69, 22-28.	2.6	64
2362	Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. <i>Kidney International</i> , 2006, 69, 2057-2063.	2.6	414
2363	The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. <i>Kidney International</i> , 2006, 70, 2021-2030.	2.6	227
2364	Nuclear Receptors in Lipid Metabolism: Targeting the Heart of Dyslipidemia. <i>Annual Review of Medicine</i> , 2006, 57, 313-329.	5.0	204
2365	Ezetimibe: Rationale and role in the management of hypercholesterolemia. <i>Clinical Cardiology</i> , 2006, 29, 52-55.	0.7	8
2366	Insufficient treatment of hypercholesterolemia among patients hospitalized with chest pain. <i>Clinical Cardiology</i> , 2006, 29, 259-262.	0.7	6
2367	The Free Radical Fantasy: A Panoply of Paradoxes. <i>Annals of the New York Academy of Sciences</i> , 2006, 1067, 22-26.	1.8	80

#	ARTICLE	IF	CITATIONS
2369	Rhabdomyolysis after Gastric Bypass: Severity and Outcome Patterns. <i>Obesity Surgery</i> , 2006, 16, 1209-1213.	1.1	19
2370	Lipid-Lowering Therapy in High-Risk Persons. <i>Comprehensive Therapy</i> , 2006, 32, 68-73.	0.2	3
2371	Genetic Approaches to Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, A10-A14.	1.2	15
2372	NICE appraisal of statins: the devil lies in the lack of detail?. <i>The Prescriber</i> , 2006, 17, 9-10.	0.1	0
2373	Statins: the evidence, side-effects and interactions in older people. <i>The Prescriber</i> , 2006, 17, 20-28.	0.1	2
2374	Managing hyperlipidaemia. <i>The Prescriber</i> , 2006, 17, 34-35.	0.1	1
2375	Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 71-76.	1.0	24
2376	Safety of Nifedipine GITS in Stable Angina: The ACTION Trial. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 45-54.	1.3	25
2377	Prognosis at 6 Months for Coronary and Cerebrovascular Patients: Impact of Antiplatelet Agents and Statins: Results from the Prevenir III Study. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 55-61.	1.3	6
2378	The Cost-Effectiveness of Fluvastatin in Hungary Following Successful Percutaneous Coronary Intervention. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 309-317.	1.3	13
2379	Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. <i>Clinical Research in Cardiology</i> , 2006, 95, 393-404.	1.5	57
2383	Perceptions of Canadian Vascular Surgeons toward Pharmacological Risk Reduction in Patients with Peripheral Arterial Disease. <i>Annals of Vascular Surgery</i> , 2006, 20, 555-563.	0.4	20
2384	Statins: the next step in adjuvant therapy for sepsis?. <i>Intensive Care Medicine</i> , 2006, 32, 11-14.	3.9	26
2385	Effects of simvastatin on cardiohemodynamic responses to ischemia-reperfusion in isolated rat hearts. <i>Heart and Vessels</i> , 2006, 21, 116-123.	0.5	13
2386	Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. <i>Heart and Vessels</i> , 2006, 21, 146-151.	0.5	27
2387	Effect of pravastatin on plasma sterols and oxysterols in men. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 9-14.	0.8	29
2388	Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 817-822.	0.8	39
2391	Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. <i>Diabetologia</i> , 2006, 49, 1881-1892.	2.9	261

#	ARTICLE	IF	CITATIONS
2393	Selection of optimal therapy for chronic stable angina. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 23-35.	0.4	10
2394	Treatment of lipid disorders in patients with diabetes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 37-45.	0.4	7
2395	Low-density lipoprotein cholesterol lowering in the prevention of CHD: How low should we go?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 289-297.	0.4	7
2396	Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. <i>Journal of General Internal Medicine</i> , 2006, 21, 171-176.	1.3	24
2397	Statin therapy for coronary heart disease and its effect on stroke. <i>Current Atherosclerosis Reports</i> , 2006, 8, 337-342.	2.0	3
2398	Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data. <i>Current Atherosclerosis Reports</i> , 2006, 8, 382-389.	2.0	1
2399	Statins and the primary prevention of cardiovascular events. <i>Current Atherosclerosis Reports</i> , 2006, 8, 390-396.	2.0	22
2400	The CARDS trial: Diabetic patients dealt a winning hand. <i>Current Atherosclerosis Reports</i> , 2006, 8, 429-432.	2.0	8
2402	Low-density lipoprotein reduction: Is the risk worth the benefit?. <i>Current Atherosclerosis Reports</i> , 2006, 8, 19-25.	2.0	1
2403	The effects of statins on high-density lipoproteins. <i>Current Atherosclerosis Reports</i> , 2006, 8, 41-49.	2.0	48
2404	Effective use of combination lipid therapy. <i>Current Atherosclerosis Reports</i> , 2006, 8, 76-84.	2.0	12
2405	New strategies in the medical treatment of carotid artery disease. <i>Current Cardiology Reports</i> , 2006, 8, 33-37.	1.3	4
2406	Metabolic syndrome in the elderly. <i>Current Diabetes Reports</i> , 2006, 6, 64-71.	1.7	46
2407	Should all patients with metabolic syndrome be treated with statins?. <i>Current Diabetes Reports</i> , 2006, 6, 72-76.	1.7	0
2408	Issues with care in the elderly patient presenting with acute ischemia. <i>Current Heart Failure Reports</i> , 2006, 3, 51-56.	1.3	4
2409	Reduction of cardiovascular risk and mortality: A population-based approach. <i>Advances in Therapy</i> , 2006, 23, 905-920.	1.3	8
2410	Peripheral arteriopathy of the lower limbs in a patient with severe congenital thrombocytopenia. <i>Internal and Emergency Medicine</i> , 2006, 1, 83-85.	1.0	0
2411	Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives. <i>Canadian Journal of Anaesthesia</i> , 2006, 53, 1126-1147.	0.7	17

#	ARTICLE	IF	CITATIONS
2412	Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes. Irish Journal of Medical Science, 2006, 175, 36-41.	0.8	1
2413	Pharmacogenomics of cholesterol-lowering therapy. Vascular Pharmacology, 2006, 44, 75-89.	1.0	75
2414	REPORT: Obesity, Dyslipidemias and Erectile Dysfunction: A Report of a Subcommittee of the Sexual Medicine Society of North America. Journal of Sexual Medicine, 2006, 3, 778-786.	0.3	70
2415	Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus as a Component of the Cardiometabolic Syndrome. Journal of the Cardiometabolic Syndrome, 2006, 1, 133-140.	1.7	10
2416	Treating the Cardiometabolic Syndrome: An Opportunity to Provide Comprehensive Cardiovascular Risk Reduction. Journal of the Cardiometabolic Syndrome, 2006, 1, 358-361.	1.7	7
2417	Management of Lipid Disorders. Geriatric Nursing, 2006, 27, 142-148.	0.9	0
2418	Statins in rheumatology. Joint Bone Spine, 2006, 73, 159-168.	0.8	12
2419	Novel non-systemic inhibitor of ileal apical Na ⁺ -dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. European Journal of Pharmacology, 2006, 539, 89-98.	1.7	33
2420	Inflammation and Atherosclerosis. European Journal of Vascular and Endovascular Surgery, 2006, 31, 386-393.	0.8	125
2421	The Prevalence of Chronic Critical Lower Limb Ischaemia in a Population of 20,000 Subjects 40-69 Years of Age. European Journal of Vascular and Endovascular Surgery, 2006, 32, 60-65.	0.8	40
2422	Managing Risk Factors for Atherosclerosis in Critical Limb Ischaemia. European Journal of Vascular and Endovascular Surgery, 2006, 32, 478-483.	0.8	27
2423	Search for an Optimal Atherogenic Lipid Risk Profile: From the Framingham Study. American Journal of Cardiology, 2006, 97, 372-375.	0.7	74
2424	Statins, Cardiovascular Disease, and Drug Safety. American Journal of Cardiology, 2006, 97, S3-S5.	0.7	50
2425	Statin Safety: An Overview and Assessment of the Data-2005. American Journal of Cardiology, 2006, 97, S6-S26.	0.7	226
2426	Statin Safety: An Appraisal from the Adverse Event Reporting System. American Journal of Cardiology, 2006, 97, S32-S43.	0.7	98
2427	Statin Safety: A Systematic Review. American Journal of Cardiology, 2006, 97, S52-S60.	0.7	674
2428	Effect of Atherosclerotic Regression on Total Luminal Size of Coronary Arteries as Determined by Intravascular Ultrasound. American Journal of Cardiology, 2006, 98, 23-27.	0.7	28
2429	What the Statin Trials Have Taught Us. American Journal of Cardiology, 2006, 98, 129-134.	0.7	29

#	ARTICLE	IF	CITATIONS
2430	Usefulness of Follow-Up Low-Density Lipoprotein Cholesterol Level as an Independent Predictor of Changes of Coronary Atherosclerotic Plaque Size as Determined by Intravascular Ultrasound Analysis After Statin (Atorvastatin or Simvastatin) Therapy. American Journal of Cardiology, 2006, 98, 866-870.	0.7	23
2431	Comparison of Mortality Rates in Statin Users Versus Nonstatin Users in a United States Veteran Population. American Journal of Cardiology, 2006, 98, 923-928.	0.7	38
2432	The Editor's Roundtable: Diabetes Mellitus and Coronary Heart Disease. American Journal of Cardiology, 2006, 98, 842-856.	0.7	4
2433	Incidence of New Stroke or New Myocardial Infarction or Death in Patients With Severe Carotid Arterial Disease Treated With and Without Statins. American Journal of Cardiology, 2006, 98, 1170-1171.	0.7	24
2434	Identifying Patients for Aggressive Cholesterol Lowering: The Risk Curve Concept. American Journal of Cardiology, 2006, 98, 1405-1408.	0.7	43
2435	Relation Between Plaque Progression and Low-Density Lipoprotein Cholesterol During Aging as Assessed With Serial Long-Term (≈12 Months) Follow-Up Intravascular Ultrasound of the Left Main Coronary Artery. American Journal of Cardiology, 2006, 98, 1419-1423.	0.7	19
2436	Atherosclerosis: Its Cause and Its Prevention. American Journal of Cardiology, 2006, 98, 1550-1555.	0.7	17
2438	Oxidative Stress at the Vascular Wall. Mechanistic and Pharmacological Aspects. Archives of Medical Research, 2006, 37, 436-448.	1.5	40
2439	Pathophysiology, Diagnosis, and Management of Dyslipidemia. Current Problems in Cardiology, 2006, 31, 445-486.	1.1	29
2440	Inflammation: A pivotal link between autoimmune diseases and atherosclerosis. Autoimmunity Reviews, 2006, 5, 331-337.	2.5	222
2441	Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochemical Pharmacology, 2006, 71, 1324-1330.	2.0	49
2442	Elevated K-ras activity with cholestyramine and lovastatin, but not konjac mannan or niacin in lung—Importance of mouse strain. Biochemical Pharmacology, 2006, 72, 1749-1755.	2.0	8
2443	Prevention of cardiovascular disease in patients with rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2006, 20, 741-756.	1.4	6
2444	Lipid metabolism in cognitive decline and dementia. Brain Research Reviews, 2006, 51, 275-292.	9.1	165
2445	Early intervention to achieve optimal outcomes in type 2 diabetes: A case presentation. Clinical Cornerstone, 2006, 8, S6-S18.	1.0	4
2448	Pathophysiology and treatment of stroke in sickle-cell disease: present and future. Lancet Neurology, The, 2006, 5, 501-512.	4.9	234
2449	The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD. American Journal of Kidney Diseases, 2006, 47, 385-395.	2.1	104
2450	How Safe Is Aggressive Statin Therapy?. Progress in Cardiovascular Nursing, 2006, 21, 140-145.	0.5	9

#	ARTICLE	IF	CITATIONS
2451	Interventions to improve guideline compliance following coronary artery bypass grafting. Surgery, 2006, 140, 541-552.	1.0	24
2452	The Nonlipid Effects of Statins on Endothelial Function. Trends in Cardiovascular Medicine, 2006, 16, 156-162.	2.3	59
2453	Cholesterol and Alzheimer's disease—“is there a relation?”. Mechanisms of Ageing and Development, 2006, 127, 138-147.	2.2	86
2454	Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: An 8-year retrospective cohort study. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 679-685.	0.4	97
2455	Isoprenoids and Alzheimer's disease: A complex relationship. Neurobiology of Disease, 2006, 22, 209-222.	2.1	72
2456	Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A β in plasma. Neurobiology of Disease, 2006, 24, 114-127.	2.1	112
2457	Mechanisms of target organ damage caused by hypertension: Therapeutic potential. , 2006, 111, 81-98.		120
2458	Estrogen therapy and thrombotic risk. , 2006, 111, 792-807.		19
2459	Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: Mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. , 2006, 112, 501-512.		32
2460	Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care. BMC Cardiovascular Disorders, 2006, 6, 21.	0.7	4
2461	Primary prevention of ischaemic heart disease. Medicine, 2006, 34, 178-180.	0.2	0
2462	Management of stable angina and unstable angina/non-ST-elevation myocardial infarction. Medicine, 2006, 34, 181-187.	0.2	1
2463	Challenges Associated with Metabolic Syndrome. Pharmacotherapy, 2006, 26, 209S-217S.	1.2	17
2464	Effect of Rosuvastatin Compared with Other Statins on Lipid Levels and National Cholesterol Education Program Goal Attainment for Low-Density Lipoprotein Cholesterol in a Usual Care Setting. Pharmacotherapy, 2006, 26, 469-478.	1.2	46
2465	New and Emerging Strategies for Reducing Cardiometabolic Risk Factors. Pharmacotherapy, 2006, 26, 13S-31S.	1.2	9
2466	Introduction: Addressing Cardiometabolic Risk. Pharmacotherapy, 2006, 26, 1S-2S.	1.2	0
2467	Inflammation and the etiology of type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2006, 22, 4-10.	1.7	188
2468	Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology, 2006, 44, 335-340.	3.6	107

#	ARTICLE	IF	CITATIONS
2469	Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice. <i>Hepatology</i> , 2006, 44, 1259-1266.	3.6	23
2470	Intra- and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. <i>Journal of Magnetic Resonance Imaging</i> , 2006, 24, 203-210.	1.9	91
2471	Simvastatin enhances learning and memory independent of amyloid load in mice. <i>Annals of Neurology</i> , 2006, 60, 729-739.	2.8	138
2472	Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. <i>European Heart Journal</i> , 2006, 27, 2310-2316.	1.0	57
2473	Niaspan® in the management of dyslipidaemia: the evidence. <i>Country Review Ukraine</i> , 2006, 8, F60-F67.	0.8	10
2474	Interventions for heart disease and their effects on Alzheimer's disease. <i>Neurological Research</i> , 2006, 28, 630-636.	0.6	33
2475	Cardiac risk factors and potential treatments in Alzheimer's disease. <i>Neurological Research</i> , 2006, 28, 595-604.	0.6	44
2476	Update on lipid-lowering therapy and LDL-cholesterol targets. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 424-436.	3.3	8
2477	Does rosuvastatin improve lipid levels in patients with the metabolic syndrome more effectively than atorvastatin?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 74-75.	3.3	2
2479	Cardiovascular risk factors in renal transplantation—current controversies. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, iii3-iii8.	0.4	44
2480	Modified Cretan Mediterranean Diet in the Prevention of Coronary Heart Disease and Cancer: An Update. , 2006, 97, 1-32.		19
2481	Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction. <i>Archives of Internal Medicine</i> , 2006, 166, 787.	4.3	124
2482	What Is the Best Choice for Combination Therapy in the Management of Dyslipidemia of Metabolic Syndrome?. <i>Cardiology</i> , 2006, 105, 139-140.	0.6	0
2483	Diabetes and lipid lowering: where are we?. <i>BMJ: British Medical Journal</i> , 2006, 332, 1103-1104.	2.4	5
2484	Balancing potential risks and benefits of using confidential data. <i>BMJ: British Medical Journal</i> , 2006, 333, 349-351.	2.4	14
2485	Biochemical liver function tests. <i>BMJ: British Medical Journal</i> , 2006, 333, 481-483.	2.4	7
2486	Prevention and early detection of vascular complications of diabetes. <i>BMJ: British Medical Journal</i> , 2006, 333, 475-480.	2.4	164
2487	Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20%536 people. <i>BMJ: British Medical Journal</i> , 2006, 333, 1145.	2.4	80

#	ARTICLE	IF	CITATIONS
2488	Patients With Transient Ischemic Attack or Minor Stroke Should Be Admitted to Hospital. <i>Stroke</i> , 2006, 37, 1137-1138.	1.0	46
2489	Patients With Transient Ischemic Attack Do Not Need To Be Admitted to Hospital for Urgent Evaluation and Treatment. <i>Stroke</i> , 2006, 37, 1139-1140.	1.0	23
2490	Repeated Tissue Plasminogen Activator Treatment for Early Stroke Recurrence: Protocol Violation Is Not an Option. <i>Stroke</i> , 2006, 37, 1151-1153.	1.0	5
2491	Compatibility of Carotid Stenting and Cardiac Surgery. <i>Stroke</i> , 2006, 37, 1153-1154.	1.0	0
2492	Statins and Stroke: Current Clinical Practice. <i>Stroke</i> , 2006, 37, 1153-1153.	1.0	8
2493	Obstructive Sleep Apnea as an Independent Risk Factor for Stroke and Mortality. <i>Stroke</i> , 2006, 37, 1150-1150.	1.0	5
2494	Hyperglycemia, Insulin and Acute Ischemic Stroke. <i>Stroke</i> , 2006, 37, 1150-1151.	1.0	5
2495	Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease. <i>Stroke</i> , 2006, 37, 1427-1431.	1.0	45
2496	Quality of Hospital and Outpatient Care After Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2006, 37, 1844-1849.	1.0	46
2497	Impact of Carotid Endarterectomy on Medical Secondary Prevention After a Stroke or a Transient Ischemic Attack. <i>Stroke</i> , 2006, 37, 2880-2885.	1.0	13
2498	The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease. <i>Circulation</i> , 2006, 114, 861-866.	1.6	73
2499	The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. <i>European Heart Journal</i> , 2006, 27, 1298-1304.	1.0	47
2500	Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2006, 27, 2945-2955.	1.0	85
2501	The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3106-3114.	0.4	93
2502	Risk stratification in acute coronary syndromes—does the TIMI risk score work in unselected cases?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 81-87.	0.2	33
2503	Apolipoproteins as markers and managers of coronary risk. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 277-287.	0.2	84
2504	Pharmacoeconomic considerations with statin therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1291-1304.	0.9	6
2505	Statins: Are They All the Same?. <i>Current Drug Therapy</i> , 2006, 1, 157-172.	0.2	0

#	ARTICLE	IF	CITATIONS
2506	Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. <i>BMJ: British Medical Journal</i> , 2006, 333, 999.	2.4	230
2507	Medical Management of Peripheral Arterial Disease: A Therapeutic Algorithm. <i>Journal of Endovascular Therapy</i> , 2006, 13, II-19-II-29.	0.8	8
2508	Are we lowering LDL cholesterol sufficiently?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 290-291.	3.3	7
2509	How low to target LDL?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 414-415.	2.9	1
2510	Diabetes: Impact on Stroke Risk and Poststroke Recovery. <i>Seminars in Neurology</i> , 2006, 26, 100-107.	0.5	24
2511	Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4408-4414.	1.8	33
2513	Chronic Obstructive Pulmonary Disease, Risk Factors, and Outcome Trials: Comparisons with Cardiovascular Disease. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 635-640.	3.5	34
2515	Lipid-lowering effects of statins: a comparative review. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1701-1714.	0.9	47
2516	Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. <i>BMJ: British Medical Journal</i> , 2006, 332, 1419.	2.4	85
2517	Spontaneous Intracerebral Hemorrhage. , 2006, , 45-59.		0
2518	Macroangiopathy in Adults and Children with Diabetes: Risk Factors (Part 2). <i>Hormone and Metabolic Research</i> , 2006, 38, 706-720.	0.7	10
2520	Atorvastatin: beyond lipid-lowering effects in the diabetic population. <i>Future Cardiology</i> , 2006, 2, 527-533.	0.5	0
2521	Management of Dyslipidemia in Special Populations. <i>Journal of Pharmacy Practice</i> , 2006, 19, 63-78.	0.5	1
2522	Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy. <i>Journal of Lipid Research</i> , 2006, 47, 1339-1351.	2.0	172
2523	Drug Insight: immunomodulatory effects of statinsâ€”potential benefits for renal patients?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 378-387.	2.0	31
2524	Lowering cholesterol in patients with stroke: Raising the standard. <i>Neurology</i> , 2006, 66, 1140-1141.	1.5	4
2526	The Argument Against the Appropriateness of Over-the-Counter Statins. <i>Circulation</i> , 2006, 114, 1315-1320.	1.6	9
2527	Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B. <i>Circulation</i> , 2006, 114, 1729-1735.	1.6	335

#	ARTICLE	IF	CITATIONS
2528	Drug Therapies in the Secondary Prevention of Cardiovascular Diseases: Successes, Shortcomings and Future Directions. <i>Current Vascular Pharmacology</i> , 2006, 4, 253-268.	0.8	10
2529	NO-Releasing Hybrids of Cardiovascular Drugs. <i>Current Medicinal Chemistry</i> , 2006, 13, 609-625.	1.2	33
2530	Novel Concepts of Statin Therapy for Cardiovascular Risk Reduction in Hypertension. <i>Current Pharmaceutical Design</i> , 2006, 12, 1593-1609.	0.9	16
2531	Statins in the Treatment of Chronic Heart Failure: A Systematic Review. <i>PLoS Medicine</i> , 2006, 3, e333.	3.9	44
2532	High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2006, 355, 549-559.	13.9	2,497
2533	Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. <i>Current Medical Research and Opinion</i> , 2006, 22, 1181-1191.	0.9	12
2535	Pharmacotherapy of Abdominal Aortic Aneurysms. <i>Current Vascular Pharmacology</i> , 2006, 4, 129-149.	0.8	14
2536	Cardiac Biomarkers for the Prediction and Diagnosis of Atherosclerotic Disease and its Complications. <i>Current Molecular Medicine</i> , 2006, 6, 557-569.	0.6	3
2537	Lipid Testing and Lipid-Lowering Therapy in Hospitalized Ischemic Stroke and Transient Ischemic Attack Patients. <i>Stroke</i> , 2006, 37, 44-49.	1.0	32
2538	Statins in the treatment of chronic heart failure: Biological and clinical considerations. <i>Cardiovascular Research</i> , 2006, 71, 443-454.	1.8	44
2539	Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. <i>Heart</i> , 2006, 92, 1047-1054.	1.2	52
2540	Stroke Prevention and Statin Treatment. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 335-344.	0.5	7
2541	At which stage of chronic kidney disease should dyslipidemia be treated?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 176-177.	2.0	7
2542	Statins for Diabetic Cardiovascular Complications. <i>Current Vascular Pharmacology</i> , 2006, 4, 245-251.	0.8	34
2543	Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. <i>Journal of Public Health</i> , 2006, 28, 361-369.	1.0	19
2544	Lipid Lowering Therapy in the Elderly: Is there a Benefit?. <i>Current Pharmaceutical Design</i> , 2006, 12, 3945-60.	0.9	10
2545	Recent Trends in Cardiovascular Complications Among Men and Women With and Without Diabetes. <i>Diabetes Care</i> , 2006, 29, 32-37.	4.3	141
2546	Differential diagnosis of elevated troponins. <i>Heart</i> , 2006, 92, 987-993.	1.2	286

#	ARTICLE	IF	CITATIONS
2547	Benefits, challenges, and registerability of the polypill. <i>European Heart Journal</i> , 2006, 27, 1651-1656.	1.0	88
2548	How Important Is Diabetes as a Risk Factor for Cardiovascular and Other Diseases in Older Adults?. <i>PLoS Medicine</i> , 2006, 3, e424.	3.9	7
2549	Evidence-Based Prescribing of Statins: A Developing World Perspective. <i>PLoS Medicine</i> , 2006, 3, e50.	3.9	10
2550	Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative. <i>Journal of the National Cancer Institute</i> , 2006, 98, 700-707.	3.0	169
2551	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. <i>Circulation</i> , 2006, 114, 2871-2891.	1.6	109
2552	Primary Prevention of Ischemic Stroke. <i>Stroke</i> , 2006, 37, 1583-1633.	1.0	1,100
2553	Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis. <i>Journal of Lipid Research</i> , 2006, 47, 2215-2222.	2.0	45
2554	Medical Management of Peripheral Arterial Disease: A Therapeutic Algorithm. <i>Journal of Endovascular Therapy</i> , 2006, 13, II-19-II-29.	0.8	5
2555	The Effect of Modifiable Risk Factors on Pancreatic Cancer Mortality in Populations of the Asia-Pacific Region. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2435-2440.	1.1	84
2556	Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , 2006, 114, 201-208.	1.6	236
2557	Predictors of patients' preferences for treatments to prevent heart disease. <i>Heart</i> , 2006, 92, 1651-1655.	1.2	16
2558	Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1090-1099.	2.2	54
2559	Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk. <i>Neurology</i> , 2006, 66, 1153-1158.	1.5	33
2560	Chronic Kidney Disease as a Situation of High Added Risk in Hypertensive Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S136-S140.	3.0	17
2561	A 39-Year-Old Woman With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 319.	3.8	0
2562	Protecting the Heart with Cardiac Medication in Patients with Left Ventricular Dysfunction Undergoing Major Noncardiac Vascular Surgery. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2006, 10, 25-31.	0.4	28
2563	Quality Assessment of Dyslipidemia in Managed Care: Current Best Evidence Should Be Used to Benchmark Quality. <i>Annals of Pharmacotherapy</i> , 2006, 40, 124-127.	0.9	4
2564	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2006, 20, 732-755.	2.0	145

#	ARTICLE	IF	CITATIONS
2565	Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. <i>Future Cardiology</i> , 2006, 2, 635-646.	0.5	0
2566	Adherence and Persistence with Single-Dosage Form Extended-Release Niacin/Lovastatin Compared with Statins Alone or in Combination with Extended-Release Niacin. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1274-1279.	0.9	23
2567	Statins Activate AMP-Activated Protein Kinase In Vitro and In Vivo. <i>Circulation</i> , 2006, 114, 2655-2662.	1.6	234
2568	Lipophilic Statins Merit Additional Study for Breast Cancer Chemoprevention. <i>Journal of Clinical Oncology</i> , 2006, 24, 2128-2129.	0.8	16
2569	Review: Comparing cardiovascular outcomes in diabetes studies. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 111-118.	0.6	4
2570	Introduction: Pharmacotherapy for Dyslipidemia. <i>Journal of Pharmacy Practice</i> , 2006, 19, 61-62.	0.5	0
2571	Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport. <i>Circulation</i> , 2006, 113, 1140-1150.	1.6	93
2572	Simvastatin–Amiodarone Interaction Resulting in Rhabdomyolysis, Azotemia, and Possible Hepatotoxicity. <i>Annals of Pharmacotherapy</i> , 2006, 40, 753-757.	0.9	62
2573	STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). <i>European Heart Journal</i> , 2006, 28, 1409-1417.	1.0	258
2575	Can a Potent Statin Actually Regress Coronary Atherosclerosis?. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1583.	3.8	20
2577	Commentary: Statins and fracture risk—unresolved questions. <i>International Journal of Epidemiology</i> , 2006, 35, 1308-1309.	0.9	0
2578	Statins and Cancer Risk. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 74.	3.8	529
2579	Case Studies in Lipid Management. , 0, , .		1
2580	Role of the Pharmacist in the Management of Dyslipidemia. <i>Journal of Pharmacy Practice</i> , 2006, 19, 94-102.	0.5	6
2581	Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. <i>International Journal of Epidemiology</i> , 2006, 35, 1301-1308.	0.9	59
2582	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. <i>Circulation</i> , 2006, 113, 2363-2372.	1.6	1,742
2583	Primary Prevention of Cardiovascular Diseases With Statin Therapy. <i>Archives of Internal Medicine</i> , 2006, 166, 2307.	4.3	303
2584	Mortality and Hospitalization in Patients After Amputation: A comparison between patients with and without diabetes. <i>Diabetes Care</i> , 2006, 29, 2252-2256.	4.3	164

#	ARTICLE	IF	CITATIONS
2585	Medical Treatment of Peripheral Arterial Disease. JAMA - Journal of the American Medical Association, 2006, 295, 547.	3.8	285
2586	Obesity and Diabetes. , 2006, , .		4
2587	Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part IV: The 1984 Coronary Primary Prevention Trial ends itâ€™almost. Journal of Lipid Research, 2006, 47, 1-14.	2.0	48
2588	A Call for Clinical Trials: Lipophilic Statins May Prove Effective in Treatment and Prevention of Particular Breast Cancer Subtypes. Journal of Clinical Oncology, 2006, 24, 2127-2127.	0.8	25
2589	Cardiology in Family Practice. , 2006, , .		0
2590	Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes and Vascular Disease Research, 2006, 3, 93-102.	0.9	65
2591	Treating to Target in Type 2 Diabetes: A Case Presentation. The Diabetes Educator, 2006, 32, 137S-145S.	2.6	0
2592	Hyperlipemia and Oxidation of LDL Induce Vascular Smooth Muscle Cell Growth: An Effect Mediated by the HLH Factor Id3. Journal of Vascular Research, 2006, 43, 123-130.	0.6	24
2593	Polypill Strategy vs. Prevention Clinics for Stroke Prevention. Cerebrovascular Diseases, 2006, 21, 35-40.	0.8	13
2594	Apolipoproteins as Predictors of Ischaemic Stroke in Patients with a Previous Transient Ischaemic Attack. Cerebrovascular Diseases, 2006, 21, 323-328.	0.8	32
2595	Neuroprotection in Vascular Dementia. Cerebrovascular Diseases, 2006, 21, 106-117.	0.8	48
2596	Effects of Pravastatin Treatment on Blood Pressure Regulation after Renal Transplantation. Kidney and Blood Pressure Research, 2006, 29, 329-337.	0.9	3
2597	Cholesteryl Ester Transfer Protein Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 681-684.	1.1	19
2598	Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2716-2723.	1.1	160
2599	ACC/AHA/SCAI Practice Guidelines, February 21, 2006. Circulation, 2006, 113, e166-286.	1.6	525
2600	Statins, cholesterol, and the prevention of coronary heart disease. FASEB Journal, 2006, 20, 200-201.	0.2	10
2601	Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.1	33
2602	What's New? Guidelines and Goals. Journal of Pharmacy Practice, 2006, 19, 103-112.	0.5	0

#	ARTICLE	IF	CITATIONS
2603	Role of computed tomography in risk assessment for coronary heart disease. <i>Postgraduate Medical Journal</i> , 2006, 82, 664-671.	0.9	6
2604	Evidence, Education and Practice. <i>Cerebrovascular Diseases</i> , 2006, 22, 342-349.	0.8	5
2605	ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary. <i>Circulation</i> , 2006, 113, 1474-1547.	1.6	138
2606	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. <i>Circulation</i> , 2006, 114, 2850-2870.	1.6	346
2607	Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. <i>European Heart Journal</i> , 2006, 28, 5-12.	1.0	46
2608	Dyslipidemia in Older Adults. <i>The American Journal of Geriatric Cardiology</i> , 2006, 15, 239-244.	0.7	2
2609	Treatment of Non-ST-Elevation Acute Coronary Syndrome in the Elderly: Current Practice and Future Opportunities. <i>The American Journal of Geriatric Cardiology</i> , 2006, 15, 42-49.	0.7	10
2610	Statin Use and Cancer Risk: An Epidemiologic Review. <i>Cancer Investigation</i> , 2006, 24, 413-424.	0.6	24
2611	Breast Cancer Growth Prevention by Statins. <i>Cancer Research</i> , 2006, 66, 8707-8714.	0.4	309
2612	REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 383-392.	1.8	132
2613	Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2006, 332, 1115-1124.	2.4	270
2614	Therapeutic approaches to Alzheimer's disease. <i>Brain</i> , 2006, 129, 2840-2855.	3.7	310
2615	Drug Insight: statin use in the elderly. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 318-328.	3.3	13
2616	"Anti-Inflammatory" Drugs and Their Effects on Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2006, 8, 18-27.	2.4	41
2617	Statin-Induced Myopathy: The Two Faces of Janus. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 105-112.	1.0	41
2618	The importance of total cardiovascular risk assessment in clinical practice. <i>European Journal of General Practice</i> , 2006, 12, 148-155.	0.9	26
2619	Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. <i>European Heart Journal</i> , 2006, 27, 2323-2329.	1.0	88
2620	Emerging therapeutics for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 695-704.	1.4	29

#	ARTICLE	IF	CITATIONS
2621	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. <i>Current Medical Research and Opinion</i> , 2006, 22, 2041-2053.	0.9	101
2622	Changing targets in the treatment of type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2006, 22, S5-S13.	0.9	29
2624	Vascular Protection of Dual Therapy (Atorvastatin-Amlodipine) in Hypertensive Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S189-S193.	3.0	11
2625	ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). <i>Circulation</i> , 2006, 113, e463-654.	1.6	2,927
2626	Results of Bariatric Surgery. <i>Annual Review of Nutrition</i> , 2006, 26, 481-511.	4.3	23
2627	Peripheral Arterial Disease. <i>Circulation</i> , 2006, 114, 688-699.	1.6	441
2628	Insig-dependent Ubiquitination and Degradation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Stimulated by $\hat{1}$ - and $\hat{3}$ -Tocotrienols. <i>Journal of Biological Chemistry</i> , 2006, 281, 25054-25061.	1.6	157
2629	Amlodipine/atorvastatin single pill for the management of hypertensive patients with additional cardiovascular risk factors. <i>Future Cardiology</i> , 2006, 2, 145-159.	0.5	1
2630	Statins in stroke: prevention, protection and recovery. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 195-202.	1.4	22
2631	Coronary Risk Attributes, Coronary Risk Reduction, and Clinical Outcomes. <i>The American Journal of Geriatric Cardiology</i> , 2006, 15, 140-141.	0.7	0
2634	Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study. <i>Diabetes Care</i> , 2006, 29, 1220-1226.	4.3	493
2635	Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. <i>Current Medical Research and Opinion</i> , 2006, 22, 823-835.	0.9	24
2636	Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. <i>Neurology</i> , 2007, 68, 737-742.	1.5	156
2637	Rationale and Public Health Implications of Changing CHD Risk Factor Definitions. <i>Annual Review of Public Health</i> , 2007, 28, 321-344.	7.6	41
2638	Economic impacts attributable to the early clinical benefit of atorvastatin therapy â€“ a US managed care perspective. <i>Current Medical Research and Opinion</i> , 2007, 23, 1517-1529.	0.9	13
2639	Transcriptional Activation of Hepatic ACSL3 and ACSL5 by Oncostatin M Reduces Hypertriglyceridemia Through Enhanced $\hat{1}$ -Oxidation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2198-2205.	1.1	52
2640	Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. <i>Circulation</i> , 2007, 115, 27-33.	1.6	145
2641	Effect of drug combinations on admission for recurrent myocardial infarction. <i>Heart</i> , 2007, 93, 1226-1230.	1.2	18

#	ARTICLE	IF	CITATIONS
2642	Skin tissue cholesterol is not related to vascular occlusive disease. <i>Vascular Medicine</i> , 2007, 12, 129-134.	0.8	4
2643	The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. <i>Pediatrics</i> , 2007, 119, 370-380.	1.0	58
2644	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- σ ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2007, 116, e148-304.	1.6	1,247
2645	Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 276-284.	0.5	16
2646	Pharmacologic Induction of Heme Oxygenase-1. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 2227-2240.	2.5	82
2647	Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 605-623.	1.9	16
2648	Exploring the natural history of atherosclerosis with intravascular ultrasound. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 295-306.	0.6	7
2649	Inhibition of Cholesterol Biosynthesis, the Discovery of the Statins, and a Revolution in Preventive Cardiology. , 2007, , 171-193.		2
2650	Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United Kingdom. <i>Journal of Human Hypertension</i> , 2007, 21, 925-933.	1.0	11
2651	Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study. <i>Journal of Public Health</i> , 2007, 29, 251-257.	1.0	26
2653	The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. <i>Family Practice</i> , 2007, 24, 189-200.	0.8	107
2654	Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. <i>Heart</i> , 2007, 93, 559-564.	1.2	30
2655	Restoring the Dysfunctional Endothelium. <i>Current Pharmaceutical Design</i> , 2007, 13, 1053-1068.	0.9	35
2656	Nutritional and nutraceutical considerations for dyslipidemia. <i>Future Lipidology</i> , 2007, 2, 313-339.	0.5	14
2657	The State of Lipid Control in Patients with Diabetes in a Public Health Care Centre. <i>Asia-Pacific Journal of Public Health</i> , 2007, 19, 16-21.	0.4	7
2659	A cross sectional survey of secondary prevention measures in patients with peripheral arterial disease in primary care. <i>Postgraduate Medical Journal</i> , 2007, 83, 602-605.	0.9	5
2660	Apolipoprotein A-I/HDL Infusion Therapy for Plaque Stabilization-Regression: A Novel Therapeutic Approach. <i>Current Pharmaceutical Design</i> , 2007, 13, 1031-1038.	0.9	34
2661	Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. <i>Neurology</i> , 2007, 69, 878-885.	1.5	212

#	ARTICLE	IF	CITATIONS
2662	Treating cardiovascular disease in women. <i>Menopause International</i> , 2007, 13, 159-164.	1.6	10
2663	Treatment of stable angina. <i>Heart</i> , 2007, 93, 868-874.	1.2	11
2664	Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis. <i>Heart</i> , 2007, 93, 848-855.	1.2	83
2665	Preprocedural Statin Therapy in Percutaneous Coronary Intervention. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1687-1693.	0.9	12
2666	Provision of laboratory services for lipid analysis in the United Kingdom. <i>Annals of Clinical Biochemistry</i> , 2007, 44, 273-280.	0.8	3
2667	How Evidence-Based Are the Recommendations in Evidence-Based Guidelines?. <i>PLoS Medicine</i> , 2007, 4, e250.	3.9	199
2668	The Therapeutic Potential of Statins in Neurological Disorders. <i>Current Medicinal Chemistry</i> , 2007, 14, 103-112.	1.2	58
2669	Influence of Statin Use on Endothelial Function: From Bench to Clinics. <i>Current Pharmaceutical Design</i> , 2007, 13, 1771-1786.	0.9	53
2670	Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease. <i>Scandinavian Cardiovascular Journal</i> , 2007, 41, 138-141.	0.4	14
2671	Epidemiology and Risk Factors of Cardiovascular Disease in Postmenopausal Women. , 2007, , 405-452.		7
2673	Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke. <i>Stroke</i> , 2007, 38, 1881-1885.	1.0	311
2674	Association of statin use with cognitive decline in elderly African Americans. <i>Neurology</i> , 2007, 69, 1873-1880.	1.5	69
2675	Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention With Drug-Eluting Stents for Patients With Multivessel Coronary Artery Disease. <i>Circulation</i> , 2007, 116, 1200-6.	1.6	134
2676	Peripheral Arterial Disease: A Guide for Nephrologists. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 839-846.	2.2	57
2677	Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. <i>Heart</i> , 2007, 93, 914-921.	1.2	108
2678	Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. <i>European Heart Journal</i> , 2007, 28, 2770-2777.	1.0	57
2679	Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. <i>European Heart Journal</i> , 2007, 29, 54-62.	1.0	54
2680	Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. <i>European Journal of Public Health</i> , 2007, 17, 492-496.	0.1	31

#	ARTICLE	IF	CITATIONS
2681	Epoetin trials: randomised controlled trials don't always mimic observational data. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 684-686.	0.4	8
2682	Pre-transplant predictors of cerebrovascular events after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1429-1435.	0.4	51
2683	Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes. <i>BMJ: British Medical Journal</i> , 2007, 334, 982-982.	2.4	16
2684	Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?. <i>Stroke</i> , 2007, 38, 441-450.	1.0	55
2685	Do We Need to Assess the Effect of Treatment Withdrawal?. <i>Stroke</i> , 2007, 38, 2629-2630.	1.0	2
2686	Should Statins Be Given Routinely Before Carotid Endarterectomy?. <i>Perspectives in Vascular Surgery and Endovascular Therapy</i> , 2007, 19, 240-245.	0.6	12
2687	Efficacy and Safety of Statin Monotherapy in Older Adults: A Meta-Analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2007, 62, 879-887.	1.7	77
2688	Statins Have No Role in Pulmonary Disease Mortality. <i>Chest</i> , 2007, 132, 1408.	0.4	3
2689	How aggressively should cholesterol targets be pursued?. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2007, 68, 232-233.	0.2	0
2690	Statin therapy after stroke or transient ischemic attackâ€”a new weapon in our secondary stroke prevention arsenal?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 130-131.	2.7	4
2691	Intermittent Claudication. <i>New England Journal of Medicine</i> , 2007, 357, 91-93.	13.9	0
2692	Poverty and chronic diseases in Asia: challenges and opportunities. <i>Cmaj</i> , 2007, 177, 1059-1062.	0.9	8
2695	Patient Knowledge of Coronary Risk Profile Improves the Effectiveness of Dyslipidemia Therapy. <i>Archives of Internal Medicine</i> , 2007, 167, 2296.	4.3	158
2696	Polymorphisms in Apolipoprotein B and Risk of Ischemic Stroke. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3611-3617.	1.8	18
2698	Risk factor status and vascular events in patients with symptomatic intracranial stenosis. <i>Neurology</i> , 2007, 69, 2063-2068.	1.5	155
2699	Mechanisms of action of statins in stroke. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 273-278.	1.5	14
2700	Clinical efficacy and costâ€”effectiveness of rosuvastatin. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 31-39.	0.7	0
2701	Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. <i>Pharmacogenomics</i> , 2007, 8, 1723-1734.	0.6	48

#	ARTICLE	IF	CITATIONS
2702	Potential of adiponectin as a cardioprotective agent. <i>Future Cardiology</i> , 2007, 3, 647-656.	0.5	7
2703	Serum lipid profile on admission for ischemic stroke: Failure to meet National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII) guidelines. <i>Neurology</i> , 2007, 68, 660-665.	1.5	25
2704	Impact of statins on atherosclerotic plaque. <i>Future Cardiology</i> , 2007, 3, 157-164.	0.5	1
2708	Impact of gender on statin efficacy. <i>Current Medical Research and Opinion</i> , 2007, 23, 565-574.	0.9	45
2709	Prevention of Alzheimer's disease. <i>International Review of Psychiatry</i> , 2007, 19, 693-706.	1.4	30
2710	Does pravastatin promote cancer in elderly patients? A meta-analysis. <i>Cmaj</i> , 2007, 176, 649-654.	0.9	49
2711	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal Supplements</i> , 2007, 9, C3-C74.	0.0	40
2712	Mendelian randomization as an instrumental variable approach to causal inference. <i>Statistical Methods in Medical Research</i> , 2007, 16, 309-330.	0.7	670
2714	Atlas of Cardiometabolic Risk. , 2007, , .		2
2715	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Nonâ€“ST-Elevation Myocardial Infarction: Executive Summary. <i>Circulation</i> , 2007, 116, 803-877.	1.6	177
2716	Use of Lipid-Lowering Agents for the Prevention of Age-Related Macular Degeneration: A Meta-Analysis of Observational Studies. <i>Ophthalmic Epidemiology</i> , 2007, 14, 367-374.	0.8	33
2717	Cholesterol Fractions and Apolipoproteins as Risk Factors for Heart Disease Mortality in Older Men. <i>Archives of Internal Medicine</i> , 2007, 167, 1373.	4.3	67
2718	Do Statins Lower Blood Pressure?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2007, 12, 112-123.	1.0	17
2719	Antithrombotic treatment for peripheral arterial disease. <i>Heart</i> , 2007, 93, 303-308.	1.2	19
2720	Role of Oxidants and Antioxidants in Atherosclerosis: Results of In Vitro and In Vivo Investigations. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2007, 12, 265-282.	1.0	56
2721	Letter by Brewster and van Montfrans Regarding Article, â€œRisks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trialsâ€. <i>Circulation</i> , 2007, 116, e7; author reply e9.	1.6	1
2722	Gaps in Public Knowledge of Peripheral Arterial Disease. <i>Circulation</i> , 2007, 116, 2086-2094.	1.6	222
2723	Cardiovascular magnetic resonance in the evaluation of heart failure. <i>Heart</i> , 2007, 93, 985-992.	1.2	33

#	ARTICLE	IF	CITATIONS
2724	Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. <i>Heart</i> , 2007, 94, 434-439.	1.2	50
2725	Acute Coronary Care in the Elderly, Part II. <i>Circulation</i> , 2007, 115, 2570-2589.	1.6	489
2726	Senile Dementia. , 2007, , 1-18.		0
2727	Screening for Coronary Artery Disease in Patients With Diabetes. <i>Diabetes Care</i> , 2007, 30, 2729-2736.	4.3	234
2728	Statins and Children. <i>Circulation</i> , 2007, 116, 594-595.	1.6	21
2729	2007 Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1105-1187.	0.3	4,778
2730	Prevention of coronary heart disease with statins in UK South Asians and Caucasians. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 333-339.	3.1	5
2731	Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis. <i>Circulation</i> , 2007, 116, 1832-1844.	1.6	1,123
2732	Only a minority of patients referred for elective coronary artery bypass surgery have risk factors diagnosed and treated according to established guidelines. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, 112-116.	0.9	14
2733	The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. <i>Endocrine Research</i> , 2007, 32, 109-142.	0.6	3
2736	State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 457-481.	0.8	14
2737	The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 766-785.	2.2	30
2738	Impact of Statins on Risk of Stroke: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1937-1945.	0.9	18
2739	Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1344.	3.8	636
2740	Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin, Amiodarone, and Atazanavir. <i>Journal of the American Board of Family Medicine</i> , 2007, 20, 411-416.	0.8	53
2741	Lifestyle Medicine Strategies for Risk Factor Reduction, Prevention, and Treatment of Coronary Heart Disease: Part II. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 79-90.	0.8	6
2742	To what extent do patients in general practice reach guideline lipid-lowering treatment goals?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 149-151.	3.1	3
2743	Use of secondary preventive medications after the first attack of acute coronary syndrome. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 386-391.	3.1	34

#	ARTICLE	IF	CITATIONS
2744	Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 77-84.	0.5	28
2745	<i>Endocrine Disorders and the Heart.</i> , 2007, , 2295-2330.		1
2746	Cardiovascular disease prevention in primary care. <i>British Medical Bulletin</i> , 2007, 81-82, 65-79.	2.7	10
2747	Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. <i>European Heart Journal</i> , 2007, 28, 2102-2109.	1.0	45
2749	How Good Is the Management of Vascular Risk after Stroke, Transient Ischaemic Attack or Carotid Endarterectomy?. <i>Cerebrovascular Diseases</i> , 2007, 23, 156-161.	0.8	28
2750	The Alchemy of Clinical Trials. <i>BioSocieties</i> , 2007, 2, 85-99.	0.8	45
2751	Primary Prevention of Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2007, 357, 1543-1545.	13.9	21
2752	Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 499.	3.8	654
2753	High-Density Lipoprotein as a Therapeutic Target. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 786.	3.8	415
2754	Survival in relation to angina symptoms and diagnosis among men aged 70â€“90 years: the Whitehall Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 280-286.	3.1	2
2755	Asymptomatic Carotid Artery Stenosis. , 0, , .		13
2756	Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. <i>Postgraduate Medical Journal</i> , 2007, 83, 277-280.	0.9	27
2758	Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA Study. <i>Kidney and Blood Pressure Research</i> , 2007, 30, 314-322.	0.9	56
2759	Lipid-Lowering Agents and the Risk of Cognitive Impairment That Does Not Meet Criteria for Dementia, in Relation to Apolipoprotein E Status. <i>Neuroepidemiology</i> , 2007, 29, 201-207.	1.1	14
2760	A comprehensive view of sex-specific issues related to cardiovascular disease. <i>Cmaj</i> , 2007, 176, S1-S44.	0.9	348
2761	Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk. <i>Current Vascular Pharmacology</i> , 2007, 5, 15-25.	0.8	41
2762	Effects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence.. <i>Current Vascular Pharmacology</i> , 2007, 5, 155-161.	0.8	10
2763	Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors. <i>Current Vascular Pharmacology</i> , 2007, 5, 259-265.	0.8	9

#	ARTICLE	IF	CITATIONS
2764	Improving end-of-life care for patients with chronic heart failure: "Let's hope it'll get better, when I know in my heart of hearts it won't". <i>Heart</i> , 2007, 93, 963-967.	1.2	153
2765	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 340-345.	3.1	0
2766	MANAGEMENT OF END STAGE HEART FAILURE. <i>Heart</i> , 2007, 93, 626-631.	1.2	74
2767	Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1872-1879.	3.0	33
2768	Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2007, 7, 231-234.	0.5	16
2769	Action on Vascular Risk Factors: Importance of Blood Pressure and Lipid Lowering in Stroke Secondary Prevention. <i>Cerebrovascular Diseases</i> , 2007, 24, 96-106.	0.8	8
2771	Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease. <i>Annals of Internal Medicine</i> , 2007, 147, 1.	2.0	124
2772	The epidemiology of sudden death. , 0, , 26-48.		6
2773	Cardiovascular Medication Prescribing in Older Adults with Psychiatric Disorders Research and Reports. <i>The Consultant Pharmacist</i> , 2007, 22, 660-668.	0.4	0
2774	A Prognostic Risk Index for Long-term Mortality in Patients With Peripheral Arterial Disease. <i>Archives of Internal Medicine</i> , 2007, 167, 2482.	4.3	74
2775	Asymptomatic carotid stenosis: what to do. <i>Current Opinion in Neurology</i> , 2007, 20, 58-64.	1.8	36
2776	Pharmacotherapeutic decisions in menopausal women with cardiovascular risk. <i>Future Lipidology</i> , 2007, 2, 197-210.	0.5	2
2778	Randomized Evaluation of Atorvastatin in Patients With Coronary Heart Disease A Serial Intravascular Ultrasound Study. <i>Circulation Journal</i> , 2007, 71, 1845-1850.	0.7	23
2779	Effect of Statins and Calcium Channel Blockers on All-Cause Mortality and Cardiovascular and Cerebrovascular Disease Mortality in 958 Chinese Hospitalized Patients with Peripheral Arterial Disease after 13 Months of Follow-up. <i>Journal of Health Science</i> , 2007, 53, 226-233.	0.9	3
2780	Effect of Colestimide Therapy for Glycemic Control in Type 2 Diabetes Mellitus with Hypercholesterolemia. <i>Endocrine Journal</i> , 2007, 54, 53-58.	0.7	74
2781	Statins and clinical outcomes in heart failure. <i>Clinical Science</i> , 2007, 113, 119-127.	1.8	23
2782	Attitudes and interests of pharmacists regarding independent pharmacy ownership. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2007, 47, 140-146.	0.7	5
2783	CYP2D6*4 polymorphism is associated with statin-induced muscle effects. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 695-707.	0.7	72

#	ARTICLE	IF	CITATIONS
2784	Effects of Diabetes on Murine Lipoproteins and Vascular Disease. <i>Current Drug Targets</i> , 2007, 8, 1196-1202.	1.0	1
2785	Cardiovascular Drug Therapy in the Elderly. <i>Cardiology in Review</i> , 2007, 15, 195-215.	0.6	32
2786	The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery. <i>Anesthesia and Analgesia</i> , 2007, 104, 1326-1333.	1.1	211
2787	New targets of high-density lipoprotein therapy. <i>Current Opinion in Lipidology</i> , 2007, 18, 421-426.	1.2	21
2788	Statin Therapy. <i>Critical Care Nursing Quarterly</i> , 2007, 30, 154-160.	0.4	8
2789	Short-Term Statin Exposure Is Associated With Reduced All-Cause Mortality in Persons With Diabetes. <i>Medical Care</i> , 2007, 45, 308-314.	1.1	10
2790	Use of statins in the elderly. <i>Future Lipidology</i> , 2007, 2, 9-13.	0.5	0
2791	Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results. <i>Medical Care</i> , 2007, 45, S131-S142.	1.1	228
2792	Effect of Impact Exercise on Physical Performance and Cardiovascular Risk Factors. <i>Medicine and Science in Sports and Exercise</i> , 2007, 39, 756-763.	0.2	33
2794	Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease. <i>Vascular Disease Prevention</i> , 2007, 4, 125-139.	0.2	0
2795	Impact Of Statin Therapy On The Artery Wall In The Low-Risk Patient: Implications From The METEOR Study. <i>Future Lipidology</i> , 2007, 2, 595-601.	0.5	0
2796	Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures. <i>Current Drug Targets</i> , 2007, 8, 942-951.	1.0	46
2800	Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels. <i>Current Drug Targets</i> , 2007, 8, 483-488.	1.0	27
2801	Lipid Management and Peripheral Arterial Disease. <i>Current Drug Targets</i> , 2007, 8, 561-570.	1.0	16
2803	Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007, 14, 116-123.	1.2	7
2804	The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 1007-1011.	0.6	20
2805	Managing Cardiometabolic Risk. <i>Critical Pathways in Cardiology</i> , 2007, 6, 5-14.	0.2	6
2806	Use of Propensity Score Technique to Account for Exposure-Related Covariates. <i>Medical Care</i> , 2007, 45, S143-S148.	1.1	81

#	ARTICLE	IF	CITATIONS
2807	Reducing the Risks of Cardiovascular Disease in Liver Allograft Recipients. <i>Transplantation</i> , 2007, 83, 1141-1150.	0.5	66
2808	Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure. <i>Yearbook of Cardiology</i> , 2007, 2007, 330-332.	0.0	0
2809	Statins and Influenza/COPD Mortality: Response. <i>Chest</i> , 2007, 132, 1407-1408.	0.4	2
2810	Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. <i>European Heart Journal</i> , 2007, 28, 1977-1983.	1.0	31
2811	Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of Statins. <i>Chest</i> , 2007, 131, 1006-1012.	0.4	258
2812	Comparison of a dietary portfolio diet of cholesterol-lowering foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants. <i>British Journal of Nutrition</i> , 2007, 98, 1229-1236.	1.2	26
2816	The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid- β 42 in the rat hippocampus in vivo. <i>Neuropharmacology</i> , 2007, 52, 136-145.	2.0	60
2817	Use of margarine enriched in phytosterols by patients at high cardiovascular risk and treated by hypolipidemic drugs. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 657-665.	1.1	5
2818	Reply to Drs Vos, Ravnskov, Mascitelli and Pezzetta. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, e21-e23.	1.1	0
2819	Reply to "Cholesterol lowering and mortality: A sea of contradictions" <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, e25-e27.	1.1	3
2820	Statins and medicalization of lifestyle issues. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, e29-e30.	1.1	2
2821	Optimal Treatment of Dyslipidemia in High-Risk Patients: Intensive Statin Treatment or Combination Therapy?. <i>Preventive Cardiology</i> , 2007, 10, 31-35.	1.1	4
2822	Intensive Statin Treatment or Combination Therapy in High-Risk Patients. <i>Preventive Cardiology</i> , 2007, 10, 7-8.	1.1	0
2823	Guidelines for Prevention of Cardiovascular Disease in Women: A Summary of Recommendations. <i>Preventive Cardiology</i> , 2007, 10, 19-25.	1.1	22
2824	Metabolic Syndrome Is Associated With Coronary Artery Calcium in Asymptomatic White Brazilian Men Considered Low-Risk by Framingham Risk Score. <i>Preventive Cardiology</i> , 2007, 10, 141-146.	1.1	15
2825	Statins and Blood Pressure: Is There an Effect or Not?. <i>Journal of Clinical Hypertension</i> , 2007, 9, 460-467.	1.0	10
2826	Statins and C-Reactive Protein Levels. <i>Journal of Clinical Hypertension</i> , 2007, 9, 622-628.	1.0	46
2827	Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: The Genetics of Hypertension-Associated Treatment (GenHAT) study. <i>American Heart Journal</i> , 2007, 153, 54-58.	1.2	25

#	ARTICLE	IF	CITATIONS
2828	Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. <i>American Heart Journal</i> , 2007, 153, 335.e1-335.e8.	1.2	69
2829	Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. <i>American Heart Journal</i> , 2007, 153, 471-477.	1.2	26
2830	The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. <i>American Heart Journal</i> , 2007, 153, 537-544.	1.2	19
2831	Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: Insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. <i>American Heart Journal</i> , 2007, 154, 313-321.	1.2	16
2832	Distribution of creatine kinase in the general population: Implications for statin therapy. <i>American Heart Journal</i> , 2007, 154, 655-661.	1.2	123
2833	Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics of a randomized trial among 12064 myocardial infarction survivors. <i>American Heart Journal</i> , 2007, 154, 815-823.e6.	1.2	88
2834	Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome. <i>American Heart Journal</i> , 2007, 154, 1108-1115.	1.2	141
2835	Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction. <i>American Journal of Medicine</i> , 2007, 120, 109-120.	0.6	16
2836	From Here to Eternity: A Unified Kinetic Model for the Pathophysiology of Atherosclerotic Events. <i>American Journal of Medicine</i> , 2007, 120, 5-11.	0.6	25
2837	Active Lipid Management In Coronary Artery Disease (ALMICAD) Study. <i>American Journal of Medicine</i> , 2007, 120, 734.e11-734.e17.	0.6	3
2838	Optimizing Cardiovascular Outcomes in Diabetes Mellitus. <i>American Journal of Medicine</i> , 2007, 120, S3-S11.	0.6	157
2839	Prevention of Macrovascular Disease in Patients with Diabetes Mellitus: Opportunities for Intervention. <i>American Journal of Medicine</i> , 2007, 120, S26-S32.	0.6	18
2840	Statins for the primary prevention of cardiovascular events in older adults: A review of the evidence. <i>American Journal of Geriatric Pharmacotherapy</i> , 2007, 5, 52-63.	3.0	32
2841	Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. <i>American Journal of Geriatric Pharmacotherapy</i> , 2007, 5, 185-194.	3.0	22
2842	Combination of plant sterols and diacylglycerol oil lowers serum cholesterol and lipoprotein (a) concentrations in postmenopausal women with mild to moderate hypercholesterolemia. <i>European E-journal of Clinical Nutrition and Metabolism</i> , 2007, 2, 4-11.	0.4	6
2843	Defining the metabolic syndrome: Resolving unresolved issues?. <i>European Journal of Internal Medicine</i> , 2007, 18, 309-313.	1.0	8
2844	Chemokines and left ventricular function in patients with acute myocardial infarction. <i>European Journal of Internal Medicine</i> , 2007, 18, 288-294.	1.0	20
2845	Peripheral arterial disease: diagnosis, treatment, and systemic implications. <i>Clinics in Dermatology</i> , 2007, 25, 93-100.	0.8	14

#	ARTICLE	IF	CITATIONS
2846	Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?. <i>Clinical Therapeutics</i> , 2007, 29, 196-209.	1.1	11
2847	A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. <i>Clinical Therapeutics</i> , 2007, 29, 242-252.	1.1	32
2848	Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. <i>Clinical Therapeutics</i> , 2007, 29, 778-794.	1.1	116
2849	Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study. <i>Clinical Therapeutics</i> , 2007, 29, 1671-1681.	1.1	27
2850	A population-based analysis of statin utilization in British Columbia. <i>Clinical Therapeutics</i> , 2007, 29, 2107-2119.	1.1	13
2851	Short term efficacy of a lifestyle intervention programme on cardiovascular health outcome in overweight Indigenous Australians with and without type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2007, 75, 65-71.	1.1	29
2852	Atorvastatin attenuates transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. <i>Biomedicine and Pharmacotherapy</i> , 2007, 61, 154-159.	2.5	15
2853	Double-Blind, Randomized, Placebo-Controlled Study of High-Dose HMG CoA Reductase Inhibitor Therapy on Ventricular Remodeling, Pro-Inflammatory Cytokines and Neurohormonal Parameters in Patients With Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 1-7.	0.7	104
2854	Statin Pre-Treatment Protects Brain Against Focal Cerebral Ischemia in Diabetic Mice. <i>Journal of Surgical Research</i> , 2007, 138, 254-258.	0.8	25
2855	Statins Inhibit Neutrophil Infiltration in Skeletal Muscle Reperfusion Injury. <i>Journal of Surgical Research</i> , 2007, 141, 267-276.	0.8	30
2857	Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway. <i>Medical Hypotheses</i> , 2007, 68, 1108-1113.	0.8	23
2858	Is daytime insulin more physiologic and less atherogenic than bedtime insulin?. <i>Medical Hypotheses</i> , 2007, 68, 1228-1232.	0.8	2
2859	Is lipid lowering treatment aiming for very low LDL levels safe in terms of the synthesis of steroid hormones?. <i>Medical Hypotheses</i> , 2007, 69, 104-112.	0.8	13
2860	The effect of statin on the aortic gene expression profiling. <i>International Journal of Cardiology</i> , 2007, 114, 71-77.	0.8	16
2861	Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. <i>International Journal of Cardiology</i> , 2007, 114, 210-217.	0.8	19
2862	Association among C-reactive protein, oxidative stress, and traditional risk factors in healthy Japanese subjects. <i>International Journal of Cardiology</i> , 2007, 115, 63-66.	0.8	50
2863	The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: A pooled analysis of double-blind, randomized trials. <i>International Journal of Cardiology</i> , 2007, 117, 64-74.	0.8	33
2864	Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. <i>International Journal of Cardiology</i> , 2007, 119, 41-47.	0.8	19

#	ARTICLE	IF	CITATIONS
2865	Current questions regarding the use of statins in patients with coronary heart disease. <i>International Journal of Cardiology</i> , 2007, 122, 188-194.	0.8	16
2866	The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. <i>Atherosclerosis</i> , 2007, 190, 205-211.	0.4	43
2867	In vivo coronary plaque histology in patients with stable and acute coronary syndromes. <i>Atherosclerosis</i> , 2007, 194, 189-195.	0.4	19
2868	Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2007, 194, 230-237.	0.4	25
2869	Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. <i>Atherosclerosis</i> , 2007, 194, e43-e51.	0.4	83
2870	To statin or to non-statin in coronary disease—considering absolute risk is the answer. <i>Atherosclerosis</i> , 2007, 195, 1-6.	0.4	38
2871	Statin-associated adverse effects beyond muscle and liver toxicity. <i>Atherosclerosis</i> , 2007, 195, 7-16.	0.4	107
2872	Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. <i>Atherosclerosis</i> , 2007, 195, 385-391.	0.4	66
2873	Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. <i>Atherosclerosis</i> , 2007, 194, e154-e164.	0.4	48
2874	European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. <i>Atherosclerosis</i> , 2007, 194, 1-45.	0.4	292
2875	Management of mild to moderate Alzheimer's disease and dementia. <i>Alzheimer's and Dementia</i> , 2007, 3, 355-384.	0.4	67
2876	Is it the blood pressure or the blood vessel?. <i>Journal of the American Society of Hypertension</i> , 2007, 1, 5-16.	2.3	16
2877	Effects of pharmacological intervention on arterial stiffness using pulse wave velocity measurement. <i>Journal of the American Society of Hypertension</i> , 2007, 1, 104-112.	2.3	12
2879	Cholesterol lowering in patients with CHD and metabolic syndrome — Authors' reply. <i>Lancet</i> , The, 2007, 369, 26-27.	6.3	2
2880	Experimental treatments for acute ischaemic stroke. <i>Lancet</i> , The, 2007, 369, 331-341.	6.3	115
2881	Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. <i>Lancet</i> , The, 2007, 369, 1090-1098.	6.3	2,172
2882	The safety of statins in clinical practice. <i>Lancet</i> , The, 2007, 370, 1781-1790.	6.3	705
2883	Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. <i>Lancet</i> , The, 2007, 369, 1876-1882.	6.3	518

#	ARTICLE	IF	CITATIONS
2884	Cuñas de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Española De Cardiología, 2007, 60, 525.e1-525.e64.	0.6	13
2885	Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL. Clínica E Investigación En Arteriosclerosis, 2007, 19, 252-263.	0.4	1
2886	Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery. Annals of Thoracic Surgery, 2007, 83, 993-1001.	0.7	86
2887	Traitement médicamenteux du diabète de type 2 recommandation de bonne pratique. Diabetes and Metabolism, 2007, 33, S26-S105.	1.4	5
2888	Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada. Canadian Journal of Cardiology, 2007, 23, 357-361.	0.8	13
2889	Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients. Canadian Journal of Cardiology, 2007, 23, 397-398.	0.8	1
2890	Effects of an enhanced secondary prevention program for patients with heart disease: A prospective randomized trial. Canadian Journal of Cardiology, 2007, 23, 1066-1072.	0.8	13
2891	Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Canadian Journal of Cardiology, 2007, 23, 1124-1130.	0.8	25
2892	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. European Heart Journal, 2007, 28, 1598-1660.	1.0	1,699
2893	Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. Current Atherosclerosis Reports, 2007, 9, 81-88.	2.0	10
2894	Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacological Research, 2007, 56, 503-508.	3.1	5
2895	Cytochrome P450 α physiological key factor against cholesterol accumulation and the atherosclerotic vascular process. Annals of Medicine, 2007, 39, 359-370.	1.5	25
2896	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789.	13.9	2,963
2899	Pharmacologic Risk Factor Treatment of Peripheral Arterial Disease is Lacking and Requires Vascular Surgeon Participation. Annals of Vascular Surgery, 2007, 21, 163-166.	0.4	42
2900	Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery, 2007, 45, 645-654.e1.	0.6	353
2901	Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery, 2007, 45, S5-S67.	0.6	5,618
2902	The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. Journal of Vascular Surgery, 2007, 45, 936-943.	0.6	89
2903	A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. Journal of Vascular Surgery, 2007, 45, 1185-1191.	0.6	327

#	ARTICLE	IF	CITATIONS
2904	2007 ESH&ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2007, 16, 135-232.	0.7	292
2905	Gender differences in dementia risk factors. Gender Medicine, 2007, 4, 120-129.	1.4	156
2906	Rosuvastatin in Elderly Patients. Drugs and Aging, 2007, 24, 933-944.	1.3	7
2907	A Composite Screening Tool for Medication Reviews of Outpatients. Drugs and Aging, 2007, 24, 733-760.	1.3	39
2908	Effects of Statins on Cognitive Function in Patients with Alzheimer's Disease in Galantamine Clinical Trials. Drugs and Aging, 2007, 24, 57-61.	1.3	25
2909	The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Review of Cardiovascular Therapy, 2007, 5, 177-193.	0.6	28
2910	Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. Drugs, 2007, 67, 29-42.	4.9	41
2911	Atorvastatin. Drugs, 2007, 67, 55-62.	4.9	15
2912	Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. Future Lipidology, 2007, 2, 285-301.	0.5	8
2913	Medical Treatment of Stable Angina. , 2007, , 911-936.		0
2914	Prevalence of Adequate and of Optimal Control of Serum Low-Density Lipoprotein Cholesterol in an Academic Nursing Home. Journal of the American Medical Directors Association, 2007, 8, 604-606.	1.2	19
2915	Therapy Insight: peripheral arterial disease and diabetes—from pathogenesis to treatment guidelines. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 151-162.	3.3	25
2916	Effect of HMG-CoA Reductase Inhibitors on β -Amyloid Peptide Levels. CNS Drugs, 2007, 21, 449-462.	2.7	53
2917	Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Expert Review of Cardiovascular Therapy, 2007, 5, 1105-1111.	0.6	18
2918	Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1246-1261.	3.0	280
2919	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 385T /Over	0.784314	385
2920	Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine, 2007, 356, 1503-1516.	13.9	4,022
2921	Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events. Pharmacoeconomics, 2007, 25, 1063-1082.	1.7	21

#	ARTICLE	IF	CITATIONS
2922	Management of Dyslipidemia in the Metabolic Syndrome. American Journal of Cardiovascular Drugs, 2007, 7, 39-58.	1.0	54
2923	Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs, 2007, 7, 95-116.	1.0	15
2924	Treatment and Control of BP and Lipids in Patients with Hypertension and Additional Risk Factors. American Journal of Cardiovascular Drugs, 2007, 7, 381-389.	1.0	16
2925	Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning. Pharmacological Reviews, 2007, 59, 418-458.	7.1	631
2926	Comparative efficacy of daily versus alternate-day dosing of atorvastatin in Type 2 diabetic patients. Therapy: Open Access in Clinical Medicine, 2007, 4, 541-545.	0.2	3
2927	Collaborative Virtual Environments as Research and Teaching Instruments in the Field of Disaster Medicine: the "e-DISTRICT CiPro" Simulator. , 2007, , .		0
2928	Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Current Medical Research and Opinion, 2007, 23, 2125-2133.	0.9	13
2929	Valutazione economica di rosuvastatina nel trattamento di prevenzione delle malattie cardiovascolari: una revisione sistematica della letteratura. Pharmacoeconomics Italian Research Articles, 2007, 9, 45-58.	0.2	0
2931	A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial. Journal of Clinical Pharmacology, 2007, 47, 1555-1569.	1.0	53
2932	Lipid-lowering for peripheral arterial disease of the lower limb. The Cochrane Library, 2007, , CD000123.	1.5	105
2933	The safety of rosuvastatin: effects on renal and hepatic function. Expert Opinion on Drug Safety, 2007, 6, 573-581.	1.0	15
2934	Simvastatin: present and future perspectives. Expert Opinion on Pharmacotherapy, 2007, 8, 2159-2127.	0.9	20
2935	Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Current Medical Research and Opinion, 2007, 23, 553-563.	0.9	45
2936	Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion, 2007, 23, 885-894.	0.9	35
2937	A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. European Heart Journal, 2007, 28, 664-672.	1.0	115
2938	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0:7843147gBT /Over	1.0	2,331
2939	Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy, 2007, 64, 1603-1610.	0.5	11
2940	Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke. Stroke, 2007, 38, 2652-2657.	1.0	150

#	ARTICLE	IF	CITATIONS
2941	Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients. <i>Journal of Clinical Oncology</i> , 2007, 25, 3462-3468.	0.8	132
2942	Glycemic Control, Lipid-Lowering Treatment, and Prognosis in Diabetic Patients with Peripheral Atherosclerotic Disease. <i>Annals of Vascular Surgery</i> , 2007, 21, 780-789.	0.4	13
2943	Assessment of the Patient With Diabetes for Coronary Heart Disease Risk: Review and Personal Reflection. <i>Canadian Journal of Diabetes</i> , 2007, 31, 153-163.	0.4	1
2944	Effects of Statins on Renal Function. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1381-1390.	1.4	69
2945	Cardiac myocyteâ€“nonmyocyte electrotonic coupling: Implications for ventricular arrhythmogenesis. <i>Heart Rhythm</i> , 2007, 4, 233-235.	0.3	41
2947	Controversy in Diagnosis and Management of the Metabolic Syndrome. <i>Medical Clinics of North America</i> , 2007, 91, 1041-1061.	1.1	20
2948	Lipid Metabolism in Chronic Kidney Disease: The Role of Statins in Cardiovascular Risk. , 2007, 17, 75-78.		12
2949	Simvastatin pretreatment reduces the severity of limb ischemia in an experimental diabetes model. <i>Journal of Vascular Surgery</i> , 2007, 45, 590-596.	0.6	18
2951	Management of Antiretroviral Treatmentâ€“Related Complications. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 103-132.	1.9	16
2952	Preoperative statin and diuretic use influence the presentation of patients undergoing carotid endarterectomy: Results of a large single-institution case-control study. <i>Journal of Vascular Surgery</i> , 2007, 45, 298-303.	0.6	32
2953	Statins: An essential component in the management of carotid artery disease. <i>Journal of Vascular Surgery</i> , 2007, 46, 373-386.e9.	0.6	79
2955	Prise en compte par les malades des facteurs de risque de la maladie vasculaire pÃ©riphÃ©rique. <i>Annales De Chirurgie Vasculaire</i> , 2007, 21, 36-41.	0.0	0
2956	ContrÃªle glycÃ©mique, traitement hypolipÃ©miant et pronostic des malades diabÃ©tiques ayant des lÃ©sions athÃ©rosclÃ©reuses pÃ©riphÃ©riques. <i>Annales De Chirurgie Vasculaire</i> , 2007, 21, 421-430.	0.0	0
2957	Cardiovascular Disease Posttransplant. <i>Seminars in Nephrology</i> , 2007, 27, 430-444.	0.6	35
2958	EpidÃ©miologie et facteurs pronostiques Ã long-terme des dissections aortiques aiguÃ«s de type B. <i>Annales De Chirurgie Vasculaire</i> , 2007, 21, 16-24.	0.0	0
2959	Patient Awareness of Risk Factors for Peripheral Vascular Disease. <i>Annals of Vascular Surgery</i> , 2007, 21, 433-437.	0.4	9
2960	Clinical Trials of Neuroprotective Therapies. <i>Stroke</i> , 2007, 38, 791-793.	1.0	17
2961	Implication of the New Low-Density Lipoprotein Goals in Dyslipidemia Management of Patients With Acute Coronary Syndrome. <i>Mayo Clinic Proceedings</i> , 2007, 82, 551-555.	1.4	7

#	ARTICLE	IF	CITATIONS
2962	Epidemiology and Long-Term Prognostic Factors in Acute Type B Aortic Dissection. <i>Annals of Vascular Surgery</i> , 2007, 21, 415-422.	0.4	36
2963	Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. <i>Journal of the Neurological Sciences</i> , 2007, 260, 100-105.	0.3	21
2973	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. <i>Revista Española De Cardiología</i> , 2007, 60, 1070.e1-1070.e80.	0.6	29
2974	Role of HMG-CoA Reductase Inhibitors in Neurological Disorders. <i>Drugs</i> , 2007, 67, 2111-2120.	4.9	34
2975	Effectiveness and Safety of Ezetimibe Added to Statin Therapy in Patients with Primary Dyslipidaemia not Achieving the LDL-C Treatment Goal on Statin Monotherapy. <i>Clinical Drug Investigation</i> , 2007, 27, 333-337.	1.1	8
2976	Risk of Colorectal Cancer in Patients Prescribed Statins, Nonsteroidal Anti-Inflammatory Drugs, and Cyclooxygenase-2 Inhibitors: Nested Case-Control Study. <i>Gastroenterology</i> , 2007, 133, 393-402.	0.6	85
2977	Atherosclerosis As a Systemic Disease. <i>Revista Española De Cardiología (English Ed)</i> , 2007, 60, 184-195.	0.4	22
2978	Cholesterol ester transfer protein (CETP) and atherosclerosis. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 137-145.	0.5	4
2979	Global cardiovascular risk: The benefits of a precocious, aggressive treatment strategy. <i>International Congress Series</i> , 2007, 1303, 113-120.	0.2	1
2980	N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study. <i>Journal of the American College of Cardiology</i> , 2007, 49, 311-319.	1.2	104
2981	Adiponectin and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2007, 49, 531-538.	1.2	253
2982	Coronary Heart Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2007, 49, 631-642.	1.2	132
2983	Screen Testing. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1915-1917.	1.2	42
2984	Safety of Aggressive Lipid Management. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1753-1762.	1.2	144
2985	Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2003-2009.	1.2	161
2986	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, e1-e157.	1.2	1,587
2987	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction Executive Summary. <i>Journal of the American College of Cardiology</i> , 2007, 50, 652-726.	1.2	252
2988	Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer. <i>Journal of the American College of Cardiology</i> , 2007, 50, 409-418.	1.2	224

#	ARTICLE	IF	CITATIONS
2990	Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis. <i>Journal of the American College of Cardiology</i> , 2007, 50, 852-858.	1.2	225
2991	Intensity of Statin Therapy in Relation to Myocardial Ischemia, Troponin T Release, and Clinical Cardiac Outcome in Patients Undergoing Major Vascular Surgery. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1649-1656.	1.2	28
2992	Beyond Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1735-1741.	1.2	115
2993	Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence. <i>Journal of Clinical Lipidology</i> , 2007, 1, 88-94.	0.6	34
2994	Implications of recent statin trials for primary care practice. <i>Journal of Clinical Lipidology</i> , 2007, 1, 182-190.	0.6	5
2995	LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. <i>Journal of Clinical Lipidology</i> , 2007, 1, 583-592.	0.6	365
2996	Plant sterols added to combination statin and colessevelam hydrochloride therapy failed to lower low-density lipoprotein cholesterol concentrations. <i>Journal of Clinical Lipidology</i> , 2007, 1, 626-633.	0.6	8
2997	Statins and Stroke Prevention. <i>Cerebrovascular Diseases</i> , 2007, 24, 170-182.	0.8	61
2998	Nurses'™ perception of their learning needs to deliver CVD prevention programmes. <i>British Journal of Cardiac Nursing</i> , 2007, 2, 571-579.	0.0	1
3000	Statins Disrupt CCR5 and RANTES Expression Levels in CD4+ T Lymphocytes In Vitro and Preferentially Decrease Infection of R5 Versus X4 HIV-1. <i>PLoS ONE</i> , 2007, 2, e470.	1.1	37
3001	The Effect of Biliary Sphincterotomy on Serum Cholesterol Levels in Postcholecystectomy Patients: A Pilot Study. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 81-84.	1.8	5
3002	Comparison of Efficacy and Safety after Administering High Potency Statin to High Risk Patients: Rosuvastatin 10 mg versus Atorvastatin 20 mg. <i>Korean Circulation Journal</i> , 2007, 37, 154.	0.7	13
3003	Integrated Primary Prevention of Cardiovascular Disease. , 0, , 129-189.		0
3005	Primary Prevention of Ischemic Heart Disease. , 2007, , 178-220.		1
3006	Increasing Use of Single and Combination Medical Therapy in Patients Hospitalized for Acute Myocardial Infarction in the 21st Century–A Multinational Perspective–. <i>Archives of Internal Medicine</i> , 2007, 167, 1766.	4.3	24
3007	Efficacy and tolerability of 12-weeks treatment with lipanthyl supra or trichol in Indonesian patients with dyslipidemia. <i>Medical Journal of Indonesia</i> , 0, , 159.	0.2	0
3008	GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. <i>Rational Pharmacotherapy in Cardiology</i> , 2007, 3, 71-99.	0.3	20
3009	Coronary fat content evaluated by morphometry in patients with severe atherosclerosis has no relation with serum lipid levels. <i>Brazilian Journal of Medical and Biological Research</i> , 2007, 40, 467-473.	0.7	4

#	ARTICLE	IF	CITATIONS
3010	Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?. Brazilian Journal of Medical and Biological Research, 2007, 40, 229-235.	0.7	11
3011	The combination of atorvastatin and ethanol is not more hepatotoxic to rats than the administration of each drug alone. Brazilian Journal of Medical and Biological Research, 2007, 40, 343-348.	0.7	4
3012	Colesevelam Hydrochloride-Ezetimibe Combination Lipid-Lowering Therapy in Patients with Diabetes or Metabolic Syndrome and a History of Statin Intolerance. Endocrine Practice, 2007, 13, 11-16.	1.1	48
3013	The 1984 Coronary Primary Prevention Trial. , 2007, , 143-170.		0
3014	Effect of Early Versus Late In-Hospital Initiation of Statin Therapy on the Clinical Outcomes of Patients With Acute Coronary Syndrome. International Heart Journal, 2007, 48, 677-688.	0.5	15
3015	Peripheral arterial occlusive disease. Vasa - European Journal of Vascular Medicine, 2007, 36, 155-164.	0.6	8
3016	Lipid-Lowering Therapy. , 2007, , 1087-1099.		1
3017	GUIDELINES ON THE MANAGEMENT OF STABLE ANGINA PECTORIS (ENDING). Rational Pharmacotherapy in Cardiology, 2007, 3, 69-100.	0.3	0
3024	Diabetes and Stroke / Transient Ischaemic Attacks. , 0, , 175-198.		0
3025	Prevention of Cardiovascular Events in Diabetic Patients. , 0, , 223-239.		0
3026	Statins and risk of cancer: A systematic review and metaanalysis. International Journal of Cancer, 2007, 120, 833-843.	2.3	199
3027	Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia. Journal of Clinical Apheresis, 2007, 22, 301-305.	0.7	25
3028	Effects of chronic hyperglycaemia on incident stroke in Hong Kong Chinese patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2007, 23, 220-226.	1.7	11
3029	Preventing microalbuminuria in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2007, 23, 100-110.	1.7	18
3030	Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes/Metabolism Research and Reviews, 2007, 23, 392-399.	1.7	50
3031	Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Movement Disorders, 2007, 22, 377-381.	2.2	177
3032	Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle and Nerve, 2007, 36, 329-335.	1.0	65
3033	Chromatography-mass spectrometry methods for the quantitation of statins in biological samples. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44, 379-387.	1.4	80

#	ARTICLE	IF	CITATIONS
3034	Fluvastatin ameliorates endotoxin induced multiple organ failure in conscious rats. Resuscitation, 2007, 74, 166-174.	1.3	33
3035	Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption – an individual-level prescription database study. BMC Clinical Pharmacology, 2007, 7, 14.	2.5	23
3036	Clinical and medication profiles stratified by household income in patients referred for diabetes care. Cardiovascular Diabetology, 2007, 6, 11.	2.7	19
3037	Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country—the case of Tanzania. Cost Effectiveness and Resource Allocation, 2007, 5, 3.	0.6	24
3038	Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials, 2007, 8, 21.	0.7	140
3039	Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiology and Drug Safety, 2007, 16, 385-392.	0.9	35
3040	Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiology and Drug Safety, 2007, 16, 132-143.	0.9	50
3041	Statins and fracture risk. A systematic review. Pharmacoepidemiology and Drug Safety, 2007, 16, 627-640.	0.9	75
3042	Effect on hematologic risk factors for coronary heart disease of a cholesterol reducing diet. European Journal of Clinical Nutrition, 2007, 61, 483-492.	1.3	20
3043	No Effect of Low-Dose Statins Treatment on Cerebral Blood Flow in Humans with Atherosclerotic Cerebrovascular Disease. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1643-1648.	2.4	8
3044	Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type-1 diabetic mice. British Journal of Pharmacology, 2007, 150, 873-882.	2.7	45
3045	Incidence of adverse events with HMG CoA reductase inhibitors in liver transplant patients. Clinical Transplantation, 2008, 22, 113-119.	0.8	43
3046	Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2007, 9, 81-86.	2.2	31
3047	Dyslipidaemia in diabetic patients: time for a rethink. Diabetes, Obesity and Metabolism, 2007, 9, 609-616.	2.2	26
3048	Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabetic Medicine, 2007, 24, 541-549.	1.2	39
3049	Assessing vascular risk in people with Type 1 diabetes: implications for the effectiveness of statin therapy. Diabetic Medicine, 2007, 24, 575-578.	1.2	4
3050	Atherogenesis: the role of inflammation and infection. Histopathology, 2007, 50, 535-546.	1.6	84
3051	Myocardial infarction: contemporary management strategies. Journal of Internal Medicine, 2007, 262, 59-77.	2.7	15

#	ARTICLE	IF	CITATIONS
3052	Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. <i>European Journal of Clinical Investigation</i> , 2007, 37, 157-164.	1.7	15
3053	Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients. <i>European Journal of Clinical Investigation</i> , 2007, 37, 454-462.	1.7	9
3054	Statins: a perspective for left ventricular hypertrophy treatment. <i>European Journal of Clinical Investigation</i> , 2007, 37, 681-691.	1.7	34
3055	Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia. <i>European Journal of Clinical Investigation</i> , 2007, 38, 11-16.	1.7	8
3056	A perioperative statin update for noncardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients. <i>Anaesthesia</i> , 2008, 63, 52-64.	1.8	22
3057	Impact of adherence to statins on coronary artery disease in primary prevention. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 698-708.	1.1	86
3058	Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 255-262.	1.1	28
3059	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: The Cholesterol Paradox Is Flawed; Cholesterol Must Be Lowered in Dialysis Patients. <i>Seminars in Dialysis</i> , 2007, 20, 504-509.	0.7	10
3060	Quality Indicators for the Care of Stroke and Atrial Fibrillation in Vulnerable Elders. <i>Journal of the American Geriatrics Society</i> , 2007, 55, S431-7.	1.3	15
3061	Reduced Mortality Rates after Intensive Statin Therapy in Managed-Care Patients. <i>Value in Health</i> , 2007, 10, 161-169.	0.1	18
3062	Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration. <i>Journal of Neurochemistry</i> , 2007, 102, 1001-1008.	2.1	31
3063	Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2537-2546.	1.9	83
3064	THE PATIENT AS CONSUMER: THE ADVERTISING OF PHARMACEUTICALS DIRECTLY TO CONSUMERS SHOULD BE ALLOWED AND ENCOURAGED. <i>Economic Affairs</i> , 2007, 27, 64-72.	0.2	4
3065	Cardiovascular disease, inflammation, and periodontal infection. <i>Periodontology 2000</i> , 2007, 44, 113-126.	6.3	81
3066	Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. <i>International Journal of Clinical Practice</i> , 2007, 61, 15-23.	0.8	47
3067	Newer, lower, better? Lipid drugs and cardiovascular disease - the continuing story. <i>International Journal of Clinical Practice</i> , 2007, 61, 1064-1067.	0.8	5
3068	Role of imaging end points in atherosclerosis trials: focus on intravascular ultrasound. <i>International Journal of Clinical Practice</i> , 2007, 61, 951-962.	0.8	5
3069	A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet*. <i>International Journal of Clinical Practice</i> , 2007, 61, 1469-1480.	0.8	11

#	ARTICLE	IF	CITATIONS
3070	A global survey of physicians' perceptions on cholesterol management: the From The Heart study. <i>International Journal of Clinical Practice</i> , 2007, 61, 1078-1085.	0.8	27
3071	Recent trials of lipid lowering. <i>International Journal of Clinical Practice</i> , 2007, 61, 1145-1159.	0.8	13
3072	Targets - who needs them? Success with statin therapies. <i>International Journal of Clinical Practice</i> , 2007, 61, 1239-1242.	0.8	1
3073	LDL-apheresis: indications and clinical experience in a tertiary cardiac centre. <i>International Journal of Clinical Practice</i> , 2007, 61, 1834-1842.	0.8	9
3074	Secondary prevention for coronary heart disease in the United Kingdom, low-density lipoprotein cholesterol goals and statin switching-an expression of concern. <i>International Journal of Clinical Practice</i> , 2007, 61, 1608-1611.	0.8	1
3075	Effectiveness of statins in Medicare-eligible patients and patients –years using clinical practice data*. <i>International Journal of Clinical Practice</i> , 2007, 61, 1634-1642.	0.8	5
3076	Absence of policy on how to use statins in England and Wales: do not let JBS2 fill the void. <i>International Journal of Clinical Practice</i> , 2007, 61, 1967-1970.	0.8	1
3077	High prevalence of undiagnosed patients with peripheral arterial disease in patients hospitalised for non-vascular disorders. <i>International Journal of Clinical Practice</i> , 2008, 62, 59-64.	0.8	25
3078	Importance of Intensive Lipid Lowering in Acute Coronary Syndrome and Percutaneous Coronary Intervention. <i>Journal of Interventional Cardiology</i> , 2007, 20, 447-457.	0.5	14
3079	Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. <i>BMC Medicine</i> , 2007, 5, 20.	2.3	334
3080	Effect of Atorvastatin on Cognitive Function in Patients from the Lipid Lowering and Onset of Renal Disease (LORD) Trial. <i>Pharmacotherapy</i> , 2007, 27, 183-190.	1.2	34
3081	Fibrates: What Have We Learned in the Past 40 Years?. <i>Pharmacotherapy</i> , 2007, 27, 412-424.	1.2	52
3082	Identification of two herbal compounds with potential cholesterol-lowering activity. <i>Biochemical Pharmacology</i> , 2007, 74, 940-947.	2.0	13
3083	The Puzzle of Dietary Fat Intake and Risk of Ischemic Stroke: A Brief Review of Epidemiologic Data. <i>Journal of the American Dietetic Association</i> , 2007, 107, 287-295.	1.3	23
3084	HDL Cholesterol: Physiology, Pathophysiology, and Management. <i>Current Problems in Cardiology</i> , 2007, 32, 268-314.	1.1	65
3085	Relatively High Pulmonary and Cardiovascular Mortality Rates in Screening-detected Aneurysmal Patients Without Previous Hospital Admissions. <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 33, 94-99.	0.8	15
3086	Organising a Nurse-driven PAD Rehabilitation Clinic Within the Vascular Surgical Department: What is Required and are Treatment Goals Reached - A Prospective Study?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 33, 26-32.	0.8	12
3087	Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 33, S1-S75.	0.8	2,274

#	ARTICLE	IF	CITATIONS
3088	The Rationale for Using HMG-CoA Reductase Inhibitors (â€˜Statinsâ€™™) in Peripheral Arterial Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 33, 192-201.	0.8	22
3089	Completing the Audit Cycle: Comparison of Cardiac Risk Factor Management in Patients with Intermittent Claudication in Two Time Periods. <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 33, 710-714.	0.8	4
3090	Medical Management of Abdominal Aortic Aneurysm. <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 34, 267-273.	0.8	54
3091	The Inflammation Hypothesis and Its Potential Relevance to Statin Therapy. <i>American Journal of Cardiology</i> , 2007, 99, 732-738.	0.7	108
3092	Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention. <i>American Journal of Cardiology</i> , 2007, 99, 718-725.	0.7	38
3093	The Things to Come of SHAPE: Cost and Effectiveness of Cardiovascular Prevention. <i>American Journal of Cardiology</i> , 2007, 99, 1013-1015.	0.7	28
3094	Expert Commentary: Niacin Safety. <i>American Journal of Cardiology</i> , 2007, 99, S32-S34.	0.7	9
3095	Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. <i>American Journal of Cardiology</i> , 2007, 99, S1-S35.	0.7	20
3096	Low-Density Lipoprotein Cholesterol Reduction: The End Is More Important Than the Means. <i>American Journal of Cardiology</i> , 2007, 100, 240-242.	0.7	55
3097	Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S4-S20.	0.7	189
3098	Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S56-S67.	0.7	87
3099	Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT]) <i>Tj ETQq1 1 0.784314 rgBT /Overloc</i>	0.7	143
3100	Prevention of Stroke in Patients with Hypertension. <i>American Journal of Cardiology</i> , 2007, 100, S17-S24.	0.7	59
3101	Effect of Coenzyme Q10 Supplementation on Simvastatin-Induced Myalgia. <i>American Journal of Cardiology</i> , 2007, 100, 1400-1403.	0.7	172
3102	High-Density Lipoprotein Metabolism: Potential Therapeutic Targets. <i>American Journal of Cardiology</i> , 2007, 100, S32-S40.	0.7	65
3103	Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>American Journal of Cardiology</i> , 2007, 100, 1659-1664.	0.7	113
3106	Statins and Peripheral Arterial Disease: Effects on Claudication, Disease Progression, and Prevention of Cardiovascular Events. <i>Archives of Medical Research</i> , 2007, 38, 479-488.	1.5	36
3107	The Cholesterol Paradox in Heart Failure. <i>Congestive Heart Failure</i> , 2007, 13, 336-341.	2.0	43

#	ARTICLE	IF	CITATIONS
3108	Low-Density Lipoprotein Cholesterol in High-Risk Asymptomatic Individuals. <i>Journal of the Cardiometabolic Syndrome</i> , 2007, 2, 49-52.	1.7	1
3109	Atorvastatin Does Not Induce Glomerular or Tubular Dysfunction Even at High Doses. <i>Journal of the Cardiometabolic Syndrome</i> , 2007, 2, 163-167.	1.7	0
3110	From pathophysiology to targeted therapy for atherothrombosis: A role for the combination of statin and aspirin in secondary prevention. , 2007, 113, 184-196.		49
3111	Prevention of stroke and dementia by statin therapy: Experimental and clinical evidence of their pleiotropic effects. , 2007, 113, 378-393.		65
3112	Activation of peroxisome proliferator-activated receptor- β (PPAR- β) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. <i>Prostaglandins and Other Lipid Mediators</i> , 2007, 84, 43-53.	1.0	28
3113	Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. <i>Toxicology and Applied Pharmacology</i> , 2007, 223, 39-45.	1.3	33
3114	Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: A possible role in statin-induced hepatotoxicity?. <i>Toxicology and Applied Pharmacology</i> , 2007, 223, 173-179.	1.3	59
3115	Medical management of risk factors for vascular disease. <i>Surgery</i> , 2007, 25, 319-322.	0.1	0
3116	Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets. <i>Journal of Neuroimmunology</i> , 2007, 184, 17-26.	1.1	42
3117	The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 335-341.	0.4	23
3118	Should CKD Be a Coronary Heart Disease Risk Equivalent?. <i>American Journal of Kidney Diseases</i> , 2007, 49, 8-11.	2.1	10
3120	A Randomized Trial of the Effect of Statin and Fibrate Therapy on Arterial Function in CKD. <i>American Journal of Kidney Diseases</i> , 2007, 49, 776-785.	2.1	49
3121	The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 2007, 50, 791-802.	2.1	42
3122	Pharmacotherapy Before and After Revascularization: Anticoagulation, Antiplatelet Agents, and Statins. <i>Seminars in Vascular Surgery</i> , 2007, 20, 10-14.	1.1	23
3123	The Effect of Statin Medications on Perioperative and Long-Term Outcomes Following Carotid Endarterectomy or Stenting. <i>Seminars in Vascular Surgery</i> , 2007, 20, 252-258.	1.1	70
3124	Comprehensive management of cardiometabolic risk factors. <i>Clinical Cornerstone</i> , 2007, 8, 69-80.	1.0	3
3125	Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. <i>Lancet Neurology</i> , The, 2007, 6, 961-969.	4.9	495
3126	Can Intensive Statin Therapy Halt the Progression of Atherosclerosis? Recent Evidence and Potential Implications for Patient Management. <i>Progress in Cardiovascular Nursing</i> , 2007, 22, 207-213.	0.5	4

#	ARTICLE	IF	CITATIONS
3127	Switching statins: potential drug interactions with simvastatin. <i>The Prescriber</i> , 2007, 18, 34-41.	0.1	0
3128	Evolution of Anticoagulant and Antiplatelet Therapy: Benefits and Risks of Contemporary Pharmacologic Agents and Their Implications for Myonecrosis and Bleeding in Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2007, 30, II4-II15.	0.7	3
3129	Management of Peripheral Arterial Disease of the Lower Extremities. <i>Comprehensive Therapy</i> , 2007, 33, 247-256.	0.2	11
3130	Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. <i>Acta Diabetologica</i> , 2007, 44, 65-68.	1.2	30
3131	Does the prevalence of nasal polyps increase in patients using statins?. <i>Advances in Therapy</i> , 2007, 24, 1330-1339.	1.3	5
3132	Aggressive statin therapy for acute coronary syndromes. <i>Current Cardiology Reports</i> , 2007, 9, 298-302.	1.3	0
3133	HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. <i>Current Cardiology Reports</i> , 2007, 9, 486-492.	1.3	40
3134	Residual risk in statin-treated patients: Future therapeutic options. <i>Current Cardiology Reports</i> , 2007, 9, 499-505.	1.3	23
3137	Statin therapy: Is the percent reduction or the attained low-density lipoprotein cholesterol level more important?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 10-17.	2.0	4
3138	Statin therapy in cardiovascular diseases other than atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2007, 9, 25-32.	2.0	6
3139	Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 376, 135-143.	1.4	10
3141	Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetologia</i> , 2007, 50, 733-740.	2.9	39
3142	Peripheral Arterial Occlusive Disease: Magnetic Resonance Imaging and the Role of Aggressive Medical Management. <i>World Journal of Surgery</i> , 2007, 31, 695-704.	0.8	21
3145	Progress In Practice UKCPA Residential Symposium. <i>International Journal of Clinical Pharmacy</i> , 2007, 29, 240-277.	1.4	1
3146	The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes. <i>International Journal of Clinical Pharmacy</i> , 2007, 29, 541-545.	1.4	19
3147	The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 297-309.	1.3	49
3148	Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 375-388.	1.3	14
3153	Current strategies for ischemic stroke prevention: role of multimodal combination therapies. <i>Journal of Neurology</i> , 2007, 254, 1414-1426.	1.8	22

#	ARTICLE	IF	CITATIONS
3154	A Green Tea Catechin Extract Upregulates the Hepatic Low-Density Lipoprotein Receptor in Rats. <i>Lipids</i> , 2007, 42, 621-627.	0.7	54
3157	Statins and dementia. <i>Current Atherosclerosis Reports</i> , 2007, 9, 154-161.	2.0	29
3158	Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. <i>Current Atherosclerosis Reports</i> , 2007, 9, 162-168.	2.0	16
3161	Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 266-273.	2.0	11
3162	Statins for stroke prevention. <i>Current Atherosclerosis Reports</i> , 2007, 9, 305-311.	2.0	7
3163	SPARCL: The glimmer of statins for stroke risk reduction. <i>Current Atherosclerosis Reports</i> , 2007, 9, 347-351.	2.0	4
3164	Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 384-388.	2.0	5
3165	Statin myopathy: Incidence, risk factors, and pathophysiology. <i>Current Atherosclerosis Reports</i> , 2007, 9, 389-396.	2.0	88
3166	The portfolio diet for cardiovascular risk reduction. <i>Current Atherosclerosis Reports</i> , 2007, 9, 501-507.	2.0	39
3167	COX-2 and the vasculature: Angel or evil?. <i>Current Hypertension Reports</i> , 2007, 9, 73-80.	1.5	5
3168	How to treat hypertension in patients with peripheral artery disease. <i>Current Hypertension Reports</i> , 2007, 9, 190-195.	1.5	6
3169	Treatment goals for the management of lipids and inflammation for patients with coronary artery disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 3-10.	0.4	1
3170	Carotid stenosis: Endarterectomy or angioplasty and stenting?. <i>Current Treatment Options in Neurology</i> , 2007, 9, 451-462.	0.7	1
3171	Treatment After Myocardial Infarction. <i>Comprehensive Therapy</i> , 2007, 33, 39-47.	0.2	3
3173	Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 290-295.	0.8	0
3174	Update in Addiction Medicine for the Generalist. <i>Journal of General Internal Medicine</i> , 2007, 22, 1190-1194.	1.3	8
3175	Mevalonate pathway: A review of clinical and therapeutical implications. <i>Clinical Biochemistry</i> , 2007, 40, 575-584.	0.8	471
3176	Interest in healthy lifestyle and adherence to medications: Impact on mortality among elderly cardiovascular patients in the DEBATE Study. <i>Patient Education and Counseling</i> , 2007, 67, 44-49.	1.0	13

#	ARTICLE	IF	CITATIONS
3177	Secondary Prevention After Acute Myocardial Infarction and Coronary Revascularisation: Focus on Angiotensin Converting Enzyme Inhibitors. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 185-191.	1.3	7
3178	Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 321-338.	1.3	134
3180	Should a statin be prescribed to every patient with heart failure?. <i>Heart Failure Reviews</i> , 2008, 13, 211-225.	1.7	17
3182	Mild cognitive impairment prevention: Diet, sports and treatment approaches. <i>Journal of Nutrition, Health and Aging</i> , 2008, 12, S86-S88.	1.5	3
3183	The under-representation of older people in clinical trials: Barriers and potential solutions. <i>Journal of Nutrition, Health and Aging</i> , 2008, 12, 194-196.	1.5	29
3184	Prevention of progression to dementia in the elderly: Rationale and proposal for a health-promoting memory consultation (an IANA task force). <i>Journal of Nutrition, Health and Aging</i> , 2008, 12, 520-529.	1.5	23
3185	Coronary, Peripheral and Cerebrovascular Disease: a Complex Relationship. <i>Herz</i> , 2008, 33, 475-480.	0.4	22
3186	Management of Patients with Carotid Artery Stenosis. <i>Herz</i> , 2008, 33, 490-497.	0.4	8
3187	Stroke Prevention. <i>Herz</i> , 2008, 33, 518-523.	0.4	7
3188	Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 651-661.	0.8	15
3189	Cholesterol in women at high cardiovascular risk is less successfully treated than in corresponding men. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 815-820.	0.8	9
3194	Cholestin (<i>Monascus purpureus</i> rice) inhibits homocysteine-induced reactive oxygen species generation, nuclear factor- κ B activation, and vascular cell adhesion molecule-1 expression in human aortic endothelial cells. <i>Journal of Biomedical Science</i> , 2008, 15, 183-196.	2.6	27
3196	Statins and congestive heart failure. <i>Current Atherosclerosis Reports</i> , 2008, 10, 369-376.	2.0	1
3197	Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. <i>Current Diabetes Reports</i> , 2008, 8, 71-77.	1.7	63
3198	Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 12-19.	2.0	23
3199	Prevalence of Musculoskeletal Pain and Statin Use. <i>Journal of General Internal Medicine</i> , 2008, 23, 1182-1186.	1.3	136
3200	New strategies in the medical treatment of carotid artery disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 156-163.	0.4	2
3201	Atherosclerosis regression. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 187-194.	0.4	1

#	ARTICLE	IF	CITATIONS
3202	Prior Statin Use Reduces Mortality in Intracerebral Hemorrhage. <i>Neurocritical Care</i> , 2008, 8, 6-12.	1.2	73
3203	Using inflammatory biomarkers to guide lipid therapy. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 29-34.	0.8	3
3204	Omega-3 fatty acids, acute coronary syndrome, and sudden death. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 161-166.	0.8	5
3205	Cardiovascular protection for all individuals at high risk: evidence-based best practice. <i>Clinical Research in Cardiology</i> , 2008, 97, 713-725.	1.5	9
3207	Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology?. <i>Human Genetics</i> , 2008, 123, 15-33.	1.8	299
3208	CRISTOPH â€“ A cluster-randomised intervention study to optimise the treatment of patients with hypertension in General Practice. <i>BMC Family Practice</i> , 2008, 9, 33.	2.9	4
3209	Trends in total cholesterol screening and in prescribing lipid-lowering drugs in general practice in the period 1994â€“2003. <i>BMC Family Practice</i> , 2008, 9, 39.	2.9	7
3210	Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. <i>BMC Family Practice</i> , 2008, 9, 42.	2.9	75
3211	A group randomized trial of a complexity-based organizational intervention to improve risk factors for diabetes complications in primary care settings: study protocol. <i>Implementation Science</i> , 2008, 3, 15.	2.5	18
3212	Estimation of risk factor associations when the response is influenced by medication use: An imputation approach. <i>Statistics in Medicine</i> , 2008, 27, 5039-5053.	0.8	27
3213	Struck by ACCORD. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008, 25, 127-129.	0.2	3
3214	Type 2 diabetes and cognitive impairment: The Edinburgh Type 2 Diabetes Study. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008, 25, 132-134.	0.2	1
3215	Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997â€“2003. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 62-69.	0.9	16
3216	Evidence-based medicine: Review of guidelines and trials in the prevention of secondary stroke. <i>Journal of Hospital Medicine</i> , 2008, 3, S6-S19.	0.7	3
3217	Optimal risk factor modification and medical management of the patient with peripheral arterial disease. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 475-489.	0.7	50
3218	Statin use and risk of breast cancer. <i>Cancer</i> , 2008, 112, 27-33.	2.0	57
3219	Differing results of trials of glucosamine for pain in arthritis: Comment on the article by VLAD et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 332-333.	6.7	3
3220	Tendinous disorders attributed to statins: A study on ninety-six spontaneous reports in the period 1990â€“2005 and review of the literature. <i>Arthritis and Rheumatism</i> , 2008, 59, 367-372.	6.7	158

#	ARTICLE	IF	CITATIONS
3221	Liquid crystal dimers derived from naturally occurring chiral moieties: synthesis and characterization. <i>Tetrahedron</i> , 2008, 64, 3760-3771.	1.0	30
3222	A pilot-study to identify the feasibility of an Internet-based coaching programme for changing the vascular risk profile of high-risk patients. <i>Patient Education and Counseling</i> , 2008, 73, 67-72.	1.0	34
3223	Preventing Cardiovascular Disease in Women: An Update. <i>Clinical Cardiology</i> , 2008, 31, 109-113.	0.7	16
3224	Atorvastatin Administration after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease and Normal Lipid Profiles: Impact on Plasma Adiponectin Level. <i>Clinical Cardiology</i> , 2008, 31, 253-258.	0.7	23
3225	Pharmacogenomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2008, 448, 213-357.	0.4	86
3226	Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. , 2008, , CD007176.		197
3227	Rosuvastatin and progression of atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 925-933.	0.6	8
3228	Critical limb ischemia: medical and surgical management. <i>Vascular Medicine</i> , 2008, 13, 281-291.	0.8	103
3229	Current drug therapies for the secondary prevention of MI. <i>The Prescriber</i> , 2008, 19, 14-25.	0.1	1
3230	Current treatment options in the management of stable angina. <i>The Prescriber</i> , 2008, 19, 29-46.	0.1	0
3231	Statins: to switch or not to switch?. <i>The Prescriber</i> , 2008, 19, 35-41.	0.1	2
3232	NICE lipid modification guidance: more questions than answers?. <i>The Prescriber</i> , 2008, 19, 26-30.	0.1	0
3233	The Neuroprotection with Statin Therapy for Acute Recovery Trial (Neustart): An Adaptive Design Phase I Dose-Escalation Study of High-Dose Lovastatin in Acute Ischemic Stroke. <i>International Journal of Stroke</i> , 2008, 3, 210-218.	2.9	52
3234	Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: a less commonly perceived therapeutic perspective in clinical practice. <i>International Journal of Clinical Practice</i> , 2008, 60, 884-888.	0.8	4
3235	Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. <i>International Journal of Clinical Practice</i> , 2008, 62, 539-554.	0.8	29
3236	Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. <i>International Journal of Clinical Practice</i> , 2008, 62, 1087-1095.	0.8	116
3237	Statin safety and chronic liver disease. <i>International Journal of Clinical Practice</i> , 2008, 62, 1831-1835.	0.8	6
3238	Characterization of Low-Density Lipoprotein Cholesterol-Lowering Efficacy for Atorvastatin in a Population-Based DNA Biorepository. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 354-359.	1.2	22

#	ARTICLE	IF	CITATIONS
3239	Form to function: current and future roles for atherosclerosis imaging in drug development. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 517-529.	21.5	68
3240	Cholesterolâ€”When Is Lower Better?. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 777-780.	2.3	8
3241	Benefit/Risk Ratio of Statins in Primary Prevention. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 498-500.	2.3	5
3242	Effect of Atorvastatin on Energy Expenditure and Skeletal Muscle Oxidative Metabolism at Rest and During Exercise. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 243-250.	2.3	21
3243	Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 251-257.	2.3	111
3244	Statin Cost-Effectiveness Comparisons Using Real-World Effectiveness Data: Formulary Implications. <i>Value in Health</i> , 2008, 11, 1061-1069.	0.1	15
3245	STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS IN ELDERLY PATIENTS: A PICTURE FROM CLINICAL PRACTICE WITHOUT STRONG EVIDENCE FROM CLINICAL TRIALS. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 175-177.	1.3	13
3246	2,3,4',5-TETRAHYDROXYSTILBENE-2-O-Î²-D-GLUCOSIDE SUPPRESSES MATRIX METALLOPROTEINASE EXPRESSION AND INFLAMMATION IN ATHEROSCLEROTIC RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 310-316.	0.9	38
3247	The Relative Merits of Populationâ€”Based and Targeted Prevention Strategies. <i>Milbank Quarterly</i> , 2008, 86, 557-580.	2.1	83
3248	A cardiologist view of vascular disease in diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 279-292.	2.2	18
3249	Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 533-544.	2.2	8
3250	PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 691-698.	2.2	21
3251	Longâ€”term adherence to statin treatment in diabetes. <i>Diabetic Medicine</i> , 2008, 25, 850-855.	1.2	74
3252	Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. <i>Diabetic Medicine</i> , 2008, 25, 909-915.	1.2	12
3253	Reduced thyroid volume and nodularity in dyslipidaemic patients on statin treatment. <i>Clinical Endocrinology</i> , 2008, 68, 16-21.	1.2	34
3254	Direct effect of statins on homocysteineâ€”induced endothelial adhesiveness: potential impact to human atherosclerosis. <i>European Journal of Clinical Investigation</i> , 2008, 38, 106-116.	1.7	15
3255	An evaluation of educational outreach to improve evidenceâ€”based prescribing in Medicaid: a cautionary tale. <i>Journal of Evaluation in Clinical Practice</i> , 2008, 14, 854-860.	0.9	18
3256	Câ€”reactive protein and coronary heart disease: a critical review. <i>Journal of Internal Medicine</i> , 2008, 264, 295-314.	2.7	316

#	ARTICLE	IF	CITATIONS
3257	A perioperative statin update for noncardiac surgery. Part I: Statin therapy for vascular surgery and perioperative statin trial design. <i>Anaesthesia</i> , 2008, 63, 162-171.	1.8	33
3258	Real-life™ reduction in cholesterol with statins, 1993 to 2002. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 587-592.	1.1	16
3259	Shift of statin use towards the elderly in 1995-2005: a nationwide register study in Finland. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 405-410.	1.1	30
3261	Switching Statin Therapy Using a Pharmacist-Managed Therapeutic Conversion Program versus Usual Care Conversion Among Indigent Patients. <i>Pharmacotherapy</i> , 2008, 28, 553-561.	1.2	29
3262	Dyslipidemia Control in Indigent Patients Receiving Medication Assistance Compared with Insured Patients. <i>Pharmacotherapy</i> , 2008, 28, 562-569.	1.2	11
3263	Impact of Systemic Hypertension on the Cardiovascular Benefits of Statin Therapy: A Meta-Analysis. <i>American Journal of Cardiology</i> , 2008, 101, 319-325.	0.7	31
3264	Factors Associated With Discharge Lipid-Lowering Drug Prescription in Patients Hospitalized for Coronary Artery Disease (from the Get With the Guidelines Database). <i>American Journal of Cardiology</i> , 2008, 101, 1242-1246.	0.7	11
3265	Anti-Inflammatory Agents and Antioxidants as a Possible "Third Great Wave" in Cardiovascular Secondary Prevention. <i>American Journal of Cardiology</i> , 2008, 101, S4-S13.	0.7	44
3266	Nicotinic Acid, Alone and in Combinations, for Reduction of Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2008, 101, S58-S62.	0.7	118
3267	Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy. <i>American Journal of Cardiology</i> , 2008, 101, S27-S35.	0.7	16
3268	Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. <i>American Journal of Cardiology</i> , 2008, 101, 1689-1693.	0.7	276
3269	Efficacy of Rosuvastatin (5 mg and 10 mg) Twice a Week in Patients Intolerant to Daily Statins. <i>American Journal of Cardiology</i> , 2008, 101, 1747-1748.	0.7	74
3270	Effect of Statin Therapy on Mortality in Patients With Peripheral Arterial Disease and Comparison of Those With Versus Without Associated Chronic Obstructive Pulmonary Disease. <i>American Journal of Cardiology</i> , 2008, 102, 192-196.	0.7	76
3271	Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines. <i>American Journal of Cardiology</i> , 2008, 101, S51-S57.	0.7	133
3272	Usefulness of Hypertensive Blood Pressure Response During a Single-Stage Exercise Test to Predict Long-Term Outcome in Patients With Peripheral Arterial Disease. <i>American Journal of Cardiology</i> , 2008, 102, 921-926.	0.7	41
3273	After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Implications for Fenofibrate. <i>American Journal of Cardiology</i> , 2008, 102, 34L-40L.	0.7	41
3274	Expert Perspective: Reducing Cardiovascular Risk in Metabolic Syndrome and Type 2 Diabetes Mellitus Beyond Low-Density Lipoprotein Cholesterol Lowering. <i>American Journal of Cardiology</i> , 2008, 102, 41L-47L.	0.7	30
3275	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1K-34K.	0.7	371

#	ARTICLE	IF	CITATIONS
3277	Cardiovascular protection by anti-inflammatory statin therapy. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2008, 22, 111-133.	1.7	14
3278	Diabetes and other vascular risk factors for dementia: Which factor matters most? A systematic review. <i>European Journal of Pharmacology</i> , 2008, 585, 97-108.	1.7	297
3279	Plaque Biology: Interesting Science or Pharmacological Treasure Trove?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2008, 36, 507-516.	0.8	10
3280	Delivery of Multifactorial Interventions by Nurse and Dietitian Teams in a Community Setting to Prevent Diabetic Complications: A Quality-Improvement Report. <i>American Journal of Kidney Diseases</i> , 2008, 51, 425-434.	2.1	29
3281	Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2008, 8, 1384-1392.	2.6	141
3282	The Food and Drug Administration and Over-the-Counter Statins: An Opportunity Lost?. <i>Journal of Clinical Hypertension</i> , 2008, 10, 245-248.	1.0	0
3283	Effect of preoperative statins in patients without coronary artery disease who undergo cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 1510-1513.	0.4	29
3284	Management of Hypertension in Peripheral Arterial Disease. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 238-263.	1.6	38
3285	NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. , 2008, 120, 254-291.		221
3286	Nurse-led risk assessment/management clinics reduce predicted cardiac morbidity and mortality in claudicants. <i>Journal of Vascular Nursing</i> , 2008, 26, 118-122.	0.2	7
3287	Stroke: management and prevention. <i>Medicine</i> , 2008, 36, 592-600.	0.2	6
3288	Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 717-725.	1.0	63
3289	Markers of instability in high-risk carotid plaques are reduced by statins. <i>Journal of Vascular Surgery</i> , 2008, 47, 513-522.	0.6	45
3290	Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2008, 47, 774-781.e1.	0.6	142
3291	Regarding "Light assisted stab phlebectomy: Report of a technique for removal of lower extremity varicose veins". <i>Journal of Vascular Surgery</i> , 2008, 47, 901-902.	0.6	0
3293	Pharmacologic risk factor management in peripheral arterial disease: A vade mecum for vascular surgeons. <i>Journal of Vascular Surgery</i> , 2008, 47, 1108-1115.	0.6	11
3294	Suboptimal use of statin therapy in elderly patients with atherosclerosis: A population-based study. <i>Journal of Vascular Surgery</i> , 2008, 48, 607-612.e1.	0.6	27
3295	Risk stratification in critical limb ischemia: Derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. <i>Journal of Vascular Surgery</i> , 2008, 48, 1464-1471.	0.6	227

#	ARTICLE	IF	CITATIONS
3296	Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 380-386.	1.5	45
3297	Effect of almonds on insulin secretion and insulin resistance in nondiabetic hyperlipidemic subjects: a randomized controlled crossover trial. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 882-887.	1.5	46
3298	Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients. <i>Pharmacological Research</i> , 2008, 57, 393-397.	3.1	17
3299	Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease. <i>Drug Safety</i> , 2008, 31, 325-334.	1.4	31
3300	Drugs for Cardiovascular Disease Prevention in Women. <i>Drugs</i> , 2008, 68, 339-358.	4.9	5
3301	Scientific Rationale for Combination of a Calcium Channel Antagonist and an HMG-CoA Reductase Inhibitor. <i>Drugs</i> , 2008, 68, 885-900.	4.9	6
3302	GuÃas de prÃ¡ctica clÃnica sobre prevenciÃ³n de la enfermedad cardiovascular: versiÃ³n resumida. <i>Revista Espanola De Cardiologia</i> , 2008, 61, 82.e1-82.e49.	0.6	19
3307	Cost-Effectiveness of Managing Familial Hypercholesterolemia Using Atorvastatin-Based Preventive Therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 382-393.	0.4	6
3308	Management of cardiovascular risk factors by primary care physicians in patients with peripheral arterial disease. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2008, 6, 144-147.	0.8	6
3309	Statins for Secondary Prevention in Elderly Patients. <i>Journal of the American College of Cardiology</i> , 2008, 51, 37-45.	1.2	326
3310	Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. <i>Journal of the American College of Cardiology</i> , 2008, 51, 724-730.	1.2	534
3311	In Search of the "Vulnerable Plaque". <i>Journal of the American College of Cardiology</i> , 2008, 51, 1539-1542.	1.2	58
3312	Lipoprotein Management in Patients With Cardiometabolic Risk. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1512-1524.	1.2	466
3313	Managing Dyslipidemia in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2375-2384.	1.2	164
3314	Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling. <i>Journal of the American College of Cardiology</i> , 2008, 52, 255-262.	1.2	296
3315	Interpretation of Amino-Terminal Pro-Brain Natriuretic Peptide Levels in the HPS and the CORONA Study. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1104-1105.	1.2	10
3316	Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy. <i>Journal of the American College of Cardiology</i> , 2008, 52, 914-920.	1.2	64
3317	Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1141-1147.	1.2	99

#	ARTICLE	IF	CITATIONS
3318	Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2008, 2, 12-18.	0.6	3
3319	Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes. <i>Journal of Clinical Lipidology</i> , 2008, 2, 19-24.	0.6	13
3320	Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. <i>Journal of Clinical Lipidology</i> , 2008, 2, 91-105.	0.6	22
3321	A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. <i>Journal of Clinical Lipidology</i> , 2008, 2, 106-111.	0.6	14
3322	Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. <i>Journal of Clinical Lipidology</i> , 2008, 2, 79-90.	0.6	37
3323	Counterpoint: Lipoproteins and dementia: Is there compelling evidence to treat Alzheimer's patients with statins?. <i>Journal of Clinical Lipidology</i> , 2008, 2, 394-396.	0.6	1
3324	Point: Lipoproteins are significant factors in Alzheimer's disease: Dementia is impacted by blood plasma lipoproteins. <i>Journal of Clinical Lipidology</i> , 2008, 2, 391-393.	0.6	1
3325	Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. <i>Journal of Clinical Lipidology</i> , 2008, 2, 436-446.	0.6	13
3326	Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. <i>Journal of Clinical Lipidology</i> , 2008, 2, 453-463.	0.6	39
3327	Limb Stress-Rest Perfusion Imaging With Contrast Ultrasound for the Assessment of Peripheral Arterial Disease Severity. <i>JACC: Cardiovascular Imaging</i> , 2008, 1, 343-350.	2.3	103
3328	Benefits of statins beyond lipid lowering. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e325-e331.	0.8	8
3329	Application in general practice of treatment guidelines for patients with dyslipidaemia: The RESPECT study. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 715-721.	0.7	8
3331	Wild-Type Food in Health Promotion and Disease Prevention. , 2008, , .		15
3332	Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. <i>Lipids in Health and Disease</i> , 2008, 7, 37.	1.2	195
3333	Cardiovascular Disease: Overview and Trends. , 2008, , 511-538.		0
3334	Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia. <i>Cardiology</i> , 2008, 111, 219-228.	0.6	32
3335	Primary Prevention and Statins: Is It Just About Going to Class?. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1313-1315.	1.4	2
3336	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2008, 358, 1431-1443.	13.9	1,180

#	ARTICLE	IF	CITATIONS
3337	Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opinion on Pharmacotherapy, 2008, 9, 2145-2160.	0.9	36
3338	Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology, 2008, 448, v-vii.	0.4	8
3340	Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial Infarction. Drugs and Aging, 2008, 25, 649-664.	1.3	21
3342	Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk. Circulation, 2008, 117, 1945-1954.	1.6	480
3344	Pleiotropic Effects of Atorvastatin in Heart Failure: Role in Oxidative Stress, Inflammation, Endothelial Function, and Exercise Capacity. Journal of Heart and Lung Transplantation, 2008, 27, 435-441.	0.3	62
3345	Questioning the "beatification" of statins. International Journal of Cardiology, 2008, 123, 197-198.	0.8	5
3346	The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. International Journal of Cardiology, 2008, 123, 102-107.	0.8	61
3347	Vascular and metabolic effects of treatment of combined hyperlipidemia: Focus on statins and fibrates. International Journal of Cardiology, 2008, 124, 149-159.	0.8	45
3348	Cholesterol "A" marker of nutritional status in mild to moderate heart failure. International Journal of Cardiology, 2008, 129, 65-68.	0.8	26
3349	HDL-C in post-menopausal women: An important therapeutic target. International Journal of Cardiology, 2008, 124, 275-282.	0.8	21
3350	Can dysfunctional HDL explain high coronary artery disease risk in South Asians?. International Journal of Cardiology, 2008, 129, 125-132.	0.8	57
3351	Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. International Journal of Cardiology, 2008, 130, 457-462.	0.8	69
3352	Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine, 2008, 14, 37-44.	3.5	522
3353	Statin Therapy Improves Outcomes After Valvular Heart Surgery. Annals of Thoracic Surgery, 2008, 85, 1521-1526.	0.7	45
3354	National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002. American Heart Journal, 2008, 156, 284-291.	1.2	11
3355	Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq1 1 outcomes in patients with acute coronary syndromes. American Heart Journal, 2008, 156, 826-832.	0.784314 1.2	rgBT /Over 280
3356	Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients. American Journal of Medicine, 2008, 121, 24-33.	0.6	198
3357	Lowering LDL Cholesterol in Adults: A Prospective, Community-Based Practice Initiative. American Journal of Medicine, 2008, 121, 604-610.	0.6	14

#	ARTICLE	IF	CITATIONS
3358	Cardiovascular risk factors and dementia. <i>American Journal of Geriatric Pharmacotherapy</i> , 2008, 6, 100-118.	3.0	183
3359	Do the cholesterol-lowering properties of statins affect cancer risk?. <i>Trends in Endocrinology and Metabolism</i> , 2008, 19, 113-121.	3.1	109
3360	Combination Polypharmacy for Cardiovascular Disease Prevention in Men: A Decision Analysis and Cost-Effectiveness Model. <i>Preventive Cardiology</i> , 2008, 11, 36-41.	1.1	13
3361	Lifestyle or Life-Saving Medicines? A Primary Healthcare Professional and Consumer Opinion Survey on Over-the-Counter Statins. <i>Annals of Pharmacotherapy</i> , 2008, 42, 413-420.	0.9	10
3362	Emerging antidyslipidemic drugs. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 363-381.	1.0	14
3363	Mevalonate independent effects of atorvastatin on angiogenesis: Relevance to cancer. <i>Bioscience Hypotheses</i> , 2008, 1, 67-69.	0.2	0
3364	Current approaches in the treatment of Alzheimer's disease. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 199-207.	2.5	139
3365	Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association. <i>Journal of Cardiac Failure</i> , 2008, 14, 615-625.	0.7	81
3366	Nutrition in the metabolic syndrome: Pharmacological treatment. <i>European E-journal of Clinical Nutrition and Metabolism</i> , 2008, 3, e108-e116.	0.4	0
3367	Statins and cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2008, 44, 2122-2132.	1.3	257
3368	Statins in stroke prevention: What an internist should know. <i>European Journal of Internal Medicine</i> , 2008, 19, 8-14.	1.0	25
3369	A national study on lipid management. <i>European Journal of Internal Medicine</i> , 2008, 19, 356-361.	1.0	4
3370	Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: A large database analysis of managed care plans in the United States. <i>Clinical Therapeutics</i> , 2008, 30, 195-205.	1.1	33
3371	The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: A nested case-control analysis. <i>Clinical Therapeutics</i> , 2008, 30, 535-542.	1.1	9
3372	Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence. <i>Clinical Therapeutics</i> , 2008, 30, 761-774.	1.1	21
3373	A 52-Week, Randomized, Open-Label, Parallel-Group Comparison of the Tolerability and Effects of Pitavastatin and Atorvastatin on High-Density Lipoprotein Cholesterol Levels and Glucose Metabolism in Japanese Patients with Elevated Levels of Low-Density Lipoprotein Cholesterol and Glucose Intolerance. <i>Clinical Therapeutics</i> , 2008, 30, 1089-1101.	1.1	93
3374	Effects of D-003, a mixture of high-molecular-weight sugar cane wax acids, on lipid peroxidation markers in older individuals: A randomized, double-blind, placebo-controlled study. <i>Current Therapeutic Research</i> , 2008, 69, 36-48.	0.5	3
3375	Characteristics and cardiovascular risk of new cases of type 2 diabetes in Otago, New Zealand, 1998-2004. <i>Diabetes Research and Clinical Practice</i> , 2008, 82, 396-401.	1.1	4

#	ARTICLE	IF	CITATIONS
3376	Dislipidemias en pacientes muy ancianos. EMC - Tratado De Medicina, 2008, 12, 1-10.	0.0	0
3377	Efficacy and Safety of Rosuvastatin in Taiwanese Patients. Journal of the Chinese Medical Association, 2008, 71, 113-118.	0.6	6
3378	Anestesia para endarterectomía carotídea. EMC - Anestesia-Reanimación, 2008, 34, 1-18.	0.1	0
3379	Coronary Artery Calcium Scanning Using Computed Tomography: Clinical Recommendations for Cardiac Risk Assessment and Treatment. Seminars in Ultrasound, CT and MRI, 2008, 29, 223-229.	0.7	11
3380	Moderately elevated plant sterol levels are associated with reduced cardiovascular risk – The LASA study. Atherosclerosis, 2008, 196, 283-288.	0.4	117
3381	Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey. Atherosclerosis, 2008, 197, 710-717.	0.4	63
3382	Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging. Atherosclerosis, 2008, 197, 951-958.	0.4	54
3383	Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy. Atherosclerosis, 2008, 199, 368-377.	0.4	16
3384	Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: Diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis, 2008, 199, 455-462.	0.4	49
3385	Prevention therapeutics of dementia. Alzheimer's and Dementia, 2008, 4, S122-30.	0.4	18
3386	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. Alzheimer's and Dementia, 2008, 4, 145-153.	0.4	56
3387	Role of statin therapy in stroke prevention. Journal of the American Society of Hypertension, 2008, 2, 131-139.	2.3	0
3389	Manejo general y extrahospitalario del paciente con diabetes. Valoración de la sintomatología. Procesos intercurrentes. Medicine, 2008, 10, 1138-1148.	0.0	2
3391	Ictus y estatinas: más allá de la reducción de los valores de colesterol. Clínica e Investigación en Arteriosclerosis, 2008, 20, 239-246.	0.4	0
3392	Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, The, 2008, 371, 117-125.	6.3	1,735
3393	Age as a modifiable risk factor for cardiovascular disease. Lancet, The, 2008, 371, 1547-1549.	6.3	125
3394	Fenofibrate and diabetic retinopathy – Authors' reply. Lancet, The, 2008, 371, 722.	6.3	0
3395	Acute myocardial infarction. Lancet, The, 2008, 372, 570-584.	6.3	557

#	ARTICLE	IF	CITATIONS
3396	Treatment of low high-density lipoprotein cholesterol. Canadian Journal of Cardiology, 2008, 24, 27C-31C.	0.8	7
3397	Effect of Atorvastatin on Serum MMP-2, MMP-9 and TIMP-1 in Rabbits with Chronic Heart Failure. Journal of Nanjing Medical University, 2008, 22, 351-355.	0.1	0
3399	The Role of Antiphospholipid Syndrome in Cardiovascular Disease. Hematology/Oncology Clinics of North America, 2008, 22, 79-94.	0.9	46
3400	Prevalence of Use of Antiplatelet Drugs, Beta Blockers, Statins, and Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Older Patients With Coronary Artery Disease in an Academic Nursing Home. Journal of the American Medical Directors Association, 2008, 9, 124-127.	1.2	18
3401	Role of Neurohormonal Modulators in Heart Failure with Relatively Preserved Systolic Function. Cardiology Clinics, 2008, 26, 23-40.	0.9	8
3403	Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, β -blockers, or statins. Gender Medicine, 2008, 5, 53-61.	1.4	46
3405	Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovascular Diseases, 2008, 25, 457-507.	0.8	2,222
3406	Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. Mayo Clinic Proceedings, 2008, 83, 1316-1325.	1.4	22
3407	Hypertension and the Older Diabetic. Clinics in Geriatric Medicine, 2008, 24, 489-501.	1.0	9
3408	Cardiovascular Risk Assessment and Hyperlipidemia. Critical Care Nursing Clinics of North America, 2008, 20, 277-285.	0.4	2
3409	Caring for the Vulnerable Elderly: Are Available Quality Indicators Appropriate?. Journal of the American Medical Directors Association, 2008, 9, 1-3.	1.2	23
3410	Simvastatin vs Therapeutic Lifestyle Changes and Supplements: Randomized Primary Prevention Trial. Mayo Clinic Proceedings, 2008, 83, 758-764.	1.4	83
3411	Cardiopathie ischémique: le point sur le traitement pharmacologique en 2008. Medecine Des Maladies Metaboliques, 2008, 2, 241-247.	0.1	1
3412	Risk Factor Management to Prevent First Stroke. Neurologic Clinics, 2008, 26, 1007-1045.	0.8	48
3413	Improved Attainment of Blood Pressure and Cholesterol Goals Using Single-Pill Amlodipine/Atorvastatin in African Americans: The CAPABLE Trial. Mayo Clinic Proceedings, 2008, 83, 35-45.	1.4	48
3414	Peripheral Arterial Disease: Diagnosis and Management. Mayo Clinic Proceedings, 2008, 83, 944-950.	1.4	28
3415	Lipid abnormalities and cardiovascular risk in the elderly. Current Medical Research and Opinion, 2008, 24, 653-657.	0.9	10
3416	Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. Current Medical Research and Opinion, 2008, 24, 2873-2882.	0.9	10

#	ARTICLE	IF	CITATIONS
3417	Cholesterol lowering, sudden cardiac death and mortality. Scandinavian Cardiovascular Journal, 2008, 42, 264-267.	0.4	2
3418	Ezetimibe: cholesterol lowering and beyond. Expert Review of Cardiovascular Therapy, 2008, 6, 447-470.	0.6	125
3419	Is New-Onset Diabetes Mellitus Important?. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 5-8.	1.0	2
3420	Cardiovascular Risk Management in Clinical Practice. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 9-16.	1.0	4
3421	A New Option for Therapeutic Management of Patients with Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 47-51.	1.0	4
3422	Secondary Stroke Prevention. CNS Drugs, 2008, 22, 113-121.	2.7	0
3423	Preventing Alzheimer's Disease. CNS Drugs, 2008, 22, 887-902.	2.7	16
3424	Amlodipine/Atorvastatin Fixed-Dose Combination. American Journal of Cardiovascular Drugs, 2008, 8, 51-67.	1.0	28
3425	Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia. American Journal of Cardiovascular Drugs, 2008, 8, 69-81.	1.0	55
3426	Statin Utilization Patterns for the Primary Prevention of Cardiovascular Events. American Journal of Cardiovascular Drugs, 2008, 8, 199-205.	1.0	10
3427	Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins. American Journal of Cardiovascular Drugs, 2008, 8, 233-242.	1.0	23
3428	Peripheral Arterial Disease in the Elderly. American Journal of Cardiovascular Drugs, 2008, 8, 353-364.	1.0	32
3429	Statin Adverse Effects. American Journal of Cardiovascular Drugs, 2008, 8, 373-418.	1.0	564
3430	Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current Medical Research and Opinion, 2008, 24, 995-1009.	0.9	43
3431	Determinants of CRP level in statin-treated patients. Current Medical Research and Opinion, 2008, 24, 1065-1068.	0.9	3
3432	Drug-drug interaction with statins. Expert Review of Clinical Pharmacology, 2008, 1, 105-113.	1.3	24
3433	Anaesthesia for vascular procedures: How do South African patients differ?. Southern African Journal of Anaesthesia and Analgesia, 2008, 14, 109-115.	0.1	4
3434	Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. Angiology, 2008, 59, 36-46.	0.8	9

#	ARTICLE	IF	CITATIONS
3435	Clinical trials update from European Society of Cardiology meeting 2008: TIMEâ€CHF, BACH, BEAUTIFUL, GISSIâ€CHF, and HOMEâ€CHF. European Journal of Heart Failure, 2008, 10, 1264-1267.	2.9	13
3436	Cholesterol ester transfer protein: a therapeutic target in atherosclerosis?. Expert Opinion on Therapeutic Targets, 2008, 12, 937-948.	1.5	5
3437	The risk of stroke within a week of minor stroke or transient ischemic attack. Expert Opinion on Pharmacotherapy, 2008, 9, 2069-2076.	0.9	9
3438	Statins in the Last Six Months of Life: A Recognizable, Life-Limiting Condition Does Not Decrease their Use. Journal of Palliative Medicine, 2008, 11, 685-693.	0.6	49
3439	New Onset Diabetes During Antihypertensive Therapy. American Journal of Hypertension, 2008, 21, 493-499.	1.0	53
3440	Clinical and therapeutic aspects of vascular dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 659-670.	1.0	0
3441	Lâ€™utilizzo delle DDD reference based per la valutazione della compliance terapeutica nel trattamento con statine. Pharmacoeconomics Italian Research Articles, 2008, 10, 77-88.	0.2	1
3442	Valutazione di un risultato del trattamento con statine: il caso dellâ€™ASL di Foligno (PG). Pharmacoeconomics Italian Research Articles, 2008, 10, 123-136.	0.2	1
3443	The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 2008, 24, 1359-1362.	0.9	74
3444	The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current Medical Research and Opinion, 2008, 24, 1919-1929.	0.9	65
3445	Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Current Medical Research and Opinion, 2008, 24, 1987-2000.	0.9	39
3446	Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Current Medical Research and Opinion, 2008, 24, 659-670.	0.9	29
3447	Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H2406-H2409.	1.5	62
3448	Retinal microvascular abnormalities and cognitive dysfunction: a systematic review. British Journal of Ophthalmology, 2008, 92, 1017-1025.	2.1	58
3449	Antioxidant supplements for preventing gastrointestinal cancers. The Cochrane Library, 2008, , CD004183.	1.5	109
3450	Statin Treatment and the Occurrence of Hemorrhagic Stroke in Patients With a History of Cerebrovascular Disease. Stroke, 2008, 39, 497-502.	1.0	157
3451	An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 287-304.	1.5	18
3452	Chapter 11 A cerebrovascular perspective of atherosclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 92, 215-238.	1.0	1

#	ARTICLE	IF	CITATIONS
3454	Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Cmaj, 2008, 178, 548-556.	0.9	201
3455	Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes. Journal of Endocrinological Investigation, 2008, 31, 42-47.	1.8	35
3456	Effect of very low LDL-cholesterol on cortisol synthesis. Journal of Endocrinological Investigation, 2008, 31, 1075-1078.	1.8	9
3457	Effect of Physical Activity on Cognitive Function in Older Adults at Risk for Alzheimer Disease. JAMA - Journal of the American Medical Association, 2008, 300, 1027.	3.8	1,331
3458	Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Heart, 2008, 95, 1-3.	1.2	7
3459	Dual Therapy With Statins and Antioxidants Is Superior to Statins Alone in Decreasing the Risk of Cardiovascular Disease in a Subgroup of Middle-Aged Individuals With Both Diabetes Mellitus and the Haptoglobin 2-2 Genotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, e18-20.	1.1	25
3460	Cognitive Performance and Plasma Levels of Homocysteine, Vitamin B ₁₂ , Folate and Lipids in Patients with Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 384-390.	0.7	38
3461	Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management. Practical Neurology, 2008, 8, 141-157.	0.5	11
3462	Explaining the Decline in Early Mortality in Men and Women With Type 2 Diabetes. Diabetes Care, 2008, 31, 1761-1766.	4.3	56
3463	The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes and Vascular Disease Research, 2008, 5, 177-183.	0.9	44
3464	Can Cheap Generic Statins Achieve National Cholesterol Lowering Targets?. Journal of Health Services Research and Policy, 2008, 13, 99-102.	0.8	5
3465	Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry. Cerebrovascular Diseases, 2008, 25, 366-374.	0.8	59
3467	Effects of total cholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula. Clinical Chemistry and Laboratory Medicine, 2008, 46, 371-5.	1.4	48
3468	Use of statistical process control charts in stroke medicine to determine if clinical evidence and changes in service delivery were associated with improvements in the quality of care. Quality and Safety in Health Care, 2008, 17, 301-306.	2.5	15
3469	Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology, 2008, 71, 344-350.	1.5	221
3470	Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Human Molecular Genetics, 2008, 17, R174-R179.	1.4	53
3471	Statins and Heart Failure. Angiology, 2008, 59, 58S-61S.	0.8	10
3473	Strategies for prescribing statins. BMJ: British Medical Journal, 2008, 336, 288-289.	2.4	8

#	ARTICLE	IF	CITATIONS
3474	eNOS and stroke: prevention, treatment and recovery. <i>Future Neurology</i> , 2008, 3, 537-550.	0.9	9
3475	Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. <i>Current Medical Research and Opinion</i> , 2008, 24, 1823-1832.	0.9	23
3476	Is chronic diabetic foot ulcer an indicator of cardiac disease?. <i>Journal of Wound Care</i> , 2008, 17, 12-16.	0.5	19
3477	Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. <i>European Heart Journal</i> , 2008, 29, 2244-2251.	1.0	222
3478	Kidney disease in cardiology. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 34-37.	0.4	18
3479	History of the cholesterol controversy in Britain. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 102, 81-86.	0.2	12
3480	Improving access to research data in Europe. <i>BMJ: British Medical Journal</i> , 2008, 336, 287-288.	2.4	10
3481	Involving users in developing health services. <i>BMJ: British Medical Journal</i> , 2008, 336, 286-287.	2.4	22
3482	Use of Ordinal Outcomes in Vascular Prevention Trials. <i>Stroke</i> , 2008, 39, 2817-2823.	1.0	43
3483	The role of antiplatelet therapy in the management of ischemic stroke: implementation of guidelines in current practice. <i>Neurological Research</i> , 2008, 30, 669-677.	0.6	3
3484	Prevalence of Albuminuria and Cardiovascular Risk Profile in a Referred Cohort of Patients with Type 2 Diabetes: An Asian Perspective. <i>Diabetes Technology and Therapeutics</i> , 2008, 10, 397-403.	2.4	27
3485	Guidelines for the management of chronic kidney disease. <i>Cmaj</i> , 2008, 179, 1154-1162.	0.9	280
3486	Ezetimibe plus simvastatin cardiovascular outcomes study program. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 17-25.	0.6	3
3487	Advances in the management of hyperlipidemia-induced atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 369-383.	0.6	18
3488	Management of Lipids in the Prevention of Cardiovascular Events. <i>Annual Review of Medicine</i> , 2008, 59, 79-94.	5.0	21
3489	Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 655-667.	4.3	68
3490	Clinical characterization and molecular mechanisms of statin myopathy. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 955-969.	0.6	45
3491	Lipoprotein Management in Patients With Cardiometabolic Risk. <i>Diabetes Care</i> , 2008, 31, 811-822.	4.3	536

#	ARTICLE	IF	CITATIONS
3492	Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque. <i>Circulation Research</i> , 2008, 103, 1084-1091.	2.0	251
3493	A Pivotal Role for Interleukin-4 in Atorvastatin-associated Neuroprotection in Rat Brain. <i>Journal of Biological Chemistry</i> , 2008, 283, 1808-1817.	1.6	78
3494	Re: The Association Between Statins and Cancer Incidence in a Veterans Population. <i>Journal of the National Cancer Institute</i> , 2008, 100, 972-973.	3.0	9
3495	Possible Role of Oxidative Stress in the Pathogenesis of Hypertension. <i>Diabetes Care</i> , 2008, 31, S181-S184.	4.3	169
3496	The importance of treating cardiometabolic risk factors in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 9-14.	0.9	20
3497	Response: Re: The Association Between Statins and Cancer Incidence in a Veterans Population. <i>Journal of the National Cancer Institute</i> , 2008, 100, 973-974.	3.0	1
3498	Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors. <i>PPAR Research</i> , 2008, 2008, 1-9.	1.1	142
3499	The Role of Statin Drugs in the Management of the Peripheral Vascular Patient. <i>Vascular and Endovascular Surgery</i> , 2008, 42, 352-366.	0.3	16
3500	Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort. <i>Current Alzheimer Research</i> , 2008, 5, 416-421.	0.7	106
3501	Epilepsy in the Elderly. <i>Seminars in Neurology</i> , 2008, 28, 336-341.	0.5	38
3502	Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States. <i>Current Vascular Pharmacology</i> , 2008, 6, 67-77.	0.8	8
3503	Disorders of Lipid Metabolism. <i>Fundamental and Clinical Cardiology</i> , 2008, , 159-178.	0.0	1
3504	Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. <i>Current Medical Research and Opinion</i> , 2008, 24, 2509-2522.	0.9	35
3505	Lipid Abnormalities and Cardiovascular Risk in Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1065-1070.	3.0	49
3506	Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. <i>Kidney International</i> , 2008, 74, S71-S74.	2.6	20
3507	Erectile dysfunction as a harbinger for increased cardiometabolic risk. <i>International Journal of Impotence Research</i> , 2008, 20, 236-242.	1.0	55
3508	Short-term effects of atorvastatin on hemorheologic parameters and endothelial dysfunction in patients with hypercholesterolemia. Lower is better?. <i>Clinical Hemorheology and Microcirculation</i> , 2008, 40, 325-326.	0.9	1
3509	Issues in Design and Conduct of Clinical Trials for Cognitive-Enhancing Drugs. , 2008, , 21-76.		8

#	ARTICLE	IF	CITATIONS
3510	Quality of Lipid Management in Outpatient Care: A National Study Using Electronic Health Records. American Journal of Medical Quality, 2008, 23, 375-381.	0.2	10
3511	Malnutrition in hospitals. BMJ: British Medical Journal, 2008, 336, 290-290.	2.4	54
3512	Editor's Special Invited Paper: Second-Guessing Clinical Trial Designs. Sequential Analysis, 2008, 27, 2-20.	0.2	3
3513	Simvastatin Plus Nitric Oxide Synthase Inhibition Modulates Remote Organ Damage Following Skeletal Muscle Ischemia-Reperfusion Injury. Journal of Investigative Surgery, 2008, 21, 119-126.	0.6	12
3514	Heartwatch: a secondary prevention programme in primary care in Ireland. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 651-656.	3.1	12
3515	Quality of diabetes care among patients managed by teleconsultation. Journal of Telemedicine and Telecare, 2008, 14, 295-299.	1.4	7
3516	Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AFâ€CHF, HART, MASTER, POISE and stem cell therapy. European Journal of Heart Failure, 2008, 10, 102-108.	2.9	23
3517	Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. European Heart Journal, 2008, 29, 1753-1760.	1.0	87
3518	Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. Circulation, 2008, 118, 672-677.	1.6	90
3519	HDL-cholesterol modulation and its impact on the management of cardiovascular risk. Annals of Clinical Biochemistry, 2008, 45, 122-128.	0.8	9
3520	Prescribing Practice of General Practitioners in Northern Ireland for Peripheral Arterial Disease. Angiology, 2008, 59, 57-63.	0.8	5
3521	Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. Journal of Leukocyte Biology, 2008, 84, 1120-1129.	1.5	32
3522	Management of Coronary Artery Disease in Type 2 Diabetes Mellitus. , 2008, , 289-319.		1
3523	Patients' acceptance of antihypertensive therapy to prevent cardiovascular disease: a comparison between South Asians and Caucasians in the United Kingdom. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 59-66.	3.1	8
3524	The Great Debate of 2008â€”How Low to Go in Preventive Cardiology?. JAMA - Journal of the American Medical Association, 2008, 299, 1718.	3.8	4
3525	Review: Stroke in type 2 diabetes. British Journal of Diabetes and Vascular Disease, 2008, 8, 222-229.	0.6	28
3526	Genetic determinants of statin-associated myopathy. Personalized Medicine, 2008, 5, 481-494.	0.8	6
3527	The impact of privacy and confidentiality laws on the conduct of clinical trials. Clinical Trials, 2008, 5, 70-74.	0.7	15

#	ARTICLE	IF	CITATIONS
3528	Statistical Significance Versus Clinical Significance. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2008, 12, 5-6.	0.4	22
3529	Chapter 20 Epidemiological implications of primary and secondary stroke prevention. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 92, 389-405.	1.0	0
3530	Risk Factors and Treatment at Recurrent Stroke Onset: Results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study. <i>Cerebrovascular Diseases</i> , 2008, 25, 254-260.	0.8	90
3531	Cardiovascular Disease in Diabetes. <i>Diabetes Care</i> , 2008, 31, 1260-1266.	4.3	20
3532	Prevention of Heart Failure. <i>Circulation</i> , 2008, 117, 2544-2565.	1.6	485
3533	Impact of telemonitoring at home on the management of elderly patients with congestive heart failure. <i>Journal of Telemedicine and Telecare</i> , 2008, 14, 300-305.	1.4	138
3534	Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 341-347.	1.1	263
3535	Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype. <i>Diabetes</i> , 2008, 57, 2794-2800.	0.3	124
3536	National health care costs of peripheral arterial disease in the Medicare population. <i>Vascular Medicine</i> , 2008, 13, 209-215.	0.8	306
3537	Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in) Tj ETQq1 1 0.784314 rgBT /Over 2008, 24, 2467-2476.	0.9	21
3538	Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3671-3689.	1.8	164
3539	Pravastatin: an evidence-based statin?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 821-825.	1.5	8
3540	Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the US. <i>Journal of Medical Economics</i> , 2008, 11, 449-470.	1.0	3
3541	Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1303-1310.	0.6	3
3542	Effects of D-003, a Mixture of Very Long Chain Saturated Fatty Acids, and Policosanol on in vivo Lipid Peroxidation in Rats. <i>Arzneimittelforschung</i> , 2008, 58, 126-130.	0.5	4
3543	Cardiovascular disease prevention tailored for women. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1123-1134.	0.6	13
3544	Fibrates and future PPAR α agonists in the treatment of cardiovascular disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 542-553.	3.3	141
3545	Drug Insight: translating evidence on statin therapy into clinical benefits. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 43-49.	2.7	18

#	ARTICLE	IF	CITATIONS
3546	Potential therapeutic role of statins in neurological disorders. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 827-837.	1.4	21
3547	Beyond Cholesterol: Statin Benefits in Alzheimer's Disease. , 2007, , 53-80.		1
3548	Antiatherogenic Effects of Cilostazol and Probucol Alone, and in Combination in Low Density Lipoprotein Receptor-deficient Mice Fed with a High Fat Diet. <i>Hormone and Metabolic Research</i> , 2008, 40, 473-478.	0.7	22
3549	Negative trials in nephrology: what can we learn?. <i>Kidney International</i> , 2008, 74, 1121-1127.	2.6	21
3551	Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1678.	3.8	217
3552	Office Care of Patients After Myocardial Infarction. <i>Postgraduate Medicine</i> , 2008, 120, 11-17.	0.9	0
3553	Role of noninvasive imaging using computed tomography for detection and quantification of coronary atherosclerosis. <i>Future Cardiology</i> , 2008, 4, 269-283.	0.5	4
3554	Endothelial Nitric Oxide Synthase â€” A Target for Stroke Protection by Statins. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2008, 8, 162-166.	0.5	0
3555	Simultaneous Determination of Atenolol, Rosuvastatin, Spironolactone, Glibenclamide and Naproxen Sodium in Pharmaceutical Formulations and Human Plasma by RPâ€”HPLC. <i>Journal of the Chinese Chemical Society</i> , 2008, 55, 1022-1029.	0.8	22
3556	Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis. <i>Circulation</i> , 2008, 118, 2506-2514.	1.6	200
3557	Potent Inhibition of Cicatricial Contraction in Proliferative Vitreoretinal Diseases by Statins. <i>Diabetes</i> , 2008, 57, 2784-2793.	0.3	62
3558	<i>SLCO1B1</i> Variants and Statin-Induced Myopathy â€” A Genomewide Study. <i>New England Journal of Medicine</i> , 2008, 359, 789-799.	13.9	1,860
3559	Simvastatin Improves Flow-Mediated Dilatation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients. <i>Diabetes Care</i> , 2008, 31, 776-782.	4.3	107
3560	Long-term (48-week) safety of ezetimibe 10â€”mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2008, 24, 2953-2966.	0.9	15
3561	A Neuromuscular Approach to Statin-Related Myotoxicity. <i>Canadian Journal of Neurological Sciences</i> , 2008, 35, 8-21.	0.3	37
3563	Peripheral Arterial Disease: Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 2008, 83, 944-950.	1.4	31
3564	Simvastatin Suppresses the Progression of Experimentally Induced Cerebral Aneurysms in Rats. <i>Stroke</i> , 2008, 39, 1276-1285.	1.0	131
3565	Endocannabinoid system and its implications for obesity and cardiometabolic risk. <i>Country Review Ukraine</i> , 2008, 10, B34-B41.	0.8	13

#	ARTICLE	IF	CITATIONS
3566	Importance of Lipid Levels in Elderly Diabetic Individuals Baseline Characteristics and 1-Year Survey of Cardiovascular Events. <i>Circulation Journal</i> , 2008, 72, 218-225.	0.7	12
3569	Investigation of Blood Lipid Levels and Statin Interventions in Outpatients With Coronary Heart Disease in China The China Cholesterol Education Program (CCEP). <i>Circulation Journal</i> , 2008, 72, 2040-2045.	0.7	15
3570	Injury and attention deficit hyperactivity disorder. <i>BMJ: British Medical Journal</i> , 2008, 337, a2244-a2244.	2.4	5
3571	Sugary drinks, fruit, and increased risk of gout. <i>BMJ: British Medical Journal</i> , 2008, 336, 285-286.	2.4	9
3572	Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease. <i>Journal of the Operational Research Society</i> , 2008, 59, 1173-1181.	2.1	19
3573	The Most Wanted Trials for Abdominal Aortic Aneurysm Treatment. <i>Scandinavian Journal of Surgery</i> , 2008, 97, 161-164.	1.3	1
3574	Managing Safety Signals in Large Endpoint Trials. <i>Current Drug Safety</i> , 2008, 3, 86-90.	0.3	0
3575	New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2008, 3, 84-91.	1.5	9
3576	Optimization of Cardiac Metabolism in Diabetes Mellitus. <i>Current Pharmaceutical Design</i> , 2008, 14, 2537-2550.	0.9	10
3577	Cardiovascular Disease in Patients with Diabetic Nephropathy. <i>Current Molecular Medicine</i> , 2008, 8, 533-543.	0.6	24
3578	Safety and Efficacy of Statin Therapy in Patients Switched From Cyclosporine A to Sirolimus After Cardiac Transplantation. <i>Transplantation</i> , 2008, 86, 1771-1776.	0.5	21
3579	Regulation of Cholesterol Biosynthesis and Absorption: Ultimate Management of Dyslipidemia with Statin and Ezetimibe. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2008, 8, 177-182.	0.5	0
3580	Reducing Cardiovascular Complications of Type 2 Diabetes by Targeting Multiple Risk Factors. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 136-144.	0.8	73
3581	Cholesterol lowering and beyond: role of statins in Alzheimer's disease. <i>Aging Health</i> , 2008, 4, 171-180.	0.3	3
3582	Dyslipidemia in Chronic Kidney Disease. , 0, , 333-344.		0
3583	Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function Å– a preliminary report. <i>Acta Cardiologica</i> , 2008, 63, 683-692.	0.3	18
3584	Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Alzheimer's Disease: Future Directions. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 327-338.	1.2	24
3585	Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR) Tj ETQq1 1 0.784314 rgBT /Overlook preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 651-656.	0.7	34

#	ARTICLE	IF	CITATIONS
3586	High-Dose Statin Therapy for Secondary Prevention of Stroke. <i>Journal of Cardiovascular Nursing</i> , 2008, 23, 8-13.	0.6	7
3587	Patient-Centered Modular Secondary Prevention Following Acute Coronary Syndrome. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2008, 28, 107-115.	1.2	35
3588	Prognostic value of hypotensive blood pressure response during single-stage exercise test on long-term outcome in patients with known or suspected peripheral arterial disease. <i>Coronary Artery Disease</i> , 2008, 19, 603-607.	0.3	16
3589	Treatment of High-Risk Older Persons With Lipid-Lowering Drug Therapy. <i>American Journal of Therapeutics</i> , 2008, 15, 102-107.	0.5	17
3590	Statins for Surgical Patients. <i>Annals of Surgery</i> , 2008, 247, 30-37.	2.1	41
3591	Response to Letter by Paraskevas. <i>Stroke</i> , 2008, 39, .	1.0	0
3592	High-density lipoprotein and atheroma monitoring. <i>Current Opinion in Cardiology</i> , 2008, 23, 386-392.	0.8	1
3593	Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. <i>Current Opinion in Cardiology</i> , 2008, 23, 502-511.	0.8	39
3594	Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008, 15, 142-146.	1.2	15
3595	Statinâ€“Drug Interactions. <i>Cardiology in Review</i> , 2008, 16, 205-212.	0.6	27
3596	Beyond lipid-lowering therapy: does ezetimibe enhance the effects of statins on atherosclerosis?. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 487-489.	0.2	0
3597	Secondary Stroke Prevention. <i>Journal of Cardiovascular Nursing</i> , 2008, 23, 34-41.	0.6	22
3598	Lipid-Lowering Therapy Today. <i>Journal of Cardiovascular Nursing</i> , 2008, 23, 414-421.	0.6	4
3599	Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 803-813.	0.7	34
3600	Association of statin therapy with reduced coronary plaque rupture: an optical coherence tomography study. <i>Coronary Artery Disease</i> , 2008, 19, 237-242.	0.3	40
3601	Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008, 15, 175-181.	1.2	16
3602	Acute Ischemic Coronary Artery Disease and Ischemic Stroke: Similarities and Differences. <i>American Journal of Therapeutics</i> , 2008, 15, 137-149.	0.5	22
3603	The Cholesterol Hypothesis: Questioned?. <i>American Journal of Therapeutics</i> , 2008, 15, 292-295.	0.5	0

#	ARTICLE	IF	CITATIONS
3604	Safety of statins. <i>Current Opinion in Lipidology</i> , 2008, 19, 558-562.	1.2	48
3607	Management of peripheral arterial disease in the elderly: focus on cilostazol. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 17-23.	1.3	11
3608	Managing hypercholesterolemia and its correlation with carotid plaque morphology in patients undergoing carotid endarterectomy. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 1259-1264.	1.0	17
3609	Effect of ramipril on renal function in patients with intermittent claudication. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 471-475.	1.0	1
3610	Complications Resulting from Antiretroviral Therapy for HIV Infection. , 2008, , 181-191.		0
3611	Relative safety profiles of high dose statin regimens. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 525-533.	1.0	37
3613	Application of the Screening for Heart Attack Prevention and Education Task Force Recommendations to an Urban Population<subtitle>Observations From the Dallas Heart Study</subtitle>. <i>Archives of Internal Medicine</i> , 2008, 168, 1055.	4.3	21
3614	Peripheral Arterial Disease Evaluation in the Saudi Project for Assessment of Coronary Events Registry Reveals a Missed Opportunity in Preventing the Adverse Cardiovascular Outcomes: A Pilot Study (SPACE-PAD-I). <i>Clinical Medicine Cardiology</i> , 2008, 2, CMC.S421.	0.1	0
3615	Atorvastatin and cardiovascular risk in the elderly – patient considerations. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 299-314.	1.3	15
3616	Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure. <i>International Heart Journal</i> , 2008, 49, 49-58.	0.5	14
3617	Non-Amyloid Approaches to Neuroprotection. <i>CNS Spectrums</i> , 2008, 13, 42-44.	0.7	0
3618	Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease"A Mendelian Randomisation Study. <i>PLoS ONE</i> , 2008, 3, e2986.	1.1	137
3620	Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting. <i>Journal of Managed Care Pharmacy</i> , 2008, 14, 1-31.	2.2	66
3621	Clinical efficacy and safety of statins in managing cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 341-353.	1.0	106
3622	Almonds Reduce Biomarkers of Lipid Peroxidation in Older Hyperlipidemic Subjects ,. <i>Journal of Nutrition</i> , 2008, 138, 908-913.	1.3	108
3623	Peripheral arterial disease in the elderly. <i>Clinical Interventions in Aging</i> , 2007, Volume 2, 645-654.	1.3	50
3624	Non-Operative or Medical Management of Abdominal Aortic Aneurysm. <i>Scandinavian Journal of Surgery</i> , 2008, 97, 121-124.	1.3	7
3625	The Effects of Rosuvastatin on Plaque Regression in Patients Who Have a Mild to Moderate Degree of Coronary Stenosis With Vulnerable Plaque. <i>Korean Circulation Journal</i> , 2008, 38, 366.	0.7	10

#	ARTICLE	IF	CITATIONS
3626	Statin Treatment as a Confounding Factor in Human Trials with Vitamin E. <i>Journal of Nutrition</i> , 2008, 138, 1179-1181.	1.3	13
3628	DIABETES MELLITUS: OLD ASSUMPTIONS AND NEW REALITIES. , 2008, , 23-32.		0
3630	Statin Reduces C-Reactive Protein and Interleukin-6 in Normocholesterolemic Patients with Acute Coronary Syndrome. <i>Chonnam Medical Journal</i> , 2008, 44, 13.	0.1	2
3631	Vascular risk factors, cognitive decline, and dementia. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 363-381.	1.0	264
3632	Excess coronary artery disease risk in South Asian immigrants: Can dysfunctional high-density lipoprotein explain increased risk?. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 953-961.	1.0	43
3633	Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. <i>Vascular Health and Risk Management</i> , 2008, 5, 31.	1.0	10
3634	Special Patient Populations: Chronic Renal Disease. , 2009, , 500-508.		0
3635	Pleiotropic vasoprotective effects of statins: The chicken or the egg?. <i>Drug Design, Development and Therapy</i> , 2009, 3, 191.	2.0	9
3636	Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. <i>Medical Journal of Australia</i> , 2009, 191, 339-344.	0.8	58
3637	Nicotinic Acid. , 2009, , 298-314.		4
3638	OBSERVATIONAL TRAILS IN LIPIDOLOGY. <i>Rational Pharmacotherapy in Cardiology</i> , 2009, 5, 75-78.	0.3	0
3639	New paradigm of treatment with statins in cardiovascular prevention. <i>Monaldi Archives for Chest Disease</i> , 2009, 72, .	0.3	0
3640	Lipid management in secondary prevention. <i>Practice Nursing</i> , 2009, 20, 592-595.	0.1	0
3641	Reducing morbidity and mortality in high risk patients with statins. <i>Vascular Health and Risk Management</i> , 2009, 5, 495.	1.0	6
3642	Lipid-Modifying and Antiatherosclerotic Drugs. , 2009, , 341-372.		2
3643	Prevalence and risk factors for microalbuminuria in a cross-sectional study of type-2 diabetic patients in Indonesia : a subset of DEMAND study. <i>Medical Journal of Indonesia</i> , 2009, , 124.	0.2	3
3644	Pharmaco-physiological approaches to the high-risk surgical patient. , 0, , 68-83.		0
3646	Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. <i>Vascular Health and Risk Management</i> , 2009, 5, 377.	1.0	30

#	ARTICLE	IF	CITATIONS
3647	Modern Drug Discovery and Development. , 2009, , 361-380.		3
3648	Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. Vascular Health and Risk Management, 2009, 5, 369.	1.0	23
3649	Simvastatin and Amiodarone: Emergence of a Potentially Toxic Interaction. Hospital Pharmacy, 2009, 44, 221-225.	0.4	0
3650	Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use. Clinical Medicine Therapeutics, 2009, 1, CMT.S2370.	0.1	1
3651	Nutraceuticals and Functional Foods for Cholesterol Reduction. , 2009, , 376-386.		1
3652	Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination. Patient Preference and Adherence, 2009, 3, 61.	0.8	5
3653	Surgical Treatment of Carotid Disease. , 2009, , 606-629.		0
3654	Secondary Stroke Prevention, and the Role of Antiplatelet Therapies. Clinical Medicine Therapeutics, 2009, 1, CMT.S2208.	0.1	0
3655	Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia. Open Cardiovascular Medicine Journal, 2009, 3, 57-68.	0.6	5
3657	Importância da HDL-c para a ocorrência de doença cardiovascular no idoso. Arquivos Brasileiros De Cardiologia, 2009, 93, 231-238.	0.3	6
3658	Markers of Inflammation and Risk of Coronary Heart Disease. Disease Markers, 2009, 26, 217-225.	0.6	41
3659	Prevention of atherosclerosis in patients living with HIV. Vascular Health and Risk Management, 2009, 5, 287.	1.0	10
3661	Pre-hospital statin therapy may not reduce incidence of all-cause mortality and overall MACCE during hospital stay after coronary artery bypass graft surgery. Acta Cardiologica, 2009, 64, 253-257.	0.3	8
3662	No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. Thrombosis and Haemostasis, 2009, 101, 157-164.	1.8	19
3664	Risk factors. , 2009, , 16-29.		0
3666	Vascular cognitive impairment: investigation and treatment. , 0, , 372-379.		0
3667	Secondary prevention. , 0, , 272-282.		0
3669	Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. Medical Journal of Australia, 2009, 190, 552-556.	0.8	7

#	ARTICLE	IF	CITATIONS
3670	Combination Therapy for Dyslipidemia. , 2009, , 352-362.		1
3671	Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. Current Medical Research and Opinion, 2009, 25, 2631-2641.	0.9	22
3672	Lipid-Lowering Drugs in Ischemic Stroke Prevention and Their Influence on Acute Stroke Outcome. Cerebrovascular Diseases, 2009, 27, 126-133.	0.8	50
3673	JUPITER: major implications for vascular risk assessment. Current Medical Research and Opinion, 2009, 25, 133-137.	0.9	8
3674	Cholesterol-modifying strategies for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2009, 9, 695-709.	1.4	33
3675	Cholesterol Was Healthy in the End. World Review of Nutrition and Dietetics, 2009, 100, 90-109.	0.1	5
3676	From 4S to IDEAL: the health economics of the statin trials. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 138-143.	3.1	6
3677	How Optimal is the Medical Management of Patients Prior to Major Reconstructive Vascular Surgery? The Results of a Cross-sectional Study. Vascular and Endovascular Surgery, 2009, 43, 238-243.	0.3	7
3678	Statins and cognitive function. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1-2.	0.9	20
3679	Who does not need a statin: too late in end-stage renal disease or heart failure?. Postgraduate Medical Journal, 2009, 85, 187-189.	0.9	5
3680	Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clinical Lipidology, 2009, 4, 291-302.	0.4	59
3681	Cardiovascular disease in patients with renal disease: the role of statins. Current Medical Research and Opinion, 2009, 25, 271-285.	0.9	34
3682	Impact of Decision Support in Electronic Medical Records on Lipid Management in Primary Care. Population Health Management, 2009, 12, 221-226.	0.8	26
3683	Perspectives on low-density lipoprotein cholesterol goal achievement. Current Medical Research and Opinion, 2009, 25, 431-447.	0.9	39
3684	Amino-Terminal Proâ€“B-Type Natriuretic Peptide as Predictor of Mortality in Patients with Symptomatic Peripheral Arterial Disease: 5-Year Follow-Up Data from the Linz Peripheral Arterial Disease Study. Clinical Chemistry, 2009, 55, 68-77.	1.5	35
3685	Low HDL Cholesterol Is Associated With the Risk of Stroke in Elderly Diabetic Individuals. Diabetes Care, 2009, 32, 1221-1223.	4.3	36
3686	Pharmacotherapy of coronary atherosclerosis. Expert Opinion on Pharmacotherapy, 2009, 10, 1587-1603.	0.9	26
3687	The Influence of Hyperlipidemia on Platelet Activity Markers in Patients after Ischemic Stroke. Cerebrovascular Diseases, 2009, 27, 131-137.	0.8	14

#	ARTICLE	IF	CITATIONS
3688	Vascular Intervention in Stroke Prevention: Endarterectomy and Angioplasty. <i>Cerebrovascular Diseases</i> , 2009, 27, 134-139.	0.8	5
3689	Statins for Asymptomatic Middle Cerebral Artery Stenosis: The Regression of Cerebral Artery Stenosis Study. <i>Cerebrovascular Diseases</i> , 2009, 28, 18-25.	0.8	27
3690	Management of Hyperlipidemia in Older Adults. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 49-58.	1.0	34
3691	Statins. , 2009, , 253-280.		5
3692	A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events â€œ Reduction of Cholesterol to Key European Targets Trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 712-721.	3.1	17
3693	High-Dose Lovastatin for Acute Ischemic Stroke: Results of the Phase I Dose Escalation Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART). <i>Cerebrovascular Diseases</i> , 2009, 28, 266-275.	0.8	61
3694	High Dietary Taurine Reduces Apoptosis and Atherosclerosis in the Left Main Coronary Artery. <i>Hypertension</i> , 2009, 53, 1017-1022.	1.3	64
3695	Risk Factors in First Presentation Acute Coronary Syndromes (ACS): How Do We Move From Population to Individualized Risk Prediction?. <i>Angiology</i> , 2009, 60, 663-667.	0.8	10
3696	Flax Lignan Complex Slows Down the Progression of Atherosclerosis in Hyperlipidemic Rabbits. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 38-48.	1.0	35
3697	Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy. <i>Vascular Medicine</i> , 2009, 14, 21-27.	0.8	2
3698	Still a long way to go to defeating atherosclerotic disease: a call to arms!. <i>European Heart Journal</i> , 2009, 30, 2297-2299.	1.0	1
3699	Update of secondary stroke prevention. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1718-1724.	0.4	10
3700	Long-term trends in use of and expenditures for cardiovascular medications in Canada. <i>Cmaj</i> , 2009, 181, E19-E28.	0.9	24
3701	Towards companion diagnostics for the management of statin therapy. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 659-671.	1.6	0
3702	Relationships Among Regional Arterial Inflammation, Calcification, Risk Factors, and Biomarkers. <i>Circulation: Cardiovascular Imaging</i> , 2009, 2, 107-115.	1.3	227
3703	From Here to JUPITER. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 41-48.	0.9	48
3704	Applying the Evidence. <i>Stroke</i> , 2009, 40, 1417-1424.	1.0	64
3705	Peripheral arterial disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2009, 70, 560-565.	0.2	10

#	ARTICLE	IF	CITATIONS
3706	Peripheral Arterial Disease: Considerations in Risks, Diagnosis, and Treatment. <i>Journal of the National Medical Association</i> , 2009, 101, 999-1008.	0.6	31
3707	Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients. <i>Journal of Investigative Medicine</i> , 2009, 57, 495-499.	0.7	106
3708	The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. <i>European Heart Journal</i> , 2009, 30, 2137-2146.	1.0	99
3709	Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 345-352.	1.4	37
3710	Predictors, Barriers, and Facilitators of Lipid-Lowering Medication Use Among African Americans in a Primary Care Clinic. <i>Journal of the National Medical Association</i> , 2009, 101, 944-952.	0.6	4
3711	The Burden of Peripheral Artery Disease and the Role of Antiplatelet Therapy. <i>Postgraduate Medicine</i> , 2009, 121, 123-135.	0.9	13
3712	Traditional Clinical Risk Assessment Tools Do Not Accurately Predict Coronary Atherosclerotic Plaque Burden: A CT Angiography Study. <i>American Journal of Roentgenology</i> , 2009, 192, 235-243.	1.0	74
3714	Opinion: The case for advertising pharmaceuticals direct to consumers. <i>Future Medicinal Chemistry</i> , 2009, 1, 587-592.	1.1	11
3715	Statins in heart failure: Retrospective cohort study using routine primary care data. <i>Annals of Medicine</i> , 2009, 41, 490-496.	1.5	5
3716	Combined Effects Of Organizational And Professional Identification On The Reciprocity Dynamic For Professional Employees. <i>Academy of Management Journal</i> , 2009, 52, 506-526.	4.3	198
3717	Use of Statins for the Treatment of Spontaneous Intracerebral Hemorrhage: Results of a Pilot Study. <i>Central European Neurosurgery</i> , 2009, 70, 15-20.	0.7	54
3718	Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets. <i>Current Medicinal Chemistry</i> , 2009, 16, 94-112.	1.2	237
3719	Dyslipidemia as a Risk Factor for Ischemic Stroke. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1291-1297.	1.0	69
3720	Does eicosapentaenoic acid truly reduce atherosclerosis?. <i>Hypertension Research</i> , 2009, 32, 934-935.	1.5	1
3721	Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. <i>Current Psychiatry Reviews</i> , 2009, 5, 73-92.	0.9	112
3722	Hypercholesterolaemia. <i>InnovAiT</i> , 2009, 2, 721-731.	0.0	0
3723	The effect of dyslipidemic drugs on mortality: A meta-analysis. <i>Indian Journal of Pharmacology</i> , 2009, 41, 4.	0.4	4
3724	Comparison of LDL Cholesterol Concentrations by Friedewald Calculation and Direct Measurement in Relation to Cardiovascular Events in 27 331 Women. <i>Clinical Chemistry</i> , 2009, 55, 888-894.	1.5	153

#	ARTICLE	IF	CITATIONS
3725	Vascular Factors and Markers of Inflammation in Offspring With a Parental History of Late-Onset Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2009, 66, 1263.	13.8	73
3726	Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 546-551.	0.5	63
3727	Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 404-423.	3.1	48
3728	Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 180-187.	3.1	12
3729	The Vytorin on Carotid Media Thickness and Overall Arterial Rigidity (VYCTOR) study. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1057-1060.	0.6	1
3730	Lipoprotein Oxidation and Modification. , 2009, , 93-110.		2
3731	Ten-Year Survival in 75-Year-Old Men and Women: Predictive Ability of Total Cholesterol, HDL-C, and LDL-C. <i>Current Gerontology and Geriatrics Research</i> , 2009, 2009, 1-7.	1.6	18
3732	Cost, Effectiveness, and Cost-Effectiveness. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 49-54.	0.9	37
3733	Evidence for Statin Pleiotropy in Humans. <i>Circulation</i> , 2009, 119, 131-138.	1.6	208
3734	Metabolic Consequences of Sleep-Disordered Breathing. <i>ILAR Journal</i> , 2009, 50, 289-306.	1.8	88
3735	Peripheral arterial disease and cognitive function. <i>Vascular Medicine</i> , 2009, 14, 51-61.	0.8	61
3736	Years needed to treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. <i>European Journal of Heart Failure</i> , 2009, 11, 256-263.	2.9	11
3737	Cholesterol in Alzheimers Disease: Unresolved Questions. <i>Current Alzheimer Research</i> , 2009, 6, 15-29.	0.7	123
3738	Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. <i>Kidney International</i> , 2009, 76, 1172-1179.	2.6	14
3739	Is It Possible to Treat Vascular Dementia?. <i>Frontiers of Neurology and Neuroscience</i> , 2009, 24, 95-106.	3.0	6
3740	Pravastatin for Cardiovascular Event Primary Prevention in Patients With Mild-to-Moderate Hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. <i>Hypertension</i> , 2009, 53, 135-141.	1.3	32
3741	Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 963-968.	1.1	37
3742	Statins for all: the new premed?. <i>British Journal of Anaesthesia</i> , 2009, 103, 99-107.	1.5	32

#	ARTICLE	IF	CITATIONS
3743	Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. <i>Journal of Lipid Research</i> , 2009, 50, 1463-1471.	2.0	72
3744	Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe?. <i>Future Cardiology</i> , 2009, 5, 129-139.	0.5	1
3745	Significance of Close Surveillance of Patients with Peripheral Arterial Disease. <i>Angiology</i> , 2009, 60, 462-467.	0.8	2
3746	Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event. <i>Cardiology</i> , 2009, 113, 89-97.	0.6	5
3747	LDL-Cholesterol is the King. <i>Angiology</i> , 2009, 60, 387-388.	0.8	0
3748	Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract. <i>Current Pharmaceutical Design</i> , 2009, 15, 490-516.	0.9	50
3749	Evaluation of Lipid Profiles and the Use of Omega-3 Essential Fatty Acid in Professional Football Players. <i>Sports Health</i> , 2009, 1, 21-30.	1.3	16
3750	Cardiovascular Benefit of Magnitude of Low-Density Lipoprotein Cholesterol Reduction. <i>Circulation</i> , 2009, 120, 1491-1497.	1.6	29
3751	Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. <i>Neurology</i> , 2009, 72, 688-694.	1.5	86
3752	Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 65-72.	0.9	59
3753	Clinical Insights From the Treating to New Targets Trial. <i>Progress in Cardiovascular Diseases</i> , 2009, 51, 487-502.	1.6	6
3754	Antiatherosclerotic and Anti-Insulin Resistance Effects of Adiponectin: Basic and Clinical Studies. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 126-140.	1.6	94
3755	An update on preventive and regenerative therapies in diabetes mellitus. , 2009, 121, 317-331.		47
3756	Statins and cardioprotection " More than just lipid lowering?. , 2009, 122, 30-43.		164
3757	The role of statins in chronic kidney disease (CKD): Friend or foe?. , 2009, 122, 312-323.		20
3758	Cardiac fibroblasts: At the heart of myocardial remodeling. , 2009, 123, 255-278.		864
3759	Synergy research: Vitamins and secondary plant components in the maintenance of the redox-homeostasis and in cell signaling. <i>Phytomedicine</i> , 2009, 16, 2-16.	2.3	53
3760	Adolescent type 1 Diabetes cardio-renal Intervention Trial (AddIT). <i>BMC Pediatrics</i> , 2009, 9, 79.	0.7	58

#	ARTICLE	IF	CITATIONS
3761	The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease: a cohort study. <i>BMC Health Services Research</i> , 2009, 9, 198.	0.9	12
3762	Pharmacologic Therapy for Intermittent Claudication. <i>Pharmacotherapy</i> , 2009, 29, 526-553.	1.2	10
3763	Statin-Associated Adverse Cognitive Effects: Survey Results from 171 Patients. <i>Pharmacotherapy</i> , 2009, 29, 800-811.	1.2	166
3764	Î²-Receptor Selectivity of Carvedilol and Metoprolol Succinate in Patients with Heart Failure (SELECT) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 26	1.2	15
3765	Factors Associated with Recurrent Coronary Events Among Patients with Cardiovascular Disease. <i>Pharmacotherapy</i> , 2009, 29, 906-913.	1.2	8
3766	Low-Density Lipoprotein Reduction and Magnitude of Cardiovascular Risk Reduction. <i>Preventive Cardiology</i> , 2009, 12, 80-87.	1.1	9
3767	Coronary Heart Disease and Dyslipidemia: A Cross-Sectional Evaluation of Prevalence, Current Treatment, and Clinical Control in a Large Cohort of Spanish High-Risk Patients: The PRINCEPS Study. <i>Preventive Cardiology</i> , 2009, 12, 65-71.	1.1	9
3768	Blood Pressure-Lowering Treatment Should Be Offered to All Patients Regardless of Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2009, 11, 698-701.	1.0	0
3769	The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: II. Therapeutic Management of Atherogenic Dyslipidemia. <i>Journal of Clinical Hypertension</i> , 2009, 11, 520-527.	1.0	20
3770	Statin Use Is Associated With Improved Survival in Patients With Advanced Heart Failure Receiving Resynchronization Therapy. <i>Congestive Heart Failure</i> , 2009, 15, 159-164.	2.0	7
3771	The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. <i>Clinical Therapeutics</i> , 2009, 31, 236-244.	1.1	144
3772	Endovascular Treatment of Peripheral Vascular Disease. <i>Current Problems in Cardiology</i> , 2009, 34, 359-476.	1.1	23
3773	Ten-Year All-Cause Mortality in Presumably Healthy Subjects on Lipid-Lowering Drugs (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 26 <i>Journal of Cardiology</i> , 2009, 103, 381-386.	0.7	31
3774	Comparison of Effects of Rosuvastatin (10 mg) Versus Atorvastatin (40 mg) on Rho Kinase Activity in Caucasian Men With a Previous Atherosclerotic Event. <i>American Journal of Cardiology</i> , 2009, 103, 437-441.	0.7	69
3775	Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials. <i>American Journal of Cardiology</i> , 2009, 104, 3E-9E.	0.7	18
3776	High-Density Lipoprotein and Progression Rate of Atherosclerosis in Intravascular Ultrasound Trials. <i>American Journal of Cardiology</i> , 2009, 104, 16E-21E.	0.7	7
3777	High-Density Lipoprotein Cholesterol as a Risk Factor and Target of Therapy after Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2009, 104, 46E-51E.	0.7	11
3778	Who Benefits Most from Intervention for Asymptomatic Carotid Stenosis: Patients or Professionals?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2009, 37, 625-632.	0.8	150

#	ARTICLE	IF	CITATIONS
3779	The influence of age on the association between cholesterol and cognitive function. <i>Experimental Gerontology</i> , 2009, 44, 112-122.	1.2	63
3780	Prevention and management of stroke in very elderly patients. <i>Lancet Neurology</i> , The, 2009, 8, 1031-1041.	4.9	66
3781	Risk Factors for Lower-Extremity Vein Graft Failure. <i>Seminars in Vascular Surgery</i> , 2009, 22, 216-226.	1.1	31
3782	What is the Optimum Perioperative Drug Therapy Following Lower-Extremity Vein Bypass Surgery?. <i>Seminars in Vascular Surgery</i> , 2009, 22, 245-251.	1.1	3
3783	Guiding clinical decisions on abdominal obesity and cardiometabolic risk. <i>Clinical Cornerstone</i> , 2009, 9, 43-54.	1.0	2
3785	Control de los factores de riesgo y tratamiento de la enfermedad arterial oclusiva. <i>Annals of Vascular Surgery</i> , 2009, 23, 28-36.	0.0	0
3786	La enfermedad polivascular aterotrombótica: un enemigo común y distintos frentes. <i>Revista Espanola De Cardiologia Suplementos</i> , 2009, 9, 4-10.	0.2	1
3788	El control del colesterol en prevención primaria. ¿Cuanto más bajo, mejor?. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2009, 16, 449-451.	0.0	0
3789	The prevention of dementia. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 452-458.	1.3	43
3790	Evidence-based Practice Guideline for the Treatment of CKD. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 537-566.	0.7	106
3791	Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. <i>European Journal of Health Economics</i> , 2009, 10, 255-265.	1.4	27
3793	Presentation and medical management of peripheral arterial disease in general practice: rationale, aims, design and baseline results of the PACE-PAD Study. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2009, 17, 127-135.	0.8	4
3794	Section Original article. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2009, 17, 425-432.	0.8	4
3795	Effects of statins on the progression of cerebral white matter lesion. <i>Journal of Neurology</i> , 2009, 256, 750-757.	1.8	91
3796	Effect of high dose statin therapy on platelet function; statins reduce aspirin resistant platelet aggregation in patients with coronary heart disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 24-28.	1.0	44
3797	Coronary Artery Diseases in South Asian Immigrants: An Update on High Density Lipoprotein Role in Disease Prevention. <i>Journal of Immigrant and Minority Health</i> , 2009, 11, 415-421.	0.8	7
3798	Management of the statin-intolerant patient. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 263-271.	0.4	10
3799	Low-density lipoprotein apheresis as a treatment option for hyperlipidemia. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 279-288.	0.4	24

#	ARTICLE	IF	CITATIONS
3800	Achieving optimum lipid-lowering goals in patients with vascular disease. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 323-330.	0.8	0
3801	Evolving concepts of cardiovascular disease prevention in older adults. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 366-373.	0.8	0
3802	Chronische periphere arterielle Verschlusskrankheit (PAVK). <i>Wiener Klinische Wochenschrift Education</i> , 2009, 4, 67-76.	0.0	0
3803	An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care. <i>Irish Journal of Medical Science</i> , 2009, 178, 179-186.	0.8	14
3804	How do you treat patients with myalgia who take statins?. <i>Current Atherosclerosis Reports</i> , 2009, 11, 9-14.	2.0	20
3805	Should we treat all patients with coronary heart disease or the equivalent with statins?. <i>Current Atherosclerosis Reports</i> , 2009, 11, 28-35.	2.0	1
3806	A review of trials evaluating nonstatin lipid-lowering therapies. <i>Current Atherosclerosis Reports</i> , 2009, 11, 64-66.	2.0	0
3807	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. <i>Current Atherosclerosis Reports</i> , 2009, 11, 243-244.	2.0	13
3808	Chronic kidney disease and statins: Improving cardiovascular outcomes. <i>Current Atherosclerosis Reports</i> , 2009, 11, 301-308.	2.0	8
3809	Review of the SPARCL trial and its subanalyses. <i>Current Atherosclerosis Reports</i> , 2009, 11, 315-321.	2.0	8
3810	Lipid-lowering drugs and risk for cancer. <i>Current Atherosclerosis Reports</i> , 2009, 11, 350-357.	2.0	7
3811	The role of cholesterol and statins in stroke. <i>Current Cardiology Reports</i> , 2009, 11, 4-11.	1.3	14
3812	AURORA and JUPITER trials: Recognizing the limitations and expanding the benefits of statin treatment. <i>Current Cardiology Reports</i> , 2009, 11, 401-403.	1.3	1
3813	Treatment of hypertension in patients with peripheral arterial disease: An update. <i>Current Hypertension Reports</i> , 2009, 11, 271-276.	1.5	8
3814	An update on treatment and prevention strategies for Alzheimer's disease. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 368-376.	2.0	39
3816	Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. <i>Advances in Therapy</i> , 2009, 26, 469-487.	1.3	13
3817	Validated treatments and therapeutics perspectives regarding pharmacological products for sarcopenia. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 746-756.	1.5	34
3818	Statins may reduce breast cancer risk, particularly hormone receptor-negative disease. <i>Current Breast Cancer Reports</i> , 2009, 1, 148-156.	0.5	13

#	ARTICLE	IF	CITATIONS
3820	Treatment of Chronic CAD – Do the Guidelines (ESC, AHA) Reflect Daily Practice?. Herz, 2009, 34, 39-54.	0.4	5
3821	Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients. Heart and Vessels, 2009, 24, 340-346.	0.5	14
3822	Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study. European Journal of Clinical Pharmacology, 2009, 65, 1071-1080.	0.8	17
3823	Systematic Review and Metaanalysis of Statins for Heterozygous Familial Hypercholesterolemia in Children: Evaluation of Cholesterol Changes and Side Effects. Pediatric Cardiology, 2009, 30, 482-489.	0.6	39
3824	Update on statin-mediated anti-inflammatory activities in atherosclerosis. Seminars in Immunopathology, 2009, 31, 127-142.	2.8	79
3825	A randomized, multicentre, open-label, parallel-group trial to compare the efficacy and safety profile of daming capsule in patients with hypercholesterolemia. Phytotherapy Research, 2009, 23, 1039-1042.	2.8	24
3826	Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clinical Pharmacology, 2009, 9, 6.	2.5	60
3827	Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovascular Diabetology, 2009, 8, 25.	2.7	42
3828	Cardiovascular magnetic resonance in carotid atherosclerotic disease. Journal of Cardiovascular Magnetic Resonance, 2009, 11, 53.	1.6	27
3829	Influence of statin treatment on platelet inhibition by clopidogrel – a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. Journal of Internal Medicine, 2009, 266, 457-466.	2.7	42
3830	Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology, 2009, 67, 99-109.	1.1	200
3831	Pharmacology, basic & clinical: contrasts & coherence. British Journal of Clinical Pharmacology, 2009, 67, 383-385.	1.1	0
3832	The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development. Clinical Pharmacology and Therapeutics, 2009, 86, 32-43.	2.3	60
3833	Biologic Effects of Simvastatin in Patients with Aneurysmal Subarachnoid Hemorrhage: A Double-Blind, Placebo-Controlled Randomized Trial. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1444-1453.	2.4	118
3834	Is There a Role for Statins in Atrial Fibrillation?. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1063-1072.	0.5	9
3835	Preventing coronary heart disease and stroke with aggressive statin therapy in older adults using a team management model. Journal of the American Academy of Nurse Practitioners, 2009, 21, 47-53.	1.4	9
3836	Emerging concepts in cardiovascular disease risk assessment: Where do women fit in?. Journal of the American Academy of Nurse Practitioners, 2009, 21, 480-487.	1.4	3
3837	Identification of patients at risk of ischemic events for long-term secondary prevention. Journal of the American Academy of Nurse Practitioners, 2009, 21, 677-689.	1.4	5

#	ARTICLE	IF	CITATIONS
3838	Statin treatment after a recent TIA or stroke: is effectiveness shown in randomized clinical trials also observed in everyday clinical practice?. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 15-20.	1.0	9
3839	Prevalence of low HDL cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS study. <i>International Journal of Clinical Practice</i> , 2009, 63, 71-81.	0.8	17
3840	Resurrecting an old drug - a flash in the pan or here to stay?. <i>International Journal of Clinical Practice</i> , 2009, 63, 3-6.	0.8	4
3841	Lipid-altering efficacy of ezetimibe/simvastatin 10/20mg compared with rosuvastatin 10mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. <i>International Journal of Clinical Practice</i> , 2009, 63, 547-559.	0.8	62
3842	(TTA)n Polymorphism in 3-Hydroxy-3-Methylglutaryl-Coenzyme A and Response to Atorvastatin in Coronary Artery Disease Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 211-215.	1.2	7
3843	Rosuvastatin Attenuates Heart Failure and Cardiac Remodelling in the Ageing Spontaneously Hypertensive Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 105, 262-270.	1.2	10
3844	How many Australian deaths from heart disease and stroke could be avoided by a small reduction in population cholesterol levels?. <i>Nutrition and Dietetics</i> , 2009, 66, 158-163.	0.9	2
3845	Status and rationale of renoprotection studies in adolescents with type 1 diabetes. <i>Pediatric Diabetes</i> , 2009, 10, 347-355.	1.2	17
3846	Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. <i>Diabetic Medicine</i> , 2009, 26, 532-539.	1.2	14
3847	Statins decrease dendritic arborization in rat sympathetic neurons by blocking RhoA activation. <i>Journal of Neurochemistry</i> , 2009, 108, 1057-1071.	2.1	44
3848	Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 687-692.	1.0	30
3849	Effects of Statin Treatments on Coronary Plaques Assessed by Volumetric Virtual Histology Intravascular Ultrasound Analysis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 679-688.	1.1	97
3850	Late Clinical Events After Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 504-512.	1.1	44
3851	Acute coronary syndrome - an overview of current management. <i>The Prescriber</i> , 2009, 20, 18-27.	0.1	0
3852	Preoperative statin treatment reduces systemic inflammatory response and myocardial damage in cardiac surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 998-1005.	0.6	43
3853	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 735-748.	0.6	37
3854	Greasing the wheels of A β clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E. <i>BioFactors</i> , 2009, 35, 239-248.	2.6	94
3855	Cholesterol Goals: Moving from Numbers to Treatment. <i>Clinical Cardiology</i> , 2009, 32, 106-108.	0.7	0

#	ARTICLE	IF	CITATIONS
3856	Statins as Antiarrhythmics: A Systematic Review Part II: Effects on Risk of Ventricular Arrhythmias. <i>Clinical Cardiology</i> , 2009, 32, 549-552.	0.7	23
3857	The Gender Differences in Baseline Characteristics and Statin Intervention Among Outpatients with Coronary Heart Disease in China: The China Cholesterol Education Program. <i>Clinical Cardiology</i> , 2009, 32, 308-314.	0.7	15
3858	Hypercholesterolemia Paradox in Relation to Mortality in Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2009, 32, E22-8.	0.7	66
3859	Statin Therapy in Patients with Diastolic Heart Failure. <i>Clinical Cardiology</i> , 2010, 33, E1-5.	0.7	15
3860	Acute Coronary Syndrome in the Elderly. <i>Clinical Cardiology</i> , 2009, 32, 608-613.	0.7	18
3861	Statins as Antiarrhythmics: A Systematic Review Part I: Effects on Risk of Atrial Fibrillation. <i>Clinical Cardiology</i> , 2009, 32, 544-548.	0.7	15
3862	Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. <i>Clinical Cardiology</i> , 2005, 28, 19-27.	0.7	7
3863	The patient with cardiovascular disease: Treatment strategies for preventing major events. <i>Clinical Cardiology</i> , 2009, 29, 4-12.	0.7	1
3864	The patient with diabetes: Preventing cardiovascular complications. <i>Clinical Cardiology</i> , 2009, 29, 13-20.	0.7	9
3865	Strategies for primary and secondary stroke prevention. <i>Clinical Cardiology</i> , 2009, 29, 21-27.	0.7	4
3866	Morbilidad y mortalidad secundaria a complicaciones cardiológicas despu�s de la revascularizaci�n de extremidad por isquemia cr�nica. <i>Annals of Vascular Surgery</i> , 2009, 23, 642-657.	0.0	0
3867	Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective oxidation vs random chain reactions. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 1375-1385.	6.6	103
3868	Cardiovascular risk factors in patients with chronic kidney disease. <i>Nature Reviews Cardiology</i> , 2009, 6, 580-589.	6.1	61
3869	Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. <i>Current Medical Research and Opinion</i> , 2009, 25, 2755-2764.	0.9	68
3870	Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 13-17.	0.9	319
3871	Effect of rosuvastatin on concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma high-sensitivity C-reactive protein in hypercholesterolemic patients with and without type 2 diabetes mellitus: A 12-week, open-label, pilot study. <i>Current Therapeutic Research</i> , 2009, 70, 439-448.	0.5	5
3872	Endothelial dysfunction and cardiovascular risk factors. <i>Diabetes Research and Clinical Practice</i> , 2009, 84, 1-10.	1.1	115
3873	Secondary stroke prevention in the elderly: New evidence in hypertension and hyperlipidemia. <i>European Journal of Internal Medicine</i> , 2009, 20, 586-590.	1.0	32

#	ARTICLE	IF	CITATIONS
3874	Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. <i>Biomedicine and Pharmacotherapy</i> , 2009, 63, 19-26.	2.5	18
3875	Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 481-490.	1.1	29
3877	Conversion to Tacrolimus and Atorvastatin in Cyclosporine-treated Heart Transplant Recipients With Dyslipidemia Refractory to Fluvastatin. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 598-604.	0.3	14
3878	Statins in the treatment of heart failure. <i>International Journal of Cardiology</i> , 2009, 132, 124-126.	0.8	1
3879	Changing trends (1986â€“2003) in the use of lipid lowering medication in patients hospitalized with acute myocardial infarction: A community-based perspective. <i>International Journal of Cardiology</i> , 2009, 132, 66-74.	0.8	5
3880	Do statins decrease cardiovascular disease at the expense of increasing cancer?. <i>International Journal of Cardiology</i> , 2009, 133, 254-255.	0.8	5
3881	Prediction of 10-year coronary heart disease risk in Caribbean type 2 diabetic patients using the UKPDS risk engine. <i>International Journal of Cardiology</i> , 2009, 132, 348-353.	0.8	8
3882	The clinical presentation of restenosis after bare metal stent implantation: Behind a facade of benignity. <i>International Journal of Cardiology</i> , 2009, 135, 401-403.	0.8	1
3883	Should statins be given routinely in all coronary patients?. <i>International Journal of Cardiology</i> , 2009, 135, 399-401.	0.8	0
3884	Risk factors for cardiovascular disease in women. <i>Maturitas</i> , 2009, 63, 186-190.	1.0	75
3885	Peripheral arterial disease in women. <i>Maturitas</i> , 2009, 64, 204-211.	1.0	20
3886	LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE). <i>Journal of Clinical Epidemiology</i> , 2009, 62, 328-336.	2.4	13
3887	Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. <i>American Heart Journal</i> , 2009, 157, 111-117.e2.	1.2	270
3888	Renal function, atherothrombosis extent, and outcomes in high-risk patients. <i>American Heart Journal</i> , 2009, 158, 141-148.e1.	1.2	51
3889	Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study. <i>American Heart Journal</i> , 2009, 158, 509-512.e1.	1.2	8
3890	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009, 158, 896-901.e3.	1.2	184
3891	The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment. <i>American Journal of Medicine</i> , 2009, 122, S3-S14.	0.6	422
3892	Effect of Statin Adherence on Cerebrovascular Disease in Primary Prevention. <i>American Journal of Medicine</i> , 2009, 122, 647-655.	0.6	56

#	ARTICLE	IF	CITATIONS
3893	Outcomes After Stroke: Risk of Recurrent Ischemic Stroke and Other Events. American Journal of Medicine, 2009, 122, S7-S13.	0.6	47
3894	High-density lipoprotein cholesterol and triglycerides in the statin era: A pending issue?. Archives of Cardiovascular Diseases, 2009, 102, 165-167.	0.7	0
3895	Meta-Analysis of the Relationship Between Non-HDL Cholesterol Reduction and Coronary Heart Disease Risk. Journal of the American College of Cardiology, 2009, 53, 316-322.	1.2	327
3896	Statins in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 1425-1433.	1.2	32
3897	Early Statin Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 1434-1437.	1.2	24
3898	Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function. Journal of the American College of Cardiology, 2009, 54, 1787-1794.	1.2	237
3899	Beyond Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2009, 55, 35-41.	1.2	268
3900	Clinical Outcomes and Cost-Effectiveness of Coronary Computed Tomography Angiography in the Evaluation of Patients With Chest Pain. Journal of the American College of Cardiology, 2009, 54, 2409-2422.	1.2	84
3901	Not so choppy SEAS. Journal of Clinical Lipidology, 2009, 3, 11-13.	0.6	1
3902	Is HDL function as important as HDL quantity in the coronary artery disease risk assessment?. Journal of Clinical Lipidology, 2009, 3, 70-77.	0.6	23
3903	Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study. Journal of Clinical Lipidology, 2009, 3, 109-118.	0.6	26
3904	Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients. Journal of Clinical Lipidology, 2009, 3, 195-200.	0.6	2
3905	Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 389-400.	2.2	22
3906	Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biological Psychiatry, 2009, 66, 1013-1022.	0.7	91
3907	Metabolic syndrome: A review of emerging markers and management. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2009, 3, 240-254.	1.8	15
3909	Rationale präoperative Risikoabschätzung - I. Kardiale und pulmonale Risikoabschätzung bei nicht-kardio-pulmonalen Operationen. Perioperative Medizin, 2009, 1, 15-30.	0.1	2
3910	Therapeutic potential of statins in Alzheimer's disease. Journal of the Neurological Sciences, 2009, 283, 230-234.	0.3	99
3911	The benefit of statins in non-cardiac vascular surgery patients. Journal of Vascular Surgery, 2009, 49, 260-265.	0.6	41

#	ARTICLE	IF	CITATIONS
3912	What a vascular surgeon should know and do about atherosclerotic risk factors. <i>Journal of Vascular Surgery</i> , 2009, 49, 1348-1354.	0.6	27
3913	Regarding "Suboptimal use of statin therapy in elderly patients with atherosclerosis: A population-based study". <i>Journal of Vascular Surgery</i> , 2009, 49, 1632-1633.	0.6	0
3917	Effects on Coronary Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol with Statins. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 109-115.	1.0	18
3918	Androgenic Anabolic Steroid Abuse and the Cardiovascular System. <i>Handbook of Experimental Pharmacology</i> , 2009, , 411-457.	0.9	94
3919	Statins and stroke prevention. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1231-1243.	0.6	20
3920	Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 79-97.	1.2	84
3921	The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 838-847.	1.0	68
3922	Statins for the prevention of dementia. , 2009, , CD003160.		131
3923	Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. <i>Current Medical Research and Opinion</i> , 2009, 25, 2621-2629.	0.9	7
3924	Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. <i>Lipids in Health and Disease</i> , 2009, 8, 56.	1.2	8
3925	Lipid-Lowering Therapy for the Primary Prevention of Cardiovascular Disease in the Elderly. <i>Drugs and Aging</i> , 2009, 26, 917-931.	1.3	14
3926	Secondary Stroke Prevention Strategies for the Oldest Patients. <i>Drugs and Aging</i> , 2009, 26, 209-230.	1.3	18
3927	Simplifying the Approach to the Management of Dyslipidemia. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2148.	3.8	12
3928	Chronic Coronary Artery Disease: Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1130-1146.	1.4	211
3930	Morbidity and Mortality Caused by Cardiac Adverse Events after Revascularization for Critical Limb Ischemia. <i>Annals of Vascular Surgery</i> , 2009, 23, 583-597.	0.4	16
3931	Lipid Management in the Geriatric Patient. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 185-206.	1.2	5
3932	Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 85-93.	0.6	2
3933	Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1171-1186.	1.4	30

#	ARTICLE	IF	CITATIONS
3934	Consuming Functional Foods Enriched with Plant Sterol or Stanol Esters for 85 Weeks Does Not Affect Neurocognitive Functioning or Mood in Statin-Treated Hypercholesterolemic Individuals. <i>Journal of Nutrition</i> , 2009, 139, 1368-1373.	1.3	17
3935	Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan. <i>Current Medical Research and Opinion</i> , 2009, 25, 205-213.	0.9	6
3936	Statins and the risk of Parkinson disease: an update on the controversy. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 261-271.	1.0	17
3937	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 955-966.	0.9	3
3938	Effect of Time to Titration to Maximum Dose of Statins on Cardiovascular Outcomes. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 103-107.	1.0	5
3939	Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 299-308.	1.0	5
3940	Role and significance of statins in the treatment of hypertensive patients. <i>Current Medical Research and Opinion</i> , 2009, 25, 1995-2005.	0.9	40
3941	Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 753-761.	2.5	2
3942	Ezetimibe/simvastatin. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 715-725.	1.0	8
3943	Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category. <i>Metabolic Syndrome and Related Disorders</i> , 2009, 7, 601-610.	0.5	9
3944	Statin Effects on LDL and HDL Cholesterol in South Asian and White Populations. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 831-837.	1.0	25
3945	Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 475-484.	0.7	48
3946	Impact of peripheral arterial disease in patients with diabetes—Results from PROactive (PROactive 11). <i>Atherosclerosis</i> , 2009, 202, 272-281.	0.4	75
3947	Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. <i>Atherosclerosis</i> , 2009, 202, 48-57.	0.4	39
3948	Why to screen heart disease in diabetes. <i>Atherosclerosis</i> , 2009, 204, 11-15.	0.4	4
3949	Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2009, 204, 483-490.	0.4	107
3950	Patterns of statin prescription in acute myocardial infarction. <i>Atherosclerosis</i> , 2009, 204, 491-496.	0.4	16
3951	Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Atherosclerosis</i> , 2009, 204, e86-e92.	0.4	220

#	ARTICLE	IF	CITATIONS
3952	Pravastatin and cardiovascular risk in moderate chronic kidney disease. <i>Atherosclerosis</i> , 2009, 206, 512-517.	0.4	76
3953	Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. <i>Atherosclerosis</i> , 2009, 207, 139-143.	0.4	142
3954	Novel uses for statins in surgical patients. <i>International Journal of Surgery</i> , 2009, 7, 285-290.	1.1	10
3955	Current Strategies and Recent Advances in the Therapy of Hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2009, 10, 1-4.	1.2	4
3956	Efficacy of alternate day versus daily dosing of rosuvastatin. <i>Canadian Journal of Cardiology</i> , 2009, 25, e28-e31.	0.8	18
3957	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult â€” 2009 recommendations. <i>Canadian Journal of Cardiology</i> , 2009, 25, 567-579.	0.8	653
3958	Can the polypill save the world from heart disease?. <i>Lancet, The</i> , 2009, 373, 1313-1314.	6.3	31
3961	Non-adherence to statin therapy: a major challenge for preventive cardiology. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2973-2985.	0.9	114
3962	Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. <i>Cardiovascular Therapeutics</i> , 2009, 27, 199-215.	1.1	10
3963	Drug Treatment and Cost of Cardiovascular Disease in Australia. <i>Cardiovascular Therapeutics</i> , 2009, 27, 164-172.	1.1	14
3964	Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 358-374.	1.9	129
3965	Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. <i>Mayo Clinic Proceedings</i> , 2009, 84, 741-757.	1.4	111
3966	Cardiovascular Disease in Women. <i>Primary Care - Clinics in Office Practice</i> , 2009, 36, 73-102.	0.7	9
3967	Morbidit� et mortalit� d'origine cardiaque apr�s revascularisation pour isch�mie critique. <i>Annales De Chirurgie Vasculaire</i> , 2009, 23, 632-646.	0.0	0
3968	Lipid Management in Chronic Kidney Disease, Hemodialysis, and Transplantation. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 223-234.	1.2	8
3969	Prevention of Cardiovascular Disease in Chronic Kidney Disease Patients. <i>Seminars in Nephrology</i> , 2009, 29, 24-29.	0.6	6
3970	Quand doit-on d�pister lâ€™art�riopathie oblit�rante des membres inf�rieurs? Quelle strat�gie m�dicale proposer??. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2009, 2009, 13-24.	0.0	0
3971	Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly. <i>Seminars in Nephrology</i> , 2009, 29, 610-620.	0.6	18

#	ARTICLE	IF	CITATIONS
3972	Managing Statin Myopathy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 121-136.	1.2	59
3973	Endovascular Treatment of External Iliac Artery Stenoses for Claudication with Systematic Stenting. <i>Annals of Vascular Surgery</i> , 2009, 23, 722-728.	0.4	23
3974	Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 99-119.	1.2	31
3976	Diabetes and Cardiovascular Disease Prevention in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 607-641.	1.0	44
3977	Is Intermittent Vasculogenic Claudication Still a Nonsurgical Disease?. <i>Advances in Surgery</i> , 2009, 43, 53-72.	0.6	0
3978	Cost-Effectiveness of Atorvastatin in the Primary Prevention of Major Cardiovascular Events in Patients with Type 2 Diabetes in Canada. <i>Canadian Journal of Diabetes</i> , 2009, 33, 363-374.	0.4	2
3979	Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 345-352.	1.4	28
3980	Primary and Secondary Prevention of Cardiovascular Disease in Older Adults: A Status Report. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 745-755.	1.0	13
3981	Update on Peripheral Arterial Disease and Claudication Rehabilitation. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2009, 20, 627-656.	0.7	7
3982	Treatment of Ventricular Arrhythmias in the Elderly. <i>Cardiology in Review</i> , 2009, 17, 136-146.	0.6	6
3983	A Review of Lipid Management in Primary and Secondary Prevention. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2009, 29, 2-12.	1.2	45
3984	Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. <i>Journal of Hypertension</i> , 2009, 27, S23-S29.	0.3	13
3985	PITAVASTATIN SUPPRESSES FORMATION AND PROGRESSION OF CEREBRAL ANEURYSMS THROUGH INHIBITION OF THE NUCLEAR FACTOR κ B PATHWAY. <i>Neurosurgery</i> , 2009, 64, 357-366.	0.6	79
3986	Increased Atherogenic Lipoproteins are Associated With Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 11-17.	0.6	35
3987	Statin-induced myopathy in the elderly: Part 1. <i>Adverse Drug Reaction Bulletin</i> , 2009, &NA;, 979-982.	0.6	0
3988	Insufficient Statin Therapy in Coronary Heart Disease Is Related to the Time of the Last Coronary Angiography. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 215-222.	0.8	0
3989	7-Difluoromethyl-5,4-dimethoxygenistein, a Novel Genistein Derivative, Has Therapeutic Effects on Atherosclerosis in a Rabbit Model. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 54, 412-420.	0.8	10
3990	Nicotinic acid and the prevention of coronary artery disease. <i>Current Opinion in Lipidology</i> , 2009, 20, 321-326.	1.2	38

#	ARTICLE	IF	CITATIONS
3991	Modification of HDL structure and function in individuals with diabetes and the haptoglobin 2-2 genotype. <i>Clinical Lipidology</i> , 2009, 4, 5-8.	0.4	1
3992	Myalgia in Patients on High-Dose and Low-Moderate Dose Statin Therapy. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 202-206.	0.5	1
3993	Editorial [Hot Topic:Are the Pleiotropic Effects of Drugs Used for the Prevention of Cardiovascular Disease Clinically Relevant?(Executive Editors: M. Elisaf and E.N. Liberopoulos)]. <i>Current Pharmaceutical Design</i> , 2009, 15, 463-466.	0.9	1
3994	Effect of Chronic Statin Pretreatment on Hospital Outcome in Patients With Acute Non-ST-Elevation Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 132-136.	0.8	17
3995	Use of Statins and Risk of Hospitalization With Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 18-22.	0.6	22
3996	On Cholesterol Levels and Statins in Cognitive Decline and Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 303-305.	0.6	10
3997	Pharmacodynamic Hybrids Coupling Established Cardiovascular Mechanisms of Action with Additional Nitric Oxide Releasing Properties. <i>Current Pharmaceutical Design</i> , 2009, 15, 614-636.	0.9	28
3998	Epidemiology and risk factors. , 0, , 120-130.		0
4000	Regional and Practice Variation in Adherence to Guideline Recommendations for Secondary and Primary Prevention Among Outpatients With Atherothrombosis or Risk Factors in the United States. <i>Critical Pathways in Cardiology</i> , 2009, 8, 104-111.	0.2	68
4001	Role of adipokines in complications related to obesity. A review. <i>Advances in Medical Sciences</i> , 2009, 54, 150-7.	0.9	132
4002	Assessment of Muscle Pain Associated with Statins – A Tool for Pharmacists. <i>Canadian Pharmacists Journal</i> , 2009, 142, 280-283.	0.4	0
4003	The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women. <i>Current Pharmaceutical Design</i> , 2009, 15, 1054-1062.	0.9	21
4004	On the road to better dyslipidemia outcomes. <i>Nurse Practitioner</i> , 2009, 34, 14-21.	0.2	0
4005	Obesity and diabetes: lipids, 'nowhere to run to'. <i>Clinical Science</i> , 2009, 116, 113-123.	1.8	55
4006	Sickle cell disease and stroke. <i>Blood</i> , 2009, 114, 5117-5125.	0.6	149
4007	Interventions in the management of serum lipids for preventing stroke recurrence. <i>The Cochrane Library</i> , 2019, 2019, CD002091.	1.5	59
4008	Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque Comparison With Atorvastatin. <i>Circulation Journal</i> , 2009, 73, 1466-1472.	0.7	74
4009	Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. <i>British Journal of General Practice</i> , 2009, 59, 43-48.	0.7	66

#	ARTICLE	IF	CITATIONS
4010	Prevalence and Prognosis of Asymptomatic Coronary Artery Disease in Patients With Abdominal Aortic Aneurysm and Minor or No Perioperative Risks. <i>Circulation Journal</i> , 2009, 73, 1203-1209.	0.7	10
4011	Treatment of latent stage Alzheimer's disease with statins?. <i>Aging Health</i> , 2009, 5, 29-32.	0.3	1
4013	Using a Drug Facts Box to Communicate Drug Benefits and Harms. <i>Annals of Internal Medicine</i> , 2009, 150, 516.	2.0	222
4014	When statin therapy stops: implications for the patient. <i>Current Opinion in Cardiology</i> , 2009, 24, 454-460.	0.8	21
4015	Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review. <i>Current Cardiology Reviews</i> , 2009, 5, 296-311.	0.6	74
4016	Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2009, 15, 3446-3462.	0.9	7
4017	Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies. <i>Current Vascular Pharmacology</i> , 2009, 7, 394-413.	0.8	15
4018	Pleiotropic Effects of Statins - Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2009, 15, 479-489.	0.9	144
4019	Statin and ezetimibe combination therapy in cardiovascular disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 183-188.	1.2	21
4020	Editorial [Hot Topic: One Century of Triglycerides, but there is Still Lots to Learn(Guest Editors: K.) Tj ETQq1 1 0.784314 rgBT ₅ /Overlook	1.0	5
4021	Cilostazol in the Management of Atherosclerosis. <i>Current Vascular Pharmacology</i> , 2010, 8, 363-372.	0.8	23
4022	Hyperlipidaemia and cardiovascular disease: low HDL-cholesterol as a therapeutic target in statin-treated patients: a role for nicotinic acid (niacin)?. <i>Current Opinion in Lipidology</i> , 2010, 21, 161-162.	1.2	0
4023	Variation in the Net Benefit of Aggressive Cardiovascular Risk Factor Control Across the US Population of Patients With Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2010, 170, 1037.	4.3	52
4024	ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis. <i>Current Vascular Pharmacology</i> , 2010, 8, 673-681.	0.8	34
4025	Method of LDL Cholesterol Measurement Influences Classification of LDL Cholesterol Treatment Goals. <i>Journal of Investigative Medicine</i> , 2010, 58, 945-949.	0.7	27
4026	Cardiovascular Benefit of Magnitude of Low-Density Lipoprotein Cholesterol Reduction: A Comparison of Subgroups by Age. <i>Yearbook of Endocrinology</i> , 2010, 2010, 82-84.	0.0	0
4027	Cardiovascular Benefit of Magnitude of Low-Density Lipoprotein Cholesterol Reduction: A Comparison of Subgroups by Age. <i>Yearbook of Medicine</i> , 2010, 2010, 515-518.	0.1	0
4029	Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease. <i>European Heart Journal</i> , 2010, 31, 992-999.	1.0	65

#	ARTICLE	IF	CITATIONS
4030	Interventions to improve adherence to lipid lowering medication. , 2010, , CD004371.		95
4031	Practical Implications of ACC/AHA 2007 Guidelines for the Management of Unstable Angina/Non-ST Elevation Myocardial Infarction. American Journal of Therapeutics, 2010, 17, e24-e40.	0.5	8
4032	Complex Atheromatosis of the Aortic Arch in Cerebral Infarction. Current Cardiology Reviews, 2010, 6, 184-193.	0.6	31
4033	Intensive statin therapy: a goal worth targeting. Interventional Cardiology, 2010, 2, 103-105.	0.0	0
4034	Management of Hypercholesterolemia in Older Persons for the Prevention of Cardiovascular Disease. Cardiology in Review, 2010, 18, 132-140.	0.6	18
4035	Renal lipid metabolism and lipotoxicity. Current Opinion in Nephrology and Hypertension, 2010, 19, 393-402.	1.0	268
4036	Pitavastatin. Cardiology in Review, 2010, 18, 264-267.	0.6	16
4037	Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause, 2010, 17, 1071-1079.	0.8	42
4038	The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. Current Opinion in Cardiology, 2010, 25, 394-398.	0.8	27
4039	Dual Inhibition, Newer Paradigms for Cholesterol Lowering. American Journal of Therapeutics, 2010, 17, e88-e99.	0.5	4
4040	The Effect of Simvastatin on Lymphocyte Secretory Function in Patients With Impaired Fasting Glucose. Journal of Cardiovascular Pharmacology, 2010, 56, 491-497.	0.8	9
4041	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. Current Opinion in Cardiology, 2010, 25, 406-410.	0.8	23
4042	Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. Current Opinion in Cardiology, 2010, 25, 622-626.	0.8	8
4043	Soft drink consumption and obesity: it is all about fructose. Current Opinion in Lipidology, 2010, 21, 51-57.	1.2	97
4044	Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. Expert Review of Endocrinology and Metabolism, 2010, 5, 825-834.	1.2	2
4046	Lipids and Cognition. Journal of Alzheimer's Disease, 2010, 20, 737-747.	1.2	96
4047	Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes. Endocrine Practice, 2010, 16, 629-640.	1.1	31
4048	Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk. Annals of Internal Medicine, 2010, 153, 800.	2.0	93

#	ARTICLE	IF	CITATIONS
4049	Long-Term Statin Therapy is Associated with Better Episodic Memory in Aged Familial Hypercholesterolemia Patients in Comparison with Population Controls. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 611-617.	1.2	16
4050	Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. <i>Annals of Internal Medicine</i> , 2010, 153, 137.	2.0	93
4051	Attainment of combined optimal lipid values: a paradigm shift in the management of dyslipidemia. <i>Clinical Lipidology</i> , 2010, 5, 527-541.	0.4	2
4052	Characteristics of Revascularization Treatment for Arteriosclerosis Obliterans in Patients With and Without Hemodialysis. <i>Circulation Journal</i> , 2010, 74, 2426-2433.	0.7	11
4053	Update on the Role of Endothelial Lipase in High-Density Lipoprotein Metabolism, Reverse Cholesterol Transport, and Atherosclerosis. <i>Circulation Journal</i> , 2010, 74, 2263-2270.	0.7	100
4054	Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease. <i>Circulation Journal</i> , 2010, 74, 1718-1730.	0.7	26
4055	Promoting Successful Cognitive Aging: A Comprehensive Review. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1101-1122.	1.2	161
4056	Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. <i>BMJ: British Medical Journal</i> , 2010, 340, c1693-c1693.	2.4	88
4057	The effects of one-year simvastatin therapy on women's bone mineral density. <i>Open Medicine (Poland)</i> , 2010, 5, 588-592.	0.6	2
4058	High-density lipoproteins and cardiovascular disease: 2010 update. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 413-423.	0.6	31
4059	Prescriber 1990-2010: key developments in drug treatment. <i>The Prescriber</i> , 2010, 21, 16-19.	0.1	0
4060	Current drug therapies used in the secondary prevention of MI. <i>The Prescriber</i> , 2010, 21, 22-45.	0.1	1
4061	Current Treatment and Recent Clinical Research in Alzheimer's Disease. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 3-16.	1.9	68
4062	Receipt of Cardiac Medications Upon Discharge Among Men and Women With Acute Coronary Syndrome and Nonobstructive Coronary Artery Disease. <i>Clinical Cardiology</i> , 2010, 33, 36-41.	0.7	22
4063	Dyslipidemia in the Elderly: Should it Be Treated?. <i>Clinical Cardiology</i> , 2010, 33, 4-9.	0.7	44
4064	Chemoprevention of colorectal cancer: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2010, 14, 1-206.	1.3	171
4065	Alzheimer Disease. <i>Disease-a-Month</i> , 2010, 56, 484-546.	0.4	391
4069	Cardiological evaluation after cerebral ischaemia. <i>Clinical Research in Cardiology</i> , 2010, 99, 609-625.	1.5	16

#	ARTICLE	IF	CITATIONS
4070	Pravastatin and cognitive function in the elderly. Results of the PROSPER study. <i>Journal of Neurology</i> , 2010, 257, 85-90.	1.8	238
4071	Antiangiogenic mechanisms of simvastatin in retinal endothelial cells. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 667-673.	1.0	12
4072	Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study. <i>European Journal of Health Economics</i> , 2010, 11, 177-184.	1.4	3
4074	Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. <i>Advances in Therapy</i> , 2010, 27, 348-364.	1.3	20
4075	Critical Limb Ischemia. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 214-229.	0.4	39
4076	High-Density Lipoprotein Therapy: Is There Hope?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 315-328.	0.4	10
4077	Mitochondrial Dysfunction Induced by Statin Contributes to Endothelial Dysfunction in Patients with Coronary Artery Disease. <i>Cardiovascular Toxicology</i> , 2010, 10, 130-138.	1.1	24
4078	Pitavastatin Reduces Lectin-Like Oxidized Low-Density Lipoprotein Receptor Ligands in Hypercholesterolemic Humans. <i>Lipids</i> , 2010, 45, 329-335.	0.7	19
4079	Die Bedeutung von körperlicher Aktivität und körperlichem Training in der Prävention der koronaren Herzkrankheit. <i>Wiener Klinische Wochenschrift Education</i> , 2010, 5, 165-179.	0.0	1
4080	New Evidence Extending the Benefit of Treating LDL-C Beyond the Current Guidelines. <i>Current Atherosclerosis Reports</i> , 2010, 12, 1-4.	2.0	0
4081	Statin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?. <i>Current Atherosclerosis Reports</i> , 2010, 12, 14-19.	2.0	4
4082	Statins and Their Role in Pre-Percutaneous Coronary Intervention. <i>Current Cardiology Reports</i> , 2010, 12, 295-301.	1.3	8
4083	Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2010, 10, 16-23.	1.7	17
4084	Secondary prevention strategies for coronary heart disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 8-24.	1.0	24
4085	Management of dyslipidemia in people with type 2 diabetes mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2010, 11, 41-51.	2.6	29
4086	Guías de tratamiento. <i>Revista Espanola De Cardiologia Suplementos</i> , 2010, 10, 22B-30B.	0.2	0
4089	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. <i>Journal of Cardiology</i> , 2010, 55, 155-162.	0.8	29
4090	Ischaemic heart disease: stable angina. <i>Medicine</i> , 2010, 38, 414-420.	0.2	0

#	ARTICLE	IF	CITATIONS
4091	Cost-Effective Prevention of Coronary Heart Disease. <i>Journal for Nurse Practitioners</i> , 2010, 6, 754-764.	0.4	2
4092	Diagnosis and Treatment of Heart Disease: Are Women Different From Men?. <i>Progress in Cardiovascular Diseases</i> , 2010, 53, 227-236.	1.6	71
4093	Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. , 2010, 126, 314-345.		196
4094	From design to implementation - The Joint Asia Diabetes Evaluation (JADE) program: A descriptive report of an electronic web-based diabetes management program. <i>BMC Medical Informatics and Decision Making</i> , 2010, 10, 26.	1.5	46
4095	Measuring quality of diabetes care by linking health care system administrative databases with laboratory data. <i>BMC Research Notes</i> , 2010, 3, 233.	0.6	7
4096	A Systematic Review of Implementation of Established Recommended Secondary Prevention Measures in Patients with PAOD. <i>European Journal of Vascular and Endovascular Surgery</i> , 2010, 39, 70-86.	0.8	56
4097	Age-Modification of Lipoprotein, Lipid, and Lipoprotein Ratio-Associated Risk for Coronary Artery Calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). <i>American Journal of Cardiology</i> , 2010, 105, 352-358.	0.7	19
4098	Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy. <i>American Journal of Cardiology</i> , 2010, 105, 1289-1296.	0.7	46
4099	Should Statin Therapy Be Allocated on the Basis of Global Risk or on the Basis of Randomized Trial Evidence?. <i>American Journal of Cardiology</i> , 2010, 106, 905-909.	0.7	5
4100	Safety and Efficacy of Ezetimibe/Simvastatin Combination Versus Atorvastatin Alone in Adults ≥65 Years of Age With Hypercholesterolemia and With or at Moderately High/High Risk for Coronary Heart Disease (the VYTELD Study). <i>American Journal of Cardiology</i> , 2010, 106, 1255-1263.	0.7	22
4101	Effect of Preoperative Statin Therapy on Patients Undergoing Isolated and Combined Valvular Heart Surgery. <i>Annals of Thoracic Surgery</i> , 2010, 89, 773-780.	0.7	27
4102	Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. <i>Clinical Therapeutics</i> , 2010, 32, 300-310.	1.1	76
4103	Restrictive diets in the elderly: Never say never again?. <i>Clinical Nutrition</i> , 2010, 29, 170-174.	2.3	53
4104	Alternative Strategies for the Management of Chronic Stable Angina. <i>Current Problems in Cardiology</i> , 2010, 35, 384-446.	1.1	6
4105	Rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 733-745.	1.4	183
4107	Statins: A Potential Therapeutic Addition to Treatment for Aneurysmal Subarachnoid Hemorrhage?. <i>World Neurosurgery</i> , 2010, 73, 646-653.	0.7	27
4108	Do Statins Improve Heart Failure Outcome in Post-Myocardial Infarction Patients With Moderate to Severe Left Ventricular Dysfunction?. <i>Congestive Heart Failure</i> , 2010, 16, 181-186.	2.0	6
4109	Statins for Primary Prevention of Cardiovascular Mortality in Women: A Systematic Review and Meta-Analysis. <i>Preventive Cardiology</i> , 2010, 13, 84-90.	1.1	40

#	ARTICLE	IF	CITATIONS
4110	A Randomized Clinical Trial to Assess the Effect of Statins on Skeletal Muscle Function and Performance: Rationale and Study Design. <i>Preventive Cardiology</i> , 2010, 13, 104-11.	1.1	30
4111	High-performance Liquid Chromatographic Analysis of Pioglitazone, Gliquidone, Rosuvastatin and Simvastatin in Formulations and Human Serum. <i>Chinese Journal of Chemistry</i> , 2010, 28, 1998-2002.	2.6	18
4112	Statin therapy in the elderly: A review. <i>Archives of Gerontology and Geriatrics</i> , 2010, 50, 114-118.	1.4	47
4113	Carotid Artery Stent Placement. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 467-474.	1.1	24
4114	Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients. <i>Journal of Trace Elements in Medicine and Biology</i> , 2010, 24, 27-30.	1.5	27
4115	Design of a novel class of biphenyl CETP inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 7469-7472.	1.0	15
4116	Statins and clinical outcome of acute ischemic stroke: a systematic review. <i>International Archive of Medicine</i> , 2010, 3, 22.	1.2	26
4117	Pharmacogenomics: a systems approach. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2010, 2, 3-22.	6.6	55
4118	“Statins should be routinely prescribed in all adults with diabetes”™. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2010, 27, 404.	0.2	4
4119	Prior use of statins and outcome in patients with intracerebral haemorrhage. <i>European Journal of Neurology</i> , 2010, 17, 78-83.	1.7	41
4120	TREATING VASCULAR RISK FACTORS IN ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 185-186.	1.3	2
4121	RESPONSE LETTER TO DR. DAE HYUN KIM. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 186-187.	1.3	0
4122	Can Statins Prevent Dementia in Older Adults?. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1393-1394.	1.3	2
4123	OUTCOME AFTER PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION IN OLD AGE. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 2236-2237.	1.3	0
4124	Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study. <i>Value in Health</i> , 2010, 13, 726-734.	0.1	20
4125	Gender differences in the treatment of chronic ischemic heart disease: prognostic implications. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 707-710.	1.0	6
4126	“Multiple action fixed combination. Present or future?”™. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 37-42.	1.0	11
4127	Role of drugs and devices in patients at risk of sudden cardiac death. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 575-594.	1.0	15

#	ARTICLE	IF	CITATIONS
4128	The cardio-protective properties of NCX-6550, a nitric oxide donating pravastatin, in the mouse. <i>Microcirculation</i> , 2010, 17, 417-26.	1.0	5
4129	Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. <i>International Journal of Clinical Practice</i> , 2010, 64, 1052-1061.	0.8	27
4130	Statin use and the prevention of venous thromboembolism: a meta-analysis. <i>International Journal of Clinical Practice</i> , 2010, 64, 1375-1383.	0.8	61
4131	The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial. <i>International Journal of Clinical Practice</i> , 2010, 64, 1228-1234.	0.8	10
4132	Erectile dysfunction and testosterone screening with prostate specific antigen screening at age 40: are these three gender specific determinants additive for overall men's health and do they improve traditional non-gender specific determinants to lessen ca. <i>International Journal of Clinical Practice</i> , 2010, 64, 1754-1762.	0.8	5
4133	Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 85-94.	1.1	27
4134	Generic and therapeutic substitutions in the UK: are they a good thing?. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 335-341.	1.1	127
4135	Lipoprotein-associated phospholipase A ₂ activity and mass in relation to vascular disease and nonvascular mortality. <i>Journal of Internal Medicine</i> , 2010, 268, 348-358.	2.7	38
4136	Excess Weight and the Risk of Incident Coronary Heart Disease Among Men and Women. <i>Obesity</i> , 2010, 18, 377-383.	1.5	96
4137	Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 219-223.	2.2	33
4138	Peripheral arterial disease in diabetes—a review. <i>Diabetic Medicine</i> , 2010, 27, 4-14.	1.2	246
4139	Improvements in glycaemic control and cholesterol concentrations associated with the Quality and Outcomes Framework: a regional 2-year audit of diabetes care in the UK. <i>Diabetic Medicine</i> , 2010, 27, 354-359.	1.2	43
4140	Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2010, 27, 303-308.	1.2	3
4141	Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid. <i>Diabetic Medicine</i> , 2010, 27, 696-700.	1.2	19
4143	Using noncontrast cardiac CT and coronary artery calcification measurements for cardiovascular risk assessment and management in asymptomatic adults. <i>Vascular Health and Risk Management</i> , 2010, 6, 579.	1.0	27
4144	Protective Vascular Treatment of Patients with Peripheral Arterial Disease: Guideline Adherence According to Year, Age and Gender. <i>Canadian Journal of Public Health</i> , 2010, 101, 96-100.	1.1	32
4146	Metabolic side effects and risk of cardiovascular disease. , 0, , 173-188.		0
4147	Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 61.	1.0	4

#	ARTICLE	IF	CITATIONS
4148	A guide to lipid modification. <i>British Journal of Cardiac Nursing</i> , 2010, 5, 410-416.	0.0	0
4149	Atorvastatin in stroke: a review of SPARCL and subgroup analysis. <i>Vascular Health and Risk Management</i> , 2010, 6, 229.	1.0	34
4151	Diagnosis and Management of Coronary Artery Disease. , 2010, , 286-294.		0
4152	High Dose Statins: Is it Beneficial over Conventional Dose of Statin in Acute Coronary Syndrome?. <i>Cardiovascular Journal</i> , 2010, 2, 245-251.	0.0	0
4153	Benefits of statin therapy and compliance in high risk cardiovascular patients. <i>Vascular Health and Risk Management</i> , 2010, 6, 843.	1.0	48
4154	Use of the Joint British Society cardiovascular risk calculator before initiating statins for primary prevention in hospital medicine: experience from a large university teaching hospital. <i>International Journal of General Medicine</i> , 2010, 3, 379.	0.8	2
4155	South African guideline for management of ischaemic stroke and transient ischaemic attack 2010: A guideline from the South African Stroke Society (SASS) and the SASS Writing Committee. <i>South African Medical Journal</i> , 2010, 100, 747.	0.2	61
4156	Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. <i>Clinical Interventions in Aging</i> , 2011, 6, 27.	1.3	16
4159	Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. <i>Vascular Health and Risk Management</i> , 2010, 6, 775.	1.0	81
4160	Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 722-729.	0.9	33
4161	Dyslipidemia Management in Women and Men. , 2010, , 175-185.		0
4162	Post-Prandial Lipid Levels for Assessing Target Goal Achievement in Type 2 Diabetic Patients Taking Statin. <i>Journal of Korean Medical Science</i> , 2010, 25, 387.	1.1	5
4163	Complications and Management of Chronic Kidney Disease. , 2010, , 145-163.		1
4164	Antipsychotics and Metabolics in the Post-CATIE Era. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 4, 23-42.	0.8	32
4165	Statins and All-Cause Mortality in High-Risk Primary Prevention. <i>Archives of Internal Medicine</i> , 2010, 170, 1024.	4.3	385
4166	Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. <i>Annals of Medicine</i> , 2010, 42, 19-35.	1.5	23
4167	Modification of the effect of lipids on the risk of cardiovascular diseases by cigarette smoking. <i>Clinical Lipidology</i> , 2010, 5, 413-420.	0.4	4
4168	Management of Spontaneous Nontraumatic Intracranial Hemorrhage. <i>Journal of Pharmacy Practice</i> , 2010, 23, 398-407.	0.5	7

#	ARTICLE	IF	CITATIONS
4169	Clinical Approach to Sudden Cardiac Death Syndromes. , 2010, , .		5
4170	Encouraging appropriate treatment for familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2010, 5, 339-354.	0.4	12
4171	Comparative Efficacy and Safety of Low-Dose Pitavastatin Versus Atorvastatin in Patients with Hypercholesterolemia. <i>Annals of Pharmacotherapy</i> , 2010, 44, 415-423.	0.9	20
4172	Rhabdomyolysis in a Patient Receiving High-Dose Simvastatin After the Induction of Therapeutic Hypothermia. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1994-1997.	0.9	7
4173	Cognitive decline: the relevance of diabetes, hyperlipidaemia and hypertension. <i>British Journal of Diabetes and Vascular Disease</i> , 2010, 10, 115-122.	0.6	18
4174	ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 Performance Measures for Adults With Peripheral Artery Disease. <i>Circulation</i> , 2010, 122, 2583-2618.	1.6	54
4175	Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease. <i>Hypertension</i> , 2010, 55, 48-53.	1.3	156
4176	Preprocedural Statin Therapy to Prevent Myocardial Damage in Percutaneous Coronary Intervention. <i>Critical Pathways in Cardiology</i> , 2010, 9, 19-22.	0.2	4
4177	Effects of Statins on Progression of Subclinical Brain Infarct. <i>Cerebrovascular Diseases</i> , 2010, 30, 51-56.	0.8	31
4178	Inflammation in Peripheral Artery Disease. <i>Circulation</i> , 2010, 122, 1862-1875.	1.6	243
4179	Inclusion of Stroke as an Outcome and Risk Equivalent in Risk Scores for Primary and Secondary Prevention of Vascular Disease. <i>Circulation</i> , 2010, 121, 2071-2078.	1.6	28
4180	Targeting Patients for Statin Therapy for the Primary Prevention of Vascular Events: What is the Best Approach?. <i>Circulation</i> , 2010, 122, 1446-1448.	1.6	2
4181	Effect of statin therapy on colorectal cancer. <i>Gut</i> , 2010, 59, 1572-1585.	6.1	139
4182	Monitoring and treatment for cardiovascular risk. <i>Primary Health Care Research and Development</i> , 2010, 11, 29.	0.5	0
4183	Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 220-226.	0.6	57
4184	Basic Science Review Section: Statin Therapyâ€™Part II: Clinical Considerations for Cardiovascular Disease. <i>Vascular and Endovascular Surgery</i> , 2010, 44, 421-433.	0.3	19
4185	Evaluation of a Pharmacist-Managed Telephone Lipid Clinic at a Veterans Affairs Medical Center. <i>Annals of Pharmacotherapy</i> , 2010, 44, 50-56.	0.9	6
4186	Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart Disease. <i>Cholesterol</i> , 2010, 2010, 1-11.	1.6	30

#	ARTICLE	IF	CITATIONS
4187	Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients. <i>Current Gerontology and Geriatrics Research</i> , 2010, 2010, 1-9.	1.6	10
4188	Primary and Secondary Prevention of Ischemic Stroke. <i>European Neurology</i> , 2010, 63, 267-278.	0.6	35
4189	Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease. <i>Clinical Medicine Insights: Cardiology</i> , 2010, 4, CMC.S5970.	0.6	3
4190	Safety of Simvastatin and Goal Attainment for Low-Density Lipoprotein Cholesterol in Sultan Qaboos University Hospital. <i>Oman Medical Journal</i> , 2010, 25, 264-8.	0.3	4
4191	Control of cholesterol synthesis through regulated ER-associated degradation of HMG CoA reductase. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2010, 45, 185-198.	2.3	134
4192	The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury. <i>Clinical Hemorheology and Microcirculation</i> , 2010, 45, 161-167.	0.9	12
4193	Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass. <i>Heart</i> , 2010, 96, 148-152.	1.2	30
4194	Long-Term Outcomes of Patients With Necrotizing Fasciitis. <i>Journal of Burn Care and Research</i> , 2010, 31, 93-99.	0.2	41
4195	Cardiovascular Disease in Chronic Kidney Disease. , 2010, , 935-950.		4
4196	Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein. <i>Circulation</i> , 2010, 121, 143-150.	1.6	157
4197	Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease. <i>Neurology</i> , 2010, 74, 956-964.	1.5	365
4198	The Association Between Achieving Low-Density Lipoprotein Cholesterol (LDL-C) Goal and Statin Treatment in an Employee Population. <i>Population Health Management</i> , 2010, 13, 1-8.	0.8	11
4199	Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1685-1691.	1.4	62
4200	Improvement of Retinal Vascular Injury in Diabetic Rats by Statins Is Associated With the Inhibition of Mitochondrial Reactive Oxygen Species Pathway Mediated by Peroxisome Proliferator-Activated Receptor β Coactivator 1 α . <i>Diabetes</i> , 2010, 59, 2315-2325.	0.3	64
4201	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. <i>Circulation</i> , 2010, 121, e266-369.	1.6	1,994
4202	High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease. , 2010, , .		6
4203	Diabetic dyslipidemia: extending the target beyond LDL cholesterol. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, s20-s24.	3.1	11
4204	Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 167-174.	1.0	35

#	ARTICLE	IF	CITATIONS
4205	Chronic stable coronary artery disease: drugs vs. revascularization. <i>European Heart Journal</i> , 2010, 31, 530-541.	1.0	74
4206	Divergent Effects of $\hat{\alpha}$ -Tocopherol and Vitamin C on the Generation of Dysfunctional HDL Associated with Diabetes and the Hp 2-2 Genotype. <i>Antioxidants and Redox Signaling</i> , 2010, 12, 209-217.	2.5	28
4207	Management of dyslipidemia in the elderly population. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 375-383.	1.0	24
4208	A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women. <i>Journal of Lipid Research</i> , 2010, 51, 625-634.	2.0	19
4209	Darapladib: an emerging therapy for atherosclerosis. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 241-248.	1.0	14
4210	ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease. <i>Vascular Medicine</i> , 2010, 15, 481-512.	0.8	20
4211	Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia. <i>Circulation</i> , 2010, 121, 1069-1077.	1.6	287
4212	Statins in the Treatment of Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 462-464.	1.6	8
4213	Long-Term Results of Carotid Artery Stents to Manage Symptomatic Carotid Artery Stenosis and Factors That Affect Outcome. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 50-56.	1.4	26
4214	Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. <i>Current Medical Research and Opinion</i> , 2010, 26, 365-375.	0.9	13
4215	Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 120-134.	1.0	48
4216	Epidemiology of Cardiovascular Disease in Type 2 Diabetes: The Indian Scenario. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 158-170.	1.3	71
4217	A Review of Perioperative Statin Therapy for Noncardiac Surgery. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2010, 14, 283-290.	0.4	15
4218	The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. <i>Heart</i> , 2010, 96, 604-609.	1.2	97
4219	Dynamics of Traditional Metabolic Risk Factors Associate With Specific Causes of Death in Old Age. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2010, 65A, 488-494.	1.7	16
4220	The Role of the Chronic Kidney Disease Clinic. , 2010, , 75-86.		1
4221	Modeling the 4D Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 856-866.	2.2	19
4222	The Risk of Revision After Primary Total Hip Arthroplasty Among Statin Users. <i>Journal of Bone and Joint Surgery - Series A</i> , 2010, 92, 1063-1072.	1.4	30

#	ARTICLE	IF	CITATIONS
4223	The Conundrum of Statins in Chronic Kidney Disease. <i>Scottish Medical Journal</i> , 2010, 55, 30-33.	0.7	0
4224	Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. <i>Pharmacogenomics</i> , 2010, 11, 675-684.	0.6	113
4225	Cholesterol and Cognitive Performance in Normal Controls and the Influence of Elective Statin Use after Conversion to Mild Cognitive Impairment: Results in a Clinical Trial Cohort. <i>Neurodegenerative Diseases</i> , 2010, 7, 183-186.	0.8	44
4226	3-Hydroxy-3-methylglutarylâ€œCoenzyme A Reductase Inhibitors in the Treatment of Central Nervous System Diseases. <i>Archives of Neurology</i> , 2010, 67, 1062-7.	4.9	73
4227	Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico. <i>Current Medical Research and Opinion</i> , 2010, 26, 1075-1081.	0.9	4
4228	Smoking bans in public places result in a reduced incidence of acute myocardial infarction. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 311-313.	0.6	2
4229	Barriers to cardiovascular disease risk scoring and primary prevention in Europe. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 727-739.	0.2	80
4230	Frequency and Determinants of Lipid Testing in Ischemic Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2010, 41, 232-238.	1.0	14
4231	Coronary artery disease in 2010. <i>European Heart Journal Supplements</i> , 2010, 12, C2-C10.	0.0	28
4232	Optimizing lipid-lowering therapy in the prevention of coronary heart disease. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 649-661.	1.3	0
4234	Developing the Evidence Base for Palliative Care: Formation of the Palliative Care Research Cooperative and Its First Trial. <i>Hospital Practice (1995)</i> , 2010, 38, 137-143.	0.5	21
4235	Undertreatment of hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2010, 26, 439-443.	0.9	11
4236	Short-term vascular risk: time to take notice?. <i>Nature Reviews Cardiology</i> , 2010, 7, 409-411.	6.1	2
4237	RAâ€œlowering cardiovascular risk with statins. <i>Nature Reviews Rheumatology</i> , 2010, 6, 123-124.	3.5	0
4238	An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 340, c2073-c2073.	2.4	151
4239	Comments on an acute myocardial infarction study. <i>Heart</i> , 2010, 96, 1781-1781.	1.2	0
4240	Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 73-85.	0.7	63
4241	National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. <i>Kidney International</i> , 2010, 78, 726-736.	2.6	48

#	ARTICLE	IF	CITATIONS
4242	The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries. <i>Current Vascular Pharmacology</i> , 2010, 8, 293-300.	0.8	18
4243	Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. <i>Hypertension Research</i> , 2010, 33, 1038-1043.	1.5	37
4245	HDL - Cholesterol: The New Target for Treatment. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2010, 4, 153-160.	0.7	0
4246	Atherosclerosis regression and high-density lipoproteins. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1325-1334.	0.6	14
4247	Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 775-779.	0.6	10
4248	Use of Rosuvastatin in Preventing Vascular Events in Patients with Elevated C-Reactive Protein. <i>Postgraduate Medicine</i> , 2010, 122, 169-171.	0.9	1
4249	Management of Cardiovascular Risk Associated with Insulin Resistance, Diabetes, and the Metabolic Syndrome. <i>Postgraduate Medicine</i> , 2010, 122, 61-70.	0.9	11
4250	The Utility of Observational Studies in Clinical Decision Making: Lessons Learned from Statin Trials. <i>Postgraduate Medicine</i> , 2010, 122, 222-229.	0.9	9
4251	Does the Choice of Statin Really Matter?. <i>Postgraduate Medicine</i> , 2010, 122, 243-247.	0.9	6
4252	Improving Cardiovascular Risk Reduction for Primary Prevention—Utility of Lifetime Risk Assessment. <i>Postgraduate Medicine</i> , 2010, 122, 192-199.	0.9	13
4253	The epidemic of nonmelanoma skin cancer and the widespread use of statins. <i>Dermato-Endocrinology</i> , 2010, 2, 37-38.	1.9	8
4254	Treating Arteries Instead of Risk Factors. <i>Stroke</i> , 2010, 41, 1193-1199.	1.0	139
4255	Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. <i>Current Medical Research and Opinion</i> , 2010, 26, 121-128.	0.9	16
4256	Statin use and cancer risk: a comprehensive review. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 603-621.	1.0	235
4257	MRI of carotid atherosclerosis: clinical implications and future directions. <i>Nature Reviews Cardiology</i> , 2010, 7, 165-173.	6.1	143
4258	Endocrine Aspects of Healthy Brain Aging. <i>Clinics in Geriatric Medicine</i> , 2010, 26, 57-74.	1.0	9
4259	Cognitive Bias and Planning Error: Nullification of Evidence-Based Medicine in the Nursing Home. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 194-203.	1.2	13
4260	Diabetes, Cardiovascular Risk and Nephropathy. <i>Cardiology Clinics</i> , 2010, 28, 467-475.	0.9	26

#	ARTICLE	IF	CITATIONS
4261	Traitement du diabète de type 2: il est temps de regarder l'Evidence Based Medicine en face!. Medecine Des Maladies Metaboliques, 2010, 4, 718-720.	0.1	2
4262	High density lipoproteins-based therapies for cardiovascular disease. Journal of Cardiovascular Disease Research (discontinued), 2010, 1, 99-103.	0.1	10
4263	Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: A Therapeutic Dilemma. Mayo Clinic Proceedings, 2010, 85, 349-356.	1.4	130
4264	Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management. Mayo Clinic Proceedings, 2010, 85, 678-692.	1.4	244
4266	Hemostatic effects of simvastatin in subjects with impaired fasting glucose. Pharmacological Reports, 2010, 62, 1090-1098.	1.5	8
4267	The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics Journal, 2010, 10, 1-11.	0.9	141
4268	Pleiotropic Effects of Statins. American Journal of Cardiovascular Drugs, 2010, 10, 10-17.	1.0	49
4269	Pleiotropic Effects of Statins. American Journal of Cardiovascular Drugs, 2010, 10, 3-9.	1.0	52
4272	Cholesterol-Lowering Interventions and Stroke. Journal of the American College of Cardiology, 2010, 55, 198-211.	1.2	88
4273	Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy. Journal of the American College of Cardiology, 2010, 55, 1611-1618.	1.2	147
4274	A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2010, 55, 2727-2735.	1.2	202
4275	Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. Journal of the American College of Cardiology, 2010, 55, 2846-2854.	1.2	145
4276	High-Density Lipoprotein and Coronary Heart Disease. Journal of the American College of Cardiology, 2010, 55, 1283-1299.	1.2	190
4277	Cardiovascular and Cancer Mortality in Very Elderly Post-Myocardial Infarction Patients Receiving Statin Treatment. Journal of the American College of Cardiology, 2010, 55, 1362-1369.	1.2	58
4278	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. Journal of the American College of Cardiology, 2010, 55, e27-e129.	1.2	1,298
4280	New Hope for Chronic Kidney Disease Patients After the JUPITER Trial. Journal of the American College of Cardiology, 2010, 56, 529.	1.2	2
4281	ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 Performance Measures for Adults With Peripheral Artery Disease. Journal of the American College of Cardiology, 2010, 56, 2147-2181.	1.2	53
4282	Prevalence of dyslipidemia and its associated factors among Jordanian adults. Journal of Clinical Lipidology, 2010, 4, 53-58.	0.6	55

#	ARTICLE	IF	CITATIONS
4283	Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2010, 4, 173-180.	0.6	33
4284	Nonoptimal high-density lipoprotein cholesterol levels are highly prevalent in patients presenting with acute coronary syndromes and well-controlled low-density lipoprotein cholesterol levels. <i>Journal of Clinical Lipidology</i> , 2010, 4, 265-271.	0.6	6
4285	Is directly measured low-density lipoprotein clinically equivalent to calculated low-density lipoprotein?. <i>Journal of Clinical Lipidology</i> , 2010, 4, 259-264.	0.6	17
4286	An assessment of cholesterol goal attainment in patients with chronic kidney disease. <i>Journal of Clinical Lipidology</i> , 2010, 4, 298-304.	0.6	13
4287	Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 26-32.	0.7	13
4288	Clinical trials for preventing post stroke cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2010, 299, 168-174.	0.3	40
4289	Process of care for carotid endarterectomy: Perioperative medical management. <i>Journal of Vascular Surgery</i> , 2010, 52, 223-231.	0.6	27
4290	Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair. <i>Journal of Vascular Surgery</i> , 2010, 51, 1390-1396.	0.6	64
4291	Uninsured South Florida vascular surgery patients are less likely to receive optimal medical management than their insured counterparts. <i>Journal of Vascular Surgery</i> , 2010, 51, S4-S8.	0.6	12
4292	An elevated neutrophil-lymphocyte ratio independently predicts mortality in chronic critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2010, 52, 632-636.	0.6	90
4293	Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. <i>Journal of Vascular Surgery</i> , 2010, 52, 825-833.e2.	0.6	278
4294	ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2010, 52, 1616-1652.	0.6	26
4295	Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy. <i>Drug Safety</i> , 2010, 33, 171-187.	1.4	167
4296	Analysis of the budget impact for the Spanish National Health System of the fixed combination of amlodipine 5 or 10mg and atorvastatin 10mg. <i>Farmacia Hospitalaria (English Edition)</i> , 2010, 34, 170-180.	0.0	2
4297	POSCH trial 25-year follow-up results: latest news from an old kid on the block. <i>Clinical Lipidology</i> , 2010, 5, 651-653.	0.4	0
4298	Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 223-229.	3.1	10
4299	Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials. <i>Current Medical Research and Opinion</i> , 2010, 26, 537-547.	0.9	6
4300	Impact of gender in primary prevention of coronary heart disease with statin therapy: A meta-analysis. <i>International Journal of Cardiology</i> , 2010, 138, 25-31.	0.8	116

#	ARTICLE	IF	CITATIONS
4301	C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: Inhibitory effects of atorvastatin. <i>International Journal of Cardiology</i> , 2010, 142, 273-278.	0.8	45
4302	Atorvastatin affects TLR4 clustering via lipid raft modulation. <i>International Immunopharmacology</i> , 2010, 10, 892-899.	1.7	31
4303	Body Weight Statuses and Their Sociodemographic Correlates Among Adolescents in Southern Taiwan: Results Using Two Sets of Cutoff References. <i>Journal of Adolescent Health</i> , 2010, 46, 62-69.	1.2	9
4304	Antilipidemic adherence post-coronary artery disease diagnosis among those with and without an ICD-9 diagnosis of depression. <i>Journal of Psychosomatic Research</i> , 2010, 69, 169-174.	1.2	35
4308	The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 117-125.	2.4	20
4309	Pharmaceutical company-sponsored drug trials: the system is broken. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 128-129.	2.4	7
4310	Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2010, 87, 98-107.	1.1	164
4311	All-cause and CVD mortality in Native Hawaiians. <i>Diabetes Research and Clinical Practice</i> , 2010, 89, 65-71.	1.1	27
4312	Carotid artery stenting: Rationale, technique, and current concepts. <i>European Journal of Radiology</i> , 2010, 75, 12-22.	1.2	8
4313	Brain cholesterol in normal and pathological aging. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 934-944.	1.2	131
4314	A cluster randomised controlled trial of pharmacist led Statin Outreach Support (SOS) in primary care: Design and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2010, 31, 303-311.	0.8	7
4315	Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. <i>Neuroscience</i> , 2010, 166, 435-444.	1.1	68
4316	Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practise. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 512-518.	1.1	8
4317	Managing cardiovascular risk factors: Trial evidence in women. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 445-450.	1.1	8
4318	Individualizing Early Use of Sirolimus in Renal Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 4518-4525.	0.3	3
4319	Why statin therapy may increase the risk for posttransplantation squamous cell carcinoma. <i>Transplant Immunology</i> , 2010, 23, 224-225.	0.6	4
4320	Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications Applied aNd SusTAINed Over Time (MAINTAIN) registry. <i>American Heart Journal</i> , 2010, 160, 1121-1129.e1.	1.2	38
4321	Office Management after Myocardial Infarction. <i>American Journal of Medicine</i> , 2010, 123, 593-595.	0.6	4

#	ARTICLE	IF	CITATIONS
4322	Office Management of Peripheral Arterial Disease. American Journal of Medicine, 2010, 123, 790-792.	0.6	20
4323	Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular Events. American Journal of Medicine, 2010, 123, 892-898.	0.6	33
4325	Introduction. Atherosclerosis Supplements, 2010, 11, 1-2.	1.2	7
4326	What Should Medical Practitioners Know about the Role of Alternative Medicines in Cardiovascular Disease Management?. Cardiovascular Therapeutics, 2010, 28, 106-123.	1.1	10
4327	Statins—Is There Potential for Uncovering New Benefits (or Detriments)?. Cardiovascular Therapeutics, 2010, 28, 67-69.	1.1	2
4328	LIPIDS IN CHRONIC KIDNEY DISEASE. Journal of Renal Care, 2010, 36, 27-33.	0.6	14
4329	Hypertension Artérielle. , 2010, , 579-610.		0
4330	Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. New England Journal of Medicine, 2010, 363, 905-917.	13.9	791
4331	Pitavastatin — from clinical trials to clinical practice. Atherosclerosis Supplements, 2010, 11, 15-22.	1.2	19
4332	Bariatric surgery: Rhabdomyolysis after open Roux-en-Y gastric bypass: A prospective study. International Journal of Surgery, 2010, 8, 484-488.	1.1	22
4333	Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis, 2010, 209, 189-194.	0.4	250
4334	Thromboxane A2 promotes soluble CD40 ligand release from human platelets. Atherosclerosis, 2010, 209, 415-421.	0.4	28
4335	Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): A follow-up study. Atherosclerosis, 2010, 210, 497-502.	0.4	64
4336	The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis, 2010, 211, 25-27.	0.4	48
4337	Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. NeuroImage, 2010, 49, 169-176.	2.1	61
4340	Papel de las estatinas en la enfermedad renal crónica (ERC). Clínica E Investigaci3n En Arteriosclerosis, 2010, 22, 17-24.	0.4	0
4341	Efficacy and benefits of lipid-lowering drug therapy. The new European guidelines for cardiovascular disease prevention. Clínica E Investigaci3n En Arteriosclerosis, 2010, 22, 48-51.	0.4	0
4342	The Health Impact Fund: incentives for improving access to medicines. Lancet, The, 2010, 375, 166-169.	6.3	72

#	ARTICLE	IF	CITATIONS
4343	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2010, 375, 998-1006.	6.3	813
4344	Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. <i>Lancet, The</i> , 2010, 376, 1658-1669.	6.3	501
4345	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. <i>Lancet, The</i> , 2010, 376, 333-339.	6.3	221
4346	Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. <i>Lancet, The</i> , 2010, 376, 1670-1681.	6.3	5,162
4347	Early Intervention Strategies to Lower Cardiovascular Risk in Early Nephropathy: Focus on Dyslipidemia. <i>Cardiology Clinics</i> , 2010, 28, 529-539.	0.9	2
4348	Statins for multiple sclerosis. , 2010, , CD008386.		5
4349	Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease. <i>Vascular and Endovascular Surgery</i> , 2010, 44, 241-251.	0.3	121
4351	Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. <i>Age and Ageing</i> , 2010, 39, 674-680.	0.7	122
4352	Long-Term Results of Eversion Carotid Endarterectomy. <i>Annals of Vascular Surgery</i> , 2010, 24, 92-99.	0.4	19
4353	Effects of β -blockers on glucose and lipid metabolism. <i>Current Medical Research and Opinion</i> , 2010, 26, 615-629.	0.9	122
4354	Management of Mixed Dementia. <i>Drugs and Aging</i> , 2010, 27, 715-728.	1.3	15
4355	Statin Prescribing in the Elderly in the Netherlands. <i>Drugs and Aging</i> , 2010, 27, 589-596.	1.3	34
4357	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2010, , 145-182.		1
4358	Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 31.	3.0	7
4359	Ischemic stroke in the elderly: an overview of evidence. <i>Nature Reviews Neurology</i> , 2010, 6, 256-265.	4.9	224
4360	Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). <i>Annals of Medicine</i> , 2010, 42, 231-240.	1.5	41
4361	Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 175-186.	1.0	32
4362	The Risk for Significant Creatine Kinase Elevation with Statins. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 187-192.	1.0	15

#	ARTICLE	IF	CITATIONS
4363	Darapladib. Expert Opinion on Investigational Drugs, 2010, 19, 161-168.	1.9	14
4364	Primary prevention using statins: to be or not to be?. Current Medical Research and Opinion, 2010, 26, 2701-2706.	0.9	3
4365	An Evaluation of Diabetes-Related Measures of Control After 6 Months of Clinical Pharmacy Specialist Intervention. Journal of Pharmacy Practice, 2011, 24, 332-338.	0.5	23
4366	Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study. Annals of Medicine, 2011, 43, 545-554.	1.5	46
4367	Type 2 diabetes and cardiovascular risk factors. Current Medical Research and Opinion, 2011, 27, 1-5.	0.9	16
4368	Epidemiological link between low cholesterol and suicidality: A puzzle never finished. Nutritional Neuroscience, 2011, 14, 268-287.	1.5	27
4369	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation, 2011, 124, 2458-2473.	1.6	1,369
4370	Blood pressure lowering in patients with diabetes—“one level might not fit all. Nature Reviews Cardiology, 2011, 8, 42-49.	6.1	16
4371	ETC-216 for coronary artery disease. Expert Opinion on Biological Therapy, 2011, 11, 387-394.	1.4	25
4372	Triglycerides and Cardiovascular Disease. Circulation, 2011, 123, 2292-2333.	1.6	1,511
4373	Peripheral artery disease. Part 2: medical and endovascular treatment. Nature Reviews Cardiology, 2011, 8, 429-441.	6.1	32
4374	Percutaneous Management of Chronic Critical Limb Ischemia. Cardiology Clinics, 2011, 29, 395-410.	0.9	1
4376	LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 262-269.	3.1	10
4377	Statin-induced myopathies. Pharmacological Reports, 2011, 63, 859-866.	1.5	155
4378	Opening a New Lipid “Apo-theory”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. Mayo Clinic Proceedings, 2011, 86, 762-780.	1.4	32
4379	The REALIST (RESidual risk, Lipids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. Endocrinología Y Nutrición (English) Tj ETQq1 1 0.784314.gBT / Overlock 107		
4380	Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. Endocrinología Y Nutrición (English Edition), 2011, 58, 283-290.	0.5	2
4382	Secular Trends in Cardiovascular Mortality Rates of Patients Receiving Dialysis Compared With the General Population. American Journal of Kidney Diseases, 2011, 58, 64-72.	2.1	110

#	ARTICLE	IF	CITATIONS
4383	Coadministration of Atorvastatin Prevents Nitroglycerin-Induced Endothelial Dysfunction and Nitrate Tolerance in Healthy Humans. <i>Journal of the American College of Cardiology</i> , 2011, 57, 93-98.	1.2	32
4384	Peripheral Arterial Disease and Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1220-1225.	1.2	84
4385	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1002-1044.	1.2	346
4386	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 57, e16-e94.	1.2	249
4388	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2037-2114.	1.2	419
4389	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- σ ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, e215-e367.	1.2	420
4390	No Impact of KIF6 Genotype on Vascular Risk and Statin Response Among 18,348 Randomized Patients in the Heart Protection Study. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2000-2007.	1.2	55
4391	Low-Density Lipoprotein Lowering Does Not Improve Calf Muscle Perfusion, Energetics, or Exercise Performance in Peripheral Arterial Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1068-1076.	1.2	27
4392	Learning to Walk Before We Run. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1077-1079.	1.2	3
4393	Non-High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification. <i>Journal of the American College of Cardiology</i> , 2011, 58, 457-463.	1.2	132
4394	Benefit of Early Statin Therapy in Patients With Acute Myocardial Infarction Who Have Extremely Low Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1664-1671.	1.2	99
4395	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2550-2583.	1.2	114
4396	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	1.2	2,027
4397	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2584-2614.	1.2	76
4398	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 58, e123-e210.	1.2	665
4399	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2432-2446.	1.2	700
4400	Statins and their influence on brain cholesterol. <i>Journal of Clinical Lipidology</i> , 2011, 5, 373-379.	0.6	37
4401	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	0.6	235

#	ARTICLE	IF	CITATIONS
4404	Statins and myocardial remodelling: cell and molecular pathways. <i>Expert Reviews in Molecular Medicine</i> , 2011, 13, e22.	1.6	44
4405	Pharmacogenomics and adverse drug reactions: the case of statins. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1499-1509.	0.9	22
4406	Biological and Pharmacological Roles of HCA Receptors. <i>Advances in Pharmacology</i> , 2011, 62, 219-250.	1.2	55
4407	Statins for acute coronary syndrome. , 2011, , CD006870.		16
4408	Will apoA-I-based therapies step up to cure coronary artery disease?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1367-1370.	0.6	0
4409	Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 83-102.	1.6	25
4410	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. <i>Nature Reviews Cardiology</i> , 2011, 8, 253-265.	6.1	90
4411	The quality of diabetes care: A comparison between patients enrolled and not enrolled on a regional diabetes register. <i>Primary Care Diabetes</i> , 2011, 5, 131-137.	0.9	8
4413	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2078-2087.	13.9	731
4414	Comprehensive Cardiovascular Medicine in the Primary Care Setting. , 2011, , .		0
4415	Nitrite and Nitrate in Human Health and Disease. , 2011, , .		45
4416	Guidelines for the Primary Prevention of Stroke. <i>Stroke</i> , 2011, 42, 517-584.	1.0	1,289
4417	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. , 2011, , .		11
4418	Statins, inflammation and kidney disease. <i>Nature Reviews Nephrology</i> , 2011, 7, 385-397.	4.1	72
4419	Ischemic Stroke: Basic Pathophysiology and Neuroprotective Strategies. , 2011, , 1-24.		4
4422	Differential Improvements in Lipid Profiles and Framingham Recurrent Risk Score in Patients With and Without Diabetes Mellitus Undergoing Long-Term Cardiac Rehabilitation. <i>Archives of Physical Medicine and Rehabilitation</i> , 2011, 92, 1382-1387.	0.5	17
4424	Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. <i>Clínica E Investigación En Arteriosclerosis</i> , 2011, 23, 230-239.	0.4	0
4425	Renal Accumulation of Biglycan and Lipid Retention Accelerates Diabetic Nephropathy. <i>American Journal of Pathology</i> , 2011, 179, 1179-1187.	1.9	43

#	ARTICLE	IF	CITATIONS
4426	Activating Peripheral Arterial Disease Patients to Reduce Cholesterol: A Randomized Trial. <i>American Journal of Medicine</i> , 2011, 124, 557-565.	0.6	21
4427	Drug Utilization Patterns and Cardiovascular Outcomes in Elderly Patients Newly Initiated on Atorvastatin or Simvastatin. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 471-482.	3.0	7
4429	Tratamiento endovascular de la patologíA obstructiva aortoiliaca. <i>Angiologia</i> , 2011, 63, 75-94.	0.0	2
4430	Cholesterol and benign prostate disease. <i>Differentiation</i> , 2011, 82, 244-252.	1.0	43
4431	The effect of atorvastatin on mRNA levels of inflammatory genes expression in human peripheral blood lymphocytes by DNA microarray. <i>Biomedicine and Pharmacotherapy</i> , 2011, 65, 118-122.	2.5	24
4432	Selenium and other antioxidants for chemoprevention of gastrointestinal cancers. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 507-518.	1.0	39
4433	Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1130-1137.	1.8	28
4434	Current status of statin therapy for stroke prevention. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1305-1314.	0.6	14
4435	Current developments in lipid-lowering therapy for the patient with chronic kidney disease. <i>Clinical Lipidology</i> , 2011, 6, 693-702.	0.4	0
4436	Observational studies in systemic reviews of comparative effectiveness: AHRQ and the Effective Health Care Program. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1178-1186.	2.4	53
4437	Duration and magnitude of the effect of a single statin tablet in primary prevention of cardiovascular events. <i>International Journal of Cardiology</i> , 2011, 149, 102-107.	0.8	5
4438	The large clinical statin trials. <i>International Journal of Cardiology</i> , 2011, 150, 108-111.	0.8	2
4439	Burden of acute myocardial infarction. <i>International Journal of Cardiology</i> , 2011, 150, 111-112.	0.8	20
4440	I. Stroke in General. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2011, 20, S7-S30.	0.7	22
4441	Anti-AÎ² Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift. <i>Neuron</i> , 2011, 69, 203-213.	3.8	350
4442	Non-cholesterol sterols in serum and endarterectomized carotid arteries after a short-term plant stanol and sterol ester challenge. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 182-188.	1.1	21
4443	ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 406-411.	1.1	36
4444	Intervenci3n sobre mÃltiples factores de riesgo para prevenir la enfermedad cardiovascular. Un enfoque basado en la evidencia. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 173-174.	0.6	3

#	ARTICLE	IF	CITATIONS
4445	Enfermedad cardiovascular en el anciano. Revista Espanola De Cardiologia, 2011, 64, 697-712.	0.6	59
4447	Prevençi3n de la diabetes mellitus 2. Semergen, 2011, 37, 496-503.	0.2	1
4448	European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus. Executive Summary. Diabetes and Metabolism, 2011, 37, S27-S38.	1.4	266
4449	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
4450	Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 109-124.	0.2	262
4451	Statins for the primary prevention of cardiovascular disease. , 2011, , CD004816.		204
4452	Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study assists the view that a fasting plasma glucose level >100mg/dL increases cardiovascular risk. Journal of Diabetes Investigation, 2011, 2, 399-405.	1.1	0
4453	Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand. International Journal of Pharmacy Practice, 2011, 19, 129-135.	0.3	8
4454	Targeting Inflammation as a Therapeutic Strategy in Accelerated Atherosclerosis in Rheumatoid Arthritis. Cardiovascular Therapeutics, 2011, 29, 231-242.	1.1	21
4455	Introduction. Atherosclerosis Supplements, 2011, 12, 265-266.	1.2	8
4456	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 34). Current Medical Research and Opinion, 2011, 27, 1119-1129.	0.9	43
4457	Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology, 2011, 8, 13-28.	6.1	148
4458	Multiple Risk Factor Intervention to Prevent Cardiovascular Disease. A High Powered and Evidence Based Approach. Revista Espanola De Cardiologia (English Ed), 2011, 64, 173-174.	0.4	1
4459	Cardiovascular Disease in the Elderly. Revista Espanola De Cardiologia (English Ed), 2011, 64, 697-712.	0.4	13
4460	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American Society of Hypertension, 2011, 5, 259-352.	2.3	125
4461	Differential metabolic effects of distinct statins. Atherosclerosis, 2011, 215, 1-8.	0.4	116
4462	Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study. Atherosclerosis, 2011, 214, 426-431.	0.4	3
4463	Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis, 2011, 215, 266-278.	0.4	37

#	ARTICLE	IF	CITATIONS
4464	The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. <i>Atherosclerosis</i> , 2011, 218, 156-162.	0.4	74
4465	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1-44.	0.4	180
4466	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.4	561
4467	HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7. <i>Atherosclerosis</i> , 2011, 217, 407-414.	0.4	42
4468	C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. <i>Lancet</i> , The, 2011, 377, 469-476.	6.3	154
4469	CRP: star trekking the galaxy of risk markers. <i>Lancet</i> , The, 2011, 377, 441-442.	6.3	6
4470	Global trends in body-mass index – Authors' reply. <i>Lancet</i> , The, 2011, 377, 1917-1918.	6.3	8
4471	C-reactive protein in the Heart Protection Study. <i>Lancet</i> , The, 2011, 377, 1918.	6.3	4
4472	C-reactive protein in the Heart Protection Study – Authors' reply. <i>Lancet</i> , The, 2011, 377, 1918-1919.	6.3	5
4473	Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. <i>Lancet</i> , The, 2011, 378, 2013-2020.	6.3	244
4474	Synergistic/Additive Health Effects of Fish Oil and Bio-Active Compounds. , 2011, , 177-203.		0
4475	Higher Baseline LDL-C Levels Amplify the Short-Term Benefit of Early Intensive Statin Treatment in Acute Coronary Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 42-48.	0.9	6
4476	Early Statin Therapy Within 48 Hours Decreased One-Year Major Adverse Cardiac Events in Patients With Acute Myocardial Infarction. <i>International Heart Journal</i> , 2011, 52, 1-6.	0.5	12
4477	Mild Cognitive Impairment and Dementia. <i>Deutsches A&#x0308;rztblatt International</i> , 2011, 108, 743-50.	0.6	147
4480	Dyslipidemia Associated with Chronic Kidney Disease. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 41-48.	0.6	111
4481	ACE up the sleeve – are vascular patients medically optimized. <i>Vascular Health and Risk Management</i> , 2011, 7, 15.	1.0	14
4482	Atherosclerotic Plaque Regression and Arterial Reverse Remodelling in Carotid and Femoral Arteries by Statin Use in Primary Prevention Setting: Ultrasound Findings. , 2011, , .		0
4483	Coronary Artery Disease in the Elderly. , 0, , .		0

#	ARTICLE	IF	CITATIONS
4484	Lipid-lowering therapy: who can benefit. <i>Vascular Health and Risk Management</i> , 2011, 7, 525.	1.0	31
4485	Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. <i>Journal of Medical Investigation</i> , 2011, 58, 86-94.	0.2	17
4486	Aspectos clínicos e socioeconômicos das dislipidemias em portadores de doenças cardiovasculares. <i>Physis</i> , 2011, 21, 417-436.	0.1	2
4487	Statin Treatment Decreased Serum Asymmetric Dimethylarginine (ADMA) Levels in Ischemic Stroke Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 131-137.	0.9	27
4488	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. <i>Research and Reports in Urology</i> , 0, Volume 3, 95-104.	0.6	0
4489	Reducing CVD Risk with Lipid Management This article was first published in <i>British Journal of Cardiac Nursing</i> Vol. 5 No. 9, pp. 410-416. <i>Practice Nursing</i> , 2011, 22, 93-97.	0.1	0
4490	Vascular risk factors and their management. , 0, , 37-48.		0
4491	Management of acute limb ischaemia. , 0, , 49-57.		0
4492	Chronic lower limb ischaemia, critical ischaemia and the diabetic foot. , 0, , 58-71.		0
4493	Secondary Pharmacotherapeutic Prevention among German Primary Care Patients with Peripheral Arterial Disease. <i>International Journal of Vascular Medicine</i> , 2011, 2011, 1-5.	0.4	10
4494	Summary of AHRQ's Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 1-15.	2.2	10
4495	Prognosis after Stroke. , 2011, , 219-241.		5
4496	Results of a Randomized, Open-Label, Clinical Trial Investigating the Effects of Supplementation with <i>Heracleum persicum</i> Extract as an Adjunctive Therapy for Dyslipidemia. <i>Scientific World Journal</i> , The, 2011, 11, 592-601.	0.8	20
4497	Awareness of Abdominal Adiposity as a Cardiometabolic Risk Factor (The 5A Study): Mexico. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2011, 4, 107.	1.1	3
4498	Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e25920.	1.1	70
4499	Astragalus Polysaccharides Lowers Plasma Cholesterol through Mechanisms Distinct from Statins. <i>PLoS ONE</i> , 2011, 6, e27437.	1.1	35
4500	Effect of statin treatment on short term mortality after pneumonia episode: cohort study. <i>BMJ: British Medical Journal</i> , 2011, 342, d1642-d1642.	2.4	74
4501	Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2011, 342, d1250-d1250.	2.4	120

#	ARTICLE	IF	CITATIONS
4502	Treatment of Stable Angina Pectoris. American Journal of Therapeutics, 2011, 18, e138-e152.	0.5	9
4503	Ideal lipid profile and genes for an extended life span. Current Opinion in Cardiology, 2011, 26, 348-355.	0.8	12
4504	Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population. Journal of Cardiovascular Medicine, 2011, 12, 714-722.	0.6	7
4505	Impact of Preoperative Statin Therapy on Adverse Postoperative Outcomes in Patients Undergoing Vascular Surgery. Survey of Anesthesiology, 2011, 55, 233-234.	0.1	0
4506	Cardiac Rehabilitation. American Journal of Physical Medicine and Rehabilitation, 2011, 90, 599-611.	0.7	30
4507	Does Nurse Case Management Improve Implementation of Guidelines for Cardiovascular Disease Risk Reduction?. Journal of Cardiovascular Nursing, 2011, 26, 145-167.	0.6	35
4508	Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. Journal of Hypertension, 2011, 29, 592-599.	0.3	24
4509	Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome*. Critical Care Medicine, 2011, 39, 1343-1350.	0.4	181
4510	The Effect of Ezetimibe and Simvastatin on Monocyte Cytokine Release in Patients With Isolated Hypercholesterolemia. Journal of Cardiovascular Pharmacology, 2011, 57, 505-512.	0.8	31
4511	Lipid Management for the Prevention of Cardiovascular Disease. Current Pharmaceutical Design, 2011, 17, 852-860.	0.9	24
4512	Pathophysiology of Atherosclerosis: The Role of Inflammation. Current Pharmaceutical Design, 2011, 17, 4089-4110.	0.9	96
4513	Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis. Current Pharmaceutical Biotechnology, 2011, 12, 1463-1480.	0.9	0
4514	Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease. Coronary Artery Disease, 2011, 22, 352-358.	0.3	11
4515	Importance of reno-protection in adolescents with diabetes and microalbuminuria. Diabetes Management, 2011, 1, 485-496.	0.5	0
4516	Effects of niacin on atherosclerosis and vascular function. Current Opinion in Cardiology, 2011, 26, 66-70.	0.8	27
4517	Cholesterol and LDL Relate to Neuritic Plaques and to APOE4 Presence but Not to Neurofibrillary Tangles. Current Alzheimer Research, 2011, 8, 303-312.	0.7	30
4518	Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension. Circulation, 2011, 123, 2985-2993.	1.6	127
4519	Pleiotropic Effects of ARB on Dyslipidemia. Current Vascular Pharmacology, 2011, 9, 129-135.	0.8	15

#	ARTICLE	IF	CITATIONS
4520	Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 1082-1089.	0.9	20
4522	Diabetes monitoring: risk factors, complications and management. <i>NursePrescribing</i> , 2011, 9, 122-130.	0.1	3
4523	Statins for multiple sclerosis. <i>The Cochrane Library</i> , 2011, , CD008386.	1.5	23
4524	Clinical Usefulness of Additional Treatment With Ezetimibe in Patients With Coronary Artery Disease on Statin Therapy - From the Viewpoint of Cholesterol Metabolism -. <i>Circulation Journal</i> , 2011, 75, 2496-2504.	0.7	20
4525	Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia. <i>Endocrine Journal</i> , 2011, 58, 185-191.	0.7	9
4526	Effects of Hesperidin on the Progression of Hypercholesterolemia and Fatty Liver Induced by High-Cholesterol Diet in Rats. <i>Journal of Pharmacological Sciences</i> , 2011, 117, 129-138.	1.1	87
4527	The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. <i>Clinical Investigation</i> , 2011, 1, 137-144.	0.0	0
4528	Controlling lipids after acute coronary syndromes: what is the best strategy?. <i>Clinical Lipidology</i> , 2011, 6, 253-255.	0.4	0
4529	The rise of cholesterol testing: how much is unnecessary. <i>British Journal of General Practice</i> , 2011, 61, e81-e88.	0.7	22
4530	The Potential of Statins for Individualized Colorectal Cancer Chemoprevention. <i>Current Drug Targets</i> , 2011, 12, 1903-1908.	1.0	11
4531	Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study. <i>Heart</i> , 2011, 97, 923-930.	1.2	37
4532	Atorvastatin inhibits collar-induced intimal thickening of rat carotid artery: Effect on C-type natriuretic peptide expression. <i>Molecular Medicine Reports</i> , 2011, 5, 675-9.	1.1	2
4533	Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis. <i>Colorectal Disease</i> , 2011, 13, 1085-1099.	0.7	51
4534	Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2011, 28, 856-864.	1.2	13
4535	Haemostatic effects of simvastatin in subjects with impaired glucose tolerance. <i>Internal Medicine Journal</i> , 2011, 41, 473-481.	0.5	5
4536	Managing statin-induced muscle toxicity in a lipid clinic. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 336-341.	0.7	10
4537	Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 766-776.	1.1	32
4538	Use of principal component analysis in the evaluation of adherence to statin treatment: a method to determine a potential target population for public health intervention. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 528-533.	1.0	6

#	ARTICLE	IF	CITATIONS
4539	The Impact of Medicare Part D on Hospitalization Rates. <i>Health Services Research</i> , 2011, 46, 1022-1038.	1.0	55
4540	Statin wars: efficacy vs. cost. <i>International Journal of Clinical Practice</i> , 2011, 65, 108-111.	0.8	0
4541	Extended-release niacin/laropirant lipid-altering consistency across patient subgroups. <i>International Journal of Clinical Practice</i> , 2011, 65, 436-445.	0.8	13
4542	Adherence to lipid-lowering agents among 11,042 patients in clinical practice. <i>International Journal of Clinical Practice</i> , 2011, 65, 741-748.	0.8	15
4543	Anti-inflammatory and Monocyte-Suppressing Effects of Simvastatin in Patients with Impaired Fasting Glucose. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 131-137.	1.2	10
4544	Health Education in Patients with a Recent Stroke or Transient Ischaemic Attack: A Comprehensive Review. <i>International Journal of Stroke</i> , 2011, 6, 67-74.	2.9	26
4545	Impact of Lipid Apheresis on Egr1, Jun, Fos, and Hsp70 Gene Expression in White Blood Cells. <i>Therapeutic Apheresis and Dialysis</i> , 2011, 15, 105-112.	0.4	8
4546	Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 188-195.	1.0	24
4547	A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. <i>Nature Genetics</i> , 2011, 43, 339-344.	9.4	643
4548	Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. <i>Pharmacogenomics Journal</i> , 2011, 11, 72-80.	0.9	16
4549	Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment?. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 232-243.	1.6	18
4550	Low-density lipoprotein cholesterol to apolipoprotein B ratio is independently associated with metabolic syndrome in Korean men. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1136-1141.	1.5	9
4551	Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. <i>Journal of Cardiology</i> , 2011, 57, 172-180.	0.8	17
4552	Comprehensive Medical Management of Peripheral Arterial Disease. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 2-13.	1.6	24
4553	ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease. <i>Journal of Vascular Nursing</i> , 2011, 29, 23-60.	0.2	7
4554	Chapter III: Management of Cardiovascular Risk Factors and Medical Therapy. <i>European Journal of Vascular and Endovascular Surgery</i> , 2011, 42, S33-S42.	0.8	27
4555	Beneficio clnico de las estatinas: hemos cubierto todo el espectro?. <i>Revista Espanola De Cardiologia Suplementos</i> , 2011, 11, 3-13.	0.2	2
4556	Eficacia de las estatinas en el manejo de la dislipemia. Un paso adelante. <i>Revista Espanola De Cardiologia Suplementos</i> , 2011, 11, 14-20.	0.2	0

#	ARTICLE	IF	CITATIONS
4557	Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. Revista Espanola De Cardiologia Suplementos, 2011, 11, 29-35.	0.2	1
4558	Control de la dislipemia en grupos clnicos especiales: mujeres, ancianos, VIH, enfermedad renal crnica, pacientes con sndrome metablico. Revista Espanola De Cardiologia Suplementos, 2011, 11, 36-41.	0.2	2
4559	Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer, 2011, 11, 409.	1.1	108
4560	Combination Therapy With Ezetimibe/Simvastatin Versus Statin Monotherapy for Low-Density Lipoprotein Cholesterol Reduction and Goal Attainment in a Real-World Clinical Setting. Clinical Therapeutics, 2011, 33, 212-224.	1.1	23
4561	Costs and health effects of adding functional foods containing phytosterols/-stanols to statin therapy in the prevention of cardiovascular disease. European Journal of Pharmacology, 2011, 668, S91-S100.	1.7	12
4562	A Randomised Placebo-controlled Double-blind Trial to Evaluate Lipid-lowering Pharmacotherapy on Proteolysis and Inflammation in Abdominal Aortic Aneurysms. European Journal of Vascular and Endovascular Surgery, 2011, 41, 28-35.	0.8	34
4563	Medical Treatment after Peripheral Bypass Surgery over the Past Decade. European Journal of Vascular and Endovascular Surgery, 2011, 41, 805-813.	0.8	5
4564	The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids. American Journal of Cardiology, 2011, 107, 230-242.	0.7	1
4565	Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. American Journal of Cardiology, 2011, 108, 3B-24B.	0.7	254
4566	Current Evidence for Perioperative Statins in Cardiac Surgery. Annals of Thoracic Surgery, 2011, 92, 372-379.	0.7	14
4567	Developing predictive CSF biomarkers—A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochemical Pharmacology, 2011, 81, 1422-1434.	2.0	41
4568	Research Highlights. Pharmacogenomics, 2011, 12, 773-778.	0.6	0
4569	Peripheral Arterial Disease—What Do We Need to Know?. Clinical Cardiology, 2011, 34, 478-482.	0.7	20
4570	Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs, 2011, 16, 247-270.	1.0	14
4571	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	0.7	97
4572	Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study. Netherlands Heart Journal, 2011, 19, 17-23.	0.3	13
4573	Personalized vascular medicine: Individualizing drug therapy. Vascular Medicine, 2011, 16, 391-404.	0.8	16
4574	Statins and Intracerebral Hemorrhage. Circulation, 2011, 124, 2233-2242.	1.6	164

#	ARTICLE	IF	CITATIONS
4575	Concise guide to recommended lipid-lowering drug treatment. <i>The Prescriber</i> , 2011, 22, 18-32.	0.1	0
4576	Statins: the key trials. <i>Trends in Urology & Men's Health</i> , 2011, 2, 30-33.	0.2	0
4577	Statins in Heart Failure—Where Do We Stand?. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 99-104.	1.3	4
4578	Combined survival analysis of cardiac patients by a Cox PH model and a Markov chain. <i>Lifetime Data Analysis</i> , 2011, 17, 496-513.	0.4	4
4579	Quantifying links between stroke and risk factors: a study on individual health risk appraisal of stroke in a community of Chongqing. <i>Neurological Sciences</i> , 2011, 32, 211-219.	0.9	3
4582	September 10-14 Munich, Germany CIRSE 2011. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 331-7.	0.9	10
4583	Suboptimal use of statins at treatment initiation. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 971-973.	0.8	9
4585	Polycystic Ovary Syndrome: A Common Endocrine Disorder and Risk Factor for Vascular Disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 289-301.	0.4	37
4586	Peripheral Artery Disease in the Elderly: Prevalence, Clinical Implications, and Therapy. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 457-466.	0.8	0
4587	Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. <i>Advances in Therapy</i> , 2011, 28, 811-823.	1.3	31
4588	Long-term efficacy of pitavastatin versus simvastatin. <i>Advances in Therapy</i> , 2011, 28, 799-810.	1.3	29
4589	A practical approach to lipid management in the elderly. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 65-70.	1.5	1
4590	Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications. <i>Neurotherapeutics</i> , 2011, 8, 361-373.	2.1	114
4591	Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled Trials. <i>Journal of General Internal Medicine</i> , 2011, 26, 783-790.	1.3	324
4592	Statins and Renal Disease: Friend or Foe?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 57-63.	2.0	3
4593	Are Cardiovascular Benefits in Statin Lipid Effects Dependent on Baseline Lipid Levels?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 64-72.	2.0	5
4594	Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2011, 13, 287-295.	1.3	10
4595	Coronary Artery Calcium: Utilization for Primary Prevention of CHD. <i>Current Cardiology Reports</i> , 2011, 13, 465-474.	1.3	7

#	ARTICLE	IF	CITATIONS
4596	Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 46.	0.7	42
4597	Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 56.	0.7	40
4598	Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. <i>BMC Family Practice</i> , 2011, 12, 59.	2.9	66
4599	Atorvastatin prevents <i>Plasmodium falciparum</i> cytoadherence and endothelial damage. <i>Malaria Journal</i> , 2011, 10, 52.	0.8	36
4600	Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2011, 13, 37.	1.6	46
4601	Inhibition of endothelial adhesion molecule expression by <i>Monascus purpureus</i> -fermented rice metabolites, monacolin K, ankaflavin, and monascin. <i>Journal of the Science of Food and Agriculture</i> , 2011, 91, 1751-1758.	1.7	59
4602	Prevalence and risk factors of muscle complications secondary to statins. <i>Muscle and Nerve</i> , 2011, 44, 877-881.	1.0	72
4603	Importance of high-density lipoprotein-cholesterol (HDL-C) levels to the incidence of cardiovascular disease (CVD) in the elderly. <i>Archives of Gerontology and Geriatrics</i> , 2011, 52, 217-222.	1.4	33
4604	Health benefits of sea buckthorn for the prevention of cardiovascular diseases. <i>Journal of Functional Foods</i> , 2011, 3, 2-12.	1.6	62
4605	A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. <i>Neurology</i> , 2011, 77, 556-563.	1.5	269
4606	Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 99-117.	0.9	5
4607	Clinical trials of lipid-modifying agents: design considerations. <i>Clinical Lipidology</i> , 2011, 6, 109-116.	0.4	0
4608	The Role of Statins in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 34, 195-202.	1.4	37
4609	Statins for secondary prevention: might less in fact be more?. <i>Nature Reviews Endocrinology</i> , 2011, 7, 131-132.	4.3	1
4610	Dyslipidemia, Statins, and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 897-902.	1.5	23
4611	Statin myopathy: A common dilemma not reflected in clinical trials. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, 393-403.	0.6	184
4612	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. <i>Stroke</i> , 2011, 42, e420-63.	1.0	132
4613	Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients. <i>Journal of Human Hypertension</i> , 2011, 25, 492-499.	1.0	10

#	ARTICLE	IF	CITATIONS
4633	Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 254-261.	3.1	18
4634	Lipoprotein(a) Genetic Variants Associated With Coronary and Peripheral Vascular Disease but Not With Stroke Risk in the Heart Protection Study. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 68-73.	5.1	47
4635	Benefit of Intensive Statin Therapy in Women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 328-336.	0.9	61
4636	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Circulation</i> , 2011, 124, 2574-2609.	1.6	500
4637	Treatment of diabetic vasculopathy: an overview. <i>Research and Reports in Endocrine Disorders</i> , 0, , 21.	0.4	2
4638	Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 209-217.	0.9	15
4639	Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. <i>Nephron Clinical Practice</i> , 2011, 118, c71-c100.	2.3	23
4640	Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. <i>Journal of Hypertension</i> , 2011, 29, 1757-1764.	0.3	31
4641	Low Cholesterol Triggers Membrane Microdomain-dependent CD44 Shedding and Suppresses Tumor Cell Migration. <i>Journal of Biological Chemistry</i> , 2011, 286, 1999-2007.	1.6	144
4642	The Metabolic Syndrome. , 2011, , 13-39.		2
4643	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. <i>Circulation</i> , 2011, 124, e54-130.	1.6	100
4644	Cholesterol Level and Statin Use in Alzheimer Disease. <i>Archives of Neurology</i> , 2011, 68, 1385.	4.9	166
4645	Treatment strategies for chronic stable angina. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2833-2844.	0.9	6
4646	Hyperlipidemia in Primary Care. , 2011, , .		2
4648	Effect of simvastatin on the expression and regulation mechanism of apolipoprotein M. <i>International Journal of Molecular Medicine</i> , 2012, 29, 510-4.	1.8	5
4649	Significance of LDL-C lowering therapy in diabetic patients. <i>Clinical Lipidology</i> , 2011, 6, 389-399.	0.4	4
4650	Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose. <i>Pharmacology</i> , 2011, 87, 63-69.	0.9	26
4651	Proteomic Approach to the Study of Statin Pleiotropy in Kidney Transplant Patients. <i>Pharmacology</i> , 2011, 87, 161-168.	0.9	10

#	ARTICLE	IF	CITATIONS
4652	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. <i>Stroke</i> , 2011, 42, e464-540.	1.0	162
4653	Previous Statin Use Is Not Associated With an Increased Prevalence or Degree of Gradient-Echo Lesions in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2011, 42, 354-358.	1.0	18
4654	Dyslipidemias in the older subject: features,significance and treatment dilemmas. <i>Clinical Lipidology</i> , 2011, 6, 339-350.	0.4	3
4655	Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. <i>European Heart Journal</i> , 2011, 32, 2650-2659.	1.0	111
4656	Vulnerable Plaque and Inflammation: Potential Clinical Strategies. <i>Current Pharmaceutical Design</i> , 2011, 17, 4190-4209.	0.9	41
4657	Medical Treatment of Critical Limb Ischemia: Current State and Future Directions. <i>Current Vascular Pharmacology</i> , 2011, 9, 658-676.	0.8	31
4658	The facts behind niacin. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 227-240.	1.0	20
4659	Statin Use in Outpatients With Obstructive Coronary Artery Disease. <i>Circulation</i> , 2011, 124, 2405-2410.	1.6	62
4660	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Nonâ€“ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2011, 123, e426-579.	1.6	658
4661	Lipid-lowering effects of ezetimibe and simvastatin in combination. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 131-145.	0.6	14
4662	Lipid parameters for measuring risk of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2011, 8, 197-206.	6.1	177
4663	Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1945-1958.	0.9	24
4664	The structure of optimal statin initiation policies for patients with Type 2 diabetes. <i>IIE Transactions on Healthcare Systems Engineering</i> , 2011, 1, 49-65.	0.8	33
4665	Atlas of Atherosclerosis and Metabolic Syndrome. , 2011, , .		5
4666	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
4667	Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. <i>Clinical Science</i> , 2011, 121, 449-458.	1.8	52
4668	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. <i>Vascular Medicine</i> , 2011, 16, 35-77.	0.8	81
4669	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. <i>Circulation</i> , 2011, 124, 2610-2642.	1.6	451

#	ARTICLE	IF	CITATIONS
4670	Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1316-1325.	2.2	116
4671	Primary prevention of stroke: blood pressure, lipids, and heart failure. <i>European Heart Journal</i> , 2011, 32, 545-552.	1.0	76
4672	Medical angioplasty - Hope and expectations: An optimistic overview. <i>Journal of Family and Community Medicine</i> , 2011, 18, 101.	0.5	0
4673	Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 75-78.	0.8	8
4674	Translating Cholesterol Guidelines Into Primary Care Practice: A Multimodal Cluster Randomized Trial. <i>Annals of Family Medicine</i> , 2011, 9, 528-537.	0.9	20
4675	Pitavastatin: finding its place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 101-117.	1.1	13
4676	What are the Evidence Based Public Health Interventions for Prevention and Control of NCDs in Relation to India?. <i>Indian Journal of Community Medicine</i> , 2011, 36, 23.	0.2	8
4677	Radiofrequency intravascular ultrasound and detection of the vulnerable plaque. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012, 73, 682-686.	0.2	0
4678	Why Do We Still Need Large Scale Clinical Trial: The Case of n ³ PUFA. <i>Frontiers in Physiology</i> , 2012, 3, 202.	1.3	2
4680	Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H153-H158.	1.5	12
4681	Stroke Prevention: Managing Modifiable Risk Factors. <i>Stroke Research and Treatment</i> , 2012, 2012, 1-15.	0.5	22
4682	Drug Trials for Older People. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67A, 152-157.	1.7	35
4683	Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. <i>PLoS Medicine</i> , 2012, 9, e1001310.	3.9	78
4684	Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics. <i>Current Alzheimer Research</i> , 2012, 9, 718-723.	0.7	51
4685	The Role of Lipid Rafts in Cancer Cell Adhesion and Migration. <i>International Journal of Cell Biology</i> , 2012, 2012, 1-6.	1.0	107
4686	Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. <i>Cholesterol</i> , 2012, 2012, 1-7.	1.6	49
4687	Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women's Health Initiative. <i>Archives of Internal Medicine</i> , 2012, 172, 144.	4.3	365
4688	Medical therapy for peripheral arterial disease. <i>Current Opinion in Cardiology</i> , 2012, 27, 592-597.	0.8	17

#	ARTICLE	IF	CITATIONS
4689	The Effects of Statins on Prevention of Stroke and Dementia. Journal of Cardiopulmonary Rehabilitation and Prevention, 2012, 32, 240-249.	1.2	10
4690	Evaluation of Cardiovascular Morbidity Associated with Adherence to Atorvastatin Therapy. American Journal of Therapeutics, 2012, 19, 24-32.	0.5	34
4691	Inclusion of Stroke in Cardiovascular Risk Prediction Instruments. Stroke, 2012, 43, 1998-2027.	1.0	125
4692	Low-density lipoprotein-lowering strategies. Current Opinion in Cardiology, 2012, 27, 405-411.	0.8	16
4693	Targeting HDL-cholesterol to reduce residual cardiovascular risk. Current Opinion in Lipidology, 2012, 23, 172-174.	1.2	7
4694	Mipomersen. Cardiology in Review, 2012, 20, 90-95.	0.6	55
4695	Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies. Diabetes and Vascular Disease Research, 2012, 9, 138-145.	0.9	7
4696	Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Therapeutic Advances in Drug Safety, 2012, 3, 35-46.	1.0	16
4697	Lipid-Modifying Therapies and Risk of Pancreatitis. JAMA - Journal of the American Medical Association, 2012, 308, 804.	3.8	140
4699	Statin Use and Intracerebral Hemorrhage. Archives of Neurology, 2012, 69, 13.	4.9	10
4700	Acute Coronary Events. Circulation, 2012, 125, 1147-1156.	1.6	244
4702	Multiple comparisons, interaction effects, and statistical inference: lessons from chronic kidney disease progression among blacks. Kidney International, 2012, 81, 516-519.	2.6	1
4703	The statin-low cholesterol-cancer conundrum. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 383-388.	0.2	70
4704	Critical Limb Ischemia : Advanced Medical Therapy. Methodist DeBakey Cardiovascular Journal, 2012, 8, 3-9.	0.5	5
4705	Do statins reduce the risk of aneurysm development: a case-control study. Journal of Neurosurgery, 2012, 116, 638-642.	0.9	47
4706	Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ, The, 2012, 345, e4535-e4535.	3.0	55
4707	Screening for Coronary Artery Disease in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1434-1442.	1.8	22
4708	Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. Journal of Medical Economics, 2012, 15, 1118-1129.	1.0	16

#	ARTICLE	IF	CITATIONS
4709	Cholesterol and Late-Life Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2012, 30, S147-S162.	1.2	82
4710	Blood pressure control status and effects of pravastatin on cardiovascular events occurrence in patients with dyslipidaemia. <i>Journal of Human Hypertension</i> , 2012, 26, 388-395.	1.0	4
4711	Prevention of Vascular Cognitive Impairment. <i>Stroke</i> , 2012, 43, 3137-3146.	1.0	92
4712	Cardiology in Family Practice. , 2012, , .		3
4713	Optimizing Statin Treatment Decisions for Diabetes Patients in the Presence of Uncertain Future Adherence. <i>Medical Decision Making</i> , 2012, 32, 154-166.	1.2	37
4714	The case for more intensive use of statins. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 201-210.	1.1	3
4715	Low Cholesterol, Statins and Outcomes in Patients with First-Ever Acute Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 2012, 34, 213-220.	0.8	40
4716	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary. <i>Circulation</i> , 2012, 126, 3097-3137.	1.6	1,188
4717	Fasting for Lipid Testing: Is It Worth the Trouble?. <i>Archives of Internal Medicine</i> , 2012, 172, 1710.	4.3	22
4718	Statin Use During Ischemic Stroke Hospitalization Is Strongly Associated With Improved Poststroke Survival. <i>Stroke</i> , 2012, 43, 147-154.	1.0	134
4719	Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease. <i>Clinical Medicine Insights: Cardiology</i> , 2012, 6, CMC.S4324.	0.6	94
4720	Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2012, 5, CMED.S7591.	1.0	15
4721	African Americans and Peripheral Arterial Disease: A Review Article. <i>ISRN Vascular Medicine</i> , 2012, 2012, 1-9.	0.7	2
4722	The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease—A Retrospective Single Center Experience. <i>ISRN Cardiology</i> , 2012, 2012, 1-5.	1.6	0
4723	Established and Emerging Approaches for the Management of Dyslipidaemia. <i>Scientifica</i> , 2012, 2012, 1-14.	0.6	2
4724	A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study. <i>Advances in Preventive Medicine</i> , 2012, 2012, 1-11.	1.1	8
4725	Understanding Postprandial Inflammation and Its Relationship to Lifestyle Behaviour and Metabolic Diseases. <i>International Journal of Vascular Medicine</i> , 2012, 2012, 1-11.	0.4	72
4726	The Quality and Impact of Risk Factor Control in Patients With Stable Claudication Presenting for Peripheral Vascular Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 850-855.	1.4	44

#	ARTICLE	IF	CITATIONS
4727	BENEFITS OF PHARMACEUTICAL INNOVATION: THE CASE OF SIMVASTATIN IN CANADA. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 390-397.	0.2	2
4728	Starting and staying on preventive medication for cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2012, 27, 533-541.	0.8	5
4729	Effect of Statins on Skeletal Muscle. <i>Exercise and Sport Sciences Reviews</i> , 2012, 40, 188-194.	1.6	104
4730	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Circulation</i> , 2012, 126, e354-471.	1.6	675
4731	Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention. <i>International Journal of Occupational and Environmental Health</i> , 2012, 18, 70-78.	1.2	3
4732	High-Dose Statins Should Be Used in All Acute Ischemic Strokes. <i>Stroke</i> , 2012, 43, 1992-1993.	1.0	15
4733	Statin Therapy and the Risk of Intracerebral Hemorrhage. <i>Stroke</i> , 2012, 43, 2149-2156.	1.0	266
4734	Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: an analysis of three successive cohorts between 2003 and 2008. <i>European Heart Journal</i> , 2012, 33, 515-522.	1.0	16
4735	A Mechanistic, Model-Based Approach to Safety Assessment in Clinical Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2012, 1, 1-8.	1.3	36
4736	American Association of Clinical Endocrinologists™ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: Executive Summary. <i>Endocrine Practice</i> , 2012, 18, 269-293.	1.1	61
4738	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. <i>Anesthesia and Analgesia</i> , 2012, 114, 11-45.	1.1	35
4739	Should patients with high cardiovascular risk and an LDL-C concentration below 70 mg/dl be treated with aggressive statin therapy?. <i>Clinical Lipidology</i> , 2012, 7, 1-4.	0.4	0
4740	Comorbidities and complications: when, how and who to screen and when to treat? Microalbuminuria in adolescents with Type 1 diabetes. <i>Diabetes Management</i> , 2012, 2, 549-557.	0.5	3
4741	Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke. <i>Current Pharmaceutical Design</i> , 2012, 18, 5261-5272.	0.9	7
4744	The Association Between Measures of Inflammation and Psychological Factors Associated with an Increased Risk of Atherosclerotic Cardiovascular Disease: Hostility, Anger and Depressed Mood and Symptoms. , 2012, , .		4
4745	Lipid Lowering Agents, Cognitive Decline, and Dementia: The Three-City Study. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 629-637.	1.2	66
4746	Module 15. Statins and their role in the prevention of cardiovascular disease. <i>NursePrescribing</i> , 2012, 10, 1-11.	0.1	0
4747	Type 2 diabetes is a poor example of the overuse of surrogate markers. <i>BMJ: British Medical Journal</i> , 2012, 344, e735-e735.	2.4	0

#	ARTICLE	IF	CITATIONS
4748	Fixed-dose combination therapy for the prevention of cardiovascular disease. , 2012, , .		1
4749	Symptomatic Low-Grade Carotid Stenosis With Intraplaque Hemorrhage and Expansive Arterial Remodeling Is Associated With a High Relapse Rate Refractory to Medical Treatment. <i>Neurosurgery</i> , 2012, 70, 1143-1151.	0.6	53
4750	Naringin Ameliorates Atherogenic Dyslipidemia but not Hyperglycemia in Rats With Type 1 Diabetes. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 133-141.	0.8	38
4751	Attainment of combined optimal lipid values with the use of niacin: has AIM-HIGH closed the book on this debate?. <i>Clinical Lipidology</i> , 2012, 7, 389-396.	0.4	0
4752	The Treatment of cardiovascular Risk in Primary care using Electronic Decision support (TORPEDO) study: intervention development and protocol for a cluster randomised, controlled trial of an electronic decision support and quality improvement intervention in Australian primary healthcare. <i>BMJ Open</i> , 2012, 2, e002177.	0.8	36
4754	Midlife Vascular Risk Factors and Alzheimer's Disease: Evidence from Epidemiological Studies. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 531-540.	1.2	113
4755	Dyslipidemia and Dementia: Current Epidemiology, Genetic Evidence, and Mechanisms Behind the Associations. <i>Journal of Alzheimer's Disease</i> , 2012, 30, S127-S145.	1.2	54
4756	Fibrates for primary prevention of cardiovascular disease events. , 2012, , .		8
4757	Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012, 52, 613-621.	0.7	74
4758	Secondary Prevention and Mortality in Peripheral Artery Disease: National Health and Nutrition Examination Study, 1999 to 2004. <i>Yearbook of Vascular Surgery</i> , 2012, 2012, 37-39.	0.0	0
4760	Statin Use in Outpatients With Obstructive Coronary Artery Disease. <i>Yearbook of Endocrinology</i> , 2012, 2012, 59-62.	0.0	0
4761	Treatment of hypercholesterolemia and hypertension in diabetics with coronary artery disease. <i>Clinical Lipidology</i> , 2012, 7, 689-695.	0.4	2
4762	Free radical biology of the cardiovascular system. <i>Clinical Science</i> , 2012, 123, 73-91.	1.8	132
4763	Emerging therapies for pulmonary arterial hypertension: a review of recently completed and ongoing clinical trials. <i>Clinical Investigation</i> , 2012, 2, 491-501.	0.0	0
4764	The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. <i>Lancet, The</i> , 2012, 380, 581-590.	6.3	2,250
4765	Targeting tumor cell metabolism with statins. <i>Oncogene</i> , 2012, 31, 4967-4978.	2.6	193
4766	Comparison of Coronary Calcium Screening Versus Broad Statin Therapy for Patients at Intermediate Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2012, 110, 530-533.	0.7	7
4767	The Antihypertensive Actions of Statins: Modulation by Salt Intake. <i>American Journal of Hypertension</i> , 2012, 25, 1140-1148.	1.0	11

#	ARTICLE	IF	CITATIONS
4768	Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: A systematic review and meta-analysis. <i>Nephrology</i> , 2012, 17, 545-551.	0.7	30
4769	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	13.9	1,754
4770	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2564-2603.	1.2	191
4771	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, e44-e164.	1.2	1,423
4772	Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. <i>Cardiovascular Therapeutics</i> , 2012, 30, 61-74.	1.1	15
4773	Statin Myopathy: A Lipid Clinic Experience on the Tolerability of Statin Rechallenge. <i>Cardiovascular Therapeutics</i> , 2012, 30, e212-8.	1.1	29
4774	Efficacy and Safety of Statins in Older Adults. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 372-379.	0.8	2
4775	Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 145-157.	0.2	60
4776	Cholesterol and Alzheimer's disease: A still poorly understood correlation. <i>IUBMB Life</i> , 2012, 64, 931-935.	1.5	40
4777	Effect of statins on coronary bifurcation atherosclerosis: an intravascular ultrasound virtual histology study. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 1643-1652.	0.7	8
4778	Inhibition of Cholesterol Absorption: Targeting the Intestine. <i>Pharmaceutical Research</i> , 2012, 29, 3235-3250.	1.7	15
4779	Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men. <i>Journal of Clinical Lipidology</i> , 2012, 6, 58-65.	0.6	3
4780	Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence. <i>Journal of Clinical Lipidology</i> , 2012, 6, 413-426.	0.6	74
4781	Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. <i>Journal of Clinical Lipidology</i> , 2012, 6, 303-309.	0.6	42
4782	Statins, Risk of Dementia, and Cognitive Function: Secondary Analysis of the Ginkgo Evaluation of Memory Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 436-444.	0.7	108
4783	Statins and Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 547-556.	2.5	133
4784	Suboptimal Attainment of Cardiovascular Disease Prevention Guideline Goals in Korean Women. <i>Asian Nursing Research</i> , 2012, 6, 49-54.	0.7	4
4785	Estatinas en pacientes sin enfermedad cardiovascular: una revisión crítica. <i>Farmacéuticos De Atención Primaria</i> , 2012, 10, 36-43.	0.0	1

#	ARTICLE	IF	CITATIONS
4786	Statins and other agents for vascular inflammation. <i>Journal of Vascular Surgery</i> , 2012, 56, 1799-1806.	0.6	11
4787	Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6503-6508.	1.0	18
4788	Epidemiología de la angina estable y comorbilidad. <i>Revista Española De Cardiología Suplementos</i> , 2012, 12, 3-8.	0.2	6
4790	AMPK in myocardial infarction and diabetes: the yin/yang effect. <i>Acta Pharmaceutica Sinica B</i> , 2012, 2, 368-378.	5.7	23
4791	Concepto y componentes del riesgo residual. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2012, 24, 8-13.	0.4	0
4792	Improving Compliance with Statins in Patients with Peripheral Arterial Disease: A Quality Improvement Study. <i>Annals of Medicine and Surgery</i> , 2012, 1, 30-33.	0.5	4
4793	Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Lowering With Atorvastatin in Patients of South Asian Compared With European Origin: Insights From the Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration (ACTFAST) Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 850-858.	1.0	15
4794	Significant Increase in High-Density Lipoprotein Cholesterol with Fibrates Is Associated with Low Pretreatment High-Density Lipoprotein Cholesterol: Findings from an Outpatient Clinic Setting. <i>Metabolic Syndrome and Related Disorders</i> , 2012, 10, 189-194.	0.5	8
4795	Implementation of Medicare Part D and statin use among the elderly population with diabetes. <i>Journal of Pharmaceutical Health Services Research</i> , 2012, 3, 191-196.	0.3	3
4796	Let's (Not) Do It Again: Secondary Prevention of Cardiovascular Disease in Women. <i>Journal of Women's Health</i> , 2012, 21, 108-109.	1.5	0
4797	An Evidence-Based Systematic Review of Vitamin A by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2012, 9, 299-416.	1.4	9
4798	Extended-release niacin with laropirant: a review on efficacy, clinical effectiveness and safety. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1345-1362.	0.9	24
4799	The risk factors of CVA in Jordan. <i>Physiotherapy Theory and Practice</i> , 2012, 28, 588-594.	0.6	3
4800	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. <i>Endocrine Practice</i> , 2012, 18, 1-78.	1.1	386
4801	Daily and intermittent rosuvastatin 5-mg therapy in statin intolerant patients: an observational study. <i>Current Medical Research and Opinion</i> , 2012, 28, 371-378.	0.9	45
4802	Industry funded clinical trials: bias and quality. <i>Current Medical Research and Opinion</i> , 2012, 28, 23-25.	0.9	7
4803	Consistency of Extended-Release Niacin/Laropirant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 197-206.	1.0	14
4804	Nutrition and the healthy heart with an exercise boost. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012, 90, 967-976.	0.7	17

#	ARTICLE	IF	CITATIONS
4805	Three Reasons to Abandon Low-Density Lipoprotein Targets. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 2-5.	0.9	108
4806	The emerging role of plasma lipidomics in cardiovascular drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 63-72.	2.5	20
4807	Statin therapy for the octogenarian?. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, 37-42.	0.4	3
4808	Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1496-1501.	0.5	38
4810	Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. <i>Neuroscience</i> , 2012, 202, 1-9.	1.1	58
4811	Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 400-408.	1.1	24
4812	The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 424-431.	1.0	18
4813	Systematic Review of Guidelines on Peripheral Artery Disease Screening. <i>American Journal of Medicine</i> , 2012, 125, 198-208.e3.	0.6	59
4814	Assessment of the use of hypolipidemic agents (HAs), mainly statins, in elderly subjects aged 80 years and more in Burgundy: Analysis of 13,211 patients. <i>Archives of Gerontology and Geriatrics</i> , 2012, 55, 101-105.	1.4	4
4817	Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: Comparative analysis with rosuvastatin alone by intravascular ultrasound. <i>International Journal of Cardiology</i> , 2012, 158, 217-224.	0.8	14
4818	Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. <i>International Journal of Cardiology</i> , 2012, 158, 400-404.	0.8	42
4819	Managing the underestimated risk of statin-associated myopathy. <i>International Journal of Cardiology</i> , 2012, 159, 169-176.	0.8	84
4820	Short-term effects of eicosapentaenoic acid on P wave signal-averaged electrocardiogram in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2012, 154, 200-202.	0.8	1
4821	Hypertensive crisis: Comparison between diabetics and non-diabetics. <i>International Journal of Cardiology</i> , 2012, 154, 198-200.	0.8	8
4822	Cytoprotective Mechanisms in the Vasculature. , 2012, , 27-43.		0
4823	A Randomized Trial Assessing the Impact of a Personal Printed Feedback Portrait on Statin Prescribing in Primary Care. <i>Journal of Continuing Education in the Health Professions</i> , 2012, 32, 153-162.	0.4	20
4824	A Case Study of Singleâ€Pill Combination Therapy: The Ezetimibe/Simvastatin Combination for Treatment of Hyperlipidemia. <i>ChemMedChem</i> , 2012, 7, 1882-1894.	1.6	5
4825	Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial. <i>BMC Health Services Research</i> , 2012, 12, 183.	0.9	10

#	ARTICLE	IF	CITATIONS
4826	Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. <i>Cardiovascular Diabetology</i> , 2012, 11, 125.	2.7	128
4827	Vascular memory: can we broaden the concept of the metabolic memory?. <i>Cardiovascular Diabetology</i> , 2012, 11, 44.	2.7	27
4828	Statins to treat Alzheimer's disease: an incomplete story. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 27-30.	1.4	10
4829	Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic postconditioning in diabetic and non-diabetic rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 938-943.	0.9	20
4830	The Burden and Management of Dyslipidemia: Practical Issues. <i>Population Health Management</i> , 2012, 15, 302-308.	0.8	7
4834	Health Care Professionals Underestimate the Mean Life Expectancy of Older People. <i>Gerontology</i> , 2012, 58, 56-59.	1.4	14
4835	Preventive aspects in peripheral artery disease. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012, 6, 53-70.	1.0	10
4836	LDL Cholesterol: The Lower the Better. <i>Medical Clinics of North America</i> , 2012, 96, 13-26.	1.1	73
4837	Fiber, Protein, and Lupin-Enriched Foods: Role for Improving Cardiovascular Health. <i>Advances in Food and Nutrition Research</i> , 2012, 66, 147-215.	1.5	23
4838	Statin Use and the Risk of Incident Diabetes Mellitus: A Review of the Literature. <i>Canadian Journal of Cardiology</i> , 2012, 28, 581-589.	0.8	26
4839	Efficient and Effective Review of Clinical Trial Safety Data Using Interactive Graphs and Tables. , 2012, , 199-215.		2
4840	Nitric Oxide: Considerations for the Treatment of Ischemic Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1332-1346.	2.4	114
4841	Carotid Endarterectomy Plus Medical Therapy or Medical Therapy Alone for Carotid Artery Stenosis in Symptomatic or Asymptomatic Patients: A Meta-Analysis. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2012, 26, 835-844.	0.6	23
4842	Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods. <i>International Journal of Gerontology</i> , 2012, 6, 241-246.	0.7	13
4843	Inclusion of the birth cohort dimension improved description and explanation of trends in statin use. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 1052-1060.	2.4	8
4844	Comparison of Lipid Control in Patients With Coronary Versus Peripheral Artery Disease Following the First Vascular Intervention. <i>American Journal of Cardiology</i> , 2012, 110, 1266-1269.	0.7	11
4845	Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials. <i>American Journal of Cardiology</i> , 2012, 110, 1468-1476.	0.7	108
4846	Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long-Term Survival. <i>American Journal of Cardiology</i> , 2012, 110, 58B-68B.	0.7	64

#	ARTICLE	IF	CITATIONS
4847	The Effect of HMG-CoA Reductase Inhibitors on Cognition in Patients With Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot Study. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 296-302.	3.0	65
4848	The Effect of Statins on Acute and Long-Term Outcome After Ischemic Stroke in the Elderly. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 313-322.	3.0	15
4849	Statin utilization according to indication and age: A Danish cohort study on changing prescribing and purchasing behaviour. <i>Health Policy</i> , 2012, 108, 216-227.	1.4	35
4850	Complicaciones macrovasculares del paciente diabético. <i>Medicine</i> , 2012, 11, 1011-1020.	0.0	0
4851	Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: Results from VOYAGER. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 697-703.	1.1	14
4852	Methodological challenges in designing dementia prevention trials – The European Dementia Prevention Initiative (EDPI). <i>Journal of the Neurological Sciences</i> , 2012, 322, 64-70.	0.3	96
4853	Stroke: management and prevention. <i>Medicine</i> , 2012, 40, 490-499.	0.2	9
4854	Global Cardiovascular Risk Reduction in People with Diabetes Mellitus and Hypertension. , 2012, , 129-141.		0
4857	Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. <i>The Cochrane Library</i> , 2012, 2012, CD007176.	1.5	479
4858	Carotid Stenting Versus Endarterectomy. <i>Annual Review of Medicine</i> , 2012, 63, 259-276.	5.0	8
4859	Complications resulting from antiretroviral therapy for HIV infection. , 2012, , 177-191.		0
4860	Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2012, 46, 64-77.	1.9	43
4862	Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management. <i>Canadian Journal of Cardiology</i> , 2012, 28, 667-677.	0.8	6
4863	Role of Lipotoxicity in Endothelial Dysfunction. <i>Heart Failure Clinics</i> , 2012, 8, 589-607.	1.0	94
4864	Understanding Gender Differences in Statin Use among Elderly Medicare Beneficiaries. <i>Drugs and Aging</i> , 2012, 29, 971-980.	1.3	17
4865	Update on guidelines for management of hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1239-1249.	0.6	5
4866	Dyslipidemia. , 2012, , 159-178.		0
4869	Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. <i>Atherosclerosis</i> , 2012, 225, 403-407.	0.4	29

#	ARTICLE	IF	CITATIONS
4870	Clinical Value of Drugs Targeting Inflammation for the Management of Coronary Artery Disease. Canadian Journal of Cardiology, 2012, 28, 678-686.	0.8	15
4871	A Picture is Worth a Thousand Tables. , 2012, , .		11
4874	The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clinical Pharmacology and Therapeutics, 2012, 92, 112-117.	2.3	294
4875	Use of statins in lower extremity artery disease: a review. BMC Surgery, 2012, 12, S15.	0.6	17
4876	Ankle/brachial index to everyone. BMC Surgery, 2012, 12, S18.	0.6	10
4878	Monitoring diabetes in patients with and without rheumatoid arthritis: a Medicare study. Arthritis Research and Therapy, 2012, 14, R166.	1.6	22
4879	Angiotensin Converting Enzyme Inhibitor and HMG-CoA Reductase Inhibitor as Adjunct Treatment for Persons with HIV Infection: A Feasibility Randomized Trial. PLoS ONE, 2012, 7, e46894.	1.1	32
4880	Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management, 2012, 8, 415.	1.0	169
4881	Disorders of Lipid Metabolism. , 2012, , 1346-1354.		2
4882	Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 2012, 19, 299-315.	0.9	67
4883	Genomics of Dementia:APOE- andCYP2D6-Related Pharmacogenetics. International Journal of Alzheimer's Disease, 2012, 2012, 1-37.	1.1	44
4884	State of the art paper Peripheral arterial disease of the lower extremities. Archives of Medical Science, 2012, 2, 375-388.	0.4	46
4885	Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review. International Journal of Nephrology and Renovascular Disease, 2012, 5, 165.	0.8	3
4886	A Neutral Risk on the Development of New-Onset Diabetes Mellitus (NODM) in Taiwanese Patients with Dyslipidaemia Treated with Fibrates. Scientific World Journal, The, 2012, 2012, 1-5.	0.8	4
4887	Dyslipidemia and Cardiovascular Risk: Lipid Ratios as Risk Factors for Cardiovascular Disease. , 0, , .		9
4888	Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly. Journal of Geriatric Cardiology, 2012, 9, 83-90.	0.2	4
4889	A survey on coronary heart disease related signal pathways, drug targets and pharmacological interventions. Journal of Integrated OMICS, 2012, 2, .	0.5	0
4890	The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model. ClinicoEconomics and Outcomes Research, 2012, 4, 337.	0.7	11

#	ARTICLE	IF	CITATIONS
4891	The role of statin therapy in patients with lower vascular risk. <i>Medical Journal of Australia</i> , 2012, 197, 130-131.	0.8	0
4892	Lowered LDL-C Levels Reduce Later Local Vascular Events after Surgical or Endovascular Treatment of Peripheral Artery Disease. <i>Annals of Vascular Diseases</i> , 2012, 5, 180-189.	0.2	2
4893	Simvastatin Reduces Endothelial NOS: Caveolin-1 Ratio but not the Phosphorylation Status of eNOS In Vivo. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, .	0.9	4
4895	Challenge of Surrogate Endpoints. <i>Southern Medical Journal</i> , 2012, 105, 156-160.	0.3	4
4896	Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials. <i>Current Pharmaceutical Design</i> , 2012, 18, 1519-1530.	0.9	349
4897	Atherosclerotic disease and risk factor modification in Saudi Arabia: a call to action. <i>Vascular Health and Risk Management</i> , 2012, 8, 349.	1.0	19
4898	UP TO DATE STATINS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES. <i>Rational Pharmacotherapy in Cardiology</i> , 2012, 8, 538-544.	0.3	0
4899	Multidisciplinary treatment for peripheral arterial occlusive disease and the role of eHealth and mHealth. <i>Journal of Multidisciplinary Healthcare</i> , 2012, 5, 257.	1.1	28
4900	Complications of stroke resulting from atrial fibrillation. <i>British Journal of Cardiac Nursing</i> , 2012, 7, 570-579.	0.0	0
4901	The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice. <i>Archives of Medical Science</i> , 2012, 1, 53-56.	0.4	10
4902	Guidelines for acute ischemic stroke treatment: part II: stroke treatment. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 885-893.	0.3	43
4903	Ezetimibe Ameliorates Atherosclerotic and Inflammatory Markers, Atherogenic Lipid Profiles, Insulin Sensitivity, and Liver Dysfunction in Japanese Patients with Hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 532-538.	0.9	33
4904	The effect of physical activity on haematological predictors of cardiovascular risk – evidence of a dose response. <i>Clinical Hemorheology and Microcirculation</i> , 2012, 52, 57-65.	0.9	10
4905	Lower Extremity Peripheral Arterial Disease. , 2012, , .		2
4906	Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. <i>Archives of Medical Science</i> , 2012, 1, 57-62.	0.4	18
4907	Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib. <i>Vascular Health and Risk Management</i> , 2012, 8, 483.	1.0	7
4908	Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer. <i>Pharmacological Reviews</i> , 2012, 64, 102-146.	7.1	370
4909	Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study. <i>Circulation</i> , 2012, 125, 2469-2478.	1.6	185

#	ARTICLE	IF	CITATIONS
4910	Medical Therapy in Peripheral Artery Disease. <i>Circulation</i> , 2012, 126, 491-500.	1.6	70
4911	The ezetimibe controversy – can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1469-1480.	0.9	10
4912	Evaluating cardio-renal protection for adolescents with type 1 diabetes: the current AddIT trial. <i>Practical Diabetes</i> , 2012, 29, 174.	0.1	1
4913	Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1027-1035.	0.9	24
4914	Cholesterol Level Goal Attainment with Statins: Clinical Management Guideline Recommendations versus Management in Actual Clinical Practice. <i>Pharmacotherapy</i> , 2012, 32, 631-641.	1.2	13
4915	Trans fat, aspirin, and ischemic stroke in postmenopausal women. <i>Annals of Neurology</i> , 2012, 72, 704-715.	2.8	50
4916	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 453-495.	0.7	157
4917	LDL cholesterol targets – how low to go?. <i>Current Opinion in Lipidology</i> , 2012, 23, 265-270.	1.2	6
4918	Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1773-1781.	1.1	58
4919	Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. <i>Journal of General Internal Medicine</i> , 2012, 27, 458-468.	1.3	46
4920	The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease. <i>Current Atherosclerosis Reports</i> , 2012, 14, 130-134.	2.0	56
4921	The Role of Statin Therapy for Primary Prevention: What is the Evidence?. <i>Current Atherosclerosis Reports</i> , 2012, 14, 167-174.	2.0	5
4922	Molecular Pathways Regulating Macrophage Polarization: Implications for Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2012, 14, 254-263.	2.0	66
4923	Approach to Lipid Therapy in the Patient With Atherosclerotic Vascular Disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 177-183.	0.4	1
4924	Neuroprotective Effects of Statins: Evidence from Preclinical and Clinical Studies. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 252-259.	0.4	21
4925	Recruitment methods for united states Alzheimer disease prevention trials. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 331-335.	1.5	20
4926	Alzheimer's disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 339-345.	1.5	38
4927	Perioperative statin therapy: understanding the evidence in a Bayesian context. <i>Canadian Journal of Anaesthesia</i> , 2012, 59, 511-515.	0.7	0

#	ARTICLE	IF	CITATIONS
4928	Costâ€“effectiveness of statins revisited: lessons learned about the value of innovation. <i>European Journal of Health Economics</i> , 2012, 13, 445-450.	1.4	17
4929	The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. <i>Journal of Internal Medicine</i> , 2012, 271, 32-42.	2.7	41
4930	By Desperate Appliance Relieved? On the Clinical Relevance of Risk Stratification to Therapeutic Decision-Making. <i>American Journal of Cardiology</i> , 2012, 109, 919-923.	0.7	4
4931	Comparison of the Effect on Long-Term Outcomes in Patients With Thoracic Aortic Aneurysms of Taking Versus Not Taking a Statin Drug. <i>American Journal of Cardiology</i> , 2012, 109, 1050-1054.	0.7	56
4932	Comparison of Lipid Profiles and Attainment of Lipid Goals in Patients <65 Years Versus Patients â%¥65 Years (from the Lipid Treatment Assessment Project [L-TAP] 2). <i>American Journal of Cardiology</i> , 2012, 109, 1738-1742.	0.7	5
4933	The effect of statins on performance in the Morris water maze in guinea pig. <i>European Journal of Pharmacology</i> , 2012, 674, 287-293.	1.7	8
4934	LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 117-123.	1.9	12
4935	SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 199-203.	1.0	9
4936	Utilization and Costs of Cardiovascular Disease Medications in Dialysis Patients in Medicare Part D. <i>American Journal of Kidney Diseases</i> , 2012, 59, 670-681.	2.1	33
4937	LDLâ€“cholesterol versus HDLâ€“cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 18-32.	1.8	138
4938	Earlier translation of evidence into public subsidy may prevent morbidity and mortality: an example using statins in diabetics with normal cholesterol levels. <i>Australian and New Zealand Journal of Public Health</i> , 2012, 36, 435-440.	0.8	2
4939	LIPIDâ€“LOWERING THERAPY IN CHRONIC KIDNEY DISEASE: IS THERE A ROLE FOR EZETIMIBE?. <i>Journal of Renal Care</i> , 2012, 38, 138-146.	0.6	5
4940	2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 4-34.	0.4	227
4941	Medical management of risk factors for vascular disease. <i>Surgery</i> , 2012, 30, 377-382.	0.1	0
4942	An independent effect of parental lipids on the offspring lipid levels in a cohort of adolescents with type 1 diabetes. <i>Pediatric Diabetes</i> , 2012, 13, 463-469.	1.2	14
4943	Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. <i>Cancer</i> , 2012, 118, 797-803.	2.0	27
4944	Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. <i>Current Atherosclerosis Reports</i> , 2012, 14, 1-10.	2.0	304
4945	The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. <i>Infection</i> , 2012, 40, 41-48.	2.3	25

#	ARTICLE	IF	CITATIONS
4946	The Pleiotropic Effects of Statins in the Prevention of Atherosclerosis. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 5-7.	1.3	7
4947	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, E76-123.	0.7	177
4948	Statins in dermatology: is nonmelanoma skin cancer the dark side of the moon?. <i>International Journal of Dermatology</i> , 2013, 52, 899-900.	0.5	5
4949	Social stratification in the dissemination of statins after stroke in Sweden. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1173-1180.	0.8	19
4950	Statin use among older Finns stratified according to cardiovascular risk. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 261-267.	0.8	17
4951	Do immigrants from Turkey, Pakistan and Ex-Yugoslavia with newly diagnosed type 2 diabetes initiate recommended statin therapy to the same extent as Danish-born residents? A nationwide register study. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 87-95.	0.8	9
4952	Diabetes Mellitus Prevention and Treatment. , 2013, , 63-79.		0
4953	Lipoproteins and Cardiovascular Disease. <i>Methods in Molecular Biology</i> , 2013, , .	0.4	5
4954	Statins and Breast Cancer: Future Directions in Chemoprevention. <i>Current Breast Cancer Reports</i> , 2013, 5, 161-169.	0.5	14
4955	Modulation of Lipoprotein Metabolism by Antisense Technology: Preclinical Drug Discovery Methodology. <i>Methods in Molecular Biology</i> , 2013, 1027, 309-324.	0.4	7
4956	Identification of Inflammatory Mediators and Their Modulation by Strategies for the Management of the Systemic Inflammatory Response During Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013, 27, 983-1033.	0.6	70
4957	Exercise-induced Myalgia may Limit the Cardiovascular Benefits of Statins. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 569-572.	1.3	17
4958	Efficacy of statin treatment after endovascular therapy for isolated below-the-knee disease in patients with critical limb ischemia. <i>Cardiovascular Intervention and Therapeutics</i> , 2013, 28, 374-382.	1.2	21
4959	Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age. <i>Cardiovascular Diabetology</i> , 2013, 12, 10.	2.7	15
4960	Statins in cardiometabolic disease: what makes pitavastatin different?. <i>Cardiovascular Diabetology</i> , 2013, 12, S1.	2.7	17
4961	Management of cardiovascular disease in patients with kidney disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 261-273.	6.1	98
4962	Contemporary and Optimal Medical Management of Peripheral Arterial Disease. <i>Surgical Clinics of North America</i> , 2013, 93, 761-778.	0.5	6
4963	Critical Limb Ischemia. <i>Surgical Clinics of North America</i> , 2013, 93, 789-812.	0.5	16

#	ARTICLE	IF	CITATIONS
4964	Diagnosis, Prevention, and Treatment of Claudication. <i>Surgical Clinics of North America</i> , 2013, 93, 779-788.	0.5	6
4965	Medical management of critical limb ischaemia: where do we stand today?. <i>Journal of Internal Medicine</i> , 2013, 274, 295-307.	2.7	51
4967	Accounting for Clinical Action Reduces Estimates of Gender Disparities in Lipid Management for Diabetic Veterans. <i>Journal of General Internal Medicine</i> , 2013, 28, 529-535.	1.3	29
4968	Assessment of lipid-lowering treatment in Bulgaria – The CEPHEUS study. <i>Open Medicine (Poland)</i> , 2013, 8, 627-637.	0.6	1
4969	When Clinical Trials Fail to Address Treatment Gaps: The Failure of Niacin-Laropiprant to Reduce Cardiovascular Events. <i>Current Atherosclerosis Reports</i> , 2013, 15, 332.	2.0	4
4970	Medical Management of Stable Coronary Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2013, 15, 313.	2.0	6
4971	The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease. <i>Current Atherosclerosis Reports</i> , 2013, 15, 312.	2.0	35
4972	Aggressive Statin Therapy and the Risk of Malignancy. <i>Current Atherosclerosis Reports</i> , 2013, 15, 316.	2.0	2
4973	Comparative Protective Effect of Hawthorn Berry Hydroalcoholic Extract, Atorvastatin, and Mesalamine on Experimentally Induced Colitis in Rats. <i>Journal of Medicinal Food</i> , 2013, 16, 593-601.	0.8	18
4974	Statin use and lower extremity amputation risk in nonelderly diabetic patients. <i>Journal of Vascular Surgery</i> , 2013, 58, 1578-1585.e1.	0.6	42
4975	Statins in the prevention of dementia and Alzheimer's disease: A meta-analysis of observational studies and an assessment of confounding. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 345-358.	0.9	96
4976	The lipid story in chronic kidney disease: a long story with a happy end?. <i>International Urology and Nephrology</i> , 2013, 45, 1273-1287.	0.6	4
4977	Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors. <i>Clinical Pharmacokinetics</i> , 2013, 52, 815-831.	1.6	116
4978	Predictors of thromboembolism during coil embolization in patients with unruptured intracranial aneurysm. <i>Acta Neurochirurgica</i> , 2013, 155, 1101-1106.	0.9	20
4979	Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2090-2099.	1.2	191
4980	Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. <i>Pharmacogenomics</i> , 2013, 14, 1295-1304.	0.6	15
4981	Effect of Equivalent On-Treatment Apolipoprotein Levels on Outcomes (from the AIM-HIGH and) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 1	0.7	11
4982	A Hospital Discharge Risk Score for 1-Year All-cause Mortality or Non-fatal Cardiovascular Events in Patients with Lower-extremity Peripheral Artery Disease, with and without Revascularisation. <i>European Journal of Vascular and Endovascular Surgery</i> , 2013, 45, 488-496.	0.8	16

#	ARTICLE	IF	CITATIONS
4983	Gender Difference in Statin Intervention on Blood Lipid Control among Patients with Coronary Heart Disease. <i>International Journal of Gerontology</i> , 2013, 7, 116-121.	0.7	6
4984	Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage. <i>Neurosurgical Review</i> , 2013, 36, 279-287.	1.2	39
4985	How to control residual cardiovascular risk despite statin treatment: Focusing on HDL cholesterol. <i>International Journal of Cardiology</i> , 2013, 166, 8-14.	0.8	54
4986	Rebuttal: Why statins have failed to reduce mortality in just about anybody. <i>Journal of Clinical Lipidology</i> , 2013, 7, 228.	0.6	0
4987	Lymphocyte-suppressing action of simvastatin in patients with isolated hypertriglyceridemia. <i>Pharmacological Reports</i> , 2013, 65, 756-760.	1.5	3
4988	Counterpoint: Statins do reduce fatal events. <i>Journal of Clinical Lipidology</i> , 2013, 7, 225-227.	0.6	0
4989	Effect of selenium and Q10 on the cardiac biomarker NT-proBNP. <i>Scandinavian Cardiovascular Journal</i> , 2013, 47, 281-288.	0.4	15
4990	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. <i>International Journal of Cardiology</i> , 2013, 168, 5437-5447.	0.8	66
4991	Closing the Loop: A 21-year Audit of Strategies for Preventing Stroke and Death Following Carotid Endarterectomy. <i>European Journal of Vascular and Endovascular Surgery</i> , 2013, 46, 161-170.	0.8	55
4992	Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2013, 58, 972-980.	0.6	55
4993	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <i>European Heart Journal</i> , 2013, 34, 2444-2452.	1.0	282
4994	Proactive Pharmaceutical Care Interventions Improve Patients' Adherence to Lipid-Lowering Medication. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1448-1456.	0.9	32
4995	American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. <i>Endocrine Practice</i> , 2013, 19, 1-48.	1.1	132
4996	Acute myocardial infarction leads to acceleration of atherosclerosis. <i>Atherosclerosis</i> , 2013, 229, 18-22.	0.4	21
4997	Myeloperoxidase in Cardiovascular Disease. <i>Advances in Clinical Chemistry</i> , 2013, 62, 1-32.	1.8	23
4998	Dyslipidemia. <i>Canadian Journal of Diabetes</i> , 2013, 37, S110-S116.	0.4	15
4999	RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. <i>Lipids in Health and Disease</i> , 2013, 12, 142.	1.2	4
5000	Statin restores cardiac autonomic response to acute hypoxia in hypercholesterolaemia. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1291-1298.	1.7	5

#	ARTICLE	IF	CITATIONS
5001	Drug treatments in the secondary prevention of ischaemic stroke. <i>Maturitas</i> , 2013, 76, 267-271.	1.0	4
5002	Dyslipidémie. <i>Canadian Journal of Diabetes</i> , 2013, 37, S484-S491.	0.4	1
5003	Statins: Perspectives in cancer therapeutics. <i>Digestive and Liver Disease</i> , 2013, 45, 795-802.	0.4	33
5004	Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in Zhejiang. <i>Trials</i> , 2013, 14, 354.	0.7	16
5006	Medication Adherence in Patients with Diabetes and Dyslipidemia: Associated Factors and Strategies for Improvement. <i>Current Cardiology Reports</i> , 2013, 15, 418.	1.3	33
5007	Low-Density Lipoprotein Cholesterol: How Low Can We Go?. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 225-232.	1.0	10
5008	First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients. <i>Lipids in Health and Disease</i> , 2013, 12, 170.	1.2	12
5009	Electrical Plasticity and Cardioprotection in Myocardial Ischemia—Role of Selective Sodium Channel Blockers. <i>Clinical Cardiology</i> , 2013, 36, 255-261.	0.7	2
5010	Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 125-129.	0.4	1
5011	The Effect of Fenofibrate on Lymphocyte Release of Proinflammatory Cytokines and Systemic Inflammation in Simvastatin-Treated Patients with Atherosclerosis and Early Glucose Metabolism Disturbances. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 112, 198-202.	1.2	13
5012	Early Statin Use is Associated with Increased Risk of Infection After Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, 66-71.	0.7	21
5013	Effect of previous statin therapy on severity and outcome in ischemic stroke patients: a population-based study. <i>Journal of Neurology</i> , 2013, 260, 30-37.	1.8	24
5015	Alzheimer's Disease, Cholesterol, and Statins: The Junctions of Important Metabolic Pathways. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 1110-1121.	7.2	56
5016	Le diabète chez les personnes âgées. <i>Canadian Journal of Diabetes</i> , 2013, 37, S567-S574.	0.4	0
5017	Statin therapy influences endothelial cell morphology and F-actin cytoskeleton structure when exposed to static and laminar shear stress conditions. <i>Life Sciences</i> , 2013, 92, 859-865.	2.0	13
5018	Economic Evaluation of Lipid-Lowering Therapy in the Secondary Prevention Setting in the Philippines. <i>Value in Health Regional Issues</i> , 2013, 2, 13-20.	0.5	5
5019	Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. <i>International Journal of Cardiology</i> , 2013, 166, 431-439.	0.8	31
5020	Diabetes in the Elderly. <i>Canadian Journal of Diabetes</i> , 2013, 37, S184-S190.	0.4	68

#	ARTICLE	IF	CITATIONS
5021	Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1250-1258.	1.2	47
5022	Long-term use of statins reduces the risk of hospitalization for dementia. <i>Atherosclerosis</i> , 2013, 230, 171-176.	0.4	35
5024	Tratamiento médico del angor. <i>Medicine</i> , 2013, 11, 2198-2206.	0.0	0
5025	Head-to-head comparison of fibrates versus statins for elevation of circulating adiponectin concentrations: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1876-1885.	1.5	14
5026	Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: Implications for statin-induced rhabdomyolysis. <i>European Journal of Pharmacology</i> , 2013, 711, 1-9.	1.7	45
5027	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e179-e347.	1.2	370
5029	Documento de consenso de la Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Y Riesgo Vascular, 2013, 30, 45-53.	0.3	0
5030	Differences in interaction and subgroup-specific effects were observed between randomized and nonrandomized studies in three empirical examples. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 599-607.	2.4	14
5031	Artériopathie oblitérante des membres inférieurs d'origine athéromateuse : évolution de la prise en charge en 2013. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 9-15.	0.0	0
5032	Best evidence for medical therapy for carotid artery stenosis. <i>Journal of Vascular Surgery</i> , 2013, 58, 1129-1139.	0.6	54
5033	Low-density lipoprotein-dependent and independent effects of statins on prevention of major coronary events: Meta-regression of randomized placebo-controlled trials. <i>International Journal of Cardiology</i> , 2013, 168, 4850-4853.	0.8	3
5034	n-3 PUFAs and heart failure. <i>International Journal of Cardiology</i> , 2013, 170, S28-S32.	0.8	9
5035	The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naïve patients undergoing primary percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013, 167, 458-463.	0.8	20
5036	Evidence based policy decisions through a Bayesian approach: The case of a statin appraisal in the Netherlands. <i>Health Policy</i> , 2013, 112, 234-240.	1.4	6
5037	La prévention primaire par les statines du risque cardiovasculaire des diabétiques : un mauvais procès en place publique. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 9-15.	0.0	0
5038	The lipid-lowering effect of atorvastatin in Taiwanese diabetic patients with hyperlipidemia. <i>Tzu Chi Medical Journal</i> , 2013, 25, 168-174.	0.4	0
5039	Vascular risk factors and cognitive disorders. <i>Revue Neurologique</i> , 2013, 169, 757-764.	0.6	26
5040	Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient education. <i>Journal of Clinical Lipidology</i> , 2013, 7, 472-483.	0.6	210

#	ARTICLE	IF	CITATIONS
5041	Statins and Cognition: A Systematic Review and Meta-analysis of Short- and Long-term Cognitive Effects. <i>Mayo Clinic Proceedings</i> , 2013, 88, 1213-1221.	1.4	181
5042	Lower Limb Peripheral Arterial Disease (Clinical Guideline 147): A Guideline Summary. <i>Annals of Medicine and Surgery</i> , 2013, 2, 26-30.	0.5	9
5043	Effect of lipid-modifying drug therapy on survival after abdominal aortic aneurysm repair. <i>Journal of Vascular Surgery</i> , 2013, 58, 355-363.	0.6	15
5044	Fat lowers fat: Purified phospholipids as emerging therapies for dyslipidemia. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 887-893.	1.2	33
5045	Statin Treatment Improves Plasma Lipid Levels but not HDL Subclass Distribution in Patients Undergoing Percutaneous Coronary Intervention. <i>Lipids</i> , 2013, 48, 127-137.	0.7	6
5046	Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 290.	2.0	3
5047	How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 291.	2.0	159
5048	Is Atherosclerosis Regression a Realistic Goal of Statin Therapy and What Does That Mean?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 294.	2.0	20
5049	Does the Benefit from Statin Therapy Extend Beyond 5 Years?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 297.	2.0	8
5050	Statins and Diabetes: The Good, the Bad, and the Unknown. <i>Current Atherosclerosis Reports</i> , 2013, 15, 299.	2.0	25
5051	Is the Future of Statins Aligned with New Novel Lipid Modulation Therapies?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 300.	2.0	5
5052	Do the Frequencies of Adverse Events Increase, Decrease, or Stay the Same with Long-Term Use of Statins?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 301.	2.0	24
5053	Statins in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Updated Review. <i>Current Atherosclerosis Reports</i> , 2013, 15, 305.	2.0	33
5054	Dyslipidemia and the Risk of Alzheimer's Disease. <i>Current Atherosclerosis Reports</i> , 2013, 15, 307.	2.0	134
5055	What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 104-117.	0.4	6
5056	Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 60-65.	0.8	0
5057	PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics. <i>Current Cardiology Reports</i> , 2013, 15, 345.	1.3	33
5058	Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events. <i>American Journal of Cardiology</i> , 2013, 111, 1221-1229.	0.7	35

#	ARTICLE	IF	CITATIONS
5059	Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 225-233.	1.1	34
5060	Statins for the primary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2021, 2021, CD004816.	1.5	933
5061	Pro-Inflammatory Genetic Markers of Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2013, 15, 329.	2.0	28
5062	Effects of Acute and Chronic Atorvastatin on Cardioprotection of Ischemic Postconditioning in Isolated Rat Hearts. <i>Cardiovascular Therapeutics</i> , 2013, 31, 187-192.	1.1	10
5063	Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. <i>Lancet, The</i> , 2013, 381, 1293-1301.	6.3	485
5064	Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies. <i>Geriatrics and Gerontology International</i> , 2013, 13, 817-824.	0.7	47
5065	A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs. <i>Drugs</i> , 2013, 73, 1025-1054.	4.9	30
5066	A randomized trial of coenzyme Q10 in patients with statin myopathy: Rationale and study design. <i>Journal of Clinical Lipidology</i> , 2013, 7, 187-193.	0.6	27
5067	Management of Coronary Atherosclerosis and Acute Coronary Syndromes in Patients With Chronic Kidney Disease. <i>Current Problems in Cardiology</i> , 2013, 38, 165-206.	1.1	11
5068	Emerging anti-inflammatory drugs for atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 193-205.	1.0	30
5069	Pharmacokinetic and Pharmacodynamic Studies of Poly(amidoamine) Dendrimer Based Simvastatin Oral Formulations for the Treatment of Hypercholesterolemia. <i>Molecular Pharmaceutics</i> , 2013, 10, 2528-2533.	2.3	47
5070	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	3.1	90
5072	Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. <i>Nature Reviews Rheumatology</i> , 2013, 9, 513-523.	3.5	212
5073	Risk Factors and Prevention, Including Hyperlipidemia. , 2013, , 405-418.		0
5074	Stable Angina. , 2013, , 419-438.		0
5075	Role of Duplex Ultrasound in Carotid Screening. , 2013, , 173-181.		0
5076	The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. <i>Current Cardiology Reports</i> , 2013, 15, 391.	1.3	9
5077	Epanova [®] and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. <i>Future Cardiology</i> , 2013, 9, 177-186.	0.5	12

#	ARTICLE	IF	CITATIONS
5078	Rosuvastatin calcium in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1215-1227.	0.9	17
5079	<i>Coronary Heart Disease and Stroke.</i> , 2013, , 85-103.		0
5080	Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. <i>American Heart Journal</i> , 2013, 165, 26-33.e3.	1.2	25
5082	Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. <i>Trials</i> , 2013, 14, 401.	0.7	16
5083	The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 240-247.	0.7	11
5084	Impact of Coronary Artery Calcium Progression and Statin Therapy on Clinical Outcome in Subjects With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2013, 111, 356-361.	0.7	43
5085	Predictive Value of Lipoprotein Indices for Residual Risk of Acute Myocardial Infarction and Sudden Death in Men With Low-Density Lipoprotein Cholesterol Levels <120 mg/dl. <i>American Journal of Cardiology</i> , 2013, 112, 1063-1068.	0.7	13
5086	The use of Statins in the perioperative period. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 29, 241-242.	0.2	0
5087	Do MDR1 and SLCO1B1 Polymorphisms Influence the Therapeutic Response to Atorvastatin? A Study on a Cohort of Egyptian Patients with Hypercholesterolemia. <i>Molecular Diagnosis and Therapy</i> , 2013, 17, 299-309.	1.6	25
5088	Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus ezetimibe on pro- and anti-inflammatory markers. <i>Clinical Lipidology</i> , 2013, 8, 151-157.	0.4	2
5089	Lipid management: maximising reduction of cardiac risk. <i>Clinical Medicine</i> , 2013, 13, 618-620.	0.8	3
5090	Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHEBUS trial. <i>European Journal of Heart Failure</i> , 2013, 15, 221-227.	2.9	10
5091	Statins in the treatment of asthma. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1661-1669.	0.5	8
5092	Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. <i>Journal of Neurology</i> , 2013, 260, 158-165.	1.8	55
5093	Adherence to Hospital Discharge Medication in Patients With Ischemic Stroke. <i>Stroke</i> , 2013, 44, 522-524.	1.0	31
5094	Modeling hard clinical end-point data in economic analyses. <i>Journal of Medical Economics</i> , 2013, 16, 1327-1343.	1.0	6
5095	Mortality, a Bar Too High for Idiopathic Pulmonary Fibrosis Clinical Trials!. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1270-1271.	2.5	1
5096	<i>Medical Treatment of Peripheral Artery Disease.</i> , 2013, , 242-258.		6

#	ARTICLE	IF	CITATIONS
5097	Selection of Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1269-1270.	2.5	13
5098	Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2013, 125, 21-32.	0.9	20
5099	The Cardiorenal Syndrome: What the Cardiologist Needs to Know. <i>Cardiology</i> , 2013, 126, 175-186.	0.6	20
5100	Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT). <i>BMJ Open</i> , 2013, 3, e002295.	0.8	22
5101	Lipid disorders. , 2013, , 68-77.		1
5102	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- σ ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2013, 127, e663-828.	1.6	219
5103	Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 628.	0.2	25
5104	Multiple Statistical Methods for Assessing Differential Gene Expression in Microarray Data of Diabetic Model Rats to Predict the Molecular Mechanism of Atorvastatin on Anti-Atherogenesis. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2013, 121, 272-279.	0.6	6
5105	Stroke Pharmacogenetics. , 2013, , 223-297.		0
5106	Prospective Analysis of Association between Statin Use and Breast Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1868-1876.	1.1	41
5107	The current management of carotid atherosclerotic disease: who, when and how?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2013, 16, 339-346.	0.5	12
5108	Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 515-532.	1.5	36
5109	Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People. <i>Diabetes Care</i> , 2013, 36, S292-S300.	4.3	5
5110	Effects of Atorvastatin on Systemic and Renal Nitric Oxide in Healthy Man. <i>Clinical and Experimental Hypertension</i> , 2013, 35, 148-157.	0.5	7
5112	High-density lipoprotein cholesterol raising. <i>Current Opinion in Cardiology</i> , 2013, 28, 464-474.	0.8	21
5113	Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 99-114.	0.9	7
5114	The Need for a Systematic Approach to Statin Switching. <i>Journal of Cardiovascular Nursing</i> , 2013, 28, 565-572.	0.6	4
5116	Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective. <i>Journal of Medical Economics</i> , 2013, 16, 907-916.	1.0	5

#	ARTICLE	IF	CITATIONS
5117	Low-Density Lipoprotein Cholesterol, Apolipoprotein B, and Risk of Coronary Heart Disease. <i>Biological Research for Nursing</i> , 2013, 15, 292-308.	1.0	37
5118	Reinitiation of Statins After Statin-Associated Musculoskeletal Symptoms. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 243-247.	0.9	4
5119	Assessment of High Cardiovascular Risk Profiles for the Clinician. <i>Angiology</i> , 2013, 64, 333-335.	0.8	0
5120	MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. <i>Heart</i> , 2013, 99, 1675-1680.	1.2	39
5121	Assessing Appropriateness of Lipid Management Among Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 66-74.	0.9	24
5122	Statins and Venous Thromboembolism. <i>Angiology</i> , 2013, 64, 489-491.	0.8	7
5123	Stable Ischemic Heart Disease/Chronic Stable Angina. , 2013, , 131-152.		0
5124	ST-Segment Elevation Myocardial Infarction. , 2013, , 178-213.		3
5125	Drugs for Elevated Low-Density Lipoprotein Cholesterol. , 2013, , 421-433.		0
5126	Peripheral Artery Disease. , 2013, , 539-552.		1
5127	Changes in Cholesterol-Lowering Medications Use Over a Decade in Community-Dwelling Older Adults. <i>Annals of Pharmacotherapy</i> , 2013, 47, 984-992.	0.9	13
5128	Outcomes for Clinical Studies Assessing Drug and Revascularization Therapies for Claudication and Critical Limb Ischemia in Peripheral Artery Disease. <i>Circulation</i> , 2013, 127, 1241-1250.	1.6	27
5129	Statins and primary liver cancer. <i>European Journal of Cancer Prevention</i> , 2013, 22, 229-234.	0.6	70
5130	Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. <i>European Heart Journal</i> , 2013, 34, 982-992.	1.0	88
5131	Role of Dyslipidemia in Patients With Chronic Kidney Disease. <i>Postgraduate Medicine</i> , 2013, 125, 28-37.	0.9	4
5132	Response to comments in: Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study by Clockaertset al. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e12-e12.	0.5	3
5133	The Effect of Simvastatin on Glucose Homeostasis in Streptozotocin Induced Type 2 Diabetic Rats. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-5.	1.0	21
5134	The Role of Simvastatin in the Therapeutic Approach of Rheumatoid Arthritis. <i>Autoimmune Diseases</i> , 2013, 2013, 1-7.	2.7	25

#	ARTICLE	IF	CITATIONS
5135	Association of Medicare Part D Medication Out-of-Pocket Costs with Utilization of Statin Medications. Health Services Research, 2013, 48, 1311-1333.	1.0	15
5136	Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients. Circulation, 2013, 128, 29-41.	1.6	123
5137	Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opinion on Drug Safety, 2013, 12, 19-27.	1.0	43
5138	Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002-2012 Literature Review. Journal of the American Geriatrics Society, 2013, 61, 2027-2037.	1.3	56
5139	A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort. European Journal of Preventive Cardiology, 2013, 20, 98-106.	0.8	3
5140	Clinical Risk Factors for Adverse Events in Allopurinol Users. Journal of Clinical Pharmacology, 2013, 53, 211-216.	1.0	29
5141	Low-Density Lipoprotein Levels in Patients With Acute Heart Failure. Congestive Heart Failure, 2013, 19, 85-91.	2.0	15
5142	What is wrong with meta-analysis? The importance of clinical heterogeneity in myocardial regeneration research. International Journal of Clinical Practice, 2013, 67, 1081-1085.	0.8	9
5143	Channelling of Statin Use towards Low-Risk Population and Patients with Diabetes. Basic and Clinical Pharmacology and Toxicology, 2013, 113, 173-178.	1.2	9
5144	Preoperative Statins and Limb Salvage After Lower Extremity Revascularization in the Medicare Population. Circulation: Cardiovascular Interventions, 2013, 6, 694-700.	1.4	47
5145	High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy. Circulation, 2013, 128, 1189-1197.	1.6	203
5146	Bariatric Surgery for Severe Obesity in Two Adolescents With Type 1 Diabetes. Pediatrics, 2013, 132, e1031-e1034.	1.0	28
5147	Comparative Tolerability and Harms of Individual Statins. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 390-399.	0.9	236
5148	A Clinician's Guide to the <scp>ABCs</scp> of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. Clinical Cardiology, 2013, 36, 383-393.	0.7	45
5149	Targeting reactive nitrogen species: a promising therapeutic strategy for cerebral ischemia-reperfusion injury. Acta Pharmacologica Sinica, 2013, 34, 67-77.	2.8	97
5150	Cardiovascular Risk Assessment in Diabetes Mellitus. Angiology, 2013, 64, 336-342.	0.8	20
5151	Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy. Therapeutic Advances in Drug Safety, 2013, 4, 9-17.	1.0	4
5152	Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults. Circulation, 2013, 128, 2422-2446.	1.6	166

#	ARTICLE	IF	CITATIONS
5153	Lack of Goal Attainment Regarding the Low-density Lipoprotein Cholesterol Level in the Management of Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , 2013, 52, 2409-2415.	0.3	4
5154	Cholesterol Levels and the Association of Statins With In-Hospital Mortality of Myocardial Infarction Patients Insights From a Chilean Registry of Myocardial Infarction. <i>Clinical Cardiology</i> , 2013, 36, 305-311.	0.7	3
5155	Dangers of non-specific composite outcome measures in clinical trials. <i>BMJ, The</i> , 2013, 347, f6782-f6782.	3.0	28
5156	Effect of Simvastatin on Hemostasis in Patients with Isolated Hypertriglyceridemia. <i>Pharmacology</i> , 2013, 92, 187-190.	0.9	11
5157	Stable Angina Pectoris: Current Medical Treatment. <i>Current Pharmaceutical Design</i> , 2013, 19, 1569-1580.	0.9	7
5159	Providing clinicians with a patient's 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 90.	0.7	14
5160	Is there a Role for Antioxidants in the Treatment of Stable Angina?. <i>Current Pharmaceutical Design</i> , 2013, 19, 1601-1615.	0.9	1
5161	One of the most urgent vascular circumstances: Acute limb ischemia. <i>SAGE Open Medicine</i> , 2013, 1, 205031211351611.	0.7	32
5162	Pulsatile hemodynamics and cardiovascular risk factors in very old patients. <i>Journal of Hypertension</i> , 2013, 31, 848-857.	0.3	9
5163	Evidence of Lifestyle Modification in the Management of Hypercholesterolemia. <i>Current Cardiology Reviews</i> , 2013, 9, 2-14.	0.6	53
5164	Gender disparity in statin response: are statins less effective in women?. <i>Clinical Lipidology</i> , 2013, 8, 161-163.	0.4	4
5165	Are we overtreating cardiovascular disease in diabetic patients?. <i>Diabetes Management</i> , 2013, 3, 271-275.	0.5	0
5166	Cost-related Nonadherence by Medication Type Among Medicare Part D Beneficiaries With Diabetes. <i>Medical Care</i> , 2013, 51, 193-198.	1.1	43
5167	Response to Letters Regarding Article, "Statins and the Risk of Cancer After Heart Transplantation". <i>Circulation</i> , 2013, 127, e442.	1.6	0
5168	Pharmacological approach to cardiovascular risk in metabolic syndrome. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 403-409.	0.6	5
5169	ROLE OF STATINS IN THE DEVELOPMENT AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2013, 33, 414-422.	1.0	39
5170	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. <i>Vascular Health and Risk Management</i> , 2013, 9, 617.	1.0	71
5171	Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. <i>Vascular Health and Risk Management</i> , 2013, 9, 671.	1.0	28

#	ARTICLE	IF	CITATIONS
5172	Statins and Cognitive Function. <i>Annals of Internal Medicine</i> , 2013, 159, 688.	2.0	212
5173	Reassessing the Benefits of Statins in the Prevention of Cardiovascular Disease in Diabetic Patients - A Systematic Review and Meta-Analysis. <i>Review of Diabetic Studies</i> , 2013, 10, 157-170.	0.5	14
5174	Effects of Rosuvastatin vs. Simvastatin/ezetimibe on Arterial Wall Stiffness in Patients with Coronary Artery Disease. <i>Internal Medicine</i> , 2013, 52, 2715-2719.	0.3	9
5175	Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 11.	1.1	13
5176	Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. <i>Molecular and Clinical Oncology</i> , 2013, 1, 365-368.	0.4	16
5177	Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. <i>Vascular Health and Risk Management</i> , 2013, 9, 273.	1.0	7
5178	Treatment of lipid disorders: targets and thresholds. <i>Italian Journal of Medicine</i> , 2013, , 75-77.	0.2	0
5179	Provider Compliance With Guidelines for Management of Cardiovascular Risk in HIV-Infected Patients. <i>Preventing Chronic Disease</i> , 2013, 10, E10.	1.7	42
5180	Early Differential Changes in Coronary Plaque Composition According to Plaque Stability Following Statin Initiation in Acute Coronary Syndrome: Classification and Analysis by Intravascular Ultrasound-Virtual Histology. <i>Yonsei Medical Journal</i> , 2013, 54, 336.	0.9	18
5181	Effects of Low Dose versus High Dose Statin Therapy on the Changes of Endothelial Function and Carotid Intima-Media Thickness in Patients with Variant Angina. <i>Journal of Cardiovascular Imaging</i> , 2013, 21, 58.	0.8	11
5182	National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 491.	0.9	16
5183	A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 55.	1.0	14
5185	Statins in heart failure: do we need another trial?. <i>Vascular Health and Risk Management</i> , 2013, 9, 303.	1.0	25
5186	Trends in Low-Density Lipoprotein Cholesterol Goal Achievement in High Risk United States Adults: Longitudinal Findings from the 1999-2008 National Health and Nutrition Examination Surveys. <i>PLoS ONE</i> , 2013, 8, e59309.	1.1	17
5187	Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>PLoS ONE</i> , 2013, 8, e72642.	1.1	41
5188	Role of Statins in Coronary Artery Disease. <i>Chonnam Medical Journal</i> , 2013, 49, 1.	0.5	30
5189	Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 407-424.	0.9	15
5190	Diabetes in Women. , 2013, , 873-882.		0

#	ARTICLE	IF	CITATIONS
5191	Muscular effects of statins in the elderly female: a review. <i>Clinical Interventions in Aging</i> , 2013, 8, 47.	1.3	63
5192	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Archives of Medical Science</i> , 2013, 3, 418-426.	0.4	40
5193	Relation between the ankle-brachial index and the complexity of coronary artery disease in older patients. <i>Clinical Interventions in Aging</i> , 2013, 8, 1611.	1.3	9
5194	Effects of Pravastatin and Atorvastatin on HDL Cholesterol and Glucose Metabolism in Patients with Dyslipidemia and Glucose Intolerance: The PRAT Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 368-379.	0.9	14
5195	Evidence of Lifestyle Modification in the Management of Hypercholesterolemia. <i>Current Cardiology Reviews</i> , 2013, 9, 2-14.	0.6	39
5196	Treatment of Coronary Artery Bypass Graft Failure. , 2013, , .		4
5197	Efficacy of Contemporary Medical Management for Asymptomatic Carotid Artery Stenosis. <i>American Surgeon</i> , 2013, 79, 987-991.	0.4	6
5198	REAL PRACTICE OF STATINS USE AND ITS DEPENDENCE ON FOLLOW-UP IN THE SPECIALIZED MEDICAL CENTRE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK (ACCORDING TO THE PROFILE REGISTER). <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 362-367.	0.3	8
5199	Multivessel Disease in the Modern Era of Percutaneous Coronary Intervention. , 0, , .		0
5200	MEDICAL SUPERVISION IN SPECIALIZED CENTER AND THE QUALITY OF LIPID-LOWERING THERAPY IN PATIENTS WITH CARDIOVASCULAR DISEASES (ACCORDING TO THE PROFIL REGISTER). <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 133-137.	0.3	15
5201	STATIN SAFETY REVISITED DATA. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 143-148.	0.3	1
5202	STATINS IN PREVENTION OF ISCHEMIC STROKE. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 409-416.	0.3	1
5203	Lipid Disorders in the Elderly. , 2014, , 719-722.		0
5204	Effects of Statins on Incident Dementia in Patients with Type 2 DM: A Population-Based Retrospective Cohort Study in Taiwan. <i>PLoS ONE</i> , 2014, 9, e88434.	1.1	25
5206	Protective Effects of Panax Notoginseng Saponins on Cardiovascular Diseases: A Comprehensive Overview of Experimental Studies. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-13.	0.5	112
5207	Medication Monitoring and Optimization: A Targeted Pharmacist Program for Effective and Cost-Effective Improvement of Chronic Therapy Adherence. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 786-792.	2.2	42
5208	Carotid revascularization: risks and benefits. <i>Vascular Health and Risk Management</i> , 2014, 10, 403.	1.0	26
5210	Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 71.	1.7	43

#	ARTICLE	IF	CITATIONS
5211	Treating the elderly diabetic patient: special considerations. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 391.	1.1	10
5212	Effect of <i>Nigella Sativa</i> and <i>Allium Sativum</i> Coadministered with Simvastatin in Dyslipidemia Patients: A Prospective, Randomized, Double-Blind Trial. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2014, 13, 68-74.	1.1	32
5213	Improving Adherence to Lipid-Lowering Therapy in a Community Pharmacy Intervention Program: A Cost-Effectiveness Analysis. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 722-732.	2.2	22
5214	Management of acute coronary syndrome in special subgroups: female, older, diabetic and Indigenous patients. <i>Medical Journal of Australia</i> , 2014, 201, S91-6.	0.8	1
5215	Dyslipidemia in women: etiology and management. <i>International Journal of Women's Health</i> , 2014, 6, 185.	1.1	57
5216	Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 815.	0.9	31
5217	Moving Branded Statins to Lowest Copay Tier Improves Patient Adherence. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 34-42.	2.2	17
5218	Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. <i>Vascular Health and Risk Management</i> , 2014, 10, 89.	1.0	32
5219	Optimal management of infrainguinal arterial occlusive disease. <i>Vascular Health and Risk Management</i> , 2014, 10, 599.	1.0	16
5220	Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemias: divergencia entre las guías europea y estadounidense. <i>Pediatría De Atención Primaria</i> , 2014, 16, e161-e172.	0.2	0
5221	THE SAFETY OF STATINS: WHAT A PHYSICIAN NEEDS TO KNOW. <i>Rational Pharmacotherapy in Cardiology</i> , 2014, 10, 334-338.	0.3	3
5222	Is Routine Testing for Proteinuria Indicated in Diabetic Eye Clinics?. <i>Journal of Clinical & Experimental Ophthalmology</i> , 2014, 05, .	0.1	0
5223	PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE. <i>Rational Pharmacotherapy in Cardiology</i> , 2014, 10, 384-390.	0.3	0
5224	Statins and the risk of colorectal cancer: An updated systematic review and meta-analysis of 40 studies. <i>World Journal of Gastroenterology</i> , 2014, 20, 1858.	1.4	94
5225	Statins: Definitive Translational Research. <i>Molecular Medicine</i> , 2014, 20, S20-S23.	1.9	7
5226	Treatment of Ventricular Arrhythmias. , 0, , .		0
5227	Clinical Predictors of Atheroma Progression Despite Optimal Glycemic Control in Early-Stage Diabetic Patients with Coronary Artery Disease: Insight from the DIANA Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 509-518.	0.9	9
5230	Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 8-19.	0.6	7

#	ARTICLE	IF	CITATIONS
5231	Simvastatin reduces leucocyte and platelet endothelial cell interaction in murine antigen-induced arthritis in vivo. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 356-363.	0.6	5
5232	Are add-on agents to statin therapy necessary in hypercholesterolemia?. <i>Clinical Lipidology</i> , 2014, 9, 695-707.	0.4	0
5234	Statinopause. <i>Journal of General Internal Medicine</i> , 2014, 29, 1702-1706.	1.3	5
5235	High prevalence of dyslipidemia and associated risk factors among rural Chinese adults. <i>Lipids in Health and Disease</i> , 2014, 13, 189.	1.2	75
5236	Case Management to Reduce Cardiovascular Disease Risk in American Indians and Alaska Natives With Diabetes: Results From the Special Diabetes Program for Indians Healthy Heart Demonstration Project. <i>American Journal of Public Health</i> , 2014, 104, e158-e164.	1.5	32
5237	The transitioning from trials to extended follow-up studies. <i>Clinical Trials</i> , 2014, 11, 635-647.	0.7	3
5238	Cognitive decline and depressive symptoms in late-life are associated with statin use: evidence from a population-based study of Sardinian old people living in their own home. <i>Neurological Research</i> , 2014, 36, 247-254.	0.6	24
5239	Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice. <i>Drugs in R and D</i> , 2014, 14, 221-225.	1.1	1
5240	The Evening versus Morning Polypill Utilization Study: the TEMPUS rationale and design. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 425-433.	0.8	10
5241	Consensus statement on management of dyslipidemia in Indian subjects. <i>Indian Heart Journal</i> , 2014, 66, S1-S51.	0.2	47
5242	LDL cholesterol: should guidelines include targets?. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 285-290.	0.6	1
5243	Statin use is associated with improved overall survival without affecting patency and limb salvage rates following open or endovascular revascularization. <i>Vascular Medicine</i> , 2014, 19, 86-93.	0.8	15
5244	Trends in Cause of Death After Percutaneous Coronary Intervention. <i>Circulation</i> , 2014, 129, 1286-1294.	1.6	149
5245	Diabetic Nephropathy in Children. , 2014, , 1-28.		0
5246	Reducing Clinical Inertia in Diabetes Management: An observational study. <i>Apollo Medicine</i> , 2014, 11, 261-263.	0.0	0
5247	Can analyses of electronic patient records be independently and externally validated? The effect of statins on the mortality of patients with ischaemic heart disease: a cohort study with nested case control analysis. <i>BMJ Open</i> , 2014, 4, e004952.	0.8	29
5248	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. <i>PLoS Medicine</i> , 2014, 11, e1001713.	3.9	75
5249	Atherosclerotic Peripheral Artery Disease: Clinical Management. , 2014, , 1-26.		0

#	ARTICLE	IF	CITATIONS
5250	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. Journal of the American Heart Association, 2014, 3, e001098.	1.6	24
5251	Phenotype Standardization for Statin-Induced Myotoxicity. Clinical Pharmacology and Therapeutics, 2014, 96, 470-476.	2.3	166
5252	Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. Current Medical Research and Opinion, 2014, 30, 1957-1965.	0.9	5
5253	Pharmacology in Peripheral Arterial Disease: What the Interventional Radiologist Needs to Know. Seminars in Interventional Radiology, 2014, 31, 330-337.	0.3	6
5254	Pharmacology of statins: A brief overview. NursePrescribing, 2014, 12, 451-456.	0.1	2
5255	Expanded Colesevelam Administration Options With Oral Suspension Formulation for Patients With Diabetes and Hypercholesterolemia. Postgraduate Medicine, 2014, 126, 126-134.	0.9	8
5256	Impact of the JUPITER Trial on Statin Prescribing for Primary Prevention. Pharmacotherapy, 2014, 34, 9-18.	1.2	5
5257	Statins Reduce Peri-procedural Complications in Carotid Stenting. European Journal of Vascular and Endovascular Surgery, 2014, 48, 626-632.	0.8	40
5258	The 2013 American College of Cardiology/American Heart Association Guidelines on Treating Blood Cholesterol and Assessing Cardiovascular Risk. Endocrinology and Metabolism Clinics of North America, 2014, 43, 869-892.	1.2	5
5259	Aggressive Lipid Management in Very Elderly Adults: Less Is More. Journal of the American Geriatrics Society, 2014, 62, 945-947.	1.3	26
5260	Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment. British Journal of Clinical Pharmacology, 2014, 78, 649-659.	1.1	27
5261	Combination Therapy with Statins. Endocrinology and Metabolism Clinics of North America, 2014, 43, 993-1006.	1.2	1
5262	Nursing typhus victims in the Second World War, 1942â€“1944: a discussion paper. Journal of Advanced Nursing, 2014, 70, 1510-1519.	1.5	1
5263	Antioxidants Use in Human Cardiovascular Disease â€“ Where Are We?. , 2014, , 1473-1478.		0
5264	Sigmoidal Maximal Effect Modeling of Lowâ€“Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials. Pharmacotherapy, 2014, 34, 452-463.	1.2	6
5265	Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals. International Journal of Cardiology, 2014, 177, 860-866.	0.8	1
5266	Association between triglyceride and high-density lipoprotein cholesterol change following fibrate therapy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 212-215.	1.8	3
5267	Bayesian network meta-analysis for unordered categorical outcomes with incomplete data. Research Synthesis Methods, 2014, 5, 162-185.	4.2	14

#	ARTICLE	IF	CITATIONS
5268	Comparison of LDL-cholesterol estimate using the Friedewald formula and the newly proposed de Cordova formula with a directly measured LDL-cholesterol in a healthy South African population. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 672-679.	0.8	26
5269	Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 519-526.	2.2	11
5270	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. <i>The Cochrane Library</i> , 2014, , CD007784.	1.5	141
5271	Alice in Lipidland. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2193-2195.	1.2	2
5272	New cholesterol guidelines: Worth the wait?. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 11-19.	0.6	25
5273	Response by Neil J. Stone, Sunny Intwala, and Dan Katz. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 947-948.	1.3	1
5274	JCL Roundtable: Lipid-lowering drugs in those older than 75 years of age. <i>Journal of Clinical Lipidology</i> , 2014, 8, 533-541.	0.6	4
5275	Pharmacokinetics, pharmacodynamics, safety, and tolerability of hyzetimibe (HS-25) in healthy Chinese subjects. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1144-1152.	1.0	13
5276	Rosuvastatin May Reduce the Incidence of Cardiovascular Events in Patients with Acute Coronary Syndromes Receiving Percutaneous Coronary Intervention by Suppressing miR-155/SHIP-1 Signaling Pathway. <i>Cardiovascular Therapeutics</i> , 2014, 32, 276-282.	1.1	28
5277	Pathogenesis of Atherosclerosis: From Cell Biology to Therapeutics. <i>Colloquium Series on Integrated Systems Physiology From Molecule To Function</i> , 2014, 6, 1-125.	0.3	1
5278	Anticoagulant effects of statins and their clinical implications. <i>Thrombosis and Haemostasis</i> , 2014, 112, 392-400.	1.8	95
5279	Modulation of the Pancreatic Islet-Stress Axis as a Novel Potential Therapeutic Target in Diabetes Mellitus. <i>Vitamins and Hormones</i> , 2014, 95, 195-222.	0.7	8
5280	Long-Term Statin Use and Dementia Risk in Taiwan. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 165-171.	1.2	15
5281	Critical Review of High-Sensitivity C-Reactive Protein and Coronary Artery Calcium for the Guidance of Statin Allocation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 315-322.	0.9	13
5282	Efficacy and safety of ezetimibe plus atorvastatin therapy. <i>Clinical Lipidology</i> , 2014, 9, 441-470.	0.4	7
5283	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.3	39
5284	Risk of Ischemic Stroke After an Acute Myocardial Infarction in Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 95-101.	0.9	16
5285	The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. <i>Current Opinion in Lipidology</i> , 2014, 25, 239-246.	1.2	12

#	ARTICLE	IF	CITATIONS
5286	Circulating Levels of Proprotein Convertase Subtilisin Kexin Type 9 are Elevated by Fibrate Therapy. <i>Cardiology in Review</i> , 2014, 22, 306-312.	0.6	21
5287	The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 43-51.	0.7	42
5288	Effect of Cardiovascular Drugs on Cardiovascular Events in 1599 Patients Followed in an Academic Outpatient Cardiology Practice. <i>American Journal of Therapeutics</i> , 2014, 21, 68-72.	0.5	0
5290	Relations of Change in Plasma Levels of LDL-C, Non-HDL-C and apoB With Risk Reduction From Statin Therapy: A Meta-Analysis of Randomized Trials. <i>Journal of the American Heart Association</i> , 2014, 3, e000759.	1.6	104
5291	Contemporary outcomes with percutaneous vascular interventions for peripheral critical limb ischemia in those with and without poly-vascular disease. <i>Vascular Medicine</i> , 2014, 19, 491-499.	0.8	33
5292	Association of a reduction in low-density lipoprotein cholesterol with incident cardiovascular and cerebrovascular events among people with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 855-865.	0.8	7
5293	Multicenter cross-sectional study of asymptomatic peripheral arterial disease among patients with a single previous coronary or cerebrovascular event in the Arabian Gulf. <i>Current Medical Research and Opinion</i> , 2014, 30, 1725-1732.	0.9	4
5294	Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 192-202.	0.8	19
5295	Statin intolerance: diagnosis, treatment and alternative therapies. <i>Clinical Lipidology</i> , 2014, 9, 355-367.	0.4	3
5296	Rates of Complications and Mortality in Older Patients With Diabetes Mellitus. <i>JAMA Internal Medicine</i> , 2014, 174, 251.	2.6	397
5297	Management of Diabetic Nephropathy in Older Patients: A Need for Flexible Guidelines. <i>Postgraduate Medicine</i> , 2014, 126, 171-177.	0.9	7
5298	Pharmacist influence on prescribing in peripheral arterial disease (PIPER). <i>Vascular Medicine</i> , 2014, 19, 118-124.	0.8	6
5299	Assessing Uncertainties Surrounding Combined Endpoints for Use in Economic Models. <i>Medical Decision Making</i> , 2014, 34, 300-310.	1.2	2
5300	Atherosclerotic cardiovascular disease risk and evidence-based management of cholesterol. <i>North American Journal of Medical Sciences</i> , 2014, 6, 191.	1.7	22
5301	Pre and post-stroke use of statins improves stroke outcome. <i>Indian Journal of Community Medicine</i> , 2014, 39, 214.	0.2	6
5302	Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence. <i>Research and Reports in Endocrine Disorders</i> , 0, , 1.	0.4	0
5303	Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 19.	0.7	28
5304	Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study. <i>BMC Family Practice</i> , 2014, 15, 8.	2.9	35

#	ARTICLE	IF	CITATIONS
5305	Adherence to Guideline-Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease. <i>Journal of the American Heart Association</i> , 2014, 3, e000697.	1.6	181
5306	Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 90-100.	2.3	55
5307	A systematic review of statin-induced muscle problems in clinical trials. <i>American Heart Journal</i> , 2014, 168, 6-15.	1.2	219
5308	Peripheral microvascular dysfunction predicts residual risk in coronary artery disease patients on statin therapy. <i>Atherosclerosis</i> , 2014, 232, 186-190.	0.4	27
5309	Lipid-Lowering Therapy in Patients 75 Years and Older: Clinical Priority or Superfluous Therapy?. <i>Progress in Cardiovascular Diseases</i> , 2014, 57, 187-196.	1.6	10
5310	LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy. <i>Clinical Therapeutics</i> , 2014, 36, 792-799.	1.1	3
5311	Medication among patients with type 1 diabetes and predialytic renal disease. <i>Diabetes Research and Clinical Practice</i> , 2014, 103, 510-515.	1.1	0
5312	High-potency statins increase the risk of acute kidney injury: Evidence from a large population-based study. <i>Atherosclerosis</i> , 2014, 234, 224-229.	0.4	19
5313	Is Myopathy the Achilles' Heel of Statins?. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2300-2301.	1.2	2
5314	Therapeutics of Alzheimer's disease: Past, present and future. <i>Neuropharmacology</i> , 2014, 76, 27-50.	2.0	601
5315	Blood pressure-lowering effect of simvastatin: a placebo-controlled randomized clinical trial with 24-h ambulatory blood pressure monitoring. <i>Journal of Human Hypertension</i> , 2014, 28, 62-67.	1.0	13
5316	Effects of Adding Statins Before Surgery on Mortality and Major Morbidity: A Meta-Analysis. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 255-266.	0.6	11
5317	Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1-17.	2.9	42
5318	Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. <i>SpringerPlus</i> , 2014, 3, 14.	1.2	15
5319	"My doctor has changed my pills without telling me": impact of generic medication switches in stroke survivors. <i>Journal of Behavioral Medicine</i> , 2014, 37, 890-901.	1.1	8
5320	Cognitive Effects of Statin Medications. <i>CNS Drugs</i> , 2014, 28, 411-419.	2.7	40
5321	Association Between Statin Medications and Mortality, Major Adverse Cardiovascular Event, and Amputation-Free Survival in Patients With Critical Limb Ischemia. <i>Journal of the American College of Cardiology</i> , 2014, 63, 682-690.	1.2	142
5322	Clinical evidence of statin therapy in non-dyslipidemic disorders. <i>Pharmacological Research</i> , 2014, 88, 20-30.	3.1	20

#	ARTICLE	IF	CITATIONS
5323	Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment. <i>Transplantation Reviews</i> , 2014, 28, 37-46.	1.2	59
5324	Update in Therapeutic Approaches to Plaque Stabilization. <i>Current Atherosclerosis Reports</i> , 2014, 16, 392.	2.0	4
5325	Targeting Inflammation: Impact on Atherothrombosis. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 9-18.	1.1	12
5326	Trends in statin therapy initiation during the period 2000â€“2010 in Israel. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 557-564.	0.8	3
5327	Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. <i>Cancer Causes and Control</i> , 2014, 25, 237-249.	0.8	107
5328	About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus. <i>Contemporary Diabetes</i> , 2014, , 329-346.	0.0	0
5330	Long-term efficacy and safety of statin treatment beyond six years: A meta-analysis of randomized controlled trials with extended follow-up. <i>Pharmacological Research</i> , 2014, 81, 64-73.	3.1	23
5331	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	0.6	289
5332	Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2491-2502.	1.2	155
5333	A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4â€™mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI). <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 63-71.	2.4	84
5335	Neurodegenerative Diseases. , 2014, , .		3
5336	Peripheral Arterial Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 149-166.	1.2	43
5338	An assessment by the Statin Diabetes Safety Task Force: 2014 update. <i>Journal of Clinical Lipidology</i> , 2014, 8, S17-S29.	0.6	102
5339	Diabetes and the brain: issues and unmet needs. <i>Neurological Sciences</i> , 2014, 35, 995-1001.	0.9	44
5340	Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. <i>New England Journal of Medicine</i> , 2014, 370, 2201-2210.	13.9	281
5341	Simvastatin dose and risk of rhabdomyolysis: Nested caseâ€“control study based on national health and drug dispensing data. <i>International Journal of Cardiology</i> , 2014, 174, 83-89.	0.8	9
5342	Targeting LDL: Is lower better and is it safe?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 309-324.	2.2	27
5343	Addressing Statin Adverse Effects in the Clinic. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 533-542.	1.0	22

#	ARTICLE	IF	CITATIONS
5344	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2889-2934.	1.2	3,414
5345	Influence of cognitive impairment on the management of ischaemic stroke. <i>Revue Neurologique</i> , 2014, 170, 177-186.	0.6	4
5346	Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets. <i>Biochemical Pharmacology</i> , 2014, 88, 605-616.	2.0	73
5347	Target-Attainment Rates of Low-Density Lipoprotein Cholesterol Using Lipid-Lowering Drugs One Year After Acute Myocardial Infarction in Sweden. <i>American Journal of Cardiology</i> , 2014, 113, 17-22.	0.7	10
5348	High Cholesterol Levels Are Associated with Improved Long-term Survival after Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, e47-e53.	0.7	52
5349	Neuropsychiatric Adverse Events Associated with Statins: Epidemiology, Pathophysiology, Prevention and Management. <i>CNS Drugs</i> , 2014, 28, 249-272.	2.7	52
5350	Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). <i>American Journal of Cardiology</i> , 2014, 113, 621-625.	0.7	14
5351	Statins, bone metabolism and treatment of bone catabolic diseases. <i>Pharmacological Research</i> , 2014, 88, 53-61.	3.1	58
5352	Neurologic complications of myocardial infarction. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 119, 93-110.	1.0	1
5353	Preoperative statin therapy in cardiac surgery: a meta-analysis of 90 000 patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 45, 17-26.	0.6	90
5354	Impact of Switching Treatment From Rosuvastatin to Atorvastatin on Rates of Cardiovascular Events. <i>Clinical Therapeutics</i> , 2014, 36, 58-69.	1.1	8
5355	Advances in the prevention of Alzheimer's disease and dementia. <i>Journal of Internal Medicine</i> , 2014, 275, 229-250.	2.7	237
5356	Guidelines for the Primary Prevention of Stroke. <i>Stroke</i> , 2014, 45, 3754-3832.	1.0	1,621
5357	The Effect of Ezetimibe on Androgen Production in Hypercholesterolemic Women with Polycystic Ovary Syndrome. <i>Cardiovascular Therapeutics</i> , 2014, 32, 219-223.	1.1	8
5358	Effect of statin therapy on cardiovascular outcomes after coronary revascularization in patients ≥80 years of age: Observations from the CREDO-Kyoto Registry Cohort-2. <i>Atherosclerosis</i> , 2014, 237, 821-828.	0.4	10
5359	Strategia di gestione delle sindromi coronariche acute. <i>EMC - Urgenze</i> , 2014, 18, 1-14.	0.0	0
5360	Providing systematic detailed information on medication upon hospital discharge as an important step towards improved transitional care. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 286-291.	0.7	21
5361	Efficacy and Safety of Pitavastatin Versus Simvastatin: A Meta-Analysis of Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2014, 34, 599-608.	1.1	8

#	ARTICLE	IF	CITATIONS
5362	Mechanisms and assessment of statin-related muscular adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 454-466.	1.1	88
5363	Trends in Stroke Treatment and Outcome between 1995 and 2010: Observations from Riks-Stroke, the Swedish Stroke Register. <i>Cerebrovascular Diseases</i> , 2014, 37, 22-29.	0.8	51
5364	Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1069-1077.	1.1	386
5365	Long-term effects of an intensive intervention in HIV-infected patients with moderate-high atherosclerotic cardiovascular risk. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3051-3056.	1.3	8
5366	Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. <i>American Journal of Cardiology</i> , 2014, 114, 1465-1472.	0.7	42
5367	Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 913-919.	0.4	5
5368	Natural Products in Medicine: Transformational Outcome of Synthetic Chemistry. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9292-9308.	2.9	82
5370	Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. <i>Vascular Pharmacology</i> , 2014, 63, 79-87.	1.0	49
5371	Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 684-698.	1.1	215
5372	Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 1215-1225.	2.8	27
5373	Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: A case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). <i>Journal of Clinical Lipidology</i> , 2014, 8, 489-493.	0.6	7
5374	Review of Clinical Practice Guidelines for the Management of LDL-Related Risk. <i>Journal of the American College of Cardiology</i> , 2014, 64, 196-206.	1.2	52
5376	Patterns of Statin Initiation, Intensification, and Maximization Among Patients Hospitalized With an Acute Myocardial Infarction. <i>Circulation</i> , 2014, 129, 1303-1309.	1.6	62
5377	The Therapeutic Role of Niacin in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 141-158.	1.0	52
5378	Secondary Prevention of Stroke in the Elderly: Focus on Drug Therapy. <i>Drugs and Aging</i> , 2014, 31, 721-730.	1.3	16
5379	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 594-605.	0.6	11
5380	IS8.06: The relationship of frailty to disability. <i>European Geriatric Medicine</i> , 2014, 5, S12.	1.2	0
5381	Questioning the Benefits of Statin Therapy in Older People without Established Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2014, 23, 991-992.	0.2	1

#	ARTICLE	IF	CITATIONS
5383	Statins for acute coronary syndrome. The Cochrane Library, 2014, , CD006870.	1.5	32
5384	Risk Stratification in Very Old Adults: How to Best Gauge Risk as the Basis of Management Choices for Patients Aged Over 80. <i>Progress in Cardiovascular Diseases</i> , 2014, 57, 197-203.	1.6	23
5385	IS8.07: Prevention of functional decline in hospitalized older patients, a high priority!. <i>European Geriatric Medicine</i> , 2014, 5, S12.	1.2	0
5386	HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model. <i>International Journal of Cardiology</i> , 2014, 175, 528-538.	0.8	28
5387	Antioxidant Vitamin Supplementation Reduces Arterial Stiffness in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Nutrition</i> , 2014, 144, 1594-1602.	1.3	36
5388	Statins in chronic kidney disease and kidney transplantation. <i>Pharmacological Research</i> , 2014, 88, 62-73.	3.1	22
5389	Non-cardiovascular effects associated with statins. <i>BMJ, The</i> , 2014, 349, g3743-g3743.	3.0	137
5390	Atorvastatin helps preserve pancreatic β^2 cell function in obese C57BL/6 mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress. <i>Lipids in Health and Disease</i> , 2014, 13, 98.	1.2	29
5391	Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 202.	0.7	15
5392	Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 351-362.	0.8	9
5393	National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 "executive summary. <i>Journal of Clinical Lipidology</i> , 2014, 8, 473-488.	0.6	396
5394	Standards of Practice for Superficial Femoral and Popliteal Artery Angioplasty and Stenting. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 592-603.	0.9	75
5395	Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial. <i>Clinical Rheumatology</i> , 2014, 33, 1273-1278.	1.0	18
5396	Older Statin Initiators in Finland "Cardiovascular Risk Profiles and Persistence of Use. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 263-272.	1.3	8
5397	Simvastatin Treatment Enhances NMDAR-Mediated Synaptic Transmission by Upregulating the Surface Distribution of the GluN2B Subunit. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 693-705.	1.7	22
5398	Inappropriate prescribing in patients accessing specialist palliative day care services. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 535-543.	1.0	29
5399	The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 423-428.	2.3	379
5400	Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality. <i>Circulation</i> , 2014, 130, 546-553.	1.6	118

#	ARTICLE	IF	CITATIONS
5401	HDL: To Treat or Not To Treat?. Current Atherosclerosis Reports, 2014, 16, 429.	2.0	12
5402	Is there Sufficient Enhancement of the Reduction in CVD Rates after a Decade of Statin Therapy to Justify Continuation?. Current Atherosclerosis Reports, 2014, 16, 432.	2.0	1
5403	Discordance in Lipid Measurements: Can we Capitalize to Better Personalize Cardiovascular Risk Assessment and Treatment?. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	1
5404	Hyperglycemia, Acute Ischemic Stroke, and Thrombolytic Therapy. Translational Stroke Research, 2014, 5, 442-453.	2.3	102
5405	The 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol. Circulation Research, 2014, 114, 761-764.	2.0	17
5406	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation, 2014, 129, S1-45.	1.6	4,842
5407	Comparison of the Efficacy and Safety Profile of Morning Administration of Controlled-release Simvastatin Versus Evening Administration of Immediate-release Simvastatin in Chronic Kidney Disease Patients With Dyslipidemia. Clinical Therapeutics, 2014, 36, 1182-1190.	1.1	12
5408	Vascular Endothelial Function. , 2014, , 1-37.		1
5409	Management of Atherosclerotic Aortoiliac Occlusive Disease. Interventional Cardiology Clinics, 2014, 3, 531-543.	0.2	5
5410	Ischaemic heart disease: stable angina. Medicine, 2014, 42, 495-501.	0.2	1
5411	Curcumin enhances cell surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Molecular Nutrition and Food Research, 2014, 58, 2133-2145.	1.5	93
5412	Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults. Journal of Clinical Lipidology, 2014, 8, 501-509.	0.6	11
5413	A Prescription at Discharge Improves Long-term Adherence for Secondary Stroke Prevention. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2308-2315.	0.7	16
5414	Strategies for treating lipids for prevention: Risk stratification models with and without imaging. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 295-307.	2.2	3
5416	Preprocedural statin use in patients undergoing percutaneous coronary intervention. American Heart Journal, 2014, 168, 110-116.e3.	1.2	5
5417	Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. Atherosclerosis, 2014, 233, 561-567.	0.4	48
5418	The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. Atherosclerosis, 2014, 233, 707-712.	0.4	61
5419	Dietary modulators of statin efficacy in cardiovascular disease and cognition. Molecular Aspects of Medicine, 2014, 38, 1-53.	2.7	13

#	ARTICLE	IF	CITATIONS
5420	Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: A meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1067-1073.	1.1	2
5421	Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. <i>Digestive and Liver Disease</i> , 2014, 46, 720-725.	0.4	32
5422	Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 61-67.	0.6	11
5423	Hypolipidemic action of chrysin on Triton WR-1339-induced hyperlipidemia in female C57BL/6 mice. <i>Toxicology Reports</i> , 2014, 1, 200-208.	1.6	82
5424	Statins in neurological disorders: An overview and update. <i>Pharmacological Research</i> , 2014, 88, 74-83.	3.1	65
5425	The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: A preliminary report. <i>Pharmacological Reports</i> , 2014, 66, 880-884.	1.5	19
5426	Fixed-dose combination therapy for the prevention of cardiovascular disease. , 2014, , CD009868.		57
5427	Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. <i>BMJ Open</i> , 2014, 4, e005402-e005402.	0.8	19
5429	Comparison of Lipid Management in Patients With Coronary Versus Peripheral Arterial Disease. <i>American Journal of Cardiology</i> , 2014, 113, 1320-1325.	0.7	19
5430	Lipid lowering in liver and chronic kidney disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 339-352.	2.2	9
5431	Change in prevalence of chronic kidney disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010. <i>BMJ Open</i> , 2014, 4, e005480-e005480.	0.8	55
5434	2014 Meet-The-Professor: Endocrine Case Management. , 2014, , .		0
5435	Secondary prevention. , 0, , 356-370.		0
5436	Review: Statins are not associated with cognitive impairment or dementia in cognitively intact adults. <i>Annals of Internal Medicine</i> , 2014, 160, JC11.	2.0	0
5438	Estimating Mortality in Survivors of the Acute Coronary Syndrome by the 4-Drug Score. <i>Cardiology</i> , 2014, 127, 83-89.	0.6	3
5440	New Cholesterol Guidelines: Has Godot Finally Arrived?. <i>Annals of Internal Medicine</i> , 2014, 160, 354-355.	2.0	15
5441	Is High-Intensity Statin Therapy Associated With Lower Statin Adherence Compared With Low-to Moderate-Intensity Statin Therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. <i>Clinical Cardiology</i> , 2014, 37, 653-659.	0.7	53
5442	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919.	2.2	19

#	ARTICLE	IF	CITATIONS
5444	Challenging treatment thresholds. <i>The Prescriber</i> , 2015, 26, 5-7.	0.1	3
5445	Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 363-371.	1.1	78
5446	Cholesterol, Statins, and Dementia: What the Cardiologist Should Know. <i>Clinical Cardiology</i> , 2015, 38, 243-250.	0.7	47
5447	Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00179.	1.1	9
5448	Ezetimibe for primary hypercholesterolemia. <i>The Cochrane Library</i> , 0, , .	1.5	0
5450	2015 Meet-The-Professor: Endocrine Case Management. , 2015, , .		0
5451	A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention: Table 1. <i>Evidence-Based Medicine</i> , 2015, 20, 162-169.	0.6	7
5452	Targeted study to evaluate the cardiovascular risk factor status among patients and efficacy of statins in attaining goal lipid levels in a regional hospital in Sultanate of Oman. <i>Saudi Pharmaceutical Journal</i> , 2015, 23, 371-376.	1.2	1
5453	How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 117.	0.7	11
5454	Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. <i>Cardiovascular Diabetology</i> , 2015, 14, 60.	2.7	3
5455	Nurses as therapeutic agents in the extreme environment of the desert-Awar, 1940-44. <i>Journal of Advanced Nursing</i> , 2015, 71, 2520-2528.	1.5	2
5456	Telmisartan in the management of abdominal aortic aneurysm (TEDY): The study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 274.	0.7	31
5457	Association of Treatment for Hyperlipidemia with Decreased Total Mortality in Japanese Individuals: the Yamagata (Takahata) Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1030-1039.	0.9	11
5458	The additive value of multiple biomarkers in prediction of premature coronary artery disease. <i>Acta Cardiologica</i> , 2015, 70, 205-210.	0.3	7
5459	Expanding the Evidence Base. <i>American Journal of Therapeutics</i> , 2015, 22, e141-e150.	0.5	11
5460	Statin intolerance. <i>Current Opinion in Lipidology</i> , 2015, 26, 492-501.	1.2	32
5461	Motivational effects of coronary artery calcium scores on statin adherence and weight loss. <i>Coronary Artery Disease</i> , 2015, 26, 225-230.	0.3	49
5462	Common statin side effects explain poor compliance. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 170-171.	1.1	4

#	ARTICLE	IF	CITATIONS
5463	Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 306-311.	0.9	26
5464	Excessive range of statin dose in Western Australian primary care. <i>Internal Medicine Journal</i> , 2015, 45, 860-863.	0.5	3
5465	Statin Use and Risk of Atrial Fibrillation or Flutter. <i>American Journal of Therapeutics</i> , 2015, 22, 186-194.	0.5	16
5466	What does the future hold for cholesteryl ester transfer protein inhibition?. <i>Current Opinion in Lipidology</i> , 2015, 26, 526-535.	1.2	1
5467	Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemias: divergencia entre las guías europea y estadounidense. <i>Revista Española De Salud Pública</i> , 2015, 89, 15-26.	0.3	2
5468	2015 Korean Guidelines for Management of Dyslipidemia. <i>Journal of Lipid and Atherosclerosis</i> , 2015, 4, 61.	1.1	38
5469	Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease. <i>Vascular Health and Risk Management</i> , 2015, 11, 185.	1.0	34
5470	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. <i>Italian Journal of Medicine</i> , 2015, 3, 309.	0.2	1
5471	Adherence to statin treatment following a myocardial infarction: an Italian population-based survey. <i>Clinical Economics and Outcomes Research</i> , 2015, 7, 273.	0.7	6
5472	The FADOI (Federation of Associations of Hospital Doctors on Internal Medicine) position paper on cardiovascular prevention in the higher risk complex patients. <i>Italian Journal of Medicine</i> , 2015, 9, 387.	0.2	1
5473	Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 14477-14489.	1.8	14
5474	A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1235-1247.	0.9	5
5475	Cardiovascular risk assessment in type 2 diabetes mellitus: comparison of the World Health Organization/International Society of Hypertension risk prediction charts versus UK Prospective Diabetes Study risk engine. <i>Vascular Health and Risk Management</i> , 2015, 11, 583.	1.0	12
5476	Target Values of Cardiovascular Risk Factors Are Not Associated with All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2015, 10, e0124536.	1.1	3
5477	State of the art paper Lipid-lowering therapy in older persons. <i>Archives of Medical Science</i> , 2015, 1, 43-56.	0.4	18
5478	Risk Factors of Coronary Artery Disease in Secondary Prevention—Results from the AtheroGene Study. <i>PLoS ONE</i> , 2015, 10, e0131434.	1.1	26
5479	The Effect of Statins on Blood Gene Expression in COPD. <i>PLoS ONE</i> , 2015, 10, e0140022.	1.1	16
5480	Addressing the Global Burden of Trauma in Major Surgery. <i>Frontiers in Surgery</i> , 2015, 2, 43.	0.6	74

#	ARTICLE	IF	CITATIONS
5481	Systemic Inflammatory Markers Are Closely Associated with Atherogenic Lipoprotein Subfractions in Patients Undergoing Coronary Angiography. <i>Mediators of Inflammation</i> , 2015, 2015, 1-9.	1.4	9
5482	Effect of Simvastatin on Arterial Stiffness in Patients with Statin Myalgia. <i>Advances in Preventive Medicine</i> , 2015, 2015, 1-6.	1.1	8
5483	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
5484	Treatment Options for Statin-Associated Muscle Symptoms. <i>Deutsches A&#x0308;rztblatt International</i> , 2015, 112, 748-55.	0.6	65
5485	HYPOLIPIDEMIC THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN 2004-2010 ACCORDING TO THE PROGNOZ IBS REGISTER. <i>Rational Pharmacotherapy in Cardiology</i> , 2015, 11, 153-158.	0.3	5
5486	Impact of predictors upon the reduction of lipid parameters in family medicine practice. <i>Sao Paulo Medical Journal</i> , 2015, 133, 428-434.	0.4	0
5487	Health Care Resource Utilization and Costs Associated with Nonfatal Major Adverse Cardiovascular Events. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 443-450.	0.5	13
5488	Edible bird’s nest attenuates procoagulation effects of high-fat diet in rats. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3951.	2.0	7
5489	Interaction Studies of ACE Inhibitors with Statins. , 2015, , .		1
5490	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 372, 2387-2397.	13.9	3,337
5491	Statin-associated muscle symptoms: impact on statin therapy"European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	1.0	1,024
5492	Cholesterol lowering: role in cancer prevention and treatment. <i>Biological Chemistry</i> , 2015, 396, 1-11.	1.2	147
5493	Limb Ischemia: Cardiovascular Diagnosis and Management from Head to Toe. <i>Current Cardiology Reports</i> , 2015, 17, 611.	1.3	19
5494	Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 43.	2.0	27
5495	Medical Treatment of Stable Angina. <i>Cardiovascular Medicine</i> , 2015, , 421-459.	0.0	0
5496	Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. <i>BMJ, The</i> , 2015, 350, h2335-h2335.	3.0	35
5497	Cognitive and Physical Function by Statin Exposure in Elderly Individuals Following Acute Myocardial Infarction. <i>Clinical Cardiology</i> , 2015, 38, 455-461.	0.7	6
5498	CYP–mediated drug"drug interactions with evacetrapib, an investigational CETP inhibitor: <i>in vitro</i> prediction and clinical outcome. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1388-1398.	1.1	9

#	ARTICLE	IF	CITATIONS
5499	Chronic lower limb peripheral arterial disease. <i>InnovAiT</i> , 2015, 8, 477-484.	0.0	0
5500	Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England. <i>BMJ Open</i> , 2015, 5, e007207-e007207.	0.8	12
5501	RhoGTPase and Atherosclerosis: Pleiotropic Effects of Statins. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	50
5502	Lipids and Cerebrovascular Disease. <i>Stroke</i> , 2015, 46, 3322-3328.	1.0	116
5503	Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. <i>Current Therapeutic Research</i> , 2015, 77, 52-57.	0.5	18
5504	Evaluation of Lipid Metabolism and Nutritional Status in Male Goalball Players. <i>Journal of Human Kinetics</i> , 2015, 48, 141-147.	0.7	5
5505	The past, present and future of lipid-lowering therapy. <i>Clinical Lipidology</i> , 2015, 10, 481-498.	0.4	6
5506	Considering gender in prescribing statins: what do physicians need to know?. <i>Clinical Lipidology</i> , 2015, 10, 499-512.	0.4	11
5507	Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 426-433.	1.1	25
5508	Cerivastatin represses atherogenic gene expression through the induction of KLF2 via isoprenoid metabolic pathways. <i>Cellular and Molecular Biology Letters</i> , 2015, 20, 825-39.	2.7	7
5509	Quality and efficiency of statin prescribing across countries with a special focus on South Africa; findings and future implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 323-330.	0.7	11
5510	A randomized trial of coenzyme Q10 in patients with confirmed Statin Myopathy. <i>Atherosclerosis</i> , 2015, 238, 329-335.	0.4	162
5511	Pravastatin-induced rhabdomyolysis and purpura fulminans in a patient with chronic renal failure. <i>International Journal of Surgery Case Reports</i> , 2015, 8, 84-87.	0.2	7
5512	New cholesterol guidelines and primary prevention in women. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 84-94.	2.3	17
5513	Statins and Cognitive Function: an Updated Review. <i>Current Cardiology Reports</i> , 2015, 17, 4.	1.3	16
5514	Management of peripheral arterial disease in primary care. <i>The Prescriber</i> , 2015, 26, 27-30.	0.1	1
5515	How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 201-210.	1.3	56
5516	Vascular Endothelial Function. , 2015, , 89-120.		5

#	ARTICLE	IF	CITATIONS
5517	Vascular Complications of Diabetes Mellitus. , 2015, , 1541-1593.		0
5518	Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry. Revista Portuguesa De Cardiologia, 2015, 34, 111-116.	0.2	12
5519	Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2015, 9, 65-71.	0.6	24
5521	Translation of acute coronary syndrome therapies: From evidence to routine clinical practice. American Heart Journal, 2015, 169, 266-273.	1.2	14
5522	Low-density lipoprotein cholesterol was inversely associated with 3-year all-cause mortality among Chinese oldest old: Data from the Chinese Longitudinal Healthy Longevity Survey. Atherosclerosis, 2015, 239, 137-142.	0.4	52
5523	Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. Journal of Vascular Surgery, 2015, 61, 2S-41S.e1.	0.6	624
5524	Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines. Drugs and Aging, 2015, 32, 87-93.	1.3	5
5525	Efficacy of statins on sirtuin 1 and endothelial nitric oxide synthase expression: the role of sirtuin 1 gene variants in human coronary atherosclerosis. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 321-330.	0.9	24
5526	Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. Canadian Pharmacists Journal, 2015, 148, 21-28.	0.4	6
5527	Mortality of patients with type 2 diabetes in Taiwan: A 10-year nationwide follow-up study. Diabetes Research and Clinical Practice, 2015, 107, 178-186.	1.1	18
5528	Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of General Internal Medicine, 2015, 30, 348-358.	1.3	176
5529	Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective. Journal of the Saudi Heart Association, 2015, 27, 179-191.	0.2	23
5530	Diagnostic performance of CE-MRA in grading stenosis and therapy planning with TASC II classification. Vascular, 2015, 23, 403-410.	0.4	2
5531	The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 388.e11-388.e18.	0.8	16
5532	Statins and Primary Prevention of Cardiovascular Disease in Women. American Journal of Lifestyle Medicine, 2015, 9, 114-129.	0.8	2
5533	Present status of statin therapy. Trends in Cardiovascular Medicine, 2015, 25, 216-225.	2.3	17
5535	Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men. AIDS Research and Human Retroviruses, 2015, 31, 593-602.	0.5	18
5536	On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate. European Journal of Clinical Pharmacology, 2015, 71, 449-459.	0.8	1

#	ARTICLE	IF	CITATIONS
5537	Statins and brain integrity in older adults: Secondary analysis of the Health ABC study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1202-1211.	0.4	14
5538	Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. <i>Pharmaceutical Research</i> , 2015, 32, 1864-1883.	1.7	52
5539	Lipid Management. , 2015, , .		1
5540	Different Effects of Atorvastatin on Metabolic and Cardiovascular Risk Factors in Hypercholesterolemic Women with Normal Thyroid Function and Subclinical Hypothyroidism. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2015, 123, 182-186.	0.6	14
5541	Medical management of risk factors for vascular disease. <i>Surgery</i> , 2015, 33, 302-307.	0.1	0
5542	Statins: Risk-Benefits and Role in Treating Dyslipidemias. <i>Contemporary Endocrinology</i> , 2015, , 403-421.	0.3	0
5543	Statins and Reduction of Oxidative Stress in the Aged Brain. , 2015, , 753-760.		3
5544	Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. <i>European Heart Journal</i> , 2015, 36, ehv340.	1.0	71
5545	Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS). <i>Atherosclerosis</i> , 2015, 242, 155-160.	0.4	4
5546	Visualization of Coronary Artery Calcification: Influence on Risk Modification. <i>American Journal of Medicine</i> , 2015, 128, 1023.e23-1023.e31.	0.6	15
5547	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1455-1461.	0.8	37
5548	Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2015, 66, 184-192.	1.2	91
5549	Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: a population-based cohort study. <i>Age and Ageing</i> , 2015, 44, 566-573.	0.7	17
5550	Birth cohort appeared to confound effect estimates of guideline changes on statin utilization. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 334-340.	2.4	4
5551	Treatment of Vascular Cognitive Impairment. <i>Current Treatment Options in Neurology</i> , 2015, 17, 367.	0.7	21
5552	Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry. <i>American Heart Journal</i> , 2015, 170, 55-61.	1.2	16
5553	High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. <i>BMJ Open</i> , 2015, 5, e006886-e006886.	0.8	36
5555	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statins and Newer Drugs. <i>Drugs</i> , 2015, 75, 1201-1228.	4.9	18

#	ARTICLE	IF	CITATIONS
5557	The Role of Statins in the Setting of HIV Infection. <i>Current HIV/AIDS Reports</i> , 2015, 12, 305-312.	1.1	29
5559	Association of C7673T polymorphism in apolipoprotein B gene with ischemic stroke in the Chinese population: a meta-analysis. <i>International Journal of Neuroscience</i> , 2016, 126, 1-9.	0.8	4
5560	Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with) trial. <i>European Heart Journal Supplements</i> , 2015, 17, B47-B56.	0.0	10
5561	Statins in Intracerebral Hemorrhage. <i>Current Atherosclerosis Reports</i> , 2015, 17, 46.	2.0	30
5562	Risk factors of the first stroke. <i>Medicinski Pregled</i> , 2015, 68, 17-21.	0.1	2
5563	Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography. <i>Atherosclerosis</i> , 2015, 241, 579-587.	0.4	54
5564	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. <i>European Journal of Heart Failure</i> , 2015, 17, 434-441.	2.9	39
5565	Prognostic and Therapeutic Implications of Statin and Aspirin Therapy in Individuals With Nonobstructive Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 981-989.	1.1	147
5566	Screening for Carotid Artery Stenosis. <i>Seminars in Roentgenology</i> , 2015, 50, 127-138.	0.2	4
5567	Genetic and immunologic susceptibility to statin-related myopathy. <i>Atherosclerosis</i> , 2015, 240, 260-271.	0.4	33
5570	Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry. <i>Revista Portuguesa De Cardiologia (English)</i>	0.0	5
5571	Dyslipidemia in Dialysis Patients. <i>Seminars in Dialysis</i> , 2015, 28, 345-353.	0.7	20
5572	Surgeon Case Volume and 30-Day Mortality After Carotid Endarterectomy Among Contemporary Medicare Beneficiaries. <i>Stroke</i> , 2015, 46, 1288-1294.	1.0	42
5573	Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2015, 34, 1065-1071.	1.0	28
5574	An Increasing Population with Metabolic Syndrome and/or Diabetes Mellitus in the Middle East—Is There an Added Value of Coronary Calcium Scoring to Myocardial Perfusion Imaging?. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.4	0
5575	Statin intolerance — an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	1.0	117
5576	Dementias. , 2015, , .		0
5577	Targeting metabolic disturbance in the diabetic heart. <i>Cardiovascular Diabetology</i> , 2015, 14, 17.	2.7	44

#	ARTICLE	IF	CITATIONS
5578	Rosuvastatin attenuates contrast-induced nephropathy through modulation of nitric oxide, inflammatory responses, oxidative stress and apoptosis in diabetic male rats. <i>Journal of Translational Medicine</i> , 2015, 13, 53.	1.8	49
5579	Spinal NF- κ B and Chemokine Ligand 5 Expression during Spinal Glial Cell Activation in a Neuropathic Pain Model. <i>PLoS ONE</i> , 2015, 10, e0115120.	1.1	35
5580	Management of Post-Stroke Complications. , 2015, , .		4
5581	Statin Therapy and Risk of Fracture. <i>JAMA Internal Medicine</i> , 2015, 175, 171.	2.6	53
5582	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. <i>Lancet</i> , The, 2015, 385, 2264-2271.	6.3	564
5583	A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. <i>Cell</i> , 2015, 161, 161-172.	13.5	827
5584	Effect of Statins on Early and Late Clinical Outcomes of Carotid Endarterectomy and the Rate of Post-Carotid Endarterectomy Restenosis. <i>Journal of the American College of Surgeons</i> , 2015, 220, 481-487.	0.2	25
5585	Statins, cognition, and dementiaâ€”systematic review and methodological commentary. <i>Nature Reviews Neurology</i> , 2015, 11, 220-229.	4.9	108
5586	Risk of cardiovascular disease: The effects of diabetes and anti-diabetic drugs â€” A nested caseâ€”control study. <i>International Journal of Cardiology</i> , 2015, 178, 292-296.	0.8	26
5587	Statins use and the risk of all and subtype hematological malignancies: a metaâ€”analysis of observational studies. <i>Cancer Medicine</i> , 2015, 4, 770-780.	1.3	28
5588	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	1.0	126
5589	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. <i>Journal of Clinical Lipidology</i> , 2015, 9, 129-169.	0.6	632
5590	Medical Management of Serum Lipids and Coronary Heart Disease. <i>Cardiovascular Medicine</i> , 2015, , 39-55.	0.0	0
5591	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. <i>Cardiology Clinics</i> , 2015, 33, 299-308.	0.9	3
5592	Effect of vitamin C and vitamin E supplementation on endothelial function: a systematic review and meta-analysis of randomised controlled trials. <i>British Journal of Nutrition</i> , 2015, 113, 1182-1194.	1.2	76
5593	Statins and Diabetes. <i>Cardiology Clinics</i> , 2015, 33, 233-243.	0.9	14
5594	Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Nonâ€”ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). <i>American Journal of Cardiology</i> , 2015, 115, 1655-1660.	0.7	7
5595	Newer targets and therapies for hypertension and dyslipidemia in diabetic patients. <i>Cardiovascular Endocrinology</i> , 2015, 4, 11-16.	0.8	0

#	ARTICLE	IF	CITATIONS
5596	Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol. <i>American Journal of Therapeutics</i> , 2015, 22, 147-158.	0.5	12
5597	Statin Use After Acute Myocardial Infarction by Patient Complexity. <i>Medical Care</i> , 2015, 53, 324-331.	1.1	11
5598	A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes. <i>Pediatric Diabetes</i> , 2015, 16, 79-89.	1.2	34
5599	Classification of reported statin intolerance. <i>Current Opinion in Lipidology</i> , 2015, 26, 65-66.	1.2	3
5600	Statin Intolerance. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1011.	3.8	55
5601	Mechanisms of action for arsenic in cardiovascular toxicity and implications for risk assessment. <i>Toxicology</i> , 2015, 331, 78-99.	2.0	37
5602	The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 134-142.	0.7	6
5603	Statins and Aspirin: Do They Really Work in Women?. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 151-162.	1.0	1
5604	Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: a 50% reduction from baseline versus <70mg/dL. <i>International Journal of Cardiology</i> , 2015, 187, 478-485.	0.8	12
5606	Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. <i>Vascular Medicine</i> , 2015, 20, 237-244.	0.8	56
5607	Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. <i>Current Cardiology Reports</i> , 2015, 17, 104.	1.3	24
5608	The IMPROVE-IT study and ezetimibe. <i>British Journal of Community Nursing</i> , 2015, 20, 243-244.	0.2	2
5609	Design and conduct of a large obstetric or neonatal randomized controlled trial. <i>Seminars in Fetal and Neonatal Medicine</i> , 2015, 20, 389-402.	1.1	17
5610	Quality of Disease Management and Risk of Mortality in English Primary Care Practices. <i>Health Services Research</i> , 2015, 50, 1452-1471.	1.0	9
5611	Male Sex Associated with Increased Long-term Cardiovascular Mortality after Peripheral Vascular Surgery for Atherosclerosis Despite Optimal Medical Treatment. <i>European Journal of Vascular and Endovascular Surgery</i> , 2015, 50, 767-773.	0.8	12
5612	Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. <i>Current Atherosclerosis Reports</i> , 2015, 17, 72.	2.0	11
5613	C-peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register. <i>Diabetic Medicine</i> , 2015, 32, 85-89.	1.2	18
5614	Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. <i>Internal Medicine Journal</i> , 2015, 45, 546-557.	0.5	21

#	ARTICLE	IF	CITATIONS
5615	Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome. <i>Contemporary Endocrinology</i> , 2015, , 137-154.	0.3	0
5616	Statins and hip fracture risk in men: a population-based case-control study. <i>Annals of Epidemiology</i> , 2015, 25, 844-848.	0.9	7
5617	The role of cardiorespiratory fitness on plasma lipid levels. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1177-1183.	0.6	29
5618	Diagnostic tools and strategies for assessing disease progression in Alkaptonuria. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 705-717.	0.5	1
5619	Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation. <i>International Journal of Angiology</i> , 2015, 24, 105-112.	0.2	3
5620	Is immunity a mechanism contributing to statin-induced diabetes?. <i>Adipocyte</i> , 2015, 4, 232-238.	1.3	34
5621	The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 355-368.	1.3	37
5622	Hard-Wired Bias. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1171-1175.	1.4	35
5623	Perspectives on Cholesterol Guidelines. <i>Contemporary Endocrinology</i> , 2015, , 313-327.	0.3	0
5624	Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1505-1515.	1.5	11
5625	Statin Alternatives: A Review of Over-the-Counter Lipid-Lowering Supplements. <i>Alternative and Complementary Therapies</i> , 2015, 21, 198-209.	0.1	1
5626	Statins and Cataracts: Reverse Causality?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 691.e11.	0.8	8
5627	Safety and efficacy of ezetimibe: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 201, 247-252.	0.8	70
5628	Cardiovascular and Renal Outcomes Trials—Is There a Difference?. <i>American Journal of Cardiology</i> , 2015, 116, 982-988.	0.7	3
5629	Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2015, 243, 60-64.	0.4	36
5630	A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES). <i>Journal of Indian College of Cardiology</i> , 2015, 5, 282-290.	0.1	3
5631	Statins and the risk of dementia in patients with atrial fibrillation: A nationwide population-based cohort study. <i>International Journal of Cardiology</i> , 2015, 196, 91-97.	0.8	31
5632	Do statins prevent Alzheimer's disease? A narrative review. <i>European Journal of Internal Medicine</i> , 2015, 26, 666-669.	1.0	30

#	ARTICLE	IF	CITATIONS
5633	Older people with diabetes “avoiding hospitalization. Diabetes Management, 2015, 5, 311-326.	0.5	2
5634	Antilipidemic Drug Therapy Today and in the Future. Handbook of Experimental Pharmacology, 2015, 233, 373-435.	0.9	5
5635	Intermittent Claudication due to Peripheral Artery Disease: Best Modern Medical and Endovascular Therapeutic Approaches. Current Cardiology Reports, 2015, 17, 86.	1.3	6
5636	Poststroke cognitive decline: an update and perspectives for clinical research. European Journal of Neurology, 2015, 22, 229.	1.7	184
5637	Statins in the Elderly: A Patient-Focused Approach. Clinical Cardiology, 2015, 38, 56-61.	0.7	38
5639	Aging and dyslipidemia: A review of potential mechanisms. Ageing Research Reviews, 2015, 19, 43-52.	5.0	183
5640	Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. American Journal of Cardiology, 2015, 115, 21-26.	0.7	134
5641	Pharmacists Role in Cholesterol Management. Journal of Pharmacy Practice, 2015, 28, 35-43.	0.5	1
5642	Impact of Pharmacologic Interventions on Peripheral Artery Disease. Progress in Cardiovascular Diseases, 2015, 57, 510-520.	1.6	7
5643	Contemporary Medical Management of Peripheral Arterial Disease. Cardiology Clinics, 2015, 33, 111-137.	0.9	15
5644	Predictors of Natriuretic Peptide Non-Response in Patients Hospitalized With Acute Heart Failure. American Journal of Cardiology, 2015, 115, 69-74.	0.7	11
5645	Man shall not live by bread alone. Nutrition, 2015, 31, 244-247.	1.1	1
5646	Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10?. Current Atherosclerosis Reports, 2015, 17, 472.	2.0	32
5647	Assessment of peripheral skeletal muscle microperfusion in a porcine model of peripheral arterial stenosis by steady-state contrast-enhanced ultrasound and Doppler flow measurement. Journal of Vascular Surgery, 2015, 61, 1312-1320.	0.6	11
5648	Essentials of Vascular Surgery for the General Surgeon. , 2015, , .		2
5649	Antithrombotic Therapy in Carotid Artery Stenosis: An Update. European Neurology, 2015, 73, 51-56.	0.6	22
5650	What the Guidelines Do Not Say: Statin Non-benefit Groups. Current Atherosclerosis Reports, 2015, 17, 468.	2.0	6
5651	Impact on Cognitive Function“Are All Statins the Same?. Current Atherosclerosis Reports, 2015, 17, 466.	2.0	7

#	ARTICLE	IF	CITATIONS
5652	Prognostic relevance of ischemia-modified albumin and NT-proBNP in patients with peripheral arterial occlusive disease. <i>Clinica Chimica Acta</i> , 2015, 438, 255-260.	0.5	12
5653	Muscle- and skeletal-related side-effects of statins: tip of the iceberg?. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 88-110.	0.8	58
5655	Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. , 0, , .		1
5656	Ubiquinone, Ezetimibe/Simvastatin and Rosuvastatin Effects on Mitochondrial Function in Diabetic Polyneuropathy. , 0, , .		0
5657	Drug treatment of dyslipidemia. <i>Journal of the Korean Medical Association</i> , 2016, 59, 366.	0.1	6
5658	Use of fibrates in the metabolic syndrome: A review. <i>World Journal of Diabetes</i> , 2016, 7, 74.	1.3	47
5659	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
5660	Artériopathie des membres inférieurs asymptomatique. , 2016, , 251-253.		0
5661	Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions. <i>World Journal of Cardiology</i> , 2016, 8, 247.	0.5	79
5662	EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY. <i>Rational Pharmacotherapy in Cardiology</i> , 2016, 12, 351-358.	0.3	0
5663	Obesity Is Associated With Progression of Atherosclerosis During Statin Treatment. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	22
5664	Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol. <i>Korean Circulation Journal</i> , 2016, 46, 324.	0.7	10
5665	Cardio Metabolic Syndrome: A Global Epidemic. <i>Journal of Diabetes & Metabolism</i> , 2016, 6, .	0.2	23
5666	Overview of guidelines for the management of dyslipidemia: EU perspectives. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 357-369.	1.0	16
5667	Present Insights on Cardiomyopathy in Diabetic Patients. <i>Current Diabetes Reviews</i> , 2016, 12, 384-395.	0.6	28
5668	Improved Outcome after Primary Vitrectomy in Diabetic Patients Treated with Statins. <i>European Journal of Ophthalmology</i> , 2016, 26, 174-181.	0.7	16
5669	Endpoint Assessment for Cell Therapy in Patients with Intermittent Claudication and Critical Limb Ischemia. , 2016, , 117-136.		0
5670	Health Outcomes of Population-Based Pharmacy Outreach to Increase Statin Use for Prevention of Cardiovascular Disease in Patients with Diabetes. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 909-917.	0.5	7

#	ARTICLE	IF	CITATIONS
5671	Drug Treatment of Stable Coronary Artery Disease. , 2016, , 167-177.		1
5672	Stabilization of high-risk plaques. Cardiovascular Diagnosis and Therapy, 2016, 6, 304-321.	0.7	19
5673	Stroke prevention. , 0, , 567-593.		0
5674	Disorders of Lipid Metabolism. , 2016, , 1660-1700.		7
5675	Early Effects of Intensive Lipid-Lowering Treatment on Plaque Characteristics Assessed by Virtual Histology Intravascular Ultrasound. Yonsei Medical Journal, 2016, 57, 1087.	0.9	8
5676	Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1533-1543.	0.9	23
5677	2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation). Korean Circulation Journal, 2016, 46, 275.	0.7	106
5678	Icaritin Inhibits Collagen Degradation-Related Factors and Facilitates Collagen Accumulation in Atherosclerotic Lesions: A Potential Action for Plaque Stabilization. International Journal of Molecular Sciences, 2016, 17, 169.	1.8	11
5679	Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial. Trials, 2016, 17, 370.	0.7	18
5680	Efficacy of Statin Therapy in Inducing Coronary Plaque Regression in Patients with Low Baseline Cholesterol Levels. Journal of Atherosclerosis and Thrombosis, 2016, 23, 1055-1066.	0.9	15
5681	The nasal delivery of nanoencapsulated statins – an approach for brain delivery. International Journal of Nanomedicine, 2016, Volume 11, 6575-6590.	3.3	65
5682	Management of intracerebral hemorrhage – use of statins. Vascular Health and Risk Management, 2016, 12, 153.	1.0	16
5683	Adding carotid total plaque area to the Framingham risk score improves cardiovascular risk classification. Archives of Medical Science, 2016, 3, 513-520.	0.4	23
5684	Simultaneous RP-HPLC Method Development and Validation of Atorvastatin, Ezetimibe and Fenofibrate. Pharmaceutical Regulatory Affairs: Open Access, 2016, 05, .	0.2	2
5685	Recent advances in pathogenesis, assessment, and treatment of atherosclerosis. F1000Research, 2016, 5, 1880.	0.8	23
5686	Hypertriglyceridemia and Cardiovascular Outcomes. American Journal of Therapeutics, 2016, 23, e862-e870.	0.5	6
5687	Flow-Mediated Dilation and Neurocognition. Psychosomatic Medicine, 2016, 78, 192-207.	1.3	26
5688	Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiology and Drug Safety, 2016, 25, 1131-1149.	0.9	97

#	ARTICLE	IF	CITATIONS
5689	High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 22-28.	1.0	53
5690	Digoxin reduces atherosclerosis in apolipoprotein E-deficient mice. <i>British Journal of Pharmacology</i> , 2016, 173, 1517-1528.	2.7	44
5691	Prescribing patterns, adherence and LDL-cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study. <i>International Journal of Clinical Practice</i> , 2016, 70, 482-492.	0.8	8
5692	Downregulation of miR-146a, cyclooxygenase-2 and advanced glycation end-products in simvastatin-treated older patients with hyperlipidemia. <i>Geriatrics and Gerontology International</i> , 2016, 16, 322-328.	0.7	8
5693	Vascular Complications of Diabetes. <i>Circulation Research</i> , 2016, 118, 1771-1785.	2.0	262
5694	Glycaemic control and lipid concentrations in a cohort of people with diabetes over 7 years of follow-up: a regional audit of diabetes care in the UK. <i>Diabetic Medicine</i> , 2016, 33, 386-390.	1.2	1
5695	Impact of cardiovascular risk factors and disease on length of stay and mortality in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2016, 220, 745-749.	0.8	10
5696	Statins for the prevention of dementia. <i>The Cochrane Library</i> , 2016, 2016, CD003160.	1.5	212
5697	The association between statin use and risk of age-related macular degeneration. <i>Scientific Reports</i> , 2016, 5, 18280.	1.6	28
5698	Relation of statin use with non-melanoma skin cancer: Prospective results from the Women's Health Initiative. <i>Women's Health</i> , 2016, 12, 453-455.	0.7	6
5699	Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 924-929.	0.9	33
5700	Statins in prevention and treatment of ischemic stroke. <i>Human Physiology</i> , 2016, 42, 858-864.	0.1	0
5701	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016, 22, 84-113.	1.1	405
5703	Interventions to improve adherence to lipid-lowering medication. <i>The Cochrane Library</i> , 2021, 2021, CD004371.	1.5	131
5705	Providing additional information about the benefits of statins in a leaflet for patients with coronary heart disease: a qualitative study of the impact on attitudes and beliefs. <i>BMJ Open</i> , 2016, 6, e012000.	0.8	4
5706	Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 297-304.	1.3	23
5707	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	1.2	45
5708	Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. <i>Herz</i> , 2016, 41, 184-192.	0.4	48

#	ARTICLE	IF	CITATIONS
5709	Simvastatin Reduces Cancerogenic Potential of Renal Cancer Cells via Geranylgeranyl Pyrophosphate and Mevalonate Pathway. <i>Nutrition and Cancer</i> , 2016, 68, 420-427.	0.9	11
5710	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. <i>Data in Brief</i> , 2016, 7, 1541-1550.	0.5	1
5711	Cost-effectiveness of Screening for Abdominal Aortic Aneurysm in Combination with Medical Intervention in Patients with Small Aneurysms. <i>European Journal of Vascular and Endovascular Surgery</i> , 2016, 51, 766-773.	0.8	29
5712	Low-carbohydrate diets increase LDL-cholesterol, and thereby indicate increased risk of CVD. <i>British Journal of Nutrition</i> , 2016, 115, 2264-2266.	1.2	5
5713	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. <i>Journal of Clinical Lipidology</i> , 2016, 10, 472-489.	0.6	219
5714	The nocebo effect in the context of statin intolerance. <i>Journal of Clinical Lipidology</i> , 2016, 10, 739-747.	0.6	103
5715	An interview-based survey to assess the knowledge of peripheral arterial disease among medical students. <i>Journal of Taibah University Medical Sciences</i> , 2016, 11, 230-235.	0.5	1
5716	Preventive effects of simvastatin nanoliposome on isoproterenol-induced cardiac remodeling in mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1899-1907.	1.7	12
5717	Does statin use cause memory decline in the elderly?. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 550-565.	2.3	24
5718	The changing face of diabetes complications. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 537-547.	5.5	403
5719	Viejos y nuevos hipolipemiantes. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2016, 23, 172-184.	0.0	0
5720	Comment on the article by Moriarty et al. <i>Journal of Clinical Lipidology</i> , 2016, 10, 209-210.	0.6	2
5721	New Insight into the Dietary Cause of Atherosclerosis: Implications for Pharmacology. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 103-108.	1.3	24
5722	Sporadic Cerebral Amyloid Angiopathy: Pathophysiology, Neuroimaging Features, and Clinical Implications. <i>Seminars in Neurology</i> , 2016, 36, 233-243.	0.5	45
5723	Applying Atherosclerotic Risk Prevention Guidelines to Elderly Patients: A Bridge Too Far?. <i>Canadian Journal of Cardiology</i> , 2016, 32, 598-602.	0.8	2
5724	Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2016, 67, 965-977.	2.1	16
5725	Arterial Graft Failure. , 2016, , 235-265.		1
5726	Diabetes Dyslipidemia. <i>Diabetes Therapy</i> , 2016, 7, 203-219.	1.2	259

#	ARTICLE	IF	CITATIONS
5727	Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease. <i>Circulation</i> , 2016, 133, 1851-1860.	1.6	48
5728	Biochemistry of Statins. <i>Advances in Clinical Chemistry</i> , 2016, 73, 127-168.	1.8	38
5729	Heme changes HIF-1 α , eNOS and nitrite production in HUVECs after simvastatin, HU, and ascorbic acid therapies. <i>Microvascular Research</i> , 2016, 106, 128-136.	1.1	15
5730	Impact of Body Mass Index on the Prognosis of Japanese Patients With Non-Valvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2016, 118, 215-221.	0.7	40
5731	Primary Prevention of Cardiovascular Disease in Older Adults. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1074-1081.	0.8	15
5732	Recent Update to the US Cholesterol Treatment Guidelines. <i>Circulation</i> , 2016, 133, 1795-1806.	1.6	89
5733	Comparative Effectiveness of Generic Atorvastatin and Lipitor [®] in Patients Hospitalized with an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2016, 5, e003350.	1.6	29
5734	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.4	1,189
5736	Statin Medications and Development and Progression of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 146-152.	0.2	0
5737	Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies. <i>American Journal of Cardiology</i> , 2016, 118, 13A-18A.	0.7	3
5738	Comparison of serum lipid management between elderly and non-elderly patients with and without coronary heart disease (CHD). <i>Preventive Medicine Reports</i> , 2016, 4, 192-198.	0.8	3
5739	The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1452-1461.	0.6	13
5740	Different cardiometabolic effects of atorvastatin in men with normal vitamin D status and vitamin D insufficiency. <i>Clinical Cardiology</i> , 2016, 39, 715-720.	0.7	12
5741	High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 607-617.	0.7	7
5742	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. <i>International Journal of Cardiology</i> , 2016, 225, 184-196.	0.8	155
5743	Composite Scores and Other Outcome Measures in Stroke Trials. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 60-70.	3.0	10
5744	Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. <i>Journal of Clinical and Translational Endocrinology</i> , 2016, 6, 8-14.	1.0	34
5745	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1248-1258.	0.6	29

#	ARTICLE	IF	CITATIONS
5746	Pragmatic Trials. <i>New England Journal of Medicine</i> , 2016, 375, 454-463.	13.9	948
5747	Advances in Lipid Therapy: The Role of Lipid Treatment in Women in Primary Prevention. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 178-189.	1.6	6
5748	Statin Intolerance: A Literature Review and Management Strategies. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 153-164.	1.6	60
5749	Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). <i>Cardiovascular Therapeutics</i> , 2016, 34, 371-382.	1.1	45
5750	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 829-839.	5.5	234
5751	Statins for people with type 1 diabetes: when should treatment start?. <i>Practical Diabetes</i> , 2016, 33, 10-11.	0.1	4
5752	Lipid-lowering treatment patterns in patients with new cardiovascular events – estimates from population-based register data in Sweden. <i>International Journal of Clinical Practice</i> , 2016, 70, 222-228.	0.8	1
5753	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	1.0	2,393
5754	Statins probably do not cause cataracts. <i>Atherosclerosis</i> , 2016, 254, 310.	0.4	0
5755	Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team. <i>Clinical Infectious Diseases</i> , 2016, 63, S39-S45.	2.9	4
5756	Genetic support for the causal role of insulin in coronary heart disease. <i>Diabetologia</i> , 2016, 59, 2369-2377.	2.9	14
5757	Defining metabolic syndrome and factors associated with metabolic syndrome in a poly-pharmaceutical population. <i>Postgraduate Medicine</i> , 2016, 128, 797-804.	0.9	4
5758	Prescription of Guideline-Based Medical Therapies at Discharge After Carotid Artery Stenting and Endarterectomy. <i>Stroke</i> , 2016, 47, 2339-2346.	1.0	9
5759	Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. <i>International Journal of Cardiology</i> , 2016, 222, 548-556.	0.8	19
5760	Safety of atorvastatin in Asian patients within clinical trials. <i>Cardiovascular Therapeutics</i> , 2016, 34, 431-440.	1.1	15
5761	Hypolipidemic drugs in elderly subjects: Indications and limits. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 1064-1070.	1.1	6
5762	Association of peripheral arterial disease with all-cause and cardiovascular mortality in hemodialysis patients: a meta-analysis. <i>BMC Nephrology</i> , 2016, 17, 195.	0.8	15
5763	Statin use in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2016, 64, 1881-1888.	0.6	42

#	ARTICLE	IF	CITATIONS
5764	Statin Adherence After Ischemic Stroke or Transient Ischemic Attack Is Associated With Clinical Outcome. <i>Circulation Journal</i> , 2016, 80, 731-737.	0.7	31
5765	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	71
5766	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet, The</i> , 2016, 388, 2532-2561.	6.3	1,399
5767	Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34 + progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia. <i>Atherosclerosis</i> , 2016, 251, 240-247.	0.4	10
5768	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1263-1282.	0.8	775
5769	Predictive factors for better bypass patency and limb salvage after prosthetic above-knee bypass reconstruction. <i>Journal of Vascular Surgery</i> , 2016, 64, 380-388.e1.	0.6	23
5771	OLDER PEOPLE WITH CHRONIC KIDNEY DISEASE: DEFINITION, AND INFLUENCE OF BIOMARKERS AND MEDICATIONS UPON CARDIOVASCULAR AND RENAL OUTCOMES. <i>Journal of Renal Care</i> , 2016, 42, 150-161.	0.6	1
5772	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. <i>International Journal of Cardiology</i> , 2016, 225, 268-283.	0.8	17
5773	The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1898-1907.	1.2	75
5774	Fibrates for primary prevention of cardiovascular disease events. <i>The Cochrane Library</i> , 2017, 2017, CD009753.	1.5	78
5775	Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. <i>Atherosclerosis</i> , 2016, 254, 215-227.	0.4	23
5776	Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e468-e495.	1.6	203
5777	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 72.	2.0	14
5778	Time trends in statin utilisation and coronary mortality in Western European countries. <i>BMJ Open</i> , 2016, 6, e010500.	0.8	63
5779	More clarity needed on the true benefits and risks of statins. <i>The Prescriber</i> , 2016, 27, 15-17.	0.1	4
5780	Stroke survivors', caregivers' and GPs' attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study. <i>BMJ Open</i> , 2016, 6, e010458.	0.8	12
5782	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 216-228.	1.0	8
5783	Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 241-253.	1.0	12

#	ARTICLE	IF	CITATIONS
5784	Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke. <i>Medicine (United States)</i> , 2016, 95, e3186.	0.4	66
5785	Efficacy of High-Intensity Atorvastatin for Asian Patients Undergoing Percutaneous Coronary Intervention. <i>Annals of Pharmacotherapy</i> , 2016, 50, 725-733.	0.9	18
5786	Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2994-3001.	1.8	17
5787	Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2016, 64, e1-e21.	0.6	285
5788	Acute coronary syndromes in women and men. <i>Nature Reviews Cardiology</i> , 2016, 13, 471-480.	6.1	90
5789	Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1407-1420.	2.4	12
5790	Familial hypercholesterolemia in a large ambulatory population: Statin use, optimal treatment, and identification for advanced medical therapies. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1182-1187.	0.6	18
5794	Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. <i>Journal of Vascular Surgery</i> , 2016, 64, 1009-1017.e3.	0.6	88
5795	Inequalities in medication adherence to statin treatment after stroke: A nationwide observational study. <i>European Stroke Journal</i> , 2016, 1, 101-107.	2.7	17
5796	Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 24.	0.7	11
5797	Low total cholesterol level is the independent predictor of poor outcomes in patients with acute ischemic stroke: a hospital-based prospective study. <i>BMC Neurology</i> , 2016, 16, 36.	0.8	41
5798	Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. <i>BMC Medicine</i> , 2016, 14, 4.	2.3	68
5799	Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage. <i>Lipids in Health and Disease</i> , 2016, 15, 43.	1.2	17
5800	Cholesterol trials and mortality. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 168-177.	1.1	17
5801	Statins and prevention of venous thromboembolism: Myth or reality?. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 216-222.	0.7	11
5802	Cardiovascular risk profile and use of statins at the age of 70 years: a comparison of two Finnish birth cohorts born 20 years apart. <i>Age and Ageing</i> , 2016, 45, 84-90.	0.7	7
5803	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. <i>Hospital Practice (1995)</i> , 2016, 44, 9-20.	0.5	1
5804	Transient ischemic attack service provision. <i>Neurology</i> , 2016, 86, 947-953.	1.5	28

#	ARTICLE	IF	CITATIONS
5805	Does IMPROVE-IT prove it?. Preventive Medicine, 2016, 85, 32-35.	1.6	2
5806	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. Expert Opinion on Pharmacotherapy, 2016, 17, 275-281.	0.9	9
5807	No evidence to support high-intensity statin in Chinese patients with coronary heart disease. International Journal of Cardiology, 2016, 204, 57-58.	0.8	19
5808	Statin therapy across the lifespan: evidence in major age groups. Expert Review of Cardiovascular Therapy, 2016, 14, 341-366.	0.6	12
5809	Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. Circulation, 2016, 133, 256-264.	1.6	80
5810	Channeling identification: How perceived regulatory focus moderates the influence of organizational and professional identification on professional employees'™ diagnosis and treatment behaviors. Human Relations, 2016, 69, 753-780.	3.8	25
5811	Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study. Indian Heart Journal, 2016, 68, 646-654.	0.2	6
5812	Dyslipidemia Part 2. Vascular and Endovascular Surgery, 2016, 50, 119-135.	0.3	4
5813	Brain cortical cholesterol metabolism is highly affected by human APP overexpression in mice. Molecular and Cellular Neurosciences, 2016, 74, 34-41.	1.0	7
5814	Statin Use and the Risk for Incident Diabetes Mellitus in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Population-Based Retrospective Cohort Study in Taiwan. Canadian Journal of Diabetes, 2016, 40, 264-269.	0.4	10
5815	Greater decreases in cholesterol levels among individuals with high cardiovascular risk than among the general population: the northern Sweden MONICA study 1994 to 2014. European Heart Journal, 2016, 37, 1985-1992.	1.0	30
5817	Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal, 2016, 173, 94-101.	1.2	158
5818	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. Endocrinology and Metabolism Clinics of North America, 2016, 45, 171-184.	1.2	1
5819	Community walking speed, sedentary or lying down time, and mortality in peripheral artery disease. Vascular Medicine, 2016, 21, 120-129.	0.8	21
5820	Statins and Diabetes. Endocrinology and Metabolism Clinics of North America, 2016, 45, 87-100.	1.2	12
5821	The Success Story of LDL Cholesterol Lowering. Circulation Research, 2016, 118, 721-731.	2.0	48
5822	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. Journal of Clinical Lipidology, 2016, 10, 240-264.	0.6	3
5823	Association between statin treatment and LDL-cholesterol levels on the rate of ST-elevation myocardial infarction among patients with acute coronary syndromes: ACS Israeli Survey (ACSIS) 2002-2010. International Journal of Cardiology, 2016, 210, 133-138.	0.8	6

#	ARTICLE	IF	CITATIONS
5824	Research progress on berberine with a special focus on its oral bioavailability. <i>FÃ-toterapÃ-Ãç</i> , 2016, 109, 274-282.	1.1	259
5825	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 24.	2.0	12
5826	The pharmacokinetic characters of simvastatin after co-administration with Shexiang Baoxin Pill in healthy volunteersâ€™ plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1026, 162-167.	1.2	4
5827	ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. <i>Nutrition</i> , 2016, 32, 767-776.	1.1	15
5828	Lipid Control and Beyond: Current and Future Indications for Statin Therapy in Stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 27.	0.4	7
5829	Varicose Remodeling of Veins Is Suppressed by 3â€Hydroxyâ€Methylglutaryl Coenzyme A Reductase Inhibitors. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	22
5830	Treatment Goals in Diabetes. <i>Endocrine Development</i> , 2016, 31, 1-27.	1.3	25
5831	Relationship between pre-stroke cardiovascular medication use and stroke severity. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 495-502.	0.8	4
5832	Current Controversies With Recent Cholesterol Treatment Guidelines. <i>Journal of Pharmacy Practice</i> , 2016, 29, 15-25.	0.5	6
5833	The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 847-855.	0.8	0
5834	Relation of statin use with non-melanoma skin cancer: prospective results from the Womenâ€™s Health Initiative. <i>British Journal of Cancer</i> , 2016, 114, 314-320.	2.9	17
5836	Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	34
5837	Engineering Integrative Stem Cell and Biomaterial Therapies for Peripheral Artery Disease. <i>Biosystems and Biorobotics</i> , 2016, , 125-156.	0.2	0
5838	Low-Grade Carotid Stenosis. <i>Neuroimaging Clinics of North America</i> , 2016, 26, 129-145.	0.5	14
5839	Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. <i>Journal of Infectious Diseases</i> , 2016, 213, 1216-1223.	1.9	53
5840	The Brazilian Cardioprotective Nutritional Program to reduce events and risk factors in secondary prevention for cardiovascular disease: study protocol (The BALANCE Program Trial). <i>American Heart Journal</i> , 2016, 171, 73-81.e2.	1.2	30
5841	Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 205-215.	0.9	2
5842	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016, 32, 311-318.	0.8	24

#	ARTICLE	IF	CITATIONS
5843	A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels. <i>Obesity Surgery</i> , 2016, 26, 843-855.	1.1	56
5844	Statin tolerability: In defence of placebo-controlled trials. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 891-896.	0.8	32
5845	Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1315-1320.	0.5	53
5846	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 747-754.	1.0	62
5847	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2016, , 715-736.e7.		5
5848	Type 2 Diabetes. , 0, , .		4
5849	Poor knowledge of peripheral arterial disease among the Saudi population: A cross-sectional study. <i>Vascular</i> , 2017, 25, 86-91.	0.4	6
5850	Safety and Effectiveness of Statins for Prevention of Recurrent Myocardial Infarction in 12 156 Typical Older Patients: A Quasi-Experimental Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 243-250.	1.7	20
5851	Individualized lipid-lowering therapy to further reduce residual cardiovascular risk. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 169, 198-201.	1.2	8
5852	Treatment of Hypercholesterolemia in 2015. <i>American Journal of Therapeutics</i> , 2017, 24, e121-e129.	0.5	2
5853	Lipid and other management to improve arterial disease and survival in end stage renal disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 343-349.	0.9	3
5854	Documento de consenso del uso clnico de la Polypill en la prevencin secundaria del riesgo cardiovascular. <i>Medicina Clnica</i> , 2017, 148, 139.e1-139.e15.	0.3	6
5855	Pleiotropic Effects of Statins on the Cardiovascular System. <i>Circulation Research</i> , 2017, 120, 229-243.	2.0	808
5857	Poliovirus Receptor-Related 2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 534-542.	1.1	23
5858	Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 12.	0.7	16
5859	Functional foods and dietary supplements for the management of dyslipidaemia. <i>Nature Reviews Endocrinology</i> , 2017, 13, 278-288.	4.3	154
5860	Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. <i>Lancet Haematology</i> , 2017, 4, e83-e93.	2.2	91
5861	Comparison of Propensity Score Methods and Covariate Adjustment. <i>Journal of the American College of Cardiology</i> , 2017, 69, 345-357.	1.2	468

#	ARTICLE	IF	CITATIONS
5862	Drug Therapy for Stable Angina Pectoris. <i>Drugs</i> , 2017, 77, 265-284.	4.9	32
5864	Assessment of Renal Function and Risk Factors for Chronic Kidney Disease in Patients With Peripheral Arterial Disease. <i>Angiology</i> , 2017, 68, 776-781.	0.8	3
5865	Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2017, 119, 1146-1152.	0.7	28
5866	Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study. <i>International Journal of Cardiology</i> , 2017, 233, 43-51.	0.8	10
5867	Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 10.	3.0	145
5868	Ezetimibe: an update on its clinical usefulness in specific patient groups. <i>Therapeutic Advances in Chronic Disease</i> , 2017, 8, 4-11.	1.1	44
5869	Comment on "Statin use and all-cancer survival: prospective results from the Women's Health Initiative". <i>British Journal of Cancer</i> , 2017, 116, e9-e9.	2.9	2
5870	Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 139.e1-139.e15.	0.1	2
5871	Associations between Ischemic Stroke Follow-Up, Socioeconomic Status, and Adherence to Secondary Preventive Drugs in Southern Sweden: Observations from the Swedish Stroke Register (Riksstroke). <i>Neuroepidemiology</i> , 2017, 48, 32-38.	1.1	15
5872	2017 Taiwan lipid guidelines for high risk patients. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 217-248.	0.8	123
5873	Stroke Risk Factors, Genetics, and Prevention. <i>Circulation Research</i> , 2017, 120, 472-495.	2.0	920
5874	Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 422-431.e2.	0.6	18
5875	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017, 135, 1819-1831.	1.6	67
5876	Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. <i>The Cochrane Library</i> , 2017, 2017, CD009868.	1.5	49
5877	Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 846-854.	1.0	13
5878	Absolute benefits of empagliflozin in type 2 diabetes: a game changer?. <i>Postgraduate Medical Journal</i> , 2017, 93, 373-375.	0.9	3
5879	Underestimation of Low Density Lipoprotein-Cholesterol With the Friedewald Equation Versus a Direct Homogenous Low Density Lipoprotein-Cholesterol Assay. <i>Laboratory Medicine</i> , 2017, 48, 220-224.	0.8	20
5880	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017, 261, 12-18.	0.4	32

#	ARTICLE	IF	CITATIONS
5881	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. <i>Endocrine Practice</i> , 2017, 23, 1-87.	1.1	766
5882	Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial's Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. <i>Lancet</i> , The, 2017, 389, 2473-2481.	6.3	279
5883	Case of Asymptomatic Carotid Artery Stenosis in a Hypertensive Patient. <i>Hypertension</i> , 2017, 69, 985-991.	1.3	3
5884	Novel regulators of plasma lipid levels. <i>Current Opinion in Lipidology</i> , 2017, 28, 231-240.	1.2	10
5885	Efficient design of clinical trials and epidemiological research: is it possible?. <i>Nature Reviews Cardiology</i> , 2017, 14, 493-501.	6.1	34
5886	Plasma Sfrp5 and adiponectin levels in relation to blood pressure among obese children. <i>Journal of Human Hypertension</i> , 2017, 31, 284-291.	1.0	16
5887	Niacin for primary and secondary prevention of cardiovascular events. <i>The Cochrane Library</i> , 2017, 2017, CD009744.	1.5	43
5888	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1193-1203.	1.6	47
5891	Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. <i>International Journal of Cardiology</i> , 2017, 240, 332-338.	0.8	36
5892	Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 919-926.	1.0	4
5893	Favourable impact of statin use on diastolic blood pressure levels. <i>Journal of Hypertension</i> , 2017, 35, 2086-2094.	0.3	13
5894	Left ventricular ejection fraction as therapeutic target: is it the ideal marker?. <i>Heart Failure Reviews</i> , 2017, 22, 641-655.	1.7	19
5895	Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b. <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 46-57.	2.5	89
5896	Lack of Association between Preoperative Statin Use and Respiratory and Neurologic Complications after Cardiac Surgery. <i>Anesthesiology</i> , 2017, 126, 799-809.	1.3	7
5897	Medical Management of Asymptomatic Carotid Artery Stenosis. <i>Progress in Cardiovascular Diseases</i> , 2017, 59, 585-590.	1.6	23
5898	A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies. <i>Journal of Medical Economics</i> , 2017, 20, 767-775.	1.0	2
5899	The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. <i>Metabolic Brain Disease</i> , 2017, 32, 949-965.	1.4	54
5900	Preoperative Cholesterol Level Is Associated With Worse Pathological Outcomes and Postoperative Survival in Localized Renal Cell Carcinoma Patients: A Propensity Score-Matched Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e935-e941.	0.9	12

#	ARTICLE	IF	CITATIONS
5901	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	3.1	21
5902	Mendelian randomisation in cardiovascular research: an introduction for clinicians. <i>Heart</i> , 2017, 103, 1400-1407.	1.2	126
5903	Effects of Intensive Statin Therapy on Left Ventricular Function in Patients with Myocardial Infarction and Abnormal Glucose Tolerance. <i>Cardiology</i> , 2017, 138, 16-25.	0.6	1
5904	Has cost inhibited the uptake of more potent statins in England?. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 984-991.	0.9	6
5905	Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. <i>American Journal of Cardiology</i> , 2017, 120, 774-781.	0.7	40
5906	Meta-analysis of statins in chronic kidney disease: who benefits?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, 493-500.	0.2	39
5907	Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. <i>European Heart Journal</i> , 2017, 38, 1608-1612.	1.0	52
5908	Cumulative in-trial and post-trial effects of blood pressure and lipid lowering. <i>Journal of Hypertension</i> , 2017, 35, 905-913.	0.3	14
5909	Dislipidemia en las personas de edad muy avanzada. <i>EMC - Tratado De Medicina</i> , 2017, 21, 1-10.	0.0	0
5910	Pharmacodynamic and pharmacokinetic interactions between simvastatin and diazepam in rats. <i>Pharmacological Reports</i> , 2017, 69, 943-952.	1.5	7
5911	Statin Use and the Risk of Cataracts: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	38
5912	Safety and efficacy of statins – Authors' reply. <i>Lancet</i> , 2017, 389, 1099-1100.	6.3	1
5913	Chronic kidney disease and dyslipidaemia. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2017, 29, 22-35.	0.1	6
5916	Association of very Low-density Lipoprotein Cholesterol with All-cause and Cardiovascular Mortality in Peritoneal Dialysis. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 52-61.	0.9	14
5917	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	1.1	362
5918	Statin associated myopathy in clinical practice. Results of DAMA study. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2017, 29, 7-12.	0.1	2
5919	Effects of dyslipidaemia on monocyte production and function in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 387-400.	6.1	66
5920	Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REGistro POLiterapie SocietÀ Italiana di Medicina) Tj ETQq1 1 0.384314 ogBT /Ov		

#	ARTICLE	IF	CITATIONS
5921	Statin prescribing for people with severe mental illnesses: a staggered cohort study of "real-world" impacts. <i>BMJ Open</i> , 2017, 7, e013154.	0.8	12
5922	Hypolipidemic effect of Î²-caryophyllene to treat hyperlipidemic rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 215-223.	1.4	42
5923	Statins and mortality: the untold story. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 938-941.	1.1	4
5924	Statins ameliorate pulmonary hypertension secondary to left ventricular dysfunction through the Rhoâ€škinase pathway and NADPH oxidase. <i>Pediatric Pulmonology</i> , 2017, 52, 443-457.	1.0	15
5925	Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. <i>American Journal of Cardiology</i> , 2017, 119, 881-885.	0.7	29
5926	Management of Lipids in Patients with Diabetes. <i>Nursing Clinics of North America</i> , 2017, 52, 605-619.	0.7	9
5927	Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targeting and Statin Therapies. <i>Current Atherosclerosis Reports</i> , 2017, 19, 43.	2.0	7
5928	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. <i>Current Diabetes Reports</i> , 2017, 17, 112.	1.7	22
5929	Statin Prescribing in the Elderly: Special Considerations. <i>Current Atherosclerosis Reports</i> , 2017, 19, 47.	2.0	19
5930	Modelling cumulative exposure for inference about drug effects in observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1527-1533.	0.9	7
5931	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	2.6	238
5932	Trial designs for statin muscle intolerance. <i>Current Opinion in Lipidology</i> , 2017, 28, 488-494.	1.2	5
5933	Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: A randomized trial: The PreFord-Study. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1544-1554.	0.8	22
5934	The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 982-994.	0.9	162
5935	Characterization of simvastatin acid uptake by organic anion transporting polypeptide 3A1 (OATP3A1) and influence of drug-drug interaction. <i>Toxicology in Vitro</i> , 2017, 45, 158-165.	1.1	12
5936	Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2362-2368.	1.3	37
5937	Relation Between a Simple Lifestyle Risk Score and Established Biological Risk Factors for Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2017, 120, 1939-1946.	0.7	15
5938	PCSK9 inhibition and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 926-927.	5.5	1

#	ARTICLE	IF	CITATIONS
5939	Shared polymorphisms and modifiable behavior factors for myocardial infarction and high cholesterol in a retrospective population study. <i>Medicine (United States)</i> , 2017, 96, e7683.	0.4	3
5940	Exploring association between statin use and breast cancer risk: an updated meta-analysis. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 1043-1053.	0.8	58
5941	Statins and venous thromboembolism: do they represent a viable therapeutic agent?. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 629-637.	0.6	7
5942	Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. <i>Atherosclerosis</i> , 2017, 263, 278-286.	0.4	13
5944	Pathologic Duodenogastric Reflux and Inhibited Gastric Acid Secretion as Potential Factors Decreasing Omeprazole Stability. <i>Clinical Therapeutics</i> , 2017, 39, e66-e67.	1.1	0
5945	Apolipoprotein B is associated with carotid atherosclerosis progression independent of individual cholesterol measures in a 9-year prospective study of Multi-Ethnic Study of Atherosclerosis participants. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1181-1191.e1.	0.6	21
5946	Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1223-1233.	0.6	61
5947	Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq1 1 0.784314,rgBT /Oyerlock 10 American Journal of Cardiology, 2017, 120, 1220-1222.	0.7	10
5948	Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes. <i>Scientific Reports</i> , 2017, 7, 7001.	1.6	12
5949	Treating Dyslipidemia for the Primary and Secondary Prevention of Stroke. <i>Seminars in Neurology</i> , 2017, 37, 286-293.	0.5	1
5950	Statins use and the risk of liver dysfunction: A Chinese cohort study in real world clinical practice. <i>IJC Metabolic & Endocrine</i> , 2017, 16, 16-20.	0.5	8
5951	Evidence for Health Decision Making â€” Beyond Randomized, Controlled Trials. <i>New England Journal of Medicine</i> , 2017, 377, 465-475.	13.9	563
5953	Three Arguments for Absolute Outcome Measures. <i>Philosophy of Science</i> , 2017, 84, 840-852.	0.5	14
5954	LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China. <i>Medicine (United States)</i> , 2017, 96, e8555.	0.4	13
5955	Assessment and management of peripheral arterial disease. <i>Practice Nursing</i> , 2017, 28, 465-470.	0.1	0
5956	Statins and Cognition in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667.	1.5	13
5957	Pharmacological postconditioning with atorvastatin calcium attenuates myocardial ischemia/reperfusion injury in diabetic rats by phosphorylating GSK3Î². <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 25-34.	0.8	15
5958	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1101-1114.	0.9	12

#	ARTICLE	IF	CITATIONS
5959	Inception and deprescribing of statins in people aged over 80 years: cohort study. <i>Age and Ageing</i> , 2017, 46, 1001-1005.	0.7	35
5960	Introduction of the DiaGene study: clinical characteristics, pathophysiology and determinants of vascular complications of type 2 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 47.	1.2	18
5961	The Immunology of Cardiovascular Homeostasis and Pathology. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	14
5962	Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. <i>International Journal of Cardiology</i> , 2017, 248, 355-360.	0.8	7
5963	Hypercholesterolaemia and vascular dementia. <i>Clinical Science</i> , 2017, 131, 1561-1578.	1.8	94
5964	Atherosclerosis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1003, 121-144.	0.8	61
5965	Risk Reduction or Treat-To-Target Strategy? Economic Assessment of Statin use in Cardiovascular Prevention. <i>Clinical Therapeutics</i> , 2017, 39, e66.	1.1	0
5966	Peripheral Artery Disease. <i>Hospital Medicine Clinics</i> , 2017, 6, 397-412.	0.2	0
5967	Endocrine Considerations in Critical Limb Ischemia. , 2017, , 543-560.		1
5968	Comparative evaluation of a heparinâ€rate anticoagulation for LDLâ€apheresis in two primary apheresis systems. <i>Journal of Clinical Apheresis</i> , 2017, 32, 319-328.	0.7	5
5969	Statin myopathy: navigating the maze. <i>Current Medical Research and Opinion</i> , 2017, 33, 327-329.	0.9	4
5971	Progression of Peripheral Artery Disease to Critical Limb Ischemia. , 2017, , 121-129.		0
5972	Renal Tubular Toxicity Associated With Rosuvastatin Therapy. <i>American Journal of Kidney Diseases</i> , 2017, 69, 473-476.	2.1	8
5973	Intensive LDL-cholesterol lowering therapy and neurocognitive function. , 2017, 170, 181-191.		55
5974	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. <i>Circulation</i> , 2017, 135, 241-250.	1.6	111
5975	Adolescent Prevention of Complications. , 2017, , 39-53.		0
5976	Treat-to-target lipid control is effective but highlighted poor prognosis without indication of statin following percutaneous coronary intervention. <i>Cardiovascular Intervention and Therapeutics</i> , 2017, 32, 358-364.	1.2	4
5978	Cardiovascular Risk Factor Management Performance in Canada and the United States: A Systematic Review. <i>Canadian Journal of Cardiology</i> , 2017, 33, 393-404.	0.8	27

#	ARTICLE	IF	CITATIONS
5979	A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. <i>Pharmacoeconomics</i> , 2017, 35, 297-318.	1.7	15
5980	Evaluating biomarkers for prognostic enrichment of clinical trials. <i>Clinical Trials</i> , 2017, 14, 629-638.	0.7	28
5981	Aggressive and fatal statin-induced dermatomyositis: a case report. <i>Oxford Medical Case Reports</i> , 2017, 2017, omx063.	0.2	7
5982	KrÄ4ppel-like factors and vascular wall homeostasis. <i>Journal of Molecular Cell Biology</i> , 2017, 9, 352-363.	1.5	76
5983	Effect of early hospital readmission and comorbid conditions on subsequent long-term mortality after transient ischemic attack. <i>Brain and Behavior</i> , 2017, 7, e00865.	1.0	7
5984	Lipid lowering in renal disease. <i>Australian Prescriber</i> , 2017, 40, 141-146.	0.5	6
5985	Cardiovascular Disease and Diabetes: Two Sides of the Same Coin!. , 2017, , .		0
5986	Carotid endarterectomy: The procedure of choice for carotid stenosis. <i>Indian Journal of Neurosurgery</i> , 2017, 02, 009-017.	0.1	0
5988	Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. <i>International Angiology</i> , 2017, 36, 467-473.	0.4	22
5989	Statin Therapy Negatively Impacts Skeletal Muscle Regeneration and Cutaneous Wound Repair in Type 1 Diabetic Mice. <i>Frontiers in Physiology</i> , 2017, 8, 1088.	1.3	6
5990	Autophagy and Proteostasis: A Unifying Theory of Neurodegenerative Disease. <i>Journal of Restorative Medicine</i> , 2017, 6, 3-18.	0.7	0
5991	Statins, Muscle Disease and Mitochondria. <i>Journal of Clinical Medicine</i> , 2017, 6, 75.	1.0	61
5992	Vitamin E Nicotinate. <i>Antioxidants</i> , 2017, 6, 20.	2.2	17
5993	Cardiovascular Effects of Berberine: A Review of the Literature. <i>Journal of Restorative Medicine</i> , 2017, 6, 37-45.	0.7	14
5994	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.4	206
5995	7.28 Drug Eluting Stents ~†. , 2017, , 548-590.		0
5996	PCSK9 inhibitors: A new era of lipid lowering therapy. <i>World Journal of Cardiology</i> , 2017, 9, 76.	0.5	200
5997	Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 29-41.	1.0	20

#	ARTICLE	IF	CITATIONS
5998	Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot ‘Prevention of Decline in Cognition after Stroke Trial’™ (PODCAST) Randomised Controlled Trial. PLoS ONE, 2017, 12, e0164608.	1.1	60
5999	Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‘ Data from a multicenter registry cohort study in Taiwan. PLoS ONE, 2017, 12, e0186861.	1.1	20
6000	Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PLoS ONE, 2017, 12, e0182625.	1.1	19
6001	Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988–2014. BMC Public Health, 2017, 17, 893.	1.2	20
6002	Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya. BMC Endocrine Disorders, 2017, 17, 73.	0.9	14
6003	Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis. BMJ: British Medical Journal, 2017, 359, j5375.	2.4	239
6004	Cardiovascular Diseases on Latin-American People. Primary Health Care: Open Access, 2017, 07, .	0.0	0
6005	Knowledge, attitude and practice of community pharmacists in relation to cholesterol screening in Delta State, Nigeria. African Journal of Pharmacy and Pharmacology, 2017, 11, 451-457.	0.2	2
6006	Stroke in Older Survivors of Ischemic Stroke: Standard Care or Something Different?. Geriatrics (Switzerland), 2017, 2, 18.	0.6	8
6007	Screening for mild cognitive impairment in patients with cardiovascular risk factors. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2925-2934.	1.0	11
6008	Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice. Current Pharmaceutical Biotechnology, 2017, 18, 231-241.	0.9	8
6009	Marketed drugs used for the management of hypercholesterolemia as anticancer armament. OncoTargets and Therapy, 2017, Volume 10, 4393-4411.	1.0	9
6010	‘Open mesh’ or ‘strictly selected population’ recruitment? The experience of the randomized controlled MeMeMe trial. Patient Preference and Adherence, 2017, Volume 11, 1127-1132.	0.8	3
6011	Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Current Alzheimer Research, 2017, 14, 426-440.	0.7	68
6012	Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II. Korean Journal of Internal Medicine, 2017, 32, 656-667.	0.7	5
6013	Hypolipidaemic Effects of Gymnema Sylvestre on High Fat Diet Induced Dyslipidaemia in Wistar Rats. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, FF01-FF05.	0.8	6
6014	Survival and event-free survival of patients with peripheral arterial disease undergoing prevention of cardiovascular disease. International Angiology, 2017, 36, 216-227.	0.4	11
6015	Is there evidence for statins in the treatment of aortic valve stenosis?. World Journal of Cardiology, 2017, 9, 667.	0.5	11

#	ARTICLE	IF	CITATIONS
6016	Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. <i>BMJ Open</i> , 2017, 7, e016604.	0.8	14
6017	Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999â€”2014. <i>Diabetes Research and Clinical Practice</i> , 2018, 139, 1-10.	1.1	27
6018	Use of quantitative optical imaging to examine the role of cholesterol-rich lipid raft microdomains in the migration of breast cancer cells. <i>Laser Physics</i> , 2018, 28, 045601.	0.6	2
6019	Diabetes in Older People. <i>Canadian Journal of Diabetes</i> , 2018, 42, S283-S295.	0.4	75
6020	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1566.	3.8	339
6021	Effects of camel milk in dyslipidaemia: A randomised clinical trial. <i>International Dairy Journal</i> , 2018, 84, 79-84.	1.5	8
6022	<i>Preventive Cardiology</i> . , 2018, , 269-289.		0
6023	<i>Cardiovascular Risk Factors and Peripheral Arterial Disease</i> . , 2018, , 189-200.		0
6024	Dyslipidemia. <i>Canadian Journal of Diabetes</i> , 2018, 42, S178-S185.	0.4	50
6025	Cardiovascular Protection in People With Diabetes. <i>Canadian Journal of Diabetes</i> , 2018, 42, S162-S169.	0.4	44
6026	Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2018, 8, 5804.	1.6	118
6027	Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular diseaseâ€”Real-world experience within a large integrated health care system: The IMPRES study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1008-1018.e1.	0.6	8
6028	Genetic Testing in Clinical Settings. <i>American Journal of Kidney Diseases</i> , 2018, 72, 569-581.	2.1	33
6029	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. <i>Canadian Journal of Cardiology</i> , 2018, 34, 532-535.	0.8	1
6030	The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials. <i>Autoimmunity Reviews</i> , 2018, 17, 215-225.	2.5	88
6031	Update on the laboratory investigation of dyslipidemias. <i>Clinica Chimica Acta</i> , 2018, 479, 103-125.	0.5	38
6032	The pharmacodynamic and clinical trial evidence for statin dose. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1128-1135.	1.1	17
6033	Antithrombotic Therapy in PeripheralÂArteryÂDisease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 352-362.	1.2	18

#	ARTICLE	IF	CITATIONS
6034	Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update. <i>Current Atherosclerosis Reports</i> , 2018, 20, 9.	2.0	8
6035	Statin Safety: What Every Health Care Provider Needs to Know. <i>Current Cardiovascular Risk Reports</i> , 2018, 12, 1.	0.8	1
6036	Implementation of smart technology to improve medication adherence in patients with cardiovascular disease: is it effective?. <i>Expert Review of Medical Devices</i> , 2018, 15, 119-126.	1.4	30
6037	The effects of folate supplementation on lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018, 12, 423-430.	1.8	8
6038	Rho kinase signaling and cardiac physiology. <i>Current Opinion in Physiology</i> , 2018, 1, 14-20.	0.9	21
6039	Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 237-257.	1.2	28
6040	Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 390-396.e8.	0.6	51
6042	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. <i>Canadian Journal of Cardiology</i> , 2018, 34, 595-604.	0.8	56
6044	Appropriateness of statin prescription in the elderly. <i>European Journal of Internal Medicine</i> , 2018, 50, 33-40.	1.0	43
6045	Dyslipidaemia in the elderly: to treat or not to treat?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 259-278.	1.3	7
6046	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. <i>Drugs</i> , 2018, 78, 203-214.	4.9	5
6047	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	1.0	262
6048	Effects of statin therapy on chronic kidney disease patients with coronary artery disease. <i>Lipids in Health and Disease</i> , 2018, 17, 84.	1.2	3
6049	Statins use and cancer: an update. <i>Future Oncology</i> , 2018, 14, 1497-1509.	1.1	39
6050	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2018, 12, 857-862.	0.6	21
6051	Medical management of risk factors for vascular disease. <i>Surgery</i> , 2018, 36, 265-271.	0.1	1
6052	Lipid Parameters are Independently Associated with Cardiovascular Ankle Vascular Index (CAVI) in Healthy Japanese Subjects. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 621-633.	0.9	26
6053	Coronary Artery Disease in Patients ≥80 Years of Age. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2015-2040.	1.2	175

#	ARTICLE	IF	CITATIONS
6054	Microangiopathie cérébrale et démençe: de la physiopathologie aux perspectives thérapeutiques. Pratique Neurologique - FMC, 2018, 9, 140-144.	0.1	0
6055	Statin use and mortality in gout: A general population-based cohort study. Seminars in Arthritis and Rheumatism, 2018, 48, 449-455.	1.6	11
6056	Management of Left Main Coronary Artery Disease. Journal of the American Heart Association, 2018, 7, .	1.6	57
6057	Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes. Stroke, 2018, 49, 820-827.	1.0	132
6058	A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. European Journal of Preventive Cardiology, 2018, 25, 844-853.	0.8	43
6059	Risk Factors and Prevention in Alzheimer's Disease and Dementia. , 2018, , 93-112.		3
6060	Clinical benefits of evolocumab appear less than hoped. Lancet, The, 2018, 391, 933-934.	6.3	3
6061	Statin use in Brazil: findings and implications. Current Medical Research and Opinion, 2018, 34, 1809-1817.	0.9	21
6063	Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. European Heart Journal, 2018, 39, 1172-1180.	1.0	150
6064	Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. Journal of Clinical Lipidology, 2018, 12, 78-88.	0.6	22
6065	Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Digestive Diseases, 2018, 36, 1-14.	0.8	24
6067	AMPK and cardiac remodelling. Science China Life Sciences, 2018, 61, 14-23.	2.3	61
6068	Comparative effect of statins on the risk of incident Alzheimer disease. Neurology, 2018, 90, e179-e187.	1.5	32
6069	Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 51-69.	0.7	8
6070	The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. Breast Cancer Research and Treatment, 2018, 167, 741-749.	1.1	2
6071	Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence. Journal of Neuroscience Research, 2018, 96, 762-764.	1.3	1
6072	Evaluation of the Pleiotropic Effects of Statins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 262-265.	1.1	32
6073	Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 1823-1873.	1.7	17

#	ARTICLE	IF	CITATIONS
6074	THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 425-433.	0.3	0
6075	The sterol-responsive RNF145 E3 ubiquitin ligase mediates the degradation of HMG-CoA reductase together with gp78 and Hrd1. <i>ELife</i> , 2018, 7, .	2.8	85
6076	Risk Stratification of Coronary Heart Disease in Postmenopausal Women Using Framingham Scale in Eastern Nepal. <i>Medical Journal of Shree Birendra Hospital</i> , 2018, 17, 51-57.	0.0	0
6077	The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia. <i>Cardiovascular Journal of Africa</i> , 2018, 29, 162-166.	0.2	4
6078	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. <i>Open Cardiovascular Medicine Journal</i> , 2018, 12, 29-40.	0.6	19
6079	Simvastatin exerts anticancer effects in osteosarcoma cell lines via geranylgeranylation and c-Jun activation. <i>International Journal of Oncology</i> , 2018, 52, 1285-1294.	1.4	21
6080	FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMOLOGY STUDY). <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 244-251.	0.3	1
6081	Role of Cholesterol as a Risk Factor in Cardiovascular Diseases. , 2018, , .		5
6082	OBSOLETE: Management and Care of Older Cardiac Patients. , 2018, , .		0
6083	50 Herz- und GefÄÄŸkrankheiten. , 2018, , .		0
6084	Effects of Plasma Lipids and Statins on Cognitive Function. <i>Chinese Medical Journal</i> , 2018, 131, 471-476.	0.9	24
6085	Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002043.	1.6	25
6086	Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 636-645.	0.3	3
6087	Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13452.	0.8	1
6088	Perioperative aspirin and long-term survival in patients undergoing coronary artery bypass graft. <i>Scientific Reports</i> , 2018, 8, 17051.	1.6	2
6089	Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study. <i>Lipids in Health and Disease</i> , 2018, 17, 290.	1.2	16
6090	Advances in developing novel therapeutic strategies for Alzheimerâ€™s disease. <i>Molecular Neurodegeneration</i> , 2018, 13, 64.	4.4	189
6091	Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. <i>Nature Communications</i> , 2018, 9, 5138.	5.8	112

#	ARTICLE	IF	CITATIONS
6092	Outcomes of STEMI patients with chronic kidney disease treated with percutaneous coronary intervention: the Malaysian National Cardiovascular Disease Database â€“ Percutaneous Coronary Intervention (NCVD-PCI) registry data from 2007 to 2014. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 184.	0.7	12
6093	Comparative Effectiveness of Combination Therapy with Statins and Angiotensinâ€Converting Enzyme Inhibitors versus Angiotensin <sc>II</sc> Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Populationâ€Based Cohort Study in Korea. <i>Pharmacotherapy</i> , 2018, 38, 1095-1105.	1.2	6
6094	Connecting the brain cholesterol and reninâ€angiotensin systems: potential role of statins and <sc>RAS</sc>â€modifying medications in dementia. <i>Journal of Internal Medicine</i> , 2018, 284, 620-642.	2.7	30
6095	The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1856-1869.	1.2	68
6096	Statins for Primary Prevention in Older Adultsâ€Moving Toward Evidenceâ€Based Decisionâ€Making. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2188-2196.	1.3	50
6097	Long-term trends in incidence and risk factors for ischaemic stroke subtypes: Prospective population study of the South London Stroke Register. <i>PLoS Medicine</i> , 2018, 15, e1002669.	3.9	32
6098	Trust the Blinded Randomized Evidence That Statin Therapy Rarely Causes Symptomatic Side Effects. <i>Circulation</i> , 2018, 138, 1499-1501.	1.6	25
6099	Long-term Survival Benefit of Statin in Patients with Coronary Chronic Total Occlusion without Revascularization. <i>Journal of Korean Medical Science</i> , 2018, 33, e134.	1.1	1
6100	<i>SLCO1B1</i> and Statin Therapy. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002320.	1.6	5
6101	Surgery, neuroinflammation and cognitive impairment. <i>EBioMedicine</i> , 2018, 37, 547-556.	2.7	230
6102	Evidence-Based Management of Diabetes in Older Adults. <i>Drugs and Aging</i> , 2018, 35, 1065-1078.	1.3	19
6103	Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer. <i>Journal of Cancer Survivorship</i> , 2018, 12, 794-802.	1.5	7
6104	Understanding ethno-cultural differences in cardiac medication adherence behavior: a Canadian study. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1737-1747.	0.8	7
6105	Glycemic effects of simvastatin: Where do we stand?. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2018, 54, .	1.2	3
6106	Response bias to a randomised controlled trial of a lifestyle intervention in people at high risk of cardiovascular disease: a cross-sectional analysis. <i>BMC Public Health</i> , 2018, 18, 1092.	1.2	13
6107	Discontinuing or continuing statin following intracerebral hemorrhage from the view of a national cohort study. <i>Atherosclerosis</i> , 2018, 278, 15-22.	0.4	11
6108	LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 959-970.	1.3	88
6109	Clinical practice guidelines for older people with multimorbidity and life-limiting illness: what are the implications for deprescribing?. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 619-630.	1.0	18

#	ARTICLE	IF	CITATIONS
6110	Statins after intracranial haemorrhage: seizing a new opportunity?. British Journal of Clinical Pharmacology, 2018, 84, 2687-2688.	1.1	1
6111	Cardiovascular medication changes over 5 years in a national data linkage study: implications for risk prediction models. Clinical Epidemiology, 2018, Volume 10, 133-141.	1.5	5
6112	The Function of Geranylgeraniol. Oleoscience, 2018, 18, 99-106.	0.0	1
6113	Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan—A Retrospective Database Analysis. Circulation Journal, 2018, 82, 1605-1613.	0.7	10
6114	Ability of B-Type Natriuretic Peptide Testing to Predict Cardioembolic Stroke in the General Population—Comparisons With C-Reactive Protein and Urinary Albumin. Circulation Journal, 2018, 82, 1017-1025.	0.7	13
6115	Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. Critical Pathways in Cardiology, 2018, 17, 53-68.	0.2	2
6116	A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. European Journal of Clinical Pharmacology, 2018, 74, 1099-1109.	0.8	52
6117	The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. Current Cardiology Reports, 2018, 20, 50.	1.3	22
6118	Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization. Annals of Vascular Surgery, 2018, 52, 138-146.	0.4	4
6119	Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions. Cardiovascular Drugs and Therapy, 2018, 32, 273-280.	1.3	10
6120	Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. Journal of the American Heart Association, 2018, 7, .	1.6	11
6122	Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?. Indian Heart Journal, 2018, 70, 331-334.	0.2	0
6123	Anti-Inflammatory Treatment. , 2018, , 237-271.		0
6124	Statin therapy improved long-term prognosis in patients with major non-cardiac vascular surgeries: a systematic review and meta-analysis. Vascular Pharmacology, 2018, 109, 1-16.	1.0	6
6125	Potential Neuroprotective Strategies for Ischemic Injuries. , 2018, , 89-154.		0
6126	Modulation of heat shock proteins by statins. Pharmacological Research, 2018, 134, 134-144.	3.1	11
6127	Cerebral Ischemic Reperfusion Injuries (CIRI). Springer Series in Translational Stroke Research, 2018, , .	0.1	0
6128	Oxidative Stress and Nitric Oxide in Cerebral Ischemic Reperfusion Injury. Springer Series in Translational Stroke Research, 2018, , 101-119.	0.1	1

#	ARTICLE	IF	CITATIONS
6129	Imaging Cardiovascular Calcification. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	92
6130	Critical limb ischemia: current challenges and future prospects. <i>Vascular Health and Risk Management</i> , 2018, Volume 14, 63-74.	1.0	117
6131	High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 159-165.	1.5	22
6132	Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2241-2248.	2.0	12
6133	Risk Factors. , 2018, , 17-34.		0
6134	Vascular Cognitive Impairment: Investigation and Treatment. , 2018, , 475-485.		0
6135	Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12463.	1.1	9
6136	Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review. <i>American Heart Journal</i> , 2018, 204, 17-33.	1.2	7
6137	Awareness of Pleiotropic and Cardioprotective Effect of Statins in Patients with Coronary Artery Disease. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	6
6138	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	1.1	388
6139	Prognostic Value of Circulating Lipoprotein in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 285-292.	1.1	6
6140	Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia. <i>Current Cardiology Reports</i> , 2018, 20, 71.	1.3	0
6141	Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 655-666.	0.7	32
6142	High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD). <i>Circulation</i> , 2018, 137, 1997-2009.	1.6	174
6143	The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. <i>Translational Neurodegeneration</i> , 2018, 7, 5.	3.6	147
6144	Comparison of lipid profiles and inflammation in pre- and post-menopausal women with cerebral infarction and the role of atorvastatin in such populations. <i>Lipids in Health and Disease</i> , 2018, 17, 20.	1.2	6
6145	Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 12.	0.7	8
6146	Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial. <i>International Heart Journal</i> , 2018, 59, 315-320.	0.5	11

#	ARTICLE	IF	CITATIONS
6147	Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?. <i>Drugs</i> , 2018, 78, 799-808.	4.9	15
6148	Effect of statins on toll-like receptors: a new insight to pleiotropic effects. <i>Pharmacological Research</i> , 2018, 135, 230-238.	3.1	100
6149	Prescription of statins at discharge and 1-year risk of major clinical outcomes among acute coronary syndromes patients with extremely low LDL-cholesterol in clinical pathways for acute coronary syndromes studies. <i>Clinical Cardiology</i> , 2018, 41, 1192-1200.	0.7	6
6150	Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 749-763.	0.6	12
6151	8 Arterial Occlusive Disease. , 2018, , .		0
6152	Carotid Artery Disease in Patients with Cancer. , 2018, , 117-134.		0
6153	Progress and perspectives in plant sterol and plant stanol research. <i>Nutrition Reviews</i> , 2018, 76, 725-746.	2.6	54
6154	Polyphenols Effect on Circulating Lipids and Lipoproteins: From Biochemistry to Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2018, 24, 178-190.	0.9	23
6155	Statin Use and the Risk of Dementia in Patients with Stroke: A Nationwide Population-Based Cohort Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 3001-3007.	0.7	14
6156	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	1.4	39
6157	Calcification of the heart: mechanisms and therapeutic avenues. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 527-536.	0.6	28
6158	Towards more specific treatment for diabetic dyslipidemia. <i>Current Opinion in Lipidology</i> , 2018, 29, 307-312.	1.2	14
6159	Lowering <sc>LDL</sc>-cholesterol and <sc>CV</sc> Benefits: Is There a Limit to How Low <sc>LDL</sc>-Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 290-296.	2.3	6
6160	Examining prescriber perceptions of statin therapy and the potential implications these perceptions may have on guideline adherence. <i>International Clinical Psychopharmacology</i> , 2018, 33, 290-296.	0.9	1
6161	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use. <i>JAMA Cardiology</i> , 2018, 3, 739.	3.0	94
6162	Does Treating Vascular Risk Factors Prevent Dementia and Alzheimer's Disease? A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 657-668.	1.2	72
6163	Editorial Commentary: Blood pressure and cognition in the elderly. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 19-21.	2.3	0
6164	Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 83-89.	1.0	13

#	ARTICLE	IF	CITATIONS
6165	The all-cause mortality and risk factors for mortality within five years among prevalent Type 1 Diabetes Mellitus Patients. <i>International Journal of Diabetes in Developing Countries</i> , 2019, 39, 284-290.	0.3	0
6166	Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 75-83.	0.9	57
6167	The Relationship Between Statin Action On Thyroid Autoimmunity And Vitamin D Status: A Pilot Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 6, 23-28.	0.6	7
6168	Does statin increase the risk of intracerebral hemorrhage in stroke survivors? A meta-analysis and trial sequential analysis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641986483.	1.5	18
6169	Secondary Prevention. , 2019, , 410-425.		0
6170	Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e012428.	1.6	10
6171	Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?. <i>Current Medicinal Chemistry</i> , 2019, 26, 1512-1524.	1.2	17
6172	Insights into Computational Drug Repurposing for Neurodegenerative Disease. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 565-576.	4.0	70
6174	Peripheral Artery Disease: Past, Present, and Future. <i>American Journal of Medicine</i> , 2019, 132, 1133-1141.	0.6	123
6175	Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 263-272.	1.0	7
6176	Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs. <i>Pharmacological Research</i> , 2019, 147, 104326.	3.1	8
6177	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. <i>Current Atherosclerosis Reports</i> , 2019, 21, 41.	2.0	53
6178	Blood Pressure and Statin Effects on Cognition: a Review. <i>Current Hypertension Reports</i> , 2019, 21, 70.	1.5	7
6179	Implementation of a Brazilian Cardioprotective Nutritional (BALANCE) Program for improvement on quality of diet and secondary prevention of cardiovascular events: A randomized, multicenter trial. <i>American Heart Journal</i> , 2019, 215, 187-197.	1.2	25
6180	Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2019, 13, 538-549.	0.6	16
6181	Vascular Cognitive Impairment and Dementia. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3326-3344.	1.2	384
6182	Current trends in non-HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2019, 13, 563-567.	0.6	17
6183	Tendon rupture associated with concomitant simvastatin and gemfibrozil use: Biological and pharmacokinetic implications. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1919-1922.	0.2	1

#	ARTICLE	IF	CITATIONS
6184	Treatment with Statins in Elderly Patients. <i>Medicina (Lithuania)</i> , 2019, 55, 721.	0.8	47
6185	Ischemic Stroke Etiology and Secondary Prevention. , 2019, , 119-152.		0
6186	The effect of guideline revisions on vascular complications of type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881987540.	1.4	4
6187	Cataracts and statins. A disproportionality analysis using data from VigiBase. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 109, 104509.	1.3	4
6188	IL-1 β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1764.	1.0	21
6189	2018 Guidelines for the Management of Dyslipidemia in Korea. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 78.	1.1	100
6190	Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2019, 40, 79-87.	1.2	7
6192	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	6.3	512
6193	Cholesterol-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 354-363.	2.0	33
6194	A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography. <i>Journal of Cardiovascular Computed Tomography</i> , 2019, 13, 99-104.	0.7	2
6195	Risk Factors Associated with Failure to Achieve the Low Density Lipoprotein Cholesterol Therapeutic Target in Patients with Acute Coronary Syndrome: A Longitudinal, Single Centre Investigation. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 37-43.	1.0	2
6196	Statin Toxicity. <i>Circulation Research</i> , 2019, 124, 328-350.	2.0	439
6197	Global vascular guidelines on the management of chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2019, 69, 3S-125S.e40.	0.6	841
6198	Role of Diet in Chronic Obstructive Pulmonary Disease Prevention and Treatment. <i>Nutrients</i> , 2019, 11, 1357.	1.7	122
6199	Stable Angina Medical Therapy Management Guidelines: A Critical Review of Guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence. <i>European Cardiology Review</i> , 2019, 14, 18-22.	0.7	26
6200	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, S1-S109.e33.	0.8	741
6201	CNS small vessel disease. <i>Neurology</i> , 2019, 92, 1146-1156.	1.5	343
6203	Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk. <i>Atherosclerosis: X</i> , 2019, 1, 100001.	0.0	3

#	ARTICLE	IF	CITATIONS
6204	Bioactive Lipids and the Gut-Brain Axis: Diet as a Modulator of Bioactivity and Diversity of Lipids in the Brain. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1127, 147-168.	0.8	1
6205	Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies. <i>Journal of Diabetes</i> , 2019, 11, 619-622.	0.8	4
6206	Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. <i>BMJ Open</i> , 2019, 9, e022702.	0.8	4
6207	Statin therapy and herpes virus reactivation response to Zuin et al. paper. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1195-1197.	1.3	1
6208	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. <i>Clínica e Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 75-88.	0.1	6
6209	Independent role of low-density lipoprotein cholesterol in subclinical coronary atherosclerosis in the absence of traditional cardiovascular risk factors. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 866-872.	0.5	22
6210	Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials. <i>Journal of General Internal Medicine</i> , 2019, 34, 1607-1614.	1.3	10
6211	Alzheimer's disease: risk factors and potentially protective measures. <i>Journal of Biomedical Science</i> , 2019, 26, 33.	2.6	415
6212	Effect of fatty acid content in the diet on lipid profile in HIV-infected patients treated with antiretroviral drugs. <i>HIV and AIDS Review</i> , 2019, 18, 25-32.	0.1	0
6213	Evidence and mechanisms for statin-induced cognitive decline. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 397-406.	1.3	13
6214	Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e026603.	0.8	15
6215	Management of transient ischemic attack or nondisabling stroke related to extracranial internal carotid artery stenosis. <i>Cmaj</i> , 2019, 191, E418-E422.	0.9	5
6216	Atherosclerosis plaque area reduction: working hypothesis to prevent cardiovascular event. <i>Comparative Clinical Pathology</i> , 2019, 28, 907-914.	0.3	2
6217	A strategy for screening bioactive components from natural products based on two-dimensional cell membrane chromatography and component-knockout approach. <i>Journal of Chromatography A</i> , 2019, 1601, 171-177.	1.8	15
6218	Is lipid goal one-size-fits-all: A review of evidence for recommended low-density lipoprotein treatment targets in Asian patients. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1496-1506.	0.8	12
6219	Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 61.	0.7	6
6220	Management of high cholesterol levels in older people. <i>Geriatrics and Gerontology International</i> , 2019, 19, 375-383.	0.7	6
6221	Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis. <i>Archives of Medical Science</i> , 2019, 15, 385-392.	0.4	11

#	ARTICLE	IF	CITATIONS
6222	The emerging concept of "individualized cholesterol-lowering therapy": A change in paradigm. , 2019, 199, 111-116.		34
6223	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry, 2019, 56, 338-356.	0.8	27
6224	Statins for the Primary Prevention of Coronary Heart Disease. BioMed Research International, 2019, 2019, 1-15.	0.9	19
6225	Association between statin use and perioperative mortality after aortobifemoral bypass in patients with aortoiliac occlusive disease. Journal of Vascular Surgery, 2019, 70, 509-515.	0.6	6
6226	Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes. JAMA Network Open, 2019, 2, e190223.	2.8	16
6227	Use of statins in the elderly according to age and indication—a cross-sectional population-based register study. European Journal of Clinical Pharmacology, 2019, 75, 959-967.	0.8	3
6228	The Role of Statins in the Management of Heart Failure with Preserved Ejection Fraction. Current Pharmacology Reports, 2019, 5, 210-213.	1.5	0
6229	Management of dyslipidaemias in the elderly population—a narrative review. Maturitas, 2019, 124, 93-99.	1.0	3
6230	Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 315-322.	1.0	14
6231	Cardiovascular research in France: Evolution of scientific activities and production over the last decade. Archives of Cardiovascular Diseases, 2019, 112, 241-252.	0.7	3
6232	Alterations in cholesterol metabolism as a risk factor for developing Alzheimer's disease: Potential novel targets for treatment. Journal of Steroid Biochemistry and Molecular Biology, 2019, 190, 104-114.	1.2	155
6233	Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage — A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 1703-1709.	0.7	31
6234	Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 934-944.	1.1	25
6235	Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Neurology, 2019, 21, 22.	0.7	16
6237	"Precision medicine" and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory). European Heart Journal Supplements, 2019, 21, B73-B75.	0.0	1
6238	Evidence-Based Cardiovascular Risk Management in Diabetes. American Journal of Cardiovascular Drugs, 2019, 19, 439-448.	1.0	10
6239	Nonalcoholic Fatty Liver Disease and the Heart. Journal of the American College of Cardiology, 2019, 73, 948-963.	1.2	259
6240	Statin use improves limb salvage after intervention for peripheral arterial disease. Journal of Vascular Surgery, 2019, 70, 539-546.	0.6	20

#	ARTICLE	IF	CITATIONS
6241	Is Alzheimer's Disease Risk Modifiable?. Journal of Alzheimer's Disease, 2019, 67, 795-819.	1.2	73
6242	Perceptions of Canadian Vascular Surgeons Toward Pharmacologic Risk Reduction in Patients with Peripheral Artery Disease: 2018 Update. Annals of Vascular Surgery, 2019, 58, 166-173.e4.	0.4	16
6243	How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clinic Proceedings, 2019, 94, 660-669.	1.4	6
6244	The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. Drugs, 2019, 79, 231-242.	4.9	18
6245	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. Endocrine Practice, 2019, 25, 69-101.	1.1	245
6246	Type 2 Diabetes. Annals of Internal Medicine, 2019, 171, ITC65-ITC80.	2.0	46
6247	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2019. Diabetes Care, 2019, 42, S103-S123.	4.3	676
6248	2018 Guidelines for the management of dyslipidemia. Korean Journal of Internal Medicine, 2019, 34, 723-771.	0.7	144
6249	Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups. , 0, , .		6
6250	Effect of atorvastatin on lipid and cardiovascular events in patients on maintenance hemodialysis. BIRDEM Medical Journal, 2019, 10, 34-39.	0.0	0
6252	Statins and Cognitive Impairment. Journal of the American College of Cardiology, 2019, 74, 2569-2571.	1.2	5
6253	Effects of Statins on Memory, Cognition, and Brain Volume in the Elderly. Journal of the American College of Cardiology, 2019, 74, 2554-2568.	1.2	49
6254	Risk-reducing medications for primary breast cancer: a network meta-analysis. The Cochrane Library, 2019, 2019, CD012191.	1.5	18
6255	How To Assess a Claudication and When To Intervene. Current Cardiology Reports, 2019, 21, 138.	1.3	12
6256	Does lowering triglycerides reduce cardiovascular risk?. Revista Portuguesa De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.2	0
6258	Does lowering triglycerides reduce cardiovascular risk?. Revista Portuguesa De Cardiologia, 2019, 38, 543-545.	0.2	1
6259	Threshold-Effect Association of Dietary Cholesterol Intake with Dyslipidemia in Chinese Adults: Results from the China Health and Nutrition Survey in 2015. Nutrients, 2019, 11, 2885.	1.7	21
6260	Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk. Current Diabetes Reports, 2019, 19, 146.	1.7	5

#	ARTICLE	IF	CITATIONS
6261	Stroke in the elderly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 393-418.	1.0	27
6262	State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications. Cardiovascular Drugs and Therapy, 2019, 33, 625-639.	1.3	27
6263	Guideline for the identification and management of cardiometabolic risk after spinal cord injury: a case of unsubstantiated recommendations. Spinal Cord Series and Cases, 2019, 5, 97.	0.3	8
6264	Does Co-administration of Antihypertensive Drugs and Statins Alter Their Efficacy and Safety? A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 2019, 73, 352-358.	0.8	5
6265	Effects of long-term statin-treatment on coronary atherosclerosis in patients with inflammatory joint diseases. PLoS ONE, 2019, 14, e0226479.	1.1	4
6266	Global trends in diabetes complications: a review of current evidence. Diabetologia, 2019, 62, 3-16.	2.9	870
6267	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. Cardiology and Therapy, 2019, 8, 5-20.	1.1	17
6268	Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos. Clínica e Investigación en Arteriosclerosis, 2019, 31, 75-88.	0.4	6
6269	Is very low LDL-C harmful?. Current Pharmaceutical Design, 2019, 24, 3658-3664.	0.9	16
6270	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1144-e1161.	1.6	87
6271	PCSK9 inhibitors: clinical evidence and implementation. Nature Reviews Cardiology, 2019, 16, 155-165.	6.1	195
6272	Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease—Report From the JASPER Study. Circulation Journal, 2019, 83, 357-367.	0.7	24
6273	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019, 73, 3210-3227.	1.2	124
6274	Intensity-Dependent Benefit of Statins in Survival Among Prospective Kidney Transplant Patients. American Journal of Cardiology, 2019, 123, 254-259.	0.7	7
6275	Effects of Statin Therapy on the Risk of Intracerebral Hemorrhage in Korean Patients with Hyperlipidemia. Pharmacotherapy, 2019, 39, 129-139.	1.2	15
6276	Drug Therapy of Dyslipidemia in the Elderly. Drugs and Aging, 2019, 36, 321-340.	1.3	22
6277	HDL and cardiovascular disease. Pathology, 2019, 51, 142-147.	0.3	56
6278	Impact of risk factors for recurrence after the first ischemic stroke in adults: A systematic review and meta-analysis. Journal of Clinical Neuroscience, 2019, 60, 24-30.	0.8	50

#	ARTICLE	IF	CITATIONS
6279	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e38-e81.	1.1	431
6280	Unstable Angina and Non-ST Elevation Myocardial Infarction. <i>Contemporary Cardiology</i> , 2019, , 233-259.	0.0	0
6281	Management of Dyslipidemia. <i>Contemporary Cardiology</i> , 2019, , 39-69.	0.0	0
6282	Dyslipidemia and Type II Diabetes. , 2019, , 47-53.		0
6283	AMPK: a therapeutic target of heart failure“not only metabolism regulation. <i>Bioscience Reports</i> , 2019, 39, .	1.1	59
6284	Nonfasting versus fasting lipid profile for cardiovascular risk prediction. <i>Pathology</i> , 2019, 51, 131-141.	0.3	112
6285	The Effects of Known Cardioprotective Drugs on Proinflammatory Cytokine Secretion From Human Coronary Artery Endothelial Cells. <i>American Journal of Therapeutics</i> , 2019, 26, e321-e332.	0.5	20
6286	Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance. <i>Journal of Pharmacy Practice</i> , 2020, 33, 276-282.	0.5	6
6287	High-density lipoprotein cholesterol and the risk of obstructive coronary artery disease beyond low-density lipoprotein cholesterol in non-diabetic individuals. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 706-714.	0.8	9
6288	Mechanisms of statin-associated skeletal muscle-associated symptoms. <i>Pharmacological Research</i> , 2020, 154, 104201.	3.1	77
6289	Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 429-440.	0.9	5
6290	Residual inflammatory risk after contemporary lipid lowering therapy. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 105-111.	1.8	6
6291	Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview. <i>International Journal of Stroke</i> , 2020, 15, 377-384.	2.9	29
6292	Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2020, 57, 100962.	5.0	41
6293	Kidney disease trials for the 21st century: innovations in design and conduct. <i>Nature Reviews Nephrology</i> , 2020, 16, 173-185.	4.1	14
6294	Statins After Myocardial Infarction in the Oldest: A Cohort Study in the Clinical Practice Research Datalink Database. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 329-336.	1.3	3
6295	New candidate genes for ST -elevation myocardial infarction. <i>Journal of Internal Medicine</i> , 2020, 287, 66-77.	2.7	7
6296	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 325-332.	1.0	0

#	ARTICLE	IF	CITATIONS
6297	Clinical guidelines for type 1 diabetes mellitus with an emphasis on older adults: an Executive Summary. <i>Diabetic Medicine</i> , 2020, 37, 53-70.	1.2	30
6298	Effectiveness of short message service intervention to improve glycated hemoglobin control and medication adherence in type-2 diabetes: A meta-analysis of prospective studies. <i>Primary Care Diabetes</i> , 2020, 14, 356-363.	0.9	11
6299	Soyasaponins A ₁ and A ₂ exert anti-atherosclerotic functionalities by decreasing hypercholesterolemia and inflammation in high fat diet (HFD)-fed ApoE ^{+/+} mice. <i>Food and Function</i> , 2020, 11, 253-269.	2.1	16
6300	Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz472.	0.4	26
6301	Editor's Choice "European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2020, 59, 173-218.	0.8	275
6302	The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population-Based Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 811-816.	1.2	9
6303	Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. <i>Mayo Clinic Proceedings</i> , 2020, 95, 77-89.	1.4	97
6304	A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. <i>New England Journal of Medicine</i> , 2020, 382, 9-19.	13.9	339
6305	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 36-49.	5.5	115
6306	Development and Evidence Base. , 2020, , 17-28.		0
6307	Waiting List and Kidney Transplant Vascular Risk: An Ongoing Unmet Concern. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 1-27.	0.9	12
6308	What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104457.	0.7	3
6309	Effect of Cytochrome P450 7A1 (CYP7A1) Polymorphism on Lipid Responses to Simvastatin Treatment. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 168-173.	0.8	7
6310	Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 175-182.	0.1	4
6311	Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016. <i>BMJ Open</i> , 2020, 10, e038423.	0.8	23
6312	Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians. <i>CJC Open</i> , 2020, 2, 530-538.	0.7	20
6313	Statins in primary prevention: is the enthusiasm justified?. <i>Indian Heart Journal</i> , 2020, 72, 221-224.	0.2	0
6314	Management of hypertriglyceridemia. <i>BMJ, The</i> , 2020, 371, m3109.	3.0	89

#	ARTICLE	IF	CITATIONS
6315	Safety of Chronic Simvastatin Treatment in Patients with Decompensated Cirrhosis: Many Adverse Events but No Liver Injury. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3199-3208.	1.1	15
6316	Use of Run-in Periods in Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 188.	3.8	12
6317	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. <i>International Journal of Stroke</i> , 2021, 16, 738-750.	2.9	11
6318	Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2202-2204.	2.4	7
6319	Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 658-670.	0.8	9
6320	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm "2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 1196-1224.	1.1	117
6321	Hyperlipidemia and mortality associated with diabetes mellitus co-existence in Chinese peritoneal dialysis patients. <i>Lipids in Health and Disease</i> , 2020, 19, 234.	1.2	9
6322	Long-Term Effectiveness and Safety of Initiating Statin Therapy After Index Revascularization In Patients With Peripheral Arterial Occlusive Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e018338.	1.6	22
6323	Hitos histÃ³ricos en el tratamiento hipolipemiante antes de la era de los inhibidores de la proproteína convertasa subtilisina/kexina tipo 9. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020, 20, 8-14.	0.2	0
6324	Anticuerpos monoclonales inhibidores de la proproteína convertasa subtilisina/kexina tipo 9: nuevas evidencias. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020, 20, 15-20.	0.2	1
6325	The Role of Statins in Current Guidelines. <i>Current Atherosclerosis Reports</i> , 2020, 22, 50.	2.0	17
6326	Emulating a target trial of statin use and risk of dementia using cohort data. <i>Neurology</i> , 2020, 95, e1322-e1332.	1.5	19
6327	Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. <i>European Heart Journal</i> , 2020, 41, 3336-3342.	1.0	27
6328	Risk Differences in Secondary Prevention Patients Who Present With Acute Coronary Syndrome and Implications of Guideline-Directed Cholesterol Management. <i>American Journal of Cardiology</i> , 2020, 133, 1-6.	0.7	0
6329	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e016506.	1.6	8
6330	Integrative Review of Managed Entry Agreements: Chances and Limitations. <i>Pharmacoeconomics</i> , 2020, 38, 1165-1185.	1.7	25
6331	Advances in the Study of Marine Products with Lipid-Lowering Properties. <i>Marine Drugs</i> , 2020, 18, 390.	2.2	9
6332	Hit or miss: the new cholesterol targets. <i>BMJ Evidence-Based Medicine</i> , 2020, 26, bmjebm-2020-111413.	1.7	9

#	ARTICLE	IF	CITATIONS
6333	The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 91.	3.0	29
6334	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 4-33.	6.6	113
6335	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2020. <i>Diabetes Care</i> , 2020, 43, S111-S134.	4.3	421
6336	Is race or ethnicity associated with underutilization of statins among women in the United States: The study of women's health across the nation. <i>Clinical Cardiology</i> , 2020, 43, 1388-1397.	0.7	11
6337	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3613-3682.	1.8	63
6338	Low-density lipoprotein cholesterol and all-cause mortality: findings from the China health and retirement longitudinal study. <i>BMJ Open</i> , 2020, 10, e036976.	0.8	11
6339	Is it possible to predict atherosclerosis in the ascending aorta by the patient's lipid panel?. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2020, 5, 237-244.	0.5	0
6340	Forty-eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas. <i>Journal of Diabetes Investigation</i> , 2020, 12, 1278-1286.	1.1	3
6341	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459.	1.4	5
6342	Higher baseline lipid levels amplify the benefit of secondary prevention therapy with statins in Chinese patients with acute coronary syndrome. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096584.	0.4	0
6343	Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population-based study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2349-2361.	1.1	16
6344	Low-density lipoprotein cholesterol lowering treatment: the current approach. <i>Lipids in Health and Disease</i> , 2020, 19, 85.	1.2	44
6345	Indian guidelines on hypertension-IV (2019). <i>Journal of Human Hypertension</i> , 2020, 34, 745-758.	1.0	50
6346	Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. <i>PLoS ONE</i> , 2020, 15, e0233230.	1.1	9
6348	Periodontal therapy and cardiovascular risk. <i>Periodontology 2000</i> , 2020, 83, 107-124.	6.3	79
6349	Innovation in medical imaging to improve disease staging, therapeutic intervention, and clinical outcomes. <i>Atherosclerosis</i> , 2020, 306, 75-84.	0.4	4
6350	Treatment Patterns of Lipid-Lowering Therapy in Patients with Coronary Artery Disease Aged Above and Below 75 Years: A Retrospective Cross-Sectional Study of 1500 Patients in a Tertiary Care Referral Center in Germany. <i>Drugs and Aging</i> , 2020, 37, 521-527.	1.3	3
6351	Effect of statins on cardiovascular complications in chronic kidney disease patients. <i>Medicine (United Tj ETQq1 1 0,784314 rgBT /Over</i>	0.4	0

#	ARTICLE	IF	CITATIONS
6352	Early ischaemic and haemorrhagic complications after atrial fibrillation-related ischaemic stroke: analysis of the IAC study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 750-755.	0.9	9
6353	Association between Serum Lipid and Hematoma Expansion after Spontaneous Intracerebral Hemorrhage in Chinese Patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104793.	0.7	3
6354	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 723-735.	1.3	11
6355	Periprocedural Myocardial Injury: Pathophysiology, Prognosis, and Prevention. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1041-1052.	0.3	7
6356	Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 17-27.	1.2	27
6357	Clinical Pharmacology of Statins: an Update. <i>Current Atherosclerosis Reports</i> , 2020, 22, 26.	2.0	31
6358	Statins in a Distorted Mirror of Media. <i>Current Atherosclerosis Reports</i> , 2020, 22, 37.	2.0	24
6359	Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. <i>Cardiovascular Diabetology</i> , 2020, 19, 28.	2.7	31
6360	Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review. <i>International Ophthalmology</i> , 2020, 40, 1587-1601.	0.6	25
6361	Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108119.	1.1	7
6362	Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia. <i>Advances in Therapy</i> , 2020, 37, 2169-2183.	1.3	1
6363	Schnyder corneal dystrophy-associated UBIAD1 is defective in MK-4 synthesis and resists autophagy-mediated degradation. <i>Journal of Lipid Research</i> , 2020, 61, 746-757.	2.0	12
6364	Triglycerides and Cardiovascular Outcomes—Can We REDUCE-IT? <i>International Journal of Angiology</i> , 2020, 29, 002-011.	0.2	5
6365	Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 175-180.	0.6	8
6366	Diabetes mellitus: an important risk factor for peripheral vascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 131-137.	0.6	13
6367	Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 68.	3.8	143
6368	Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100013.	1.3	10
6369	The Efficacy of Squalene in Cardiovascular Disease Risk-A Systematic Review. <i>Nutrients</i> , 2020, 12, 414.	1.7	41

#	ARTICLE	IF	CITATIONS
6370	Lipids and Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1505.	1.8	250
6372	The Magic of Randomization versus the Myth of Real-World Evidence. <i>New England Journal of Medicine</i> , 2020, 382, 674-678.	13.9	296
6373	Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study. <i>Diabetes Therapy</i> , 2020, 11, 859-871.	1.2	11
6374	Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study. <i>European Heart Journal</i> , 2020, 41, 3913-3920.	1.0	70
6375	Heart Failure Risk Reduction: Hydrophilic or Lipophilic Statins?. <i>Cardiology</i> , 2020, 145, 384-386.	0.6	6
6376	Carotid Artery Stenting in Asymptomatic Carotid Artery Stenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 648-656.	1.2	12
6377	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. <i>Journal of the American College of Cardiology</i> , 2020, 75, 835-837.	1.2	1
6378	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. <i>Trials</i> , 2020, 21, 34.	0.7	19
6379	Impact of Statin Use on Dementia Incidence in Elderly Men and Women with Ischemic Heart Disease. <i>Biomedicines</i> , 2020, 8, 30.	1.4	12
6380	The importance of stroke as a risk factor of cognitive decline in community dwelling older and oldest peoples: the SONIC study. <i>BMC Geriatrics</i> , 2020, 20, 24.	1.1	13
6381	Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India. <i>Journal of Clinical Lipidology</i> , 2020, 14, e1-e13.	0.6	17
6382	Meta-Analysis of Usefulness of Treatment of Hypercholesterolemia With Statins for Primary Prevention in Patients Older Than 75 Years. <i>American Journal of Cardiology</i> , 2020, 125, 1154-1157.	0.7	11
6383	Statins Disrupt Macrophage Rac1 Regulation Leading to Increased Atherosclerotic Plaque Calcification. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 714-732.	1.1	45
6384	Lipidomics perturbations in the brain of adult zebrafish (<i>Danio rerio</i>) after exposure to chiral ibuprofen. <i>Science of the Total Environment</i> , 2020, 713, 136565.	3.9	25
6385	Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: A systematic review and meta-analysis. <i>Vascular Medicine</i> , 2020, 25, 106-117.	0.8	50
6386	Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study. <i>BJS Open</i> , 2020, 4, 59-70.	0.7	6
6387	Combining Nanomaterials and Developmental Pathways to Design New Treatments for Cardiac Regeneration: The Pulsing Heart of Advanced Therapies. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 323.	2.0	13
6388	Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1945-1955.	1.2	47

#	ARTICLE	IF	CITATIONS
6389	Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2020, 72, 2130-2138.	0.6	11
6390	Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1804-1818.	1.2	189
6391	The Cognitive Effects of Statins are Modified by Age. <i>Scientific Reports</i> , 2020, 10, 6187.	1.6	20
6392	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	1.1	410
6393	Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 833-843.	2.3	13
6394	Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000719.	1.2	7
6395	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157
6396	MiR-21 antagomir improves insulin resistance and lipid metabolism disorder in streptozotocin-induced type 2 diabetes mellitus rats. <i>Annals of Palliative Medicine</i> , 2020, 9, 394-404.	0.5	18
6397	Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. <i>Frontiers in Pharmacology</i> , 2020, 11, 108.	1.6	79
6398	Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 905-916.	0.8	13
6399	Association between statin use and cognitive function: A systematic review of randomized clinical trials and observational studies. <i>Journal of Clinical Lipidology</i> , 2021, 15, 22-32.e12.	0.6	19
6400	Clinical outcomes of high-intensity doses of atorvastatin in patients with acute coronary syndrome: A retrospective cohort study using real-world data. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2043-2052.	1.1	3
6401	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 553-564.	2.5	134
6402	Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark. <i>Circulation</i> , 2021, 143, 907-920.	1.6	12
6403	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2021. <i>Diabetes Care</i> , 2021, 44, S125-S150.	4.3	359
6404	Cerebral vasospasm after subarachnoid hemorrhage: Developing treatments. <i>Brain Hemorrhages</i> , 2021, 2, 15-23.	0.4	6
6405	Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease. <i>American Heart Journal</i> , 2021, 231, 36-44.	1.2	9
6406	The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. <i>Postgraduate Medicine</i> , 2021, 133, 28-41.	0.9	10

#	ARTICLE	IF	CITATIONS
6407	Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population-Based Retrospective Cohort Study From the United Kingdom. <i>Arthritis and Rheumatology</i> , 2021, 73, 504-511.	2.9	20
6408	Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 286-296.	1.2	0
6409	Detecting unstable plaques in humans using cardiac CT: Can it guide treatments?. <i>British Journal of Pharmacology</i> , 2021, 178, 2204-2217.	2.7	5
6410	National Trends in Statin Medication Prescribing in Patients With a History of Stroke or Transient Ischemic Attack. <i>Journal of Pharmacy Practice</i> , 2021, 34, 216-223.	0.5	2
6411	A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. <i>PLoS ONE</i> , 2021, 16, e0245481.	1.1	5
6412	Statins. <i>Stroke Revisited</i> , 2021, , 77-89.	0.2	0
6414	Practical Dyslipidemia Management in Stroke-Specific Situations. <i>Stroke Revisited</i> , 2021, , 165-172.	0.2	0
6415	Bipolar disorders, obesity, and metabolic disturbances: Mechanisms and implications. , 2021, , 257-274.		0
6416	Effects of statins on mitochondrial pathways. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 237-251.	2.9	94
6417	Dyslipidemia in Women: Etiology and Management. <i>Stroke Revisited</i> , 2021, , 173-202.	0.2	3
6419	Bipolar disorder and cardiovascular dysfunction: Mechanisms and implications. , 2021, , 223-233.		0
6420	Endothelial Klf2-Foxp1-TGF β 2 signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. <i>Theranostics</i> , 2021, 11, 1609-1625.	4.6	17
6421	Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. <i>Clinical Gastroenterology</i> , 2021, , 61-88.	0.0	1
6422	Impact of Dyslipidemia on Ischemic Stroke. <i>Stroke Revisited</i> , 2021, , 23-41.	0.2	0
6423	Impact of statin pretreatment on the complications of carotid stenting in asymptomatic patients: observational study. <i>BMC Neurology</i> , 2021, 21, 75.	0.8	1
6424	Changes in the Diagnosis and Management of Diabetes in Mexico City Between 1998-2004 and 2015-2019. <i>Diabetes Care</i> , 2021, 44, 944-951.	4.3	6
6425	Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study. <i>European Respiratory Journal</i> , 2021, 58, 2001798.	3.1	16
6426	Long-Term Levels of LDL-C and Cognitive Function: The CARDIA Study. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 1048-1057.	1.2	9

#	ARTICLE	IF	CITATIONS
6427	Emerging views of statin pleiotropy and cholesterol lowering. <i>Cardiovascular Research</i> , 2022, 118, 413-423.	1.8	54
6428	Lipid Management in the Elderly Population. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 60-63.	0.1	0
6429	Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs. <i>Current Oncology Reports</i> , 2021, 23, 29.	1.8	17
6430	Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. <i>International Journal of COPD</i> , 2021, Volume 16, 499-517.	0.9	17
6431	A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. <i>BMC Gastroenterology</i> , 2021, 21, 120.	0.8	18
6432	Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. <i>Endocrine Reviews</i> , 2021, 42, 658-690.	8.9	50
6433	High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: results from the IMPRES study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 352-360.	1.8	11
6434	Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e017948.	1.6	9
6435	The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. <i>Health Technology Assessment</i> , 2021, 25, 1-62.	1.3	6
6436	Opinion paper: Is the Friedewald equation obsolete?. <i>Clinica Chimica Acta</i> , 2021, 514, 122-124.	0.5	4
6437	Association between Previous Statin Use and Alzheimer's Disease: A Nested Case-Control Study Using a National Health Screening Cohort. <i>Brain Sciences</i> , 2021, 11, 396.	1.1	7
6438	Impact of Statins on Hematoma, Edema, Seizures, Vascular Events, and Functional Recovery After Intracerebral Hemorrhage. <i>Stroke</i> , 2021, 52, 975-984.	1.0	18
6439	Peripheral Arterial Disease in Persons with Diabetic Foot Ulceration: a Current Comprehensive Overview. <i>Current Diabetes Reviews</i> , 2021, 17, 474-485.	0.6	13
6441	Gender- and age-related differences of statin use on incident dementia in patients with rheumatoid arthritis: a Nationwide population-based cohort study. <i>Lipids in Health and Disease</i> , 2021, 20, 37.	1.2	2
6442	Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab. <i>Current Medicinal Chemistry</i> , 2021, 28, 1025-1041.	1.2	10
6443	Reduction of small dense LDL and Il-6 after intervention with <i>Plantago psyllium</i> in adolescents with obesity: a parallel, double blind, randomized clinical trial. <i>European Journal of Pediatrics</i> , 2021, 180, 2493-2503.	1.3	6
6444	Statin Therapy in Children. , 0, , .		0
6445	Dyslipidemia and its associated factors in southern Iranian women, Bandare-Kong Cohort study, a cross-sectional survey. <i>Scientific Reports</i> , 2021, 11, 9125.	1.6	12

#	ARTICLE	IF	CITATIONS
6447	Clinical considerations after endovascular therapy of peripheral artery disease. Expert Review of Cardiovascular Therapy, 2021, 19, 369-378.	0.6	1
6448	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	2.3	56
6449	The Role of Carotid Stenosis in a Prediction of Prognosis of Coronary Artery Disease. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2021, 42, 53-66.	0.2	1
6450	Medical management of risk factors for vascular disease. Surgery, 2021, 39, 248-256.	0.1	0
6451	Effect and significance of hyperlipoproteinemia on stent thrombosis in patients with implanted drug-eluting stents: The 5-year follow up study. American Journal of the Medical Sciences, 2022, 364, 758-765.	0.4	0
6452	COVID-19 vaccines: effectiveness and number needed to treat. Lancet Microbe, The, 2021, 2, e281.	3.4	4
6453	Do statins reduce the rate of revision surgery after chronic subdural hematoma drain?. Acta Neurochirurgica, 2021, 163, 1843-1848.	0.9	4
6454	Prevalence of SLCO1B1 single nucleotide variations and their association with hypercholesterolaemia in hypercholesterolemic patients in Gauteng, South Africa. Xenobiotica, 2021, 51, 949-959.	0.5	1
6455	Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. BMJ Open, 2021, 11, e043714.	0.8	14
6457	Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials. Current Atherosclerosis Reports, 2021, 23, 42.	2.0	2
6458	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1671-1690.	1.1	5
6459	Drugs in secondary stroke prevention. Australian Prescriber, 2021, 44, 85-90.	0.5	6
6460	Pharmacological Management of Hyperlipidemia in Older Individuals. , 2021, 36, 284-303.		1
6461	Modifiable Risk Factors in Alzheimer Disease and Related Dementias: A Review. Clinical Therapeutics, 2021, 43, 953-965.	1.1	34
6462	Clinical Benefit, Harm, and Cost Effectiveness of Screening Men for Peripheral Artery Disease: A Markov Model Based on the VIVA Trial. European Journal of Vascular and Endovascular Surgery, 2021, 61, 971-979.	0.8	9
6463	Contemporary Medical Management of Peripheral Artery Disease. Circulation Research, 2021, 128, 1868-1884.	2.0	53
6464	Management of Dyslipidemia in Women and Men with Coronary Heart Disease: Results from POLASPIRE Study. Journal of Clinical Medicine, 2021, 10, 2594.	1.0	4
6465	Molecular enhancement of fracture healing - Is there a role for Bone Morphogenetic Protein-2, parathyroid hormone, statins, or sclerostin-antibodies?. Injury, 2021, 52, S49-S57.	0.7	5

#	ARTICLE	IF	CITATIONS
6466	A review of the mechanisms underlying selected comorbidities in Alzheimer's disease. <i>Pharmacological Reports</i> , 2021, 73, 1565-1581.	1.5	23
6467	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 461-481.	1.8	146
6468	High Apolipoprotein E Levels Predict Adverse Limb Events in Patients with Peripheral Artery Disease Due to Peripheral Artery Disease Undergoing Endovascular Treatment and On-Statins Treatment. <i>International Heart Journal</i> , 2021, 62, 872-878.	0.5	0
6469	Evolution of Evidence-Based Medicine in Stroke. <i>Cerebrovascular Diseases</i> , 2021, 50, 1-12.	0.8	1
6470	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.3	45
6471	Associations of coprescribed medications for chronic comorbid conditions in very old adults with clinical dementia: a retrospective cohort study using insurance claims data. <i>BMJ Open</i> , 2021, 11, e043768.	0.8	0
6472	Statins and Cognitive Decline in the Cardiovascular Health Study: A Comparison of Different Analytical Approaches. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 994-1001.	1.7	4
6473	Association between statin use and Alzheimer's disease with dose response relationship. <i>Scientific Reports</i> , 2021, 11, 15280.	1.6	16
6474	Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. <i>CJC Open</i> , 2021, 3, 936-949.	0.7	6
6475	Ovarian Cancer Risk in Relation to Blood Cholesterol and Triglycerides. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2044-2051.	1.1	13
6476	Comparison of the Reductions in LDL-C and Non-HDL-C Induced by the Red Yeast Rice Extract Xuezhikang Between Fasting and Non-fasting States in Patients With Coronary Heart Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 674446.	1.1	3
6477	Cardiovascular disease in diabetes, beyond glucose. <i>Cell Metabolism</i> , 2021, 33, 1519-1545.	7.2	87
6478	Dyslipidemia in Patients with Kidney Disease. <i>Cardiology Clinics</i> , 2021, 39, 353-363.	0.9	14
6479	Evidence-based public policy making for medicines across countries: findings and implications for the future. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1019-1052.	0.6	30
6481	Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. <i>Health Technology Assessment</i> , 2021, 25, 1-70.	1.3	0
6482	The Interdependency and Co-Regulation of the Vitamin D and Cholesterol Metabolism. <i>Cells</i> , 2021, 10, 2007.	1.8	24
6483	Pharmacoepidemiology Research-Real-World Evidence for Decision Making. <i>Frontiers in Pharmacology</i> , 2021, 12, 723427.	1.6	7
6484	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes) <i>Tj ETQqb.30.784314 rgBT</i>		

#	ARTICLE	IF	CITATIONS
6485	Similarities and Differences Between HFmrEF and HFpEF. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 678614.	1.1	14
6486	That Myalgia of Yours Is Not From Statin Intolerance. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1223-1226.	1.2	6
6487	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. <i>Circulation</i> , 2021, 144, 1380-1395.	1.6	24
6488	Reply. <i>Journal of the American College of Cardiology</i> , 2021, 78, e103.	1.2	0
6489	Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy. <i>American Heart Journal</i> , 2021, 240, 89-100.	1.2	3
6490	Letter to the Editor: Higher dose statins after stroke. <i>Australian Prescriber</i> , 2021, 44, 146-147.	0.5	0
6491	<i>Preventive Cardiology</i> . , 2022, , 341-375.		0
6492	Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110140.	1.1	6
6493	Cardiovascular preventive pharmacotherapy stratified by predicted cardiovascular risk: a national data linkage study. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1905-1913.	0.8	6
6494	Atorvastatin is associated with reduced cisplatin-induced hearing loss. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	32
6495	Complementary Medications (Statins, Nicergoline, Naftidrofuryl) in Dementia. , 2021, , 1-14.		1
6496	Treatment With Cardiovascular Medications: Prognosis in Patients With Myocardial Injury. <i>Journal of the American Heart Association</i> , 2021, 10, e017239.	1.6	8
6497	Association Between BMI and Cardiovascular Benefits After More Intensive LDL-C Lowering Strategy: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
6499	Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. <i>Life</i> , 2021, 11, 105.	1.1	22
6501	Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction. , 0, , 397-425.		2
6505	CANCER AMONG OLDER ADULTS: INCIDENCE, PROGNOSIS AND NEW AVENUES OF PREVENTION. , 2006, , 139-151.		2
6506	Protection of Endothelial Function. <i>Handbook of Experimental Pharmacology</i> , 2005, , 619-644.	0.9	14
6507	Cholesterol—A Janus-Faced Molecule in the Central Nervous System. , 2007, , 151-170.		2

#	ARTICLE	IF	CITATIONS
6508	Translational Vascular Medicine. , 2012, , .		2
6510	Diabetes Mellitus and Cardiovascular Disease. , 2011, , 227-252.		2
6511	Heart Disease in the Elderly. , 2013, , 669-686.		3
6512	Diastolic Dysfunction, Redox Stress, Extracellular Matrix Remodeling and Congestive Heart Failure in Diabetes Mellitus. Progress in Experimental Cardiology, 2003, , 563-582.	0.0	1
6513	Menopausal Hormone Therapy. , 2004, , 321-348.		1
6514	Antioxidant Vitamin Supplementation and Cardiovascular Disease. , 2005, , 245-277.		4
6515	Lipid Metabolism and Coronary Artery Disease. , 2006, , 130-137.		7
6516	Oxidative and Glycooxidative Stress in Diabetic Nephropathy. , 2006, , 151-172.		5
6517	Cardiovascular Disease in Women. , 2007, , 349-368.		2
6518	High-Density Lipoproteins. , 2007, , 159-199.		1
6519	Antioxidant and B-vitamins and Atherosclerosis. , 2010, , 285-323.		1
6520	Cholesterol and Alzheimer's Disease. , 2007, , 142-158.		1
6521	Secondary Prevention of Coronary Heart Disease: Impact of Nutrition on the Risk of Fatal Complications and Importance of the Concept of Omega-3 Deficiency. , 2007, , 181-193.		2
6522	Rehabilitation in Elderly Patients. , 2007, , 383-392.		1
6523	Statin-Associated Muscle Symptoms Are Real. Contemporary Cardiology, 2020, , 5-19.	0.0	1
6524	Kardiologie. , 2008, , 343-387.		2
6527	Anesthesia for Lower Extremity Bypass. , 2018, , 625-633.		1
6528	Intervention Trials. , 2005, , 345-370.		2

#	ARTICLE	IF	CITATIONS
6529	Arzneiverordnungen für Ältere Patienten. , 2008, , 923-960.		2
6532	Long-term outcome of peritoneal dialysis and hemodialysis in pediatric patients. , 2004, , 485-499.		2
6533	Lipid-Modifying Drugs: Pharmacology and Perspectives. Advances in Experimental Medicine and Biology, 2020, 1177, 133-148.	0.8	6
6534	Management and Care of Older Cardiac Patients. , 2018, , 245-265.		6
6535	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer's disease. , 2020, , 469-504.		5
6536	Anesthesia for Vascular Surgery. , 2010, , 1985-2044.		8
6537	DYSLIPIDEMIAS. , 2009, , 303-320.		1
6538	ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction—A Summary Article. , 2011, , 385-404.		2
6539	Kidney Disease. , 2012, , 1523-1607.		5
6540	Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080.		5
6541	Presentation and Clinical Management of Dementia. , 2010, , 392-401.		2
6542	Lipid-Lowering Strategies and Reduction of Coronary Heart Disease Risk. , 2010, , 81-86.e2.		3
6543	Complications of Diabetes Mellitus. , 2011, , 1462-1551.		8
6544	Unstable Angina and Non-ST Elevation Myocardial Infarction. , 2012, , 1178-1209.		5
6545	High-Density Lipoprotein Metabolism. , 2009, , 45-55.		3
6546	High-Density Lipoprotein Cholesterol in Coronary Heart Disease Risk Assessment. , 2009, , 119-129.		1
6547	Special Patient Populations: Diabetes and Metabolic Syndrome. , 2009, , 443-462.		1
6548	Special Patient Populations: Women and Elderly. , 2009, , 463-472.		1

#	ARTICLE	IF	CITATIONS
6549	Tratamiento hipolipemiante en la prevención secundaria de la enfermedad cerebrovascular isquémica. Clínica e Investigación en Arteriosclerosis, 2020, 32, 175-182.	0.4	7
6550	Balancing cardiovascular benefit and diabetogenic harm of therapy with statins: Real-world evidence from Italy. Diabetes Research and Clinical Practice, 2020, 164, 108197.	1.1	3
6551	Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clinic Proceedings, 2009, 84, 741-57.	1.4	57
6553	ESVM Guideline on peripheral arterial disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 1-79.	0.6	110
6554	5 Conservative treatment for PAD – Risk factor management. Vasa - European Journal of Vascular Medicine, 2019, 48, 1-12.	0.6	15
6555	Oxidized cholesterol species as signaling molecules in the brain: diabetes and Alzheimer's disease. Neuronal Signaling, 2019, 3, NS20190068.	1.7	8
6557	Diabetes management in older people: a focus on cardiovascular risk reduction. Postgraduate Medicine, 2017, 129, 169-177.	0.9	3
6558	The new European guidelines for prevention of cardiovascular disease are misleading. Expert Review of Clinical Pharmacology, 2020, 13, 1289-1294.	1.3	9
6559	Pharmaceuticals Other Than Hormones. , 2006, , 489-506.		7
6560	Lipids and cholesterol. , 2005, , 174-186.		1
6561	Metabolic syndrome, diabetes, and coronary heart disease. , 2005, , 311-330.		1
6562	Life course influences on coronary heart disease. , 2005, , 568-590.		5
6563	Risk factors in the elderly. , 2005, , 606-628.		1
6564	The secondary prevention of cardiovascular disease. , 2005, , 769-791.		1
6565	Triglycerides as a Shared Risk Factor between Dementia and Atherosclerotic Cardiovascular Disease: A Study of 125 727 Individuals. Clinical Chemistry, 2021, 67, 245-255.	1.5	24
6566	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.0	19
6567	Diabetes Mellitus and Metabolic Syndrome. , 2009, , 465-496.		5
6568	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, S1-S78.	3.1	174

#	ARTICLE	IF	CITATIONS
6569	Treatment of Patients with Lipid Disorders in the Primary Care Setting: New Treatment Guidelines and their Implications. <i>Southern Medical Journal</i> , 2003, 96, 266-275.	0.3	5
6570	Diabetes on a Cardiovascular Ward: Adherence to Current Recommendations. <i>Southern Medical Journal</i> , 2004, 97, 1031-1037.	0.3	4
6571	Statin Therapy in Rheumatoid Arthritis. <i>Southern Medical Journal</i> , 2005, 98, 534-540.	0.3	9
6572	Simvastatin Restores Ischemic Preconditioning in the Presence of Hyperglycemia through a Nitric Oxide-mediated Mechanism. <i>Anesthesiology</i> , 2008, 108, 634-642.	1.3	28
6573	Advances in the management of statin myopathy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 142-151.	1.2	3
6574	Long-term Follow-up of a Randomized Clinical Trial Comparing Endovascular Revascularization Plus Supervised Exercise With Supervised Exercise Only for Intermittent Claudication. <i>Annals of Surgery</i> , 2022, 276, e1035-e1043.	2.1	13
6575	The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 143-152.	0.5	1
6576	Might money spent on statins be better spent?. <i>BMJ: British Medical Journal</i> , 2003, 327, 933-b-933.	2.4	4
6577	Dietary fat intake and risk of stroke: Association may differ with subtypes of ischaemic stroke. <i>BMJ: British Medical Journal</i> , 2003, 327, 1348-a-1348.	2.4	1
6578	Timing of simvastatin treatment: No matter the time of day, does UK policy reflect the evidence?. <i>BMJ: British Medical Journal</i> , 2004, 328, 168-b-168.	2.4	2
6579	Guidelines from the British Hypertension Society: BHS is set to bankrupt NHS: Fig 1. <i>BMJ: British Medical Journal</i> , 2004, 329, 569.3-570.	2.4	3
6580	A taxi driver with type 2 diabetes. <i>BMJ: British Medical Journal</i> , 2009, 338, b1369-b1369.	2.4	1
6581	Beneficial effects of statins on the kidney. <i>Journal of Clinical Pathology</i> , 2004, 57, 673-4.	1.0	7
6582	Evidence-Based Medical Management of Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 541-553.	1.1	94
6583	Blood pressure goal attainment in multi-ethnic Asian patients with hypertension and dyslipidaemia in primary care. <i>Singapore Medical Journal</i> , 2020, 61, 469-475.	0.3	7
6584	Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. <i>Journal of Clinical Investigation</i> , 2003, 111, 1795-1803.	3.9	225
6585	Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. <i>Journal of Clinical Investigation</i> , 2003, 111, 1795-1803.	3.9	421
6586	Insulin resistance and atherosclerosis. <i>Journal of Clinical Investigation</i> , 2006, 116, 1813-1822.	3.9	350

#	ARTICLE	IF	CITATIONS
6587	Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. <i>Journal of Clinical Investigation</i> , 2010, 120, 627-635.	3.9	103
6588	2016 Chinese guidelines for the management of dyslipidemia in adults. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 1-29.	0.2	226
6589	2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 182-241.	0.2	380
6590	Primary prevention trials in Alzheimer disease. <i>Neurology</i> , 2006, 67, S2-5.	1.5	18
6591	Effect of Three Statins on Glucose Uptake of Cardiomyocytes and its Mechanism. <i>Medical Science Monitor</i> , 2016, 22, 2825-2830.	0.5	17
6592	Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study. <i>PLoS Medicine</i> , 2017, 14, e1002265.	3.9	79
6593	The Pleiotropic Effects of Simvastatin on Retinal Microvascular Endothelium Has Important Implications for Ischaemic Retinopathies. <i>PLoS ONE</i> , 2008, 3, e2584.	1.1	52
6594	Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus—An Observational Study from the Swedish National Diabetes Register. <i>PLoS ONE</i> , 2011, 6, e18744.	1.1	26
6595	Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study. <i>PLoS ONE</i> , 2013, 8, e52828.	1.1	43
6596	Statins for the Prevention of Stroke: A Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2014, 9, e92388.	1.1	35
6597	RNA-Sequencing Analysis of HepG2 Cells Treated with Atorvastatin. <i>PLoS ONE</i> , 2014, 9, e105836.	1.1	13
6598	A Cluster Randomised Controlled Trial of a Pharmacist-Led Collaborative Intervention to Improve Statin Prescribing and Attainment of Cholesterol Targets in Primary Care. <i>PLoS ONE</i> , 2014, 9, e113370.	1.1	35
6599	Statin Use and Cognitive Function: Population-Based Observational Study with Long-Term Follow-Up. <i>PLoS ONE</i> , 2014, 9, e115755.	1.1	13
6600	Determinants for Achieving the LDL-C Target of Lipid Control for Secondary Prevention of Cardiovascular Events in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0116513.	1.1	33
6601	ACEI/ARB Underused in Patients with Type 2 Diabetes in Chinese Population (CCMR-3B Study). <i>PLoS ONE</i> , 2015, 10, e0116970.	1.1	8
6602	Development of the CHARIOT Research Register for the Prevention of Alzheimer's Dementia and Other Late Onset Neurodegenerative Diseases. <i>PLoS ONE</i> , 2015, 10, e0141806.	1.1	18
6603	Factors Influencing the Prescription of Cardiovascular Preventive Therapies in Patients with Peripheral Arterial Disease. <i>PLoS ONE</i> , 2016, 11, e0148069.	1.1	6
6604	Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. <i>PLoS ONE</i> , 2016, 11, e0150785.	1.1	21

#	ARTICLE	IF	CITATIONS
6605	Role of Patient and Practice Characteristics in Variance of Treatment Quality in Type 2 Diabetes between General Practices. PLoS ONE, 2016, 11, e0166012.	1.1	12
6606	Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol. PLoS ONE, 2016, 11, e0166246.	1.1	9
6607	Diabetes mellitus type 1 in adults. Diabetes Mellitus, 2020, 23, 42-114.	0.5	7
6608	Statins: Then and Now. Methodist DeBaKey Cardiovascular Journal, 2021, 15, 23.	0.5	54
6609	Red Yeast Rice for Hypercholesterolemia. Methodist DeBaKey Cardiovascular Journal, 2021, 15, 192.	0.5	47
6610	Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation. The Journal of Critical Care Medicine, 2015, 1, 43-54.	0.3	3
6611	Statin drugs mitigate cellular inflammatory response after ST elevation myocardial infarction, but do not affect in-hospital mortality. Journal of Cardiovascular and Thoracic Research, 2016, 8, 34-39.	0.3	5
6612	Cardiovascular outcomes trials with statins in diabetes. British Journal of Diabetes, 2018, 18, 7-13.	0.1	12
6613	The Effects of Lipid-Lowering Therapy on Graft Patency in Coronary Bypass Surgery Patients. Heart Surgery Forum, 2006, 9, E626-E629.	0.2	4
6615	Beyond confusion and controversy, can we evaluate the real efficacy and safety of cholesterol-lowering with statins?. Journal of Controversies in Biomedical Research, 2015, 1, 67-92.	0.5	6
6618	Quality of lipid-lowering therapy in outpatient practice: RECVAS Register data. Profilakticheskaya Meditsina, 2016, 19, 9.	0.2	5
6619	Acute atorvastatin treatment restores the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats. Oncotarget, 2017, 8, 55187-55193.	0.8	4
6620	Asian-Indians: a review of coronary artery disease in this understudied cohort in the United States. Annals of Translational Medicine, 2018, 6, 12-12.	0.7	29
6621	Vascular dementia: prevention and treatment. Clinical Interventions in Aging, 2006, 1, 229-235.	1.3	48
6622	Management of hyperlipidemia with statins in the older patient. Clinical Interventions in Aging, 2006, 1, 433-438.	1.3	10
6623	Ongoing clinical trials of the pleiotropic effects of statins. Vascular Health and Risk Management, 2005, 1, 29-40.	1.0	41
6624	A new paradigm of cardiovascular risk factor modification. Vascular Health and Risk Management, 2005, 1, 101-109.	1.0	4
6625	Optimal lipid modification: the rationale for combination therapy. Vascular Health and Risk Management, 2005, 1, 317-331.	1.0	21

#	ARTICLE	IF	CITATIONS
6626	Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study. <i>Vascular Health and Risk Management</i> , 2005, 1, 351-356.	1.0	9
6627	Complementary therapy to target LDL cholesterol: the role of the ezetimibe/ simvastatin combination. <i>Vascular Health and Risk Management</i> , 2006, 2, 31-38.	1.0	10
6628	Ximelagatran, direct thrombin inhibitor, oral anticoagulants, thromboprophylaxis. <i>Vascular Health and Risk Management</i> , 2006, 2, 49-58.	1.0	38
6629	Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?. <i>Vascular Health and Risk Management</i> , 2006, 2, 441-446.	1.0	2
6630	Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. <i>Vascular Health and Risk Management</i> , 2006, 2, 507-514.	1.0	18
6631	Practical algorithms for managing patients with cognitive impairments. <i>Meditinskiy Sovet</i> , 2019, , 27-33.	0.1	4
6632	Cardiovascular risk reduction in African Americans: Current concepts and controversies. <i>Global Cardiology Science & Practice</i> , 2016, 2016, e201602.	0.3	7
6633	Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review. <i>Current Medicinal Chemistry</i> , 2020, 27, 3168-3186.	1.2	10
6634	Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. <i>Current Pharmaceutical Design</i> , 2019, 25, 85-95.	0.9	11
6635	The Role of Vascular Aging in Atherosclerotic Plaque Development and Vulnerability. <i>Current Pharmaceutical Design</i> , 2019, 25, 3098-3111.	0.9	14
6636	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. <i>Current Drug Metabolism</i> , 2019, 20, 72-82.	0.7	12
6637	The Many Roles of Statins in Ischemic Stroke. <i>Current Neuropharmacology</i> , 2015, 12, 564-574.	1.4	39
6638	The Pleiotropic Effects of Statins “ From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. <i>Current Vascular Pharmacology</i> , 2019, 17, 222-232.	0.8	54
6639	Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes. <i>Current Diabetes Reviews</i> , 2007, 3, 260-263.	0.6	22
6640	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice. <i>Current Diabetes Reviews</i> , 2020, 16, 949-956.	0.6	2
6641	Management of Measurable Variable Cardiovascular Disease' Risk Factors. <i>Current Cardiology Reviews</i> , 2018, 14, 153-163.	0.6	199
6642	Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review. <i>Current Cardiology Reviews</i> , 2021, 17, .	0.6	48
6643	Effects of Probiotics on Diabetic Nephropathy: A Systematic Review. <i>Current Clinical Pharmacology</i> , 2020, 15, 234-242.	0.2	19

#	ARTICLE	IF	CITATIONS
6644	Initiation and Persistence to Statin Treatment in Patients with Diabetes Receiving Glucose-Lowering Medications 1997- 2006. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 152-159.	0.6	18
6645	Patient-Reported Outcomes in Online Communications on Statins, Memory, and Cognition: Qualitative Analysis Using Online Communities. <i>Journal of Medical Internet Research</i> , 2019, 21, e14809.	2.1	6
6646	An Electronic Clinical Decision Support Tool to Assist Primary Care Providers in Cardiovascular Disease Risk Management: Development and Mixed Methods Evaluation. <i>Journal of Medical Internet Research</i> , 2009, 11, e51.	2.1	59
6650	Primary prevention strategy for cardiovascular disease in Lithuania. <i>Seminars in Cardiovascular Medicine</i> , 2019, 25, 14-39.	0.3	6
6651	Adverse effects of statin therapy: real evidence. <i>Cardiosomatics</i> , 2019, 10, 51-61.	0.2	4
6652	Cardiovascular Drug Therapy in the Elderly. <i>Fundamental and Clinical Cardiology</i> , 2008, , 99-136.	0.0	4
6653	Epidemiology of Coronary Heart Disease in the Elderly. <i>Fundamental and Clinical Cardiology</i> , 2008, , 215-242.	0.0	9
6654	Angina in the Elderly. <i>Fundamental and Clinical Cardiology</i> , 2008, , 269-292.	0.0	10
6655	Management of the Older Patient After Myocardial Infarction. <i>Fundamental and Clinical Cardiology</i> , 2008, , 327-350.	0.0	2
6657	Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 111-128.	1.8	855
6658	An assessment of the cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation. <i>Health Technology Assessment</i> , 2014, 18, 1-368.	1.3	63
6659	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. <i>Health Technology Assessment</i> , 2015, 19, 1-402.	1.3	30
6660	The Asymptomatic Carotid Surgery Trial-2 (ACST-2): an ongoing randomised controlled trial comparing carotid endarterectomy with carotid artery stenting to prevent stroke. <i>Health Technology Assessment</i> , 2017, 21, 1-40.	1.3	28
6661	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION (STEMI). <i>Eurasian Heart Journal</i> , 2020, , 4-77.	0.2	17
6662	Flexible Initial Dosing of Atorvastatin Based Upon Initial Low-Density Lipoprotein Cholesterol Levels in Type 2 Diabetic Patients. <i>Korean Journal of Internal Medicine</i> , 2008, 23, 22.	0.7	10
6663	Characteristics of Subjects with Very Low Serum Low-Density Lipoprotein Cholesterol and the Risk for Intracerebral Hemorrhage. <i>Korean Journal of Internal Medicine</i> , 2012, 27, 317.	0.7	12
6664	The Influencing Aspects of Atorvastatin on C-Reactive Protein and Lipid Profile in Patients with Stroke. <i>International Journal of Biological Chemistry</i> , 2008, 3, 30-34.	0.3	5
6665	Severely frail elderly patients do not need lipid-lowering drugs. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 131-142.	0.6	14

#	ARTICLE	IF	CITATIONS
6666	Comparative Drug Evaluation of Atorvastatin versus Rosuvastatin in Pharmacotherapy of Korean Patients with Dyslipidemia. <i>Biomolecules and Therapeutics</i> , 2008, 16, 54-60.	1.1	2
6667	Development of validated bioanalytical HPLC-UV method for simultaneous estimation of amlodipine and atorvastatin in rat plasma. <i>Indian Journal of Pharmaceutical Sciences</i> , 2015, 77, 742.	1.0	12
6668	Suboptimal use of risk reduction therapy in peripheral arterial disease patients at a major teaching hospital. <i>Annals of Saudi Medicine</i> , 2011, 31, 371-375.	0.5	12
6669	Stroke management. <i>Annals of Indian Academy of Neurology</i> , 2011, 14, 82.	0.2	32
6670	Statins: Past and Present. <i>Heart Views</i> , 2011, 12, 121.	0.1	44
6671	Correlation of Friedewald's calculated low-density lipoprotein cholesterol levels with direct low-density lipoprotein cholesterol levels in a tertiary care hospital. <i>International Journal of Applied & Basic Medical Research</i> , 2017, 7, 57.	0.2	10
6672	Pleiotropic effects of statins. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015, 19, 554.	0.2	125
6673	Triglyceride and cardiovascular risk: A critical appraisal. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 418.	0.2	29
6674	Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients. <i>Advanced Biomedical Research</i> , 2014, 3, 168.	0.2	8
6675	Perioperative myocardial injury and infarction following non-cardiac surgery: A review of the eclipsed epidemic. <i>Saudi Journal of Anaesthesia</i> , 2020, 14, 91.	0.2	9
6676	Outcomes of a Multidisciplinary Partnership to Improve Cardiac Wellness: An Opportunity for Pharmacists. <i>The Consultant Pharmacist</i> , 2010, 25, 105-116.	0.4	6
6677	The Emerging Role of Statins in Glaucoma Pathological Mechanisms and Therapeutics. <i>Open Journal of Ophthalmology</i> , 2014, 04, 124-138.	0.1	9
6678	Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study. <i>EuroIntervention</i> , 2012, 7, 1420-1427.	1.4	5
6679	Glucose lowering effect of <i>Zornia gibbosa</i> Span extracts in diabetic rats. <i>Turkish Journal of Pharmaceutical Sciences</i> , 2018, 15, 339-346.	0.6	1
6680	The role of vitamin E in the prevention of cancer: a meta-analysis of randomized controlled trials. <i>Annals of Saudi Medicine</i> , 2007, 27, 409-414.	0.5	30
6681	The Elderly. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 180-185.	0.9	1
6682	Gender Disparities In Optimal Lipid Control Among Patients with Coronary Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21 Suppl 1, S20-S28.	0.9	17
6683	Effects of Low-Dose Simvastatin on the Distribution of Plasma Cholesterol and Oxidized Low-Density Lipoprotein in Three Ultra-centrifugally Separated Low-Density Lipoprotein Subfractions: 12- Month, Open-Label Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 1049-1053.	0.9	10

#	ARTICLE	IF	CITATIONS
6684	Pravastatin Potentiates Increases in Serum Adiponectin Concentration in Dyslipidemic Patients Receiving Thiazolidinedione: the DOLPHIN Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 1063-1069.	0.9	9
6685	Treatment - Drug Therapy. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 167-178.	0.9	4
6686	Elderly Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 223-227.	0.9	3
6687	Gene Expression Analysis for Statin-induced Cytotoxicity from Rat Primary Hepatocytes. <i>Genomics and Informatics</i> , 2010, 8, 41-49.	0.4	2
6688	Statin Therapy: Review of Safety and Potential Side Effects. <i>Acta Cardiologica Sinica</i> , 2016, 32, 631-639.	0.1	203
6689	Hypoalbuminaemia " A Marker of Cardiovascular Disease in Patients with Chronic Kidney Disease Stages II - IV. <i>International Journal of Medical Sciences</i> , 2008, 5, 366-370.	1.1	37
6690	Diffusing Innovation in Your Practice. , 2005, 9, 78-80.		1
6691	The Care Management Institute: Harvesting Innovation, Maximizing Transfer. , 2005, 9, 37-9.		2
6692	Collaborative Cardiac Care Service: A Multidisciplinary Approach to Caring for Patients with Coronary Artery Disease. , 2008, 12, 4-11.		23
6693	Community Implementation and Translation of Kaiser Permanente's Cardiovascular Disease Risk-Reduction Strategy. , 2011, 15, 36-41.		10
6694	Implementation and Methodology of a Multidisciplinary Disease-State-Management Program for Comprehensive Diabetes Care. , 2011, 15, 43-8.		18
6695	Association Between Total Cholesterol and All-Cause Mortality in Oldest Old: A National Longitudinal Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
6697	Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. <i>BMC Medical Research Methodology</i> , 2021, 21, 218.	1.4	4
6698	Benefit/risk ratio profile of single inhaler triple therapy for Chronic obstructive pulmonary disease patients. <i>Pulmonologiya</i> , 2021, 31, 645-652.	0.2	0
6699	Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor. <i>Global Cardiology Science & Practice</i> , 2021, 2021, e202119.	0.3	2
6700	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1575.	2.6	28
6701	Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 713007.	1.6	6
6704	Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101816.	0.7	22

#	ARTICLE	IF	CITATIONS
6705	Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies. <i>Thrombosis and Haemostasis</i> , 2022, 122, 445-455.	1.8	14
6706	Rac GTPase Signaling in Immune-Mediated Mechanisms of Atherosclerosis. <i>Cells</i> , 2021, 10, 2808.	1.8	9
6707	Challenges in Optimizing Lipid Management in Women. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1197-1220.	1.3	6
6708	O uso de estatinas no Acidente Vascular Cerebral. <i>Revista Neurociencias</i> , 2011, 19, 145-152.	0.0	0
6709	Tough targets are necessary in effective diabetes care. <i>BMJ: British Medical Journal</i> , 2002, 325, 775-775.	2.4	2
6710	Statine. <i>Pharma-Kritik (discontinued)</i> , 2002, 24, .	0.0	0
6711	Risk factor thresholds. <i>BMJ: British Medical Journal</i> , 2002, 325, 1114-1114.	2.4	0
6712	Medical Treatment of Carotid Artery Disease. <i>Japanese Journal of Neurosurgery</i> , 2003, 12, 362-369.	0.0	0
6713	Geneesmiddelen bij hart- en vaatziekten. , 2003, , 74-95.		0
6715	Lipidsenkende Mittel. , 2003, , 517-529.		0
6716	Therapie von Fettstoffwechselstörungen, Harnsäuremetabolismus bzw. Gicht. , 2003, , 533-552.		0
6717	Journal of JCS Cardiologists, 2003, 1(1), 141-146		0
6721	Interpretation of randomised trials is indeed open to debate. <i>BMJ: British Medical Journal</i> , 2003, 327, 752-b-752.	2.4	0
6722	Diabetes and the Heart. , 2003, , 51-84.		0
6723	Future Challenges. , 2003, , 215-224.		0
6724	Early detection of vascular disease in Type 2 Diabetes. , 2003, , 19-37.		0
6726	Angiographic and IVUS techniques evaluating progression and regression of coronary atherosclerosis. , 2003, , 73-95.		0
6727	The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). , 2003, , 175-188.		0

#	ARTICLE	IF	CITATIONS
6728	Statin therapy for the 21st century. , 2003, , 241-252.		0
6729	Der ganze Patient. , 2004, , 375-405.		0
6730	Long-Term Medical Management of Ischemic Stroke and Transient Ischemic Attack Due to Arterial Disease. , 2004, , 1129-1150.		0
6731	Sujetos a incluir en el anÃ¡lisis. , 2004, , 217-227.		0
6732	Treatment Strategies for Women With Stable Angina. , 2004, , 197-214.		0
6733	Gender and Its Impact on Risk Factors for Cardiovascular Disease. , 2004, , 193-214.		2
6734	Coronary Risk Factors. , 2004, , 328-330.		0
6735	Lipid Disorders in the Elderly. , 2004, , 178-181.		2
6736	Verordnungsprofil der Internisten. , 2004, , 1013-1041.		0
6737	Herz, GefÃ¤Ãe, Lunge. , 2004, , 81-196.		0
6738	DyslipoproteinÃmie. , 2004, , 367-376.		0
6739	Evaluation and Management of Hyperlipidemia for Stroke Prevention. , 2004, , 51-78.		0
6740	Elevated high-sensitivity C-reactive protein and interleukin-6 in chronic stroke patients-Effects of statin agents and subtype of stroke-. Nosotchu, 2004, 26, 423-429.	0.0	0
6741	The Principle Syndromes of Dementia. , 2004, , 1216-1233.		0
6742	What's New About Old Drugs. Journal of Gerontological Nursing, 2004, 30, 4-9.	0.3	0
6743	Lipidsenkende Mittel. , 2004, , 570-583.		0
6744	PrÃvention der koronaren Herzerkrankung. , 2004, , 1119-1147.		0
6745	PoblaciÃ³n de estudio. , 2004, , 132-139.		0

#	ARTICLE	IF	CITATIONS
6746	Weitere Organsysteme und Besonderheiten. , 2004, , 333-374.		0
6747	Lipid-Lowering Responses Modified by Genetic Variation. Handbook of Experimental Pharmacology, 2004, , 107-147.	0.9	1
6748	Kardiologie. , 2004, , 313-356.		0
6749	Lipidsenkende Mittel. , 2004, , 641-658.		0
6750	Molekulare Grundlagen altersspezifischer Erkrankungen des Herz-Kreislauf-Systems und der Arteriosklerose. , 2004, , 371-401.		2
6751	Prevention of coronary heart disease. BMJ: British Medical Journal, 2004, 328, 404.2.	2.4	1
6752	The poorly controlled type 2 diabetic patient. , 2004, , 197-231.		1
6754	Tutorials in Therapeutics Should Cholesterol Level be lowered below "Normal"? Insights from the Heart Protection Study. Qatar Medical Journal, 2004, 2004, .	0.2	0
6755	STATINS. Neurology Today: an Official Publication of the American Academy of Neurology, 2004, 4, 28-29.	0.0	1
6757	Bedside Platelet Monitoring. , 2004, , 495-520.		0
6758	PIES Method of Critique. Critical Pathways in Cardiology, 2004, 3, 205-208.	0.2	7
6759	Treatment of Vulnerable Plaques. , 2004, , 164-202.		0
6760	Risk Factors and Prevention, Including Hyperlipidemias. , 2005, , 419-437.		0
6762	Advances in the Acute Treatment and Secondary Prevention of Stroke. , 2005, , 21-33.		0
6763	Autoimmune hepatitis induced by pravastatin: two cases. Acta Hepatologica Japonica, 2005, 46, 133-141.	0.0	2
6764	Initial Evaluation and Follow-Up Assessment. , 2005, , 295-304.		0
6765	Plant Stanol Ester as a Cholesterol-Lowering Ingredient of Benecol® Foods. , 2005, , .		0
6766	Statin prescribing in primary care. Independent Nurse, 2005, 2005, .	0.0	0

#	ARTICLE	IF	CITATIONS
6767	The Care Management Institute: Making the Right Thing Easier to Do. , 2005, 9, 56-7.		2
6768	From Evidence to Outcomes: Implementing Clinically Effective and Cost-Efficient Population-Based Interventions. , 2005, 9, 63-4.		0
6769	With what to treat which patient with recently symptomatic carotid stenosis?. Practical Neurology, 2005, 5, 68-83.	0.5	1
6770	Periphere arterielle Verschlusskrankheit. Pharma-Kritik (discontinued), 2005, 26, .	0.0	0
6772	Screening for type 2 diabetes. , 2005, , 714-750.		0
6773	The effectiveness and safety of Tulip in patients with hyperlipidemia. Arterial Hypertension (Russian) Tj ETQq1 1 0.784314 rgBT /Overlo 0.1	0.1	0
6774	Antioxidants and cardiovascular disease. , 2005, , 220-238.		0
6775	Prescribing for dyslipidaemia. Independent Nurse, 2005, 2005, .	0.0	0
6776	Stroke Prevention, Blood Cholesterol and Statins. Neurological Disease and Therapy, 2005, , 123-150.	0.0	0
6778	Antihypertensives - Making the right choice. Independent Nurse, 2005, 2005, .	0.0	0
6780	Cardiovascular Risk Assessment. , 2005, , 12-30.		0
6781	Atorvastatin in Patients With Type 2 Diabetes Mellitus Undergoing Hemodialysis. Yearbook of Endocrinology, 2006, 2006, 114-117.	0.0	0
6782	Statin-Induced Myopathy. , 2006, , 389-395.		0
6783	Implications of Changing National Cholesterol Education Program Goals for the Treatment and Control of Hypercholesterolemia. Journal of General Internal Medicine, 2006, .	1.3	0
6785	Is er nog plaats voor fibrinaten allÃ©n, of moet altijd een statine eerst worden gebruikt en bij slecht resultaat een fibraat toegevoegd?. , 2006, , 2137-2137.		0
6786	Medical Treatment of Peripheral Arterial Disease. , 2006, , 271-292.		0
6787	The benefits and pitfalls of evidence-based medicine. Cor Et Vasa, 2006, 48, 24-31.	0.1	3
6788	Is het zinvol patiÃ«nten met familiale hypercholesterolemie naast statines ook met een plaatjesaggregatieremmer te behandelen?. , 2006, , 2098-2099.		0

#	ARTICLE	IF	CITATIONS
6789	Epidemiology of Cerebrovascular Disease * *This work was supported in part by the National Institute of Neurological Disorders and Stroke Grant No. 5R01 NS17950 and the National Heart, Lung, and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195.. , 2006, , 411-432.		0
6791	Measurement of Atherogenic Lipoproteins in Cardiovascular Risk Assessment. , 2006, , 497-517.		0
6792	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2006, , 133-140.		0
6793	Anormalidades lipídicas y reducción de factores de riesgo. , 2006, , 620-627.		0
6794	The Interpretation of the P-Values. , 2006, , 103-115.		0
6795	Medical Management of Peripheral Arterial Disease:A Therapeutic Algorithm. Journal of Endovascular Therapy, 2006, 13, 11-19-11-29.	0.8	2
6796	Statins and Toxicity. , 2006, , 273-295.		1
6797	Statins, Inflammation, and Cardiomyopathy: Old Pathways, New Targets. Fundamental and Clinical Cardiology, 2006, , 155-166.	0.0	0
6798	Angiotensin II antagonists, diabetes and metabolic syndrome. , 2006, , 99-109.		0
6799	Secondary Prevention of Coronary Heart Disease in Primary Health Care. Bosnian Journal of Basic Medical Sciences, 2018, 6, 37-41.	0.6	2
6800	Hypolipidemic Therapy. Nutrition and Disease Prevention, 2006, , 31-61.	0.1	0
6801	Should we lower cholesterol as much as possible?: Cholesterol is good?. BMJ: British Medical Journal, 2006, 332, 1453.1.	2.4	0
6802	The Metabolic Syndrome: Identification and Management of the Patient at High Risk for Cardiovascular Disease. Fundamental and Clinical Cardiology, 2006, , 409-440.	0.0	0
6803	Women and Coronary Heart Disease. Fundamental and Clinical Cardiology, 2006, , 689-720.	0.0	0
6804	Stroke Prevention. Fundamental and Clinical Cardiology, 2006, , 545-584.	0.0	0
6806	Cardiovascular Disease in Racial and Ethnic Minorities. Fundamental and Clinical Cardiology, 2006, , 721-751.	0.0	1
6807	Safety of Dyslipidemic Agents. Fundamental and Clinical Cardiology, 2006, , 389-408.	0.0	0
6808	Type 2 Diabetes. Fundamental and Clinical Cardiology, 2006, , 187-254.	0.0	0

#	ARTICLE	IF	CITATIONS
6809	Vascular Biology of the Metabolic Syndrome. , 2006, , 79-108.		1
6810	The case for a generic statin. Independent Nurse, 2006, 2006, .	0.0	0
6811	Case 7. Lipid-Modifying Therapy In A Person With Diabetes And An Acute Coronary Syndrome. , 2006, , 43-48.		0
6812	Sudden cardiac death: the size of the problem. , 2006, , 25-36.		0
6814	Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. , 2007, , 141-156.		0
6815	Frequently cited criticisms. , 2007, , 205-213.		0
6816	Pharmacological Therapy for Cardiovascular Disease. , 2007, , 121-148.		1
6820	Peripheral Arterial Diseases. , 2007, , 1681-1703.		0
6821	Special Considerations in Research. , 2007, , 275-350.		0
6822	Aging and the Cardiovascular System. , 2007, , 2439-2451.		0
6823	Chronic Stable Angina. , 2007, , 290-313.		0
6824	Series: Lab medicine in primary care Biochemical liver function tests. BMJ, The, 2007, 334, 070115.	3.0	0
6826	Lowering Low-Density Lipoprotein Cholesterol Levels to Reduce Atherosclerotic Coronary Heart Disease Risk. , 2007, , 221-240.		0
6827	Pharmacologic Therapy for Hypertriglyceridemia and Low HDL: Rationale for Combination Therapy. , 2007, , 515-527.		0
6829	Study on Drugs Prescribed for Treatment of Hyperlipidemia. Iryo Yakugaku (Japanese Journal of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 18	0.0	0
6830	Complementary and Alternative Medicine. , 2007, , 7-44.		3
6831	Management of Cholesterol Disorders. , 2007, , 2667-2691.		0
6832	Atherosclerosis: Pathogenesis, Morphology, and Risk Factors. , 2007, , 1593-1613.		2

#	ARTICLE	IF	CITATIONS
6858	Traitement des dyslipidémies. , 2008, , 443-462.		0
6859	Japanese Journal of Clinical Pharmacology and Therapeutics. 2008; 39(4): 343-348.		0
6860	Cholesterol: a Century of Research and Debate. Libyan Journal of Medicine, 2008, 3, 63-63.	0.8	1
6861	Interventional Trials of Antioxidants. , 2008, , 25-50.		0
6862	Dietary Prevention of Coronary Heart Disease. , 2008, , 227-242.		1
6863	Akutes Koronarsyndrom, Myokardinfarkt, instabile Angina pectoris. , 2008, , 407-428.		1
6864	CHOLESTEROL: A CENTURY OF RESEARCH AND DEBATE. Libyan Journal of Medicine, 2008, 3, 64-64.	0.8	2
6866	Biochemical Aspects, Laboratory Diagnosis and Follow-Up of High Blood Cholesterol: NCEP ATP III Guidelines. Journal of Medical Biochemistry, 2008, 27, 64-85.	0.7	0
6867	La maladie d'Alzheimer : des mécanismes moléculaires aux perspectives thérapeutiques. Bulletin De L'Académie Nationale De Médecine, 2008, 192, 363-380.	0.0	6
6868	Modern pharmacotherapy: opportunities to effect outcomes of chronic obstructive pulmonary disease. Pulmonologiya, 2008, , 110-114.	0.2	0
6869	Management of Peripheral Arterial Disease in the Elderly. Fundamental and Clinical Cardiology, 2008, , 749-768.	0.0	0
6872	Redeeming Measure of Atorvastatin in the Risk Factors of Cardiovascular Disease. International Journal of Pharmacology, 2008, 4, 305-309.	0.1	5
6873	Pharmacological treatment in peripheral arterial disease. , 2008, , 811-821.		0
6874	Tocotrienols and the Regulation of Cholesterol Biosynthesis. , 2008, , 237-256.		0
6875	Deciding When Blood Pressure Is Too High. , 2009, , 73-94.		0
6876	Effect of Simvastatin on the spectrum of blood plasma fat acids change in the patients with ischemia heart disease. Bulletin of Siberian Medicine, 2008, 7, 13-19.	0.1	0
6877	Lipid Screening in Children and Adolescents. Pediatric Annals, 2008, 37, 757-62.	0.3	0
6878	Evolving Targets of Therapy. , 2009, , 387-395.		0

#	ARTICLE	IF	CITATIONS
6879	Acute Ischemic Stroke. , 2009, , 57-75.		1
6880	Prise en charge des diabétiques. , 2009, , 105-117.		0
6882	Which Therapy for Which Condition?. , 2009, , 388-458.		1
6884	REGULATIONS AND PHARMACOVIGILANCE. , 2009, , 29-40.		0
6886	Invasive Imaging Modalities and Atherosclerosis: The Role of Intravascular Ultrasound. , 2009, , 410-419.		1
6887	Y a-t-il une place pour les régimes alimentaires restrictifs chez la personne âgée?. , 2009, , 131-140.		1
6888	Dyslipidemia in Racial/Ethnic Groups. , 2009, , 119-138.		1
6889	Reduction of carotid arterial plaque volume during fluvastatin treatment assessed by three-dimensional (3D) ultrasonography. Neurosonology, 2009, 22, 74-78.	0.0	2
6890	Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. , 2009, , 279-317.		1
6891	Coronary Artery Disease Prevention. , 2009, , 17-32.		0
6892	Lipid Disorders. , 2009, , 65-75.		0
6893	NHG-Standaard Cardiovasculair risicomanagement. , 2009, , 106-152.		4
6894	Malattie cerebrovascolari dell'encefalo. , 2009, , 3-39.		0
6895	Intravascular Ultrasound. , 2009, , 83-93.		0
6896	CMS and Type 2 Diabetes Mellitus: Bound Together by the Renin Angiotensin Aldosterone System. , 2009, , 187-206.		0
6897	Treatment Guidelines Overview. , 2009, , 202-216.		0
6898	Noninvasive Imaging Modalities and Atherosclerosis: The Role of Ultrasound. , 2009, , 420-431.		1
6899	Special Patient Populations: Acute Coronary Syndromes. , 2009, , 473-485.		0

#	ARTICLE	IF	CITATIONS
6900	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2009, , 87-105.		1
6902	Achieving lipid targets with combination therapy. Independent Nurse, 2009, 2009, .	0.0	0
6903	PrÃ©vention de la dÃ©pendance : le dÃ©fi de la longÃ©vitÃ©. Bulletin De L'Academie Nationale De Medecine, 2009, 193, 455-471.	0.0	3
6904	Estatinas en la insuficiencia cardiaca. Acta Medica Costarricense, 2009, 51, .	0.1	0
6905	Recent advances in management of cerebrovascular diseases. F1000 Medicine Reports, 2009, 1, .	2.9	0
6906	Clinical Pharmacology of Cardiovascular Drugs. , 2009, , 367-402.		0
6907	Nutrition, Metabolic Syndrome, and Diabetes in the Senior Years. , 2010, , 389-417.		1
6908	Prevention of Cardiovascular Disease. , 2009, , 403-436.		0
6910	The ESCAPE randomized clinical trial: 20-80 mg of Zokor (Simvastatin) in patients with familial hypercholesterolemia in ischemia heart disease. Part 1. Hypolipidemic efficacy, safety and tolerance. Arterial Hypertension (Russian Federation), 2009, 15, 543-549.	0.1	0
6913	The Frail Elderly Patient with Heart Disease. , 2010, , 295-299.		1
6920	AthÃ©rosclÃ©rose. , 2010, , 287-491.		0
6921	Op welke leeftijd kan een statine worden gestopt?. , 2010, , 59-63.		0
6922	PrÃ©vention des rÃ©cidives d'Ã©vÃ©nement vasculaire cÃ©rÃ©bral. , 2010, , 19-25.		0
6923	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2010, , 165-172.		0
6926	Bewegungstherapie bei koronarer Herzkrankheit. , 2010, , 115-142.		1
6927	Is het zinvol patiÃ«nten met familiale hypercholesterolemie naast statines ook met een plaatjesaggregatieremmer te behandelen?. , 2010, , 64-67.		0
6928	Clinical Effects of Statin in Elderly Patients with Acute Myocardial Infarction and Left Ventricular Dysfunction Who underwent Percutaneous Coronary Intervention. Chonnam Medical Journal, 2010, 46, 74.	0.1	0
6931	Early Initiation of Statin Treatment Immediately after Acute Myocardial Infarction Improves Clinical Outcomes. Chonnam Medical Journal, 2010, 46, 25.	0.1	0

#	ARTICLE	IF	CITATIONS
6932	Diabetic Kidney Disease. , 2010, , 319-339.		0
6933	Assessment of Cardiovascular Calcium: Interpretation, Prognostic Value, and Relationship to Lipids and Other Cardiovascular Risk Factors. , 2010, , 39-57.		0
6934	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2010, , 788-807.		0
6935	A Time to Live: Dynamic Changes in Risk as the Basis for Therapeutic Triage. , 2011, , 597-601.		0
6936	Role of Noninvasive Imaging using CT for Detection and Quantitation of Coronary Atherosclerosis. , 2011, , 335-349.		0
6937	Evidence-based data on Simvastatin: A 15-year experience. Arterial Hypertension (Russian Federation), 2010, 16, 238-249.	0.1	0
6938	The Metabolic Syndrome: 2009. , 2011, , 137-163.		0
6939	Management of Dyslipidemia. , 2011, , 59-89.		0
6940	Unstable Angina and Non-ST Elevation Myocardial Infarction. , 2011, , 195-225.		0
6941	Pharmacological Prerequisites for Treatment of Complex Patients with Peripheral Artery Disease. , 2010, , 10-21.		0
6943	Strategies for Treating Abnormal Lipid Profiles with Drugs. , 2011, , 163-193.		1
6944	Gender Differences in Coronary Risk Factors and Risk Interventions. , 2011, , 253-299.		0
6945	Rust and Rupture: Atherosclerosis. , 2011, , 89-97.		0
6946	Diabetic Dyslipidemia. , 2011, , 213-238.		1
6947	Current Therapy Targeting Oxidative Stress: Statin. , 2011, , 351-366.		0
6950	Nutritional Impact on the Nitric Oxide Pathway. , 2011, , 97-122.		0
6951	Behandelbare somatische Risikofaktoren. , 2011, , 317-336.		0
6953	Kardiovaskuläre Risikofaktoren und deren therapeutische Beeinflussung. , 2011, , 1-12.		1

#	ARTICLE	IF	CITATIONS
6954	The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice. <i>Medical Science Monitor</i> , 2011, 17, CR683-CR686.	0.5	6
6955	Correlation between LDL-cholesterol and C-reactive protein among an apparently healthy population in the city of Athens. <i>Health</i> , 2011, 03, 338-342.	0.1	0
6957	Kardiovaskuläre Erkrankungen. , 2011, , 1-186.		0
6959	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2011, , 341-359.		0
6960	Risk Factors for Atherosclerosis in the Elderly. , 2011, , 635-648.		0
6961	Lower Limb Peripheral Vascular Disease. , 2011, , 1347-1369.		1
6962	Treatment of Dyslipidemia in Patients with Renal Insufficiency and End-Stage Renal Disease. , 2011, , 205-218.		0
6963	Lipid management after a coronary event. , 2011, , 328-337.		0
6964	Insuffisance R�onale et Vaisseaux. , 2011, , 553-579.		0
6965	Complications Vasculaires du Diab�te. , 2011, , 541-552.		0
6966	Disorders of Lipid Metabolism. , 2011, , 1633-1674.		5
6967	Cardiovascular Aging. , 2011, , 415-432.		3
6968	Absolute risk, relative risk, and number needed to treat. <i>BMJ</i> , The, 0, , d146.	3.0	0
6972	Hyperlipidemia. , 2012, , 141-151.		1
6973	Dynamics of clinical, functional, and immune parameters in patients with myocardial infarction and early fluvastatin administration. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2011, 10, 52-58.	0.4	0
6974	Long-Term Follow-Up of Cognitive Function and Activities of Daily Living in Older People: A Feasibility Study in the PROSPER Cohort. <i>The Open Clinical Trials Journal</i> , 2011, 3, 6-12.	0.0	0
6975	Disturbed Chylomicron Metabolism in Type 2 Diabetes - A Preventable Cause of Atherosclerosis?. , 0, , .		0
6976	Secondary Prevention Strategies. , 2012, , 169-182.		0

#	ARTICLE	IF	CITATIONS
6977	Lipid-lowering therapy in elderly patients: Focus on statins and outcome. Arterial Hypertension (Russian Federation), 2011, 17, 415-424.	0.1	1
6980	Diabetes and Coronary Heart Disease. , 2012, , 471-484.		0
6981	The Interpretation of the p-Values. , 2012, , 119-131.		0
6982	Plant sterols and stanols as dietary factors reducing hypercholesterolemia by inhibiting intestinal cholesterol absorption. Cardiovascular Therapy and Prevention (Russian Federation), 2011, 10, 124-132.	0.4	2
6983	Dietary Paradoxes to Optimize Cardiovascular Risk Management in Chronic Kidney Disease. , 2012, , 213-237.		0
6984	Les enjeux de la prÃ©vention. Gerontologie Et Societe, 2012, vol. 35 / HS nÂ° 1, 27-40.	0.1	2
6985	Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease. Southern Medical Journal, 2012, 105, 48-55.	0.3	3
6986	Lifestyle Interventions and Behavior Change. , 2012, , 100-111.		0
6988	39 Perifere arteriÃ«n. , 2012, , 459-469.		0
6990	Krankheiten des Herzens. , 2012, , 335-393.		0
6991	Predictors of plaque area for culprit lesion in patients with ischemic heart disease who underwent percutaneous coronary intervention. Journal of the Japanese Coronary Association, 2012, 18, 21-29.	0.0	0
6993	The impact of simvastatin vs. atorvastatin on cognitive function in obese hypertensives. Arterial Hypertension (Russian Federation), 2012, 18, 228-234.	0.1	0
6995	Treatment algorithm in patients with stable angina. , 2012, , 312-330.		0
6998	How to avoid statin hepatotoxicity in patients with obesity and liver disease? Focus on the combination of ursodeoxycholic acid and atorvastatin. Cardiovascular Therapy and Prevention (Russian Federation), 2012, 11, 81-84.	0.4	1
7001	Role of Lipoproteins in Carotid Arterial Disease. , 2013, , 29-36.		0
7002	Oral low-dose estradiol plus norethisterone acetate with or without simvastatin in dyslipidemic and symptomatic menopausal women: A randomized clinical trial. Health, 2013, 05, 110-118.	0.1	0
7003	Intravascular infusion of autologous delipidated plasma induces antiatherogenic lipoproteins and causes regression of atherosclerosis
â€”Studies in non-primates, monkeys and humans. Health, 2013, 05, 19-33.	0.1	2
7005	Exact P-Values and Their Interpretation. , 2013, , 47-61.		0

#	ARTICLE	IF	CITATIONS
7011	Dyslipidemia. , 2014, , 489-502.		1
7012	Classification of Cardiovascular Disease Risk and Cardiovascular Disease Prevention in Women. , 2014, , 13-42.		0
7013	CVD in CKD: Focus on the Dyslipidemia Problem. , 2014, , 67-91.		0
7014	How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly. , 2014, , 45-65.		0
7016	Vascular Complications of Diabetes Mellitus. , 2014, , 1-65.		0
7017	Dyslipidemias in the Geriatric Chronic Kidney Disease Patients. , 2014, , 255-267.		0
7018	Nongenetic Risk Factors for Alzheimerâ€™s Disease. , 2014, , 77-92.		0
7019	Monitoring the Progression and Regression of Coronary Atherosclerosis with Intravascular Ultrasound. Contemporary Cardiology, 2014, , 67-79.	0.0	0
7020	Interventional Treatment of the Chronic Ischemic Syndromes of the Lower Extremity. , 2014, , 1-37.		0
7021	Vitamin D Status, C-Reactive Protein and Risk of Coronary Artery Diseaseâ€”A Hospital-Based Study. Pharmacology & Pharmacy, 2014, 05, 1148-1156.	0.2	0
7022	Medical Management of Coronary Artery Disease. , 2014, , 1-17.		0
7023	PERIFERINIÄ² ARTERIJÄ² OKLIUZINÄ–S LIGOS YPATUMAI SERGANT CUKRINIÜ DIABETU: LITERATÄ²ROS APÄ½VALGA. Medicinos Teorija Ir Praktika, 2014, 20, 401-409.	0.0	0
7025	The Current Status of Statins in Stroke Prevention. Journal of Neurology & Stroke, 2014, 1, .	0.0	0
7026	PAD and Claudication. , 2015, , 85-100.		0
7027	Hallmark Clinical Trials. Contemporary Cardiology, 2015, , 675-727.	0.0	0
7029	Adding CT Measurements of Coronary Artery Calcification to Nuclear Myocardial Perfusion Imaging for Risk Stratification. , 2015, , 225-239.		0
7030	Medical Management of Coronary Artery Disease. , 2015, , 2369-2382.		0
7031	Atherosclerotic Peripheral Artery Disease: Clinical Management. , 2015, , 2983-3006.		0

#	ARTICLE	IF	CITATIONS
7032	Interventional Treatment of the Chronic Ischemic Syndromes of the Lower Extremity. , 2015, , 3119-3149.		0
7033	Raised Blood Cholesterol: Preventable Risk Factor for Cardiovascular Disease. , 2015, , 69-79.		0
7034	Peripheral Vascular Disease-Epidemiology, Natural History, Risk Factors. , 2015, , 2973-2982.		0
7035	Koronare Herzkrankheit â€“ Allgemeine und interventionelle Therapie. , 2015, , 1-33.		0
7036	ZerebrovaskulÃre Erkrankungen â€“ Hirnblutungen. , 2015, , 1-5.		0
7037	Pharmacogenetics of Adverse Drug Reactions. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 109-156.	0.6	0
7038	Cardiovascular Disease in Women: An Update. , 2015, , 129-141.		0
7039	The Effect of the Treatment on the Risk Factors of Arteriosclerotic Diseases in the Elderly: Investigating the Specific Health Checkup. Journal of St Marianna University, 2015, 6, 41-45.	0.1	0
7040	ZerebrovaskulÃre Erkrankungen â€“ zerebrale IschÃmie. , 2015, , 1-6.		0
7041	Effects of Exercise on Lipid-Lipoproteins. Molecular and Translational Medicine, 2015, , 285-300.	0.4	0
7042	Diabetic Nephropathy in Children. , 2016, , 1545-1568.		0
7043	è,,,è³ªç•°â„ç—†æ²»»ç™,ã@ç³/4çš¶ã•ã¿fè¡çç©¡ç—...æ®•ã½™ãfªã,1ã,ãã®ã³/4ã¿æ. Journal of JCS Cardiologists, 2016,24, 230-236.		0
7044	Coronary Artery Disease and Cardiomyopathy. , 2016, , 1-21.		0
7045	Statin Myopathy. , 2016, , 113-122.		0
7046	Prevalence, Treatment Pattern and Resource Use in Patients with Mixed Dyslipidemia Using Lipid Modifying Agents in Korea (PRIMULA): An Observational Study. Journal of Lipid and Atherosclerosis, 2016, 5, 121.	1.1	0
7047	ArtÃriopathie du sujet ÃgÃ©. , 2016, , 475-476.		0
7048	The Stroke Prevention Programme: a programme of research to inform optimal stroke prevention in primary care. Programme Grants for Applied Research, 2016, 4, 1-290.	0.4	2
7049	Statin therapy for elderly patients should be assessed for each individual. Clinical Research in Practice the Journal of Team Hippocrates, 2016, 2, .	0.0	0

#	ARTICLE	IF	CITATIONS
7050	COMPLICATIONS OF STATIN THERAPY AND THEIR MANAGEMENT. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 4745-4750.	0.1	0
7052	Coronary Artery Disease and Cardiomyopathy. , 2017, , 1-21.		0
7053	Coronary Artery Disease and Cardiomyopathy. , 2017, , 637-657.		0
7054	Stroke Pharmacogenetics. , 2017, , 327-410.		0
7055	Role of Duplex Ultrasound in Carotid Screening. , 2017, , 139-150.		0
7056	Arterial Complications in Patients with Cancer. , 2018, , 93-115.		0
7057	Assessment of Atorvastatin Effect on Body Weight and Blood Glucose Levels Among Diabetic and Non-Diabetic Patients. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2017, 24, 255-262.	0.3	0
7058	A comparison of the effectiveness of rosuvastatin, atorvastatin and simvastatin in achieving target lipid levels (according to the PROFILE-I registry). Journal of Clinical Medicine of Kazakhstan, 2017, 4, 20-25.	0.1	0
7059	Epidemiology of hypercholesterolemia. Vnitri Lekarstvi, 2018, 64, 30-37.	0.1	1
7060	Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. Advances in Medical Diagnosis, Treatment, and Care, 2018, , 320-342.	0.1	0
7061	General view and medical therapy for polyvascular disease. Journal of the Japanese Coronary Association, 2018, 24, 101-104.	0.0	0
7062	ZerebrovaskulÄre Erkrankungen â€“ Hirnblutungen. , 2018, , 717-721.		0
7063	Strategy for coronary artery disease complicated with peripheral artery disease. Journal of the Japanese Coronary Association, 2018, 24, 112-118.	0.0	0
7064	Traitement des dyslipidÃ©mies. , 2018, , 123-139.e1.		0
7065	Effect of Aerobic and Anaerobic Exercises on Anthropometric Parameters, Chemerin and Adiponectin Levels in Non-Athletic Men. Health Scope, 2018, 7, .	0.4	0
7066	The Effects of a Flavonoid-Rich Diet on Oxidative Stress, Inflammation, and Lipid Profile after Elective Percutaneous Coronary Intervention : A Randomized Clinical Trial. Preventive Nutrition and Food Science, 2018, 23, 108-114.	0.7	3
7068	New clinical and pharmacological aspects of the use of atorvastatin for primary and secondary prevention of complications of cardiovascular diseases. Meditsinskiy Sovet, 2018, , 110-117.	0.1	0
7070	Statin therapy in elderly patients. Vnitri Lekarstvi, 2018, 64, 1021-1027.	0.1	0

#	ARTICLE	IF	CITATIONS
7071	Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. , 2019, , 218-240.		0
7072	INVESTIGATION OF THE INTERNAL RISK FACTORS INFLUENCE ON THE TIME OF THE ISCHEMIC STROKE ONSET. World of Medicine and Biology, 2019, 15, 021.	0.1	0
7073	ZerebrovaskulÄre Erkrankungen â€œ zerebrale IschÄmie. , 2019, , 481-486.		0
7074	Paradoxes in Old Age. , 2019, , 18-18.		0
7075	Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. , 2019, , 593-615.		0
7076	Current Medical and Surgical Stroke Prevention Therapies for Patients with Carotid Artery Stenosis. Current Neurovascular Research, 2019, 16, 96-103.	0.4	2
7077	CLINICAL AND ANGIOGRAPHIC PROFILE OF CALCIFIC VS. NON-CALCIFIC CORONARY LESIONS. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 1715-1718.	0.0	0
7078	ATORVASTATIN IN ACUTE STROKE: A STEPPING STONE TO THE SERENDIPITY. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 1645-1648.	0.0	0
7079	COMPARING THE SAFETY AND EFFICACY OF ROSUVASTATIN AND ATORVASTATIN IN PATIENTS WITH CORONARY HEART DISEASES. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 2415-2417.	0.0	0
7080	The application of the STOPP/START criteria in the elderly patients with type 2 diabetes mellitus and essential hypertension at the endocrinology department of a multidisciplinary hospital. Arterial Hypertension (Russian Federation), 2019, 25, 214-224.	0.1	1
7082	Prescription Selection and Dosing. , 2020, , 169-175.		0
7083	Statins and the risk of cataract. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 75-79.	0.4	0
7084	LDL como objetivo terapÄutico. ClÄnica E Investigaci3n En Arteriosclerosis, 2019, 31, 1-15.	0.4	2
7085	Management of acute coronary syndrome. , 2020, , 3626-3655.		0
7086	Evaluation of the effectiveness of lipid-lowering agents. UÄenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2020, 26, 78-85.	0.0	0
7087	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS,) Tj ETQq1 1 0.784314 rgBT TREATMENT OF ATHEROSCLEROSIS (2020). Eurasian Heart Journal, 2020, , 6-29.	0.2	28
7088	History of Lipidology. Contemporary Cardiology, 2021, , 1-9.	0.0	0
7089	Management of Hypertriglyceridemia (Including Fibrates and n-3 FattyÄAcids). Contemporary Cardiology, 2021, , 295-306.	0.0	1

#	ARTICLE	IF	CITATIONS
7090	Prevention of Ischemic Stroke. Contemporary Cardiology, 2021, , 581-609.	0.0	0
7091	Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition. Contemporary Cardiology, 2021, , 269-294.	0.0	0
7092	The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. Contemporary Cardiology, 2021, , 121-138.	0.0	0
7093	Pharmacology of Statins. Contemporary Cardiology, 2021, , 191-205.	0.0	0
7094	Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. Global Cardiology Science & Practice, 2020, 2020, e202039.	0.3	2
7095	Management of Dyslipidaemia in the Elderly. Contemporary Cardiology, 2021, , 489-505.	0.0	0
7097	A cross-sectional study to evaluate cardiovascular risk score in type 2 diabetes mellitus. International Journal of Applied & Basic Medical Research, 2020, 10, 276.	0.2	0
7098	Lower Extremity Ischemia. , 2020, , 331-347.		0
7099	Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib. ACS Symposium Series, 2020, , 339-372.	0.5	1
7101	Atherogenic dyslipidemia typical for metabolic syndrome. Vnitri Lekarstvi, 2020, 66, 15-20.	0.1	0
7102	Analysis of drug prescription appropriateness according to the STOPP/START criteria of the elderly patients with type 2 diabetes mellitus in the endocrinology department of a multi-speciality hospital. Russian Journal of Geriatric Medicine, 2020, , 47-56.	0.3	2
7103	Primary Cardiovascular Disease Prevention: Risk Factors Control vs. Imaging Subclinical Atherosclerosis. International Cardiovascular Forum Journal, 0, 19, .	1.1	0
7104	Medical Management for Secondary Stroke Prevention. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 435-456.	0.4	6
7105	Are statins effective in the prevention of dementia?. Evidence-Based Practice, 2021, 24, 38-39.	0.0	0
7106	A practical approach to lipid management in the elderly. Journal of Nutrition, Health and Aging, 0, , .	1.5	0
7107	Krankheiten des Herzens. , 2008, , 311-373.		0
7109	COMMENTARY: CANCER IN THE ELDERLY: PREVENTION AND BETTER CARE NEEDED. , 2006, , 153-158.		0
7111	Assessment of Cardiovascular Calcium: Interpretation and Relevance of Calcium Scoring Relationship to Lipids and Other Cardiovascular Risk Factors. , 2006, , 81-96.		0

#	ARTICLE	IF	CITATIONS
7112	Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. <i>Journal of General Internal Medicine</i> , 2006, 21, 171-6.	1.3	14
7115	Lipidsenkende Mittel. , 0, , 698-715.		0
7116	Spezielle therapeutische Probleme im hÄrteren Alter. , 2005, , 98-122.		0
7117	Lipide. , 2005, , 362-377.		0
7118	The Role of the Neurologist in Assessment and Management of Individuals with Acquired Brain Injury. , 2007, , 39-63.		1
7120	Risk Factors. , 2005, , 475-516.		0
7121	Stable Angina. , 2005, , 451-470.		0
7122	Heart Disease in the Elderly. , 2005, , 705-727.		0
7123	Dyslipidemia Associated With Diabetes and Insulin Resistance Syndromes. , 2006, , 193-212.		0
7124	The New Endocrinologist. , 2006, , 1-8.		0
7125	Innovative Models for the Delivery Preventive Cardiovascular Care. , 2006, , 325-338.		0
7126	Hallmark Clinical Trials. , 2007, , 381-394.		0
7127	Controversies in Evaluation and Management of Lipid Disorders in Diabetes. , 2008, , 291-315.		0
7129	Effectiveness of using rosuvastatin in difficult-to-control dyslipidemia patients: an audit in secondary care. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 895-900.	0.2	0
7131	Extracranial Carotid Artery Disease. , 2007, , 137-153.		0
7132	Endovascular Treatment of Carotid Stenosis. , 2007, , 181-199.		0
7133	Lipids and Peripheral Arterial Disease. , 2007, , 35-40.		0
7135	Stellenwert der frÄhzeitigen Diagnostik und Behandlung der Peripheren Arteriellen Verschlusskrankheit fÄr die PrÄvention kardiovaskulÄrer Ereignisse. , 2008, , 787-805.		1

#	ARTICLE	IF	CITATIONS
7136	Kardiovaskuläre Risikofaktoren und deren therapeutische Beeinflussung. , 2009, , 1-12.		0
7137	The effects of one-year simvastatin therapy on women's bone mineral density. Central European Journal of Medicine, 0, , .	0.0	0
7138	Biomarkers of Alzheimer disease in plasma. Neurotherapeutics, 2004, 1, 226-234.	2.1	0
7139	Early, aggressive lipid management in the treatment of acute coronary syndromes. Therapy: Open Access in Clinical Medicine, 2004, 1, 213-216.	0.2	0
7140	Hypertension and Hypercholesterolemia: is it Time for Anti-Lipitensive Therapy?. Rational Pharmacotherapy in Cardiology, 2020, 16, 842-851.	0.3	0
7141	LIPID PROFILE AND CHRONIC RENAL FAILURE. , 2020, , 79-80.		0
7142	Association of small dense LDL-cholesterol with disease severity, hypertension status and clinical outcome in patients with coronary artery disease. Journal of Hypertension, 2021, 39, 511-518.	0.3	9
7144	Can statins reduce risk of lung cancer, especially among elderly people? A meta-analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 679-88.	0.7	4
7145	Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?. Cmaj, 2003, 168, 1689.	0.9	1
7146	Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Cmaj, 2003, 169, 921-4.	0.9	87
7147	The use of cholesterol-lowering medications after coronary revascularization. Cmaj, 2003, 169, 1153-7.	0.9	1
7148	Tough targets are necessary in effective diabetes care. BMJ, The, 2002, 325, 775.	3.0	0
7149	Risk factor thresholds. Threshold is 37 000 pounds sterling per QALY. BMJ, The, 2002, 325, 1114; author reply 1114.	3.0	0
7150	Metabolic syndrome and type 2 diabetes: the Hong Kong perspective. Clinical Biochemist Reviews, 2005, 26, 51-7.	3.3	4
7151	Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. Preventing Chronic Disease, 2005, 2, A05.	1.7	3
7152	Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD. British Journal of General Practice, 2005, 55, 369-75.	0.7	15
7153	Barriers to detecting and treating hypercholesterolaemia in patients with ischaemic heart disease: primary care perceptions. British Journal of General Practice, 2005, 55, 534-8.	0.7	25
7154	Advances in diabetes for the millennium: vitamins and oxidant stress in diabetes and its complications. MedGenMed: Medscape General Medicine, 2004, 6, 4.	0.2	4

#	ARTICLE	IF	CITATIONS
7155	Management of carotid artery stenosis. Update for family physicians. Canadian Family Physician, 2005, 51, 984-9.	0.1	9
7156	Management strategies of dyslipidemia in the elderly: 2005. MedGenMed: Medscape General Medicine, 2005, 7, 8.	0.2	0
7157	Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. MedGenMed: Medscape General Medicine, 2006, 8, 54.	0.2	1
7159	Peripheral arterial disease and ankle-brachial pressure index as predictors of mortality in residents of Metlika County, Slovenia. Croatian Medical Journal, 2006, 47, 327-34.	0.2	8
7160	Effect of statin therapy on total mortality. Trial in a more varied population. Canadian Family Physician, 2003, 49, 757-9.	0.1	0
7161	Family practice patients' adherence to statin medications. Canadian Family Physician, 2007, 53, 2144-5.	0.1	21
7162	Cholesterol lowering for secondary prevention: what statin dose should we use?. Vascular Health and Risk Management, 2007, 3, 615-27.	1.0	8
7163	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. Vascular Health and Risk Management, 2007, 3, 711-9.	1.0	3
7164	Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vascular Health and Risk Management, 2007, 3, 521-6.	1.0	15
7165	Multivariate risk assessment and risk score cards in hypertension. Vascular Health and Risk Management, 2007, 3, 313-20.	1.0	4
7166	Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease. Vascular Health and Risk Management, 2007, 3, 1019-27.	1.0	22
7167	Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction. Vascular Health and Risk Management, 2007, 3, 1045-51.	1.0	3
7168	Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Experimental and Clinical Cardiology, 2007, 12, 17-28.	1.3	60
7170	Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands. Netherlands Heart Journal, 2004, 12, 331-336.	0.3	10
7171	Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vascular Health and Risk Management, 2008, 4, 673-81.	1.0	54
7172	Managing cardiovascular risk in minority patients. Journal of the National Medical Association, 2005, 97, 459-66.	0.6	25
7174	Recommendations for management of dyslipidemia in high cardiovascular risk patients. Experimental and Clinical Cardiology, 2008, 13, 71-4.	1.3	2
7175	Progress update: Pharmacological treatment of Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2007, 3, 569-78.	1.0	18

#	ARTICLE	IF	CITATIONS
7177	Atherosclerosis, cholesterol, nutrition, and statins--a critical review. <i>GMS German Medical Science</i> , 2007, 5, Doc04.	2.7	15
7180	From evidence to practice: consensus in cardiovascular risk assessment and diabetes. <i>Clinical Biochemist Reviews</i> , 2009, 30, 179-86.	3.3	2
7181	Does screening for peripheral arterial disease improve risk stratification for patients at intermediate risk for coronary artery disease?. <i>Open Medicine</i> , 2007, 1, e55-7.	1.5	0
7182	Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients. <i>Journal of the Canadian Chiropractic Association</i> , 2010, 54, 43-51.	0.2	4
7184	Modulation of cholesterol in midlife affords cognitive advantage during ageing - a role for altered redox balance. <i>International Journal of Clinical and Experimental Medicine</i> , 2010, 3, 103-9.	1.3	5
7185	Peripheral arterial disease. <i>Clinical Evidence</i> , 2007, 2007, .	0.2	1
7186	Diabetes: managing dyslipidaemia. <i>Clinical Evidence</i> , 2008, 2008, .	0.2	2
7187	Ultrasound diagnosis of bilateral quadriceps tendon rupture after statin use. <i>Western Journal of Emergency Medicine</i> , 2010, 11, 306-9.	0.6	15
7188	Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?. <i>Transactions of the American Clinical and Climatological Association</i> , 2011, 122, 256-89.	0.9	35
7190	Does Clinical Inertia Vary According to Provider Type?. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2008, 25, 21-27.	0.6	0
7192	Peripheral arterial disease. <i>Clinical Evidence</i> , 2011, 2011, .	0.2	4
7193	The effect of statin therapy in stroke outcome: a double blind clinical trial. <i>International Journal of Preventive Medicine</i> , 2012, 3, 68-72.	0.2	5
7194	Optimal management of peripheral arterial disease for the non-specialist. <i>Ulster Medical Journal</i> , 2011, 80, 33-41.	0.2	9
7195	Multifactorial approach to the primary and secondary prevention of atherosclerosis. <i>Ochsner Journal</i> , 2003, 5, 12-7.	0.5	2
7197	Niacin added to statins for cardiovascular disease. <i>Canadian Family Physician</i> , 2012, 58, 842.	0.1	0
7198	Preoperative statin therapy in cardiac surgery is more effective in patients who display preoperative activation of the inflammatory system. <i>Texas Heart Institute Journal</i> , 2013, 40, 42-9.	0.1	5
7199	Is Friedewald formula a good estimation for low density lipoprotein level in Iranian population?. <i>Journal of Research in Medical Sciences</i> , 2012, 17, 519-22.	0.4	12
7200	Cholesterol and cardiovascular disease in the elderly. <i>Facts and gaps.</i> , 2013, 4, 154-69.		41

#	ARTICLE	IF	CITATIONS
7201	Statin-induced diabetes: too sweet a deal?. Canadian Family Physician, 2013, 59, e311.	0.1	2
7202	Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering. Hippokratia, 2012, 16, 100-5.	0.3	3
7203	Management of Diabetic Nephropathy in the Elderly: Special Considerations. Journal of Nephrology & Therapeutics, 2012, 2, .	0.1	1
7204	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Open Access Journal of Urology, 2011, 3, 95-104.	0.3	1
7205	Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?. American Journal of Cardiovascular Disease, 2013, 3, 197-226.	0.5	126
7206	Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer. International Journal of Molecular Epidemiology and Genetics, 2013, 4, 183-92.	0.4	2
7207	High-dose atorvastatin pretreatment could diminishes microvascular impairment in patients undergoing elective percutaneous coronary intervention. Journal of Geriatric Cardiology, 2013, 10, 355-60.	0.2	4
7208	Fixed drug combination in hypertension and hyperlipidaemia in the developing world. Cardiovascular Journal of Africa, 2008, 19, 124-6.	0.2	3
7209	The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). Cardiovascular Journal of Africa, 2008, 19, 88-94.	0.2	4
7210	Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study. Journal of Investigative Medicine, 2010, 58, 945-9.	0.7	10
7211	Estimates of commercial population at high risk for cardiovascular events: impact of aggressive cholesterol reduction. American Health and Drug Benefits, 2009, 2, 224-32.	0.5	0
7212	Recurrent stroke: what have we learnt?. Malaysian Family Physician, 2007, 2, 70-3.	0.2	0
7213	Break the fast? Update on patient preparation for cholesterol testing. Canadian Family Physician, 2014, 60, 895-7, e471-4.	0.1	6
7215	Profile of atherosclerotic risk factors and management in patients of peripheral arterial disease at a tertiary care teaching hospital of north India. Indian Journal of Pharmaceutical Sciences, 2014, 76, 504-9.	1.0	3
7216	The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident. ARYA Atherosclerosis, 2014, 10, 298-304.	0.4	5
7217	Goal attainments and their discrepancies for low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apo B) in over 2,000 Chinese patients with known coronary artery disease or type 2 diabetes. Cardiovascular Diagnosis and Therapy, 2015, 5, 98-103.	0.7	0
7218	Simvastatin ameliorates low-dose streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model. International Journal of Clinical and Experimental Medicine, 2015, 8, 6388-96.	1.3	6
7219	Different regulation of Toll-like receptor 4 expression on blood CD14(+) monocytes by simvastatin in patients with sepsis and severe sepsis. International Journal of Clinical and Experimental Medicine, 2015, 8, 13830-5.	1.3	1

#	ARTICLE	IF	CITATIONS
7221	Prognostic Factors for Neurologic Outcome in Patients with Carotid Artery Stenting. <i>Acta Cardiologica Sinica</i> , 2016, 32, 205-14.	0.1	15
7222	Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia. <i>American Health and Drug Benefits</i> , 2016, 9, 123-6.	0.5	9
7223	Cancer risk in older people receiving statin therapy: a meta-analysis of randomized controlled trials. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 693-700.	0.2	4
7224	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. <i>European Heart Journal Supplements</i> , 2017, 19, D163-D189.	0.0	0
7225	Predictors of Mortality in Elderly Patients with Non-ST Elevation Acute Coronary Syndrome - Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. <i>Acta Cardiologica Sinica</i> , 2017, 33, 377-383.	0.1	11
7226	Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. <i>Acta Cardiologica Sinica</i> , 2018, 34, 371-378.	0.1	12
7227	Longitudinal hyperlipidemia outcomes at three student-run free clinic sites. <i>Family Medicine</i> , 2015, 47, 309-14.	0.3	10
7228	Impact of Pharmacist Interventions on the Long-Term Clinical Outcomes in Patients with Myocardial Infarction. <i>Acta Cardiologica Sinica</i> , 2019, 35, 290-300.	0.1	6
7229	Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 463-477.	0.0	6
7231	Fish Oil Supplements for Prevention of Cardiovascular Disease: The Jury Is Still Out: CON: Fish Oil is Useful to Prevent or Treat Cardiovascular Disease. <i>Missouri Medicine</i> , 2021, 118, 219-225.	0.3	1
7232	Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer. <i>Prostate</i> , 2022, 82, 314-322.	1.2	3
7233	Statins for secondary prevention and major adverse events after coronary artery bypass grafting. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1875-1886.e4.	0.4	8
7234	Idiopathic chronic pancreatitis: Beyond antioxidants. <i>World Journal of Gastroenterology</i> , 2021, 27, 7423-7432.	1.4	4
7235	Crosstalk between Statins and Cancer Prevention and Therapy: An Update. <i>Pharmaceuticals</i> , 2021, 14, 1220.	1.7	11
7236	Statin Therapy in Very Old Patients: Lights and Shadows. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 779044.	1.1	7
7237	An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1455-1472.	1.4	3
7238	Cerebrovascular Disease and Statins. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 778740.	1.1	8
7240	Analysis of Serum Cholesterol, Statins and Atherosclerotic Plaque in Ruptured and Unruptured Intracranial Aneurysm. <i>Brazilian Neurosurgery</i> , 2022, 41, e43-e50.	0.0	0

#	ARTICLE	IF	CITATIONS
7241	Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 1085-1096.	0.6	2
7242	Genetic Predisposition to Low-Density Lipoprotein Cholesterol May Increase Risks of Both Individual and Familial Alzheimer's Disease. <i>Frontiers in Medicine</i> , 2021, 8, 798334.	1.2	7
7243	Development and validation of a novel risk score to predict 5-year mortality in patients with acute myocardial infarction in China: a retrospective study. <i>PeerJ</i> , 2022, 9, e12652.	0.9	1
7244	Trials and Treatments for Vascular Brain Health: Risk Factor Modification and Cognitive Outcomes. <i>Stroke</i> , 2022, 53, 444-456.	1.0	8
7245	Prevalence of statin intolerance: a meta-analysis. <i>European Heart Journal</i> , 2022, 43, 3213-3223.	1.0	151
7246	Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. <i>Revista Espanola De Cardiologia Suplementos</i> , 2011, 11, 29-35.	0.2	1
7247	The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. , 2021, 12, 1857.		2
7248	Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly. <i>Minerva Medica</i> , 2022, 112, .	0.3	7
7249	Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments. <i>Trials</i> , 2022, 23, 62.	0.7	8
7250	Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988).. <i>Archives of Medical Science</i> , 2022, , .	0.4	2
7252	Association of major blood lipids with post-stroke dementia: A community-based cohort study. <i>European Journal of Neurology</i> , 2022, 29, 968-979.	1.7	2
7253	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. <i>Atherosclerosis</i> , 2022, 343, 28-50.	0.4	12
7254	Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics. <i>Annals of Medicine and Surgery</i> , 2022, 74, 103304.	0.5	11
7255	Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults. <i>International Journal of Epidemiology</i> , 2022, 51, 1178-1189.	0.9	5
7256	Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. <i>European Journal of Pharmacology</i> , 2022, 919, 174800.	1.7	7
7257	TREATMENT EFFECTIVENESS ANALYSIS OF OUTPATIENTS WITH ARTERIAL HYPERTENSION PLUS CORONARY HEART DISEASE IN UKRAINE. <i>Eurasian Heart Journal</i> , 2012, , 17-29.	0.2	0
7258	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S144-S174.	4.3	282
7260	The myocardial ischemia reduction with aggressive cholesterol lowering study. <i>Current Cardiology Reports</i> , 2002, 4, 485.	1.3	0

#	ARTICLE	IF	CITATIONS
7261	Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease. <i>Current Atherosclerosis Reports</i> , 2006, 8, 7-8.	2.0	0
7262	High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction. <i>Current Atherosclerosis Reports</i> , 2007, 9, 5-6.	2.0	1
7263	Clinical significance of single nucleotide polymorphisms in PCSK9. <i>Current Atherosclerosis Reports</i> , 2007, 9, 175-6.	2.0	1
7264	Effects of lipid-lowering therapy on coronary heart disease in older patients: the SAGE study. <i>Current Atherosclerosis Reports</i> , 2008, 10, 5-6.	2.0	2
7266	A Propensity Score Matched Analysis of Statin Effects on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients Over 75 Years Old. <i>Internal Medicine</i> , 2022, , .	0.3	2
7267	The Inflammatory Pattern of Chronic Limb-Threatening Ischemia in Muscles: The TNF- α Hypothesis. <i>Biomedicines</i> , 2022, 10, 489.	1.4	3
7268	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	4.9	14
7269	Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2848.	1.8	1
7270	Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. <i>Cardiovascular Research</i> , 2023, 118, 3288-3304.	1.8	57
7271	Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review. <i>Geriatrics (Switzerland)</i> , 2022, 7, 38.	0.6	0
7272	LDL como objetivo terapéutico. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2022, , .	0.4	0
7273	Statin use is associated with lower risk of dementia in stroke patients: a community-based cohort study with inverse probability weighted marginal structural model analysis. <i>European Journal of Epidemiology</i> , 2022, 37, 615-627.	2.5	6
7274	Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach. <i>Pharmacogenomics Journal</i> , 2022, , .	0.9	0
7275	Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality: Systematic Review and Updated Meta-Analysis. <i>Circulation</i> , 2022, 145, 1506-1520.	1.6	25
7276	Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 804-814.	0.8	46
7277	Revascularization Strategies for Stable Left Main Coronary Artery Disease: Analysis of Current Evidence. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, , .	0.6	1
7278	COPD "do the right thing". <i>BMC Family Practice</i> , 2021, 22, 244.	2.9	23
7279	Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 170-179.	2.3	2

#	ARTICLE	IF	CITATIONS
7280	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trialâ€“Adjudicated Direct Follow-up Data in the UK. JAMA Network Open, 2021, 4, e2139748.	2.8	15
7283	Efficacy, Safety and Protective Effects of Lipid Lowering Drugs in Patients with Diabetes. European Journal of Medical and Health Sciences, 2022, 4, 89-92.	0.1	1
7284	Medical Optimization of the PAD Patient. Seminars in Vascular Surgery, 2022, 35, 113-113.	1.1	0
7285	Cholesterol and its biological significance. Atherosclerosis. Statin therapy (Part 1). Sibirskij Å¾urnal KliniÅšeskoj I Åšperimental'noj Mediciny, 2022, 37, 27-35.	0.1	2
7286	Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis. JAMA Network Open, 2022, 5, e227624.	2.8	8
7289	Intervention Trials. , 2005, , 345-370.		0
7291	What Caused This Transient or Persisting Ischaemic Event?. , 0, , 259-351.		1
7292	An Interventionalist's Perspective. , 0, , 343-349.		0
7293	Lipids and Cardiovascular Disease. , 0, , 121-129.		1
7294	Use of Lipid Lowering Agents in the Prevention of Cardiovascular Disease. , 0, , 130-145.		0
7295	Other Medical Therapies. , 0, , 330-347.		2
7296	Vascular Function and Diabetes Mellitus. , 0, , 232-244.		2
7299	Rosuvastatin Attenuates Hypertension-induced Cardiovascular Remodeling Without Affecting Blood Pressure in DOCA-salt Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2006, 47, 396-404.	0.8	32
7300	Association between statin use and physical performance in home-dwelling older patients receiving polypharmacy: cross-sectional study. BMC Geriatrics, 2022, 22, 242.	1.1	5
7308	Calm the raging hormone - A new therapeutic strategy involving progesterone-signaling for hemorrhagic CCMs.. Vessel Plus, 2021, 5, .	0.4	0
7309	Clinical strategies for reducing cholesterol levels. , 2022, , 853-901.		0
7310	Chitosan Nanoparticles in Atherosclerosisâ€”Development to Preclinical Testing. Pharmaceutics, 2022, 14, 935.	2.0	4
7311	New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. Biomedicines, 2022, 10, 970.	1.4	8

#	ARTICLE	IF	CITATIONS
7312	Undertreatment or Overtreatment With Statins: Where Are We?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 808712.	1.1	9
7314	Do drugs interact together in cardiovascular prevention? A meta-analysis of powerful or factorial randomized controlled trials. <i>Therapie</i> , 2022, , .	0.6	1
7315	Commentary: Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential. <i>Frontiers in Oncology</i> , 2022, 12, 891352.	1.3	1
7316	Zerebrovaskuläre Erkrankungen – zerebrale Ischämie. , 2021, , 1-7.		0
7317	Lipid-modifying and antiatherosclerotic drugs. , 2013, , 398-435.		3
7318	Which therapy for which condition?. , 2013, , 463-541.		1
7319	Acute myocardial infarction and diabetes mellitus. , 2015, 49, 16-19.		0
7320	Observational and Genetic Associations of Modifiable Risk Factors with Aortic Valve Stenosis: A Prospective Cohort Study of 0.5 Million Participants. <i>Nutrients</i> , 2022, 14, 2273.	1.7	7
7321	Impact of diet on ten-year absolute cardiovascular risk in a prospective cohort of 94 321 individuals: A tool for implementation of healthy diets. <i>Lancet Regional Health - Europe</i> , The, 2022, 19, 100419.	3.0	4
7328	Terapia endocrina para la prevención primaria del cáncer de seno: Revisión sistemática y metaanálisis actualizado. <i>Revista Colombiana De Cirugía</i> , 0, , .	0.2	0
7329	Temporal trends in abdominal aortic aneurysmal disease: a nationwide cohort study on cardiovascular morbidity and medical cardioprotective therapy. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1957-1964.	0.8	8
7330	Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage. <i>Stroke</i> , 2022, 53, 2161-2170.	1.0	11
7331	Insights into the Association of Chronic Kidney Disease (CKD) and Cardiovascular Risk Among Diabetic vs. Non-Diabetic Patients. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2022, 20, .	0.4	0
7332	Prevalence and initiation of statin therapy in the oldest old – a longitudinal population-based study. <i>European Journal of Clinical Pharmacology</i> , 0, , .	0.8	0
7333	Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. <i>Clinical Trials</i> , 2022, 19, 593-604.	0.7	2
7334	Critical Limb Ischemia: Update for the Cardiovascular Anesthesiologist. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 3939-3944.	0.6	1
7338	Does the magnitude of lipid lowering with statin therapy indicate higher intracranial bleeding risk?. <i>Brain</i> , 0, , .	3.7	1
7340	Combination therapy in the guidelines: from high-intensity statins to high-intensity lipid-lowering therapies: Combination therapy in the guideline. , 2022, 1, 25-29.		2

#	ARTICLE	IF	CITATIONS
7342	The 2nd European Carotid Surgery Trial (ECST-2): rationale and protocol for a randomised clinical trial comparing immediate revascularisation versus optimised medical therapy alone in patients with symptomatic and asymptomatic carotid stenosis at low to intermediate risk of stroke. <i>Trials</i> , 2022, 23, .	0.7	13
7343	Pharmacotherapy and Mortality in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1201-1207.	2.5	2
7344	Retrospective Evaluation of In-Hospital and Thirty-Month Mortality Parameters in Cases of Acute Coronary Syndrome. , 0, , .		0
7345	Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
7346	Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2023, 81, 35-44.	0.8	2
7347	Effect of statins on oxidative stress and cognitive function in patients with cerebral atherosclerosis: results of a prospective cohort study. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2022, 14, 25-32.	0.2	1
7348	Circulating vitamin C and digestive system cancers: Mendelian randomization study. <i>Clinical Nutrition</i> , 2022, 41, 2031-2035.	2.3	8
7350	Effectiveness of red yeast rice on carotid atherosclerosis: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
7351	Impact of Guideline-Directed Medical Therapy on 10-Year Mortality after Revascularization for Patients with Chronic Limb-Threatening Ischemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, , .	0.9	1
7352	Weight loss in a cardiovascular trial population identifies people at future risk of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	0
7353	LDL as a therapeutic target. <i>ClĀnica E InvestigaciĀn En Arteriosclerosis (English Edition)</i> , 2022, 34, 271-284.	0.1	0
7354	Low-density lipoprotein cholesterol in oldest old with acute myocardial infarction: Is lower the better?. <i>Age and Ageing</i> , 2022, 51, .	0.7	4
7355	Evaluating Statin Tolerability in Historically Intolerant Patients After Correcting for Subclinical Hypothyroidism and Vitamin D Insufficiency. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 409-415.	1.0	0
7356	Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. <i>Lancet, The</i> , 2022, 400, 832-845.	6.3	87
7357	Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review. <i>Brain Sciences</i> , 2022, 12, 1290.	1.1	33
7358	International Union of Angiology Position Statement on no-option chronic limb threatening ischemia. <i>International Angiology</i> , 2022, 41, .	0.4	5
7359	Prevalence and Pattern of Dyslipidemia and Its Associated Factors Among Patients with Type 2 Diabetes Mellitus in Jordan: A Cross-Sectional Study. <i>International Journal of General Medicine</i> , 0, Volume 15, 7669-7683.	0.8	7
7361	Statin Myopathy. , 2022, , 137-147.		0

#	ARTICLE	IF	CITATIONS
7362	Clinical associations between exercise and lipoproteins. <i>Current Opinion in Lipidology</i> , 2022, 33, 364-373.	1.2	2
7363	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. , 2022, 1, 100513.		3
7364	Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	1
7365	Routine Î²-Blockade in Vascular Surgery. <i>Vascular</i> , 2003, 11, 459-463.	0.5	0
7366	Pharmacological Treatment of Alzheimerâ€™s Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 122-167.	0.2	3
7367	Podocytopathy in Diabetes: A Metabolic Disorder. <i>Contributions To Nephrology</i> , 2014, , 157-173.	1.1	0
7368	Complementary Medications (Statins, Nicergoline, Naftidrofuryl) in Dementia. , 2022, , 2789-2801.		0
7369	Protecting the Heart in Cancer Patients: The Role of Cardio-Oncology. <i>EMJ Cardiology</i> , 0, , 47-52.	0.0	1
7371	The associations between exercise and lipid biomarkers. <i>Progress in Cardiovascular Diseases</i> , 2022, 75, 59-68.	1.6	12
7372	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad EspaÃ±ola de CardiologÃa [Spanish Society of Cardiology] and the Sociedad EspaÃ±ola de Diabetes [Spanish Diabetes Society]. <i>EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed)</i> , 2023, 70, 51-62.	0.1	0
7373	Closing gaps in medication taking for secondary prevention of coronary heart disease patients among US adults. <i>Heliyon</i> , 2022, 8, e11530.	1.4	1
7374	Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. <i>BMC Medicine</i> , 2022, 20, .	2.3	6
7375	Statin associated muscle symptoms: An update and review. <i>Progress in Cardiovascular Diseases</i> , 2022, 75, 40-48.	1.6	10
7376	Effects of Vitamin D Supplementation in Patients with Statin-Associated Muscle Symptoms and Low Vitamin D Levels. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 567-575.	0.5	2
7377	Development of Machine Learning Tools for Predicting Coronary Artery Disease in the Chinese Population. <i>Disease Markers</i> , 2022, 2022, 1-18.	0.6	0
7383	Evidence of the Impact of Programmes to Prevent and Manage Heart Disease and Stroke. , 2022, , 1-45.		0
7384	Prevalence and Control of Hypercholesterolaemia as Defi ned by NCEP-ATPIII Guidelines and Predictors of LDL-C Goal Attainment in a Multi-Ethnic Asian Population. <i>Annals of the Academy of Medicine, Singapore</i> , 2013, 42, 379-387.	0.2	10
7385	Statin-related Muscle Toxicity: An Evidence-based Review. <i>European Endocrinology</i> , 2022, 18, 89.	0.8	1

#	ARTICLE	IF	CITATIONS
7386	Analysis of the structure of drug prescriptions in patients with arterial hypertension and atrial fibrillation in conditions of comorbidity and their compliance with the STOPP/START criteria. Arterial Hypertension (Russian Federation), 2022, 28, 557-572.	0.1	0
7387	Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid. Journal of the Association of Physicians of India, The, 2022, 70, 67-75.	0.0	3
7388	Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension. Liver International, 2023, 43, 888-895.	1.9	3
7389	Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review. Journal of Clinical Neuromuscular Disease, 2022, 24, 75-79.	0.3	2
7390	Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria. Journal of the American Heart Association, 2023, 12, .	1.6	11
7391	Impact of Statins on Survival and Limb Salvage in Patients Undergoing Peripheral Endovascular Intervention for Chronic Limb-Threatening Ischemia. Annals of Vascular Surgery, 2023, 91, 20-27.	0.4	5
7392	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2023. Diabetes Care, 2023, 46, S158-S190.	4.3	156
7393	Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of STOPDAPT-2 ACS. Circulation Journal, 2022, , .	0.7	0
7394	Statin related muscle symptoms: is it time to move on. BMJ, The, 0, , o2939.	3.0	2
7395	The role of statins in diabetic retinopathy. Trends in Cardiovascular Medicine, 2024, 34, 128-135.	2.3	5
7397	Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study. Frontiers in Pharmacology, 0, 13, .	1.6	3
7398	The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study. PeerJ, 0, 11, e14609.	0.9	4
7399	Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?. American Journal of Preventive Cardiology, 2023, 13, 100451.	1.3	1
7400	Primary prevention statin therapy in older adults. Current Opinion in Cardiology, 2023, 38, 11-20.	0.8	2
7401	Cardiac complexities: all we have to know about our heart. International Journal of Pharmaceutics and Drug Analysis, 0, , 95-105.	0.0	0
7402	Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. Journal of Lipid and Atherosclerosis, 2023, 12, 12.	1.1	6
7403	Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. Diabetes and Metabolism Journal, 2023, 47, 1-9.	1.8	9
7404	Risk Factor Profile and Treatment Patterns of Patients with Atherothrombosis in Singapore: Insight from the REACH Registry. Annals of the Academy of Medicine, Singapore, 2008, 37, 365-371.	0.2	9

#	ARTICLE	IF	CITATIONS
7405	Estimated mortality with early empirical antibiotic coverage of methicillin-resistant <i>Staphylococcus aureus</i> in hospitalized patients with bacterial infections: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 1150-1159.	1.3	5
7406	Lipid-lowering therapy and the risk of dementia: lessons learned from two decades of controversy. <i>European Heart Journal</i> , 0, , .	1.0	0
7407	Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. <i>Mayo Clinic Proceedings</i> , 2023, 98, 301-315.	1.4	5
7408	Statin Use and the Risk of All-cause Mortality. <i>Korean Journal of Medicine</i> , 2023, 98, 4-10.	0.1	0
7409	Does statin use affect amyloid beta deposition and brain metabolism?. <i>CNS Neuroscience and Therapeutics</i> , 2023, 29, 1434-1443.	1.9	3
7410	How to Measure Effect Sizes for Rational Decision Making. <i>Philosophy of Science</i> , 2023, 90, 1183-1193.	0.5	2
7411	Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: A Focus on Insulin Resistance. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4354.	1.8	13
7412	THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART) Tj ETQq1 1 0,784314	0.0	0
7414	Lipid-lowering Efficacy and Safety of High Doses of Atorvastatin and Rosuvastatin. <i>Kardiologiya</i> , 2023, 63, 59-67.	0.3	1
7415	Koronare Herzkrankheit â€“ Begutachtung. <i>Springer Reference Medizin</i> , 2022, , 1-25.	0.0	0
7416	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. <i>Frontiers in Clinical Drug Research Diabetes and Obesity</i> , 2023, , 117-167.	0.1	0
7417	Women with type 2 diabetes have LDL cholesterol levels higher than those of men, regardless of their treatment and their cardiovascular risk level. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 1254-1262.	1.1	0
7418	Naoin capsules protect brain function and structure in patients with vascular cognitive impairment. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
7419	Established Statin Use Reduces Mortality From Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. <i>European Medical Journal Respiratory</i> , 0, , 46-55.	1.0	1
7420	Specific recommendations to improve the design and conduct of clinical trials. <i>Trials</i> , 2023, 24, .	0.7	1
7422	Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. <i>Medicina (Lithuania)</i> , 2023, 59, 776.	0.8	3
7423	Short-Term Effect of Nutraceutical Fruit Juices on Lipid Metabolism in Patients with Acquired Hypercholesterolemia. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7358.	1.8	0
7424	Understanding the molecular mechanisms of statin pleiotropic effects. <i>Archives of Toxicology</i> , 2023, 97, 1529-1545.	1.9	9

#	ARTICLE	IF	CITATIONS
7425	Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease. Journal of Sexual Medicine, 2023, 20, 925-934.	0.3	1
7435	Updated Clinical Guide to Exercise and Lipids. , 2024, , 132-140.e2.		0
7438	Intensive Versus Moderate Lipid Lowering for Acute Coronary Syndrome-2004. , 2023, , 149-151.		0
7439	Managing Stable Coronary Artery Disease in Diabetes. Contemporary Cardiology, 2023, , 655-681.	0.0	0
7440	Diabetes and Dyslipidemia. Contemporary Cardiology, 2023, , 425-472.	0.0	3
7443	Lipoproteins and Ischemic Stroke in Diabetes. Contemporary Diabetes, 2023, , 503-522.	0.0	0
7445	Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes. Contemporary Diabetes, 2023, , 579-595.	0.0	0
7446	About Randomized Clinical Trials Related to Lipoproteins in Diabetes Mellitus. Contemporary Diabetes, 2023, , 525-553.	0.0	0
7453	Special Patient Populations. , 2024, , 375-382.e2.		0
7454	Nutraceuticals and Functional Foods for Cholesterol Reduction. , 2024, , 236-245.e3.		0
7457	Diabetes and Hypertension. Contemporary Cardiology, 2023, , 399-424.	0.0	0
7458	Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review. Inflammopharmacology, 2023, 31, 1647-1656.	1.9	0
7494	Evidence of the Impact of Programs to Prevent and Manage Heart Disease and Stroke. , 2023, , 515-557.		0
7501	Beyond Cholesterol Reduction: Statin Pleiotropy and Peripheral Arterial Disease. , 0, , .		0
7523	Zerebrale Ischämie. , 2024, , 1-7.		0
7525	How Will Our Practice Change After the CLEAR Outcomes Trial?. Current Atherosclerosis Reports, 2024, 26, 83-89.	2.0	0
7541	Intervention Trials. , 2024, , 1-30.		0